PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	RIDKER, PM; HENNEKENS, CH; LINDPAINTER, K; STAMPFER, MJ; EISENBERG, PR; MILETICH, JP				RIDKER, PM; HENNEKENS, CH; LINDPAINTER, K; STAMPFER, MJ; EISENBERG, PR; MILETICH, JP			MUTATION IN THE GENE CODING FOR COAGULATION-FACTOR-V AND THE RISK OF MYOCARDIAL-INFARCTION, STROKE, AND VENOUS THROMBOSIS IN APPARENTLY HEALTHY-MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POOR ANTICOAGULANT RESPONSE; DEEP-VEIN THROMBOSIS; ACTIVATED PROTEIN-C; PLASMINOGEN-ACTIVATOR; HEART-DISEASE; THROMBOPHILIA; FIBRINOGEN; INHIBITOR; PLASMA	Background. A specific point mutation in the gene coding for coagulation factor V is associated with resistance to degradation by activated protein C, a recently described abnormality of coagulation that may be associated with an increased risk of venous thrombosis. Whether this mutation also predisposes patients to arterial thrombosis is unknown, as is the value of screening for the mutation in order to define the risk of venous thrombosis among unselected healthy people. Methods. Among 14,916 apparently healthy men in the Physicians' Health Study who provided base-line blood samples, 374 had myocardial infarctions, 209 had strokes, and 121 had deep venous thrombosis, pulmonary embolism, or both, during a mean follow-up of 8.6 years. We determined whether a mutation at nucleotide position 1691 of the factor V gene was present or absent in these 704 men and in an equal number of matched participants who remained free of vascular disease. Results. The prevalence of heterozygosity for the mutation among men who had myocardial infarctions (6.1 percent, P=0.9) or strokes (4.3 percent, P=0.4) was similar to that among men who remained free of vascular disease (6.0 percent). However, the prevalence of the mutation was significantly higher among men who had venous thrombosis, pulmonary embolism, or both (11.6 percent, P=0.02). In adjusted analyses, the relative risk of venous thrombosis among men with the mutation was 2.7 (95 percent confidence interval, 1.3 to 5.6; P=0.008). This increased risk was seen with primary venous thrombosis (relative risk, 3.5; 95 percent confidence interval, 1.5 to 8.4; P=0.004) but not with secondary venous thrombosis (relative risk, 1.7; 95 percent confidence interval, 0.6 to 5.3; P=0.3), and it was most apparent among older men. Specifically, the prevalence of the mutation among men over the age of 60 in whom primary venous thrombosis developed was 25.8 percent (relative risk, 7.0; 95 percent confidence interval, 2.6 to 19.1; P<0.001). Conclusions. In a large cohort of apparently healthy men, the presence of a specific point mutation in the factor V gene was associated with an increased risk of venous thrombosis, particularly primary venous thrombosis. The presence of the mutation was not associated with an increased risk of myocardial infarction or stroke. This mutation appears to be the most common inherited factor thus far recognized that predisposes patients to venous thrombosis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV PREVENT MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV CARDIOVASC DIS,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,CHANNING LAB,BOSTON,MA 02115; CHILDRENS HOSP,DEPT CARDIOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115; WASHINGTON UNIV,SCH MED,DIV CARDIOVASC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV LAB MED,ST LOUIS,MO 63110	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595, P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-34595, HL-14147, HL-26490] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DALEN JE, 1975, PROG CARDIOVASC DIS, V17, P257; FOWKES FGR, 1993, LANCET, V342, P84, DOI 10.1016/0140-6736(93)91288-W; GOLDHABER SZ, 1985, PULMONARY EMBOLISM D; GRIFFIN JH, 1993, BLOOD, V82, P1989; HALBMAYER WM, 1994, BLOOD COAGUL FIBRIN, V5, P51, DOI 10.1097/00001721-199402000-00008; HAMSTEN A, 1987, LANCET, V2, P3; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HIRSH J, 1981, VENOUS THROMBOEMBOLI; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; PRANDONI P, 1992, NEW ENGL J MED, V327, P11228; RIDKER PM, 1993, LANCET, V341, P1165, DOI 10.1016/0140-6736(93)90998-V; RIDKER PM, 1994, CIRCULATION, V90, P2236, DOI 10.1161/01.CIR.90.5.2236; RIDKER PM, 1994, LANCET, V343, P940, DOI 10.1016/S0140-6736(94)90064-7; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; ZOLLER B, 1994, LANCET, V343, P1536, DOI 10.1016/S0140-6736(94)92940-8; 1971, ISCHEMIC HEART DISEA	29	986	1009	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					912	917		10.1056/NEJM199504063321403	http://dx.doi.org/10.1056/NEJM199504063321403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877648				2022-12-28	WOS:A1995QP89300003
J	GUILLEMINAULT, C; STOOHS, R; KIM, YD; CHERVIN, R; BLACK, J; CLERK, A				GUILLEMINAULT, C; STOOHS, R; KIM, YD; CHERVIN, R; BLACK, J; CLERK, A			UPPER AIRWAY SLEEP-DISORDERED BREATHING IN WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						SLEEP APNEA SYNDROMES; AIRWAY OBSTRUCTION; MENOPAUSE; OBESITY; NECK	APNEA SYNDROME; POSTMENOPAUSAL WOMEN; ABNORMALITIES	Objective: To investigate the various clinical presentations of sleep-disordered breathing in women. Design: A retrospective case-control study. Setting: A sleep disorders clinic. Patients: 334 women, aged 18 years and older, seen between 1988 and 1993, who were diagnosed with upper airway sleep-disordered breathing. Controls were 60 women with insomnia and 100 men with sleep-disordered breathing. Measurements: Clinical, anatomic, and polygraphic information. Results: The mean lag time (+/- SD) in women between the appearance of symptoms and a positive diagnosis was 9.7 +/- 3.1 years; among participants 30 to 60 years of age, the duration of untreated symptoms differed (P <0.001) between women and men. Sleep-disordered breathing was blamed for divorce or social isolation by 40% of the case patients. Abnormal maxillomandibular features were noted in 45% of the women with disordered breathing. Dysmenorrhea and amenorrhea (which disappeared after treatment with nasal continuous positive airway pressure) were reported in 43% of premenopausal women compared with 13% of persons in the control group of women with insomnia. Thirty-eight women (11.4%) with upper airway sleep-disordered breathing had a respiratory disturbance index of less than 5 and were significantly younger, had a smaller neck circumference, and had a lower body mass index than women with a respiratory disturbance index of 5 or more. Conclusion: Physicians should revise their understanding of upper airway sleep-disordered breathing so that they notice women with certain craniofacial features, a low body mass index, a small neck circumference, and a respiratory disturbance index of less than 5. These revisions may enable more rapid diagnosis and treatment of women with sleep-disordered breathing.	TOYAMA MED & PHARMACEUT UNIV, TOYAMA, JAPAN; SLEEP DISORDERS CTR, ANN ARBOR, MI 48109 USA	University of Toyama	GUILLEMINAULT, C (corresponding author), STANFORD SLEEP DISORDERS CLIN & RES CTR, 701 WELCH RD, SUITE 2226, PALO ALTO, CA 94304 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG007772] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR 00070] Funding Source: Medline; NIA NIH HHS [AG 07772] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CARSKADON MA, 1986, SLEEP, V9, P519, DOI 10.1093/sleep/9.4.519; DAVIES RJO, 1992, THORAX, V47, P101, DOI 10.1136/thx.47.2.101; Douglass AB., 1986, SLEEP RES, V15, P117; Douglass AB, 1990, SLEEP RES, V19, P215; FLEMALE A, 1988, EUR RESPIR J, V1, P51; GISLASON T, 1993, CHEST, V103, P1147, DOI 10.1378/chest.103.4.1147; GUILLEMINAULT C, 1988, CHEST, V93, P104, DOI 10.1378/chest.93.1.104; GUILLEMINAULT C, 1993, CHEST, V104, P781, DOI 10.1378/chest.104.3.781; HOFFSTEIN V, 1992, EUR RESPIR J, V5, P377; JAMIESON A, 1986, SLEEP, V9, P469, DOI 10.1093/sleep/9.4.469; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; JOHNS MW, 1991, SLEEP, V14, P540, DOI 10.1093/sleep/14.6.540; KATZ I, 1990, AM REV RESPIR DIS, V141, P1228, DOI 10.1164/ajrccm/141.5_Pt_1.1228; KHOSLA T, 1967, BRIT J PREV SOC MED, V21, P122; PARTINEN M, 1988, CHEST, V93, P1199, DOI 10.1378/chest.93.6.1199; PEIRIS AN, 1989, ANN INTERN MED, V110, P867, DOI 10.7326/0003-4819-110-11-867; PHILIP P, 1994, SLEEP, V17, P242; PICKETT CK, 1989, J APPL PHYSIOL, V66, P1656, DOI 10.1152/jappl.1989.66.4.1656; RAJALA R, 1991, J INTERN MED, V230, P125, DOI 10.1111/j.1365-2796.1991.tb00419.x; RECHTSCHAFFEN A, 1968, NIH204G U CAL LOS AN; WILHOIT SC, 1987, CHEST, V91, P654, DOI 10.1378/chest.91.5.654; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; YOUNG T, 1993, NEW ENGL J MED, V329, P1429; 1985, HLTH US 1985	24	148	155	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					493	501		10.7326/0003-4819-122-7-199504010-00003	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872583				2022-12-28	WOS:A1995QP00800003
J	HARRIS, A; MISIEWICZ, JJ				HARRIS, A; MISIEWICZ, JJ			HITTING HELICOBACTER-PYLORI FOR 4	LANCET			English	Editorial Material							HELICOBACTER-PYLORI; ERADICATION; THERAPY				HARRIS, A (corresponding author), CENT MIDDLESEX HOSP,NHS TRUST,DEPT GASTROENTEROL & NUTR,LONDON,ENGLAND.							AXON ATR, 1991, J GASTROEN HEPATOL, V6, P131, DOI 10.1111/j.1440-1746.1991.tb01452.x; BANATVALA N, 1994, GUT, V35, P1562, DOI 10.1136/gut.35.11.1562; BAZZOLI F, 1994, EUR J GASTROEN HEPAT, V6, P773, DOI 10.1097/00042737-199409000-00004; BAZZOLI F, 1993, GASTROENTEROLOGY, V104, pA40; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; Jaup B. H., 1994, American Journal of Gastroenterology, V89, P1400; JAUP BH, GASTROENTEROLOGY; LABENZ J, 1995, EUR J GASTROEN HEPAT, V7, P9; LOGAN RPH, 1991, LANCET, V338, P1249, DOI 10.1016/0140-6736(91)92111-E; MOAYYEDI P, 1994, GUT, V35, pF248; MOAYYEDI P, 1994, GUT, V35, pW63	11	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					806	807		10.1016/S0140-6736(95)92957-6	http://dx.doi.org/10.1016/S0140-6736(95)92957-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898223				2022-12-28	WOS:A1995QQ19500002
J	MATZUK, MM; KUMAR, TR; VASSALLI, A; BICKENBACH, JR; ROOP, DR; JAENISCH, R; BRADLEY, A				MATZUK, MM; KUMAR, TR; VASSALLI, A; BICKENBACH, JR; ROOP, DR; JAENISCH, R; BRADLEY, A			FUNCTIONAL-ANALYSIS OF ACTIVINS DURING MAMMALIAN DEVELOPMENT	NATURE			English	Article							PREIMPLANTATION MOUSE EMBRYOS; XENOPUS EMBRYOGENESIS; AXIAL STRUCTURES; EXPRESSION; MESODERM; INHIBIN; CLONING; INDUCE; GENES	ACTIVINS are dimeric (beta A beta A; beta B beta B; beta A beta B) members of the transforming growth factor-beta superfamily(1). They are widely expressed during murine development(1-6), are highly conserved during vertebrate evolution(1,7-11), and may be involved in mesoderm induction and neurulation in Xenopus laevis and Oryzias latipes(10-17). To investigate the function of mammalian activins in vivo, we generated mice with mutations either in activin-beta A or in both activin-beta A and activin-beta B. Activin-beta A-deficient mice develop to term but die within 24 h of birth. They lack whiskers and lower incisors and have defects in their secondary palates, including cleft palate, demonstrating that activin-beta A must have a role during craniofacial development. Mice lacking both activin subunits show the defects of both individual mutants but no additional defects, indicating that there is no functional redundancy between these proteins during embryogenesis. In contrast to observations in lower vertebrates(10-17), zygotic expression of activins is not essential for mesoderm formation in mice.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)	MATZUK, MM (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.		Vassalli, Anne/M-7866-2016	Vassalli, Anne/0000-0002-5314-5620; Bradley, Allan/0000-0002-2349-8839				ALBANO RM, 1994, DEVELOPMENT, V120, P803; ALBANO RM, 1993, DEVELOPMENT, V117, P711; BRADLEY A, 1987, TERATOCARCINOMAS EMB; CENTRELLA M, 1991, MOL CELL BIOL, V11, P250, DOI 10.1128/MCB.11.1.250; CONLON FL, 1994, DEVELOPMENT, V120, P1919; ESCH FS, 1987, MOL ENDOCRINOL, V1, P388, DOI 10.1210/mend-1-5-388; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; GE W, 1993, BIOCHEM BIOPH RES CO, V193, P711, DOI 10.1006/bbrc.1993.1683; GLUECKSOHN, 1961, MNI, V25, P12; GORLIN RJ, 1990, OXFORD MONOGRAPHS ME, V19, P693; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; KONDO M, 1991, BIOCHEM BIOPH RES CO, V181, P684, DOI 10.1016/0006-291X(91)91245-8; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LU RZ, 1993, BIOL REPROD, V49, P1163, DOI 10.1095/biolreprod49.6.1163; LUYTEN FP, 1994, EXP CELL RES, V210, P224, DOI 10.1006/excr.1994.1033; MANOVA K, 1992, MECH DEVELOP, V36, P141, DOI 10.1016/0925-4773(92)90065-R; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MITRANI E, 1990, CELL, V63, P495, DOI 10.1016/0092-8674(90)90446-L; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SATOKATA I, 1994, NAT GENET, V6, P348, DOI 10.1038/ng0494-348; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VALE WW, 1990, PEPTIDE GROWTH FACTO, V2; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WITTBRODT J, 1994, GENE DEV, V8, P1448, DOI 10.1101/gad.8.12.1448; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	31	497	508	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					354	356		10.1038/374354a0	http://dx.doi.org/10.1038/374354a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885473				2022-12-28	WOS:A1995QN63000058
J	SOAVE, R; JOHNSON, WD				SOAVE, R; JOHNSON, WD			CYCLOSPORA - CONQUEST OF AN EMERGING PATHOGEN	LANCET			English	Editorial Material							DIARRHEA; ORGANISM; TRAVELERS; NEPAL				SOAVE, R (corresponding author), CORNELL UNIV, MED CTR, NEW YORK HOSP, DIV INFECT DIS & INT MED, NEW YORK, NY 10021 USA.							ASHFORD RW, 1979, ANN TROP MED PARASIT, V73, P497, DOI 10.1080/00034983.1979.11687291; BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; CONNOR BA, 1993, ANN INTERN MED, V119, P377, DOI 10.7326/0003-4819-119-5-199309010-00005; HART AS, 1990, LANCET, V335, P169, DOI 10.1016/0140-6736(90)90042-4; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; WURTZ R, 1994, CLIN INFECT DIS, V18, P620, DOI 10.1093/clinids/18.4.620; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; 1991, MMWR-MORBID MORTAL W, V40, P325	13	19	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	1995	345	8951					667	668		10.1016/S0140-6736(95)90863-3	http://dx.doi.org/10.1016/S0140-6736(95)90863-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885121				2022-12-28	WOS:A1995QM73200004
J	CABELLI, RJ; HOHN, A; SHATZ, CJ				CABELLI, RJ; HOHN, A; SHATZ, CJ			INHIBITION OF OCULAR DOMINANCE COLUMN FORMATION BY INFUSION OF NT-4/5 OR BDNF	SCIENCE			English	Article							NERVE GROWTH-FACTOR; CATS VISUAL-CORTEX; NEUROTROPHIC FACTOR; MESSENGER-RNA; FACTOR FAMILY; MONOCULAR DEPRIVATION; MOLECULAR-CLONING; LIMBIC SEIZURES; STRIATE CORTEX; NGF	During the development of the visual system of higher mammals, axons from the lateral geniculate nucleus (LGN) become segregated into eye-specific patches (the ocular dominance columns) within their target, layer 4 of the primary visual cortex. This occurs as a consequence of activity-dependent synaptic competition between axons representing the two eyes, The possibility that this competition could be mediated through neurotrophin-receptor interactions was tested. Infusion of neurotrophin-4/5 (NT-4/5) or brain-derived neurotrophic factor (BDNF) into cat primary visual cortex inhibited column formation within the immediate vicinity of the infusion site but not elsewhere in the visual cortex. Infusion of nerve growth factor, neurotrophin 3 (NT-3), or vehicle solution did not affect column formation. These observations implicate TrkB, the common receptor for BDNF and NT-4/5, in the segregation of LGN axons into ocular dominance columns in layer 4. Moreover, they suggest that in addition to their better known roles in the prevention of cell death, neurotrophins may also mediate the activity-dependent control of axonal branching during development of the central nervous system.	UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720	University of California System; University of California Berkeley	CABELLI, RJ (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,BERKELEY,CA 94720, USA.				NATIONAL EYE INSTITUTE [R01EY002858, R37EY002858] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH048108] Funding Source: NIH RePORTER; NEI NIH HHS [EY06327, EY02858] Funding Source: Medline; NIMH NIH HHS [MH 48108] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLENDOERFER KL, 1994, J NEUROSCI, V14, P1795; ANTONINI A, 1993, J NEUROSCI, V13, P3549; BARDE YA, 1982, EMBO J, V1, P549, DOI 10.1002/j.1460-2075.1982.tb01207.x; BEAR MF, 1986, NATURE, V320, P172, DOI 10.1038/320172a0; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; CABELLI RJ, 1993, 23RD ANN M SOC NEUR; CARMIGNOTO G, 1993, J PHYSIOL-LONDON, V464, P343, DOI 10.1113/jphysiol.1993.sp019638; CASTREN E, 1992, P NATL ACAD SCI USA, V89, P9444, DOI 10.1073/pnas.89.20.9444; CHAO MV, 1992, NEURON, V9, P583, DOI 10.1016/0896-6273(92)90023-7; CHUN JJM, 1989, J COMP NEUROL, V282, P555, DOI 10.1002/cne.902820407; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COHENCORY S, 1991, J NEUROSCI, V11, P462; DIAMOND J, 1992, J NEUROSCI, V12, P1454; DOMENICI L, 1991, P NATL ACAD SCI USA, V88, P8811, DOI 10.1073/pnas.88.19.8811; ERNFORS P, 1991, NEURON, V7, P164; GALL CM, 1989, SCIENCE, V245, P758, DOI 10.1126/science.2549634; GHOSH A, 1994, J NEUROSCI, V14, P3862; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GU Q, 1994, P NATL ACAD SCI USA, V91, P8408, DOI 10.1073/pnas.91.18.8408; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; HAYASHI M, 1990, NEUROSCIENCE, V36, P683, DOI 10.1016/0306-4522(90)90011-R; HOHN A, 1990, NATURE, V344, P339, DOI 10.1038/344339a0; HOHN A, 1994, 24TH ANN M SOC NEUR; HOLTZMAN DM, 1992, NEURON, V9, P465, DOI 10.1016/0896-6273(92)90184-F; HUBEL DH, 1977, PHILOS T ROY SOC B, V278, P377, DOI 10.1098/rstb.1977.0050; IP NY, 1992, P NATL ACAD SCI USA, V89, P3060, DOI 10.1073/pnas.89.7.3060; ISAACSON LG, 1992, J COMP NEUROL, V326, P327, DOI 10.1002/cne.903260302; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; JONES KR, 1990, P NATL ACAD SCI USA, V87, P8060, DOI 10.1073/pnas.87.20.8060; LEIBROCK J, 1989, NATURE, V341, P149, DOI 10.1038/341149a0; LEVAY S, 1975, J COMP NEUROL, V159, P559, DOI 10.1002/cne.901590408; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LOHOF AM, 1993, NATURE, V363; MAFFEI L, 1992, J NEUROSCI, V12, P4651; MAISONPIERRE PC, 1990, SCIENCE, V247, P1446, DOI 10.1126/science.2321006; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PURVES D, 1988, NATURE, V336, P123, DOI 10.1038/336123a0; ROSENTHAL A, 1990, NEURON, V4, P767, DOI 10.1016/0896-6273(90)90203-R; SCHNELL L, 1994, NATURE, V367, P170, DOI 10.1038/367170a0; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; TIMMUSK T, 1993, EUR J NEUROSCI, V5, P605, DOI 10.1111/j.1460-9568.1993.tb00526.x; VAZQUEZ ME, 1991, NEUROREPORT, V2, P593, DOI 10.1097/00001756-199110000-00010; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	44	525	532	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1662	1666		10.1126/science.7886458	http://dx.doi.org/10.1126/science.7886458			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886458				2022-12-28	WOS:A1995QM39700042
J	BUSHMAN, F				BUSHMAN, F			TARGETING RETROVIRAL INTEGRATION	SCIENCE			English	Editorial Material											BUSHMAN, F (corresponding author), SALK INST BIOL STUDIES,INFECT DIS LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BUSHMAN FD, 1994, P NATL ACAD SCI USA, V91, P9233, DOI 10.1073/pnas.91.20.9233; BUSHMAN FD, 1990, SCIENCE, V249, P1555, DOI 10.1126/science.2171144; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; Coffin JM, 1990, VIROLOGY, V2, P1437; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; JI H, 1993, CELL, V73, P1; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KIRCHNER J, 1995, SCIENCE, V267, P1488, DOI 10.1126/science.7878467; SHIRAMIZU B, 1994, CANCER RES, V54, P2069	10	34	36	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1443	1444		10.1126/science.7878462	http://dx.doi.org/10.1126/science.7878462			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878462				2022-12-28	WOS:A1995QL49700023
J	CLARK, CLI				CLARK, CLI			CONTENT OF ADVERTISEMENTS FOR JUNIOR DOCTORS - IS THERE SUFFICIENT DETAIL	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether employers follow BMA guidelines on advertisements when advertising for junior doctors. Design-Survey of advertisements for junior doctors in the BMJ's classified advertisements supplement from 12 March to 14 May 1994. Subjects-300 advertisements for substantive posts for junior doctors. Outcome measures-Compliance with BMA guidelines, compared by grade, specialty, and employer (trust or regional health authority); observation of any useful information not included in the guidelines. Results-Only eight advertisements included all the recommended information. Amount of information given was related to grade, specialty, or employer in only one respect: advertisements for basic trainees were more likely than those for higher specialist trainees to include information on pay and hours of work (P<0.001). Conclusion-Advertisements for junior doctors in the BMJ do not comply with BMA guidelines and often contain little useful information for potential applicants.			CLARK, CLI (corresponding author), UNIV LONDON ROYAL FREE HOSP,DEPT SURG,LONDON NW3 2QG,ENGLAND.							1991, JUNIOR DOCTORS NEW D; 1993, HOSPITAL DOCTORS TRA	2	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					512	514		10.1136/bmj.310.6978.512	http://dx.doi.org/10.1136/bmj.310.6978.512			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888897	Green Published			2022-12-28	WOS:A1995QJ59800031
J	THURNHAM, DI				THURNHAM, DI			VITAMIN-A, IRON, AND HEMATOPOIESIS	LANCET			English	Editorial Material							CHILDREN; SUPPLEMENTATION; DEFICIENCY; MALARIA; MEASLES; TRIAL				THURNHAM, DI (corresponding author), UNIV ULSTER,DEPT BIOL & BIOMED SCI,HUMAN NUTR GRP,COLERAINE,LONDONDERRY,NORTH IRELAND.							COUTSOUDIS A, 1991, AM J CLIN NUTR, V54, P890, DOI 10.1093/ajcn/54.5.890; DeMaeyer E, 1985, World Health Stat Q, V38, P302; HUSSEY GD, 1990, NEW ENGL J MED, V323, P160, DOI 10.1056/NEJM199007193230304; MEJIA LA, 1979, J NUTR, V109, P129, DOI 10.1093/jn/109.1.129; RESNIKOFF S, 1992, EUR J CLIN NUTR, V46, P25; SHEARMAN CP, 1988, LANCET, V2, P906; SMITH AW, 1989, ANN TROP PAEDIATR, V9, P17, DOI 10.1080/02724936.1989.11748589; THURNHAM DI, 1991, T ROY SOC TROP MED H, V85, P194, DOI 10.1016/0035-9203(91)90017-S; UDOMKESMALEE E, 1992, AM J CLIN NUTR, V56, P50, DOI 10.1093/ajcn/56.1.50	9	20	21	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1312	1313		10.1016/0140-6736(93)92239-P	http://dx.doi.org/10.1016/0140-6736(93)92239-P			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901629				2022-12-28	WOS:A1993MJ03900002
J	JEEVAN, A; KRIPKE, ML				JEEVAN, A; KRIPKE, ML			OZONE DEPLETION AND THE IMMUNE-SYSTEM	LANCET			English	Article							HUMANS; RADIATION; INDUCTION; SKIN		UNIV TEXAS,MD ANDERSON CANC CTR,DEPT IMMUNOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center								COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; JEEVAN A, 1992, BIOL EFFECTS LIGHT, P83; KRIPKE ML, 1990, J NATL CANCER I, V82, P1392, DOI 10.1093/jnci/82.17.1392; VERMEER M, 1991, J INVEST DERMATOL, V97, P729, DOI 10.1111/1523-1747.ep12484259; YOSHIKAWA T, 1990, J INVEST DERMATOL, V95, P530, DOI 10.1111/1523-1747.ep12504877	5	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1159	1160		10.1016/0140-6736(93)92131-C	http://dx.doi.org/10.1016/0140-6736(93)92131-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901483				2022-12-28	WOS:A1993MF19800017
J	WRIGHT, SW; EDWARDS, KM; DECKER, MD; ZELDIN, MH				WRIGHT, SW; EDWARDS, KM; DECKER, MD; ZELDIN, MH			PERTUSSIS INFECTION IN ADULTS WITH PERSISTENT COUGH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							OUTBREAK; DIAGNOSIS; FACILITY	Objective.-To determine the prevalence of Bordetella pertussis infection in adult patients with persistent cough. Design.-Prospective case series. Setting.-Urban university hospital emergency department. Patients.-Convenience sample of 75 patients aged 18 years or older with a cough lasting 2 weeks or longer. Serum specimens from 67 patients without respiratory complaints were used to develop reference values. Interventions.-In patients with cough, nasopharyngeal culture and direct fluorescent antibody testing for B pertussis were performed and serum samples were obtained at the first visit and 1 month later. Serum specimens were assayed for antibody to pertussis toxin (PT) and filamentous hemagglutinin (FHA). Main Outcome Measures.-A subject with one or more of the following was defined as having a pertussis infection: a positive B pertussis culture result, a fourfold change in PT or FHA titer, and/or a single PT or FHA titer at least 2 SDs greater than the geometric mean of the control group. Results.-No subject tested culture positive for B pertussis. Sixteen (21%) (95% confidence interval [CI], 13% to 32%) of 75 subjects met the serologic criteria for pertussis infection; for 13 (81%; 95% CI, 54% to 96%) of the 16, the criteria were met by the initial serum specimen. In contrast, the geometric mean levels of antibody to PT and FHA for the remaining 59 subjects with cough did not differ from those of the control group. Clinical symptoms and the lymphocyte count did not differentiate patients with pertussis from those without the disease. Conclusion.-Pertussis is a common cause of persistent cough in adults and should be considered in the differential diagnosis. Clinical symptoms, pertussis culture, direct fluorescent antibody testing, and lymphocytosis are of limited value in making the diagnosis.	VANDERBILT UNIV,MED CTR,DEPT PEDIAT,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT PREVENT MED,DIV INFECT DIS,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT MED,DIV INFECT DIS,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University; Vanderbilt University	WRIGHT, SW (corresponding author), VANDERBILT UNIV,MED CTR,DEPT EMERGENCY MED,703 OXFORD HOUSE,NASHVILLE,TN 37232, USA.			Decker, Michael/0000-0003-1008-7472	PHS HHS [N0I-M-02645] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADDISS DG, 1991, J INFECT DIS, V164, P704, DOI 10.1093/infdis/164.4.704; BRAMAN SS, 1985, PRIMARY CARE, V12, P217; CHERRY JD, 1989, WESTERN J MED, V150, P319; CHRISTIE CDC, 1994, NEW ENGL J MED, V331, P16, DOI 10.1056/NEJM199407073310104; CROMER BA, 1993, AM J DIS CHILD, V147, P575, DOI 10.1001/archpedi.1993.02160290081031; EDWARDS KM, 1993, JAMA-J AM MED ASSOC, V269, P53, DOI 10.1001/jama.269.1.53; FARIZO KM, 1992, CLIN INFECT DIS, V14, P708, DOI 10.1093/clinids/14.3.708; HE QS, 1994, J PEDIATR-US, V124, P421, DOI 10.1016/S0022-3476(94)70365-5; HERWALDT LA, 1993, JAMA-J AM MED ASSOC, V269, P93, DOI 10.1001/jama.269.1.93; HERWALDT LA, 1991, ARCH INTERN MED, V109, P1510; LINNEMANN CC, 1977, ANNU REV MED, V28, P179, DOI 10.1146/annurev.me.28.020177.001143; LONG SS, 1990, J INFECT DIS, V161, P480, DOI 10.1093/infdis/161.3.480; Manclark CR, 1986, MANUAL CLIN LAB IMMU, V3rd, P388; MARCHANT CD, 1994, J INFECT DIS, V169, P1297, DOI 10.1093/infdis/169.6.1297; MERTSOLA J, 1983, J PEDIATR-US, V103, P359, DOI 10.1016/S0022-3476(83)80403-X; MINK CM, 1992, CLIN INFECT DIS, V14, P464, DOI 10.1093/clinids/14.2.464; ONORATO IM, 1987, PEDIATR INFECT DIS J, V6, P145, DOI 10.1097/00006454-198702000-00002; PATRIARCA PA, 1988, AM J PUBLIC HEALTH, V78, P833, DOI 10.2105/AJPH.78.7.833; ROBERTSON PW, 1987, MED J AUSTRALIA, V147, P522; STEKETEE RW, 1988, J INFECT DIS, V157, P441, DOI 10.1093/infdis/157.3.441; STEKETEE RW, 1988, J INFECT DIS, V157, P434, DOI 10.1093/infdis/157.3.434; 1994, MMWR-MORBID MORTAL W, V42, P959; 1994, MMWR-MORBID MORTAL W, V42, P952	23	194	207	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1044	1046		10.1001/jama.273.13.1044	http://dx.doi.org/10.1001/jama.273.13.1044			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897789				2022-12-28	WOS:A1995QP89000036
J	GILDEN, DL; THORNTON, T; MALLON, MW				GILDEN, DL; THORNTON, T; MALLON, MW			1/F NOISE IN HUMAN COGNITION	SCIENCE			English	Article							SELF-ORGANIZED CRITICALITY; NONCONSERVATIVE MODELS; 1-F NOISE	When a person attempts to produce from memory a given spatial or temporal interval, there is inevitably some error associated with the estimate. The time course of this error was measured in a series of experiments where subjects repeatedly attempted to replicate given target intervals. Sequences of the errors in both spatial and temporal replications were found to fluctuate as 1/f noises. 1/f noise is encountered in a wide variety of physical systems and is theorized to be a characteristic signature of complexity.			GILDEN, DL (corresponding author), UNIV TEXAS,DEPT PSYCHOL,AUSTIN,TX 78712, USA.							ALLAN LG, 1979, PERCEPT PSYCHOPHYS, V26, P340, DOI 10.3758/BF03204158; BABCOCK KL, 1990, PHYS REV LETT, V64, P2168, DOI 10.1103/PhysRevLett.64.2168; BAK P, 1988, PHYS REV A, V38, P364, DOI 10.1103/PhysRevA.38.364; BAK P, 1989, NATURE, V342, P780, DOI 10.1038/342780a0; BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381; BAK P, 1990, PHYSICA A, V163, P403, DOI 10.1016/0378-4371(90)90348-V; BAK P, 1992, PHYSICA A, V191, P41, DOI 10.1016/0378-4371(92)90503-I; BORING EG, 1948, F PSYCH; CHRISTENSEN K, 1992, PHYS REV LETT, V68, P2417, DOI 10.1103/PhysRevLett.68.2417; DUTTA P, 1981, REV MOD PHYS, V53, P497, DOI 10.1103/RevModPhys.53.497; Guilford JP, 1927, AM J PSYCHOL, V38, P534, DOI 10.2307/1414394; JENSEN HJ, 1990, PHYS REV LETT, V64, P3103, DOI 10.1103/PhysRevLett.64.3103; MANDELBROT BB, 1968, WATER RESOUR RES, V4, P909, DOI 10.1029/WR004i005p00909; MEIJER PHE, 1981, 6TH INT S NOISE PHYS; MONTROLL EW, 1982, P NATL ACAD SCI USA, V79, P3380, DOI 10.1073/pnas.79.10.3380; MUSHA T, 1976, JPN J APPL PHYS, V15, P1271, DOI 10.1143/JJAP.15.1271; Press W. H., 1978, Comments on Astrophysics. Comments on Modern Physics: Part C, V7, P103; Press W. H., 1992, NUMERICAL RECIPES, P550; Thomas, 1986, HDB PERCEPTION HUMAN, VII; VANVLEIT CM, 1987, 9TH INT S NOIS PHYS; VOSS RF, 1978, J ACOUST SOC AM, V63, P258, DOI 10.1121/1.381721; VOSS RF, 1992, PHYS REV LETT, V68, P3805, DOI 10.1103/PhysRevLett.68.3805; WEARDEN JH, 1991, LEARN MOTIV, V22, P59, DOI 10.1016/0023-9690(91)90017-3; WEISSMAN MB, 1988, REV MOD PHYS, V60, P537, DOI 10.1103/RevModPhys.60.537; West B. J., 1989, International Journal of Modern Physics B, V3, P795, DOI 10.1142/S0217979289000609; Wing A.M., 1980, ADV PSYCHOL, V1, P469, DOI [10.1016/S0166-4115(08)61963-9, DOI 10.1016/S0166-4115(08)61963-9, DOI 10.1016/S0166-4115(08)61963.9]; WING AM, 1973, PERCEPT PSYCHOPHYS, V14, P5, DOI 10.3758/BF03198607	27	474	480	1	37	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1837	1839		10.1126/science.7892611	http://dx.doi.org/10.1126/science.7892611			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	QN702	7892611				2022-12-28	WOS:A1995QN70200044
J	SEABORG, GT				SEABORG, GT			MY CAREER AS A RADIOISOTOPE HUNTER	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											SEABORG, GT (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,OFF ASSOCIATE DIRECTOR AT LARGE,BLDG 70A,ROOM 3307,BERKELEY,CA 94720, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					961	964		10.1001/jama.273.12.961	http://dx.doi.org/10.1001/jama.273.12.961			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884957				2022-12-28	WOS:A1995QM17300033
J	HAMMEL, HB; BEEBE, RF; INGERSOLL, AP; ORTON, GS; MILLS, JR; SIMON, AA; CHODAS, P; CLARKE, JT; DEJONG, E; DOWLING, TE; HARRINGTON, J; HUBER, LF; KARKOSCHKA, E; SANTORI, CM; TOIGO, A; YEOMANS, D; WEST, RA				HAMMEL, HB; BEEBE, RF; INGERSOLL, AP; ORTON, GS; MILLS, JR; SIMON, AA; CHODAS, P; CLARKE, JT; DEJONG, E; DOWLING, TE; HARRINGTON, J; HUBER, LF; KARKOSCHKA, E; SANTORI, CM; TOIGO, A; YEOMANS, D; WEST, RA			HST IMAGING OF ATMOSPHERIC PHENOMENA CREATED BY THE IMPACT OF COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article							GREAT RED SPOT; JUPITERS	Hubble Space Telescope (HST) images reveal major atmospheric changes created by the collision of comet Shoemaker-Levy 9 with Jupiter. Plumes rose to 3000 kilometers with ejection velocities on the order of 10 kilometers second(-1); some plumes were visible in the shadow of Jupiter before rising into sunlight. During some impacts, the incoming bolide may have been detected. Impact times were on average about 8 minutes later than predicted. Atmospheric waves were seen with a wave front speed of 454 +/- 20 meters second(-1). The HST images reveal impact site evolution and record the overall change in Jupiter's appearance as a result of the bombardment.	MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA; CALTECH, DIV GEOL & PLANETARY SCI, PASADENA, CA 91125 USA; CALTECH, JET PROP LAB, PASADENA, CA 91109 USA; UNIV MICHIGAN, DEPT ATMOSPHER & OCEAN SCI, ANN ARBOR, MI 48109 USA; UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; NEW MEXICO STATE UNIV, DEPT ASTRON, LAS CRUCES, NM 88003 USA	Massachusetts Institute of Technology (MIT); California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Michigan System; University of Michigan; University of Arizona; New Mexico State University	HAMMEL, HB (corresponding author), MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA.		Clarke, John/C-8644-2013; Dowling, Timothy E/J-4537-2013; Simon, Amy/C-8020-2012; Harrington, Joseph/E-6250-2011; Santori, Charles/A-7314-2009; Orton, Glenn/AAD-9862-2020	Dowling, Timothy E/0000-0002-7400-2274; Simon, Amy/0000-0003-4641-6186; Harrington, Joseph/0000-0002-8955-8531				AHRENS TJ, 1994, GEOPHYS RES LETT, V21, P1087, DOI 10.1029/94GL01325; [Anonymous], COMMUNICATION; Atreya S. K., 1986, ATMOSPHERES IONOSPHE; BELTON MJS, 1992, SPACE SCI REV, V60, P413, DOI 10.1007/BF00216864; BOSLOUGH MB, 1994, GEOPHYS RES LETT, V21, P1555, DOI 10.1029/94GL01582; BRONSHTEN VA, 1983, PHYSICS METEORIC PHE; BURROWS CJ, 1994, WIDE FIELD PLANETARY; CHODAS PW, COMMUNICATION; CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; DOWLING T, 1980, CLASSICAL MECHANICS, P40; DOWLING TE, 1989, J ATMOS SCI, V46, P3256, DOI 10.1175/1520-0469(1989)046<3256:JGRSAA>2.0.CO;2; HARRINGTON J, 1994, NATURE, V368, P525, DOI 10.1038/368525a0; HERBST T, UNPUB; HOLTZMAN JA, IN PRESS PUBL ASTRON; INGERSOLL AP, 1994, GEOPHYS RES LETT, V21, P1083, DOI 10.1029/94GL01057; INGERSOLL AP, 1981, J GEOPHYS RES-SPACE, V86, P8733, DOI 10.1029/JA086iA10p08733; INGERSOLL AP, UNPUB; LOW MMM, 1986, ICARUS, V65, P353, DOI 10.1016/0019-1035(86)90143-0; MACLOW MM, 1994, B AM ASTRON SOC, V26, P926; MARCUS PS, 1988, NATURE, V331, P693, DOI 10.1038/331693a0; Martin T, COMMUNICATION; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; SCOTTI J, 1994, 26TH ANN DIV PLAN SC; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEISSMAN P, 1994, NATURE, V370, P94, DOI 10.1038/370094a0; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; WILLIAMS GP, 1988, J ATMOS SCI, V45, P207, DOI 10.1175/1520-0469(1988)045<0207:TSAGOR>2.0.CO;2; [No title captured]	31	177	181	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	1995	267	5202					1288	1296		10.1126/science.7871425	http://dx.doi.org/10.1126/science.7871425			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871425				2022-12-28	WOS:A1995QK06800030
J	HEIM, MH; KERR, IM; STARK, GR; DARNELL, JE				HEIM, MH; KERR, IM; STARK, GR; DARNELL, JE			CONTRIBUTION OF STAT SH2 GROUPS TO SPECIFIC INTERFERON SIGNALING BY THE JAK-STAT PATHWAY	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; MUTANT-CELL LINE; TRANSCRIPTION FACTOR; TRANSDUCTION; GAMMA; ALPHA; COMPLEMENTATION; PHOSPHORYLATION; POLYPEPTIDE; ACTIVATION	In response to specific ligands, various STAT proteins (signal transducers and activators of transcription) are phosphorylated on tyrosine by Jak protein kinases and translocated to the nucleus to direct gene transcription. Selection of a STAT at the interferon gamma receptor as well as specific STAT dimer formation depended on the presence of particular SH2 groups (phosphotyrosine-binding domains), whereas the amino acid sequence Surrounding the phosphorylated tyrosine on the STAT could vary. Thus, SH2 groups in STAT proteins may play crucial roles in specificity at the receptor kinase complex and in subsequent dimerization, whereas the kinases are relatively nonspecific.	ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021; IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND; CLEVELAND CLIN FDN,RES INST,CLEVELAND,OH 44195	Rockefeller University; Cancer Research UK; Cleveland Clinic Foundation			Heim, Markus/A-7526-2008	Heim, Markus/0000-0002-7523-4894	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI034420, R01AI032489, R01AI034420] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32489, AI34420] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARTGETSINGER LS, 1993, CELL, V74, P237; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HEIM MH, UNPUB; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; IMPROTA T, 1994, P NATL ACAD SCI USA, V91, P4776, DOI 10.1073/pnas.91.11.4776; LEUNG S, IN PRESS MOL CELL BI; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; QURESHI SA, 1991, J BIOL CHEM, V266, P20594; QURESHI SA, UNPUB; REIS LFL, 1992, EMBO J, V11, P185, DOI 10.1002/j.1460-2075.1992.tb05041.x; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAL K, 1994, NATURE, V366, P580; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG ZP, UNPUB	25	312	318	0	13	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1347	1349		10.1126/science.7871432	http://dx.doi.org/10.1126/science.7871432			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871432				2022-12-28	WOS:A1995QK06800045
J	LEFROY, DG; SCOTT, J; OAKLEY, CM; DAVIES, DW; DAVIES, K; WHYTE, M				LEFROY, DG; SCOTT, J; OAKLEY, CM; DAVIES, DW; DAVIES, K; WHYTE, M			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - CARDIAC-ARREST AND HYPERTROPHIC CARDIOMYOPATHY	BRITISH MEDICAL JOURNAL			English	Discussion							IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR; CLINICAL MANIFESTATIONS; PATHO-PHYSIOLOGY; INTERRELATIONS; THERAPY		ST MARYS HOSP,LONDON,ENGLAND	Imperial College London	LEFROY, DG (corresponding author), HAMMERSMITH HOSP,DEPT CARDIOL,LONDON W12 0HS,ENGLAND.							ANAN R, 1994, J CLIN INVEST, V93, P280, DOI 10.1172/JCI116957; BOTVINICK EH, 1993, J AM COLL CARDIOL, V22, P805, DOI 10.1016/0735-1097(93)90194-6; CAMICI P, 1991, J AM COLL CARDIOL, V17, P879, DOI 10.1016/0735-1097(91)90869-B; DELISSOVOY G, 1993, PROG CARDIOVASC DIS, V36, P209, DOI 10.1016/0033-0620(93)90014-5; DILSIZIAN V, 1993, J AM COLL CARDIOL, V22, P796, DOI 10.1016/0735-1097(93)90193-5; FANANAPAZIR L, 1991, AM J CARDIOL, V67, P280, DOI 10.1016/0002-9149(91)90560-8; FANANAPAZIR L, 1994, CIRCULATION, V89, P22, DOI 10.1161/01.CIR.89.1.22; FANANAPAZIR L, 1992, CIRCULATION, V86, P730, DOI 10.1161/01.CIR.86.3.730; GILLIGAN DM, 1992, CIRCULATION, V85, P2140, DOI 10.1161/01.CIR.85.6.2140; LEFROY DC, 1993, J AM COLL CARDIOL, V22, P1653, DOI 10.1016/0735-1097(93)90591-N; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1978, AM J CARDIOL, V41, P1133, DOI 10.1016/0002-9149(78)90870-6; MOSS AJ, 1993, PROG CARDIOVASC DIS, V36, P85, DOI 10.1016/0033-0620(93)90001-T; POWELL AC, 1993, CIRCULATION, V88, P1083, DOI 10.1161/01.CIR.88.3.1083; TROUTON TG, 1993, PROG CARDIOVASC DIS, V36, P195, DOI 10.1016/0033-0620(93)90013-4; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703	17	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1277	1279		10.1136/bmj.309.6964.1277	http://dx.doi.org/10.1136/bmj.309.6964.1277			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888852	Green Published			2022-12-28	WOS:A1994PT03300027
J	[Anonymous]				[Anonymous]			HAS THE HOLY-SEE BECOME AN NGO	NATURE			English	Editorial Material																		1994, NATURE, V370, P583	1	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	SEP 15	1994	371	6494					185	185						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	PG290	7872972				2022-12-28	WOS:A1994PG29000001
J	BONITA, R; BROAD, JB; BEAGLEHOLE, R				BONITA, R; BROAD, JB; BEAGLEHOLE, R			CHANGES IN STROKE INCIDENCE AND CASE-FATALITY IN AUCKLAND, NEW-ZEALAND, 1981-91	LANCET			English	Article							CEREBROVASCULAR-DISEASE; COMMUNITY; DECLINE; PROJECT; TRENDS; RATES	The explanation for the substantial decline in stroke death rates can be investigated only by measuring trends in stroke incidence and case-fatality. Two community-based studies carried out in Auckland, New Zealand, in 1981 and 1991 used comparable methods and definitions, met criteria for well-designed studies, and had the power to detect small changes in incidence and case-fatality rates. 703 events (representing 50% of all strokes) were registered in 1981 and 1735 events in 1991. 521 (74.1%) and 1255 (72.3%) events in 1981 and 1991, respectively, were first-ever (in a lifetime) strokes. Although there was no change in overall stroke incidence between 1981 and 1991, there were changes in age and sex groups. The incidence rate among women younger than 75 years rose by a fifth (rate ratio 1.23 [95% CI 1.04-1.47]), whereas that in men of 75 years and older fell by a third (rate ratio 0.67 [0.54-0.82]). The 28-day case-fatality declined from 27.1 (21.7-32.6)% to 21.9 (18.1-25.7)% in men and from 37.6 (31.8-43.5)%to 25.8 (22.3-29.4)% in women from 1981 to 1991, but the decline was not statistically significant in any age or sex group. These findings suggest that we need to reappraise strategies for the prevention of stroke and assess the implications of improved survival in elderly stroke patients.	UNIV AUCKLAND,SCH MED,DEPT MED,AUCKLAND,NEW ZEALAND; UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,AUCKLAND,NEW ZEALAND	University of Auckland; University of Auckland			Broad, Joanna B/D-1194-2010	Broad, Joanna B/0000-0003-0157-7031				ANDERSON CS, 1993, MED J AUSTRALIA, V158, P80, DOI 10.5694/j.1326-5377.1993.tb137528.x; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BONITA R, 1983, COMMUNITY HEALTH ST, V7, P111; BONITA R, 1990, STROKE, V21, P989, DOI 10.1161/01.STR.21.7.989; BONITA R, 1984, AM J EPIDEMIOL, V120, P236, DOI 10.1093/oxfordjournals.aje.a113885; BONITA R, 1993, LANCET, V341, P1510, DOI 10.1016/0140-6736(93)90640-3; BRODERICK JP, 1989, STROKE, V20, P577, DOI 10.1161/01.STR.20.5.577; FRASER GE, 1978, INT J EPIDEMIOL, V7, P277, DOI 10.1093/ije/7.3.277; GARRAWAY WM, 1983, MAYO CLIN PROC, V58, P520; HARMSEN P, 1992, STROKE, V23, P1410, DOI 10.1161/01.STR.23.10.1410; JORGENSEN HS, 1992, STROKE, V23, P1701, DOI 10.1161/01.STR.23.12.1701; LINDENSTROM E, 1992, STROKE, V23, P28, DOI 10.1161/01.STR.23.1.28; MALMGREN R, 1987, LANCET, V2, P1196; MALMGREN R, 1989, BRIT MED J, V298, P656, DOI 10.1136/bmj.298.6674.656; SANDERCOCK P, 1985, BRIT MED J, V290, P193, DOI 10.1136/bmj.290.6463.193; TERENT A, 1988, STROKE, V19, P598, DOI 10.1161/01.STR.19.5.598; Waterhouse J., 1976, CANCER INCIDENCE 5 C, V3, P456; 1988, J CLIN EPIDEMIOL, V41, P105	18	148	149	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1470	1473		10.1016/0140-6736(93)92938-P	http://dx.doi.org/10.1016/0140-6736(93)92938-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902487				2022-12-28	WOS:A1993ML21700014
J	NICHOLLS, N				NICHOLLS, N			EL-NINO-SOUTHERN OSCILLATION AND VECTOR-BORNE DISEASE	LANCET			English	Article											NICHOLLS, N (corresponding author), BUR METEOROL RES CTR,POB 1289K,MELBOURNE 3001,AUSTRALIA.		Nicholls, Neville/A-1240-2008	Nicholls, Neville/0000-0002-1298-4356				LIEHNE PFS, 1988, GREENHOUSE PLANNING, P752; MEEHL GA, 1993, SCIENCE, V260, P1101, DOI 10.1126/science.260.5111.1101; NICHOLLS N, 1986, AUST J EXP BIOL MED, V64, P587, DOI 10.1038/icb.1986.62; Nicholls N., 1991, TELECONNECTIONS LINK, P493; 1990, CLIMATE CHANGE IPCC	5	105	110	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1284	1285		10.1016/0140-6736(93)92368-4	http://dx.doi.org/10.1016/0140-6736(93)92368-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901589				2022-12-28	WOS:A1993MH56600018
J	FIORETTO, P; MAUER, SM; BILOUS, RW; GOETZ, FC; SUTHERLAND, DER; STEFFES, MW				FIORETTO, P; MAUER, SM; BILOUS, RW; GOETZ, FC; SUTHERLAND, DER; STEFFES, MW			EFFECTS OF PANCREAS TRANSPLANTATION ON GLOMERULAR STRUCTURE IN INSULIN-DEPENDENT DIABETIC-PATIENTS WITH THEIR OWN KIDNEYS	LANCET			English	Article							ISLET TRANSPLANTATION; NEPHROPATHY; MELLITUS; SURFACE; VOLUME; RATS	Pancreas transplantation prevents or retards development of earlY diabetic glomerular lesions in renal allografts transplanted to patients with insulin-dependent diabetes mellitus (IDDM), but its effect on established renal lesions in native kidneys of such patients is unknown. Renal biopsy samples were taken before and 5 years after pancreas transplantation from 13 non-uraemic IDDM patients and compared with baseline and 5-year biopsy samples from 10 persistently hyperglycaemic IDDM patients who did not undergo transplantation. The two groups were similar in age, duration of diabetes, metabolic control, renal function, and blood pressure. Glomerular structures were measured by standard morphometric techniques. Haemoglobin A1 concentrations fell to within the normal range after pancreas transplantation but did not change in the comparison group. Glomerular basement membrane width did not significantly change in either group. Glomerular volume decreased and mesangial fractional volume increased in the pancreas transplant recipients but there was no significant change in total mesangial volume over 5 years. By contrast, both glomerular volume and mesangial fractional volume increased in the comparison patients, resulting in increased total mesangial volume. Diabetic glomerular lesions in patients with their own kidneys were not ameliorated by pancreas transplantation, despite 5 years of normoglycaemia. Pancreas transplantation can correct severe metabolic instability and thus improve quality of life, but it cannot yet be recommended for the treatment of established lesions of diabetic nephropathy.	UNIV MINNESOTA,SCH MED,DEPT PEDIAT,DULUTH,MN 55812; UNIV MINNESOTA,SCH MED,DEPT MED,DULUTH,MN 55812; UNIV MINNESOTA,SCH MED,DEPT SURG,DULUTH,MN 55812; UNIV MINNESOTA,SCH MED,DEPT LAB MED & PATHOL,DULUTH,MN 55812; MIDDLESBROUGH GEN HOSP,DEPT MED,MIDDLESBROUGH,ENGLAND	University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth; University of Minnesota System; University of Minnesota Duluth			fioretto, paola/AHD-4415-2022	FIORETTO, PAOLA/0000-0003-3445-0387	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017697, P01DK013083, R01DK043605] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-17697, DK-43605, DK-13083] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARBOSA J, 1992, DIABETES S1, V41; BERTANI T, 1991, KIDNEY INT, V40, P243, DOI 10.1038/ki.1991.206; BILOUS RW, 1989, NEW ENGL J MED, V321, P80, DOI 10.1056/NEJM198907133210204; BILOUS RW, 1989, DIABETES, V38, P1142, DOI 10.2337/diabetes.38.9.1142; BOHMAN SO, 1985, DIABETES, V34, P306, DOI 10.2337/diabetes.34.3.306; De Francisco A M, 1987, J Diabet Complications, V1, P128, DOI 10.1016/S0891-6632(87)80070-3; ELLIS EN, 1986, KIDNEY INT, V29, P889, DOI 10.1038/ki.1986.82; ELLIS EN, 1986, METHODS DIABETES RES, V2, P633; FUETREN G, 1992, NEW ENGL J MED, V326, P1654; JENSEN EB, 1979, J MICROSC-OXFORD, V115, P19, DOI 10.1111/j.1365-2818.1979.tb00149.x; KENNEDY WR, 1990, NEW ENGL J MED, V322, P1031, DOI 10.1056/NEJM199004123221503; MAUER SM, 1984, J CLIN INVEST, V74, P1143, DOI 10.1172/JCI111523; MYERS BD, 1988, KIDNEY INT, V33, P590, DOI 10.1038/ki.1988.38; ORLOFF MJ, 1986, DIABETES, V35, P347, DOI 10.2337/diabetes.35.3.347; OSTERBY R, 1980, DIABETOLOGIA, V18, P493; PEREJDA AJ, 1982, COLLAGEN REL RES, V2, P83; RAMSAY RC, 1988, NEW ENGL J MED, V318, P208, DOI 10.1056/NEJM198801283180403; ROY S, 1990, P NATL ACAD SCI USA, V87, P404, DOI 10.1073/pnas.87.1.404; STEFFES MW, 1980, DIABETES, V29, P509, DOI 10.2337/diab.29.7.509; STEFFES MW, 1979, LAB INVEST, V41, P116; STEFFES MW, 1992, DIABETES, V41, P679, DOI 10.2337/diabetes.41.6.679; SUTHERLAND DER, 1989, ANN SURG, V210, P274, DOI 10.1097/00000658-198909000-00003; SUTHERLAND DER, 1988, SURGERY, V104, P453; ZEHRER CL, 1991, DIABETOLOGIA S1, V34, P145	25	131	132	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1193	1196		10.1016/0140-6736(93)92183-T	http://dx.doi.org/10.1016/0140-6736(93)92183-T			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901527				2022-12-28	WOS:A1993MG27400007
J	THURSZ, MR; KWIATKOWSKI, D; ALLSOPP, CEM; GREENWOOD, BM; THOMAS, HC; HILL, AVS				THURSZ, MR; KWIATKOWSKI, D; ALLSOPP, CEM; GREENWOOD, BM; THOMAS, HC; HILL, AVS			ASSOCIATION BETWEEN AN MHC CLASS-II ALLELE AND CLEARANCE OF HEPATITIS-B VIRUS IN THE GAMBIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE MALARIA; HLA ANTIGENS; WEST-AFRICA; INFECTION	Background. The course of hepatitis B virus (HBV) infection does not appear to be determined by variations in viral virulence and may be influenced by the host immune response. We studied the distribution of human leukocyte antigens in children and adult men in the Gambia who spontaneously recovered from HBV infection as compared with the distribution of these antigens in subjects with persistent infection. Methods. In a two-stage, case-control study, we analyzed the frequency of MHC class I antigens and class II haplotypes in subjects with either transient or persistent HBV infection. MHC class I typing was performed by microlymphocytotoxicity assays. MHC class II typing was performed with analysis of restriction-fragment-length polymorphisms (RFLPs), supplemented by other techniques. Results. In the first stage (the study of children up to the age of 10 years), the RFLP pattern 25-1, which includes the class II allele HLA-DRB1*1302, was found in 58 of 218 subjects with transient HBV infection (26.6 percent) and 30 of 185 subjects with persistent infection (16.2 percent) (relative risk of carrying the 25-1 pattern in the persistently infected group as compared with the transiently infected group, 0.53; 95 percent confidence interval, 0.32 to 0.90; P=0.012). In the second stage (the study of adults), HLA-DRB1*1302 was found in 50 of 195 subjects with transient HBV infection (25.6 percent) and in 3 of 40 subjects with persistent infection (7.5 percent) (relative risk, 0.24; 95 percent confidence interval, 0.04 to 0.80; P=0.012). The RFLP pattern 13-2, which includes the class II allele DRB1*1301, was less frequent in children with persistent infection than in those with transient infection, an association that was neither confirmed nor excluded by the data on adults. Possible associations with HLA class I antigens found in children were not supported by the data on adults. Conclusions. The MHC class II allele DRB1*1302 was associated with protection against persistent HBV infection among both children and adults in the Gambia.	UNIV OXFORD,JOHN RADCLIFFE HOSP,INST MOLEC MED,OXFORD OX3 9DU,ENGLAND; MRC LABS,FAJARA,SENEGAL	University of Oxford	THURSZ, MR (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,ACAD DEPT MED,HEPATOL UNIT,LONDON W2 1NY,ENGLAND.		HILL, Adrian V>S>/C-1306-2008; Thomas, Howard C/A-3152-2009	Thursz, Mark/0000-0002-8218-192X; Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALMARRI A, 1994, LANCET, V344, P128; APPLE RJ, 1994, NAT GENET, V6, P157, DOI 10.1038/ng0294-157; BEASLEY RP, 1981, LANCET, V2, P1129; BOTHA JF, 1984, LANCET, V1, P1210; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FERRARI C, 1990, J IMMUNOL, V145, P3442; FORZANI B, 1984, HEPATOLOGY, V4, P1107, DOI 10.1002/hep.1840040602; HERMASZEWSKI RA, 1993, Q J MED, V86, P31; HILL AVS, 1992, J ROY COLL PHYS LOND, V26, P11; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; HILL AVS, 1992, P NATL ACAD SCI USA, V89, P2277, DOI 10.1073/pnas.89.6.2277; KASLOW RA, 1981, EPIDEMIOL REV, V3, P90, DOI 10.1093/oxfordjournals.epirev.a036241; KIIRE CF, 1990, VACCINE, V8, pS107, DOI 10.1016/0264-410X(90)90229-F; KROGSGAARD K, 1987, HEPATOLOGY, V7, P37, DOI 10.1002/hep.1840070109; LEPAGE V, 1981, TISSUE ANTIGENS, V18, P105, DOI 10.1111/j.1399-0039.1981.tb01372.x; MARINIER E, 1985, J PEDIATR-US, V106, P843, DOI 10.1016/S0022-3476(85)80371-1; MCGUIRE W, 1994, NATURE, V371, P508, DOI 10.1038/371508a0; RYDER RW, 1984, LANCET, V2, P449; RYDER RW, 1992, AM J EPIDEMIOL, V136, P1122, DOI 10.1093/oxfordjournals.aje.a116578; SCULLY LJ, 1990, HEPATOLOGY, V12, P1111, DOI 10.1002/hep.1840120506; TSAI SL, 1992, J CLIN INVEST, V89, P87, DOI 10.1172/JCI115590; TSUJI K, 1992, 11TH HLA 1991 P ANN; VANHATTUM J, 1987, HEPATOLOGY, V7, P11, DOI 10.1002/hep.1840070104	25	367	398	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1065	1069		10.1056/NEJM199504203321604	http://dx.doi.org/10.1056/NEJM199504203321604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898524	Bronze, Green Accepted			2022-12-28	WOS:A1995QT18700004
J	ROMAN, GC				ROMAN, GC			ON POLITICS AND HEALTH - AN EPIDEMIC OF NEUROLOGIC DISEASE IN CUBA	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Political decisions may cause disease. During 1992 and 1993, an epidemic of neuropathy in Cuba-largely overlooked by U.S. physicians-affected more than 50 000 persons and caused optic neuropathy, deafness, myelopathy, and sensory neuropathy. Patients with the neurologic disease responded to B group vitamins, and oral vitamin supplementation of the population curbed the epidemic. Dietary restrictions and excessive carbohydrate intake were the immediate cause of the epidemic; however, the primary cause might have been political. Political changes in eastern Europe had major repercussions on Cuba's economy and food supply. In turn, these changes compounded the effects of internal political decisions in the island, leading toward isolationism and economic dependence on the former Soviet Union. Also, for more than 30 years, the United States has maintained an economic embargo against Cuba. In 1992, the U.S. embargo was tightened by the Torricelli amendment (or the Cuba Democracy Act), which prohibited third-country subsidiaries of U.S. companies from trading with Cuba and prevented food and medicines from reaching the island; this amendment produced a virtual economic blockade. Penuries resulting from all these political events resulted in the largest epidemic of neurologic disease in this century. Physicians may need to use their influence to modify political decisions when these decisions result in adverse health consequences. The American Academy of Neurology has issued a plea to encourage physicians and other health personnel to support efforts leading to lifting of the U.S. embargo against Cuba for humanitarian reasons.	NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA								BELOTE JH, 1967, CORREGIDOR SAGA FORT; BORRAJERO I, 1994, J NEUROL SCI, V127, P68, DOI 10.1016/0022-510X(94)90137-6; CRUICKSHANK EK, 1946, LANCET, V251, P369; Cruickshank EK, 1976, HDB CLIN NEUROLOGY, V28, P1; DENNYBROWN D, 1947, MEDICINE, V26, P41, DOI 10.1097/00005792-194702000-00002; Gay John, 1994, Boletin de la Oficina Sanitaria Panamericana, V117, P389; Kerr E.B., 1985, SURRENDER SURVIVAL E; KING JH, 1955, AM J OPHTHALMOL, V39, P173, DOI 10.1016/0002-9394(55)90166-5; Kirkpatrick A F, 1994, J Fla Med Assoc, V81, P681; LINCOFF NS, 1993, JAMA-J AM MED ASSOC, V270, P511, DOI 10.1001/jama.270.4.511; NEWMAN NJ, 1994, AM J OPHTHALMOL, V118, P158, DOI 10.1016/S0002-9394(14)72895-8; PERAITA M, 1946, BRIT MED J, V2, P784, DOI 10.1136/bmj.2.4481.784; PEREZ JT, 1992, CUBAS FAMILY DOCTOR; ROMAN GC, 1994, NEUROLOGY, V44, P1784, DOI 10.1212/WNL.44.10.1784; ROMAN GC, 1994, J NEUROL SCI, V127, P11, DOI 10.1016/0022-510X(94)90130-9; SADUN AA, 1994, ARCH OPHTHALMOL-CHIC, V112, P691, DOI 10.1001/archopht.1994.01090170139037; SPILLANE JD, 1947, NUTRITIONAL DISORDER; YOUNG DJ, 1992, BATTLE BATAAN HIST 9; 1993, NEUROPATFA EPIDEMICA; 1994, MMWR-MORBID MORTAL W, V43, P183; 1994, AM ACADEMY NEUROLOGY, V7, P7; 1994, MMWR-MORBID MORTAL W, V43, P189	22	34	35	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					530	533		10.7326/0003-4819-122-7-199504010-00009	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872589				2022-12-28	WOS:A1995QP00800009
J	BISCHOF, RO				BISCHOF, RO			WHITE COATS IN THE CARE OF CHILDREN	LANCET			English	Editorial Material							PHYSICIAN; PARENTS				BISCHOF, RO (corresponding author), THOMAS JEFFERSON UNIV HOSP,JEFFERSON MED COLL,DEPT FAMILY MED,401 CURTIS,1015 WALNUT,PHILADELPHIA,PA 19107, USA.							ADLER L, 1991, CONSULTANT, V31, P28; BATES B, 1991, GUIDE PHYSICAL EXAMI, P13; BLUMHAGEN DW, 1979, ANN INTERN MED, V91, P111, DOI 10.7326/0003-4819-91-1-111; HATHAWAY WE, 1993, CURRENT PEDIATRIC DI; HOEKELMAN RA, 1992, PRIMARY PEDIATRIC CA, P69; HUGHES E, 1979, HOSPITALS, V53, P113; KAI J, 1993, BRIT MED J, V307, P660, DOI 10.1136/bmj.307.6905.660; KOUMBOURLIS AC, 1987, JAMA-J AM MED ASSOC, V257, P2032, DOI 10.1001/jama.1987.03390150047016; Larimore W L, 1993, Am Fam Physician, V48, P253; MARINO RV, 1991, J DEV BEHAV PEDIATR, V12, P98; MAY HL, 1984, EMERGENCY MED; MCGOWIN RL, 1987, DEGOWIN DEGOWINS BED; Mitchell S R, 1986, Pharos Alpha Omega Alpha Honor Med Soc, V49, P31; NEINSTEIN LS, 1985, J ADOLESCENT HEALTH, V6, P456, DOI 10.1016/S0197-0070(85)80053-X; NELSON WE, 1992, NELSON TXB PEDIATRIC; POTTER PA, 1985, FUNDAMENTALS NURSING; PRIOR JA, PHYSICAL DIAGNOSIS H; RUDOLPH AM, 1991, RUDOLPHS PEDIATRICS; SEIDEL H, 1987, MOSBYS GUIDE PHYSICA; SWARTZ MH, 1989, TXB PHYSICAL DIAGNOS, P535; Taylor RB., 1988, FAMILY MED PRINCIPLE, V3rd ed; TERR LC, 1991, AM J PSYCHIAT, V148, P10; Whaley L, 1987, NURSING CARE INFANTS; Williams W. C., 1984, DOCTOR STORIES; 1989, AM J MED SCI, V297, P265	25	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					777	778		10.1016/S0140-6736(95)90647-9	http://dx.doi.org/10.1016/S0140-6736(95)90647-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891493				2022-12-28	WOS:A1995QN70100018
J	SWALES, J				SWALES, J			RENAL DYSFUNCTION IN ESSENTIAL-HYPERTENSION	LANCET			English	Editorial Material							BLOOD-PRESSURE; BIOPSY				SWALES, J (corresponding author), UNIV LEICESTER, SCH MED, DEPT MED & THERAPEUT, LEICESTER, LEICS, ENGLAND.							BING RF, 1986, J HYPERTENS, V4, pS42; FARRINGTON K, 1989, Q J MED, V70, P221; HARVEY JM, 1992, LANCET, V340, P1435, DOI 10.1016/0140-6736(92)92624-O; LINDEMAN RD, 1984, KIDNEY INT, V26, P861, DOI 10.1038/ki.1984.229; MADHAVAN S, 1995, LANCET, V345, P749, DOI 10.1016/S0140-6736(95)90638-X; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; WEISSTUCH JM, 1992, KIDNEY INT, V41, pS33; WHELTON PK, 1992, J HYPERTENS, V10, pS77	9	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	1995	345	8952					740	741		10.1016/S0140-6736(95)90631-2	http://dx.doi.org/10.1016/S0140-6736(95)90631-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891478				2022-12-28	WOS:A1995QN70100002
J	ERNST, JA; CLUBB, RT; ZHOU, HX; GRONENBORN, AM; CLORE, GM				ERNST, JA; CLUBB, RT; ZHOU, HX; GRONENBORN, AM; CLORE, GM			DEMONSTRATION OF POSITIONALLY DISORDERED WATER WITHIN A PROTEIN HYDROPHOBIC CAVITY BY NMR	SCIENCE			English	Article							3-DIMENSIONAL STRUCTURE; FOLDING THERMODYNAMICS; TRYPSIN-INHIBITOR; CRYSTAL-STRUCTURE; AQUEOUS-SOLUTION; INTERLEUKIN-1-BETA; HYDRATION; SPECTROSCOPY; RESOLUTION; MOLECULES	The presence and location of water of hydration (thai is, bound water) in the solution structure of human interleukin-1 beta (hIL-1 beta) was investigated with water-selective two-dimensional heteronuclear magnetic resonance spectroscopy. It is shown here that in addition to water al the surface of the protein and ordered internal water molecules involved in bridging hydrogen bonds, positionally disordered water is present within a large, naturally occurring hydrophobic cavity located at the center oi the molecule. These water molecules of hydration have residency times in the range of 1 to 2 nanoseconds to 100 to 200 microseconds and can be readily detected by nuclear magnetic resonance (NMR). Thus, large hydrophobic cavities in proteins may not be truly empty, as analysis oi crystal structures appears to show, but may contain mobile water molecules that are crystallographically invisible but detectable by NMR.	NIDDKD, CHEM PHYS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Zhou, Huan-Xiang/M-5170-2016; Zhou, Huan-Xiang/AAH-9836-2020; zhou, huan/GYJ-4398-2022; Clore, G. Marius/A-3511-2008	Zhou, Huan-Xiang/0000-0001-9020-0302; Zhou, Huan-Xiang/0000-0001-9020-0302; Gronenborn, Angela M/0000-0001-9072-3525; Clore, G. Marius/0000-0003-3809-1027				Ben-Naim A., 1987, SOLVATION THERMODYNA; BENNAIM A, 1984, J CHEM PHYS, V81, P2016, DOI 10.1063/1.447824; CHOTHIA C, 1974, NATURE, V248, P338, DOI 10.1038/248338a0; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P8172, DOI 10.1021/bi00487a027; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1994, STRUCTURE, V2, P89, DOI 10.1016/S0969-2126(00)00011-3; DELAGLIO F, 1994, 35TH P EXP NUCL MAGN, P262; EDSALL JT, 1983, ADV BIOPHYS, V16, P53; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FINNEY JL, 1977, PHILOS T ROY SOC B, V278, P3, DOI 10.1098/rstb.1977.0029; FINZEL BC, 1989, J MOL BIOL, V209, P779, DOI 10.1016/0022-2836(89)90606-2; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; GRZESIEK S, 1994, J AM CHEM SOC, V116, P1581, DOI 10.1021/ja00083a058; GRZESIEK S, 1993, J BIOMOL NMR, V3, P627; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; HUBBARD SJ, 1994, PROTEIN ENG, V7, P613, DOI 10.1093/protein/7.5.613; JEFFERY GA, 1994, HYDROGEN BONDING BIO, V14, P770; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; KARPLUS PA, 1994, CURR OPIN STRUC BIOL, V4, P770, DOI 10.1016/S0959-440X(94)90178-3; KOSSIAKOFF AA, 1992, PROTEINS, V12, P223, DOI 10.1002/prot.340120303; LEE TW, 1970, J CHEM PHYS, V52, P6353; LEVITT M, 1988, J MOL BIOL, V201, P751, DOI 10.1016/0022-2836(88)90471-8; LEVITT M, 1993, STRUCTURE, V1, P223, DOI 10.1016/0969-2126(93)90011-5; Lovas F. J., 1978, Journal of Physical and Chemical Reference Data, V7, P1445, DOI 10.1063/1.555588; MAKHATADZE GI, 1993, J MOL BIOL, V232, P639, DOI 10.1006/jmbi.1993.1416; MCLACHLAN AD, 1979, J MOL BIOL, V133, P557, DOI 10.1016/0022-2836(79)90408-X; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ONESTI S, 1991, J MOL BIOL, V217, P153, DOI 10.1016/0022-2836(91)90618-G; OTTING G, 1989, J AM CHEM SOC, V111, P1871, DOI 10.1021/ja00187a050; OTTING G, 1991, SCIENCE, V254, P974, DOI 10.1126/science.1948083; PERUTZ MF, 1986, J AM CHEM SOC, V108, P1064, DOI 10.1021/ja00265a036; PRATT LR, 1980, J CHEM PHYS, V73, P3430, DOI 10.1063/1.440540; PRIESTLE JP, 1989, P NATL ACAD SCI USA, V86, P9667, DOI 10.1073/pnas.86.24.9667; PRIVALOV PL, 1993, J MOL BIOL, V232, P660, DOI 10.1006/jmbi.1993.1417; QIN J, 1994, STRUCTURE, V2, P503, DOI 10.1016/S0969-2126(00)00051-4; RASHIN AA, 1986, BIOCHEMISTRY-US, V25, P3619, DOI 10.1021/bi00360a021; RAVISHANKER G, 1982, FARADAY S CHEM SER, V17, P70; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P12315, DOI 10.1021/bi00164a005; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; WALSHAW J, 1993, J MOL BIOL, V231, P392, DOI 10.1006/jmbi.1993.1290; Westhof E., 1993, WATER BIOL MACROMOLE; WILLIAMS MA, 1994, PROTEIN SCI, V3, P1224, DOI 10.1002/pro.5560030808; WOLFENDEN R, 1994, SCIENCE, V265, P936, DOI 10.1126/science.8052849; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHOU HX, 1993, BIOPHYS J, V65, P955, DOI 10.1016/S0006-3495(93)81094-4; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556	49	238	243	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1813	1817		10.1126/science.7892604	http://dx.doi.org/10.1126/science.7892604			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892604				2022-12-28	WOS:A1995QN70200037
J	WILCOCKSON, RW; CREAN, CS; DAY, TH				WILCOCKSON, RW; CREAN, CS; DAY, TH			HERITABILITY OF A SEXUALLY SELECTED CHARACTER EXPRESSED IN BOTH SEXES	NATURE			English	Article							TAIL ORNAMENT SIZE; COELOPA-FRIGIDA; SEAWEED FLY; MATING PREFERENCE; MATE CHOICE; EVOLUTION; DIMORPHISM; PARASITES; TRAITS	SEXUAL selection is thought to be responsible for the evolution of exaggerated male characters and of female mate preferences(1-7). Evolutionary mechanisms driven by an advantage to the progeny are only effective if the preferred character has a large genetic component of variance; in most systems in which sexual selection operates, little is known of the relevant genetics(8), We have measured parent-offspring correlations, and report here that the preferred character (adult size) in seaweed flies has large additive genetic variance in males, but not in females, Virtually all the variance in male size is attributable to a chromosomal inversion system and, consequently, because this system is also a major determinant of larval viability(9,10), male size could be used by females as a reliable indicator of offspring survival.	UNIV NOTTINGHAM, QUEENS MED CTR, DEPT GENET, NOTTINGHAM NG7 2UH, ENGLAND	University of Nottingham								ALATALO RV, 1988, BIOL J LINN SOC, V34, P363, DOI 10.1111/j.1095-8312.1988.tb01969.x; ANDERSSON M, 1982, NATURE, V299, P818, DOI 10.1038/299818a0; Andersson Malte, 1994; AZIZ JB, 1975, THESIS U NEWCASTLE T; BORGIA G, 1990, AM ZOOL, V30, P279; BUTLIN RK, 1985, HEREDITY, V54, P107, DOI 10.1038/hdy.1985.14; BUTLIN RK, 1984, HEREDITY, V52, P415, DOI 10.1038/hdy.1984.49; BUTLIN RK, 1982, HEREDITY, V48, P45, DOI 10.1038/hdy.1982.5; Charlesworth B, 1987, SEXUAL SELECTION TES, P21; DAY TH, 1982, HEREDITY, V48, P35, DOI 10.1038/hdy.1982.4; Falconer D. S., 1989, Introduction to quantitative genetics.; GILBURN AS, 1994, GENET RES, V64, P19, DOI 10.1017/S001667230003250X; GILBURN AS, 1992, HEREDITY, V69, P209, DOI 10.1038/hdy.1992.118; HOULE D, 1992, GENETICS, V130, P195; KIRKPATRICK M, 1991, NATURE, V350, P33, DOI 10.1038/350033a0; LANDE R, 1980, EVOLUTION, V34, P292, DOI [10.2307/2407393, 10.1111/j.1558-5646.1980.tb04817.x]; LANDE R, 1985, J THEOR BIOL, V117, P651, DOI 10.1016/S0022-5193(85)80245-9; MILINSKI M, 1990, NATURE, V344, P330, DOI 10.1038/344330a0; MOLLER AP, 1991, EVOLUTION, V45, P1823, DOI 10.1111/j.1558-5646.1991.tb02690.x; POMIANKOWSKI A, 1991, EVOLUTION, V45, P1422, DOI 10.1111/j.1558-5646.1991.tb02645.x; POMIANKOWSKI A, IN PRESS P R SOC B; RITCHIE MG, 1992, TRENDS ECOL EVOL, V7, P328, DOI 10.1016/0169-5347(92)90123-S; SIMMONS LW, 1991, J EVOLUTION BIOL, V4, P593, DOI 10.1046/j.1420-9101.1991.4040593.x; SMITH JM, 1991, TRENDS ECOL EVOL, V6, P146, DOI 10.1016/0169-5347(91)90055-3; ZUK M, 1990, AM ZOOL, V30, P235; [No title captured]	26	43	43	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	1995	374	6518					158	159		10.1038/374158a0	http://dx.doi.org/10.1038/374158a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877687				2022-12-28	WOS:A1995QL39700057
J	ARMSTRONG, D; NICOLL, M				ARMSTRONG, D; NICOLL, M			CONSULTANTS WORKLOAD IN OUTPATIENT CLINICS	BRITISH MEDICAL JOURNAL			English	Article								The impact on hospital resources of variability in referral rates among general practitioners was of concern throughout the 1980s. The overall number of patients referred to outpatient clinics, however, has increased only slowly since the NHS began; in contrast, the number of new outpatients seen by each hospital consultant has declined appreciably. Ironically, despite this decline, further increasing the number of consultants is now being presented as a solution to the demand for outreach clinics in general practice.			ARMSTRONG, D (corresponding author), UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON,ENGLAND.		Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				ACHESON D, 1985, HLTH ED GENERAL PRAC; ARMSTRONG D, 1992, J PUBLIC HEALTH MED, V14, P173; MOORE AT, 1989, BRIT MED J, V298, P500, DOI 10.1136/bmj.298.6672.500; WILKIN D, 1990, GENERAL PRACTITIONER; 1994, HLTH PERSONAL SOCIAL	5	15	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					581	582		10.1136/bmj.310.6979.581	http://dx.doi.org/10.1136/bmj.310.6979.581			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QK700	7888937	Green Published			2022-12-28	WOS:A1995QK70000026
J	DICKERSON, JEC; BROWN, MJ				DICKERSON, JEC; BROWN, MJ			INFLUENCE OF AGE ON GENERAL-PRACTITIONERS DEFINITION AND TREATMENT OF HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT		UNIV CAMBRIDGE,ADDENBROOKES HOSP,CLIN PHARMACOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND	Addenbrooke's Hospital; University of Cambridge								BEARD K, 1992, BMJ-BRIT MED J, V304, P412, DOI 10.1136/bmj.304.6824.412; HART JT, 1993, BRIT MED J, V306, P437, DOI 10.1136/bmj.306.6875.437; SEVER P, 1993, BMJ-BRIT MED J, V306, P983, DOI 10.1136/bmj.306.6883.983; 1985, BRIT MED J, V291, P97; 1992, BRIT MED J, V304, P405	5	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					574	574		10.1136/bmj.310.6979.574	http://dx.doi.org/10.1136/bmj.310.6979.574			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888934	Green Published, Green Submitted			2022-12-28	WOS:A1995QK70000022
J	ORTON, G; AHEARN, M; BAINES, K; DEMING, D; DOWLING, T; GOGUEN, J; GRIFFITH, C; HAMMEL, H; HOFFMANN, W; HUNTEN, D; JEWITT, D; KOSTIUK, T; MILLER, S; NOLL, K; ZAHNLE, K; ACHILLEOS, N; DAYAL, A; DEUTSCH, L; ESPENAK, F; ESTERLE, P; FRIEDSON, J; FAST, K; HARRINGTON, J; HORA, J; JOSEPH, R; KELLY, D; KNACKE, R; LACY, J; LISSE, C; RAYNER, J; SPRAGUE, A; SHURE, M; WELLS, K; YANAMANDRAFISHER, P; ZIPOY, D; BJORAKER, G; BUHL, D; GOLISCH, W; GRIEP, D; KAMINSKI, C; ARDEN, C; CHAIKIN, A; GOLDSTEIN, J; GILMORE, D; FAZIO, G; KANAMORI, T; LAM, H; LIVENGOOD, T; MACLOW, MM; MARLEY, M; MOMARY, T; ROBERTSON, D; ROMANI, P; SPITALE, J; SYKES, M; TENNYSON, J; WELLNITZ, D; YING, SW				ORTON, G; AHEARN, M; BAINES, K; DEMING, D; DOWLING, T; GOGUEN, J; GRIFFITH, C; HAMMEL, H; HOFFMANN, W; HUNTEN, D; JEWITT, D; KOSTIUK, T; MILLER, S; NOLL, K; ZAHNLE, K; ACHILLEOS, N; DAYAL, A; DEUTSCH, L; ESPENAK, F; ESTERLE, P; FRIEDSON, J; FAST, K; HARRINGTON, J; HORA, J; JOSEPH, R; KELLY, D; KNACKE, R; LACY, J; LISSE, C; RAYNER, J; SPRAGUE, A; SHURE, M; WELLS, K; YANAMANDRAFISHER, P; ZIPOY, D; BJORAKER, G; BUHL, D; GOLISCH, W; GRIEP, D; KAMINSKI, C; ARDEN, C; CHAIKIN, A; GOLDSTEIN, J; GILMORE, D; FAZIO, G; KANAMORI, T; LAM, H; LIVENGOOD, T; MACLOW, MM; MARLEY, M; MOMARY, T; ROBERTSON, D; ROMANI, P; SPITALE, J; SYKES, M; TENNYSON, J; WELLNITZ, D; YING, SW			COLLISION OF COMET SHOEMAKER-LEVY-9 WITH JUPITER OBSERVED BY THE NASA INFRARED TELESCOPE FACILITY	SCIENCE			English	Article							ETHANE	The National Aeronautics and Space Administration (NASA) Infrared Telescope Facility was used to investigate the collision of comet Shoemaker-Levy 9 with Jupiter from 12 July to 7 August 1994. Strong thermal infrared emission lasting several minutes was observed after the impacts of fragments C, G, and R. All impacts warmed the stratosphere and some the troposphere up to several degrees. The abundance of stratospheric ammonia increased by more than 50 times. Impact-related particles extended up to a level where the atmospheric pressure measured several millibars. The north polar near-infrared aurora brightened by nearly a factor of 5 a week after the impacts.	UNIV MARYLAND, DEPT ASTRON, COLLEGE PK, MD 20742 USA; NASA, GODDARD SPACE FLIGHT CTR, GREENBELT, MD 20771 USA; MIT, CAMBRIDGE, MA 02139 USA; NO ARIZONA UNIV, DEPT PHYS & ASTRON, FLAGSTAFF, AZ 86011 USA; UNIV ARIZONA, STEWARD OBSERV, TUCSON, AZ 85721 USA; UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; UNIV HAWAII, INST ASTRON, HONOLULU, HI 96822 USA; UCL, DEPT PHYS & ASTRON, LONDON WC1E 6BT, ENGLAND; SPACE TELESCOPE SCI INST, BALTIMORE, MD 21218 USA; NASA, AMES RES CTR, MOFFETT FIELD, CA 94053 USA; UNIV MASSACHUSETTS, FIVE COLL ASTRON DEPT, AMHERST, MA 01003 USA; UNIV TEXAS, DEPT ASTRON, AUSTIN, TX 78712 USA; PENN STATE UNIV, ERIE, PA 16563 USA; UNIV ST ANDREWS, DEPT PHYS, ST ANDREWS, FIFE, SCOTLAND; SMITHSONIAN INST, NATL AIR & SPACE MUSEUM, WASHINGTON, DC 20560 USA; SMITHSONIAN ASTROPHYS OBSERV, CAMBRIDGE, MA 02138 USA; STANFORD UNIV, DEPT MECH ENGN & DESIGN, STANFORD, CA 94305 USA; UNIV CHICAGO, DEPT ASTRON & ASTROPHYS, CHICAGO, IL 60637 USA; NEW MEXICO STATE UNIV, DEPT ASTRON, LAS CRUCES, NM 88003 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA; UNIV LEICESTER, DEPT PHYS & ASTRON, LEICESTER LE1 7RH, LEICS, ENGLAND; CALTECH, PASADENA, CA 91126 USA; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, LONDON SW7 2BZ, ENGLAND	University System of Maryland; University of Maryland College Park; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Massachusetts Institute of Technology (MIT); Northern Arizona University; University of Arizona; University of Arizona; University of Hawaii System; University of London; University College London; Space Telescope Science Institute; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Massachusetts System; University of Massachusetts Amherst; University of Texas System; University of Texas Austin; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; University of St Andrews; Smithsonian Institution; Harvard University; Smithsonian Institution; Stanford University; University of Chicago; New Mexico State University; University of California System; University of California Los Angeles; University of Leicester; California Institute of Technology; Imperial College London	ORTON, G (corresponding author), CALTECH, JET PROP LAB, 4800 OAK GROVE DR, PASADENA, CA 91109 USA.		Romani, Paul N/D-2729-2012; Harrington, Joseph/E-6250-2011; Bjoraker, Gordon L/D-5032-2012; Achilleos, Nicholas/C-1647-2008; Kostiuk, Theodor/A-3077-2014; Goguen, Jay/E-5389-2018; Orton, Glenn/AAD-9862-2020; Livengood, Timothy A/C-8512-2012; Wellnitz, Dennis/B-4080-2012; Marley, Mark S/I-4704-2013; Tennyson, Jonathan/I-2222-2012; Dowling, Timothy E/J-4537-2013; Lisse, Carey M/B-7772-2016; Low, Mordecai-Mark Mac/AAN-1967-2021; Noll, Keith/C-8447-2012	Tennyson, Jonathan/0000-0002-4994-5238; Dowling, Timothy E/0000-0002-7400-2274; Lisse, Carey M/0000-0002-9548-1526; Low, Mordecai-Mark Mac/0000-0003-0064-4060; Miller, Steven/0000-0002-7159-6871; Rayner, John/0000-0002-3165-159X; Achilleos, Nicholas/0000-0002-5886-3509; Hora, Joseph/0000-0002-5599-4650; Harrington, Joseph/0000-0002-8955-8531				ATREYA SK, 1981, ASTROPHYS J, V147, pL43; CALDWELL J, 1983, ICARUS, V53, P133, DOI 10.1016/0019-1035(83)90026-X; DROSSART P, 1989, NATURE, V340, P539, DOI 10.1038/340539a0; FESTOU MC, 1981, J GEOPHYS RES-SPACE, V86, P5715, DOI 10.1029/JA086iA07p05715; FLASAR M, 1986, NASA SPEC PUBL, V494, P324; GRAHAM JR, 1995, SCIENCE, V167, P1320; GREENE TP, 1993, P SOC PHOTO-OPT INS, V1946, P313, DOI 10.1117/12.158684; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; HARRINGTON J, 1994, NATURE, V368, P525, DOI 10.1038/368525a0; HOFFMANN WF, 1993, P SOC PHOTO-OPT INS, V1946, P449, DOI 10.1117/12.158697; HOFFMANN WF, 1994, INFRARED PHYS TECHN, V35, P175, DOI 10.1016/1350-4495(94)90079-5; HUNTEN DH, 1994, GEOPHYS RES LETT, V1, P1094; JEWITT D, 1994, COMMUNICATION   0719; KIM SJ, 1988, ICARUS, V75, P399, DOI 10.1016/0019-1035(88)90153-4; KOSTIUK T, 1987, ICARUS, V72, P394, DOI 10.1016/0019-1035(87)90182-5; KOSTIUK T, 1983, APPL OPTICS, V22, P2644, DOI 10.1364/AO.22.002644; KOSTIUK T, 1994, INFRARED PHYS TECHN, V35, P243, DOI 10.1016/1350-4495(94)90084-1; LACY JH, 1989, PUBL ASTRON SOC PAC, V101, P1166, DOI 10.1086/132593; LIVENGOOD TA, 1993, J GEOPHYS RES-PLANET, V98, P18813, DOI 10.1029/93JE01043; MARLEY MS, 1994, ASTROPHYS J, V427, pL63, DOI 10.1086/187365; MILLER S, 1995, GEOPHYS RES LETT, V22, P1629, DOI 10.1029/95GL00700; NICHOLSON PD, IN PRESS GEOPHYS RES; ORTON G, 1992, B AM ASTRON SOC, V24, P1041; ORTON GS, 1991, SCIENCE, V252, P537, DOI 10.1126/science.252.5005.537; ORTON GS, 1994, SCIENCE, V265, P625, DOI 10.1126/science.265.5172.625; RAYNER J, 1993, P SOC PHOTO-OPT INS, V1946, P490, DOI 10.1117/12.158701; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426	28	64	64	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1277	1282		10.1126/science.7871423	http://dx.doi.org/10.1126/science.7871423			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871423				2022-12-28	WOS:A1995QK06800028
J	ZORAB, JSM; LLOYD, A				ZORAB, JSM; LLOYD, A			MANAGEMENT FOR DOCTORS - ANALYZING YOUR ORGANIZATION AND ENVIRONMENT AND SETTING ITS STRATEGY	BRITISH MEDICAL JOURNAL			English	Article											ZORAB, JSM (corresponding author), FRENCHAY HOSP,FRENCHAY HEALTHCARE NHS TRUST,BRISTOL BS16 1LE,AVON,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					514	517		10.1136/bmj.310.6978.514	http://dx.doi.org/10.1136/bmj.310.6978.514			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888898	Green Published			2022-12-28	WOS:A1995QJ59800032
J	AJAYI, V; MISKELLY, FG; WALTON, IG				AJAYI, V; MISKELLY, FG; WALTON, IG			THE NHS AND COMMUNITY CARE ACT 1990 - IS IT A SUCCESS FOR ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article									CHARING CROSS HOSP,DEPT MED ELDERLY,LONDON W6 8RP,ENGLAND	Imperial College London								TONKS A, 1993, BRIT MED J, V307, P1163; WARDEN J, 1993, BRIT MED J, V306, P812; 1993, MIMS WEEKLY MAGAZINE, V20, P3	3	3	3	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					439	439		10.1136/bmj.310.6977.439	http://dx.doi.org/10.1136/bmj.310.6977.439			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873950	Green Published			2022-12-28	WOS:A1995QJ24200020
J	STRACHAN, DP; LEON, DA; DODGEON, B				STRACHAN, DP; LEON, DA; DODGEON, B			MORTALITY FROM CARDIOVASCULAR-DISEASE AMONG INTERREGIONAL MIGRANTS IN ENGLAND AND WALES	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; GEOGRAPHIC VARIATIONS; DEATH RATES; ADULT LIFE; MIGRATION; INFANCY; BRITAIN; STROKE	Objective-To investigate the extent to which geographical variations in mortality from ischaemic heart disease and stroke in Britain are influenced by factors in early life or in adulthood. Design-Longitudinal study of migrants. Subjects-1% sample of residents in England and Wales born before October 1939 and enumerated at the 1971 census (the Office of Population Censuses and Surveys' longitudinal study). Main outcome measure-18221 deaths from ischaemic heart disease and 9899 deaths from stroke during 1971-88 were analysed by areas of residence in 1939 and 1971. These included 2928 deaths from ischaemic heart disease and 1608 deaths from stroke among individuals moving between 14 areas defined by the major conurbations and nine standard administrative regions of England and Wales. Results-The southeast to northwest gradient in mortality from ischaemic heart disease was related significantly to both the 1939 area (chi(2)=6.09, df=1) and area in 1971 (chi(2)=5.05, df=1). Geographical variations in mortality from stroke were related significantly to the 1939 area (chi(2)=4.09, df=1) but the effect of area in 1971 was greater (chi(2)=8.07, df=1). The effect of 1971 area on mortality from stroke was largely due to a lower risk of death from stroke among individuals moving into Greater London compared with migrants to the rest of the South East region (chi(2)=4.54, df=1). Conclusions-Geographical variations in mortality from cardiovascular disease in Britain may be partly determined by genetic factors, environmental exposures, or lifestyle acquired early in life, but the risk of fatal ischaemic heart disease and stroke changes on migration between areas with differing mortality. The low risk of death from stroke associated with residence in Greater London is acquired by individuals who move there.	LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,LONDON WC1E 7HT,ENGLAND; CITY UNIV LONDON,SOCIAL STAT RES UNIT,LONDON EC1V 0HB,ENGLAND	University of London; London School of Hygiene & Tropical Medicine; City University London	STRACHAN, DP (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.		Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762				BAKER RJ, 1978, GLIM SYSTEM; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, J EPIDEMIOL COMMUN H, V43, P237, DOI 10.1136/jech.43.3.237; BARKER DJP, 1987, BMJ-BRIT MED J, V295, P83, DOI 10.1136/bmj.295.6590.83; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1986, LANCET, V1, P1077; BARKER DJP, 1992, BRIT MED J, V305, P1551, DOI 10.1136/bmj.305.6868.1551; Barker DJP, 1992, FETAL INFANT ORIGINS; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; BRITTON M, 1990, SERIES DS, V9, P80; ELFORD J, 1989, LANCET, V1, P343; ELFORD J, 1990, BRIT MED J, V300, P291, DOI 10.1136/bmj.300.6720.291; FOX AJ, 1982, SERIES LS, V1; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEON DA, 1993, ENVIRON PLANN A, V25, P1441, DOI 10.1068/a251441; MARMOT MG, 1984, LANCET, V1, P1003; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; OSMOND C, 1990, SERIES DS, V9, P96; WILLIAMS DRR, 1979, J EPIDEMIOL COMMUNIT, V39, P199; 1944, NATIONAL REGISTER UK; 1932, REGISTRAR GENERALS 1; 1937, REGISTRAR GENERALS 1; 1935, REGISTRAR GENERALS 1; 1933, REGISTRAR GENERALS 1; 1936, REGISTRAR GENERALS 1; 1934, REGISTRAR GENERALS 1; 1931, REGISTRAR GENERALS 1; 1938, REGISTRAR GENERALS 1; 1975, REORGANISATION LOCAL	29	54	56	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					423	427		10.1136/bmj.310.6977.423	http://dx.doi.org/10.1136/bmj.310.6977.423			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873946	Green Published			2022-12-28	WOS:A1995QJ24200015
J	CHOYKE, PL; GOMES, MN				CHOYKE, PL; GOMES, MN			SURGERY FOR SMALL ABDOMINAL AORTIC-ANEURYSM	LANCET			English	Editorial Material									GEORGETOWN UNIV HOSP,DEPT SURG,WASHINGTON,DC 20007	Georgetown University	CHOYKE, PL (corresponding author), NIH,DEPT DIAGNOST RADIOL,BETHESDA,MD 20892, USA.							BERNSTEIN EF, 1976, SURGERY, V80, P765; COLIN J, 1989, SURG GYNECOL OBSTET, V169, P527; CRONENWETT JL, 1985, SURGERY, V98, P472; DELIN A, 1985, BRIT J SURG, V72, P530, DOI 10.1002/bjs.1800720709; ERNST CB, 1993, NEW ENGL J MED, V16, P1167; GEROULAKOS G, 1992, EUR J VASCULAR SURG, V6, P616, DOI 10.1016/S0950-821X(05)80838-2	6	3	3	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1377	1377						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901677				2022-12-28	WOS:A1993MK09500005
J	DURRINGTON, PN				DURRINGTON, PN			HOW HDL PROTECTS AGAINST ATHEROMA	LANCET			English	Editorial Material							CHOLESTERYL-ESTER TRANSFER; DENSITY-LIPOPROTEIN; MUTATION				DURRINGTON, PN (corresponding author), UNIV MANCHESTER, DEPT MED, MANCHESTER M13 9PL, LANCS, ENGLAND.							[Anonymous], 1991, LANCET, V338, P666; ASSMANN G, 1989, INT CONGR SER, V826, P51; BAGDADE JD, 1991, EUR J CLIN INVEST, V21, P161, DOI 10.1111/j.1365-2362.1991.tb01805.x; BHATNAGAR D, 1992, ATHEROSCLEROSIS, V92, P49, DOI 10.1016/0021-9150(92)90009-6; BREWER HB, 1984, CLIN METABOLIC ASPEC, P273; DEEB SS, 1990, AM J HUM GENET, V46, P822; FAGER G, 1981, ARTERIOSCLEROSIS, V1, P273, DOI 10.1161/01.ATV.1.4.273; INAZU A, 1990, NEW ENGL J MED, V323, P1234, DOI 10.1056/NEJM199011013231803; MACKNESS MI, 1993, BIOCHEM J, V294, P829, DOI 10.1042/bj2940829; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; NEARY R, 1991, ATHEROSCLEROSIS, V89, P35, DOI 10.1016/0021-9150(91)90005-N; PARTHASARATHY S, 1990, BIOCHIM BIOPHYS ACTA, V1044, P275, DOI 10.1016/0005-2760(90)90314-N; SIMONS LA, 1986, AM J CARDIOL, V57, pG5, DOI 10.1016/0002-9149(86)90659-4; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912	14	26	26	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1993	342	8883					1315	1316		10.1016/0140-6736(93)92243-M	http://dx.doi.org/10.1016/0140-6736(93)92243-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901633				2022-12-28	WOS:A1993MJ03900006
J	LAU, JYN; MIZOKAMI, M; OHNO, T; DIAMOND, DA; KNIFFEN, J; DAVIS, GL				LAU, JYN; MIZOKAMI, M; OHNO, T; DIAMOND, DA; KNIFFEN, J; DAVIS, GL			DISCREPANCY BETWEEN BIOCHEMICAL AND VIROLOGICAL RESPONSES TO INTERFERON-ALPHA IN CHRONIC HEPATITIS-C	LANCET			English	Note							CONTROLLED TRIAL; THERAPY; ALFA	Serial serum samples and pretreatment and post-treatment liver tissue from patients with chronic hepatitis C virus (HCV) infection were tested for HCV RNA by reverse-transcription polymerase chain reaction and branched DNA signal amplification assays. At the end of treatment with interferon-alpha (IFNalpha), 4 of 5 patients showing no biochemical response (in alanine aminotransferase activity), 4 of 5 with transient responses, and 1 of 5 showing complete and sustained responses had HCV RNA detectable in serum. The corresponding numbers for liver tissue were 5, 5, and 0 (of 4). However, all 5 complete responders had virological relapses within 6 months. Biochemical response may not reflect virological profile during IFNalpha treatment of HCV.	NAGASAKI UNIV,SCH MED,DEPT MED 2,NAGASAKI 852,JAPAN	Nagasaki University	LAU, JYN (corresponding author), UNIV FLORIDA,DEPT MED,HEPATOBILIARY DIS SECT,POB 100214 JHMHC,GAINESVILLE,FL 32610, USA.				NCRR NIH HHS [5M01RR00082] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000082] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIAMOND DA, IN PRESS J MED VIROL; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; LAU JYN, IN PRESS HEPATOLOGY; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; QIAN C, 1992, J HEPATOL, V16, P380, DOI 10.1016/S0168-8278(05)80674-9; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700	8	163	163	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1208	1209		10.1016/0140-6736(93)92187-X	http://dx.doi.org/10.1016/0140-6736(93)92187-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901531				2022-12-28	WOS:A1993MG27400011
J	SMITH, BB				SMITH, BB			FROM AN OBSERVER	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											SMITH, BB (corresponding author), UNIV HLTH SCI, COLL OSTEOPATH MED, DEPT MICROBIOL, 2105 INDEPENDENCE AVE, KANSAS CITY, MO 64124 USA.								0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					628	629		10.7326/0003-4819-122-8-199504150-00014	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887561				2022-12-28	WOS:A1995QR52500014
J	THOMAS, GAO; RHODES, J; MANI, V; WILLIAMS, GT; NEWCOMBE, RG; RUSSELL, MAH; FEYERABEND, C				THOMAS, GAO; RHODES, J; MANI, V; WILLIAMS, GT; NEWCOMBE, RG; RUSSELL, MAH; FEYERABEND, C			TRANSDERMAL NICOTINE AS MAINTENANCE THERAPY FOR ULCERATIVE-COLITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMOKING; NONSMOKING; CESSATION; COTININE; SMOKERS	Background. Ulcerative colitis is largely a disease of nonsmokers. Having found previously that treatment with transdermal nicotine patches and mesalamine (5-aminosalicylic acid) has a beneficial effect on active colitis, we examined the value of transdermal nicotine for the maintenance of remission. Methods. We treated 80 patients with ulcerative colitis in remission with either transdermal nicotine or placebo patches for six months in a randomized, double-blind study. Incremental doses of nicotine were given for the first three weeks to achieve a maintenance dose; most patients tolerated 15 mg for 16 hours daily. All patients were taking mesalamine preparations as maintenance treatment at entry into the study; this treatment was stopped once the maintenance dose of nicotine was achieved. Clinical, sigmoidoscopic, and histologic assessments were made at the beginning and the end of the study, or at relapse. Side effects and serum nicotine and cotinine concentrations were monitored throughout the study. Results. There was no significant difference in the number of relapses between the groups. Twenty-two patients in the nicotine group were prematurely withdrawn from the study, 14 because of relapse and 8 for other reasons, including side effects and protocol violations. In the placebo group, 20 patients were withdrawn prematurely, 17 because of relapse and 3 for other reasons, Among patients using 15-mg nicotine patches, serum nicotine and cotinine concentrations were lower than expected and may reflect poor compliance. Side effects were reported by 35 patients - 21 in the nicotine group and 14 in the placebo group - the most common of which were nausea, lightheadedness, and itching. Conclusions. Transdermal nicotine alone was no better than placebo in maintaining remission of ulcerative colitis, and early withdrawal due to side effects was more common in the nicotine group.	UNIV WALES HOSP, DEPT GASTROENTEROL, CARDIFF CF4 4XW, S GLAM, WALES; LEIGH INFIRM, LEIGH, ENGLAND; UNIV WALES COLL MED, DEPT PATHOL, CARDIFF CF4 4XN, S GLAM, WALES; UNIV WALES COLL MED, DEPT MED COMP & STAT, CARDIFF CF4 4XN, S GLAM, WALES; MAUDSLEY HOSP & INST PSYCHIAT, HLTH BEHAV UNIT, LONDON SE5 8AZ, ENGLAND; NEW CROSS HOSP, POISONS UNIT, NICOTINE LAB, LONDON, ENGLAND	Cardiff University; Cardiff University; Cardiff University; South London & Maudsley NHS Trust; University of London; King's College London; New Cross Hospital			Newcombe, Robert G/B-4897-2009; qin, zhen/F-1263-2014					CALKINS BM, 1989, DIGEST DIS SCI, V34, P1841, DOI 10.1007/BF01536701; DECASTELLA H, 1982, BRIT MED J, V284, P1706, DOI 10.1136/bmj.284.6330.1706; DICK AP, 1964, GUT, V5, P437, DOI 10.1136/gut.5.5.437; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450, DOI 10.1111/j.2042-7158.1990.tb06592.x; GALEAZZI RL, 1985, EUR J CLIN PHARMACOL, V28, P301, DOI 10.1007/BF00543327; HARRIES AD, 1982, BRIT MED J, V284, P706, DOI 10.1136/bmj.284.6317.706; LENNARDJONES JE, 1965, LANCET, V1, P188; LOGAN RFA, 1984, BRIT MED J, V288, P751, DOI 10.1136/bmj.288.6419.751; MEE RW, 1984, BIOMETRICS, V40, P1175; MISIEWICZ JJ, 1965, LANCET, V1, P185; MOTLEY RJ, 1988, INT J COLORECTAL DIS, V3, P171, DOI 10.1007/BF01648362; MOTLEY RJ, 1987, DIGESTION, V37, P125, DOI 10.1159/000199478; PULLAN RD, 1994, NEW ENGL J MED, V330, P811, DOI 10.1056/NEJM199403243301202; RUDRA T, 1989, SCAND J GASTROENTERO, V24, P61, DOI 10.3109/00365528909091354; SRIVASTAVA ED, 1991, EUR J GASTROEN HEPAT, V3, P815; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; TRUELOVE SC, 1955, BRIT MED J, V2, P1041, DOI 10.1136/bmj.2.4947.1041; TRUELOVE SC, 1958, BRIT MED J, V2, P1072, DOI 10.1136/bmj.2.5104.1072; TRUELOVE SC, 1959, BRIT MED J, V1, P386, DOI 10.1136/bmj.1.5119.387	19	164	167	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					988	992		10.1056/NEJM199504133321503	http://dx.doi.org/10.1056/NEJM199504133321503			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885427				2022-12-28	WOS:A1995QT73700003
J	EPSTEIN, IR				EPSTEIN, IR			THE CONSEQUENCES OF IMPERFECT MIXING IN AUTOCATALYTIC CHEMICAL AND BIOLOGICAL-SYSTEMS	NATURE			English	Review							CHLORITE-IODIDE REACTION; SICKLE HEMOGLOBIN POLYMERIZATION; BELOUSOV-ZHABOTINSKII REACTION; THIOSULFATE REACTION; STRANGE ATTRACTOR; OSCILLATORS; BEHAVIOR; DESIGN; DYNAMICS; MODEL	When chemical reactions whose rate increases with the concentration of a product species are carried out in imperfectly mixed systems, a variety of complex behaviours can occur. These phenomena, which have relevance for biological processes as well, include chaotic and stochastic behaviour and selection of one final state over an equally probable alternative.	BRANDEIS UNIV,VOLEN CTR COMPLEX SYST,WALTHAM,MA 02254	Brandeis University	EPSTEIN, IR (corresponding author), BRANDEIS UNIV,DEPT CHEM,WALTHAM,MA 02254, USA.							AGUDA BD, 1991, J AM CHEM SOC, V113, P7913, DOI 10.1021/ja00021a014; ALAMGIR M, 1985, INT J CHEM KINET, V17, P429, DOI 10.1002/kin.550170409; CASTETS V, 1990, PHYS REV LETT, V64, P2953, DOI 10.1103/PhysRevLett.64.2953; DEKEPPER P, 1990, J PHYS CHEM-US, V94, P6525, DOI 10.1021/j100380a004; DEVREOTES P, 1987, METHOD CELL BIOL, V28, P299; Eigen M, 1979, THE HYPERCYCLE, P60; EPSTEIN IR, 1989, J CHEM EDUC, V66, P191, DOI 10.1021/ed066p191; FERRONE FA, 1985, J MOL BIOL, V183, P611, DOI 10.1016/0022-2836(85)90175-5; FERRONE FA, 1985, J MOL BIOL, V183, P591, DOI 10.1016/0022-2836(85)90174-3; FIELD RJ, 1974, J CHEM PHYS, V60, P1877, DOI 10.1063/1.1681288; GYORGYI L, 1991, J PHYS CHEM-US, V95, P6594, DOI 10.1021/j100170a041; GYORGYI L, 1992, NATURE, V355, P808, DOI 10.1038/355808a0; GYORGYI L, 1989, J CHEM PHYS, V91, P6131, DOI 10.1063/1.457432; HOFRICHTER J, 1986, J MOL BIOL, V189, P533; JAHNKE W, 1991, J CHEM EDUC, V68, P320, DOI 10.1021/ed068p320; KAREIVA P, IN PRESS NATURE; KONDEPUDI DK, 1994, CHEM PHYS LETT, V217, P364, DOI 10.1016/0009-2614(93)E1392-T; KONDEPUDI DK, 1990, SCIENCE, V250, P975, DOI 10.1126/science.250.4983.975; KUMPINSKY E, 1985, J CHEM PHYS, V82, P53, DOI 10.1063/1.448777; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; LEMARCHAND A, 1989, CHEM PHYS LETT, V162, P92, DOI 10.1016/0009-2614(89)85073-0; LUO Y, 1986, J CHEM PHYS, V85, P5733, DOI 10.1063/1.451534; Malthus Thomas, 1798, ESSAY PRINCIPLE POPU, V14; MASELKO J, 1984, J CHEM PHYS, V80, P3175, DOI 10.1063/1.447132; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MENZINGER M, 1990, J PHYS CHEM-US, V94, P4510, DOI 10.1021/j100374a031; METCALFE G, 1994, PHYS REV LETT, V72, P2875, DOI 10.1103/PhysRevLett.72.2875; NAGYPAL I, 1986, J PHYS CHEM-US, V90, P6285, DOI 10.1021/j100281a044; NAGYPAL I, 1988, J CHEM PHYS, V89, P6925, DOI 10.1063/1.455316; OLSEN LF, 1977, NATURE, V267, P177, DOI 10.1038/267177a0; ROUX JC, 1983, PHYSICA D, V8, P257, DOI 10.1016/0167-2789(83)90323-8; ROUX JC, 1980, PHYS LETT A, V77, P391, DOI 10.1016/0375-9601(80)90519-8; ROUX JC, 1983, J PHYS A, V97, pL168; SAGUES F, 1990, J CHEM PHYS, V92, P4786, DOI 10.1063/1.457696; SCHMITZ RA, 1977, J CHEM PHYS, V67, P3040, DOI 10.1063/1.435267; SWANSON PD, 1990, J FLUID MECH, V213, P227, DOI 10.1017/S0022112090002300; SZABO A, 1988, J MOL BIOL, V199, P539, DOI 10.1016/0022-2836(88)90624-9; TURING AM, 1952, PHILOS T ROY SOC B, V237, P37, DOI 10.1098/rstb.1952.0012; VILLERMAUX J, 1991, REV CHEM ENG, V7, P51	39	146	147	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					321	327		10.1038/374321a0	http://dx.doi.org/10.1038/374321a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885470				2022-12-28	WOS:A1995QN63000050
J	ALMROTH, S; LATHAM, MC				ALMROTH, S; LATHAM, MC			RATIONAL HOME MANAGEMENT OF DIARRHEA	LANCET			English	Editorial Material							CHILDHOOD DIARRHEA; HEALTH-EDUCATION; MOTHERS; DISEASE		CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Cornell University								[Anonymous], 1978, LANCET, V2, P300; BARROS FC, 1991, B WORLD HEALTH ORGAN, V69, P59; Benakappa D G, 1990, Indian J Pediatr, V57, P21, DOI 10.1007/BF02722124; BENTLEY ME, 1988, SOC SCI MED, V27, P75, DOI 10.1016/0277-9536(88)90165-7; BENTLEY ME, 1988, SOC SCI MED, V27, P107, DOI 10.1016/0277-9536(88)90168-2; CHUNG AW, 1948, J PEDIATR-US, V33, P1, DOI 10.1016/S0022-3476(48)80147-2; CHUNG AW, 1948, J PEDIATR-US, V33, P14, DOI 10.1016/S0022-3476(48)80148-4; FIELD M, 1977, NEW ENGL J MED, V297, P1121, DOI 10.1056/NEJM197711172972011; GREEN EC, 1985, SOC SCI MED, V20, P277, DOI 10.1016/0277-9536(85)90242-4; GREENOUGH WB, 1987, CEREAL BASED ORAL RE, P52; HOYLE B, 1980, AM J CLIN NUTR, V33, P2365, DOI 10.1093/ajcn/33.11.2365; HUFFMAN SL, 1991, J DIARRHOEAL DIS RES, V9, P295; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; Mahalanabis D, 1983, J Diarrhoeal Dis Res, V1, P76; MARTINEZ H, 1991, J DIARRHOEAL DIS RES, V9, P235; MULL JD, 1984, J FAM PRACTICE, V18, P485; OYOO A, 1991, HEALTH POLICY PLANN, V6, P380, DOI 10.1093/heapol/6.4.380; RASHEED P, 1993, SOC SCI MED, V36, P373, DOI 10.1016/0277-9536(93)90022-V; SCHULTZ SG, 1977, AM J PHYSIOL, V233, pE249, DOI 10.1152/ajpendo.1977.233.4.E249; Tulloch J, 1987, World Health Stat Q, V40, P110; WILSON R, 1989, CEREAL BASED ORAL RE, P13; 1993, SELECTION FLUIDS FOO; 1983, LANCET, V2, P259; 1990, WHO1988 1989 PROGR C; 1987, DECISION PROCESS EST; 1978, WHO CHRON, V32, P369; 1993, WHO1992 PROGR CONTR	27	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	1995	345	8951					709	711		10.1016/S0140-6736(95)90873-0	http://dx.doi.org/10.1016/S0140-6736(95)90873-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM732	7885128				2022-12-28	WOS:A1995QM73200014
J	HOGE, CW; SHLIM, DR; GHIMIRE, M; RABOLD, JG; PANDEY, P; WALCH, A; RAJAH, R; GAUDIO, P; ECHEVERRIA, P				HOGE, CW; SHLIM, DR; GHIMIRE, M; RABOLD, JG; PANDEY, P; WALCH, A; RAJAH, R; GAUDIO, P; ECHEVERRIA, P			PLACEBO-CONTROLLED TRIAL OF COTRIMOXAZOLE FOR CYCLOSPORA INFECTIONS AMONG TRAVELERS AND FOREIGN RESIDENTS IN NEPAL	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ISOSPORA-BELLI INFECTION; CYANOBACTERIUM-LIKE BODIES; DIARRHEA; TRAVELERS; ORGANISM; PATHOGEN	Cyclospora is a coccidian (previously referred to as cyanobacterium-like bodies) that has been implicated in cases of prolonged diarrhoea. The average duration of symptoms is more than three weeks, and no specific treatment has been shown to shorten the illness. A case report suggested that co-trimoxazole may be effective. Expatriate persons with gastrointestinal complaints and cyclospora detected on examination of faeces were recruited from two clinics in Kathmandu, Nepal, between May and August, 1994. Participants were assigned in a randomised, double-blinded manner to receive either co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole) or placebo tablets twice daily for 7 days. Of 40 patients included in the study, 21 received co-trimoxazole and 19 placebo. There were no significant differences between these two groups in age, sex, time in Nepal, duration or severity of illness, or presence of other enteric pathogens. After 3 days, 71% of patients receiving co-trimoxazole still had cyclospora detected, compared with 100% of patients receiving placebo (p=0.016). After 7 days, cyclospora was detected in 1 (6%) of 16 patients treated with co-trimoxazole who submitted stool specimens compared with 15 (88%) of 17 patients receiving placebo (p<0.0001). Eradication of the organism was correlated with clinical improvement. There was no evidence of relapse of infection among treated patients followed for an additional 7 days. Treatment with co-trimoxazole for 7 days was effective in curing cyclospora infection among an expatriate population in Nepal.	CIWEC CLIN,KATMANDU,NEPAL; US EMBASSY & PEACE CORPS MED UNIT,KATMANDU,NEPAL		HOGE, CW (corresponding author), ARMED FORCES RES INST MED SCI,USA MED COMPONENT,DEPT BACTERIOL IMMUNOL & MOLEC GENET,BANGKOK 10400,THAILAND.							BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; CONNOR BA, 1993, ANN INTERN MED, V119, P377, DOI 10.7326/0003-4819-119-5-199309010-00005; Dean A.G., 1994, EPI INFO VERSION 6 W; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; MADICO G, 1993, LANCET, V342, P122, DOI 10.1016/0140-6736(93)91330-O; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; POLLOK RCG, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91759-2; SHEAR M, 1994, GASTROENTEROLOGY, V106, pA772; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; WESTERMAN EL, 1979, ANN INTERN MED, V91, P413; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; 1993, MED LETT, V35, P111	18	130	137	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					691	693		10.1016/S0140-6736(95)90868-4	http://dx.doi.org/10.1016/S0140-6736(95)90868-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885125				2022-12-28	WOS:A1995QM73200009
J	ACKAH, AN; COULIBALY, D; DIGBEU, H; DIALLO, K; VETTER, KM; COULIBALY, IM; GREENBERG, AE; DECOCK, KM				ACKAH, AN; COULIBALY, D; DIGBEU, H; DIALLO, K; VETTER, KM; COULIBALY, IM; GREENBERG, AE; DECOCK, KM			RESPONSE TO TREATMENT, MORTALITY, AND CD4 LYMPHOCYTE COUNTS IN HIV-INFECTED PERSONS WITH TUBERCULOSIS IN ABIDJAN, COTE-DIVOIRE	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; HIV-1-INFECTED PATIENTS; PULMONARY TUBERCULOSIS; ZAIRE; KENYA; MORBIDITY; KINSHASA; NAIROBI; CITY	We examined the severity of immune deficiency in patients with HIV-associated tuberculosis in Cote d'Ivoire and assessed its effect on mortality and response to treatment. Consecutive patients attending a tuberculosis treatment in Abidjan with smear-positive pulmonary or diagnosed extrapulmonary tuberculosis were tested for HIV-1 and HIV-2 infections and had CD4 lymphocyte counts measured. Patients received standard short-course chemotherapy. Analysis of outcome (restricted to smear-positive tuberculosis patients) was done at 6 months. The 247 HIV-positive patients were significantly more likely than the 312 HIV-negative patients to have CD4 lymphocyte counts of less than 200/mu L (43% vs 1%; odds ratio 56.9; [95% CI 19.7-185.3]) and 200-499/mu L (39% vs 14%, odds ratio 3.8; [2.5-5.9]). HIV-positive patients, median CD4 lymphocyte in those with extrapulmonary tuberculosis (198/mu L; n=67) was lower, but not significantly so, than among those with pulmonary tuberculosis (257/mu L; n=180). Among 460 patients with pulmonary tuberculosis, the overall mortality rate was significantly higher in HIV-positive than HIV-negative persons (6% vs 0.4%; relative risk 17.1 [2.2-131.4]), and increased with the severity of immune deficiency; mortality rates in HIV-positive patients with CD4 counts of <200/mu L and 200-499/mu L were 10% and 4%, relative risk 27.6 (3.5-220.8); and 11.5 (1.2-109), respectively, compared to HIV-negatives. Among patients completing treatment, cure rates were similar in HIV-positive patients (93%) and HIV-negative patients (92%), and were not related to CD4 counts. Severity of immune deficiency was the major determinant of mortality in HIV-associated tuberculosis. Among people completing treatment, microbiological response was satisfactory irrespective of serological or immune status.	PROJET RETRO CI,ABIDJAN,COTE IVOIRE; CTR ANTITUBERCULEUX,ABIDJAN,COTE IVOIRE; EMORY UNIV,SCH PUBL HLTH,ATLANTA,GA; CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	Emory University; Centers for Disease Control & Prevention - USA								BRINDLE RJ, 1993, AIDS, V7, P1469, DOI 10.1097/00002030-199311000-00010; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CHAISSON RE, 1987, AM REV RESPIR DIS, V136, P570, DOI 10.1164/ajrccm/136.3.570; COLEBUNDERS RL, 1989, AM REV RESPIR DIS, V139, P1082, DOI 10.1164/ajrccm/139.5.1082; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DECOCK KM, 1993, LANCET, V342, P437, DOI 10.1016/0140-6736(93)92853-L; DECOCK KM, 1992, JAMA-J AM MED ASSOC, V268, P1581, DOI 10.1001/jama.1992.03490120095035; DJOMAND G, 1994, AIDS, V8, P843, DOI 10.1097/00002030-199406000-00019; DJOMAND G, 1993, 8TH INT C AIDS AFR 8; HAWKEN M, 1993, LANCET, V342, P332, DOI 10.1016/0140-6736(93)91474-Z; KASSIM S, 1993, 8TH INT C AIDS AFR 8; LANGE JMA, 1993, AIDS, V7, P1675, DOI 10.1097/00002030-199312000-00021; LOUIE E, 1986, CHEST, V256, P362; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MUKADI Y, 1993, LANCET, V342, P143, DOI 10.1016/0140-6736(93)91346-N; NUNN P, 1992, AM REV RESPIR DIS, V146, P849, DOI 10.1164/ajrccm/146.4.849; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; POZNIAK A, 1992, 8 INT C AIDS 3 STD W; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; 1986, WHO WKLY EPIDEMIOL R, V61, P72	20	190	194	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					607	610		10.1016/S0140-6736(95)90519-7	http://dx.doi.org/10.1016/S0140-6736(95)90519-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898177				2022-12-28	WOS:A1995QM07500007
J	PEYRAT, JP; BONNETERRE, J; LUBIN, R; VANLEMMENS, L; FOURNIER, J; SOUSSI, T				PEYRAT, JP; BONNETERRE, J; LUBIN, R; VANLEMMENS, L; FOURNIER, J; SOUSSI, T			PROGNOSTIC-SIGNIFICANCE OF CIRCULATING P53 ANTIBODIES IN PATIENTS UNDERGOING SURGERY FOR LOCOREGIONAL BREAST-CANCER	LANCET			English	Note							PROTEIN; EPITOPES	P53 mutations can lead to the production of P53 antibodies in serum of cancer patients. Here we studied the prognostic value of P53 antibodies in 353 primary breast cancer patients. P53 antibodies were detected in 42 cases (12%) and were negatively related to oestradiol and progesterone receptors. The median duration of follow-up for live patients was 5.3 years. In actuarial analyses, overall survival was worse in patients with P53 antibody (p<0.0005); in Cox's multivariate analysis, P53 antibody was an independent prognostic variable. Thus plasma assay of P53 antibody would be useful to select rapidly and easily a population of patients with poor prognosis.	CTR OSCAR LAMBRET,DEPT MED ONCOL,F-59020 LILLE,FRANCE; INST GENET MOLEC,INSERM,U301,F-75010 PARIS,FRANCE	UNICANCER; Centre Oscar Lambret; Institut National de la Sante et de la Recherche Medicale (Inserm)	PEYRAT, JP (corresponding author), CTR OSCAR LAMBRET,ONCOL MOLEC HUMAINE LAB,BP 307,F-59020 LILLE,FRANCE.			VANLEMMENS, LAURENCE/0000-0001-7799-1648; soussi, thierry/0000-0001-8184-3293				BARNES DM, 1993, HUM PATHOL, V24, P469, DOI 10.1016/0046-8177(93)90158-D; BONNETERRE J, 1990, CANCER RES, V50, P6931; CALLAHAN R, 1992, J NATL CANCER I, V84, P826, DOI 10.1093/jnci/84.11.826; CRAWFORD LV, 1982, INT J CANCER, V30, P403, DOI 10.1002/ijc.2910300404; DAVIDOFF AM, 1992, P NATL ACAD SCI USA, V89, P3439, DOI 10.1073/pnas.89.8.3439; LUBIN R, 1993, CANCER RES, V53, P5872; SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380; SOUSSI T, 1994, INT J CANCER, V57, P1, DOI 10.1002/ijc.2910570102; THOR AD, 1992, JNCI-J NATL CANCER I, V84, P845, DOI 10.1093/jnci/84.11.845	9	141	142	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					621	622		10.1016/S0140-6736(95)90523-5	http://dx.doi.org/10.1016/S0140-6736(95)90523-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898180				2022-12-28	WOS:A1995QM07500011
J	TONG, G; SHEPHERD, D; JAHR, CE				TONG, G; SHEPHERD, D; JAHR, CE			SYNAPTIC DESENSITIZATION OF NMDA RECEPTORS BY CALCINEURIN	SCIENCE			English	Article							ISOLATED HIPPOCAMPAL-NEURONS; PROTEIN PHOSPHATASE-ACTIVITY; D-ASPARTATE RECEPTOR; CONDUCTANCES; PROBABILITY; RESPONSES; CULTURE; RELEASE; ACTIN; RAT	Desensitization is a phenomenon that is common to many ligand-gated ion channels but has been demonstrated only rarely with physiological stimulation. Numerous studies describe desensitization of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptor by exogenous agonists, but whether synaptic stimulation causes desensitization has been unknown. Synaptic stimulation of NMDA receptors on rat hippocampal neurons resulted in desensitization that was prevented by intracellular 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA), adenosine-5'-O-(3-thiotriphosphate) (ATP-gamma-S), or inhibitors of phosphatase 2B (calcineurin), but not by inhibitors of phosphatases 1 and 2A or of tyrosine phosphatases. Synaptic NMDA receptors may fluctuate between phosphorylated and dephosphorylated forms, depending on the rate of synaptic stimulation and the magnitude of the associated influx of calcium through NMDA receptors.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University			Tong, Gary/AAC-9426-2022		NINDS NIH HHS [NS21419] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021419] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASCHER P, 1988, J PHYSIOL-LONDON, V399, P247; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; CHIZHMAKOV IV, 1992, J PHYSIOL-LONDON, V448, P453, DOI 10.1113/jphysiol.1992.sp019051; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; GOTO S, 1986, BRAIN RES, V397, P161, DOI 10.1016/0006-8993(86)91381-8; HASHIMOTO Y, 1990, J BIOL CHEM, V265, P1924; HESSLER NA, 1993, NATURE, V366, P569, DOI 10.1038/366569a0; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; JAHR CE, 1990, J NEUROSCI, V10, P3178; JAHR CE, 1987, NATURE, V325, P522, DOI 10.1038/325522a0; KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; MAYER ML, 1987, J NEUROSCI, V7, P3230; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; PETHIG R, 1989, CELL CALCIUM, V10, P491, DOI 10.1016/0143-4160(89)90026-2; ROSENMUND C, 1995, J NEUROPHYSIOL, V73, P427, DOI 10.1152/jn.1995.73.1.427; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; ROSENMUND C, 1993, NEURON, V10, P805, DOI 10.1016/0896-6273(93)90197-Y; SATHER W, 1990, NEURON, V4, P725, DOI 10.1016/0896-6273(90)90198-O; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TONG G, 1994, J NEUROPHYSIOL, V72, P754, DOI 10.1152/jn.1994.72.2.754; WANG LY, 1994, NATURE, V369, P230, DOI 10.1038/369230a0; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0	26	339	345	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1510	1512		10.1126/science.7878472	http://dx.doi.org/10.1126/science.7878472			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878472				2022-12-28	WOS:A1995QL49700041
J	NOLL, KS; MCGRATH, MA; TRAFTON, LM; ATREYA, SK; CALDWELL, JJ; WEAVER, HA; YELLE, RV; BARNET, C; EDGINGTON, S				NOLL, KS; MCGRATH, MA; TRAFTON, LM; ATREYA, SK; CALDWELL, JJ; WEAVER, HA; YELLE, RV; BARNET, C; EDGINGTON, S			HST SPECTROSCOPIC OBSERVATIONS OF JUPITER AFTER THE COLLISION OF COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article							CROSS-SECTION MEASUREMENTS; CARBON-MONOXIDE; NM; REGION; SO2; S2	Ultraviolet spectra obtained with the Hubble Space Telescope identified at least 10 molecules and atoms in the perturbed stratosphere near the G impact site, most never before observed in Jupiter. The large mass of sulfur-containing material, more than 10(14) grams in S-2 alone, indicates that many of the sulfur-containing molecules S-2, CS2, CS, H2S, and S+ may be derived from a sulfur-bearing parent molecule native to Jupiter. If so, the fragment must have penetrated at least as deep as the predicted NH4SH cloud at a pressure of approximately 1 to 2 bars, Stratospheric NH3 was also observed, which is consistent with fragment penetration below the cloud tops. Approximately 10(7) grams of neutral and ionized metals were observed in emission, including Mg II, Mg I, Si I, Fe I, and Fe II. Oxygen-containing molecules were conspicuous by their absence; upper limits for SO2, SO, CO, SiO, and H2O are derived,	UNIV TEXAS,DEPT ASTRON,AUSTIN,TX 78712; UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; INST SPACE & TERR SCI,SPACE ASTROPHYS LAB,N YORK,ON M3J 3K1,CANADA; NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	University of Texas System; University of Texas Austin; University of Michigan System; University of Michigan; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	NOLL, KS (corresponding author), SPACE TELESCOPE SCI INST,3700 SAN MARTIN DR,BALTIMORE,MD 21218, USA.		Barnet, Christopher/F-5573-2010; Weaver, Harold A/D-9188-2016; Noll, Keith/C-8447-2012	Weaver, Harold A/0000-0003-0951-7762; 				AHEARN MF, 1983, ASTROPHYS J, V274, pL99, DOI 10.1086/184158; AHEARN MF, 1983, TR AP83044 U MAR TEC; ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ANDERSON WR, 1979, J CHEM PHYS, V71, P821, DOI 10.1063/1.438372; Atreya S. K., 1987, ATMOSPHERES IONOSPHE; ATREYA SK, 1977, ICARUS, V31, P348, DOI 10.1016/0019-1035(77)90027-6; ATREYA SK, 1985, PLANETARY METEOROLOG, P17; BARROW RF, 1965, ELEMENTAL SULFUR; BEEBE R, COMMUNICATION; Chen F., UNPUB; CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; FELDMAN PD, 1993, ASTROPHYS J, V406, P279, DOI 10.1086/172439; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; JESSBURGER EK, 1989, COMPOSITION CORNETS; LANGHOFF S, COMMUNICATION; LARSON HP, 1984, ICARUS, V60, P621, DOI 10.1016/0019-1035(84)90169-6; LELLOUCH E, B AM ASTRON SOC; LEWIS JS, 1970, SCIENCE, V169, P472, DOI 10.1126/science.169.3944.472; MARTINEZ RD, 1992, GEOPHYS RES LETT, V19, P277, DOI 10.1029/91GL03165; MCGRATH MA, 1995, SCIENCE, V267, P1313, DOI 10.1126/science.7871429; MEYER KA, 1973, J CHEM PHYS, V59, P1933, DOI 10.1063/1.1680279; MOSES JI, UNPUB; NOLL KS, 1988, ASTROPHYS J, V324, P1210, DOI 10.1086/165975; ORTON G, 1995, SCIENCE, V267, P1277, DOI 10.1126/science.7871423; PRATHER MJ, 1978, ASTROPHYS J, V223, P1072, DOI 10.1086/156340; QUICK CR, 1981, J CHEM PHYS, V74, P4951, DOI 10.1063/1.441748; SMITH WH, 1969, J QUANT SPECTROSC RA, V9, P1191, DOI 10.1016/0022-4073(69)90106-X; TOZZI GP, UNPUB; TRAFTON LM, 1994, ASTROPHYS J, V421, P816, DOI 10.1086/173694; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; WIESE WL, 1969, NSRDSNBS22, V2; WU CYR, 1981, GEOPHYS RES LETT, V8, P769, DOI 10.1029/GL008i007p00769; XU H, 1993, GEOPHYS RES LETT, V20, P1035, DOI 10.1029/93GL00809; YEOMANS DK, COMMUNICATION	36	109	109	0	10	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1307	1313		10.1126/science.7871428	http://dx.doi.org/10.1126/science.7871428			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871428				2022-12-28	WOS:A1995QK06800033
J	SWAFFIELD, JC; MELCHER, K; JOHNSTON, SA				SWAFFIELD, JC; MELCHER, K; JOHNSTON, SA			A HIGHLY CONSERVED ATPASE PROTEIN AS A MEDIATOR BETWEEN ACIDIC ACTIVATION DOMAINS AND THE TATA-BINDING PROTEIN	NATURE			English	Article							MOLECULAR-WEIGHT PROTEASES; SACCHAROMYCES-CEREVISIAE; MULTICATALYTIC PROTEINASE; 26-S PROTEASE; YEAST; GENE; GAL4; MEMBER; FAMILY; PURIFICATION	BIOCHEMICAL and genetic studies suggest the existence of mediators that work between the activation domains (ADs) of regulatory proteins and the basic transcriptional machinery. We have previously shown genetically that Sug1 interacts with the AD of the yeast activator Ga14(1). Here we provide evidence that the Sug1 protein of yeast binds directly to the ADs of Ga14 and the viral activator, VP16. Sug1 protein is associated with the TATA-binding protein in vivo and binds to it in vitro, consistent with a mediator function. We also demonstrate that Sug1 is not a component of the 26S proteasome, contrary to previous reports(2-5). Sug1 is a member of a large, highly conserved family of ATPases, implying a role for ATP hydrolysis in the activation of transcription.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75325; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75325	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Melcher, Karsten/AAZ-3861-2020	Melcher, Karsten/0000-0002-9125-4027				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CONFALONIERI F, 1994, J MOL BIOL, V235, P396, DOI 10.1016/S0022-2836(05)80047-6; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DEMARTINO GN, 1994, J BIOL CHEM, V269, P20878; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; ERDMANN R, 1991, CELL, V64, P499, DOI 10.1016/0092-8674(91)90234-P; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GORDON C, 1993, NATURE, V366, P355, DOI 10.1038/366355a0; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HOUGH R, 1987, J BIOL CHEM, V262, P8303; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LEUTHER KK, 1993, CELL, V72, P575, DOI 10.1016/0092-8674(93)90076-3; LUE NF, 1987, MOL CELL BIOL, V7, P3446, DOI 10.1128/MCB.7.10.3446; MA CP, 1992, J BIOL CHEM, V267, P10515; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; NISHIZAWA M, 1990, P NATL ACAD SCI USA, V87, P5373, DOI 10.1073/pnas.87.14.5373; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; OCONNOR V, 1994, CELL, V76, P785, DOI 10.1016/0092-8674(94)90352-2; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; TOMAYAZU T, 1993, J BACTERIOL, V176, P1344; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; WAXMAN L, 1987, J BIOL CHEM, V262, P2451	30	133	136	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					88	91		10.1038/374088a0	http://dx.doi.org/10.1038/374088a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870180				2022-12-28	WOS:A1995QK07900060
J	SNAITH, ML				SNAITH, ML			ABC OF RHEUMATOLOGY - GOUT, HYPERURICEMIA, AND CRYSTAL ARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article											SNAITH, ML (corresponding author), NETHER EDGE HOSP,SHEFFIELD,S YORKSHIRE,ENGLAND.								0	16	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					521	524		10.1136/bmj.310.6978.521	http://dx.doi.org/10.1136/bmj.310.6978.521			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888900	Green Published			2022-12-28	WOS:A1995QJ59800035
J	BENCHETRIT, E; PUTTERMAN, C				BENCHETRIT, E; PUTTERMAN, C			STILL HAZY AFTER ALL THESE YEARS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							DIAGNOSIS		ALBERT EINSTEIN COLL MED,DEPT MED,DIV RHEUMATOL,BRONX,NY 10467	Yeshiva University; Albert Einstein College of Medicine	BENCHETRIT, E (corresponding author), HADASSAH UNIV HOSP,DIV MED,RHEUMATOL UNIT,POB 12000,IL-91120 JERUSALEM,ISRAEL.							BENCHETRIT E, 1991, SEMIN ARTHRITIS RHEU, V20, P241, DOI 10.1016/0049-0172(91)90019-V; KASSIRER JP, 1991, PROCESSES CLIN REASO, P2; KAUPPINEN R, 1992, MEDICINE, V71, P1; KUSHNER JP, 1991, NEW ENGL J MED, V324, P1432, DOI 10.1056/NEJM199105163242010; LOSSOS I, 1989, J CLIN EPIDEMIOL, V42, P649, DOI 10.1016/0895-4356(89)90008-5	5	5	5	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 6	1994	331	14					934	938		10.1056/NEJM199410063311409	http://dx.doi.org/10.1056/NEJM199410063311409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ419	7888006				2022-12-28	WOS:A1994PJ41900009
J	BIGNALL, J				BIGNALL, J			THE CASE OF THE LONDON PRACTITIONER	LANCET			English	Editorial Material																		DOYLE AC, 1882, LANCET, V1, P490; KITTLER CF, 1982, STARK MUNRO LETT, P145; RODIN AE, 1992, CONANDOYLES TALES ME; 1887, LANCET, V1, P450	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1500	1501		10.1016/S0140-6736(05)80078-9	http://dx.doi.org/10.1016/S0140-6736(05)80078-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902895				2022-12-28	WOS:A1993MM40200005
J	LUCARELLI, G; ANGELUCCI, E; GIARDINI, C; BARONCIANI, D; GALIMBERTI, M; POLCHI, P; BARTOLUCCI, M; MURETTO, P; ALBERTINI, F				LUCARELLI, G; ANGELUCCI, E; GIARDINI, C; BARONCIANI, D; GALIMBERTI, M; POLCHI, P; BARTOLUCCI, M; MURETTO, P; ALBERTINI, F			FATE OF IRON STORES IN THALASSEMIA AFTER BONE-MARROW TRANSPLANTATION	LANCET			English	Article							THALASSEMIA; CHELATION	After successful bone-marrow transplantation (BMT) in thalassaemia, the individual acquires the pattern of globin synthesis of the donor. We call such an individual ''exthalassaemic after BMT'', a term that underscores the cure of the genetic defect but maintenance of residual signs of organ damage due to iron overload and dysfunction acquired during the pretransplant years. We have analysed the extent and fate of tissue iron overload in 151 ex-thalassaemic patients after BMT, according to the risk factors of hepatomegaly, hepatic portal fibrosis, and inadequate chelation therapy. Serum ferritin concentrations decreased and unbound iron binding capacity (UIBC) increased slowly during the years after the transplant. When analysed according to risk group (assigned at the time of the transplant), ferritin and UIBC returned within the normal ranges in only the low-risk group (without hepatomegaly or portal fibrosis, and with adequate chelation pre-BMT). Ferritin and UIBC were still abnormal 7 years after the transplant in the moderate-risk group (those with one or two risk factors) and highly abnormal in the high-risk group (all three risk factors) indicating persistence of, respectively, moderate and severe iron overload at the time of transplant. In ex-thalassaemic patients who were studied before and yearly after the transplant the extent of haemosiderosis, as judged by staining of liver biopsy samples, decreased during the years after transplant. The degree of iron deposition and rate of post-BMT linear growth seem to influence rate of post-BMT decrease in tissue iron overload in different risk groups at the time of BMT.	OSPED PESARO,CTR TRAPIANTO MIDOLLO OSSEO MURAGLIA,I-61100 PESARO,ITALY; OSPED PESARO,SERV LAB ANAL,I-61100 PESARO,ITALY; OSPED PESARO,SERV ANAT PATOL,I-61100 PESARO,ITALY		LUCARELLI, G (corresponding author), OSPED PESARO,DIV EMATOL,I-61100 PESARO,ITALY.		Angelucci, Emanuele/AAC-1855-2021	Angelucci, Emanuele/0000-0002-6512-6080; Baronciani, Donatella/0000-0001-6087-2431				[Anonymous], 1978, Br J Haematol, V38, P281, DOI 10.1111/j.1365-2141.1978.tb01044.x; BORGNAPIGNATTI C, 1991, HAEMATOLOGICA, V76, P409; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRONSPIEGELWEINTROB N, 1990, NEW ENGL J MED, V323, P713, DOI 10.1056/NEJM199009133231104; DEVIRGILIIS S, 1980, ARCH DIS CHILD, V55, P43, DOI 10.1136/adc.55.1.43; FORSBURG MT, 1990, BLOOD, V76, P435; LEY TS, 1982, CCLIN HAEMATOL, V11, P439; LUCARELLI G, 1985, LANCET, V1, P1355; LUCARELLI G, 1990, NEW ENGL J MED, V322, P417, DOI 10.1056/NEJM199002153220701; MURETTO P, IN PRESS LIVER; OVERMOYER BA, 1987, ARCH PATHOL LAB MED, V111, P549; THOMAS ED, 1982, LANCET, V2, P227; 1993, BONE MARROW TRANS S1, V12, pS56	13	62	62	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1388	1391		10.1016/0140-6736(93)92753-G	http://dx.doi.org/10.1016/0140-6736(93)92753-G			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901682				2022-12-28	WOS:A1993MK09500010
J	WILDEN, JN				WILDEN, JN			RAPID RESUSCITATION IN SEVERE HEAD-INJURY	LANCET			English	Editorial Material											WILDEN, JN (corresponding author), ROYAL LONDON HOSP,DEPT NEUROSURG,LONDON,ENGLAND.							ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; DeWitt DS, 1988, J NEUROTRAUM, V5, P303, DOI 10.1089/neu.1988.5.303; Foulkes MA, 1991, J NEUROSURG S, V75, P8, DOI 10.3171/sup.1991.75.1s.00s8; GRAHAM DI, 1989, J NEUROL NEUROSUR PS, V52, P346, DOI 10.1136/jnnp.52.3.346; KONG DL, 1991, CRIT CARE MED, V19, P532, DOI 10.1097/00003246-199104000-00013; MARION DW, 1991, NEUROSURGERY, V29, P869, DOI 10.1227/00006123-199112000-00011; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845	10	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1378	1378		10.1016/0140-6736(93)92750-N	http://dx.doi.org/10.1016/0140-6736(93)92750-N			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901679				2022-12-28	WOS:A1993MK09500007
J	BLACKSTONE, MG				BLACKSTONE, MG			BALLOON SPHINCTEROPLASTY VS ENDOSCOPIC PAPILLOTOMY FOR BILEDUCT STONES	LANCET			English	Editorial Material							DUCT STONES; MANAGEMENT				BLACKSTONE, MG (corresponding author), UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637, USA.							BADER M, 1986, GASTROINTEST ENDOSC, V32, P158; COTTON PB, 1984, GUT, V25, P587, DOI 10.1136/gut.25.6.587; HERNANDEZ CA, 1993, LANCET, V341, P1371, DOI 10.1016/0140-6736(93)90942-A; MACMATHUNA P, 1993, GUT, V35, P127; SHERMAN S, 1990, SEMIN LIVER DIS, V10, P205, DOI 10.1055/s-2008-1040476	5	10	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1314	1315		10.1016/0140-6736(93)92241-K	http://dx.doi.org/10.1016/0140-6736(93)92241-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901631				2022-12-28	WOS:A1993MJ03900004
J	GILGRANDE, LA; RODRIGUEZCAABEIRO, F; PRIETO, JG; SANCHEZRUANO, JJ; BRASA, C; AGUILAR, L; GARCIAHOZ, F; CASADO, N; BARCENA, R; ALVAREZ, AI; DALRE, R				GILGRANDE, LA; RODRIGUEZCAABEIRO, F; PRIETO, JG; SANCHEZRUANO, JJ; BRASA, C; AGUILAR, L; GARCIAHOZ, F; CASADO, N; BARCENA, R; ALVAREZ, AI; DALRE, R			RANDOMIZED CONTROLLED TRIAL OF EFFICACY OF ALBENDAZOLE IN INTRAABDOMINAL HYDATID-DISEASE	LANCET			English	Article							SURGICAL-TREATMENT; ULTRASOUND CHANGES; ECHINOCOCCOSIS; CHEMOTHERAPY; SULFOXIDE; INVITRO; THERAPY	The efficacy of albendazole in hydatid disease is still unclear, because there has been no study that assessed the status of the parasite after treatment. The significance of albendazole-induced echographic changes in the cyst therefore cannot be judged. We did a prospective, controlled, randomised, open study of albendazole in patients with liver hydatid disease, and assessed parasite viability after treatment. 18 patients received no albendazole treatment (controls), 18 received albendazole (10 mg/kg daily) for 1 month (group A), and 19 received the drug for about 3 months (group B). Echography was done before and during treatment; all patients underwent surgery on completion. Parasite (protoscolex viability and development of cysts in mice) and ultrastructure studies were done for all cysts removed. 8 (50%) of cysts in the control group, 13 (72%) in group A, and 16 (94%) in group B were non-viable (p=0.015). Protoscolex and cyst viability were significantly (p=0.039 and p=0.018, respectively) lower in treated patients than in controls. Treatment was also significantly associated with total cyst membrane disintegration. 68% of cysts treated for 3 months showed echographic changes, and only 1 of 20 cysts showing echographic changes during treatment was judged viable. The efficacy of albendazole at a dose of 10 mg/kg daily for 3 months suggests that it is a suitable alternative to surgery in uncomplicated hydatid liver disease, as initial treatment.	UNIV ALCALA DE HENARES, SCH PHARM, DEPT PARASITOL, ALCALA DE HENARES, SPAIN; SMITHKLINE BEECHAM PHARMACEUT, DEPT MED, MADRID, SPAIN; UNIV LEON, DEPT PHYSIOL PHARMACOL & TOXICOL, LEON, SPAIN	Universidad de Alcala; GlaxoSmithKline; Universidad de Leon	GILGRANDE, LA (corresponding author), HOSP RAMON Y CAJAL, SERV GASTROENTEROL, CTR COLMENAR KM 9 1, E-28034 MADRID, SPAIN.		/I-1716-2015; Alvarez, Ana I/H-5669-2015	Alvarez, Ana I/0000-0001-9206-9539; Prieto Fernandez, Julio Gabriel/0000-0002-6194-4967				BEKHTI A, 1977, BMJ-BRIT MED J, V2, P1047, DOI 10.1136/bmj.2.6094.1047; CASADO N, 1986, Z PARASITENKD, V72, P273, DOI 10.1007/BF00931155; CASADO-ESCRIBANO N, 1988, Revista Iberica de Parasitologia, V48, P25; CHINNERY JB, 1986, T ROY SOC TROP MED H, V80, P815, DOI 10.1016/0035-9203(86)90392-5; DEROSA F, 1990, ANN TROP MED PARASIT, V84, P467, DOI 10.1080/00034983.1990.11812496; GONZALEZ EM, 1991, WORLD J SURG, V15, P254, DOI 10.1007/BF01659061; GRANDE LAG, 1987, ENF INFEC MICROBIOL, V5, P627; GRANDE LAG, 1989, LANCET, V1, P905; HORTON RJ, 1989, T ROY SOC TROP MED H, V83, P97, DOI 10.1016/0035-9203(89)90724-4; Jones T. C., 1990, Principles and practice of infectious diseases., P2151; LITTLE JM, 1988, WORLD J SURG, V12, P700, DOI 10.1007/BF01655892; MAGISTRELLI P, 1991, ARCH SURG-CHICAGO, V126, P518, DOI 10.1001/archsurg.1991.01410280122020; MONEO I, 1980, ALLERGOL IMMUNOPAT S, V7, P311; MORRIS DL, 1985, JAMA-J AM MED ASSOC, V253, P2053, DOI 10.1001/jama.253.14.2053; MORRIS DL, 1983, BRIT MED J, V286, P103, DOI 10.1136/bmj.286.6359.103-a; MORRIS DL, 1986, LANCET, V2, P1035; MORRIS DL, 1987, GUT, V28, P75, DOI 10.1136/gut.28.1.75; MORRIS DL, 1984, CLIN RADIOL, V35, P297, DOI 10.1016/S0009-9260(84)80099-9; PRIETO JG, 1988, J PHARMACEUT BIOMED, V6, P1059, DOI 10.1016/0731-7085(88)80135-3; RODRIGUEZCAABEIRO F, 1988, PARASITOL RES, V74, P558, DOI 10.1007/BF00531634; SCIARRINO E, 1991, J CLIN ULTRASOUND, V19, P143, DOI 10.1002/jcu.1870190304; SIRAGANIAN RP, 1976, MANUAL CLIN IMMUNOLO, P603; STEIGER U, 1990, CLIN PHARMACOL THER, V47, P347, DOI 10.1038/clpt.1990.38; TEGGI A, 1993, ANTIMICROB AGENTS CH, V37, P1679, DOI 10.1128/AAC.37.8.1679; TODOROV T, 1990, BRIT J RADIOL, V63, P523, DOI 10.1259/0007-1285-63-751-523; WEN H, 1993, BRIT J CLIN PHARMACO, V35, P565, DOI 10.1111/j.1365-2125.1993.tb04182.x; WILSON JF, 1987, AM J TROP MED HYG, V37, P162, DOI 10.4269/ajtmh.1987.37.162	27	187	199	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1993	342	8882					1269	1272		10.1016/0140-6736(93)92361-V	http://dx.doi.org/10.1016/0140-6736(93)92361-V			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901585				2022-12-28	WOS:A1993MH56600011
J	CASSCELLS, W; FERGUSON, JJ; WILLERSON, JT; FISH, RD; SCHROTH, G; SMALLING, R; ANDERSON, HV; BUJA, LM				CASSCELLS, W; FERGUSON, JJ; WILLERSON, JT; FISH, RD; SCHROTH, G; SMALLING, R; ANDERSON, HV; BUJA, LM			THROMBUS AND UNSTABLE ANGINA	LANCET			English	Discussion							CANINE CORONARY-ARTERIES; ISCHEMIC-HEART-DISEASE; ATHEROSCLEROTIC PLAQUES; PLATELET-AGGREGATION; FLOW; PATHOGENESIS; ANGIOPLASTY; ATHERECTOMY; ENDOTHELIUM; MECHANISMS		ST LUKES EPISCOPAL HOSP, TEXAS HEART INST, HOUSTON, TX 77030 USA; UNIV TEXAS, SCH MED, DEPT NEUROL & PSYCHIAT, HOUSTON, TX 77025 USA	Saint Lukes Episcopal Hospital; Texas Heart Institute; University of Texas System				Buja, Louis Maximilian/0000-0001-8386-7029				ANDERSON HV, 1990, CORONARY ARTERY DIS, V1, P717, DOI 10.1097/00019501-199011000-00012; ANDERSON HV, 1992, AM J CARDIOL, V69, P1373, DOI 10.1016/0002-9149(92)91242-V; BARGER AC, 1990, AM J CARDIOL, V66, pG41, DOI 10.1016/0002-9149(90)90394-G; BUJA LM, 1981, AM J CARDIOL, V47, P343, DOI 10.1016/0002-9149(81)90407-0; CALIFF RM, 1992, THROMBOSIS CARDIOVAS, P389; CASSCELLS W, 1992, CIRCULATION, V86, P723, DOI 10.1161/01.CIR.86.3.723; DAVIES MJ, 1990, CIRCULATION, V82, P38; DAVIES MJ, 1988, BRIT HEART J, V60, P459; EIDT JF, 1989, J CLIN INVEST, V84, P18, DOI 10.1172/JCI114138; FALK E, 1991, AM J CARDIOL, V68, pB28, DOI 10.1016/0002-9149(91)90382-U; FLUGELMAN M Y, 1991, Journal of the American College of Cardiology, V17, p73A; FOLTS JD, 1974, FED PROC, V33, P413; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GERTZ SD, 1990, AM J CARDIOL, V66, P1368, DOI 10.1016/0002-9149(90)91170-B; GOLD HK, 1993, J AM COLL CARDIOL, V21, P1039, DOI 10.1016/0735-1097(93)90222-M; HAMPTON JR, 1993, LANCET, V341, P573; HIRSH PD, 1981, NEW ENGL J MED, V304, P687; JOHNSON DE, 1990, J AM COLL CARDIOL, V15, P419, DOI 10.1016/S0735-1097(10)80071-3; KRAGEL AH, 1990, AM J CARDIOL, V66, P562, DOI 10.1016/0002-9149(90)90482-G; LENDON CL, 1991, ATHEROSCLEROSIS, V87, P87, DOI 10.1016/0021-9150(91)90235-U; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; NOBUYOSHI M, 1991, J AM COLL CARDIOL, V18, P904, DOI 10.1016/0735-1097(91)90745-U; PEPINE CJ, 1993, J MYOCARDIAL ISCHEMI, V5, P9; SAFIAN RD, 1990, CIRCULATION, V82, P69, DOI 10.1161/01.CIR.82.1.69; SHERMAN CT, 1986, NEW ENGL J MED, V315, P913, DOI 10.1056/NEJM198610093151501; THEROUX P, 1992, NEW ENGL J MED, V327, P141, DOI 10.1056/NEJM199207163270301; UCHIDA Y, 1975, JPN HEART J, V16, P454; WILLERSON JT, 1991, J AM COLL CARDIOL, V17, pB101; WILLERSON JT, 1993, J AM COLL CARDIOL, V21, P1048, DOI 10.1016/0735-1097(93)90223-N; WILLERSON JT, 1991, P NATL ACAD SCI USA, V15, P1667; YAO SK, 1992, CIRC RES, V70, P39, DOI 10.1161/01.RES.70.1.39	32	4	4	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1993	342	8880					1151	1155		10.1016/0140-6736(93)92129-H	http://dx.doi.org/10.1016/0140-6736(93)92129-H			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901481				2022-12-28	WOS:A1993MF19800015
J	ZIV, TA; LO, B				ZIV, TA; LO, B			DENIAL OF CARE TO ILLEGAL IMMIGRANTS - PROPOSITION-187 IN CALIFORNIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASCH S, 1994, WESTERN J MED, V161, P373; AYRES BD, 1994, NY TIMES        1110, pB7; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P425; BREST P, 1992, PROCESSES CONSTITUTI, pR52; GELLERT GA, 1993, SOC SCI MED, V37, P1489, DOI 10.1016/0277-9536(93)90183-5; KATZ J, 1972, EXPT HUMAN BEINGS, P311; LO B, 1995, RESOLVING ETHICAL DI, P44; LUNDBERG GD, 1989, JAMA-J AM MED ASSOC, V262, P945, DOI 10.1001/jama.1989.03430070093040; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; PELLEGRINO ED, 1995, VIRTUES MED PRACTICE, P44; PELLEGRINO ED, 1995, VIRTUES MED PRACTICE, P36; ROBERTS A, 1989, DOCUMENTS LAWS WAR, P175; THORBURN KM, 1981, WESTERN J MED, V134, P457; 1993, CONSENT MANUAL REFER	14	48	48	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1095	1098		10.1056/NEJM199504203321612	http://dx.doi.org/10.1056/NEJM199504203321612			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898532				2022-12-28	WOS:A1995QT18700012
J	ANGLARET, X; TAELMAN, H; LADNER, J; BATUNGWANAYO, J; DABIS, F				ANGLARET, X; TAELMAN, H; LADNER, J; BATUNGWANAYO, J; DABIS, F			TUBERCULOSIS AND CHEMOPROPHYLAXIS IN AFRICA	LANCET			English	Letter							HIV-INFECTION		UNIV NAIROBI,DEPT MED MICROBIOL,NAIROBI,KENYA; CTR HOSP KIGALI,DEPT INTERNAL MED,KIGALI,RWANDA; UNIV BORDEAUX 2,INSERM,U330,F-33076 BORDEAUX,FRANCE	University of Nairobi; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux	ANGLARET, X (corresponding author), CHU TREICHVILLE,CEDRES,01 BP 1839,ABIDJAN 01,COTE IVOIRE.		Anglaret, Xavier/F-7333-2013; Anglaret, Xavier/T-2757-2019; DABIS, FRANCOIS/S-9298-2019; Ladner, Joel/AAU-3564-2020	DABIS, FRANCOIS/0000-0002-1614-8857; Anglaret, Xavier/0000-0003-3319-8423				FITZGERALD, 1995, LANCET, V345, P404; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; WADHAWAN D, 1993, 9TH INT C AIDS BERL, P321; 1993, AIDS, V7, P711	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					867	868		10.1016/S0140-6736(95)93008-6	http://dx.doi.org/10.1016/S0140-6736(95)93008-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898261				2022-12-28	WOS:A1995QQ19500059
J	DEBINSKI, HS; TROJAN, J; NUGENT, KP; SPIGELMAN, AD; PHILLIPS, RKS				DEBINSKI, HS; TROJAN, J; NUGENT, KP; SPIGELMAN, AD; PHILLIPS, RKS			EFFECT OF SULINDAC ON SMALL POLYPS IN FAMILIAL ADENOMATOUS POLYPOSIS	LANCET			English	Letter									IMPERIAL CANC RES FUND,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	DEBINSKI, HS (corresponding author), ST MARKS HOSP,POLYPOSIS REGISTRY,CITY RD,LONDON EC1V 2PS,ENGLAND.			nugent, karen/0000-0002-0408-2950				ARVANITIS ML, 1990, DIS COLON RECTUM, V33, P639, DOI 10.1007/BF02150736; LABAYLE D, 1991, GASTROENTEROLOGY, V101, P635, DOI 10.1016/0016-5085(91)90519-Q; NUGENT KP, 1993, DIS COLON RECTUM, V36, P1059, DOI 10.1007/BF02047300; NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244; WADDELL WR, 1989, AM J SURG, V157, P175, DOI 10.1016/0002-9610(89)90442-X	5	55	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					855	856		10.1016/S0140-6736(95)92989-4	http://dx.doi.org/10.1016/S0140-6736(95)92989-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898240				2022-12-28	WOS:A1995QQ19500036
J	KUMAR, L				KUMAR, L			SECONDARY LEUKEMIA AFTER AUTOLOGOUS BONE-MARROW TRANSPLANTATION	LANCET			English	Editorial Material							HODGKINS-DISEASE; LEUKEMIA; THERAPY; DRUG				KUMAR, L (corresponding author), ALL INDIA INST MED SCI,INST ROTARY CANC HOSP,NEW DELHI,INDIA.							ARMITAGE J, 1993, P AN M AM SOC CLIN, V12, P363; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; CANNELL PK, 1992, BONE MARROW TRANSPL, V9, P301; CHAN T, 1994, BONE MARROW TRANSPL, V13, P145; CHOPRA R, 1993, BLOOD, V81, P1137; International Non-Hodgkin's Lymphoma Prognostic Factors Project, 1993, NEW ENGL J MED, V329, P987; LEVINE EG, 1992, SEMIN ONCOL, V19, P47; MAROLLEAU JP, 1993, J CLIN ONCOL, V11, P590, DOI 10.1200/JCO.1993.11.3.590; MILLER JS, 1994, BLOOD, V83, P3780; SOUTAR RL, 1991, BRIT MED J, V303, P123, DOI 10.1136/bmj.303.6794.123-c; STONE RM, 1994, BLOOD, V83, P3437; TRAWEEK ST, 1993, BLOOD S, V82, P455	12	15	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					810	810		10.1016/S0140-6736(95)92960-6	http://dx.doi.org/10.1016/S0140-6736(95)92960-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898226				2022-12-28	WOS:A1995QQ19500005
J	ROLFE, I; MCPHERSON, J				ROLFE, I; MCPHERSON, J			FORMATIVE ASSESSMENT - HOW AM I DOING	LANCET			English	Article									UNIV NEWCASTLE,FAC MED & HLTH SCI,NEWCASTLE,NSW,AUSTRALIA	University of Newcastle								BLACK NM, 1986, ED EFFECTIVENESS FEE; Bloom B. S., 1981, EVALUATION IMPROVE L; ENTWISTLE NJ, 1992, S AFR MED J, V81, P596; EPSTEIN L, 1994, ANN COMMUNITY ORIENT, V7, P389; HODDER RU, 1987, VALUE IMMEDIATE FEED; INSELL PM, 1975, WHAT DO YOU EXPECT E; NASH R, 1976, TEACHER EXPECTATIONS; NEWBLE DI, 1983, MED EDUC, V17, P165, DOI 10.1111/j.1365-2923.1983.tb00657.x; ROLFE IE, 1994, 1994 P PBL C NEWC; Rowntree D., 1987, ASSESSING STUDENTS S, V1st; URDANATA IS, 1992, IMPROVING LEARNING A	11	146	149	2	27	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					837	839		10.1016/S0140-6736(95)92968-1	http://dx.doi.org/10.1016/S0140-6736(95)92968-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898233				2022-12-28	WOS:A1995QQ19500013
J	THOMPSON, GR; MAHER, VMG; MATTHEWS, S; KITANO, Y; NEUWIRTH, C; SHORTT, MB; DAVIES, G; REES, A; MIR, A; PRESCOTT, RJ; DEFEYTER, P; HENDERSON, A				THOMPSON, GR; MAHER, VMG; MATTHEWS, S; KITANO, Y; NEUWIRTH, C; SHORTT, MB; DAVIES, G; REES, A; MIR, A; PRESCOTT, RJ; DEFEYTER, P; HENDERSON, A			FAMILIAL HYPERCHOLESTEROLEMIA REGRESSION STUDY - A RANDOMIZED TRIAL OF LOW-DENSITY-LIPOPROTEIN APHERESIS	LANCET			English	Article							CORONARY HEART-DISEASE; PLASMA-EXCHANGE; DEFECTIVE APOLIPOPROTEIN-B-100; ATHEROSCLEROSIS-REGRESSION; ARTERY DISEASE; LDL-APHERESIS; THERAPY; CHOLESTEROL; CHOLESTYRAMINE; LOVASTATIN	Low-density-lipoprotein (LDL) apheresis has the theoretical advantage over anion-exchange resins and hydroxymethylglutaryl coenzyme A inhibitors of decreasing lipoprotein(a) as well as LDL. To confirm this advantage, patients with heterozygous familial hypercholesterolaemia and coronary artery disease were randomised to receive LDL apheresis fortnightly (with disposable dextran sulphate/cellulose columns) plus simvastatin 40 mg daily, or colestipol 20 g plus simvastatin 40 mg daily. Quantitative coronary angiography was repeated after a mean of 2.1 years in 20 patients undergoing apheresis and in 19 on combination drug therapy. Changes in serum lipoproteins were similar in both groups apart from greater lowering by apheresis of LDL cholesterol (3.2 vs 3.4 mmol/L in drug group, p=0.03) and lipoprotein(a) (geometric means 14 vs 21 mg/dL, p=0.03). There were no significant differences in primary angiographic endpoints per patient but lesion-based and segment-based secondary endpoints were biased in favour of the drug group (change in minimum lumen diameter of lesions 0.07 vs -0.004 mm, p=0.046; change in mean lumen diameter of segments 0.02 vs -0.06 mm, p=0.01). None of the angiographic changes correlated with lipoprotein(a) concentrations. Per patient changes in % diameter stenosis and minimum lumen diameter in the two groups were as or more favourable than those observed in five published trials that assessed lipid-lowering drug therapy by quantitative coronary angiography. Although LDL apheresis combined with simvastatin was more effective than colestipol plus simvastatin in reducing LDL cholesterol and lipoprotein(a), it was less beneficial in influencing coronary atherosclerosis and should be reserved for patients unresponsive to drugs. Decreasing lipoprotein(a) seems to be unnecessary if LDL cholesterol is reduced to 3.4 mmol/L or less.	HAMMERSMITH HOSP, DEPT CARDIOL, LONDON W12 0NN, ENGLAND; LLANDOUGH HOSP, NHS TRUST, PENARTH, S GLAM, WALES; UNIV WALES HOSP, CARDIFF, S GLAM, WALES; UNIV EDINBURGH, SCH MED, DEPT PUBL HLTH SCI, EDINBURGH, MIDLOTHIAN, SCOTLAND; UNIV HOSP DIJKZIGT, CATHETERIZAT LAB, ROTTERDAM, NETHERLANDS	Imperial College London; Cardiff University; University of Edinburgh; Erasmus University Rotterdam; Erasmus MC	THOMPSON, GR (corresponding author), MRC, LIPOPROT TEAM, LONDON, ENGLAND.			Maher, Vincent/0000-0002-3592-4508				[Anonymous], 1991, BMJ, V303, P893; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gordon Bruce R., 1994, Current Opinion in Lipidology, V5, P69, DOI 10.1097/00041433-199402000-00011; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JURGENS G, 1989, LANCET, V1, P911; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KOIZUMI J, 1993, ATHEROSCLEROSIS, V100, P65, DOI 10.1016/0021-9150(93)90068-6; MAHER VMG, 1992, ATHEROSCLEROSIS, V95, P231, DOI 10.1016/0021-9150(92)90026-D; MAHER VMG, 1991, ATHEROSCLEROSIS, V91, P73, DOI 10.1016/0021-9150(91)90188-9; MAHER VMG, 1994, JACC; MARBURGER C, 1994, AM J CARDIOL, V73, P742, DOI 10.1016/0002-9149(94)90874-5; MYANT NB, 1993, ATHEROSCLEROSIS, V104, P1, DOI 10.1016/0021-9150(93)90171-P; OLIVER MF, 1994, LANCET, V344, P633; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; STOFFEL W, 1981, LANCET, V2, P1005; TATAMI R, 1992, ATHEROSCLEROSIS, V95, P1, DOI 10.1016/0021-9150(92)90170-L; THOMPSON GR, 1985, BMJ-BRIT MED J, V291, P1671, DOI 10.1136/bmj.291.6510.1671; THOMPSON GR, 1975, LANCET, V1, P1208; THOMPSON GR, 1980, BRIT HEART J, V43, P680, DOI 10.1136/hrt.43.6.680; THOMPSON GR, 1989, ARTERIOSCLEROSIS, V9, pI152; TYBJAERGHANSEN A, 1990, ATHEROSCLEROSIS, V80, P235, DOI 10.1016/0021-9150(90)90031-D; UREN NG, 1994, NEW ENGL J MED, V330, P1782, DOI 10.1056/NEJM199406233302503; WARNICK GR, 1978, J LIPID RES, V19, P65; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WIKLUND O, 1990, LANCET, V335, P1360, DOI 10.1016/0140-6736(90)91242-3	34	220	225	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	1995	345	8953					811	816		10.1016/S0140-6736(95)92961-4	http://dx.doi.org/10.1016/S0140-6736(95)92961-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898227				2022-12-28	WOS:A1995QQ19500006
J	VANBERGEN, PFMM; JONKER, JJC; VANHOUT, BA; VANDOMBURG, RT; DECKERS, JW; AZAR, AJ; HOFMAN, A				VANBERGEN, PFMM; JONKER, JJC; VANHOUT, BA; VANDOMBURG, RT; DECKERS, JW; AZAR, AJ; HOFMAN, A			COSTS AND EFFECTS OF LONG-TERM ORAL ANTICOAGULANT TREATMENT AFTER MYOCARDIAL-INFARCTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OF-THE-NETHERLANDS; THROMBOLYTIC THERAPY; TRIAL; MORTALITY; BENEFIT; FOLLOW	Objective.-To investigate the costs and effects of long-term oral anticoagulant treatment after myocardial infarction. Design.-Cost-effectiveness analysis, based on a randomized, double-blind, placebo-controlled trial. Setting.-Sixty Dutch hospitals. Patients.-A total of 3404 hospital survivors of acute myocardial infarction randomized within a median period of 4 days after discharge to either oral anticoagulant treatment or placebo. The mean follow-up was 37 months. Intervention.-Oral anticoagulant treatment aimed at a target international normalized ratio of 2.8 to 4.8. Main Outcome Measurements.-Costs of hospital stay during readmissions, costs related to major cardiologic interventions, and costs of oral anticoagulant treatment. Results.-The costs of oral anticoagulant treatment were estimated at 394 Dutch guilders (Dfl) per patient-year (Dfl1=US $0.58). Placebo patients stayed 18 830 days in the hospital compared with 15 083 days for anticoagulation patients. Average costs per patient of medical care during follow-up were estimated at Dfl 10 784 for placebo patients and Dfl 9878 for anticoagulation patients. Conclusions.-Costs of long-term anticoagulant treatment are outweighed by the costs of prevented clinical events.	ERASMUS UNIV ROTTERDAM, ASPECT COORDINATING CTR, ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, INST MED TECHNOL ASSESSMENT, ROTTERDAM, NETHERLANDS; UNIV ROTTERDAM HOSP, THORAXCTR, ROTTERDAM, NETHERLANDS; ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, 3000 DR ROTTERDAM, NETHERLANDS	Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam				Azar, Aida J./0000-0001-7659-8262				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1994, Lancet, V343, P499; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; LOELIGER EA, 1985, ACTA HAEMATOL-BASEL, V74, P125, DOI 10.1159/000206187; LOELIGER EA, 1982, LANCET, V1, P64; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; ROOS J, 1980, LANCET, V2, P989; RUTTEN FFH, 1993, KOSTENBEREKENING BIJ; SIMOONS ML, 1991, EUR HEART J, V12, P694, DOI 10.1093/eurheartj/12.6.694; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; VANDENBRAND M, 1990, EUR HEART J, V11, P765; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; VERMEER F, 1988, BRIT HEART J, V59, P527; 1994, DRG HDB COMP CLIN FI	17	30	30	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					925	928		10.1001/jama.273.12.925	http://dx.doi.org/10.1001/jama.273.12.925			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884950				2022-12-28	WOS:A1995QM17300026
J	KANG, HJ; SCHUMAN, EM				KANG, HJ; SCHUMAN, EM			LONG-LASTING NEUROTROPHIN-INDUCED ENHANCEMENT OF SYNAPTIC TRANSMISSION IN THE ADULT HIPPOCAMPUS	SCIENCE			English	Article							TERM POTENTIATION; KINASE-ACTIVITY; MESSENGER-RNAS; TRK FAMILY; CA1 REGION; BDNF; INHIBITOR; EXPRESSION; RECEPTORS; NT-3	The neurotrophins are signaling factors important for the differentiation and survival of distinct neuronal populations during development, To test whether the neurotrophins also function in the mature nervous system, the effects of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and neurotrophic factor 3 (NT-3) on the strength of synaptic transmission in hippocampal slices were determined. Application of BDNF or NT-3 produced a dramatic and sustained (2 to 3 hours) enhancement of synaptic strength at the Schaffer collateral-CA1 synapses; NGF was without significant effect. The enhancement was blocked by K252a, an inhibitor of receptor tyrosine kinases, BDNF and NT-3 decreased paired-pulse facilitation, which is consistent with a possible presynaptic modification. Long-term potentiation could still be elicited in slices previously potentiated by exposure to the neurotrophic factors, which implies that these two forms of plasticity may use at least partially independent cellular mechanisms.	CALTECH,DIV BIOL 21676,PASADENA,CA 91125	California Institute of Technology			Schuman, Erin M/D-6204-2011					BELLINGER FP, 1993, BRAIN RES, V628, P227, DOI 10.1016/0006-8993(93)90959-Q; BERG MM, 1992, J BIOL CHEM, V267, P13; ENFORS P, 1992, EUR J NEUROSCI, V4, P1140; FREY U, 1988, BRAIN RES, V452, P57, DOI 10.1016/0006-8993(88)90008-X; GHOSH A, 1994, SCIENCE, V263, P1618, DOI 10.1126/science.7907431; ISACKSON PJ, 1991, NEURON, V6, P937, DOI 10.1016/0896-6273(91)90234-Q; KANG H, UNPUB; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KLEIN R, 1990, CELL, V61, P647, DOI 10.1016/0092-8674(90)90476-U; KNUSEL B, 1991, J NEUROCHEM, V57, P955, DOI 10.1111/j.1471-4159.1991.tb08243.x; LAMBALLE F, 1991, CELL, V66, P967, DOI 10.1016/0092-8674(91)90442-2; LOHOF AM, 1993, NATURE, V363, P350, DOI 10.1038/363350a0; LU B, 1991, P NATL ACAD SCI USA, V88, P937; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; PATTERSON SL, 1992, NEURON, V9, P1081, DOI 10.1016/0896-6273(92)90067-N; TAPLEY P, 1992, ONCOGENE, V7, P371; VASQUEZ ME, 1991, NEUROREPORT, V2, P593; ZAFRA F, 1990, EMBO J, V9, P3545, DOI 10.1002/j.1460-2075.1990.tb07564.x	19	1163	1174	2	45	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1658	1662		10.1126/science.7886457	http://dx.doi.org/10.1126/science.7886457			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886457				2022-12-28	WOS:A1995QM39700041
J	SCHONWETTER, BS; STOLZENBERG, ED; ZASLOFF, MA				SCHONWETTER, BS; STOLZENBERG, ED; ZASLOFF, MA			EPITHELIAL ANTIBIOTICS INDUCED AT SITES OF INFLAMMATION	SCIENCE			English	Article							ANTIMICROBIAL PEPTIDES; INSECT IMMUNITY; MESSENGER-RNA; DEFENSINS; CELLS; PURIFICATION; PRECURSOR; CDNA	The role of antimicrobial peptides in epithelial defense is not fully understood. An epithelial beta-defensin, lingual antimicrobial peptide (LAP), was isolated from bovine tongue and the corresponding complementary DNA cloned. LAP showed a broad spectrum of antibacterial and antifungal activities. LAP messenger RNA abundance was markedly increased in the epithelium surrounding naturally occurring tongue lesions. This increase coincided with the cellular hallmarks of acute and chronic inflammation in the underlying lamina propria, supporting a role for epithelial antimicrobial peptides as integral components of the inflammatory response.			SCHONWETTER, BS (corresponding author), MAGAININ PHARMACEUT INC,MAGAININ RES INST,5110 CAMPUS DR,PLYMOUTH MEETING,PA 19462, USA.							BEVINS CL, COMMUNICATION; BLAND PW, 1991, GASTROENTEROL CLIN N, V20, P577; BREY PT, 1993, P NATL ACAD SCI USA, V90, P6275, DOI 10.1073/pnas.90.13.6275; CHIRGWIN JJ, 1979, BIOCHEMISTRY-US, V13, P5294; DAHER KA, 1986, J VIROL, V60, P1068, DOI 10.1128/JVI.60.3.1068-1074.1986; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; DIAMOND G, 1994, CHEST, V105, pS51, DOI 10.1378/chest.105.3_Supplement.51S; GALLIN JI, 1988, INFLAMMATION; GANZ T, 1990, EUR J HAEMATOL, V44, P1; JACOB L, 1994, CIBA F SYMP, V186, P197; JONES DE, 1992, J BIOL CHEM, V267, P23216; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; MOORE KS, 1991, J BIOL CHEM, V266, P19851; NAKASHIMA H, 1993, AIDS, V7, P1129, DOI 10.1097/00002030-199308000-00019; NALLY F, 1991, PRACTITIONER, V235, P65; OUELLETTE AJ, 1989, J CELL BIOL, V108, P1687, DOI 10.1083/jcb.108.5.1687; REICHHART JM, 1992, EMBO J, V11, P1469, DOI 10.1002/j.1460-2075.1992.tb05191.x; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SUN SC, 1992, COMP BIOCHEM PHYS B, V103, P225, DOI 10.1016/0305-0491(92)90436-U; WERSHIL BK, 1992, GASTROENTEROL CLIN N, V21, P387; YOUNG WS, 1986, NEUROSCI LETT, V70, P198; ZASLOFF M, 1987, P NATL ACAD SCI USA, V84, P5449, DOI 10.1073/pnas.84.15.5449; ZEGARELLI DJ, 1993, OTOLARYNG CLIN N AM, V26, P1069	24	359	399	0	8	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1645	1648		10.1126/science.7886453	http://dx.doi.org/10.1126/science.7886453			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886453				2022-12-28	WOS:A1995QM39700037
J	FRANKLIN, BA; HOGAN, P; BONZHEIM, K; BAKALYAR, D; TERRIEN, E; GORDON, S; TIMMIS, GC				FRANKLIN, BA; HOGAN, P; BONZHEIM, K; BAKALYAR, D; TERRIEN, E; GORDON, S; TIMMIS, GC			CARDIAC DEMANDS OF HEAVY SNOW SHOVELING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							MYOCARDIAL OXYGEN-CONSUMPTION; ISCHEMIC-HEART-DISEASE; PHYSICAL EXERTION; SUDDEN-DEATH; EXERCISE; INFARCTION; COLD; MORTALITY	Objective.-To assess the physiologic responses to manual (shoveling) vs automated (electric snow thrower) snow removal in healthy, untrained men. Design.-Observational, controlled trial. Setting.-A community-based, acute care, teaching-research hospital. Participants.-A volunteer sample of 10 apparently healthy untrained men (mean+/-SD age = 32.4+/-2.1 years) met all eligibility criteria and completed the study. Intervention.-Each subject cleared two 10+/-2-cm-high, 15-m-long tracts of heavy, wet snow in the cold (2 degrees C), using self-paced manual and automated methods, in random order, with 10- to 15-minute rest periods between each 10-minute bout of work. Main Outcome Measures.-Heart rate, blood pressure, oxygen uptake, and perceived exertion during snow removal were compared with values obtained during maximal arm-ergometer and treadmill tests. Results.-Mean heart rate during shoveling was 154 and 173 beats per minute at 2 and 10 minutes, respectively, corresponding to 86% and 97% of maximal heart rate. Relative heart rate (percentage of maximal heart rate) during shoveling was inversely related to aerobic fitness (r= -0.65; P=.05). The highest heart rate and perceived exertion responses during shoveling, arm-ergometer, and treadmill testing were comparable. Systolic blood pressure during snow shoveling (198+/-17 mm Hg) was significantly greater (P<.003) than during arm ergometry or automated snow removal and slightly greater than during maximal treadmill testing (181+/-25 mm Hg). Oxygen uptake during shoveling was similar to that for arm ergometry (5.7 vs 6.3 metabolic equivalents), but lower than for treadmill testing (9.3 metabolic equivalents). Cardiorespiratory and perceived exertion responses were reduced during automated snow removal. Conclusion.-Heavy snow shoveling elicits myocardial and aerobic demands that rival maximal treadmill and arm-ergometer testing in sedentary men. These responses may contribute to cardiovascular events reported after heavy snowfalls.	WILLIAM BEAUMONT HOSP,DEPT MED,DIV CARDIOL,CARDIAC REHABIL & EXERCISE LABS,ROYAL OAK,MI 48072	Beaumont Health								ANDERSON TW, 1979, CAN MED ASSOC J, V121, P1580; BAKERBLOCKER A, 1982, AM J PUBLIC HEALTH, V72, P261, DOI 10.2105/AJPH.72.3.261; BORG G, 1970, Scandinavian Journal of Rehabilitation Medicine, V2, P92; BRUCE RA, 1973, AM HEART J, V85, P546, DOI 10.1016/0002-8703(73)90502-4; COBB LA, 1986, J AM COLL CARDIOL, V7, P215, DOI 10.1016/S0735-1097(86)80284-4; Franklin Barry A, 1980, Phys Sportsmed, V8, P40, DOI 10.1080/00913847.1980.11948665; GLASS RI, 1981, JAMA-J AM MED ASSOC, V245, P164, DOI 10.1001/jama.245.2.164; GLASS RI, 1979, LANCET, V1, P485; HATTENHAUER M, 1975, CIRCULATION, V51, P1053, DOI 10.1161/01.CIR.51.6.1053; HEPPELL R, 1991, BRIT MED J, V302, P469, DOI 10.1136/bmj.302.6774.469-c; JUNEAU M, 1989, CIRCULATION, V79, P1015, DOI 10.1161/01.CIR.79.5.1015; KAWAHARA J, 1989, AM J HYPERTENS, V2, P724, DOI 10.1093/ajh/2.9.724; KEATIN AS, 1993, CIRCULATION, V88, P1502; KITAMURA K, 1972, J APPL PHYSIOL, V32, P516, DOI 10.1152/jappl.1972.32.4.516; Matthews DE, 1988, USING UNDERSTANDING, P178; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; MUNDAL R, 1987, EUR J APPL PHYSIOL O, V56, P245, DOI 10.1007/BF00690888; NELSON RR, 1974, CIRCULATION, V50, P1179, DOI 10.1161/01.CIR.50.6.1179; RICHARDSON PD, 1989, LANCET, V2, P941; Segal K. R., 1994, Medicine and Science in Sports and Exercise, V26, pS54, DOI 10.1249/00005768-199405001-00302; SHELDAHL LM, 1992, J AM COLL CARDIOL, V20, P1111, DOI 10.1016/0735-1097(92)90366-U; WETHERBEE S, 1991, CHEST, V99, P1271, DOI 10.1378/chest.99.5.1271; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; 1991, GUIDELINES GRADED EX, P98	24	45	45	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					880	882		10.1001/jama.273.11.880	http://dx.doi.org/10.1001/jama.273.11.880			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869560				2022-12-28	WOS:A1995QL40200027
J	BRACKBILL, RM; SIEGEL, PZ; ACKERMANN, SP				BRACKBILL, RM; SIEGEL, PZ; ACKERMANN, SP			SELF-REPORTED HYPERTENSION AMONG UNEMPLOYED PEOPLE IN THE UNITED-STATES	BRITISH MEDICAL JOURNAL			English	Article											BRACKBILL, RM (corresponding author), CTR DIS CONTROL & PREVENT,MAILSTOP E-44,ATLANTA,GA 30333, USA.							FRANCO LJ, 1985, AM J EPIDEMIOL, V21, P684; LEEFLANG RLI, 1992, SOC SCI MED, V34, P351, DOI 10.1016/0277-9536(92)90295-2; SMITH R, 1991, BRIT MED J, V305, P972; THEORELL T, 1975, INT J EPIDEMIOL, V4, P281, DOI 10.1093/ije/4.4.281; 1989, SURVEY DATA ANAL SUD	5	9	11	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					568	568		10.1136/bmj.310.6979.568	http://dx.doi.org/10.1136/bmj.310.6979.568			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QK700	7888932	Green Published			2022-12-28	WOS:A1995QK70000020
J	BOOTH, BE; VERMA, M; BERI, RS				BOOTH, BE; VERMA, M; BERI, RS			FETAL SEX DETERMINATION IN INFANTS IN PUNJAB, INDIA - CORRELATIONS AND IMPLICATIONS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To determine the proportion of children whose sex was determined prenatally among those attending one Indian hospital and to identify factors which affect use of fetal sex determination. Design-Cross sectional study using interviews with mothers. Setting-Medical school hospital in Punjab, India. Subjects-596 children delivered or seen for inpatient or outpatient care. Main outcome measures-Fetal sex determination, sex of child, number and sex of siblings, type of care received, socioeconomic status, and maternal education. Results-Sex had been determined prenatally for fewer girls (5/236, 2%) than boys (49/360, 14%). Fetal sex determination had been done for only 2% (3/154) of first born boys compared with 18% (12/66) with one older sister and no older brother and 63% (30/48) with more than one older sister and no older brother. Only four boys whose sex had been determined prenatally had older brothers. The five girls whose sex had been determined prenatally either had a male twin or were incorrectly identified as male. Prenatal sex determination had been done for 21% (26/122) of boys admitted for inpatient care compared with 11% (19/173) seen as outpatients. Use of fetal sex determination increased with increasing monthly income (chi(2) for trend = 6.384, P = 0.0115). None of the mothers who had had no education had used fetal sex determination, but among mothers with some education the frequency of use did not change with increasing education. The sex ratio of children born at the hospital rose from 107 boys/100 girls in 1982 to 132 boys/100 girls in 1993. Conclusions-Fetal sex determination was common, especially if the family already had daughters. Sex determination seems to be driven by a desire to have sons, with socioeconomic status and education having little effect. The lower prevalence of fetal sex determinations for girls is likely to be due to abortion of fetuses found to be female.	CHRISTIAN MED COLL & HOSP,DEPT PAEDIAT,LUDHIANA,PUNJAB,INDIA									BOOTH BE, 1992, AM J PUBLIC HEALTH, V82, P1155, DOI 10.2105/AJPH.82.8.1155; GABLE SG, 1986, OBSTETRICS NORMAL PR; KHOSLA T, 1980, J EPIDEMIOL COMMUN H, V34, P143, DOI 10.1136/jech.34.2.143; Miller BD, 1981, ENDANGERED SEX NEGLE; PLATTNER G, 1983, OBSTET GYNECOL, V61, P454; RAMANAMMA A, 1980, SOC SCI MED-MED ANTH, V14, P107, DOI 10.1016/0160-7987(80)90059-9; RAO R, 1986, NATURE, V324, P202, DOI 10.1038/324202b0; Reese E.A., 1987, AM J OBSTET GYNECOL, V156, P579; WALTER SD, 1975, SOC SCI MED, V9, P105, DOI 10.1016/0037-7856(75)90102-X; 1983, LANCET, V1, P812	10	43	43	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1259	1261		10.1136/bmj.309.6964.1259	http://dx.doi.org/10.1136/bmj.309.6964.1259			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PT033	7888845	Green Published			2022-12-28	WOS:A1994PT03300018
J	POWELL, JT; GREENHALGH, RM; RUCKLEY, CV; FOWKES, FGR				POWELL, JT; GREENHALGH, RM; RUCKLEY, CV; FOWKES, FGR			PROLOGUE TO A SURGICAL TRIAL	LANCET			English	Editorial Material							ABDOMINAL AORTIC-ANEURYSMS		UNIV EDINBURGH,WOLFSON UNIT PREVENT PERIPHERAL VASC DIS,EDINBURGH EH8 9AG,MIDLOTHIAN,SCOTLAND	University of Edinburgh	POWELL, JT (corresponding author), CHARING CROSS & WESTMINSTER MED SCH,DEPT SURG,LONDON W6 8RF,ENGLAND.		Powell, Janet/AAW-8669-2021	Powell, Janet/0000-0002-3905-1468				ELLIS M, 1991, BRIT J SURG, V78, P614, DOI 10.1002/bjs.1800780529; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; HARRIS PL, 1992, BMJ-BRIT MED J, V305, P697, DOI 10.1136/bmj.305.6855.697; HORTON R, 1993, LANCET, V342, P192, DOI 10.1016/0140-6736(93)92295-5; Naylor A R, 1988, Eur J Vasc Surg, V2, P217, DOI 10.1016/S0950-821X(88)80029-X; 1991, LANCET, V337, P1235	6	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1473	1474		10.1016/0140-6736(93)92939-Q	http://dx.doi.org/10.1016/0140-6736(93)92939-Q			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902488				2022-12-28	WOS:A1993ML21700015
J	MCKENNA, MT; MCCRAY, E; ONORATO, I				MCKENNA, MT; MCCRAY, E; ONORATO, I			THE EPIDEMIOLOGY OF TUBERCULOSIS AMONG FOREIGN-BORN PERSONS IN THE UNITED-STATES, 1986 TO 1993	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INDOCHINESE REFUGEES; BRITISH-COLUMBIA; IMMIGRANTS; CONVERSIONS; COUNTRIES; INFECTION; CHILDREN; HEALTH	Background. One third of the world's population is infected with Mycobacterium tuberculosis, and in the developed countries immigration is a major force that sustains the incidence of tuberculosis. We studied the effects of immigration on the epidemiology of tuberculosis and its recent resurgence in the United States. Methods. We analyzed data from the national tuberculosis reporting system of the Centers for Disease Control and Prevention. Since 1986 reports of tuberculosis have included the patient's country of origin. Population estimates for foreign-born persons were derived from special samples from the 1980 and 1990 censuses. Results. The proportion of persons reported to have tuberculosis who were foreign-born increased from 21.6 percent (4925 cases) in 1986 to 29.6 percent (7346 cases) in 1993. For the entire eight-year period, most foreign-born patients with tuberculosis were from Latin America (43.9 percent; 21,115 cases) and Southeast Asia (34.6 percent; 16,643 cases). Among foreign-born persons the incidence rate was almost quadruple the rate for native residents of the United States (30.6 vs. 8.1 per 100,000 person-years), and 55 percent of immigrants with tuberculosis had the condition diagnosed in their first five years in the United States. Conclusions. Immigration has had an increasingly important effect on the epidemiology of tuberculosis in the United States. It will be difficult to eliminate tuberculosis without better efforts to prevent and control it among immigrants and greater efforts to control it in the countries from which they come.			MCKENNA, MT (corresponding author), CTR DIS CONTROL & PREVENT,DIV TUBERCULOSIS ELIMINAT,1600 CLIFTON RD E-10,ATLANTA,GA 30333, USA.							AICKIN M, 1991, AM J PUBLIC HEALTH, V81, P918, DOI 10.2105/AJPH.81.7.918; ASCH S, 1994, WESTERN J MED, V161, P373; BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670; BROEKMANS JF, 1993, TUBERCULOSIS COMPREH, P641; CANTWELL MF, 1994, JAMA-J AM MED ASSOC, V272, P535, DOI 10.1001/jama.272.7.535; CLAYTON D, 1993, STATISTICAL MODELS E; ENARSON DA, 1989, AM J EPIDEMIOL, V129, P1268, DOI 10.1093/oxfordjournals.aje.a115246; FEIN DJ, 1990, DEMOGRAPHY, V27, P285, DOI 10.2307/2061454; JACOBSON ML, 1987, AM J PUBLIC HEALTH, V77, P29, DOI 10.2105/AJPH.77.1.29; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOCHI A, 1991, TUBERCLE, V72, P1, DOI 10.1016/0041-3879(91)90017-M; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MORSE DL, 1985, AM REV RESPIR DIS, V132, P516; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; NOLAN CM, 1988, AM REV RESPIR DIS, V137, P805, DOI 10.1164/ajrccm/137.4.805; NOLAN CM, 1989, AM REV RESPIR DIS, V140, P996, DOI 10.1164/ajrccm/140.4.996; ONORATO IM, 1992, J INFECT DIS, V165, P87, DOI 10.1093/infdis/165.1.87; ORMEROD LP, 1990, RESP MED, V84, P269, DOI 10.1016/S0954-6111(08)80051-0; ORR P, 1993, TUBERCULOSIS COMPREH, P531; ORR PH, 1990, CAN MED ASSOC J, V142, P453; PEREZSTABLE EJ, 1985, PEDIATR INFECT DIS J, V4, P476, DOI 10.1097/00006454-198509000-00007; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; POWELL KE, 1983, JAMA-J AM MED ASSOC, V249, P1455, DOI 10.1001/jama.249.11.1455; POWELL KE, 1981, AM J PUBLIC HEALTH, V71, P1223, DOI 10.2105/AJPH.71.11.1223; RAVIGLIONE MC, 1993, B WORLD HEALTH ORGAN, V71, P297; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; RIEDER HL, 1989, JAMA-J AM MED ASSOC, V262, P385, DOI 10.1001/jama.262.3.385; RIEDER HL, 1989, EPIDEMIOL REV, V11, P79, DOI 10.1093/oxfordjournals.epirev.a036046; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; STARKE JR, 1992, J PEDIATR-US, V120, P839, DOI 10.1016/S0022-3476(05)81949-3; STEHRGREEN JK, 1992, NEW ZEAL MED J, V105, P301; STYBLO K, 1989, REV INFECT DIS, V11, pS339; SUTTER RW, 1990, AM REV RESPIR DIS, V141, P1483, DOI 10.1164/ajrccm/141.6.1483; WANG JS, 1991, TUBERCLE, V72, P277, DOI 10.1016/0041-3879(91)90054-V; WANG JS, 1989, TUBERCLE, V70, P179, DOI 10.1016/0041-3879(89)90048-2; 1990, MMWR-MORBID MORTAL W, V39, P1; 1992, AM REV RESPIR DIS, V146, P1623; 1991, DHHS PHS911101; 1977, PROCEDURAL GUIDE REC; 1993, 1993 WORLD BANK WORL; 1992, 1990 CENSUS POPULATI; 1993, 1990 CENSUS POPULATI; 1994, STATISTICAL YB IMMIG; 1994, MMWR-MORBID MORTAL W, V43, P361; 1994, LANCET, V344, P277; 1991, TECHNICAL INSTRUCTIO; 1992, THORAX, V47, P770; 1989, MMWR MORB MORTAL SS3, V38, P1; 1993, MMWR-MORBID MORTAL W, V42, P1	49	320	324	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1071	1076		10.1056/NEJM199504203321606	http://dx.doi.org/10.1056/NEJM199504203321606			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT187	7898526	Bronze			2022-12-28	WOS:A1995QT18700006
J	CHARON, R; BANKS, JT; CONNELLY, JE; HAWKINS, AH; HUNTER, KM; JONES, AH; MONTELLO, M; POIRER, S				CHARON, R; BANKS, JT; CONNELLY, JE; HAWKINS, AH; HUNTER, KM; JONES, AH; MONTELLO, M; POIRER, S			LITERATURE AND MEDICINE - CONTRIBUTIONS TO CLINICAL-PRACTICE	ANNALS OF INTERNAL MEDICINE			English	Review							NONMEDICAL LITERATURE; STORIES; ETHICS; EXPERIENCE; PHYSICIANS; EDUCATION; PORTRAYAL; DISCOURSE; ILLNESS; RECORD	Introduced to U.S. medical schools in 1972, the field of literature and medicine contributes methods and texts that help physicians develop skills in the human dimensions of medical practice. Five broad goals are met by including the study of literature in medical education: 1) Literary accounts of illness can teach physicians concrete and powerful lessons about the lives of sick people; 2) great works of fiction about medicine enable physicians to recognize the power and implications of what they do; 3) through the study of narrative, the physician can better understand patients' stories of sickness and his or her own personal stake in medical practice; 4) literary study contributes to physicians' expertise in narrative ethics; and 5) literary theory offers new perspectives on the work and the genres of medicine. Particular texts and methods have been found to be well suited to the fulfillment of each of these goals. Chosen from the traditional literary canon and from among the works of contemporary and culturally diverse writers, novels, short stories, poetry, and drama can convey both the concrete particularity and the metaphorical richness of the predicaments of sick people and the challenges and rewards offered to their physicians. in more than 20 years of teaching literature to medical students and physicians, practitioners of literature and medicine have clarified its conceptual frameworks and have identified the means by which its studies strengthen the human competencies of doctoring, which are a central feature of the art of medicine.	PENN STATE UNIV, COLL MED, HERSHEY, PA USA; UNIV VIRGINIA, SCH MED, CHARLOTTESVILLE, VA 22908 USA; NORTHWESTERN UNIV, SCH MED, CHICAGO, IL USA; UNIV ILLINOIS, COLL MED, CHICAGO, IL USA; UNIV TEXAS, MED BRANCH, GALVESTON, TX 77550 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Virginia; Northwestern University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Texas System; University of Texas Medical Branch Galveston; Harvard University; Harvard Medical School	CHARON, R (corresponding author), COLUMBIA UNIV, COLL PHYS & SURG, DEPT MED, 622 W 168TH ST, PH 9E, NEW YORK, NY 10032 USA.							ALCORN MW, 1985, PMLA, V100, P342, DOI 10.2307/462087; [Anonymous], 1983, RHETORIC FICTION; ARNOLD M, 1989, DISCOURSES AM, P72; BAKER NJ, 1990, MINN MED, V73, P19; Bakhtin M.M, 1981, DIALOGIC IMAGINATION; BANKS JT, 1992, LIT MED, V11, pR7; BANKS JT, 1990, LIT MED, V9, P162; BARTHES R, 1988, SEMIOTIC CHALLENGE, P202; BELKIN BM, 1992, ANN INTERN MED, V116, P863, DOI 10.7326/0003-4819-116-10-863; Benjamin W., 1969, ILLUMINATIONS; BENNER P, 1991, ADV NURS SCI, V14, P1; BILLINGS JA, 1985, J MED EDUC, V60, P855; BISHOP MGH, 1991, J ROY SOC MED, V84, P637; Blackmur R. P., 1983, STUDIES H JAMES, P91; BLOOM H, 1985, DECONSTRUCTION CRITI; Booth Wayne, 1988, CO WE KEEP ETHICS FI; BORKAN JM, 1991, SOC SCI MED, V33, P947, DOI 10.1016/0277-9536(91)90265-E; Brody H., 1987, STORIES SICKNESS; Brooks Peter, 1985, READING PLOT; Broyard, 1992, INTOXICATED MY ILLNE; Bruner JS, 1986, ACTUAL MINDS POSSIBL, DOI DOI 10.4159/9780674029019; BURRELL D, 1977, KNOWLEDGE VALUE BELI, V2, P111; CADY J, 1992, SEMIN NEUROL, V12, P70; CALMAN KC, 1988, MED EDUC, V22, P265, DOI 10.1111/j.1365-2923.1988.tb00752.x; CARSON RA, 1990, THEOR MED, V11, P51, DOI 10.1007/BF00489238; CASSELL EJ, 1985, HEALERS ART; CHARON R, 1986, LIT MED, V5, P58; Charon R., 1994, MATTER PRINCIPLES FE, P260; Charon R., 1993, EMPATHY PRACTICE MED, P147; Charon R., 1993, J NARRAT LIFE HIST, V3, P79, DOI [https://doi.org/10.1075/jnlh.3.1.03med, DOI 10.1075/JNLH.3.1.03MED]; Christian Reginald Frank, 1969, TOLSTOY CRITICAL INT; Churchill L, 1979, Soundings, V62, P24; CLOUSER KD, 1990, J MED PHILOS, V15, P289, DOI 10.1093/jmp/15.3.289; COINER C, 1992, FEMINIST STUD, V18, P257, DOI 10.2307/3178227; Coles R, 1989, CALL STORIES TEACHIN; CONNELLY JE, 1987, ARCH INTERN MED, V147, P1829, DOI 10.1001/archinte.147.10.1829; CONNELLY JE, 1990, LIT MED, V9, P150, DOI 10.1353/lm.2011.0150; CONNELLY JE, 1988, JAMA-J AM MED ASSOC, V260, P812, DOI 10.1001/jama.260.6.812; COULEHAN JL, 1992, QUALITATIVE HLTH RES, V2, P358; CULLER J, 1982, DECONSTRUCTION, P64; Daniel H J 3rd, 1990, N C Med J, V51, P406; Daniel S L, 1986, Theor Med, V7, P195, DOI 10.1007/BF00489230; De Man P, 1986, BLINDNESS INSIGHT; Derrida J, 1976, POSICOES; Dirckx J H, 1991, Pharos Alpha Omega Alpha Honor Med Soc, V54, P32; DIREKX JH, 1992, PHAROS, V55, P27; Donnelly W J, 1991, Pharos Alpha Omega Alpha Honor Med Soc, V54, P21; DONNELLY WJ, 1988, JAMA-J AM MED ASSOC, V260, P823, DOI 10.1001/jama.260.6.823; DOWNIE RS, 1991, J MED ETHICS, V17, P93, DOI 10.1136/jme.17.2.93; Epstein L C, 1993, R I Med, V76, P333; FLORES A, 1963, KAFKA PROBLEM NEW UP; Flynn E., 1986, GENDER READING ESSAY; FOUCAULT M, 1973, BIRTH CLINIC; FRANK AW, 1993, SOCIOL QUART, V34, P39, DOI 10.1111/j.1533-8525.1993.tb00129.x; FRANK AW, 1994, LIT MED, V13, P1, DOI 10.1353/lm.2011.0180; FREUD S, 1953, STANDARD EDITION COM, V12, P291; GAEGAN P, 1962, COLLECTION CRITICAL, P145; GERHARDT U, 1990, SOC SCI MED, V30, P1149, DOI 10.1016/0277-9536(90)90255-Q; GILBERT SM, 1979, MADWOMAN IN ATTIC; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GOOD MJD, 1994, SOC SCI MED, V38, P855, DOI 10.1016/0277-9536(94)90157-0; GUSTAFSON JM, 1990, J MED PHILOS, V15, P125, DOI 10.1093/jmp/15.2.125; HAWKINS AH, 1992, LIT MED, V11, P200; HAWKINS AH, 1993, CONFIGURATIONS, V2, P229; HAWKINS AH, 1994, MED HUMANITIES REV, V8, P9; Hawkins Anne Hunsaker, 1999, RECONSTRUCTING ILLNE; Hillman J., 1983, HEALING FICTION, P3; HOLLAND NN, 1989, DYNAMICS LITERARY RE; HUNTER KM, 1994, LIT MED, V13, pR9; HUNTER KM, 1992, DOCTORS STORIES NARR; ISER W, 1978, ACT READING; JONES AH, 1987, NEOHELICON, V14, P383, DOI 10.1007/BF02094701; JONES AH, 1990, ST COMPAR L, V22, P11; JONES AH, 1991, LIT MED, P10; Jones Anne Hudson, 1988, PERSONAL CHOICES PUB, P1; JONSEN A, 1988, ABUSE CASUITRY HIST; KIRSCH A, 1988, SHAKESPEARE QUART, V39, P154, DOI 10.2307/2870627; Kleinman A., 1988, ILLNESS NARRATIVES; KOHN M, 1992, LIT AGING ANTHOLOGY; Konner M., 1993, MED CROSSROADS CRISI; KREISWIRTH M, 1992, NEW LITERARY HIST, V23, P629, DOI 10.2307/469223; LEDER D, 1990, THEOR MED, V11, P9, DOI 10.1007/BF00489234; LOUGHMAN C, 1992, GERONTOLOGIST, V32, P726, DOI 10.1093/geront/32.6.726; MARCUS S, 1985, DORAS CASE FREUD HYS, P00056; MARSHALL A, 1994, SOC SCI MED, V40, P67; Miles S H, 1990, Second Opin, P55; MILES SH, 1990, 2ND OPINION, V11, P54; Miller J. Hillis, 1987, ETHICS READING; Mishler EG, 1984, DISCOURSE MED DIALEC; MONTELLO MW, 1961, ACAD MED, V66, P332; MORE ES, 1994, EMPATHIC PRATITIONER; MURDOCH I, 1986, SOVEREIGNTY OF GOOD; MURPHY TF, 1993, WRITINGS AIDS GAY LI; Nashold J R, 1992, N C Med J, V53, P205; Nixon L L, 1991, Law Med Health Care, V19, P291; Nussbaum M.C., 1990, LOVES KNOWLEDGE; OZER IJ, 1991, EPILEPSIA, V32, P798, DOI 10.1111/j.1528-1157.1991.tb05536.x; Peabody Francis W., 1930, PAPERS RELATIONSHIP; POIRIER S, 1990, THEOR MED, V11, P29, DOI 10.1007/BF00489236; POIRIER S, 1988, HASTINGS CENT REP, V18, P5, DOI 10.2307/3563220; POLKINGHORNE DE, 1908, NARRATIVE KNOWING HU; Porter W G, 1993, N C Med J, V54, P96; POSEN S, 1993, J ROY SOC MED, V86, P345; POSEN S, 1992, J ROY SOC MED, V85, P314; PRESTON RP, 1979, DILEMMAS CARE SOCIAL, P3; PUMA JL, 1989, J GEN INTERN MED, V4, P413; QUILL TE, 1994, MED ENCOUNTER, V11; RABUZZI K, 1982, LIT MED, P1; RADEY C, 1990, HASTINGS CENT REP, V20, P25, DOI 10.2307/3563423; Radey C, 1992, J Clin Ethics, V3, P38; RADWANY SM, 1987, JAMA-J AM MED ASSOC, V257, P1629, DOI 10.1001/jama.257.12.1629; Reich Warren Thomas, 1988, J Appl Commun Res, V16, P16; Ricoeur P, 1985, TIME NARRATIVE, V2; RISSE GB, 1992, WESTERN J MED, V156, P431; ROCKNEY R, 1991, J MED HUMANITIES, V12, P153; RODIN AE, 1992, SOUTHERN MED J, V85, P528, DOI 10.1097/00007611-199205000-00014; SCHWARTZ MA, 1986, AM J PSYCHIAT, V143, P1213; SECUNDY MG, 1991, TRIALS TRIBULATIONS; SELZER R, 1987, MORTAL LESSONS; SERTIMA IV, 1986, GREAT AFRICAN THINKE, V1, P7; SHAFER A, 1994, LIT MED, V13, P124; SHELDON SH, 1990, ACAD MED, V65, P234, DOI 10.1097/00001888-199004000-00004; Showalter Elaine, 1985, NEW FEMINIST CRITICI; SHUTTLEWORTH S, 1984, G ELIOT 19TH CENTURY; Siebers Tobin, 1988, ETHICS CRITICISM; Skura Meredith A., 1981, LIT USE PSYCHOANALYT; SLAVNEY PR, 1984, PERSPECT BIOL MED, V27, P279; Snow Charles Percy, 1959, 2 CULTURES SCI REVOL; SPIRO H, 1992, ANN INTERN MED, V116, P843, DOI 10.7326/0003-4819-116-10-843; Stanford Ann Folwell, 1994, NWSA J PUBLICATION N, V6, P28; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; TERRY JS, 1987, LIT MED, V6, P43, DOI 10.1353/lm.2011.0012; Tompkins Jane P., 1980, READER RESPONSE CRIT; Toombs S K, 1988, Theor Med, V9, P201, DOI 10.1007/BF00489413; TOULMIN S, 1983, POLITICS INTERPRETAT, P99; TRAUTMANN J, 1982, MOBIUS, V2, P23; Trautmann J., 1981, HEALING ARTS DIALOGU; TRAUTMANN J, 1975, ETHICS SCI MED, V2, P105; TRILLING L, 1965, CULTURE ESSAYS LIT L, P77; Trilling Lionel, 1965, CULTURE ESSAYS LIT L, P3; Trilling Lionel, 1965, CULTURE ESSAYS LIT L, P126; Vaughan S C, 1990, Pharos Alpha Omega Alpha Honor Med Soc, V53, P38; Wear D, 1991, Pharos Alpha Omega Alpha Honor Med Soc, V54, P7; WEAR D, 1987, 1984 P NE OH U COLL; WEIGAND HJ, 1994, MAGIC MOUNTAINS STUD; Wellek Rene, 1984, CHEKHOV NEW PERSPECT; WILSON J, 1980, GEN HOSP PSYCHIAT, V2, P127, DOI 10.1016/0163-8343(80)90026-2; Young-Mason J, 1988, Clin Nurse Spec, V2, P180, DOI 10.1097/00002800-198800240-00007; Younger J B, 1990, Image J Nurs Sch, V22, P39	149	171	178	1	26	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					599	606		10.7326/0003-4819-122-8-199504150-00008	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Arts &amp; Humanities Citation Index (A&amp;HCI)	General & Internal Medicine	QR525	7887555				2022-12-28	WOS:A1995QR52500008
J	DECOCK, KM; GRANT, A; PORTER, JDH				DECOCK, KM; GRANT, A; PORTER, JDH			PREVENTIVE THERAPY FOR TUBERCULOSIS IN HIV-INFECTED PERSONS - INTERNATIONAL RECOMMENDATIONS, RESEARCH, AND PRACTICE	LANCET			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; NEW-YORK-CITY; RESISTANT TUBERCULOSIS; DEVELOPING-COUNTRIES; ACTIVE TUBERCULOSIS; DRUG-USERS; RISK; SURVEILLANCE; HEPATITIS				DECOCK, KM (corresponding author), LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND.							AISU T, 1995, AIDS, V9, P267, DOI 10.1097/00002030-199509030-00008; ALLAND D, 1994, NEW ENGL J MED, V330, P1710, DOI 10.1056/NEJM199406163302403; [Anonymous], 1993, Wkly Epidemiol Rec, V68, P361; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CANTWELL MF, 1994, 28TH WORLD C IUATLD; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GUELAR A, 1993, AIDS, V7, P1345, DOI 10.1097/00002030-199310000-00007; HALSEY N, 1994, 10TH INT C AIDS INT; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; LUCAS SB, 1994, BRIT MED J, V308, P1531, DOI 10.1136/bmj.308.6943.1531; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MURRAY JF, 1989, AM REV RESPIR DIS, V140, P1788, DOI 10.1164/ajrccm/140.6.1788; NARAIN JP, 1992, TUBERCLE LUNG DIS, V73, P311, DOI 10.1016/0962-8479(92)90033-G; NELSON AM, 1993, AIDS, V7, P1241, DOI 10.1097/00002030-199309000-00014; OBRIEN RJ, 1994, TUBERCULOSIS BACK FU, P151; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PIRGNOT J, 1994, 28TH WORLD C IUATLD; RODRIGUES LC, 1990, T ROY SOC TROP MED H, V84, P739, DOI 10.1016/0035-9203(90)90172-B; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; SALPETER SR, 1993, WESTERN J MED, V159, P560; SELWYN PA, 1989, NEW ENGL J MED, V320, P545, DOI 10.1056/NEJM198903023200901; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; SMALL PM, 1993, NEW ENGL J MED, V328, P1137, DOI 10.1056/NEJM199304223281601; SMALL PM, 1991, NEW ENGL J MED, V324, P289, DOI 10.1056/NEJM199101313240503; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; WADHAWAN D, 1993, 9TH INT C AIDS AFF 4; WALLIS RS, 1993, J INFECT DIS, V167, P43, DOI 10.1093/infdis/167.1.43; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011; WHALEN C, 1995, AM J CRIT CARE MED, V151, P121; 1990, MMWR-MORBID MORTAL W, V39, P1; 1989, MMWR-MORBID MORTAL W, V38, P243; 1991, MMWR-MORBID MORTAL W, V40, P27; 1994, MMWR-MORBID MORTAL W, V43, P1; 1992, MANAGING TUBERCULOSI; 1989, MMWR-MORBID MORTAL W, V38, P1; 1993, MMWR-MORBID MORTAL W, V42, P545; 1992, BRIT MED J, V304, P1231; 1989, MMWR-MORBID MORTAL W, V38, P236	40	76	77	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					833	836		10.1016/S0140-6736(95)92967-3	http://dx.doi.org/10.1016/S0140-6736(95)92967-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898232				2022-12-28	WOS:A1995QQ19500012
J	HALLIDAY, J; LUMLEY, J; WATSON, L				HALLIDAY, J; LUMLEY, J; WATSON, L			COMPARISON OF WOMEN WHO DO AND DO NOT HAVE AMNIOCENTESIS OR CHORIONIC VILLUS SAMPLING	LANCET			English	Article							PRENATAL-DIAGNOSIS; ATTITUDES	Even in areas where prenatal diagnostic testing is offered at no cost to women over a certain age, uptake of testing is not complete. We have studied the factors that affect uptake in Victoria, Australia. In 1988-92, 43% of 37-39-year-old women and 29% of those 40 years and over had no diagnostic testing despite their eligibility for a free test. We compared the characteristics of untested women (n=3074) with those of tested women (2462 amniocentesis, 1575 chorionic villus sampling) by use of record-linkage between the Victorian birth register and fetal diagnosis data collection. The indication for testing was maternal age alone. Women who had had 3 or more previous births were less likely than those of lower parity to undergo testing (odds ratio 0.54 [95% Cl 0.46-0.63], p<0.001), whereas those who had had a previous termination of pregnancy were more likely to be tested than those who had not (1.52 [1.26-1.83], p<0.001). Women born in non-English-speaking countries and women who lived in rural areas were less likely to be tested. Women who gave birth in private hospitals were more likely to be tested than those who gave birth in any public hospital or at home. These data help to distinguish between issues of choice and access to diagnostic testing. Factors that hinder testing of rural women and of those from non-English-speaking backgrounds should be addressed.	DEPT HLTH & COMMUNITY SERV,PERINATAL DATA COLLECT UNIT,MELBOURNE,VIC,AUSTRALIA; CTR STUDY MOTHERS & CHILDRENS HLTH,CARLTON,VIC,AUSTRALIA		HALLIDAY, J (corresponding author), ROYAL CHILDRENS HOSP,MURDOCH INST,FLEMINGTON RD,PARKVILLE,VIC 3052,AUSTRALIA.		halliday, jane/T-1476-2019					ABRAMSKY L, 1991, PRENATAL DIAG, V11, P23, DOI 10.1002/pd.1970110105; BELL R, 1992, AUST J PUBLIC HEALTH, V16, P15; Bryce R L, 1989, Paediatr Perinat Epidemiol, V3, P137, DOI 10.1111/j.1365-3016.1989.tb00507.x; HALLIDAY JL, 1992, LANCET, V340, P886, DOI 10.1016/0140-6736(92)93293-V; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; JULIANREYNIER C, 1993, PRENATAL DIAG, V13, P613, DOI 10.1002/pd.1970130712; KNOTT PD, 1986, BRIT J OBSTET GYNAEC, V93, P1246, DOI 10.1111/j.1471-0528.1986.tb07859.x; Kolker A, 1989, Int J Technol Assess Health Care, V5, P601; LIPPMAN A, 1985, AM J MED GENET, V22, P395, DOI 10.1002/ajmg.1320220224; MARRIOTT S, 1990, J PSYCHOSOMATIC OBST, V11, P41; MARTEAU TM, 1991, BRIT J OBSTET GYNAEC, V98, P282, DOI 10.1111/j.1471-0528.1991.tb13394.x; RAPP Y, 1984, TEST TUBE WOMEN WHAT; RICE PL, 1994, ASIAN MOTHERS AUSTR; ROBERTSON H, 1993, APPROACHING QUALITY; Robertson H., 1986, VALIDATION STUDY VIC; Rothman Barbara Katz, 1987, TENTATIVE PREGNANCY; SCHOLZ C, 1990, J PSYCHOSOMATIC OBST, V11, P27; SJOGREN B, 1989, PRENATAL DIAG, V9, P477, DOI 10.1002/pd.1970090705; SJOGREN B, 1988, PRENATAL DIAG, V8, P263, DOI 10.1002/pd.1970080404; TYMSTRA T, 1991, PRENATAL DIAG, V11, P893, DOI 10.1002/pd.1970111203; VERJAAL M, 1982, PRENATAL DIAG, V2, P195, DOI 10.1002/pd.1970020309	21	64	64	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					704	709		10.1016/S0140-6736(95)90872-2	http://dx.doi.org/10.1016/S0140-6736(95)90872-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885127				2022-12-28	WOS:A1995QM73200013
J	KIKUYAMA, S; TOYODA, F; OHMIYA, Y; MATSUDA, K; TANAKA, S; HAYASHI, H				KIKUYAMA, S; TOYODA, F; OHMIYA, Y; MATSUDA, K; TANAKA, S; HAYASHI, H			SODEFRIN - A FEMALE-ATTRACTING PEPTIDE PHEROMONE IN NEWT CLOACAL GLANDS	SCIENCE			English	Article							CRESTED NEWT; GOLDFISH	A decapeptide called sodefrin was isolated from the abdominal gland of the cloaca of the male red-bellied newt, Cynops pyrrhogaster. The native peptide, as well as the synthetic one, had a female-attracting activity. Sodefrin was found in the apical portion of the epithelial cells of the abdominal gland. Sodefrin is apparently species specific because it did not attract females of Cynops ensicauda. This is the first amphibian pheromone to be identified and the first peptide pheromone identified in a vertebrate.	NARA MED UNIV,DEPT PHYSIOL,KASHIHARA,NARA 634,JAPAN; RIKEN,RES DEV CORP,WAKO,SAITAMA 35101,JAPAN; NIPPON MED COLL,DEPT PHARMACOL,TOKYO 113,JAPAN; GUNMA UNIV,INST ENDOCRINOL,MAEBASHI,GUMMA 371,JAPAN; GUNMA PREFECTURAL COLL HLTH SCI,MAEBASHI,GUMMA 371,JAPAN	Nara Medical University; RIKEN; Nippon Medical School; Gunma University	KIKUYAMA, S (corresponding author), WASEDA UNIV,SCH EDUC,DEPT BIOL,NISHIWASEDA,TOKYO 16950,JAPAN.		Ohmiya, Yoshihiro/J-7143-2013	Ohmiya, Yoshihiro/0000-0002-4944-509X				CEDRINI L, 1971, Monitore Zoologico Italiano, V5, P223; COLOMBO L, 1980, Bollettino di Zoologia, V47, P355; Houck L.D., 1986, CHEM SIGNALS VERTEBR, P173; Lebedeva N.Y., 1975, J ICHTHYOL, V15, P472; MALACARNE G, 1984, MONIT ZOOL ITAL, V18, P33; MALACARNE G, 1982, BEHAV PROCESS, V7, P307, DOI 10.1016/0376-6357(82)90003-1; MASON RT, 1989, SCIENCE, V245, P290, DOI 10.1126/science.2749261; NOVOTNY M, 1990, CHEM SIGNAL, V5, P1; OKADA H, 1979, SCI REP HOKKAIDO FIS, V33, P89; PFEIFFER W, 1978, J CHEM ECOL, V4, P665, DOI 10.1007/BF00990277; PFUDERER P, 1974, J EXP ZOOL, V187, P375, DOI 10.1002/jez.1401870306; RODRIGUEZ H, 1989, TECHNIQUES PROTEIN C, P186; Salthe S.N., 1974, P309; SORENSEN PW, 1988, BIOL REPROD, V39, P1039, DOI 10.1095/biolreprod39.5.1039; STACEY NE, 1986, CAN J ZOOL, V64, P2412, DOI 10.1139/z86-360; TAKATA K, 1991, J HISTOCHEM CYTOCHEM, V39, P287, DOI 10.1177/39.3.1993828; TOYODA F, 1994, PHYSIOL BEHAV, V55, P569, DOI 10.1016/0031-9384(94)90118-X; Tucker D., 1972, OLFACTION TASTE, VIV, P121	18	190	193	1	20	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1643	1645		10.1126/science.7886452	http://dx.doi.org/10.1126/science.7886452			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886452				2022-12-28	WOS:A1995QM39700036
J	BOND, RA; LEFF, P; JOHNSON, TD; MILANO, CA; ROCKMAN, HA; MCMINN, TR; APPARSUNDARAM, S; HYEK, MF; KENAKIN, TP; ALLEN, LF; LEFKOWITZ, RJ				BOND, RA; LEFF, P; JOHNSON, TD; MILANO, CA; ROCKMAN, HA; MCMINN, TR; APPARSUNDARAM, S; HYEK, MF; KENAKIN, TP; ALLEN, LF; LEFKOWITZ, RJ			PHYSIOLOGICAL-EFFECTS OF INVERSE AGONISTS IN TRANSGENIC MICE WITH MYOCARDIAL OVEREXPRESSION OF THE BETA(2)-ADRENOCEPTOR	NATURE			English	Article							NUCLEOTIDE BINDING-PROTEIN; TERNARY COMPLEX MODEL; REGULATORY PROTEINS; INTRINSIC ACTIVITY; BETA-ADRENOCEPTOR; OPIOID RECEPTORS; ANTAGONISTS; MUTATION	G-PROTEIN-COUPLED receptors are thought to have an inactive conformation (R), requiring an agonist-induced conformational change for receptor/G-protein coupling(1-3). But new evidence suggests a two-state model(4-19) in which receptors are in equilibrium between the inactive conformation (R), and a spontaneously active conformation (R*) that can couple to G protein in the absence of ligand (Fig, 1). Classic agonists have a high affinity for R* and increase the concentration of R*, whereas inverse agonists have a high affinity for R and decrease the concentration of R*. Neutral competitive antagonists have equal affinity for R and R* and do not displace the equilibrium, but can competitively antagonize the effects both of agonists and of inverse agonists. The lack of suitable in vivo model systems has restricted the evidence for the existence of inverse agonists to computer simulations(7,8) and in vitro systems(5,9-12,20-23). We have used a transgenic mouse model in which there is such marked myocardial overexpression of beta(2)-adrenoceptors that a significant population of spontaneously activated receptor (R*) is present, inducing a maximal response without agonist(24). We show that the beta(2)-adrenoceptor ligand ICI-118,551 functions as an inverse agonist, providing evidence supporting the existence of inverse agonists and validating the two-state model of G-protein-coupled receptor activation.	FISONS PLC,DEPT PHARMACOL,LOUGHBOROUGH LE11 0RH,LEICS,ENGLAND; BAYLOR COLL MED,DEPT ANESTHESIOL,HOUSTON,TX 77030; DUKE UNIV,MED CTR,DEPT SURG,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CARDIOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT HEMATOL ONCOL,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,LA JOLLA,CA 92093; GLAXO INC,RES,RES TRIANGLE PK,NC 27709	Baylor College of Medicine; Duke University; Duke University; Duke University; Duke University; Howard Hughes Medical Institute; University of California System; University of California San Diego; GlaxoSmithKline	BOND, RA (corresponding author), UNIV HOUSTON,DEPT PHARMACOL & PHARMACEUT SCI,HOUSTON,TX 77204, USA.		Lefkowitz, Robert/AAW-2649-2021					AHRIENS EJ, 1954, ARCH INT PHARMACOD T, V99, P32; ARCH JRS, 1993, MED RES REV, V13, P663, DOI 10.1002/med.2610130604; BARKER EL, 1994, J BIOL CHEM, V269, P11687; CERIONE RA, 1984, BIOCHEMISTRY-US, V23, P4519, DOI 10.1021/bi00315a003; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; Clark Alfred Joseph., 1933, MODE ACTION DRUGS CE; Colquhoun D., 1973, DRUG RECEPTORS, P149, DOI [10.1007/978-1-349-00910-7_11, DOI 10.1007/978-1-349-00910-7_11]; COSTA T, 1989, P NATL ACAD SCI USA, V86, P7321, DOI 10.1073/pnas.86.19.7321; COSTA T, 1992, MOL PHARMACOL, V41, P549; COSTA T, 1990, MOL PHARMACOL, V37, P383; DELEAN A, 1980, J BIOL CHEM, V255, P7108; EHLERT FJ, 1986, TRENDS PHARMACOL SCI, V7, P28, DOI 10.1016/0165-6147(86)90237-3; GOTZE K, 1964, EUR J PHARMACOL, V268, P151; LEFF P, IN PRESS TRENDS PHAR; LEFKOWITZ RJ, 1993, TRENDS PHARMACOL SCI, V14, P303, DOI 10.1016/0165-6147(93)90048-O; MEWES T, 1993, CIRCULATION, V88, P2916, DOI 10.1161/01.CIR.88.6.2916; MILANO CA, 1994, SCIENCE, V264, P582, DOI 10.1126/science.8160017; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; ONARAN HO, 1992, MOL PHARMACOL, V43, P245; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHUTZ W, 1992, TRENDS PHARMACOL SCI, V13, P376, DOI 10.1016/0165-6147(92)90116-N; SCHWARTZ DD, 1988, J PHARMACOL EXP THER, V244, P11; SEEMAN P, 1993, NATURE, V365, P441, DOI 10.1038/365441a0; SENOGLES SE, 1987, J BIOL CHEM, V262, P4860; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; STEPHENSON RP, 1956, BRIT J PHARM CHEMOTH, V11, P379, DOI 10.1111/j.1476-5381.1956.tb00006.x; TIAN WN, 1994, MOL PHARMACOL, V45, P524	29	410	436	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					272	276		10.1038/374272a0	http://dx.doi.org/10.1038/374272a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885448	Green Submitted			2022-12-28	WOS:A1995QM38700053
J	SERIZAWA, H; MAKELA, TP; CONAWAY, JW; CONAWAY, RC; WEINBERG, RA; YOUNG, RA				SERIZAWA, H; MAKELA, TP; CONAWAY, JW; CONAWAY, RC; WEINBERG, RA; YOUNG, RA			ASSOCIATION OF CDK-ACTIVATING KINASE SUBUNITS WITH TRANSCRIPTION FACTOR TFIIH	NATURE			English	Article							RNA POLYMERASE-II; C-TERMINAL DOMAIN; FACTOR-DELTA; RAT-LIVER; INITIATION; PHOSPHORYLATION; PROMOTERS; HELICASE; ATPASE; YEAST	THE RNA polymerase II large subunit contains an essential carboxy-terminal domain (CTD) believed to be involved in the response to regulators during transcription initiation(1-10). The CTD is phosphorylated on a portion of RNA polymerase II molecules in vivo(11,12) and it can be phosphorylated by the general transcription factor TFIIH in vitro(13-15). A highly purified TFIIH from rat liver has been described(16); this, like human and yeast TFIIH, contains associated CTD kinase and helicase activities(13-18). We report here that two polypeptides of the purified mammalian TFIIH are the MO15/Cdk7 kinase and cyclin H subunits of the Cdk-activating kinase Cak(19-21), previously identified as a positive regulator of Cdc2 and Cdk2. TFIIH and Cak preparations are each capable of phosphorylating recombinant CTD and recombinant Cdk2 proteins. The presence of Cak in TFIIH indicates that Cak may have roles in transcriptional regulation and in cell-cycle control.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,OKLAHOMA CITY,OK 73104	Massachusetts Institute of Technology (MIT); Oklahoma Medical Research Foundation	SERIZAWA, H (corresponding author), WHITEHEAD INST BIOMED RES,9 CAMBRIDGE CTR,CAMBRIDGE,MA 02142, USA.		makela, tomi/B-3734-2009; Young, Richard A/F-6495-2012	makela, tomi/0000-0002-4869-8044; Young, Richard A/0000-0001-8855-8647; Conaway, Joan/0000-0002-2786-0663				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; BURATOWSKI S, 1990, MOL CELL BIOL, V10, P5562, DOI 10.1128/MCB.10.10.5562; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CONAWAY RC, 1988, J BIOL CHEM, V263, P2962; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HARLOW E, 1989, ANTIBODIES LABORATOR; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, MOL CELL BIOL, V14, P7265, DOI 10.1128/MCB.14.11.7265; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	32	327	342	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					280	282		10.1038/374280a0	http://dx.doi.org/10.1038/374280a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885450				2022-12-28	WOS:A1995QM38700055
J	OBOYLE, C				OBOYLE, C			MAKING SUBJECTIVITY SCIENTIFIC	LANCET			English	Editorial Material											OBOYLE, C (corresponding author), ROYAL COLL SURGEONS IRELAND,DEPT PSYCHOL,DUBLIN 2,IRELAND.			O'Boyle, Ciaran/0000-0003-0254-8603				CLAYTON MG, 1994, MEASURING HLTH MED O, P160	1	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					602	602		10.1016/S0140-6736(95)90517-0	http://dx.doi.org/10.1016/S0140-6736(95)90517-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898175				2022-12-28	WOS:A1995QM07500005
J	PEREZTRALLERO, E; MONTES, M; ALCORTA, M; ZUBILLAGA, P; TELLERIA, E				PEREZTRALLERO, E; MONTES, M; ALCORTA, M; ZUBILLAGA, P; TELLERIA, E			NON-ENDOSCOPIC METHOD TO OBTAIN HELICOBACTER-PYLORI FOR CULTURE	LANCET			English	Note								A sampling method to collect samples for Helicobacter pylori culture that is easier than endoscopy would be useful. We used a capsule attached to a highly absorbent nylon string, which is swallowed to obtain gastric secretions. Antral biopsy and string specimens, sequentially obtained from 36 adults with clinically suspected ulcer or gastric disease were cultured. 9 (25%) patients were negative in both tests; 18 (50%) were positive by both methods; 6 (17%) were biopsy positive and string-test negative; and 3 (8%) were biopsy negative and string-test positive. The new test is useful, simple, and causes little discomfort.	HOSP NS ARANZAZU,FAC MED,UNIDAD EPIDEMIOL INFECCIOSA,E-20080 SAN SEBASTIAN,SPAIN		PEREZTRALLERO, E (corresponding author), HOSP NS ARANZAZU,FAC MED,MICROBIOL SERV,E-20080 SAN SEBASTIAN,SPAIN.								0	43	44	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					622	623		10.1016/S0140-6736(95)90524-3	http://dx.doi.org/10.1016/S0140-6736(95)90524-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898181				2022-12-28	WOS:A1995QM07500012
J	JEFFREY, PD; GORINA, S; PAVLETICH, NP				JEFFREY, PD; GORINA, S; PAVLETICH, NP			CRYSTAL-STRUCTURE OF THE TETRAMERIZATION DOMAIN OF THE P53 TUMOR-SUPPRESSOR AT 1.7 ANGSTROMS	SCIENCE			English	Article							WILD-TYPE P53; CELL-CYCLE CHECKPOINT; DNA-BINDING; MUTANT P53; GENE AMPLIFICATION; PROTEIN; TRANSCRIPTION; SEQUENCE; IDENTIFICATION; REFINEMENT	The p53 protein is a tetrameric transcription factor that plays a central role in the prevention of neoplastic transformation. Oligomerization appears to be essential for the tumor suppressing activity of p53 because oligomerization-deficient p53 mutants cannot suppress the growth of carcinoma cell lines. The crystal structure of the tetramerization domain of p53 (residues 325 to 356) was determined at 1.7 angstrom resolution and refined to a crystallographic R factor of 19.2 percent. The monomer, which consists of a beta strand and an alpha helix, associates with a second monomer across an antiparallel beta sheet and an antiparallel helix-helix interface to form a dimer. Two of these dimers associate across a second and distinct parallel helix-helix interface to form the tetramer.			JEFFREY, PD (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,NEW YORK,NY 10021, USA.			Jeffrey, Philip/0000-0002-4351-5341	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748-29] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1990, X PLOR V3 1 MANUAL; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, SCIENCE, V267, P1515, DOI 10.1126/science.7878474; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P273; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GREENBLATT MS, 1994, DATABASE P53 MUTATIO; HALVEY O, 1990, SCIENCE, V250, P113; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; LEE WT, 1994, NAT STRUCT BIOL, V1, P877, DOI 10.1038/nsb1294-877; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; PARK DJ, 1994, ONCOGENE, V9, P1899; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	51	433	454	0	24	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1498	1502		10.1126/science.7878469	http://dx.doi.org/10.1126/science.7878469			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878469				2022-12-28	WOS:A1995QL49700038
J	DIXON, JM; SAINSBURY, JRC; RODGER, A				DIXON, JM; SAINSBURY, JRC; RODGER, A			ABC OF BREAST DISEASES - BREAST-CANCER - TREATMENT OF ELDERLY PATIENTS AND UNCOMMON CONDITIONS	BRITISH MEDICAL JOURNAL			English	Article									WESTERN GEN HOSP,EDINBURGH,MIDLOTHIAN,SCOTLAND; HUDDERSFIELD ROYAL INFIRM,HUDDERSFIELD,W YORKSHIRE,ENGLAND; MONASH UNIV,MELBOURNE,VIC,AUSTRALIA	University of Edinburgh; Monash University	DIXON, JM (corresponding author), EDINBURGH ROYAL INFIRM,EDINBURGH,MIDLOTHIAN,SCOTLAND.								0	5	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1292	1295		10.1136/bmj.309.6964.1292	http://dx.doi.org/10.1136/bmj.309.6964.1292			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888856	Green Published			2022-12-28	WOS:A1994PT03300034
J	CHAN, TYK; CHAN, JCN; TOMLINSON, B; CRITCHLEY, JAJH				CHAN, TYK; CHAN, JCN; TOMLINSON, B; CRITCHLEY, JAJH			CHINESE HERBAL MEDICINES REVISITED - A HONG-KONG PERSPECTIVE	LANCET			English	Review							PRODUCTS	Chinese herbal medicines (CHM) and Chinese proprietary medicines (CPM) are widely used by people of Chinese origin throughout the world. Although the use of these medicinal materials rarely causes significant toxic effects, cases of severe and even fatal poisoning have occurred after medication with herbs containing aconitine, podophyllin, and anticholinergic substances. Furthermore, CHM and CPM are often adulterated with substituted herbs, heavy metals, and western medicines; such contamination can have important clinical consequences. In Hong Kong, surveillance and legislation are required to control the use of some of these herbal preparations. In other countries, medical practitioners should also be aware of the possibility that these herbal-medicine-related remedies may cause significant clinical problems in their Chinese patients.			CHAN, TYK (corresponding author), CHINESE UNIV HONG KONG, PRINCE WALES HOSP, DEPT CLIN PHARMACOL, SHA TIN, HONG KONG.		Tomlinson, Brian/AAD-9404-2019; Tomlinson, Brian/P-5365-2015; Chan, Thomas/K-3794-2014; Chan, Juliana/B-7918-2016	Tomlinson, Brian/0000-0001-6717-5444; Chan, Juliana/0000-0003-1325-1194				[Anonymous], 1989, MED PLANTS CHINA; BAKER D, 1985, MMWR-MORBID MORTAL W, V38, P612; CHAN H, 1977, CLIN TOXICOL, V10, P273, DOI 10.3109/15563657708992423; Chan Thomas Y. K., 1993, Journal of the Hong Kong Medical Association, V45, P202; CHAN TYK, 1993, AUST NZ J MED, V23, P268, DOI 10.1111/j.1445-5994.1993.tb01730.x; CHAN TYK, 1992, J TROP MED HYG, V95, P296; CHANG HM, 1987, PHARM APPLICATIONS C, P902; CHONGHAI T, 1975, MED J AUSTRALIA, V2, P424, DOI 10.5694/j.1326-5377.1975.tb105939.x; DESMET PAG, 1989, INT PHARM J, V3, P98; DESMET PAG, 1992, ADVERSE EFFECTS HERB, V1, P1; HUXTABLE RJ, 1990, DRUG SAFETY, V5, P126, DOI 10.2165/00002018-199000051-00020; KANGYUM E, 1992, VET HUM TOXICOL, V34, P235; LAM CLK, 1989, H K PRACTNR, V11, P272; LIN HR, 1988, ORIGINAL COLOUR ATLA; NG THK, 1991, J NEUROL SCI, V101, P107, DOI 10.1016/0022-510X(91)90024-2; PENN RG, 1986, IATROGENIC DISEASES, P898; RIES CA, 1975, JAMA-J AM MED ASSOC, V231, P352, DOI 10.1001/jama.231.4.352; SIEGEL RK, 1977, JAMA-J AM MED ASSOC, V237, P24; STEWART PM, 1987, LANCET, V2, P821; TAI YT, 1992, LANCET, V340, P1254, DOI 10.1016/0140-6736(92)92951-B; TAY SAB, 1989, MED J AUSTRALIA, V151, P52, DOI 10.5694/j.1326-5377.1989.tb128456.x; TOMLINSON B, 1993, LANCET, V341, P370, DOI 10.1016/0140-6736(93)90169-H; TSE C Y, 1989, Journal of the Hong Kong Medical Association, V41, P177; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; YEUNG CY, 1990, BIOL NEONATE, V58, P98, DOI 10.1159/000243239	25	116	120	1	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1532	1534		10.1016/S0140-6736(05)80091-1	http://dx.doi.org/10.1016/S0140-6736(05)80091-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902907				2022-12-28	WOS:A1993MM40200018
J	SKRABANEK, P				SKRABANEK, P			THE EPIDEMIOLOGY OF ERRORS	LANCET			English	Editorial Material											SKRABANEK, P (corresponding author), UNIV DUBLIN TRINITY COLL,DEPT COMMUNITY HLTH & GEN PRACTICE,DUBLIN 2,IRELAND.							ANGELL M, 1990, NEW ENGL J MED, V323, P823, DOI 10.1056/NEJM199009203231209; GORI GB, 1993, LANCET, V341, P965; LANGMUIR I, 1989, PHYS TODAY, V42, P36, DOI 10.1063/1.881205; LUIK JC, 1993, BOSTONIA, P50; MAYES LC, 1988, INT J EPIDEMIOL, V17, P680, DOI 10.1093/ije/17.3.680; MCCORMICK JS, 1992, PERSPECT BIOL MED, V35, P186; PHILLIPS AN, 1993, J CLIN EPIDEMIOL, V46, P1203, DOI 10.1016/0895-4356(93)90120-P; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; THOMAS L, 1993, DISCOVER         NOV, P78; VANDENBROUCKE JP, 1989, J EPIDEMIOL COMMUN H, V43, P207, DOI 10.1136/jech.43.3.207	10	17	18	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1502	1502		10.1016/S0140-6736(05)80080-7	http://dx.doi.org/10.1016/S0140-6736(05)80080-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902897				2022-12-28	WOS:A1993MM40200007
J	TUDDENHAM, EGD				TUDDENHAM, EGD			THROMBOPHILIA - A NEW FACTOR EMERGES FROM THE MISTS	LANCET			English	Editorial Material											TUDDENHAM, EGD (corresponding author), CLIN RES CTR,HAEMOSTASIS RES GRP,HARROW HA1 3UJ,MIDDX,ENGLAND.		Tuddenham, Edward/AAS-6196-2020	Tuddenham, Edward/0000-0001-8955-2909				DAHLBACK, 1993, LANCET, V342; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; FAIONI EM, 1993, BLOOD, V82, pA406; GRIFFIN JH, 1993, BLOOD, V82, P1989; TUDDENHAM EGD, 1993, MOL GENETICS HAEMOST	5	10	11	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1501	1502		10.1016/S0140-6736(05)80079-0	http://dx.doi.org/10.1016/S0140-6736(05)80079-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902896				2022-12-28	WOS:A1993MM40200006
J	RITTER, K; KUHLENCORD, A; THOMSSEN, R; BOMMER, W				RITTER, K; KUHLENCORD, A; THOMSSEN, R; BOMMER, W			PROLONGED HEMOLYTIC-ANEMIA IN MALARIA AND AUTOANTIBODIES AGAINST TRIOSEPHOSPHATE ISOMERASE	LANCET			English	Note							PLASMODIUM-FALCIPARUM MALARIA; IGM ANTIBODIES; ANEMIA	Prolonged haemolysis may accompany infection with Plasmodium falciparum. We observed prolonged haemolysis in 4 of 10 patients with this type of malaria after parasitological cure. IgM antibodies specific for the glycolytic enzyme triosephosphate isomerase were detected in these patients' sera. Clinical recovery and a decrease in haemolysis coincided with a fall in these autoantibodies. In vitro, affinity purified autoantibodies isolated from the sera directed against triosephosphate isomerase induced lysis of erythrocytes and activation of complement as shown by the Cr-51 release assay. We assume that autoantibodies against triosephosphate isomerase contribute to the development of prolonged haemolysis and anaemia in P. falciparum malaria.	UNIV GOTTINGEN,DEPT TROP MED,D-37075 GOTTINGEN,GERMANY	University of Gottingen	RITTER, K (corresponding author), UNIV GOTTINGEN,ZENTRUM HYG & HUMANGENET,MED MIKROBIOL ABT,D-37075 GOTTINGEN,GERMANY.							Brown I. N., 1969, Adv. Immunol., V11, P267, DOI 10.1016/S0065-2776(08)60481-2; GEURS F, 1992, ACTA HAEMATOL-BASEL, V88, P142; RITTER K, 1991, J IMMUNOL METHODS, V137, P209, DOI 10.1016/0022-1759(91)90026-C; RITTER K, 1990, J EXP MED, V171, P565, DOI 10.1084/jem.171.2.565; ROSENBERG EB, 1973, AM J TROP MED HYG, V22, P146, DOI 10.4269/ajtmh.1973.22.146; ROSENBERG YJ, 1978, NATURE, V274, P170, DOI 10.1038/274170a0; ROSSI F, 1990, EUR J IMMUNOL, V20, P2089, DOI 10.1002/eji.1830200930; WEATHERALL DJ, 1982, BRIT MED BULL, V38, P147, DOI 10.1093/oxfordjournals.bmb.a071751; WEATHERALL DJ, 1983, CIBA F SYMP, V94, P74; YUAN PM, 1981, MECH AGEING DEV, V17, P151, DOI 10.1016/0047-6374(81)90081-6	10	40	40	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1333	1334		10.1016/0140-6736(93)92248-R	http://dx.doi.org/10.1016/0140-6736(93)92248-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901638				2022-12-28	WOS:A1993MJ03900011
J	JENSEN, GB; PAKKENBERG, B				JENSEN, GB; PAKKENBERG, B			DO ALCOHOLICS DRINK THEIR NEURONS AWAY	LANCET			English	Article							BRAIN; ATROPHY; DENDRITES; ETHANOL; NUMBER	Although it is commonly believed that chronic alcohol abuse results in loss of neocortical neurons, this assumption has not been properly tested. We used new stereological techniques to make a precise and unbiased estimate of the total number of neurons in the neocortex of brains obtained at necropsy from 11 chronic alcoholic men and 11 control men. The groups were matched with respect to age and height. Total mean neocortical neuron numbers in the two groups did not differ (alcoholics 23.4 x 10(9), controls 23.2 x 10(9)). Estimation of macroscopic brain volumes showed significant reductions in alcoholics compared with controls of the volume/weight ratios of white matter (11%, p = 0.013) and of archicortex (30%, p = 0.028). The volume of the ventricles in the alcoholic group was enlarged by 26%, but this was not statistically significant. There was no difference in the volumes of the neocortices. Our study confirms that chronic alcoholics lose white matter, and this could provide the basis for their functional impairment. However, the results also suggest that the observed brain damage in the alcoholic group is potentially reversible since preserved nerve-cell bodies might allow lost or malfunctioning axons to be re-established and restored to function after prolonged abstinence and/or treatment. By contrast, lost neocortical neurons cannot be replaced.	KOMMUNE HOSP COPENHAGEN, BARTHOLIN INST, NEUROL RES LAB, DK-1399 COPENHAGEN K, DENMARK; AARHUS UNIV, BARTHOLIN BYGNINGEN, STEREOL RES LAB, DK-8000 AARHUS, DENMARK	Aarhus University				pakkenberg, bente/0000-0003-3851-6494				BRAENDGAARD H, 1990, J MICROSC-OXFORD, V157, P285, DOI 10.1111/j.1365-2818.1990.tb02967.x; CARLEN PL, 1987, ACTA MED SCAND, P19; CARLEN PL, 1981, NEUROLOGY, V31, P377; CHARNESS ME, 1989, NEW ENGL J MED, V321, P442, DOI 10.1056/NEJM198908173210706; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; DELAMONTE SM, 1988, ARCH NEUROL-CHICAGO, V45, P990, DOI 10.1001/archneur.1988.00520330076013; FERRER I, 1986, NEUROSCI LETT, V69, P115, DOI 10.1016/0304-3940(86)90425-8; GUNDERSEN HJG, 1988, APMIS, V96, P857, DOI 10.1111/j.1699-0463.1988.tb00954.x; GUNDERSEN HJG, 1987, J MICROSC-OXFORD, V147, P229, DOI 10.1111/j.1365-2818.1987.tb02837.x; HANSEN LA, 1991, ARCH NEUROL-CHICAGO, V48, P939, DOI 10.1001/archneur.1991.00530210065025; HARPER C, 1987, BRIT MED J, V294, P534, DOI 10.1136/bmj.294.6571.534; HARPER C, 1985, J NEUROL NEUROSUR PS, V48, P211, DOI 10.1136/jnnp.48.3.211; HARPER C, 1990, J NEUROL NEUROSUR PS, V53, P856, DOI 10.1136/jnnp.53.10.856; HARPER CG, 1982, J NEUROL NEUROSUR PS, V45, P838, DOI 10.1136/jnnp.45.9.838; HARPER CG, 1990, ALCOHOL ALCOHOLISM, V25, P445; HARPER CG, 1990, ALCOHOL ALCOHOLISM, V25, P207, DOI 10.1093/oxfordjournals.alcalc.a044994; HARPER CG, 1985, BRIT MED J, V290, P501, DOI 10.1136/bmj.290.6467.501; HILL SY, 1979, SCIENCE, V204, P1237, DOI 10.1126/science.451571; ISHII T, 1983, ACTA PSYCHIAT SCAND, V309, P7; KJELLSTROM C, 1993, ACTA NEUROPATHOL, V85, P117; LEE K, 1979, LANCET, V2, P759; LISHMAN WA, 1987, ACTA MED SCAND, P5; MCMULLEN PA, 1984, J COMP NEUROL, V225, P111, DOI 10.1002/cne.902250112; Pakkenberg B, 1989, ACTA STEREOL, V8, P251; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; TAVARES MA, 1983, J NEUROCYTOL, V12, P939, DOI 10.1007/BF01153343; THOMSON AD, 1982, BRIT MED BULL, V38, P87, DOI 10.1093/oxfordjournals.bmb.a071740; TORVIK A, 1987, ACTA MED SCAND, P47; 1987, DIAGNOSTIC STATISTIC	29	80	83	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1201	1204						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901529				2022-12-28	WOS:A1993MG27400009
J	CLARKE, IMC				CLARKE, IMC			PEPPERING PAIN	LANCET			English	Editorial Material							CAPSAICIN				CLARKE, IMC (corresponding author), UNIV CALGARY,CALGARY T2N 1N4,ALBERTA,CANADA.							CARPENTER SE, 1983, ADV PAIN RES THER, V5, P83; DRAY A, 1992, LIFE SCI, V51, P1759, DOI 10.1016/0024-3205(92)90045-Q; GEPPETTI P, 1992, REGUL PEPTIDES, V41, P83, DOI 10.1016/0167-0115(92)90516-W; LAMOTTE RH, 1992, J PHYSIOL-LONDON, V448, P749, DOI 10.1113/jphysiol.1992.sp019068; LEVINE JD, 1988, 5TH P WORLD C PAIN, P33	5	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1130	1130		10.1016/0140-6736(93)92120-I	http://dx.doi.org/10.1016/0140-6736(93)92120-I			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901472				2022-12-28	WOS:A1993MF19800006
J	NAKAMURA, T; EBIHARA, I; SHIRATO, I; FUKUI, M; TOMINO, Y; KOIDE, H				NAKAMURA, T; EBIHARA, I; SHIRATO, I; FUKUI, M; TOMINO, Y; KOIDE, H			ENDOTHELIN-1 MESSENGER-RNA EXPRESSION BY PERIPHERAL-BLOOD MONOCYTES IN IGA NEPHROPATHY	LANCET			English	Note							CELLS	We investigated endothelin-1 mRNA expression in peripheral blood monocytes from 40 patients with IgA nephropathy, 40 with other glomerulonephritides and 10 with essential hypertension without renal diseases, and from 30 healthy age-matched controls. 95% of patients with IgA nephropathy had increased endothelin-1 mRNA expression in monocytes but little was detected from the other groups. Endothelin-1 mRNA was positively correlated with urinary protein excretion (95% CI 0.835-0.952) and histopathological findings (0.796-0.939). In. 15 patients with IgA nephropathy endothelin-1 mRNA values and proteinuria decreased gradually after treatment Endathelin-1 mRNA-expressing activated monocytes may be associated with the progression of IgA nephropathy.	JUNTENDO UNIV,SCH MED,DEPT MED,DIV NEPHROL,TOKYO 113,JAPAN	Juntendo University								BADR KF, 1989, J CLIN INVEST, V83, P336, DOI 10.1172/JCI113880; EHRENREICH H, 1990, J EXP MED, V172, P1741, DOI 10.1084/jem.172.6.1741; ISHIMURA E, 1989, AM J PATHOL, V134, P843; LEE SMK, 1982, HUM PATHOL, V13, P314, DOI 10.1016/S0046-8177(82)80221-9; NAKAMURA T, 1992, AM J NEPHROL, V12, P292, DOI 10.1159/000168463; NAKAMURA T, 1992, J LAB CLIN MED, V120, P212	6	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1147	1148		10.1016/0140-6736(93)92126-E	http://dx.doi.org/10.1016/0140-6736(93)92126-E			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901478				2022-12-28	WOS:A1993MF19800012
J	ROWINSKY, EK; DONEHOWER, RC				ROWINSKY, EK; DONEHOWER, RC			DRUG-THERAPY - PACLITAXEL (TAXOL)	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PHASE-I TRIAL; COLONY-STIMULATING FACTOR; METASTATIC BREAST-CANCER; MICROTUBULE-ASSOCIATED PROTEINS; COOPERATIVE-ONCOLOGY-GROUP; REFRACTORY OVARIAN-CANCER; CELL LUNG-CANCER; EVERY 21 DAYS; HYPERSENSITIVITY REACTIONS; HISTAMINE-RELEASE		JOHNS HOPKINS UNIV, SCH MED, CTR ONCOL, DEPT MED ONCOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine	ROWINSKY, EK (corresponding author), JOHNS HOPKINS UNIV, SCH MED,CTR ONCOL,DIV PHARMACOL & EXPTL THERAPEUT, 1-121, 600 N WOLFE ST, BALTIMORE, MD 21287 USA.							Adams J D, 1993, J Natl Cancer Inst Monogr, P141; AJANI JA, 1994, J NATL CANCER I, V86, P51, DOI 10.1093/jnci/86.1.51; AJANI JA, 1994, J NATL CANCER I, V86, P1086, DOI 10.1093/jnci/86.14.1086; ARBCK SG, 1993, MONOGR NCI, V15, P117; BISSERY MC, 1991, CANCER RES, V51, P4845; BROWN T, 1991, J CLIN ONCOL, V9, P1261, DOI 10.1200/JCO.1991.9.7.1261; BROWN T, 1993, P AN M AM SOC CLIN, V13, P200; BURKHART CA, 1994, CANCER RES, V54, P5779; CABRAL F, 1983, J CELL BIOL, V97, P30, DOI 10.1083/jcb.97.1.30; CAPRI G, 1994, J NATL CANCER I, V86, P1099, DOI 10.1093/jnci/86.14.1099; CHANG AY, 1993, J NATL CANCER I, V85, P388, DOI 10.1093/jnci/85.5.388; CHAUDHRY V, 1994, ANN NEUROL, V35, P304, DOI 10.1002/ana.410350310; CHEALLIER B, 1995, J CLIN ONCOL, V13, P314; CHOY H, 1994, J CLIN ONCOL, V12, P2682, DOI 10.1200/JCO.1994.12.12.2682; CRESTEIL T, 1994, CANCER RES, V54, P386; CROSSIN KL, 1981, CELL, V27, P341, DOI 10.1016/0092-8674(81)90417-7; DEBRABANDER M, 1981, P NATL ACAD SCI-BIOL, V78, P5608; DEFORNI M, 1994, ANN ONCOL, V5, P202; DENIS JN, 1990, J ORG CHEM, V55, P1957, DOI 10.1021/jo00293a052; DONEHOWER RC, 1987, CANCER TREAT REP, V71, P1171; DUSTIN P, 1980, SCI AM, V243, P67, DOI 10.1038/scientificamerican0880-66; EINZIG AI, 1991, CANCER INVEST, V9, P133, DOI 10.3109/07357909109044223; EINZIG AI, 1991, INVEST NEW DRUG, V9, P59; EINZIG AI, 1992, J CLIN ONCOL, V10, P1748, DOI 10.1200/JCO.1992.10.11.1748; EINZIG AI, 1993, P ASCO, V12, P194; EISENHAUER EA, 1994, J CLIN ONCOL, V12, P2654, DOI 10.1200/JCO.1994.12.12.2654; ETTINGER DS, 1993, P AN M AM SOC CLIN, V12, P329; FORASTIERE AA, 1993, MONOGR NATL CANC I, V15, P181; FOSSELLA FV, 1994, J CLIN ONCOL, V12, P1238, DOI 10.1200/JCO.1994.12.6.1238; FRANCIS P, 1994, J CLIN ONCOL, V12, P2301, DOI 10.1200/JCO.1994.12.11.2301; FRANCIS PA, 1994, J CLIN ONCOL, V12, P1232, DOI 10.1200/JCO.1994.12.6.1232; GELMON K, 1994, ANN ONCOL, V5, P198; GIANNI L, 1995, J CLIN ONCOL, V13, P180, DOI 10.1200/JCO.1995.13.1.180; GIANNI L, 1994, P AN M AM SOC CLIN, V13, P74; GREM JL, 1987, CANCER TREAT REP, V71, P1179; GUPTA RS, 1983, J CELL PHYSIOL, V114, P137, DOI 10.1002/jcp.1041140122; HAMEL E, 1981, J BIOL CHEM, V256, P1887; HARRIS JW, 1994, CANCER RES, V54, P4026; HOLMES FA, 1991, J NATL CANCER I, V83, P1797, DOI 10.1093/jnci/83.24.1797-a; HOLMES FA, 1994, ANN ONCOL, V5, P197; HOLMES FA, 1993, P AN M AM SOC CLIN, V12, P94; HOLTON RA, 1994, J AM CHEM SOC, V116, P1597, DOI 10.1021/ja00083a066; HOLTON RA, 1994, J AM CHEM SOC, V116, P1599, DOI 10.1021/ja00083a067; HORWITZ SB, 1993, MONOGR NATL CANCER I, V15, P55; Hudis C., 1994, P AM SOC CLIN ONCOL, V13, P65; HUIZING MT, 1993, J CLIN ONCOL, V11, P2127, DOI 10.1200/JCO.1993.11.11.2127; HURWITZ CA, 1993, J CLIN ONCOL, V11, P2324, DOI 10.1200/JCO.1993.11.12.2324; JORDAN MA, 1993, P NATL ACAD SCI USA, V90, P9552, DOI 10.1073/pnas.90.20.9552; KENNEDY MJ, 1994, P AN M AM SOC CLIN, V13, P137; KIRSCHLING RJ, 1994, P AN M AM SOC CLIN, V13, P326; KOHN EC, 1994, J NATL CANCER I, V86, P18, DOI 10.1093/jnci/86.1.18; KRIS MG, 1986, CANCER TREAT REP, V70, P605; KUMAR N, 1981, J BIOL CHEM, V256, P435; LASKIN MS, 1993, J CLIN ONCOL, V11, P2456, DOI 10.1200/JCO.1993.11.12.2456; LASSER EC, 1971, RADIOLOGY, V100, P683, DOI 10.1148/100.3.683; Lassus M, 1985, P AN M AM SOC CLIN, V4, P268; LEBLANC GA, 1992, CANCER RES, V52, P540; LEGHA SS, 1990, CANCER, V65, P2478, DOI 10.1002/1097-0142(19900601)65:11<2478::AID-CNCR2820651114>3.0.CO;2-S; LEGHA SS, 1986, J CLIN ONCOL, V4, P762, DOI 10.1200/JCO.1986.4.5.762; LONGNECKER SM, 1987, CANCER TREAT REP, V71, P340; LONGNECKER SM, 1987, CANCER TREAT REP, V71, P53; LORENZ W, 1977, AGENTS ACTIONS, V7, P63, DOI 10.1007/BF01964882; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MCGUIRE WP, 1993, P AN M AM SOC CLIN, V12, P255; MCGUIRE WP, 1994, 30TH AM SOC CLIN ONC, P204; MONSARRAT B, 1990, DRUG METAB DISPOS, V18, P895; MONSARRAT B, 1993, MONOGR NCI, V15, P39; MOTZER RJ, 1994, J CLIN ONCOL, V12, P2277, DOI 10.1200/JCO.1994.12.11.2277; MURPHY WK, 1993, J NATL CANCER I, V85, P384, DOI 10.1093/jnci/85.5.384; NICOLAOU KC, 1994, NATURE, V367, P630, DOI 10.1038/367630a0; OHNUMA T, 1985, P AM ASSOC CANC RES, V26, P167; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; PEEREBOOM DM, 1993, J CLIN ONCOL, V11, P885, DOI 10.1200/JCO.1993.11.5.885; PESTALOZZI BC, 1993, CANCER, V71, P1797, DOI 10.1002/1097-0142(19930301)71:5<1797::AID-CNCR2820710514>3.0.CO;2-B; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1992, J NATL CANCER I, V84, P785, DOI 10.1093/jnci/84.10.785; REICHMAN BS, 1993, J CLIN ONCOL, V11, P1943, DOI 10.1200/JCO.1993.11.10.1943; RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093/jnci/83.4.288; ROBERTS JR, 1990, CANCER RES, V50, P710; ROTH BJ, 1993, CANCER, V72, P2457, DOI 10.1002/1097-0142(19931015)72:8<2457::AID-CNCR2820720825>3.0.CO;2-Z; ROTH BJ, 1994, P AN M AM SOC CLIN, V13, P230; ROWINSKY EK, 1993, J CANCER RES CLIN, V119, P727, DOI 10.1007/BF01195344; ROWINSKY EK, 1989, CANCER RES, V49, P4640; ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1692, DOI 10.1200/JCO.1991.9.9.1692; ROWINSKY EK, 1993, J CLIN ONCOL, V11, P2010, DOI 10.1200/JCO.1993.11.10.2010; ROWINSKY EK, 1988, CANCER RES, V48, P4093; ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1704, DOI 10.1200/JCO.1991.9.9.1704; ROWINSKY EK, 1992, SEMIN ONCOL, V19, P646; ROWINSKY EK, 1993, SEMIN ONCOL, V20, P1; ROWINSKY EK, 1990, JNCI-J NATL CANCER I, V82, P1247, DOI 10.1093/jnci/82.15.1247; ROWINSKY EK, 1993, SEMIN ONCOL, V20, P16; ROWINSKY EK, 1993, MONOGR NCI, V15, P107; SAROSY G, 1992, J CLIN ONCOL, V10, P1165, DOI 10.1200/JCO.1992.10.7.1165; SCHIFF PB, 1981, BIOCHEMISTRY-US, V20, P3247, DOI 10.1021/bi00514a041; SCHIFF PB, 1979, NATURE, V277, P665, DOI 10.1038/277665a0; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; SCHILDER LE, 1994, P AN M AM SOC CLIN, V13, P136; SCHILLER JH, 1994, J CLIN ONCOL, V12, P241, DOI 10.1200/JCO.1994.12.2.241; SEIDMAN AD, 1993, P AN M AM SOC CLIN, V12, P63; SHENKIER T, 1994, J CLIN ONCOL, V12, P439, DOI 10.1200/JCO.1994.12.2.439; SONNICHSEN DS, 1994, J CLIN ONCOL, V12, P532, DOI 10.1200/JCO.1994.12.3.532; SPRIGGS DR, 1992, INVEST NEW DRUG, V10, P275, DOI 10.1007/BF00944181; STANHOPE CR, 1977, GYNECOL ONCOL, V5, P52, DOI 10.1016/0090-8258(77)90007-5; THIGPEN JT, 1994, J CLIN ONCOL, V12, P1748, DOI 10.1200/JCO.1994.12.9.1748; TISHLER RB, 1992, INT J RADIAT ONCOL, V22, P613, DOI 10.1016/0360-3016(92)90888-O; TISHLER RB, 1992, CANCER RES, V52, P3495; TRIMBLE EL, 1993, J CLIN ONCOL, V11, P2405, DOI 10.1200/JCO.1993.11.12.2405; TRUDEAU ME, 1993, P AN M AM SOC CLIN, V12, P64; VENOOK AP, 1994, P AN M AM SOC CLIN, V13, P139; WANI MC, 1971, J AM CHEM SOC, V93, P2325, DOI 10.1021/ja00738a045; WEISS RB, 1990, J CLIN ONCOL, V8, P1263, DOI 10.1200/JCO.1990.8.7.1263; WIERNIK PH, 1987, CANCER RES, V47, P2486; WIERNIK PH, 1987, J CLIN ONCOL, V5, P1232, DOI 10.1200/JCO.1987.5.8.1232; WILSON L, 1985, BIOCHEMISTRY-US, V24, P5254, DOI 10.1021/bi00340a045; WILSON L, 1975, ANN NY ACAD SCI, V253, P213, DOI 10.1111/j.1749-6632.1975.tb19201.x; WILSON WH, 1995, J CLIN ONCOL, V13, P381, DOI 10.1200/JCO.1995.13.2.381; WILSON WH, 1994, J CLIN ONCOL, V12, P1621, DOI 10.1200/JCO.1994.12.8.1621; WILTSHAW E, 1979, CANCER TREAT REP, V63, P1545; YOUNES A, 1995, J CLIN ONCOL, V13, P583, DOI 10.1200/JCO.1995.13.3.583	120	1759	1880	11	437	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					1004	1014		10.1056/NEJM199504133321507	http://dx.doi.org/10.1056/NEJM199504133321507			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885406				2022-12-28	WOS:A1995QT73700007
J	LEE, K; HOLMAN, BL				LEE, K; HOLMAN, BL			CEREBRAL ARTERIOVENOUS MALFORMATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											LEE, K (corresponding author), BRIGHAM & WOMENS HOSP,BOSTON,MA 02115, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					923	923		10.1056/NEJM199504063321405	http://dx.doi.org/10.1056/NEJM199504063321405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877650				2022-12-28	WOS:A1995QP89300005
J	SNYDER, EY; TAYLOR, RM; WOLFE, JH				SNYDER, EY; TAYLOR, RM; WOLFE, JH			NEURAL PROGENITOR-CELL ENGRAFTMENT CORRECTS LYSOSOMAL STORAGE THROUGHOUT THE MPS-VII MOUSE-BRAIN	NATURE			English	Article							MUCOPOLYSACCHARIDOSIS TYPE-VII; BETA-GLUCURONIDASE DEFICIENCY; BONE-MARROW TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; GENE-TRANSFER; MICE; IMPLANTATION; SPLEEN; LINES; MODEL	MANY metabolic diseases affecting the central nervous system are refractory to treatment because the blood-brain barrier restricts entry of therapeutic molecules. It may be possible to deliver therapeutic gene products directly to the brain by transplantation of neural progenitor cells, which can integrate into the murine central nervous system in a cytoarchitecturally appropriate manner(1-7). We tested this approach in mucopolysaccharidosis VII (Sly disease), a lysosomal storage disorder of humans, dogs and mice caused by an inherited deficiency of beta-glucuronidase(8-10). Lysosomal accumulation of glycosaminoglycans occurs in the brain and other tissues, causing a fatal progressive degenerative disorder, including mental retardation(11). Treatments are designed to provide a source of normal enzyme for uptake by diseased cells(12-20). We report here that by transplanting beta-glucuronidase-expressing neural progenitors into the cerebral ventricles of newborn mice, donor cells engrafted throughout the neuraxis. At maturity, donor-derived cells were present as normal constituents of diverse brain regions. beta-Glucuronidase activity was expressed along the entire neuraxis, resulting in widespread correction of lysosomal storage in neurons and glia in affected mice.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,BOSTON,MA 02115; UNIV PENN,SCH VET MED,PATHOL LAB,PHILADELPHIA,PA 19104; UNIV PENN,SCH VET MED,MED GENET SECT,PHILADELPHIA,PA 19104	Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; University of Pennsylvania; University of Pennsylvania								ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ANTON R, 1994, EXP NEUROL, V127, P207, DOI 10.1006/exnr.1994.1097; BIRKENMEIER EH, 1989, J CLIN INVEST, V83, P1258, DOI 10.1172/JCI114010; BIRKENMEIER EH, 1991, BLOOD, V78, P3081; BREAKEFIELD XO, 1993, NAT GENET, V3, P187, DOI 10.1038/ng0393-187; CHRISTIE D, 1994, ARCH DIS CHILD, V70, P275, DOI 10.1136/adc.70.4.275; FISHER LJ, 1994, FASEB J, V8, P489, DOI 10.1096/fasebj.8.8.8181667; GROVES AK, 1993, NATURE, V362, P453, DOI 10.1038/362453a0; HASKINS M, 1991, TREATMENT GENETIC DI, P183; HASKINS ME, 1984, PEDIATR RES, V18, P980, DOI 10.1203/00006450-198418100-00014; KITCHENS DL, 1994, J NEUROBIOL, V25, P797, DOI 10.1002/neu.480250705; KYLE JW, 1990, P NATL ACAD SCI USA, V87, P3914, DOI 10.1073/pnas.87.10.3914; MACKLIS JD, 1994, EXP NEUROL, V129, P9; MARECHAL V, 1993, BLOOD, V82, P1358; MOULLIER P, 1993, NAT GENET, V4, P154, DOI 10.1038/ng0693-154; Neufeld EF, 1995, METABOLIC MOL BASES, P2465; ONNIFER SM, 1993, EXP NEUROL, V122, P130; RENFRANZ PJ, 1991, CELL, V66, P713, DOI 10.1016/0092-8674(91)90116-G; RYDER EF, 1990, J NEUROBIOL, V21, P356, DOI 10.1002/neu.480210209; SANDS MS, 1993, P NATL ACAD SCI USA, V90, P6567, DOI 10.1073/pnas.90.14.6567; SANDS MS, 1993, LAB INVEST, V68, P676; SANDS MS, 1994, J CLIN INVEST, V93, P2324, DOI 10.1172/JCI117237; SLY WS, 1973, J PEDIATR-US, V82, P249, DOI 10.1016/S0022-3476(73)80162-3; Snyder E. Y., 1993, Society for Neuroscience Abstracts, V19, P613; SNYDER EY, 1992, CELL, V68, P33, DOI 10.1016/0092-8674(92)90204-P; SNYDER EY, 1992, SEMIN PERINATOL, V16, P106; SUHR ST, 1993, ARCH NEUROL-CHICAGO, V50, P1252, DOI 10.1001/archneur.1993.00540110122012; TAYLOR RM, 1994, EXP CELL RES, V214, P606, DOI 10.1006/excr.1994.1298; VOGLER C, 1990, AM J PATHOL, V136, P207; VOGLER C, 1993, PEDIATR RES, V34, P837, DOI 10.1203/00006450-199312000-00028; WOLFE JH, 1995, GENE THER, V2, P70; WOLFE JH, 1990, P NATL ACAD SCI USA, V87, P2877, DOI 10.1073/pnas.87.8.2877; WOLFE JH, 1992, NATURE, V360, P749, DOI 10.1038/360749a0; WOLFE JH, 1992, NAT GENET, V1, P379, DOI 10.1038/ng0892-379	34	397	412	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					367	370		10.1038/374367a0	http://dx.doi.org/10.1038/374367a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885477				2022-12-28	WOS:A1995QN63000062
J	RUMBYRT, JS; BORISH, LC				RUMBYRT, JS; BORISH, LC			HOME ADMINISTRATION OF ALLERGEN EXTRACTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											RUMBYRT, JS (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DENVER,CO 80206, USA.							REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; TURKELTAUB PC, 1994, FDA MED B, V24, P7; 1990, J ALLERGY CLIN IMMUN, V85, P526	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					897	897						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869565				2022-12-28	WOS:A1995QL40200033
J	STARZL, TE; DEMETRIS, AJ				STARZL, TE; DEMETRIS, AJ			TRANSPLANTATION MILESTONES - VIEWED WITH ONE-WAY AND 2-WAY PARADIGMS OF TOLERANCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL-ALLOGRAFT RECIPIENTS; BONE-MARROW; LIVER-TRANSPLANTATION; GRAFT ACCEPTANCE; CELL-MIGRATION; HOST-CELLS; CHIMERISM; BLOOD; TRANSFUSIONS; ORGANS		UNIV PITTSBURGH,MED CTR,DEPT PATHOL,PITTSBURGH,PA; UNIV PITTSBURGH,MED CTR,PITTSBURGH TRANSPLANTAT INST,PITTSBURGH,PA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	STARZL, TE (corresponding author), UNIV PITTSBURGH,MED CTR,DEPT SURG,FALK CLIN 5C,3601 5TH AVE,PITTSBURGH,PA 15213, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK029961, R37DK029961] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 29961, R01 DK029961-19] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CB, 1982, SURGERY, V92, P315; BACH F, 1964, SCIENCE, V143, P813, DOI 10.1126/science.143.3608.813; BACH FH, 1968, LANCET, V2, P1364; BAIN B, 1964, BLOOD, V23, P108, DOI 10.1182/blood.V23.1.108.108; BARBER WH, 1991, TRANSPLANTATION, V51, P70, DOI 10.1097/00007890-199101000-00011; BARNARD CN, 1968, J THORAC CARDIOV SUR, V56, P457, DOI 10.1016/S0022-5223(19)42805-5; BILLINGHAM R, 1956, PHILOS T R SOC LOND, V289, P357; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; BILLINGHAM RE, 1957, TRANSPLAN B, V4, P67; CALNE RY, 1960, LANCET, V1, P417; CALNE RY, 1979, LANCET, V2, P1033; CALNE RY, 1961, TRANSPLAN B, V28, P445; Dausset Jean, 1990, HIST HLA 10 RECOLLEC, P1; DEMETRIS AJ, 1993, TRANSPL P, V25, P3337; DEROM F, 1971, J THORAC CARDIOV SUR, V61, P835, DOI 10.1016/S0022-5223(19)42145-4; ELION GB, 1955, ANN NY ACAD SCI, V60, P297; FONTES P, 1994, LANCET, V344, P151, DOI 10.1016/S0140-6736(94)92756-1; GATTI RA, 1968, LANCET, V2, P1366; GOULET O, 1992, TRANSPLANTATION, V53, P940, DOI 10.1097/00007890-199204000-00046; HAMBURGER J, 1962, AM J MED, V32, P854, DOI 10.1016/0002-9343(62)90032-3; HUME DM, 1960, ANN SURG, V152, P354, DOI 10.1097/00000658-196015230-00002; KELLY WD, 1967, SURGERY, V61, P827; KUSS R, 1962, POSTGRAD MED J, V38, P528, DOI 10.1136/pgmj.38.443.528; MAIN JM, 1955, J NATL CANCER I, V15, P1023; MANNICK JA, 1959, SURGERY, V46, P821; Medawar PB, 1944, J ANAT, V78, P176; MEEKER W, 1959, P SOC EXP BIOL MED, V102, P459; MERRILL JP, 1956, JAMA-J AM MED ASSOC, V160, P277, DOI 10.1001/jama.1956.02960390027008; MERRILL JP, 1960, NEW ENGL J MED, V262, P1251, DOI 10.1056/NEJM196006232622501; MICHIE D, 1961, IMMUNOLOGY, V4, P413; MONACO AP, 1976, SURGERY, V79, P384; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; MURRAY JE, 1962, ANN SURG, V156, P337, DOI 10.1097/00000658-196209000-00002; PRZEPIORKA D, 1991, AM J CLIN PATHOL, V95, P201, DOI 10.1093/ajcp/95.2.201; QIAN SW, 1994, HEPATOLOGY, V19, P916, DOI 10.1002/hep.1840190418; RAPAPORT FT, 1979, ANN SURG, V190, P461, DOI 10.1097/00000658-197910000-00006; SALVATIERRA O, 1980, ANN SURG, V192, P543, DOI 10.1097/00000658-198010000-00012; SCHWARTZ R, 1959, NATURE, V183, P1682, DOI 10.1038/1831682a0; SCHWARTZ R, 1960, J CLIN INVEST, V39, P952, DOI 10.1172/JCI104116; SIMONSEN M, 1960, ANN NY ACAD SCI, V87, P382, DOI 10.1111/j.1749-6632.1960.tb23207.x; SIMONSEN M, 1962, PROG ALLERGY, V6, P349, DOI 10.1159/000313805; SIMONSEN MORTEN, 1957, ACTA PATHOL ET MICROBLOL SCAND, V40, P480; SNELL GD, 1957, ANNU REV MICROBIOL, V11, P439, DOI 10.1146/annurev.mi.11.100157.002255; SOLLINGER HW, 1984, TRANSPLANTATION, V38, P612, DOI 10.1097/00007890-198412000-00013; STARZL TE, 1967, SURG GYNECOL OBSTETR, V124, P301; STARZL TE, 1989, LANCET, V2, P1000; STARZL TE, 1968, ANN SURG, V168, P392, DOI 10.1097/00000658-196809000-00009; STARZL TE, 1963, SURG GYNECOL OBSTET, V117, P385; STARZL TE, 1993, NEW ENGL J MED, V328, P745, DOI 10.1056/NEJM199303183281101; STARZL TE, 1993, HEPATOLOGY, V17, P1127; STARZL TE, 1993, LANCET, V341, P65, DOI 10.1016/0140-6736(93)92553-6; STARZL TE, 1984, JAMA-J AM MED ASSOC, V251, P2572; STARZL TE, 1992, LANCET, V339, P1579, DOI 10.1016/0140-6736(92)91840-5; STARZL TE, 1989, JAMA-J AM MED ASSOC, V261, P1449, DOI 10.1001/jama.261.10.1449; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; Steinmann RM, 1999, ANNU REV IMMUNOL, V9, P271; STEINMULLER D, 1967, SCIENCE, V158, P127, DOI 10.1126/science.158.3797.127; Terasaki P.I, 1990, HIST HLA 10 RECOLLEC; THOMAS ED, 1991, HIST TRANSPLANTATION, P379; TRENTIN JJ, 1957, P SOC EXP BIOL MED, V96, P139; WESSMAN M, 1993, BONE MARROW TRANSPL, V11, P279; ZUKOSKI C F, 1960, Surg Forum, V11, P470	62	48	48	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					876	879						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869559				2022-12-28	WOS:A1995QL40200026
J	TABIN, C				TABIN, C			THE INITIATION OF THE LIMB BUD - GROWTH-FACTORS, HOX GENES, AND RETINOIDS	CELL			English	Review							APICAL ECTODERMAL RIDGE; CHICK WING BUD; POLARIZING ACTIVITY; HOMEOBOX GENE; ACID; EMBRYO; CELLS; EXPRESSION; FLANK				TABIN, C (corresponding author), HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115, USA.							BALINSKY BI, 1925, MECH ORG, V143, P718; CARRINGTON JL, 1984, J EMBRYOL EXP MORPH, V84, P19; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; COHN MJ, 1995, CELL, V80, P730; CROSSLEY PH, 1995, IN PRESS DEV; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; Harrison RG, 1918, J EXP ZOOL, V25, P413, DOI 10.1002/jez.1400250204; HELMS J, 1994, DEVELOPMENT, V120, P3267; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; JOHNSON RL, 1994, CURR OPIN GENET DEV, V4, P535, DOI 10.1016/0959-437X(94)90069-F; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; MARSHALL H, 1994, NATURE, V370, P567, DOI 10.1038/370567a0; MAVILIO F, 1988, DIFFERENTIATION, V37, P73, DOI 10.1111/j.1432-0436.1988.tb00798.x; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; OLIVER G, 1990, EMBO J, V9, P3093, DOI 10.1002/j.1460-2075.1990.tb07506.x; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; SAUNDERS JW, 1972, ANN NY ACAD SCI, V193, P29, DOI 10.1111/j.1749-6632.1972.tb27821.x; SUMMERBELL D, 1983, J EMBRYOL EXP MORPH, V78, P269; SUMMERBELL D, 1973, NATURE, V224, P492; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; TICKLE C, 1994, ANNU REV CELL BIOL, V10, P121; TICKLE C, 1982, NATURE, V296, P264; VOGEL A, 1993, DEVELOPMENT, V119, P199; WANEK N, 1991, NATURE, V350, P81, DOI 10.1038/350081a0; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; ZWILLING E, 1964, DEV BIOL, V9, P20, DOI 10.1016/0012-1606(64)90012-0	33	156	156	0	8	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					671	674		10.1016/0092-8674(95)90343-7	http://dx.doi.org/10.1016/0092-8674(95)90343-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889562	Bronze			2022-12-28	WOS:A1995QM39900001
J	BARNES, PC				BARNES, PC			MANAGEMENT FOR DOCTORS - MANAGING CHANGE .9.	BRITISH MEDICAL JOURNAL			English	Article											BARNES, PC (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.							CASSE P, 1979, TRAINING CROSS CULTU; [No title captured]	2	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					590	592		10.1136/bmj.310.6979.590	http://dx.doi.org/10.1136/bmj.310.6979.590			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888940	Green Published			2022-12-28	WOS:A1995QK70000029
J	DELMAR, CB; GREEN, AC				DELMAR, CB; GREEN, AC			AID TO DIAGNOSIS OF MELANOMA IN PRIMARY MEDICAL-CARE	BRITISH MEDICAL JOURNAL			English	Article							PIGMENTED LESIONS	Objective-To evaluate an intervention designed to reduce the number of benign melanocytic lesions excised from the skin. Design-A randomised controlled field trial based in the medical practices of two cities. Examination of histopathological reports of 5823 melanocytic skin lesions excised over the intervention period and in the preceding six months Intervention-Medical practitioners were offered an algorithm and use of an instant developing camera. Setting and subjects-Over 50 medical practitioners, mostly in general practice, in each of two cities in tropical Queensland, Australia. Main outcome measures-Percentages of benign (neither malignant nor potentially malignant) melanocytic lesions excised during the two year intervention period. Results-There were no significant differences in the percentages of benign lesions reported in the intervention and control cities before the intervention started (93.6% and 94.0%, respectively), but there was a significant difference afterwards (88.8% and 93.8%, P<0.001). There was no difference in the percentage of invasive melanomas excised per month in the intervention city (3.4%) compared with control city (3.4%). Conclusion-Clinical diagnostic accuracy may be enhanced by offering to clinicians managing suspicious melanocytic skin lesions a simple algorithm and a camera with which to record the appearance of lesions objectively.	QUEENSLAND INST MED RES,BRISBANE,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute	DELMAR, CB (corresponding author), UNIV QUEENSLAND,SCH MED,BRISBANE,QLD 4006,AUSTRALIA.		Green, Adele C/B-5324-2011; Green, Adele C/P-2736-2014; Del Mar, Chris B/B-1136-2008	Green, Adele C/0000-0002-2753-4841; Del Mar, Chris B/0000-0003-3821-8163				COOKE K, 1993, NEW ZEAL MED J, V106, P493; CURLEY RK, 1989, BRIT MED J, V299, P16, DOI 10.1136/bmj.299.6690.16; DAVIS NC, 1991, MALIGNANT SKIN TUMOU, P71; DECOSTE SD, 1993, ARCH DERMATOL, V129, P57, DOI 10.1001/archderm.129.1.57; DELMAR C, 1994, AUST J PUBLIC HEALTH, V18, P221; Fernando S S, 1987, Australas J Dermatol, V28, P126, DOI 10.1111/j.1440-0960.1987.tb00352.x; Green A, 1991, Melanoma Res, V1, P231, DOI 10.1097/00008390-199111000-00002; KENET RO, 1993, ARCH DERMATOL, V129, P157, DOI 10.1001/archderm.129.2.157; MACKIE RM, 1990, BRIT MED J, V301, P1005, DOI 10.1136/bmj.301.6759.1005; MACKIE RM, 1989, MALIGNANT MELANOMA G, P28; MACLENNAN R, 1992, J NATL CANCER I, V84, P1427, DOI 10.1093/jnci/84.18.1427; MILTON G, 1992, CUTANEOUS MELANOMA, P13; Pehamberger H, 1993, J INVEST DERMATOL, V100, P356	13	40	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					492	495		10.1136/bmj.310.6978.492	http://dx.doi.org/10.1136/bmj.310.6978.492			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888887	Green Published			2022-12-28	WOS:A1995QJ59800019
J	SIMOONS, ML; MAGGIONI, AP; KNATTERUD, G; LEIMBERGER, JD; DEJAEGERE, P; VANDOMBURG, R; BOERSMA, E; FRANZOSI, MG; CALIFF, R; SCHRODER, R; BRAUNWALD, E				SIMOONS, ML; MAGGIONI, AP; KNATTERUD, G; LEIMBERGER, JD; DEJAEGERE, P; VANDOMBURG, R; BOERSMA, E; FRANZOSI, MG; CALIFF, R; SCHRODER, R; BRAUNWALD, E			INDIVIDUAL RISK ASSESSMENT FOR INTRACRANIAL HEMORRHAGE DURING THROMBOLYTIC THERAPY	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; TISSUE PLASMINOGEN-ACTIVATOR; INTRAVENOUS STREPTOKINASE; INTRACEREBRAL HEMORRHAGE; RANDOMIZED TRIAL; PHASE-II; STROKE; EPIDEMIOLOGY; NETHERLANDS; ANGIOPLASTY	Thrombolytic therapy improves outcome in patients with myocardial infarction but is associated with an increased risk of intracranial haemorrhage. For some patients, this risk may outweigh the potential benefits of thrombolytic treatment. Using data from other studies, we developed a model for the assessment of an individual's risk of intracranial haemorrhage during thrombolysis. Data were available from 150 patients with documented intracranial haemorrhage and 294 matched controls. 49 patients with intracranial haemorrhage and 122 controls had been treated with streptokinase, whereas 88 cases and 148 controls had received alteplase. By multivariate analysis, four factors were identified as independent predictors of intracranial haemorrhage; age over 65 years (odds ratio 2.2 [95% CI 1.4-3.5]), bodyweight below 70 kg (2.1 [1.3-3.2]), hypertension on hospital admission (2.0 [1.2-3.2]), and administration of alteplase (1.6 [1.0-2.5]). If the overall incidence of intracranial haemorrhage is assumed to be 0.75%, patients without risk factors who receive streptokinase have a 0.26% probability of intracranial haemorrhage. The risk is 0.96%, 1.32%, and 2.17% in patients with one, two, or three risk factors, respectively. We present a model for individual risk assessment that can be used easily in clinical practice.	ERASMUS UNIV ROTTERDAM, THORAXCTR, 3000 DR ROTTERDAM, NETHERLANDS; MARIO NEGRI INST PHARMACOL RES, I-20157 MILAN, ITALY; DUKE UNIV, DEPT CARDIOL, DURHAM, NC 27706 USA; FREE UNIV BERLIN, W-1000 BERLIN 33, GERMANY; MARYLAND MED RES INST, BALTIMORE, MD USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Erasmus University Rotterdam; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Duke University; Free University of Berlin; Harvard University; Brigham & Women's Hospital	SIMOONS, ML (corresponding author), UNIV HOSP ROTTERDAM, THORAXCTR, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.		Maggioni, Aldo Pietro/AAL-5334-2020	Maggioni, Aldo Pietro/0000-0003-2764-6779				[Anonymous], 1990, LANCET, V336, P65; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V1, P397; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BONITA R, 1992, LANCET, V339, P342, DOI 10.1016/0140-6736(92)91658-U; BOSSUYT PMM, 1990, KLINISCHE BESLISKUND, P127; BRAUNWALD E, 1987, J AM COLL CARDIOL, V10, P970, DOI 10.1016/S0735-1097(87)80296-6; CALIFF RM, 1988, AM J MED, V85, P353, DOI 10.1016/0002-9343(88)90586-4; CAPLAN LR, 1992, LANCET, V339, P656, DOI 10.1016/0140-6736(92)90804-C; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HERMAN B, 1982, STROKE, V13, P629, DOI 10.1161/01.STR.13.5.629; KASE CS, 1992, AM J MED, V92, P384, DOI 10.1016/0002-9343(92)90268-G; MAGGIONI AP, 1992, NEW ENGL J MED, V327, P1, DOI 10.1056/NEJM199207023270101; MARMOT MG, 1992, LANCET, V339, P344, DOI 10.1016/0140-6736(92)91659-V; MUELLER HS, 1987, J AM COLL CARDIOL, V10, P479, DOI 10.1016/S0735-1097(87)80188-2; NEUHAUS KL, 1989, J AM COLL CARDIOL, V14, P1566, DOI 10.1016/0735-1097(89)90399-9; PASSAMANI E, 1987, J AM COLL CARDIOL, V10, pB51, DOI 10.1016/S0735-1097(87)80429-1; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1988, LANCET, V1, P199; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TOPOL EJ, 1989, CIRCULATION, V79, P281, DOI 10.1161/01.CIR.79.2.281; TOPOL EJ, 1988, CIRCULATION, V77, P1100, DOI 10.1161/01.CIR.77.5.1100; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; VANDEWERF F, 1990, LANCET, V336, P71; VANDEWERF F, 1988, BMJ-BRIT MED J, V297, P1374, DOI 10.1136/bmj.297.6660.1374; VERMEER F, 1986, CIRCULATION, V74, P1379, DOI 10.1161/01.CIR.74.6.1379; VERMEER F, 1988, BRIT HEART J, V59, P527; VERSTRAETE M, 1985, LANCET, V1, P842, DOI 10.1016/S0140-6736(85)92208-1; WALL TC, 1992, J AM COLL CARDIOL, V19, P482, DOI 10.1016/S0735-1097(10)80259-1; WILCOX RG, 1988, LANCET, V2, P525	33	232	237	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1523	1528		10.1016/S0140-6736(05)80089-3	http://dx.doi.org/10.1016/S0140-6736(05)80089-3			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902905	Green Submitted			2022-12-28	WOS:A1993MM40200016
J	GRAHAMESMITH, DG				GRAHAMESMITH, DG			AN ENCOUNTER WITH BEETHOVEN CLEANING LADY	LANCET			English	Editorial Material											GRAHAMESMITH, DG (corresponding author), UNIV OXFORD,DEPT CLIN PHARMACOL,OXFORD,ENGLAND.								0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1315	1315		10.1016/0140-6736(93)92242-L	http://dx.doi.org/10.1016/0140-6736(93)92242-L			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901632				2022-12-28	WOS:A1993MJ03900005
J	MARTIN, GB; BROMMONSCHENKEL, SH; CHUNWONGSE, J; FRARY, A; GANAL, MW; SPIVEY, R; WU, TY; EARLE, ED; TANKSLEY, SD				MARTIN, GB; BROMMONSCHENKEL, SH; CHUNWONGSE, J; FRARY, A; GANAL, MW; SPIVEY, R; WU, TY; EARLE, ED; TANKSLEY, SD			MAP-BASED CLONING OF A PROTEIN-KINASE GENE CONFERRING DISEASE RESISTANCE IN TOMATO	SCIENCE			English	Article							CLONED AVIRULENCE GENES; SYRINGAE PV GLYCINEA; VIRULENCE DETERMINANT; CONSERVED FEATURES; BRASSICA-OLERACEA; RAF ONCOGENE; IDENTIFICATION; LOCUS; SEQUENCE; INCOMPATIBILITY	The Pto gene in tomato confers resistance to races of Pseudomonas syringae pv. tomato that carry the avirulence gene avrPto. A yeast artificial chromosome clone that spans the Pto region was identified and used to probe a leaf complementary DNA (cDNA) library. A cDNA clone was isolated that represents a gene family, at least six members of which genetically cosegregate with Pto. When susceptible tomato plants were transformed with a cDNA from this family, they were resistant to the pathogen. Analysis of the amino acid sequence revealed similarity to serine-threonine protein kinases, suggesting a role for Pto in a signal transduction pathway.	CORNELL UNIV, DEPT PLANT BREEDING & BIOMETRY, ITHACA, NY 14853 USA	Cornell University			Frary, Anne/A-5417-2015; Martin, Gregory B/F-6262-2011; Brommonschenkel, Sergio/C-5748-2013	Frary, Anne/0000-0002-8973-0100; Martin, Gregory B/0000-0003-0044-6830; 				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arumuganathan K., 1991, PLANT MOL BIOL REP, V9, P229, DOI [10.1007/BF02672073, DOI 10.1007/BF02672073]; BENNETZEN JL, 1992, PLANT MOL BIOL, V20, P575, DOI 10.1007/BF00046442; BERNATZKY R, 1986, GENETICS, V112, P887; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1993, CELL, V73, P903, DOI 10.1016/0092-8674(93)90270-Z; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BUSS JE, 1986, J VIROL, V58, P468, DOI 10.1128/JVI.58.2.468-474.1986; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; CHUNWONGSE J, UNPUB; DEBENER T, 1991, PLANT J, V1, P289, DOI 10.1046/j.1365-313X.1991.t01-7-00999.x; DICKINSON MJ, 1993, MOL PLANT MICROBE IN, V6, P341, DOI 10.1094/MPMI-6-341; DONG XN, 1991, PLANT CELL, V3, P61, DOI 10.1105/tpc.3.1.61; FARMER EE, 1991, J BIOL CHEM, V266, P3140; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FELIX G, 1991, P NATL ACAD SCI USA, V88, P8831, DOI 10.1073/pnas.88.19.8831; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; FRARY A, UNPUB; GABRIEL DW, 1990, ANNU REV PHYTOPATHOL, V28, P365, DOI 10.1146/annurev.py.28.090190.002053; GABRIEL DW, 1986, P NATL ACAD SCI USA, V83, P6415, DOI 10.1073/pnas.83.17.6415; GOUGH CL, 1992, MOL PLANT MICROBE IN, V5, P384, DOI 10.1094/MPMI-5-384; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; HULBERT SH, 1985, THEOR APPL GENET, V70, P520, DOI 10.1007/BF00305985; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; KEEN NT, 1991, THEOR APPL GENET, V81, P133, DOI 10.1007/BF00226123; KING EO, 1954, J LAB CLIN MED, V44, P301; KOBAYASHI DY, 1989, P NATL ACAD SCI USA, V86, P157, DOI 10.1073/pnas.86.1.157; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MARTIN G, UNPUB; MARTIN GB, 1991, P NATL ACAD SCI USA, V88, P2336, DOI 10.1073/pnas.88.6.2336; MARTIN GB, 1992, MOL GEN GENET, V233, P25, DOI 10.1007/BF00587557; MARTIN GB, 1993, MOL PLANT MICROBE IN, V6, P26, DOI 10.1094/MPMI-6-026; MARX J, 1993, SCIENCE, V260, P1588, DOI 10.1126/science.8503004; MESHI T, 1989, PLANT CELL, V1, P515, DOI 10.1105/tpc.1.5.515; MESSEGUER R, 1991, THEOR APPL GENET, V82, P529, DOI 10.1007/BF00226787; OCHMAN H, 1988, GENETICS, V120, P621; RAZ V, 1993, PLANT CELL, V5, P523, DOI 10.1105/tpc.5.5.523; RONALD PC, 1992, J BACTERIOL, V174, P1604, DOI 10.1128/jb.174.5.1604-1611.1992; SAMBROOK J, 1989, MOL CLONING LABORATO, pCH7; SARFATTI M, 1989, THEOR APPL GENET, V78, P755, DOI 10.1007/BF00262574; SCHULTZ AM, 1985, SCIENCE, V227, P427, DOI 10.1126/science.3917576; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; TANKSLEY SD, 1992, GENETICS, V132, P1141; TOBIAS CM, 1992, PLANT PHYSIOL, V99, P284, DOI 10.1104/pp.99.1.284; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; WALKER JC, 1990, NATURE, V345, P743, DOI 10.1038/345743a0; Watterson J.C., 1986, TOMATO CROP SCI BASI, P443; ZAMIR D, 1988, MOL GEN GENET, V213, P254, DOI 10.1007/BF00339589	55	1081	1262	5	118	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1993	262	5138					1432	1436		10.1126/science.7902614	http://dx.doi.org/10.1126/science.7902614			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MJ046	7902614				2022-12-28	WOS:A1993MJ04600037
J	NOBLE, BK				NOBLE, BK			IMMUNOLOGICALLY COMPLEX KIDNEYS	LANCET			English	Editorial Material							EXPRESSION; C-4				NOBLE, BK (corresponding author), SUNY BUFFALO,SCH MED & BIOMED SCI,DEPT MICROBIOL,BUFFALO,NY 14260, USA.							COUSER WG, 1985, KIDNEY INT, V28, P879, DOI 10.1038/ki.1985.214; FEUCHT HE, 1989, NEPHRON, V53, P338, DOI 10.1159/000185778; OLIVERA PBG, 1992, IMMUNOLOGICAL ASPECT; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; SAKAKIBARA K, 1990, THROMB RES, V57, P625, DOI 10.1016/0049-3848(90)90080-V; SCHULZE M, 1991, KIDNEY INT, V40, P533, DOI 10.1038/ki.1991.242; WITTE DP, 1991, AM J PATHOL, V139, P717	7	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1250	1251		10.1016/0140-6736(93)92352-T	http://dx.doi.org/10.1016/0140-6736(93)92352-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901576				2022-12-28	WOS:A1993MH56600002
J	LLOYD, SA				LLOYD, SA			STRATOSPHERIC OZONE DEPLETION	LANCET			English	Article							ANTARCTIC VORTEX; SUNLIGHT; EXPOSURE; RISK		HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University								ANDERSON DE, 1990, J GEOPHYS RES-ATMOS, V95, P7429, DOI 10.1029/JD095iD06p07429; ANDERSON JG, 1989, J GEOPHYS RES-ATMOS, V94, P11480, DOI 10.1029/JD094iD09p11480; ANDERSON JG, 1991, SCIENCE, V251, P39, DOI 10.1126/science.251.4989.39; BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027; EMMETT EA, 1986, EFFECTS CHANGES STRA, V1, P129; GLEASON JF, 1993, SCIENCE, V260, P523, DOI 10.1126/science.260.5107.523; KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366; ROWLAND FS, 1974, NATURE, V249, P810; SETLOW RB, 1974, P NATL ACAD SCI USA, V71, P3363, DOI 10.1073/pnas.71.9.3363; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1481, DOI 10.1001/archopht.1989.01070020555039; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; TUCKER MA, 1985, NEW ENGL J MED, V313, P789, DOI 10.1056/NEJM198509263131305; WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038; 1986, NASA16 WORLD MET ORG, V1; 1991, REPORT INT OZONE TRE; [No title captured]	16	42	44	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1156	1158		10.1016/0140-6736(93)92130-L	http://dx.doi.org/10.1016/0140-6736(93)92130-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901482				2022-12-28	WOS:A1993MF19800016
J	NICHOLSON, DA; OKEEFFE, D; DRISCOLL, PA				NICHOLSON, DA; OKEEFFE, D; DRISCOLL, PA			ABC OF EMERGENCY RADIOLOGY - THE FOOT	BRITISH MEDICAL JOURNAL			English	Article									ROYAL ALBERT & EDWARD INFIRM,WIGAN,ENGLAND		NICHOLSON, DA (corresponding author), HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1993	307	6910					997	1001		10.1136/bmj.307.6910.997	http://dx.doi.org/10.1136/bmj.307.6910.997			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MC441	7902156	Green Published, Bronze			2022-12-28	WOS:A1993MC44100027
J	KATON, W; VONKORFF, M; LIN, E; WALKER, E; SIMON, GE; BUSH, T; ROBINSON, P; RUSSO, J				KATON, W; VONKORFF, M; LIN, E; WALKER, E; SIMON, GE; BUSH, T; ROBINSON, P; RUSSO, J			COLLABORATIVE MANAGEMENT TO ACHIEVE TREATMENT GUIDELINES - IMPACT ON DEPRESSION IN PRIMARY-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To compare the effectiveness of a multifaceted intervention in patients with depression in primary care with the effectiveness of ''usual care'' by the primary care physician. Design.-A randomized controlled trial among primary care patients with major depression or minor depression. Patients.-Over a 12-month period a total of 217 primary care patients who were recognized as depressed by their primary care physicians and were willing to take antidepressant medication were randomized, with 91 patients meeting criteria for major depression and 126 for minor depression. Interventions.-lntervention patients received increased intensity and frequency of visits over the first 4 to 6 weeks of treatment (visits 1 and 3 with a primary care physician, visits 2 and 4 with a psychiatrist) and continued surveillance of adherence to medication regimens during the continuation and maintenance phases of treatment. Patient education in these visits was supplemented by videotaped and written materials. Main Outcome Measures.-Primary outcome measures included short-term (30-day) and long-term (90-day) use of antidepressant medication at guideline dosage levels, satisfaction with overall care for depression and antidepressant medication, and reduction in depressive symptoms. Results.-In patients with major depression, the intervention group had greater adherence than the usual care controls to adequate dosage of antidepressant medication for 90 days or more (75.5% vs 50.0%; P<.01), were more likely to rate the quality of the care they received for depression as good to excellent (93.0% vs 75.0%; P<.03), and were more likely to rate antidepressant medications as helping somewhat to helping a great deal (88.1% vs 63.3%; P<.01). Seventy-four percent of intervention patients with major depression showed 50% or more improvement on the Symptom Checklist-90 Depressive Symptom Scale compared with 43.8% of controls (P<.01), and the intervention patients also demonstrated a significantly greater decrease in depression severity over time compared with controls (P<.004). In patients with minor depression, the intervention group had significantly greater adherence than controls to adequate dosage of antidepressant medication for 90 days or more (79.7% vs 40.3%; P<.001) and more often rated antidepressant medication as helping somewhat to helping a great deal (81.8% vs 61.4%; P<.02). However, no significant differences were found between the intervention and control groups in the percentage of patients who were satisfied with the care they received for depression (94.4% vs 89.3%), in the percentage who experienced a 50% or more decrease in depressive symptoms, or in the decrease of depressive symptoms over time. Conclusion.-A multifaceted intervention consisting of collaborative management by the primary care physician and a consulting psychiatrist, intensive patient education, and surveillance of continued refills of antidepressant medication improved adherence to antidepressant regimens in patients with major and with minor depression. It improved satisfaction with care and resulted in more favorable depressive outcomes in patients with major, but not minor, depression.	GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,SEATTLE,WA 98101	Group Health Cooperative	KATON, W (corresponding author), UNIV WASHINGTON,SCH MED,DEPT PSYCHIAT & BEHAV SCI,RP-10,SEATTLE,WA 98195, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH041739] Funding Source: NIH RePORTER; NIMH NIH HHS [MH4-1739] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		[Anonymous], 1989, GUIDE CLIN PREVENTIV; COOPERPATRICK L, 1994, MED CARE, V32, P15, DOI 10.1097/00005650-199401000-00002; Costa P.T., 1985, NEO PERSONALITY INVE; Derogatis LR, 1974, PSYCHOL MEASUREMENTS, P79; EISENBERG L, 1992, NEW ENGL J MED, V326, P1080, DOI 10.1056/NEJM199204163261610; ELKIN I, 1989, ARCH GEN PSYCHIAT, V46, P971; HAYNES RB, 1976, COMPLIANCE HLTH CARE, P23; KATON W, 1992, GEN HOSP PSYCHIAT, V14, P237, DOI 10.1016/0163-8343(92)90094-Q; KATON W, 1992, MED CARE, V30, P67, DOI 10.1097/00005650-199201000-00007; KATON W, 1994, J AFFECT DISORDERS, V31, P81, DOI 10.1016/0165-0327(94)90111-2; KELLER MB, 1982, JAMA-J AM MED ASSOC, V246, P1848; LIN E, 1994, 8TH ANN NAT I MENT H; LIN EHB, 1995, MED CARE, V33, P67, DOI 10.1097/00005650-199501000-00006; MARROW WE, 1993, ARCH GEN PSYCHIAT, V50, P95; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MCCANN DP, 1990, WESTERN J MED, V153, P44; OBRIEN RG, 1985, PSYCHOL BULL, V97, P316, DOI 10.1037/0033-2909.97.2.316; PAYKEL ES, 1988, J AFFECT DISORDERS, V4, P83; Robins L.N., 1985, DIAGNOSTIC INTERVIEW; RUSH AJ, 1986, PSYCHIAT RES, V18, P65; SCHULBERG HC, 1993, INT J PSYCHIAT MED, V23, P29, DOI 10.2190/TPTQ-M91J-6907-62RW; SCHULBERG HC, 1991, GEN HOSP PSYCHIAT, V13, P156, DOI 10.1016/0163-8343(91)90138-M; Simon G E, 1992, Psychiatr Med, V10, P49; SIMON GE, 1993, GEN HOSP PSYCHIAT, V15, P399, DOI 10.1016/0163-8343(93)90009-D; SIMON GE, 1991, AM J PSYCHIAT, V148, P1494; STARFIELD B, 1973, NEW ENGL J MED, V289, P132, DOI 10.1056/NEJM197307192890305; VONKORFF M, 1992, J CLIN EPIDEMIOL, V45, P197, DOI 10.1016/0895-4356(92)90016-G; WELLS KB, 1994, AM J PSYCHIAT, V151, P694; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WILLIAMS JBW, 1992, ARCH GEN PSYCHIAT, V49, P630; 1987, DIAGNOSTIC STATISTIC; 1993, AHCPR93051 US DEP HL, P2; 1993, AHCPR930551 US DEP H, P1	33	1107	1116	1	58	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1026	1031		10.1001/jama.273.13.1026	http://dx.doi.org/10.1001/jama.273.13.1026			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP890	7897786				2022-12-28	WOS:A1995QP89000033
J	COLDITZ, GA; WILLETT, WC; ROTNITZKY, A; MANSON, JE				COLDITZ, GA; WILLETT, WC; ROTNITZKY, A; MANSON, JE			WEIGHT-GAIN AS A RISK FACTOR FOR CLINICAL DIABETES-MELLITUS IN WOMEN	ANNALS OF INTERNAL MEDICINE			English	Article						WEIGHT GAIN; DIABETES MELLITUS; BODY MASS INDEX; AGE FACTORS; RISK FACTORS	GUIDELINES; AMERICANS; MASS	Objective: To examine the relation between adult weight change and the risk for clinical diabetes mellitus among middle-aged women. Design: Prospective cohort study with follow-up from 1976 to 1990. Setting: if U.S. states. Participants: 114 281 female registered nurses aged 30 to 55 years who did not have diagnosed diabetes mellitus, coronary heart disease, stroke, or cancer in 1976. Outcome Measures: Non-insulin-dependent diabetes mellitus. Results: 2204 cases of diabetes were diagnosed during 1.49 million person-years of follow-up. After adjustment for age, body mass index was the dominant predictor of risk for diabetes mellitus. Risk increased with greater body mass index, and even women with average weight (body mass index, 24.0 kg/m(2)) had an elevated risk. Compared with women with stable weight (those who gained or lost less than 5 kg between age 18 years and 1976) and after adjustment for age and body mass index at age 18 years, the relative risk for diabetes mellitus among women who had a weight gain of 5.0 to 7.9 kg was 1.9 (95% CI, 1.5 to 2.3). The corresponding relative risk for women who gained 8.0 to 10.9 kg was 2.7 (CI, 2.1 to 3.3). In contrast, women who lost more than 5.0 kg reduced their risk for diabetes mellitus by 50% or more. These results were independent of family history of diabetes. Conclusion: The excess risk for diabetes with even modest and typical adult weight gain is substantial. These findings support the importance of maintaining a constant body weight throughout adult life and suggest that the 1990 U.S. Department of Agriculture guidelines that allow a substantial weight gain after 35 years of age are misleading.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR & EPIDEMIOL, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	COLDITZ, GA (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA40935] Funding Source: Medline; NIDDK NIH HHS [P30-DK-46200, DK36798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036798, P30DK046200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDRES R, 1985, ANN INTERN MED, V103, P1030, DOI 10.7326/0003-4819-103-6-1030; BERGER M, 1975, RECENT ADV OBESITY R, P128; BRAY GA, 1992, AM J CLIN NUTR, V55, P481, DOI 10.1093/ajcn/55.2.481a; BRAY GA, 1992, INT J OBESITY, V16, pS13; CALLAWAY CW, 1991, AM J CLIN NUTR, V54, P171, DOI 10.1093/ajcn/54.1.171a; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; HARLAN WR, 1988, AM J EPIDEMIOL, V128, P1065; HARRIS M, 1979, DIABETES, V28, P1039; HOLBROOK TL, 1989, INT J OBESITY, V13, P723; MANSON JE, 1994, AM J EPIDEMIOL, V139, pS46; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROTH A, 1977, PHS HRP0900603, P182; SPIEGELMAN D, 1992, AM J CLIN NUTR, V55, P1033, DOI 10.1093/ajcn/55.6.1033; SWINBURN BA, 1991, J CLIN INVEST, V88, P168, DOI 10.1172/JCI115274; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT W, 1994, AM J EPIDEMIOL, V139, pS25; WILLETT WC, 1991, AM J CLIN NUTR, V53, P1102, DOI 10.1093/ajcn/53.5.1102; 1990, REPORT CRUDELINES AD; 1987, DHHS PHS871688 US DE	20	1303	1358	3	64	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					481	486		10.7326/0003-4819-122-7-199504010-00001	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872581				2022-12-28	WOS:A1995QP00800001
J	BROPHY, JM; JOSEPH, L				BROPHY, JM; JOSEPH, L			PLACING TRIALS IN CONTEXT USING BAYESIAN-ANALYSIS - GUSTO REVISITED BY REVEREND BAYES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CLINICAL-TRIALS	Standard statistical analyses of randomized clinical trials fail to provide a direct assessment of which treatment is superior or the probability of a clinically meaningful difference. A Bayesian analysis permits the calculation of the probability that a treatment is superior based on the observed data and prior beliefs. The subjectivity of prior beliefs in the Bayesian approach is not a liability, but rather explicitly allows different opinions to be formally expressed and evaluated. The usefulness of this approach is demonstrated using the results of the recent GUSTO study of various thrombolytic strategies in acute myocardial infarction. This analysis suggests that the clinical superiority of tissue-type plasminogen activator over streptokinase remains uncertain.	MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL, PQ, CANADA; MONTREAL GEN HOSP, DEPT MED, DIV CLIN EPIDEMIOL, MONTREAL, PQ H3G 1A4, CANADA; MONTREAL GEN HOSP, DEPT MED, CTR ANAL COST EFFECT CARE, MONTREAL, PQ H3G 1A4, CANADA	McGill University; McGill University; McGill University	BROPHY, JM (corresponding author), CTR HOSP VERDUN, DEPT MED, 400 BOUL LASALLE, VERDUN, PQ H4G 2A3, CANADA.		brophy, james/H-6673-2019	brophy, james/0000-0001-8049-6875				BERGER JO, 1988, AM SCI, V76, P159; BROWNER WS, 1987, JAMA-J AM MED ASSOC, V257, P2459, DOI 10.1001/jama.257.18.2459; DIAMOND GA, 1983, ANN INTERN MED, V98, P385, DOI 10.7326/0003-4819-98-3-385; DIAMOND GA, 1993, CIRCULATION, V88, P452; Eddy DM., 1992, META ANAL CONFIDENCE; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; HUGHES MD, 1993, STAT MED, V12, P1651, DOI 10.1002/sim.4780121802; Rapaport E., 1993, J MYOCARDIAL ISCHEMI, V5, P15; RIDKER PM, 1994, ANN INTERN MED, V120, P882, DOI 10.7326/0003-4819-120-10-199405150-00010; RIDKER PM, 1993, ANN INTERN MED, V119, P530, DOI 10.7326/0003-4819-119-6-199309150-00017; Sleight P, 1993, J MYOCARDIAL ISCHEMI, V5, P25; SPIEGELHALTER DJ, 1994, J R STAT SOC A STAT, V157, P357, DOI 10.2307/2983527; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VANDEWERF F, 1990, LANCET, V336, P71; 1993, LANCET, V339, P753	15	124	122	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					871	875		10.1001/jama.273.11.871	http://dx.doi.org/10.1001/jama.273.11.871			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869558				2022-12-28	WOS:A1995QL40200025
J	BLUNT, T; FINNIE, NJ; TACCIOLI, GE; SMITH, GCM; DEMENGEOT, J; GOTTLIEB, TM; MIZUTA, R; VARGHESE, AJ; ALT, FW; JEGGO, PA; JACKSON, SP				BLUNT, T; FINNIE, NJ; TACCIOLI, GE; SMITH, GCM; DEMENGEOT, J; GOTTLIEB, TM; MIZUTA, R; VARGHESE, AJ; ALT, FW; JEGGO, PA; JACKSON, SP			DEFECTIVE DNA-DEPENDENT PROTEIN-KINASE ACTIVITY IS LINKED TO V(D)J RECOMBINATION AND DNA-REPAIR DEFECTS ASSOCIATED WITH THE MURINE SCID MUTATION	CELL			English	Article							STRAND BREAK REPAIR; COMBINED IMMUNE-DEFICIENCY; RAY SENSITIVE MUTANTS; HAMSTER OVARY CELLS; RNA POLYMERASE-II; TRANSCRIPTION FACTORS; JUNCTIONAL SEQUENCES; IONIZING-RADIATION; HUMAN CHROMOSOME-8; RECEPTOR GAMMA	Murine cells homozygous for the severe combined immune deficiency mutation (scid) and V3 mutant hamster cells fall into the same complementation group and show similar defects in V(D)J recombination and DNA double-stranded break repair. Here we show that both cell types lack DNA-dependent protein kinase (DNA-PK) activity owing to defects in DNA-PKcs, the catalytic subunit of this enzyme. Furthermore, we demonstrate that yeast artificial chromosomes containing the DNA-PKcs, gene complement both the DNA repair and recombination deficiencies of V3 cells, and we conclude that DNA-PKcs, is encoded by the XRCC7 gene. As DNA-PK binds to DNA ends and is activated by these structures, our findings provide novel insights into V(D)J recombination and DNA repair processes.	UNIV CAMBRIDGE,DEPT ZOOL,CAMBRIDGE CB2 1QR,ENGLAND; UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND; HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CTR BLOOD RES,DEPT GENET,BOSTON,MA 02115; ONTARIO CANC INST,TORONTO,ON M4X 1K9,CANADA	University of Cambridge; University of Sussex; Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto	BLUNT, T (corresponding author), UNIV CAMBRIDGE,WELLCOME CANC RES CAMPAIGN INST,TENNIS COURT RD,CAMBRIDGE CB2 1QR,ENGLAND.		Dry, Kate/I-2328-2014; demengeot, jocelyne/K-8072-2014; Jackson, Stephen Philip/R-4548-2019	demengeot, jocelyne/0000-0002-4761-614X; Jackson, Stephen Philip/0000-0001-9317-7937	NIAID NIH HHS [AI-20047, AI-35714-01] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020047, R37AI020047, P01AI035714] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALT FW, 1992, IMMUNOL TODAY, V13, P306, DOI 10.1016/0167-5699(92)90043-7; ANAND R, 1990, NUCLEIC ACIDS RES, V8, P1951; Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; BANGA SS, 1994, MUTAT RES-DNA REPAIR, V315, P239, DOI 10.1016/0921-8777(94)90035-3; BANNISTER AJ, 1993, NUCLEIC ACIDS RES, V21, P1289, DOI 10.1093/nar/21.5.1289; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLACKWELL KT, 1988, ANNU REV GENET, V23, P630; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; DVIR A, 1993, J BIOL CHEM, V268, P10440; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GELLERT M, 1992, ANNU REV GENET, V22, P425; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GIACCIA A, 1985, SOMAT CELL MOLEC GEN, V11, P485, DOI 10.1007/BF01534842; GOTLIEB TM, 1994, TRENDS BIOCHEM SCI, V19, P500; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; HESSE JE, 1987, CELL, V49, P775, DOI 10.1016/0092-8674(87)90615-5; ITOH M, 1993, RADIAT RES, V134, P364, DOI 10.2307/3578198; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1989, P NATL ACAD SCI USA, V86, P1781, DOI 10.1073/pnas.86.6.1781; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JEGGO PA, 1991, MUTAT RES, V254, P125, DOI 10.1016/0921-8777(91)90003-8; JEGGO PA, 1985, MUTAT RES, V145, P171, DOI 10.1016/0167-8817(85)90024-0; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIENKER LJ, 1991, J EXP MED, V174, P769, DOI 10.1084/jem.174.4.769; KIRCHGESSNER CU, 1993, CANCER RES, V53, P6011; KOMATSU K, 1993, HUM MOL GENET, V7, P1031; KUHN A, 1995, GENE DEV, V9, P198; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; LIEBER MR, 1991, FASEB J, V5, P2934, DOI 10.1096/fasebj.5.14.1752360; LIEBER MR, 1988, CELL, V55, P7, DOI 10.1016/0092-8674(88)90004-9; MALYNN BA, 1988, CELL, V54, P453, DOI 10.1016/0092-8674(88)90066-9; MARKIE D, 1993, SOMAT CELL MOLEC GEN, V19, P161, DOI 10.1007/BF01233531; MOMBAERT P, 1992, CELL, V68, P867; OETTINGER MA, 1990, SCIENCE, V248, P1517, DOI 10.1126/science.2360047; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; ROTH DB, 1993, P NATL ACAD SCI USA, V90, P10788, DOI 10.1073/pnas.90.22.10788; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SCHULER W, 1991, EUR J IMMUNOL, V21, P589, DOI 10.1002/eji.1830210309; SCHULER W, 1986, CELL, V46, P963, DOI 10.1016/0092-8674(86)90695-1; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; TACCIOLI GE, 1994, J BIOL CHEM, V269, P4739; WEIBEZAHN KF, 1985, MUTAT RES, V145, P177, DOI 10.1016/0167-8817(85)90025-2; WHITMORE GF, 1989, INT J RADIAT BIOL, V56, P657, DOI 10.1080/09553008914551881	54	759	771	0	17	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					813	823		10.1016/0092-8674(95)90360-7	http://dx.doi.org/10.1016/0092-8674(95)90360-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889575	Bronze			2022-12-28	WOS:A1995QM39900018
J	LUNDBLAD, JR; KWOK, RPS; LAURANCE, ME; HARTER, ML; GOODMAN, RH				LUNDBLAD, JR; KWOK, RPS; LAURANCE, ME; HARTER, ML; GOODMAN, RH			ADENOVIRAL E1A-ASSOCIATED PROTEIN P300 AS A FUNCTIONAL HOMOLOG OF THE TRANSCRIPTIONAL COACTIVATOR CBP	NATURE			English	Article							REGION 1A PROTEINS; ESCHERICHIA-COLI; PROMOTER; IDENTIFICATION; ASSOCIATION; BINDS; GENE	THE 265K nuclear protein CBP was initially identified as a coactivator for the protein kinase A (PKA)-phosphorylated form of the transcription factor CREB(1). The domains in CBP that are involved in CREB binding and transcriptional activation are highly related to the adenoviral E1A-associated cellular protein p300 (refs 2, 3), and to two hypothetical proteins from Caenorhabditis elegans, R10E11.1 and K03H1.10 (refs 4 and 5, respectively), whose functions are unknown. Here, we show that CBP and p300 have similar binding affinity for the PKA-phosphorylated form of CREB, and that p300 can substitute for CBP in potentiating CREB-activated gene expression. We find that E1A binds to CBP through a domain conserved with p300 acid represses the CREB-dependent co-activator functions of both CBP and p300. Our results indicate that the gene repression and cell immortalization functions associated with E1A involve the inactivation of a family of related proteins that normally participate in second-messenger-regulated gene expression.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; CLEVELAND CLIN,RES INST,DEPT MOLEC BIOL,CLEVELAND,OH 44195	Oregon Health & Science University; Cleveland Clinic Foundation								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARANY Z, 1994, CELL, V77, P7799; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANERJEE AC, 1994, ONCOGENE, V5, P1733; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HARLOW E, 1986, MOL CELL BIOL, V6, P1579, DOI 10.1128/MCB.6.5.1579; HEYDUK T, 1993, NATURE, V364, P548, DOI 10.1038/364548a0; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KRAUS VB, 1992, MOL CELL BIOL, V12, P4391, DOI 10.1128/MCB.12.10.4391; KWOK RPS, 1994, NATURE, V378, P223; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; SIMON MC, 1988, CELL, V52, P723, DOI 10.1016/0092-8674(88)90410-2; SMITH M, 1994, Z29560 GENB ACC; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; WANG DM, 1992, PROTEIN EXPRES PURIF, V3, P8, DOI 10.1016/1046-5928(92)90050-7; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	21	530	541	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					85	88		10.1038/374085a0	http://dx.doi.org/10.1038/374085a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870179				2022-12-28	WOS:A1995QK07900059
J	PICCIOTTO, MR; ZOLL, M; LENA, C; BESSIS, A; LALLEMAND, Y; LENOVERE, N; VINCENT, P; PICH, EM; BRULET, P; CHANGEUX, JP				PICCIOTTO, MR; ZOLL, M; LENA, C; BESSIS, A; LALLEMAND, Y; LENOVERE, N; VINCENT, P; PICH, EM; BRULET, P; CHANGEUX, JP			ABNORMAL AVOIDANCE-LEARNING IN MICE LACKING FUNCTIONAL HIGH-AFFINITY NICOTINE RECEPTOR IN THE BRAIN	NATURE			English	Article							RAT-BRAIN; ACETYLCHOLINE-RECEPTORS; ALPHA-BUNGAROTOXIN; GENE; BETA-2-SUBUNIT; LOCALIZATION; BEHAVIOR; BINDING; SYSTEM	NICOTINE affects many aspects of behaviour including learning and memory(1,2) through its interaction with neuronal nicotinic acetylcholine receptors (nAChR). Functional nAChRs are pentameric proteins containing at least one type of alpha-subunit and one type of beta-subunit(3-5). The involvement of a particular neuronal nicotinic subunit in pharmacology and behaviour was examined using gene targeting to mutate beta 2, the most widely expressed nAChR subunit in the central nervous system(6-8). We report here that high-affinity binding sites for nicotine are absent from the brains of mice homozygous for the beta 2-subunit mutation. Further, electrophysiological recording from brain slices reveals that thalamic neurons from these mice do not respond to nicotine application. Finally, bebavioural tests demonstrate that nicotine no longer augments the performance of beta 2(-/-) mice on passive avoidance, a test of associative memory. Paradoxically, mutant mice are able to perform better than their non-mutant siblings on this task.	INST PASTEUR,UNITE EMBRYOL MOLEC,ERS 67,PARIS,FRANCE; GLAXO INST MOLEC BIOL SA,DEPT NEUROBIOL,CH-1211 GENEVA,SWITZERLAND	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; GlaxoSmithKline	PICCIOTTO, MR (corresponding author), INST PASTEUR,CNRS,UNITE NEUROBIOL MOLEC D1284,28 RUE DR ROUX,F-75724 PARIS 15,FRANCE.		, clement/ADN-8076-2022; Zoli, Michele/C-8899-2016; Vincent, Pierre/A-1055-2012; Léna, Clément/P-6929-2019; Beldar, Sagar V/C-8542-2011; Léna, Clément/ABE-4862-2021; Léna, Clément/T-8458-2018; Le Novère, Nicolas/F-9973-2010; Picciotto, Marina R./F-8747-2012	Zoli, Michele/0000-0002-8034-2849; Vincent, Pierre/0000-0002-8479-1908; Léna, Clément/0000-0002-1431-7717; Léna, Clément/0000-0002-1431-7717; Léna, Clément/0000-0002-1431-7717; Le Novère, Nicolas/0000-0002-6309-7327; Picciotto, Marina R./0000-0002-4404-1280; Bessis, Alain/0000-0001-8362-6874				ANAND R, 1991, J BIOL CHEM, V266, P11192; CLARKE PBS, 1985, J NEUROSCI, V5, P1307; CRAWLEY JN, 1985, NEUROSCI BIOBEHAV R, V9, P37, DOI 10.1016/0149-7634(85)90030-2; DECKER MW, 1994, J PHARMACOL EXP THER, V2270, P319; FAIMAN CP, 1991, BEHAV NEURAL BIOL, V56, P1183; FLICKER C, 1983, PHARMACOL BIOCHEM BE, V18, P973, DOI 10.1016/S0091-3057(83)80023-9; FLORES CM, 1992, MOL PHARMACOL, V41, P31; GALZI JL, 1991, ANNU REV PHARMACOL, V31, P37, DOI 10.1146/annurev.pa.31.040191.000345; HILL JA, 1993, J NEUROSCI, V13, P1551; LEMOUELLIC H, 1992, CELL, V69, P251, DOI 10.1016/0092-8674(92)90406-3; LEVIN ED, 1992, PSYCHOPHARMACOLOGY, V108, P417, DOI 10.1007/BF02247415; LUETJE CW, 1991, J NEUROSCI, V11, P837; MAGIN TM, 1992, NUCLEIC ACIDS RES, V20, P3795, DOI 10.1093/nar/20.14.3795; MARKS MJ, 1982, MOL PHARMACOL, V22, P554; MMARKS MJ, 1982, J NEUROSCI, V12, P2765; MORRIS RGM, 1989, J NEUROSCI, V9, P3040; NORDBERG A, 1985, ACTA PHARMACOL TOX, V56, P337; OLIVERIO A, 1966, J PHARMACOL EXP THER, V154, P350; PICH EM, 1989, PHARMACOL RES, V21, P595; ROMANO C, 1980, SCIENCE, V210, P647, DOI 10.1126/science.7433991; Sambrook J, 1989, MOL CLONING LABORATO; SARGENT PB, 1993, ANNU REV NEUROSCI, V16, P403, DOI 10.1146/annurev.ne.16.030193.002155; SELFRIDGE J, 1992, SOMAT CELL MOLEC GEN, V18, P325, DOI 10.1007/BF01235756; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SWANSON LW, 1983, P NATL ACAD SCI-BIOL, V80, P4532, DOI 10.1073/pnas.80.14.4532; WADA E, 1989, J COMP NEUROL, V284, P314, DOI 10.1002/cne.902840212; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; ZOLI M, IN PRESS J NEUROSCI	28	540	556	1	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					65	67		10.1038/374065a0	http://dx.doi.org/10.1038/374065a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870173				2022-12-28	WOS:A1995QK07900053
J	PENTTINEN, J				PENTTINEN, J			BACK PAIN AND RISK OF FATAL ISCHEMIC-HEART-DISEASE - 13 YEAR FOLLOW-UP OF FINNISH FARMERS	BRITISH MEDICAL JOURNAL			English	Article											PENTTINEN, J (corresponding author), KUOPIO REG INST OCCUPAT HLTH,POB 93,SF-70701 KUOPIO,FINLAND.							BIERINGSORENSEN F, 1983, SCAND J REHABIL MED, V15, P71; BOSHUIZEN HC, 1993, SPINE, V18, P35, DOI 10.1097/00007632-199301000-00007; KAUPPILA LI, 1993, J SPINAL DISORD, V6, P124; NUWAYHID IA, 1993, AM J EPIDEMIOL, V137, P539, DOI 10.1093/oxfordjournals.aje.a116707; SVENSSON HO, 1983, SPINE, V8, P277, DOI 10.1097/00007632-198304000-00008	5	33	33	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1267	1268		10.1136/bmj.309.6964.1267	http://dx.doi.org/10.1136/bmj.309.6964.1267			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888848	Green Published			2022-12-28	WOS:A1994PT03300021
J	WHITFORD, DL; SOUTHERN, AJ				WHITFORD, DL; SOUTHERN, AJ			AUDIT OF SECONDARY PROPHYLAXIS AFTER MYOCARDIAL-INFARCTION	BMJ-BRITISH MEDICAL JOURNAL			English	Article									N TYNESIDE MED AUDIT ADVISORY GRP, N SHIELDS NE29 7BJ, TYNE & WEAR, ENGLAND					Whitford, David/0000-0003-4715-4755				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; [Anonymous], 1988, LANCET, V2, P349; ECCLES M, 1991, BMJ-BRIT MED J, V302, P91, DOI 10.1136/bmj.302.6768.91; Russell IT GJ, 1992, HOSP REFERRALS, P179; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	5	26	26	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	1994	309	6964					1268	1269		10.1136/bmj.309.6964.1268	http://dx.doi.org/10.1136/bmj.309.6964.1268			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888849	Green Published			2022-12-28	WOS:A1994PT03300022
J	KALKSTEIN, LS				KALKSTEIN, LS			DIRECT IMPACTS IN CITIES	LANCET			English	Article							HUMAN MORTALITY; UNITED-STATES; WEATHER				KALKSTEIN, LS (corresponding author), UNIV DELAWARE,DEPT GEOG,CTR CLIMAT RES,NEWARK,DE 19716, USA.							KAKSTEIN LS, IN PRESS DIFFERENTIA; KALKSTEIN LS, 1989, ANN ASSOC AM GEOGR, V79, P44, DOI 10.1111/j.1467-8306.1989.tb00249.x; KALKSTEIN LS, 1991, ENVIRON HEALTH PERSP, V96, P145, DOI 10.2307/3431223; KALKSTEIN LS, 1993, EXPERIENTIA, V49, P1; KALKSTEIN LS, IN PRESS POTENTIAL I; MCMICHAEL AJ, 1993, INT J EPIDEMIOL, V22, P1, DOI 10.1093/ije/22.1.1; RANGO N, 1984, AM J PUBLIC HEALTH, V74, P1159, DOI 10.2105/AJPH.74.10.1159; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106, DOI 10.1093/oxfordjournals.aje.a116413; SCHERAGA JS, IN PRESS PRELIMINARY; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600, DOI 10.1164/ajrccm/145.3.600; SMITH J, 1989, POTENTIAL EFFECTS GL, P172; 1990, POTENTIAL HLTH EFFEC	12	120	123	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1397	1399		10.1016/0140-6736(93)92757-K	http://dx.doi.org/10.1016/0140-6736(93)92757-K			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901686				2022-12-28	WOS:A1993MK09500014
J	HEISS, MM; MEMPEL, W; JAUCH, KW; DELANOFF, C; MAYER, G; MEMPEL, M; EISSNER, HJ; SCHILDBERG, FW				HEISS, MM; MEMPEL, W; JAUCH, KW; DELANOFF, C; MAYER, G; MEMPEL, M; EISSNER, HJ; SCHILDBERG, FW			BENEFICIAL EFFECT OF AUTOLOGOUS BLOOD-TRANSFUSION ON INFECTIOUS COMPLICATIONS AFTER COLORECTAL-CANCER SURGERY	LANCET			English	Article							TUMOR-GROWTH; METASTASES; RECURRENCE; MORTALITY; TRAUMA; SEPSIS; MODEL	Homologous blood transfusion has been associated with an increased risk of postoperative infectious complications. To test the clinical consequences of this apparently immunosuppressive effect of homologous blood in a controlled trial, we designed a study in which the control group deposited autologous blood before their operations for use should transfusion be needed. We enrolled 120 patients with apparently curable colorectal cancer who were able to predeposit autologous blood (haemoglobin > 12.5 g/dL). 58 patients were assigned to receive homologous blood if blood transfusions were needed during operation, and the other 62 to receive their own predeposited blood followed, if necessary, by homologous blood. Despite the similarity between the groups in factors known to affect the risk of postoperative infections, there was a significant difference in postoperative infection rate between the homologous and autologous blood groups (17 [27%] vs 7 [12%], p < 0.05; unadjusted odds ratio 2.75 [95% CI 1.07-7.11). The rates of non-infectious complications were similar. Probably because their preoperative blood depositing caused the autologous blood patients to have lower haemoglobin concentrations, they were more likely to require transfusion than were the homologous blood group (53 [91%] vs 37 [60%], p < 0.001; relative risk 1.53 [1.24-1.89]).20 (35%) required homologous as well as autologous blood. To adjust for the many infection-related factors, we did multivariate regression analysis; tumour location, preoperative ASA index, and study group assignment were the only significant risk factors. The odds ratio for postoperative infections adjusted for these factors was 2.84 (1.02-7.98, homologous vs autologous). Testing of delayed-type hypersensitivity responses before and after surgery showed decreases in both mean diameter and number of positive reactions in recipients of homologous blood and slight increases in those who received autologous blood. This study shows the clinical potential of blood-transfusion-mediated immunomodulation, which may be important also in tumour immunology.	UNIV MUNICH,KLINIKUM GROSSHADERN,CTR TRANSFUS,DEPT MED 3,W-8000 MUNICH 70,GERMANY; UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT MED INFORMAT BIOMETRY & EPIDEMIOL,W-8000 MUNICH 70,GERMANY	University of Munich; University of Munich	HEISS, MM (corresponding author), UNIV MUNICH,KLINIKUM GROSSHADERN,DEPT SURG,MARCHIONINISTR 15,W-8000 MUNICH 70,GERMANY.							Aldrich J.H., 1984, SAGE U PAPER SERIES; ALEXANDER JW, 1991, TRANSFUSION, V31, P195, DOI 10.1046/j.1537-2995.1991.31391165165.x; BEYNON J, 1989, DIS COLON RECTUM, V32, P975, DOI 10.1007/BF02552276; BURROWS L, 1982, LANCET, V2, P662; CRAPP AR, 1975, LANCET, V2, P1239; FISCHER E, 1980, HUM IMMUNOL, V3, P187; FRANCIS DMA, 1981, LANCET, V2, P871; GEORGE CD, 1986, AM J SURG, V152, P329, DOI 10.1016/0002-9610(86)90269-2; GOLDMAN M, 1991, TRANSFUSION, V31, P710, DOI 10.1046/j.1537-2995.1991.31892023495.x; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; JUBERT AV, 1973, J SURG RES, V15, P399, DOI 10.1016/0022-4804(73)90110-8; KEOWN PA, 1979, LANCET, V1, P20; KNIKER WT, 1979, ANN ALLERGY, V43, P73; MEZROW CK, 1992, TRANSFUSION, V32, P27, DOI 10.1046/j.1537-2995.1992.32192116427.x; MURPHY P, 1991, TRANSFUSION, V31, P212, DOI 10.1046/j.1537-2995.1991.31391165169.x; NWILOH J, 1991, AM J SURG, V162, P83, DOI 10.1016/0002-9610(91)90209-V; OPELZ G, 1973, TRANSPLANT P, V5, P253; PALDER SBO, 1984, J TRAUMA, V24, P869; PARK SK, 1971, LANCET, V1, P53; RUSH BF, 1988, ANN SURG, V207, P549, DOI 10.1097/00000658-198805000-00009; SHIRWADKAR S, 1992, J CANCER RES CLIN, V118, P176, DOI 10.1007/BF01410130; SINGH SK, 1987, EUR J CANCER CLIN ON, V23, P1537, DOI 10.1016/0277-5379(87)90097-6; STEPHAN RN, 1987, ARCH SURG-CHICAGO, V122, P62; TARTTER PI, 1988, BRIT J SURG, V75, P789, DOI 10.1002/bjs.1800750822; TINKER J, 1986, TXB ANESTHESIA, P359; TRIULZI DJ, 1992, TRANSFUSION, V32, P517, DOI 10.1046/j.1537-2995.1992.32692367194.x; WAYMACK JP, 1987, ARCH SURG-CHICAGO, V122, P935; WEIDEN PL, 1987, CANCER-AM CANCER SOC, V60, P870, DOI 10.1002/1097-0142(19870815)60:4<870::AID-CNCR2820600425>3.0.CO;2-0	28	315	322	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1328	1333		10.1016/0140-6736(93)92247-Q	http://dx.doi.org/10.1016/0140-6736(93)92247-Q			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901637				2022-12-28	WOS:A1993MJ03900010
J	BAKKER, AJ; KOELEMAY, MJW; GORGELS, JPMC; VANVLIES, B; SMITS, R; TIJSSEN, JGP; HAAGEN, FDM				BAKKER, AJ; KOELEMAY, MJW; GORGELS, JPMC; VANVLIES, B; SMITS, R; TIJSSEN, JGP; HAAGEN, FDM			FAILURE OF NEW BIOCHEMICAL MARKERS TO EXCLUDE ACUTE MYOCARDIAL-INFARCTION AT ADMISSION	LANCET			English	Article							CREATINE-KINASE TYPE-2; CARDIAC TROPONIN-T; EARLY DIAGNOSIS; MASS CONCENTRATION; ISOENZYME-MB; CK-MB; MYOGLOBIN; SERUM; IMMUNOASSAY	In a substantial proportion of patients with suspected myocardial infarction, biochemical markers are needed for clinical decision-making at the time of admission, because electrocardiographic (ECG) recordings are inconclusive. We have assessed the usefulness for exclusion of myocardial infarction at admission of the newer markers creatine kinase MB (CK-MB) mass concentration, troponin T, and myoglobin in comparison with the routinely used markers creatine kinase (CK) and CK-MB activity. 290 consecutive patients were enrolled. Acute myocardial infarction was diagnosed on the basis of clinical history, ECG criteria, and time-dependent changes in CK and CK-MB activity. 153 patients had definite acute myocardial infarction. Troponin T had the highest sensitivity for prediction of acute myocardial infarction; high concentrations (above the upper reference limits) were found in 98 (64%) of the patients with infarctions compared with 92 (60%) for CK-MB mass concentration, 76 (50%) for myoglobin, 61 (40%) for CK activity, and 53 (35%) for CK-MB activity. However, troponin T also had the highest ''false-positive'' rate; of 137 patients without myocardial infarction, 36 (26%) had high troponin T concentrations. Sensitivity, specificity, and positive and negative predictive values were calculated in relation to time between onset of chest pain and hospital admission. Although CK-MB mass concentration was, by a small margin, the best marker in patients admitted within 8-10 h of onset of chest pain, all the markers had negative predictive values too low to allow exclusion of acute myocardial infarction at admission in patients with symptoms suggestive of myocardial infarction of less than 10 h duration.	MED CENTRUM LEEUWARDEN,DEPT CARDIOL,LEEUWARDEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN CHEM,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CARDIOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1105 AZ AMSTERDAM,NETHERLANDS	Medical Center Leeuwarden; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	BAKKER, AJ (corresponding author), KLIN CHEM LAB,DEPT CLIN CHEM,POB 850,8901 BR LEEUWARDEN,NETHERLANDS.							BACHEM MG, 1983, DEUT MED WOCHENSCHR, V108, P1190, DOI 10.1055/s-2008-1069720; BAKKER AJ, 1993, CLIN CHEM, V39, P653; BAKKER AJ, IN PRESS EUR J CLIN; BAR FW, 1987, AM J CARDIOL, V59, P6, DOI 10.1016/S0002-9149(87)80060-7; BRANDT DR, 1990, CLIN CHEM, V36, P375; CAIRNS JA, 1983, CLIN CHEM, V29, P469; COLLINSON PO, 1992, ANN CLIN BIOCHEM, V29, P43, DOI 10.1177/000456329202900105; DELANGHE JR, 1990, CLIN CHEM, V36, P149; GERHARDT W, 1991, CLIN CHEM, V37, P1405; GRIFFITHS PD, 1986, ANN CLIN BIOCHEM, V23, P238, DOI 10.1177/000456328602300303; HORDER M, 1991, EUR J CLIN CHEM CLIN, V29, P435; KAGEN LJ, 1978, CRC CR REV CL LAB SC, V9, P273, DOI 10.3109/10408367809150922; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1989, J MOL CELL CARDIOL, V21, P1349, DOI 10.1016/0022-2828(89)90680-9; KATUS HA, 1992, CLIN CHEM, V38, P386; LEE TH, 1987, ARCH INTERN MED, V147, P115, DOI 10.1001/archinte.147.1.115; MAIR J, 1991, AM J CARDIOL, V68, P1545, DOI 10.1016/0002-9149(91)90307-7; MCCOMB JM, 1985, ANN CLIN BIOCHEM, V22, P152, DOI 10.1177/000456328502200208; Moss D. W., 1986, TXB CLIN CHEM, P619; OHMAN EM, 1990, BRIT HEART J, V63, P335; ROGALSKY VY, 1985, CLIN BIOCHEM, V18, P338, DOI 10.1016/S0009-9120(85)80071-0; ROXIN LE, 1984, ACTA MED SCAND, V215, P417; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; STEIN W, 1985, CLIN CHEM, V31, P1952	24	111	113	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1220	1222		10.1016/0140-6736(93)92192-V	http://dx.doi.org/10.1016/0140-6736(93)92192-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901536				2022-12-28	WOS:A1993MG27400016
J	SPORN, MB				SPORN, MB			CHEMOPREVENTION OF CANCER	LANCET			English	Editorial Material							RECEPTOR SUPERFAMILY; PREVENTION; CARCINOGENESIS; TAMOXIFEN; DISEASE; EFFICACY; TRIALS; TUMORS				SPORN, MB (corresponding author), NCI, CHEMOPREVENT LAB, BLDG 41, ROOM C629, BETHESDA, MD 20892 USA.							ABE O, 1992, LANCET, V339, P71; [Anonymous], 1992, Lancet, V339, P1; BOONE CW, 1992, CANCER RES, V52, P1651; CHIESA F, 1992, ORAL ONCOL, V28B, P97; COLSTON KW, 1992, BIOCHEM PHARMACOL, V44, P2273, DOI 10.1016/0006-2952(92)90669-A; CONNEY AH, 1977, FED PROC, V36, P1647; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUGHBERMAN A, 1992, LANCET, V340, P1143, DOI 10.1016/0140-6736(92)93161-F; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GREEN S, 1986, NATURE, V324, P615, DOI 10.1038/324615a0; HONG WK, 1986, NEW ENGL J MED, V315, P1501, DOI 10.1056/NEJM198612113152401; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; KOHN EC, 1992, CANCER RES, V52, P3208; LIPPMAN SM, 1990, JNCI-J NATL CANCER I, V82, P555, DOI 10.1093/jnci/82.7.555; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; POWLES TJ, 1992, LANCET, V340, P1145, DOI 10.1016/0140-6736(92)93162-G; RATKO TA, 1989, CANCER RES, V49, P4472; ROBERTS AB, 1992, CANCER SURV, V14, P205; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SPORN MB, 1976, FED PROC, V35, P1332; SPORN MB, 1991, CANCER RES, V51, P6215; SPORN MB, 1980, NATURE, V287, P107, DOI 10.1038/287107a0; WATTENBERG LW, 1983, CANCER RES, V43, P2448; WATTENBERG LW, 1985, CANCER RES, V45, P1; Yoshizawa S., 1987, PHYTOTHER RES, V1, P44, DOI [10.1002/ptr.2650010110, DOI 10.1002/PTR.2650010110]; ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399; 1976, CANCER RES, V36, P2475	29	69	70	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1211	1213						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901533				2022-12-28	WOS:A1993MG27400013
J	MCGAVOCK, H; WEBB, CH; JOHNSTON, GD; MILLIGAN, E				MCGAVOCK, H; WEBB, CH; JOHNSTON, GD; MILLIGAN, E			MARKET PENETRATION OF NEW DRUGS IN ONE UNITED-KINGDOM REGION - IMPLICATIONS FOR GENERAL-PRACTITIONERS AND ADMINISTRATORS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine the use of new drugs in one United Kingdom region. Design-Examination of data on prescribing of angiotensin converting enzyme inhibitors, new broad spectrum antibiotics, and H-2 receptor antagonists. Calculation of number of defined daily doses prescribed each month. Setting-All general practices in Northern Ireland. Main outcome measures-Drug use index and market share of each drug. Results-During 1988-91 prescribing of angiotensin converting enzyme inhibitors increased by 126%, of H-2 receptor antagonists by 46%, and of new antibiotics by 207%. The first drug on the market usually retained the largest market share. Use of oral antibiotics increased threefold irrespective of the reporting policy of the general practitioners' local laboratory. Conclusions-The increase in prescribing of these drugs seems to be greater than can be accounted for by an increase in patients with specific indications for these drugs. This suggests that the profession has not instituted effective checks to ensure that the legitimate promotion of new products does not lead to inappropriate and wasteful use.	ROYAL VICTORIA HOSP,DEPT BACTERIOL,BELFAST BT12 6BA,NORTH IRELAND		MCGAVOCK, H (corresponding author), QUEENS UNIV BELFAST,DEPT THERAPEUT & PHARMACOL,DRUG UTILIZAT RES UNIT,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.							Elmes P C, 1978, Ulster Med J, V47, P79; GRIFFITHS K, 1985, EUR J CLIN PHARMACOL, V29, P1; HAWKEY PM, 1989, J ANTIMICROB CHEMOTH, V24, P477, DOI 10.1093/jac/24.4.477; HOOD H, 1968, LANCET, V2, P96; MARSHALL BJ, 1988, LANCET, V2, P1437; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; WADE OL, 1972, BRIT J PREV SOC MED, V26, P121; 1992, BMJ, V304, P405; 1985, BMJ, V291, P97; 1993, ANATOMICAL THERAPEUT, P1; 1993, BRIT NATIONAL FORMUL, V25, P203; 1987, DRUG THERAPEUTICS B, V25, P69	12	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 30	1993	307	6912					1118	1120		10.1136/bmj.307.6912.1118	http://dx.doi.org/10.1136/bmj.307.6912.1118			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ME918	7902744	Green Published, Bronze			2022-12-28	WOS:A1993ME91800021
J	ROSENMUND, C; CLEMENTS, JD; WESTBROOK, GL				ROSENMUND, C; CLEMENTS, JD; WESTBROOK, GL			NONUNIFORM PROBABILITY OF GLUTAMATE RELEASE AT A HIPPOCAMPAL SYNAPSE	SCIENCE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; QUANTAL ANALYSIS; CELL-CULTURE; TIME COURSE; CURRENTS; NEURONS; SLICES; TRANSMISSION; CHANNELS	A change in the probability of neurotransmitter release (P(r)) is an important mechanism underlying synaptic plasticity. Although P(r) is often assumed to be the same for all terminals at a single synapse, this assumption is difficult to reconcile with the nonuniform size and structure of synaptic terminals in the central nervous system. Release probability was measured at excitatory synapses on cultured hippocampal neurons by analysis of the progressive block of N-methyl-D-aspartate receptor-mediated synaptic currents by the irreversible open channel blocker MK-801. Release probability was nonuniform (range of 0.09 to 0.54) for terminals arising from a single axon, the majority of which had a low P(r). However, terminals with high P(r) are more likely to be affected by the activity-dependent modulation that occurs in long-term potentiation.	OREGON HLTH SCI UNIV,VOLLUM 1ST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT NEUROL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University			Rosenmund, Christian/AAC-3596-2020	Rosenmund, Christian/0000-0002-3905-2444	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH046613, R37MH046613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026494, R29NS026494] Funding Source: NIH RePORTER; NIMH NIH HHS [MH46613] Funding Source: Medline; NINDS NIH HHS [NS26494] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; BROWN TH, 1976, P NATL ACAD SCI USA, V73, P2913, DOI 10.1073/pnas.73.8.2913; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; CLEMENTS JD, 1993, PRESYNAPTIC RECEPTOR, P180; DELCASTILLO J, 1954, J PHYSIOL-LONDON, V124, P560, DOI 10.1113/jphysiol.1954.sp005129; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1986, NEUROSCIENCE, V19, P857, DOI 10.1016/0306-4522(86)90304-0; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HUETTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307, DOI 10.1073/pnas.85.4.1307; JAHR CE, 1992, SCIENCE, V255, P470, DOI 10.1126/science.1346477; KORN H, 1982, J NEUROPHYSIOL, V48, P679, DOI 10.1152/jn.1982.48.3.679; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; LANTHORN TH, 1981, BRAIN RES, V225, P171, DOI 10.1016/0006-8993(81)90326-7; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; McLachlan E M, 1978, Int Rev Physiol, V17, P49; POTIER B, 1993, EUR J PHARMACOL, V231, P427, DOI 10.1016/0014-2999(93)90120-7; PUN RYK, 1986, J NEUROPHYSIOL, V56, P1242, DOI 10.1152/jn.1986.56.5.1242; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; REDMAN S, 1983, J PHYSIOL-LONDON, V343, P135, DOI 10.1113/jphysiol.1983.sp014885; SEGAL MM, 1991, J NEUROPHYSIOL, V65, P761, DOI 10.1152/jn.1991.65.4.761; TONG G, 1993, SOC NEUR ABSTR, V19; TRUSSELL LO, 1993, NEURON, V10, P1185, DOI 10.1016/0896-6273(93)90066-Z; WALMSLEY B, 1988, J NEUROPHYSIOL, V60, P889, DOI 10.1152/jn.1988.60.3.889	30	498	501	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					754	757		10.1126/science.7901909	http://dx.doi.org/10.1126/science.7901909			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	7901909				2022-12-28	WOS:A1993MD95200046
J	LANGE, PA; STOLLER, JK				LANGE, PA; STOLLER, JK			THE HEPATOPULMONARY SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Review							ORTHOTOPIC LIVER-TRANSPLANTATION; HEPATOGENIC PULMONARY ANGIODYSPLASIA; NITRIC-OXIDE; SEVERE HYPOXEMIA; HEPATIC CIRRHOSIS; PORTAL-HYPERTENSION; GAS-EXCHANGE; HYPERDYNAMIC CIRCULATION; ARTERIOVENOUS-FISTULAS; ALMITRINE BISMESYLATE	Objective: To review current knowledge about the hepatopulmonary syndrome, including definition and clinical features, methods for diagnosing it, pathophysiologic mechanisms of the associated vascular dilatations, and considerations in treatment, with emphasis on potential reversibility of the syndrome after liver transplantation. Data Sources: The MEDLINE database from January 1986 to December 1993 and bibliographies of selected articles. Study Selection: Case studies and series reporting results from patients with the hepatopulmonary syndrome were reviewed. Clinical reviews and animal studies relevant to the hepatopulmonary syndrome were examined. Data Extraction: Outcomes, including survival and the frequency of reversibility of the hepatopulmonary syndrome, were extracted from available clinical reports. Data Synthesis: Mild hypoxemia is multifactorial and occurs in approximately one third of all patients with chronic liver disease. The hepatopulmonary syndrome is one cause of hypoxemia that may also cause dyspnea, platypnea, and orthopnea. Intrapulmonary vascular dilatations and the resulting right-to-left intrapulmonary shunt are characteristic of the syndrome. Pharmacologic treatment with almitrine bismesylate, somatostatin analog, and indomethacin and treatment with plasmapheresis have been disappointing. The underlying cause and the predictors of reversibility of the hepatopulmonary syndrome remain unknown, but it has recently been shown that such reversibility is possible and that contrast-enhanced echocardiography appears to be the most sensitive diagnostic test for detecting intrapulmonary vascular dilatations. Conclusions: In the context of persisting uncertainty about the cause and treatment of the hepatopulmonary syndrome, future studies must focus on better understanding the pathophysiology of the hepatopulmonary syndrome, predicting reversibility after liver transplantation, and identifying other treatment options.	CASE WESTERN RESERVE UNIV, DEPT PULM & CRIT CARE MED, RESP THERAPY SECT, CLEVELAND, OH 44106 USA	Case Western Reserve University								AGUSTI AG, 1989, AM REV RESPIR DIS, V139, P485, DOI 10.1164/ajrccm/139.2.485; AGUSTI AGN, 1990, J HEPATOL, V10, P251, DOI 10.1016/0168-8278(90)90061-U; ALTMAN M, 1969, NEW ENGL J MED, V281, P1347, DOI 10.1056/NEJM196912112812408; ANDRIVET P, 1993, CHEST, V103, P500, DOI 10.1378/chest.103.2.500; ASTRUP J, 1973, SCAND J CLIN LAB INV, V31, P311, DOI 10.3109/00365517309082436; BANK ER, 1983, AM J ROENTGENOL, V140, P967, DOI 10.2214/ajr.140.5.967; BARRY S, 1993, TRANSPLANT P, V25, P1801; BASHOUR FA, 1966, AM HEART J, V71, P734, DOI 10.1016/0002-8703(66)90593-X; BERTHELO.P, 1966, NEW ENGL J MED, V274, P291, DOI 10.1056/NEJM196602102740601; BRAILLON A, 1986, GUT, V27, P1204, DOI 10.1136/gut.27.10.1204; BRUIX J, 1985, GASTROENTEROLOGY, V88, P430, DOI 10.1016/0016-5085(85)90503-7; CADRANEL JL, 1992, AM REV RESPIR DIS, V146, P526, DOI 10.1164/ajrccm/146.2.526; CALABRESI P, 1957, J CLIN INVEST, V36, P1257, DOI 10.1172/JCI103523; CALDWELL PR, 1965, J APPL PHYSIOL, V20, P316, DOI 10.1152/jappl.1965.20.2.316; CALDWELL SH, 1992, J CLIN GASTROENTEROL, V15, P248, DOI 10.1097/00004836-199210000-00017; CARAMELO C, 1987, EUR J CLIN INVEST, V17, P7, DOI 10.1111/j.1365-2362.1987.tb01218.x; CARUSO G, 1991, J HEPATOL, V12, P262, DOI 10.1016/0168-8278(91)90950-G; CASTAING Y, 1989, CHEST, V96, P1064, DOI 10.1378/chest.96.5.1064; CASTRO A, 1993, HEPATOLOGY, V18, P367, DOI 10.1016/0270-9139(93)90020-N; CHANG SW, 1992, AM REV RESPIR DIS, V145, P798, DOI 10.1164/ajrccm/145.4_Pt_1.798; CHEN NS, 1984, CLIN NUCL MED, V9, P279, DOI 10.1097/00003072-198405000-00009; CHEZMAR JL, 1992, AM J ROENTGENOL, V159, P317, DOI 10.2214/ajr.159.2.1632346; CHIMOWITZ MI, 1991, NEUROLOGY, V41, P1902, DOI 10.1212/WNL.41.12.1902; CLARIA J, 1992, HEPATOLOGY, V15, P343, DOI 10.1002/hep.1840150227; DAOUD FS, 1972, J CLIN INVEST, V51, P1076, DOI 10.1172/JCI106899; DAVIS HH, 1978, CHEST, V73, P507, DOI 10.1378/chest.73.4.507; DIMAND RJ, 1991, HEPATOLOGY, V14, pA55; EBEID AM, 1978, ANN SURG, V188, P28, DOI 10.1097/00000658-197807000-00004; EDELL ES, 1989, AM REV RESPIR DIS, V140, P1631, DOI 10.1164/ajrccm/140.6.1631; ERIKSSON LS, 1990, HEPATOLOGY, V12, P1350, DOI 10.1002/hep.1840120616; ERIKSSON LS, 1990, ACTA GASTRO-ENT BELG, V53, P209; ERIKSSON LS, 1989, PEPTIDES, V10, P481; FAHY JV, 1992, AM REV RESPIR DIS, V146, P1430, DOI 10.1164/ajrccm/146.6.1430; FELT RW, 1987, CHEST, V91, P920, DOI 10.1378/chest.91.6.920; Fluckiger M., 1884, WIEN MED WOCHENSCHR, V34, P1457; FURUKAWA T, 1984, AM J MED SCI, V287, P10, DOI 10.1097/00000441-198405000-00003; GATES GF, 1974, RADIOLOGY, V112, P649, DOI 10.1148/112.3.649; GENOVESI MG, 1976, AM REV RESPIR DIS, V114, P59; GINES P, 1988, HEPATOLOGY, V8, P636, DOI 10.1002/hep.1840080333; GLAUSER FL, 1990, CHEST, V98, P1210, DOI 10.1378/chest.98.5.1210; GUNNARSSON L, 1990, TRANSPLANT INT, V3, P103; HADENGUE A, 1993, HEPATOLOGY, V17, P175, DOI 10.1002/hep.1840170202; HALL GH, 1966, J APPL PHYSIOL, V21, P923, DOI 10.1152/jappl.1966.21.3.923; HAMDANI R, 1991, HEPATOLOGY, V14, pA282; HAMILTON G, 1982, HEPATOLOGY, V2, P236; HEDENSTIERNA G, 1991, EUR RESPIR J, V4, P711; HEINEMANN HO, 1960, AM J MED, V28, P239, DOI 10.1016/0002-9343(60)90187-X; HENDERSON JM, 1992, HEPATOLOGY, V15, P258, DOI 10.1002/hep.1840150214; HENRIKSEN JH, 1985, SCAND J GASTROENTERO, V20, P1185, DOI 10.3109/00365528509089274; HENRIKSEN JH, 1980, SCAND J GASTROENTERO, V15, P787, DOI 10.3109/00365528009181531; HIND CRK, 1981, GUT, V22, P1042, DOI 10.1136/gut.22.12.1042; HOBEIKA J, 1994, TRANSPLANTATION, V57, P224, DOI 10.1097/00007890-199401001-00012; HOPKINS WE, 1992, AM J CARDIOL, V70, P516, DOI 10.1016/0002-9149(92)91200-N; HORTNAGL H, 1984, LANCET, V1, P480; HOURANI JM, 1991, AM J MED, V90, P693; ITASAKA H, 1993, TRANSPLANTATION, V55, P212; IWATSUKI S, 1983, SEMIN LIVER DIS, V3, P173, DOI 10.1055/s-2008-1040683; KENNEDY TC, 1977, CHEST, V72, P305, DOI 10.1378/chest.72.3.305; Keys A, 1938, J CLIN INVEST, V17, P59, DOI 10.1172/JCI100928; KOBAYASHI S, 1993, CHEST, V103, P958, DOI 10.1378/chest.103.3.958; KROWKA MJ, 1987, MAYO CLIN PROC, V62, P164, DOI 10.1016/S0025-6196(12)62438-0; KROWKA MJ, 1989, CLIN CHEST MED, V10, P593; KROWKA MJ, 1985, MAYO CLIN PROC, V60, P407, DOI 10.1016/S0025-6196(12)60852-0; KROWKA MJ, 1990, CHEST, V97, P1165, DOI 10.1378/chest.97.5.1165; KROWKA MJ, 1990, HEPATOLOGY, V11, P138, DOI 10.1002/hep.1840110123; KROWKA MJ, 1990, CHEST, V98, P1053, DOI 10.1378/chest.98.5.1053; KROWKA MJ, 1993, CHEST, V104, P515, DOI 10.1378/chest.104.2.515; KROWKA MJ, 1992, CHEST, V102, P1161, DOI 10.1378/chest.102.4.1161; LABERGE J-M, 1992, Transplantation (Baltimore), V53, P1135; LANGE PA, 1993, AM REV RESPIR DIS, V147, pA540; LEBREC D, 1979, AM REV RESPIR DIS, V120, P849; LEE SS, 1989, WESTERN J MED, V151, P530; LEVIN DP, 1991, J NUCL MED, V32, P862; LOCKHART A, 1985, CLIN GASTROENTEROL, V14, P123; MADDREY WC, 1988, HEPATOLOGY, V8, P948, DOI 10.1002/hep.1840080440; MARCO J, 1973, NEW ENGL J MED, V289, P1107, DOI 10.1056/NEJM197311222892103; MCCLOSKEY JJ, 1991, J PEDIATR-US, V118, P902, DOI 10.1016/S0022-3476(05)82203-6; MCDONNELL PJ, 1983, AM REV RESPIR DIS, V127, P437, DOI 10.1164/arrd.1983.127.4.437; MELOT C, 1989, AM REV RESPIR DIS, V139, P632, DOI 10.1164/ajrccm/139.3.632; MELTZER RS, 1980, ULTRASOUND MED BIOL, V6, P263, DOI 10.1016/0301-5629(80)90022-8; MEWS CF, 1990, J PEDIATR GASTR NUTR, V10, P230, DOI 10.1097/00005176-199002000-00014; NAEIJE R, 1985, SEMIN RESPIR MED, V7, P164, DOI 10.1055/s-2007-1012654; NAEIJE R, 1981, CHEST, V80, P570, DOI 10.1378/chest.80.5.570; NAKOS G, 1993, RESP MED, V87, P93, DOI 10.1016/0954-6111(93)90134-L; NAVASA M, 1993, HEPATOLOGY, V17, P355; Nemec J J, 1991, J Am Soc Echocardiogr, V4, P79; OH KS, 1983, PEDIATR RADIOL, V13, P111, DOI 10.1007/BF01624390; PERRELLA MA, 1992, AM J PHYSIOL, V263, pR45, DOI 10.1152/ajpregu.1992.263.1.R45; PIZCUETA MP, 1992, BRIT J PHARMACOL, V105, P184, DOI 10.1111/j.1476-5381.1992.tb14233.x; PIZCUETA P, 1992, GASTROENTEROLOGY, V103, P1909, DOI 10.1016/0016-5085(92)91451-9; Robin E D, 1975, Trans Assoc Am Physicians, V88, P202; ROBIN ED, 1982, CHEST, V81, P357, DOI 10.1378/chest.81.3.357; ROBIN ED, 1976, NEW ENGL J MED, V294, P941, DOI 10.1056/NEJM197604222941711; RODMAN T, 1960, NEW ENGL J MED, V263, P73, DOI 10.1056/NEJM196007142630205; RODRIGUEZROISIN R, 1992, THORAX, V47, P897, DOI 10.1136/thx.47.11.897; RODRIGUEZROISIN R, 1988, CURR OPIN GASTROEN, V4, P609, DOI 10.1097/00001574-198807000-00015; RODRIGUEZROISIN R, 1987, AM REV RESPIR DIS, V135, P1085; RUFF F, 1971, J CLIN INVEST, V50, P2403, DOI 10.1172/JCI106739; RYDELL R, 1956, AM J MED, V21, P450, DOI 10.1016/0002-9343(56)90043-2; SALEM O, 1989, HEPATOLOGY, V10, P569; SCHWARTZ S M, 1992, Gastroenterology, V102, pA882; SCHWARZENBERG SJ, 1993, CHEST, V103, P1271, DOI 10.1378/chest.103.4.1271; SCOTT V, 1993, TRANSPLANT P, V25, P1787; SHERLOCK S, 1988, SEMIN RESPIR MED, V9, P247, DOI 10.1055/s-2007-1012711; SHIJO H, 1989, CLIN NUCL MED, V14, P909, DOI 10.1097/00003072-198912000-00011; SHIJO H, 1991, CHEST, V99, P1027, DOI 10.1378/chest.99.4.1027; SHIJO H, 1993, GASTROENTEROL JPN, V28, P126; SHUB C, 1976, MAYO CLIN PROC, V51, P81; SIEBER CC, 1993, GASTROENTEROLOGY, V104, P1750, DOI 10.1016/0016-5085(93)90655-V; SILVERMAN A, 1968, J PEDIATR-US, V72, P70, DOI 10.1016/S0022-3476(68)80402-0; Snell AM, 1935, ANN INTERN MED, V9, P690, DOI 10.7326/0003-4819-9-6-690; STANLEY NN, 1972, THORAX, V27, P315, DOI 10.1136/thx.27.3.315; STARZL TE, 1968, SURGERY, V63, P549; STOLLER JK, 1990, HEPATOLOGY, V11, P54, DOI 10.1002/hep.1840110111; THORENS JB, 1992, EUR RESPIR J, V5, P754; VALLANCE P, 1991, LANCET, V337, P776, DOI 10.1016/0140-6736(91)91384-7; VANOBBERGH L, 1993, AM REV RESPIR DIS, V148, P1408, DOI 10.1164/ajrccm/148.5.1408; VANTHIEL DH, 1984, HEPATOLOGY, V4, pS79, DOI 10.1002/hep.1840040721; VERA SR, 1989, TRANSPLANT P, V21, P2302; WILLIAMS A, 1979, THORAX, V34, P447, DOI 10.1136/thx.34.4.447; WOLFE JD, 1977, AM J MED, V63, P746, DOI 10.1016/0002-9343(77)90161-9; YAO EH, 1987, AM J GASTROENTEROL, V82, P352; ZIPSER RD, 1979, J CLIN ENDOCR METAB, V48, P895, DOI 10.1210/jcem-48-6-895	123	283	297	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					521	529		10.7326/0003-4819-122-7-199504010-00008	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872588				2022-12-28	WOS:A1995QP00800008
J	FLOURNOY, N; OLKIN, I				FLOURNOY, N; OLKIN, I			DO SMALL TRIALS SQUARE WITH LARGE ONES	LANCET			English	Editorial Material									STANFORD UNIV,STANFORD,CA 94305	Stanford University	FLOURNOY, N (corresponding author), AMERICAN UNIV,WASHINGTON,DC 20016, USA.			Flournoy, Nancy/0000-0003-1299-9299				Flournoy N., 1995, ADAPTIVE DESIGNS; VILLAR J, 1995, LANCET, V345, P772, DOI 10.1016/S0140-6736(95)90646-0	2	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					741	742		10.1016/S0140-6736(95)90632-0	http://dx.doi.org/10.1016/S0140-6736(95)90632-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891479				2022-12-28	WOS:A1995QN70100003
J	MATZUK, MM; LU, NF; VOGEL, H; SELLHEYER, K; ROOP, DR; BRADLEY, A				MATZUK, MM; LU, NF; VOGEL, H; SELLHEYER, K; ROOP, DR; BRADLEY, A			MULTIPLE DEFECTS AND PERINATAL DEATH IN MICE DEFICIENT IN FOLLISTATIN	NATURE			English	Article							ACTIVIN-BINDING PROTEIN; EMBRYONIC-DEVELOPMENT; RAT FOLLISTATIN; MESSENGER-RNA; EXPRESSION; RECEPTOR; INHIBIN	FOLLISTATIN, an activin-binding protein and activin antagonist in vitro(1,2), can bind to heparan sulphate proteoglycans(3) and may function in vivo to present activins to their receptors. In the mouse, follistatin messenger RNA is first detected in the deciduum (on embryonic day 5.5), and later in the developing hindbrain, somites, vibrissae, teeth, epidermis and muscle(4-11). In Xenopus laevis, overexpression of follistatin leads to induction of neural tissue(12). Here we use loss-of-function mutant mice to investigate the function of follistatin in mammals. We find that follistatin-deficient mice are retarded in their growth, have decreased mass of the diaphragm and intercostal muscles, shiny taut skin, skeletal defects of the hard palate and the thirteenth pair of ribs, their whisker and tooth development is abnormal, they fail to breathe, and die within hours of birth. These defects are more widespread than those seen in activin-deficient mutant mite, indicating that follistatin may modulate the actions of several members of the transforming growth factor-beta family.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	MATZUK, MM (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.			Vogel, Otto Hannes/0000-0002-0960-3508; Bradley, Allan/0000-0002-2349-8839				ALBANO RM, 1994, DEVELOPMENT, V120, P803; CHISAKA O, 1992, NATURE, V335, P516; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; HASHIMOTO M, 1992, J BIOL CHEM, V267, P7203; HEMMATI-BRIVANLOUA, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; MICHEL U, 1993, MOL CELL ENDOCRINOL, V91, P1, DOI 10.1016/0303-7207(93)90248-I; MICHEL U, 1990, BIOCHEM BIOPH RES CO, V173, P401, DOI 10.1016/S0006-291X(05)81072-1; MICHEL U, 1991, BIOCHEM BIOPH RES CO, V180, P223, DOI 10.1016/S0006-291X(05)81280-X; NAKAMURA T, 1991, J BIOL CHEM, V266, P19432; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; PIERARDFRANCHIM.C, 1992, J PATHOL, V167, P2223; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAMIREZSOLIS R, 1993, CELL, V83, P279; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SELLHEYER K, 1993, P NATL ACAD SCI USA, V90, P5237, DOI 10.1073/pnas.90.11.5237; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P652; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; VANDENEIJNDENVA.AJ, 1992, DEV BIOL, V154, P356; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397	23	489	515	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					360	363		10.1038/374360a0	http://dx.doi.org/10.1038/374360a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885475				2022-12-28	WOS:A1995QN63000060
J	PORTER, JA; VONKESSLER, DP; EKKER, SC; YOUNG, KE; LEE, JJ; MOSES, K; BEACHY, PA				PORTER, JA; VONKESSLER, DP; EKKER, SC; YOUNG, KE; LEE, JJ; MOSES, K; BEACHY, PA			THE PRODUCT OF HEDGEHOG AUTOPROTEOLYTIC CLEAVAGE ACTIVE IN LOCAL AND LONG-RANGE SIGNALING	NATURE			English	Article							POLARITY GENE HEDGEHOG; DROSOPHILA-EMBRYO; TRANSFORMATION; CUTICLE; VECTORS; LARVAL	THE secreted protein products of the hedgehog (hh) gene family are associated with local and long-range signalling activities that are responsible far developmental patterning in multiple systems, including Drosophila embryonic and larval tissues(1-8) and vertebrate neural tube, limbs and somites(9-15). In a process that is critical for full biological activity, the hedgehog protein (Hh) undergoes autoproteolysis to generate two biochemically distinct products, an 18K amino-terminal fragment, N, and a 25K carboxy-terminal fragment, C (ref. 16); mutations that block autoproteolysis impair Hh function. We have identified the site of autoproteolytic cleavage and find that it is broadly conserved throughout the hedgehog family. Knowing the site of cleavage, we were able to test the function of the N and C cleavage products in Drosophila assays. We show here that the N product is the active species in both local and long-range signalling. Consistent with this, all twelve mapped hedgehog mutations either affected the structure of the N product directly or otherwise blocked the release of N from the Hh precursor as a result of deletion or alteration of sequences in the C domain.	UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of Southern California	PORTER, JA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205, USA.			Ekker, Stephen/0000-0003-0726-4212				ASHBURNER M, 1989, DROSOPHILA LABORATOR; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BRAND AH, 1993, DEVELOPMENT, V118, P401; CHANG DT, 1994, DEVELOPMENT, V120, P3339; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1994, CELL, V76, P449, DOI 10.1016/0092-8674(94)90110-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; KOONIN EV, IN PRESS TRENDS BIOC; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MOHLER J, 1988, GENETICS, V120, P1061; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDERSLICE P, 1988, J BIOL CHEM, V263, P10583; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x	26	439	468	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					363	366		10.1038/374363a0	http://dx.doi.org/10.1038/374363a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885476				2022-12-28	WOS:A1995QN63000061
J	GONZALES, R; SANDE, M				GONZALES, R; SANDE, M			WHAT WILL IT TAKE TO STOP PHYSICIANS FROM PRESCRIBING ANTIBIOTICS IN ACUTE BRONCHITIS	LANCET			English	Editorial Material							ERYTHROMYCIN				GONZALES, R (corresponding author), SAN FRANCISCO GEN HOSP,DEPT MED,SAN FRANCISCO,CA 94110, USA.							BRICKFIELD FX, 1986, J FAM PRACTICE, V23, P119; DUNLAY J, 1987, J FAM PRACTICE, V25, P137; FRANKS P, 1984, J FAM PRACTICE, V19, P185; HOWIE JGR, 1970, LANCET, V2, P1099; KAYSER FH, 1990, EUR J CLIN MICROBIOL, V9, P810, DOI 10.1007/BF01967379; MASON EO, 1992, ANTIMICROB AGENTS CH, V36, P1703, DOI 10.1128/AAC.36.8.1703; NORDENSTAM I, 1992, SWEDISH STATISTICS M; ORR PH, 1993, J FAM PRACTICE, V36, P507; PARKINSON AJ, 1994, J INFECT DIS, V170, P461, DOI 10.1093/infdis/170.2.461; STOTT NCH, 1976, BRIT MED J, V2, P556, DOI 10.1136/bmj.2.6035.556; VERHEIJ TJM, 1990, FAM PRACT, V7, P175, DOI 10.1093/fampra/7.3.175; VERHEIJ TJM, 1994, BRIT J GEN PRACT, V44, P400; WILLIAMSON HA, 1984, J FAM PRACTICE, V19, P185	13	93	95	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					665	666		10.1016/S0140-6736(95)90861-7	http://dx.doi.org/10.1016/S0140-6736(95)90861-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885119				2022-12-28	WOS:A1995QM73200002
J	HAMILTON, MI; DICK, R; CRAWFORD, L; THOMPSON, NP; POUNDER, RE; WAKEFIELD, AJ				HAMILTON, MI; DICK, R; CRAWFORD, L; THOMPSON, NP; POUNDER, RE; WAKEFIELD, AJ			IS PROXIMAL DEMARCATION OF ULCERATIVE-COLITIS DETERMINED BY THE TERRITORY OF THE INFERIOR MESENTERIC-ARTERY	LANCET			English	Article							INFLAMMATORY BOWEL-DISEASE; VASCULITIS	The sharp demarcation between diseased and normal mucosa often observed in ulcerative colitis remains unexplained by current hypotheses of disease pathogenesis. To investigate whether this demarcation occurs at the watershed of vascular territories, the colonic arterial anatomy of 10 patients with ulcerative colitis was studied by in-vitro angiography and macroscopic and histological examination of total colectomy specimens. Of the 10 perfusion-fixed colectomy specimens studied, 7 had pancolitis associated with a complete marginal artery (Arteria marginalis coli) that spanned the entire length of the large bowel. 3 specimens had sharply demarcated disease in which the marginal artery arose from the inferior mesenteric artery and ended abruptly at the point of mucosal demarcation. The colon proximal to this point was histologically normal. These findings suggest that the proximal extent of colitis is determined by the limit of the marginal artery. We suggest that some characteristic of the mucosal microvasculature in the territory of the inferior mesenteric artery, possibly embryological in origin, predisposes the dependent colon to develop ulcerative colitis.	ROYAL FREE HOSP,SCH MED,INFLAMMATORY BOWEL DIS STUDY GRP,LONDON NW3 2PF,ENGLAND; ROYAL FREE HOSP,SCH MED,DEPT RADIOL,LONDON NW3 2PF,ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School								BACANER MB, 1966, GASTROENTEROLOGY, V51, P764; COLLINS WJ, 1979, GASTROENTEROLOGY, V77, P1091; DHILLON AP, 1992, HISTOPATHOLOGY, V21, P127, DOI 10.1111/j.1365-2559.1992.tb00360.x; GAFFNEY PR, 1993, GASTROENTEROLOGY, V104, pA703; HAMILTON WK, 1972, EMBRYOLOGY, P268; HOLLISHEAD WH, 1956, ANATOMY SURGEONS, P503; HULTEN L, 1977, GASTROENTEROLOGY, V72, P388; JEWELL DP, 1992, ULCERATIVE COLITIS C, P1; LUNDERQUIST A, 1967, AMER J ROENTGENOL RA, V99, P18, DOI 10.2214/ajr.99.1.18; MISIEWICZ JJ, 1987, ATLAS CLIN GASTROENT; NELSON J, 1986, NEUROLOGY, V36, P719, DOI 10.1212/WNL.36.5.719; SAXON A, 1990, J ALLERGY CLIN IMMUN, V86, P202, DOI 10.1016/S0091-6749(05)80067-3; SHUBICH M G, 1976, Arkhiv Patologii, V38, P60; TALBOT RW, 1986, MAYO CLIN PROC, V61, P140, DOI 10.1016/S0025-6196(12)65200-8; THOMPSON NP, IN PRESS GASTROENTER; TSUCHIYA M, 1980, ANGIOLOGY, V31, P147, DOI 10.1177/000331978003100301; WAKEFIELD AJ, 1989, LANCET, V2, P1057	17	31	31	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					688	690		10.1016/S0140-6736(95)90867-6	http://dx.doi.org/10.1016/S0140-6736(95)90867-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885124				2022-12-28	WOS:A1995QM73200008
J	SEGALAT, L; ELKES, DA; KAPLAN, JM				SEGALAT, L; ELKES, DA; KAPLAN, JM			MODULATION OF SEROTONIN-CONTROLLED BEHAVIORS BY G(O) IN CAENORHABDITIS-ELEGANS	SCIENCE			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEIN; NERVOUS-SYSTEM; ALPHA-SUBUNIT; NEMATODE; MYRISTOYLATION; STIMULATION; GENES	Seven transmembrane receptors and their associated heterotrimeric guanine nucleotide-binding proteins (G proteins) have been proposed to play a key role in modulating the activities of neurons and muscles. The physiological function of the Caenorhabditis elegans G protein G(o) has been genetically characterized. Mutations in the goa-l gene, which encodes an a subunit of G(o) (G alpha(o)), cause behavioral defects similar to those observed in mutants that lack the neurotransmitter serotonin (5-HT), and goa-1 mutants are partially resistant to exogenous 5-HT. Mutant animals that lack G alpha(o) and transgenic animals that overexpress G alpha(o) [goa-l(xs) animals] have reciprocal defects in locomotion, feeding, and egg laying behaviors. In normal animals, all of these behaviors are regulated by 5-HT. These results demonstrate that the level of G(o) activity is a critical determinant of several C. elegans behaviors and suggest that G(o) mediates many of the behavioral effects of 5-HT.	MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NINDS NIH HHS [NS32196] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS032196] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AVERY L, 1993, GENETICS, V133, P897; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; DENKER BM, 1992, J BIOL CHEM, V267, P6272; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FINNEY M, 1987, THESIS MIT; HAGA K, 1992, J BIOL CHEM, V267, P2222; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; HORVITZ HR, 1982, SCIENCE, V216, P1012, DOI 10.1126/science.6805073; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; JORGENSEN E, COMMUNICATION; JORGENSEN EO, UNPUB; KAPLAN J, UNPUB; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; LOGETHETIS DE, 1987, NATURE, V325, P321; MARDER E, 1989, SEMIN NEUROSCI, V1, P1; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; SEGALAT L, UNPUB; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; THOMAS JH, 1990, GENETICS, V124, P855; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; TRENT C, 1983, GENETICS, V104, P619; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	37	253	258	1	18	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1648	1651		10.1126/science.7886454	http://dx.doi.org/10.1126/science.7886454			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886454				2022-12-28	WOS:A1995QM39700038
J	SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; RAO, G; GUIDA, P; SKOULTCHI, AI; DEPINHO, RA				SCHREIBERAGUS, N; CHIN, L; CHEN, K; TORRES, R; RAO, G; GUIDA, P; SKOULTCHI, AI; DEPINHO, RA			AN AMINO-TERMINAL DOMAIN OF MXI1 MEDIATES ANTI-MYC ONCOGENIC ACTIVITY AND INTERACTS WITH A HOMOLOG OF THE YEAST TRANSCRIPTIONAL REPRESSOR SIN3	CELL			English	Article							C-MYC; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; MAX; PROTEIN; EXPRESSION; GENE; RECOGNITION; ACTIVATION; HELIX	Documented interactions among members of the Myc superfamily support a yin-yang model for the regulation of Myc-responsive genes in which transactivation-competent Myc-Max heterodimers are opposed by repressive Mxi1-Max or Mad-Max complexes. Analysis of mouse mxi1 has led to the identification of two mxi1 transcript forms possessing open reading frames that differ in their capacity to encode a short aminoterminal alpha-helical domain. The presence of this segment dramatically augments the suppressive potential of Mxi1 and allows for association with a mammalian protein that is structurally homologous to the yeast transcriptional repressor SIN3, These findings provide a mechanistic basis for the antagonistic actions of Mxi1 on Myc activity that appears to be mediated in part through the recruitment of a putative transcriptional repressor.	ALBERT EINSTEIN COLL MED,DEPT MED,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DIV DERMATOL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT CELL BIOL,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	SCHREIBERAGUS, N (corresponding author), ALBERT EINSTEIN COLL MED,DEPT MICROBIOL & IMMUNOL,BRONX,NY 10461, USA.			DePinho, Ronald/0000-0002-5625-577X	NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000194] Funding Source: NIH RePORTER; NCI NIH HHS [RT32CA-09173] Funding Source: Medline; NIA NIH HHS [2T32AG00194] Funding Source: Medline; NIGMS NIH HHS [T32GM07128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1994, CURR OPIN GENET DEV, V4, P102, DOI 10.1016/0959-437X(94)90098-1; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHENG GH, 1989, MOL CELL BIOL, V9, P2332, DOI 10.1128/MCB.9.6.2332; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; COWELL IG, 1994, TRENDS BIOCHEM SCI, V19, P38, DOI 10.1016/0968-0004(94)90172-4; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EDELHOFF S, 1994, ONCOGENE, V9, P665; EVAN GI, 1993, CURR OPIN GENET DEV, V3, P44, DOI 10.1016/S0959-437X(05)80339-9; FASANO O, 1983, Journal of Molecular and Applied Genetics, V2, P173; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; JANSENDURR P, 1993, P NATL ACAD SCI USA, V90, P3685, DOI 10.1073/pnas.90.8.3685; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KATO GJ, 1992, FASEB J, V6, P30565; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; Maxam A M, 1980, Methods Enzymol, V65, P499; MORGENBESSER SD, 1994, SEMIN CANCER BIOL, V5, P21; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; PRENDERGAST GC, 1992, GENE DEV, V6, P2429, DOI 10.1101/gad.6.12a.2429; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; Sambrook J, 1989, MOL CLONING LABORATO; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; SCHREIBERAGUS N, 1993, MOL CELL BIOL, V13, P2456, DOI 10.1128/MCB.13.4.2456; SCHREIBERAGUS N, 1994, ONCOGENE, V9, P3167; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRICH R, 1989, P NATL ACAD SCI USA, V86, P10018, DOI 10.1073/pnas.86.24.10018; TORRES R, 1992, Current Opinion in Cell Biology, V4, P468, DOI 10.1016/0955-0674(92)90013-3; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V83, P5455; YOSHIMOTO H, 1992, MOL GEN GENET, V233, P327, DOI 10.1007/BF00587597; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, CELL, V79; ZIMMERMAN KA, 1986, NATURE, V319, P780, DOI 10.1038/319780a0	55	344	351	1	6	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					777	786		10.1016/0092-8674(95)90356-9	http://dx.doi.org/10.1016/0092-8674(95)90356-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889571	Bronze			2022-12-28	WOS:A1995QM39900014
J	THOMPSON, CB				THOMPSON, CB			APOPTOSIS IN THE PATHOGENESIS AND TREATMENT OF DISEASE	SCIENCE			English	Review							PROGRAMMED CELL-DEATH; AMYOTROPHIC-LATERAL-SCLEROSIS; CD4+ T-CELLS; B-CELLS; SUPEROXIDE-DISMUTASE; GROWTH-FACTORS; C-MYC; CAENORHABDITIS-ELEGANS; CHROMOSOMAL BREAKPOINT; PROTOONCOGENE BCL-2	In multicellular organisms, homeostasis is maintained through a balance between cell proliferation and cell death. Although much is known about the control of cell proliferation, less is known about the control of cell death. Physiologic cell death occurs primarily through an evolutionarily conserved form of cell suicide termed apoptosis. The decision of a cell to undergo apoptosis can be influenced by a wide variety of regulatory stimuli. Recent evidence suggests that alterations in cell survival contribute to the pathogenesis of a number of human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome). Treatments designed to specifically alter the apoptotic threshold may have the potential to change the natural progression of some of these diseases.	UNIV CHICAGO, GWEN KNAPP CTR LUPUS & IMMUNOL RES, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	THOMPSON, CB (corresponding author), UNIV CHICAGO, GWEN KNAPP CTR LUPUS & IMMUNOL RES, HOWARD HUGHES MED INST, DEPT MED, CHICAGO, IL 60637 USA.							ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BLACKWELL S, 1992, PHARMACOTHERAPY, V12, pS20; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CASTLE VP, 1993, AM J PATHOL, V143, P1543; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLARKE ML, UNPUB; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COHEN DA, 1993, CELL IMMUNOL, V151, P392, DOI 10.1006/cimm.1993.1248; COHEN JJ, 1993, HOSP PRACT, V28, P35, DOI 10.1080/21548331.1993.11442887; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COLOMBEL M, 1992, CANCER RES, V52, P4313; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DUNSTAN CR, 1993, CALCIFIED TISSUE INT, V53, pS113, DOI 10.1007/BF01673417; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EMLEN W, 1994, J IMMUNOL, V152, P3685; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FLEISCHMAN RA, 1993, AM J MED SCI, V305, P248, DOI 10.1097/00000441-199304000-00009; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GARCHON HJ, 1994, EUR J IMMUNOL, V24, P380, DOI 10.1002/eji.1830240217; GENARO AM, 1994, EUR J IMMUNOL, V24, P2515, DOI 10.1002/eji.1830241038; GOLDIN RD, 1993, J PATHOL, V171, P73, DOI 10.1002/path.1711710115; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; GUIOT AL, 1993, CR ACAD SCI III-VIE, V316, P1297; HAASE D, 1990, BLUT, V60, P192, DOI 10.1007/BF01720275; HAGUE A, 1994, ONCOGENE, V9, P3367; HALL SE, 1994, J IMMUNOL, V153, P3218; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HERRERO MT, 1993, NEUROSCIENCE, V56, P965, DOI 10.1016/0306-4522(93)90142-3; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; ISACSON O, 1993, TRENDS NEUROSCI, V16, P306, DOI 10.1016/0166-2236(93)90104-T; ISHIZAKI Y, 1994, J CELL BIOL, V126, P1069, DOI 10.1083/jcb.126.4.1069; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KELLEY LL, 1993, BLOOD, V82, P2340; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; LEVY Y, 1994, J CLIN INVEST, V93, P424, DOI 10.1172/JCI116977; LIN EY, 1993, J IMMUNOL, V151, P1979; LITTMAN DR, 1994, CURR BIOL, V4, P618, DOI 10.1016/S0960-9822(00)00135-4; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MATTSON MP, 1993, ANN NY ACAD SCI, V679, P1, DOI 10.1111/j.1749-6632.1993.tb18285.x; MAY WS, 1994, J BIOL CHEM, V269, P26865; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MINN A, UNPUB; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MOHR W, 1992, Z RHEUMATOL, V51, P35; MOUNTZ JD, 1994, ARTHRITIS RHEUM, V37, P1415, DOI 10.1002/art.1780371002; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NETA R, 1994, J IMMUNOL, V153, P4230; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; OKAMOTO M, 1994, BRAIN RES, V637, P57, DOI 10.1016/0006-8993(94)91217-3; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARFITT AM, 1993, CALCIFIED TISSUE INT, V53, pS82, DOI 10.1007/BF01673408; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REED JC, 1990, CANCER RES, V50, P6565; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROEDERER M, 1993, PHARMACOLOGY, V46, P121, DOI 10.1159/000139037; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSENBAUM DM, 1994, STROKE, V25, P857, DOI 10.1161/01.STR.25.4.857; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; UYAMA O, 1992, STROKE, V23, P75, DOI 10.1161/01.STR.23.1.75; VASCONCELOS AC, 1994, J GEN VIROL, V75, P1803, DOI 10.1099/0022-1317-75-7-1803; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOSHIDA Y, 1993, LEUKEMIA, V7, P144; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	148	5966	6402	11	724	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1456	1462		10.1126/science.7878464	http://dx.doi.org/10.1126/science.7878464			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878464				2022-12-28	WOS:A1995QL49700026
J	CROSS, SM; SANCHEZ, CA; MORGAN, CA; SCHIMKE, MK; RAMEL, S; IDZERDA, RL; RASKIND, WH; REID, BJ				CROSS, SM; SANCHEZ, CA; MORGAN, CA; SCHIMKE, MK; RAMEL, S; IDZERDA, RL; RASKIND, WH; REID, BJ			A P53-DEPENDENT MOUSE SPINDLE CHECKPOINT	SCIENCE			English	Article							WILD-TYPE P53; MITOTIC CHROMOSOME TRANSMISSION; CELL-CYCLE EVENTS; T-ANTIGEN; SACCHAROMYCES-CEREVISIAE; SV40-TRANSFORMED CELLS; GENE AMPLIFICATION; DNA CONTENT; CARCINOMA; MITOSIS	Cell cycle checkpoints enhance genetic fidelity by causing arrest at specific stages of the cell cycle when previous events have not been completed. The tumor suppressor p53 has been implicated in a G(1) checkpoint. To investigate whether p53 also participates in a mitotic checkpoint, cultured fibroblasts from p53-deficient mouse embryos were exposed to spindle inhibitors. The fibroblasts underwent multiple rounds of DNA synthesis without completing chromosome segregation, thus forming tetraploid acid octaploid cells. Deficiency of p53 was also associated with the development of tetraploidy in vivo. These results suggest that murine p53 is a component of a spindle checkpoint that ensures the maintenance of diploidy.	UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195; ERSTA HOSP,DEPT SURG,S-11635 STOCKHOLM,SWEDEN; UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; Ersta Sjukhus; University of Washington; University of Washington Seattle			Reid, Brian John/AFT-8587-2022	Reid, Brian John/0000-0002-9613-979X	NATIONAL CANCER INSTITUTE [R01CA055814] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA55814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNDTJOVIN DJ, 1977, J HISTOCHEM CYTOCHEM, V25, P585, DOI 10.1177/25.7.70450; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BARBER HN, 1942, P ROY SOC LOND B BIO, V131, P258; BLOUNT PL, 1994, CANCER RES, V54, P2292; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; BROWN M, 1991, COLD SH Q B, V56, P359; BUNN PA, 1982, BLOOD, V59, P528; BURHOLT DR, 1989, CANCER RES, V49, P3355; CARDER P, 1993, ONCOGENE, V8, P1397; DASSO M, 1990, CELL, V61, P811, DOI 10.1016/0092-8674(90)90191-G; GONG J, 1994, CANCER RES, V54, P428; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HARTWELL LH, 1985, GENETICS, V110, P381; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HARVEY M, 1993, ONCOGENE, V8, P2457; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JAKOBSEN A, 1983, CYTOMETRY, V4, P170, DOI 10.1002/cyto.990040211; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KIRKLAND JA, 1967, CANCER, V20, P1934, DOI 10.1002/1097-0142(196711)20:11<1934::AID-CNCR2820201122>3.0.CO;2-4; KNOEFEL W T, 1987, Cancer Research, V47, P221; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; KUHAR SG, 1991, ONCOGENE, V6, P1499; KUNG AL, 1990, P NATL ACAD SCI USA, V87, P9553, DOI 10.1073/pnas.87.24.9553; LAFFIN J, 1989, CYTOMETRY, V10, P205, DOI 10.1002/cyto.990100212; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVAN A, 1956, ANN NY ACAD SCI, V63, P774, DOI 10.1111/j.1749-6632.1956.tb50892.x; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LEVINE DS, 1991, P NATL ACAD SCI USA, V88, P6427, DOI 10.1073/pnas.88.15.6427; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; LIEBMANN J, 1994, CANCER CHEMOTH PHARM, V33, P331; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOPES NM, 1993, CANCER CHEMOTH PHARM, V32, P235, DOI 10.1007/BF00685842; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MURRAY AW, 1991, COLD SPRING HARB SYM, V56, P399; NESHAT K, 1994, GASTROENTEROLOGY, V106, P1589, DOI 10.1016/0016-5085(94)90415-4; OFFERHAUS GJA, 1992, GASTROENTEROLOGY, V102, P1612, DOI 10.1016/0016-5085(92)91721-F; ORNITZ DM, 1987, SCIENCE, V238, P188, DOI 10.1126/science.2821617; RAMEL S, IN PRESS PANCREAS; RASKIND WH, 1992, CANCER RES, V52, P2946; REIDER CL, 1989, MECHANISMS CHROMOSOM, P185; ROBERTS JR, 1990, CANCER RES, V50, P710; SCHIMKE RT, 1991, COLD SH Q B, V56, P417; SHACKNEY SE, 1989, CANCER RES, V49, P3344; SHAPIRO JR, 1985, CANCER METAST REV, V4, P107, DOI 10.1007/BF00050691; WANG RJ, 1976, EXP CELL RES, V101, P331, DOI 10.1016/0014-4827(76)90385-2; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120; WIJKSTROM H, 1984, CANCER, V53, P1718, DOI 10.1002/1097-0142(19840415)53:8<1718::AID-CNCR2820530817>3.0.CO;2-E; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZIRKLE RE, 1970, RADIAT RES, V41, P516, DOI 10.2307/3572841	53	690	696	0	7	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1353	1356		10.1126/science.7871434	http://dx.doi.org/10.1126/science.7871434			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871434				2022-12-28	WOS:A1995QK06800047
J	GALE, JL; THAPA, PB; WASSILAK, SGF; BOBO, JK; MENDELMAN, PM; FOY, HM				GALE, JL; THAPA, PB; WASSILAK, SGF; BOBO, JK; MENDELMAN, PM; FOY, HM			RISK OF SERIOUS ACUTE NEUROLOGICAL ILLNESS AFTER IMMUNIZATION WITH DIPHTHERIA-TETANUS-PERTUSSIS VACCINE - A POPULATION-BASED CASE-CONTROL STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE REACTIONS; DISORDERS; CHILDREN	Objective.-To evaluate the association between serious acute neurological illness and receipt of whole-cell pertussis vaccine, given as diphtheria-tetanus-pertussis (DTP) vaccine. Design.-Population-based case-control study. Setting.-Outpatient and inpatient hospital settings, physician practices, and the general population in Washington and Oregon states. Subjects.-A total of 424 confirmed cases of neurological illness were identified prospectively during a 12-month period by statewide active surveillance from the population of 218 000 children 1 to 24 months of age living in Washington and Oregon (estimated 368 000 DTP immunizations given). Each case child was matched to two population control children by birth date (+/-5 days), gender, and county of birth. Written immunization records were used to determine whether illness occurred within 7 days of immunization in case children, or within 7 days of the same reference date in control children, thus qualifying as exposed. Main Outcome Measures.-Outpatient and inpatient cases of complex febrile seizures, seizures without fever, infantile spasms, and acute encephalitis/encephalopathy confirmed by an expert panel masked to immunization history. Results.-The estimated odds ratio (OR) for onset of serious acute neurological illness within 7 days for young children exposed to DTP vaccine was 1.1 (95% confidence interval [CI], 0.6 to 2.0). When the analysis was restricted to children with encephalopathy or complicated seizures and adjusted for factors possibly affecting vaccine administration, the OR was 3.6 (95% Cl, 0.8 to 15.2). Odds ratios for specific study diagnoses varied, but all CIs included 1. No elevated risk was observed for the largest group of illnesses studied, nonfebrile seizures (OR, 0.5; 95% CI, 0.2 to 1.5). Conclusions.-This study did not find any statistically significant increased risk of onset of serious acute neurological illness in the 7 days after DTP vaccine exposure for young children.	UNIV WASHINGTON,SCH MED,DEPT PEDIAT,SEATTLE,WA 98195; CTR DIS CONTROL,ATLANTA,GA 30333	University of Washington; University of Washington Seattle; Centers for Disease Control & Prevention - USA	GALE, JL (corresponding author), UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195, USA.				PHS HHS [200-87-0506] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BELLMAN MH, 1983, LANCET, V1, P1031; BOBO JK, 1993, PEDIATRICS, V91, P308; BRESLOW NE, 1980, STAT METHODS CANC RE, P176; BYERS RK, 1948, PEDIATRICS, V1, P437; CHERRY JD, 1988, PEDIATRICS S, V81, P959; CODY CL, 1981, PEDIATRICS, V68, P650; CORSELLIS JAN, 1983, NEUROPATH APPL NEURO, V9, P261, DOI 10.1111/j.1365-2990.1983.tb00113.x; FINE PEM, 1992, AM J EPIDEMIOL, V136, P121, DOI 10.1093/oxfordjournals.aje.a116479; GLOBUS JH, 1949, JAMA-J AM MED ASSOC, V141, P507, DOI 10.1001/jama.1949.02910080007003; GRIFFIN MR, 1990, JAMA-J AM MED ASSOC, V263, P1641, DOI 10.1001/jama.263.12.1641; KULENKAMPFF M, 1974, ARCH DIS CHILD, V49, P46, DOI 10.1136/adc.49.1.46; Madsen T, 1933, J AMER MED ASSOC, V101, P187, DOI 10.1001/jama.1933.02740280007003; MARCUSE EK, 1990, VACCINE, V8, P531, DOI 10.1016/0264-410X(90)90003-5; Miller D, 1985, Dev Biol Stand, V61, P389; MILLER D, 1988, Tokai Journal of Experimental and Clinical Medicine, V13, P145; MILLER DL, 1981, BRIT MED J, V282, P1595, DOI 10.1136/bmj.282.6276.1595; NICOLL A, 1989, MANUAL INFECTIONS IM, P207; POLLOCK TM, 1983, LANCET, V1, P753; SHIELDS WD, 1988, J PEDIATR-US, V113, P801, DOI 10.1016/S0022-3476(88)80004-0; SUTHERLAND JM, 1953, ARCH DIS CHILD, V28, P149, DOI 10.1136/adc.28.138.149; WALKER AM, 1988, PEDIATRICS, V81, P345; WENTZ KR, 1991, PEDIATRICS, V87, P287; 1990, BRIT JOINT COMMITTEE, P20; 1989, CANADIAN IMMUNIZATIO, P78; 1991, ADVERSE EFFECTS PERT; 1991, PEDIATRICS, V88, P397	26	64	69	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					37	41		10.1001/jama.271.1.37	http://dx.doi.org/10.1001/jama.271.1.37			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	7903109				2022-12-28	WOS:A1994MN72500028
J	EKBOM, A; HSIEH, CC; YUEN, J; TRICHOPOULOS, D; MCLAUGHLIN, J; LAN, SJ; ADAMI, HO				EKBOM, A; HSIEH, CC; YUEN, J; TRICHOPOULOS, D; MCLAUGHLIN, J; LAN, SJ; ADAMI, HO			RISK OF EXTRAHEPATIC BILEDUCT CANCER AFTER CHOLECYSTECTOMY	LANCET			English	Article							SCLEROSING CHOLANGITIS; ULCERATIVE-COLITIS; CARCINOMA; CHOLANGIOCARCINOMA; CYSTS	The aetiology of cancer of the extrahepatic bile duct is unknown. Gallstones have been proposed to be a risk factor on the basis of ecological and epidemiological evidence. As gallstones are formed in the gallbladder, the occurrence of extrahepatic bileduct cancer in patients after cholecystectomy is of interest. All patients (62 734) who had had a cholecystectomy during 1965-1983 within the Uppsala Health Care Region, Sweden, were followed up to the end of 1987. Excluding the first year of follow-up, 23 cancers of the extrahepatic bileduct occurred vs 26.3 expected for a standardised incidence ratio (SIR) of 0.88 (95% confidence interval [CI] 0.56-1.31). 10 years or more after operation there was a greater reduction of risk (SIR = 0.27; 95% CI 0.06-0.80). Similar patterns were observed for men and women, and among patients who had undergone cholecystectomy only compared with those who had had their common bileducts explored. To assess surveillance bias the incidence of primary liver cancer was also analysed: SIR = 1.15; 95% CI 0.91-1.44 overall, and 10 years or more after cholecystectomy SIR = 0.98; 95% CI 0.66-1.40. This study shows a reduced risk of extrahepatic bileduct cancer 10 or more years after cholecystectomy, indicating that gallstones may be a cause of this cancer.	NCI,BIOSTAT BRANCH,BETHESDA,MD 20892; HARVARD UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BOSTON,MA 02115	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Harvard T.H. Chan School of Public Health	EKBOM, A (corresponding author), UNIV HOSP UPPSALA,CANC EPIDEMIOL UNIT,S-75185 UPPSALA,SWEDEN.		Yuen, Jonathan/AAI-2035-2021	Yuen, Jonathan/0000-0003-2944-9226	NATIONAL CANCER INSTITUTE [R01CA044683] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1CA44683] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAILAR JC, 1964, BIOMETRICS, V20, P639; BRETT M, 1976, INT J EPIDEMIOL, V5, P335, DOI 10.1093/ije/5.4.335; CARBONI M, 1986, SCAND J GASTROENTERO, V21, P461, DOI 10.3109/00365528609015163; CETTA F, 1991, ANN SURG, V213, P315, DOI 10.1097/00000658-199104000-00006; DAY NE, 1984, IARC SCI PUBL, V56, P339; DONALDSON DR, 1975, BR J CLIN PRACT, V33, P297; Drinka P, 1985, Wis Med J, V84, P16; EKBOM A, 1993, GASTROENTEROLOGY, V105, P142, DOI 10.1016/0016-5085(93)90019-9; FLANIGAN DP, 1977, CANCER-AM CANCER SOC, V40, P880, DOI 10.1002/1097-0142(197708)40:2<880::AID-CNCR2820400242>3.0.CO;2-X; FRAUMENI JF, 1982, CANCER EPIDEMIOL, P683; GLENN F, 1974, ANN SURG, V179, P528, DOI 10.1097/00000658-197405000-00003; HERBA MJ, 1986, AM J ROENTGENOL, V147, P513, DOI 10.2214/ajr.147.3.513; JARHULT J, 1981, ACTA CHIR SCAND, V147, P147; KATO K, 1989, JPN J CANCER RES, V80, P932, DOI 10.1111/j.1349-7006.1989.tb01629.x; LEBORGNE J, 1984, ANN CHIR, V38, P369; MIRMADJLESSI SH, 1987, DIGEST DIS SCI, V32, P145, DOI 10.1007/BF01297102; NAESSEN T, 1989, AM J EPIDEMIOL, V130, P289, DOI 10.1093/oxfordjournals.aje.a115335; ROBBINS S, 1988, AM J GASTROENTEROL, V83, P675; ROSSI RL, 1987, ANN SURG, V205, P377, DOI 10.1097/00000658-198704000-00006; SCHWARTZ DA, 1986, AM J GASTROENTEROL, V81, P76; SRIVATANAKUL P, 1991, INT J CANCER, V48, P821, DOI 10.1002/ijc.2910480606; TODANI T, 1979, CANCER-AM CANCER SOC, V44, P1134, DOI 10.1002/1097-0142(197909)44:3<1134::AID-CNCR2820440350>3.0.CO;2-T; WARREN KW, 1987, DISEASES LIVER, P1289; WEE A, 1985, HUM PATHOL, V16, P719, DOI 10.1016/S0046-8177(85)80158-1; WELTON JC, 1979, LANCET, V1, P791; YEN S, 1987, CANCER, V59, P2112, DOI 10.1002/1097-0142(19870615)59:12<2112::AID-CNCR2820591226>3.0.CO;2-H; 1991, CANCER INCIDENCE SWE	27	47	48	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1262	1265		10.1016/0140-6736(93)92359-2	http://dx.doi.org/10.1016/0140-6736(93)92359-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901583				2022-12-28	WOS:A1993MH56600009
J	MURPHY, DGM; DECARLI, C; DALY, E; HAXBY, JV; ALLEN, G; WHITE, BJ; MCINTOSH, AR; POWELL, CM; HORWITZ, B; RAPOPORT, SI; SCHAPIRO, MB				MURPHY, DGM; DECARLI, C; DALY, E; HAXBY, JV; ALLEN, G; WHITE, BJ; MCINTOSH, AR; POWELL, CM; HORWITZ, B; RAPOPORT, SI; SCHAPIRO, MB			X-CHROMOSOME EFFECTS ON FEMALE BRAIN - A MAGNETIC-RESONANCE-IMAGING STUDY OF TURNERS-SYNDROME	LANCET			English	Article							INACTIVATION; MEMORY	Many neuropsychiatric disorders differ between the sexes in incidence, symptoms, and age at onset. To investigate the effects of X-chromosome aneuploidy and of sex steroid deficiency during childhood on brain structure and function, we used neuropsychological tests and quantitative magnetic resonance imaging (MRI) to study the brains of eighteen women with Turner's syndrome (TS) and nineteen healthy control women of similar age. Nine TS subjects had mosaic 45,X karyotypes, and 9 had non-mosaic 45,X. The TS group had significantly lower scores than the controls for all the Wechsler adult intelligence scale tests, except verbal comprehension and reading level. The greatest difference was in visuospatial construction (mean 90 [SD 12] vs 118 [13], p < 0.0001). The TS subjects also had a greater discrepancy than controls between verbal and performance intelligence quotients (9 [8] vs -5 [9], p<0.001). We found that TS subjects had significantly smaller values than controls in MRI-measured volumes of hippocampus, caudate, lenticular, and thalamic nuclei, and parieto-occipital brain matter, on both sides. Women with mosaic TS had values between the full TS and control groups for cerebral hemisphere and lenticular and thalamic nuclei volume and for verbal ability. Within the mosaic TS group, visuospatial ability was significantly correlated with the percentage of lymphocytes that had the 45,X karyotype. Hippocampal volume and memory test scores were significantly lower in mosaic and non-mosaic 45,X TS subjects than in controls. We postulate that in human beings the X chromosome plays an important part in the development and ageing of grey matter in striatum, diencephalon, and cerebral hemispheres.	NIDDKD,CHEM BIOL LAB,CYTOGENET UNIT,BETHESDA,MD; NIH,MED GENET PROGRAM,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA	MURPHY, DGM (corresponding author), NIA,NEUROSCI LAB,BLDG 10,ROOM 6C-414,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		DeCarli, Charles/B-5541-2009; daly, eileen m/B-6716-2011; McIntosh, Anthony R/G-4955-2011	McIntosh, Anthony/0000-0002-1784-5662; Daly, Eileen/0000-0003-3625-3467				BARTKO JJ, 1976, J NERV MENT DIS, V163, P307, DOI 10.1097/00005053-197611000-00003; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; HARNDEN DG, 1985, ISCN 1985 INT SYSTEM; Jastak J., 1978, WIDE RANGE ACHIEVEME; LYON MF, 1988, AM J HUM GENET, V42, P8; MIZOGUCHI K, 1992, NEUROSCI LETT, V138, P157, DOI 10.1016/0304-3940(92)90495-S; MONEY JOHN, 1966, J MED GENET, V3, P47, DOI 10.1136/jmg.3.1.47; MURPHY DGM, 1992, ARCH NEUROL-CHICAGO, V49, P839, DOI 10.1001/archneur.1992.00530320063013; RESKENIELSEN E, 1982, CORTEX, V18, P181, DOI 10.1016/S0010-9452(82)80001-4; RUSSELL EW, 1975, J CONSULT CLIN PSYCH, V43, P800, DOI 10.1037/0022-006X.43.6.800; SQUIRE LR, 1992, J COGNITIVE NEUROSCI, V4, P232, DOI 10.1162/jocn.1992.4.3.232; TELLEGEN A, 1967, J CONSULT PSYCHOL, V31, P499, DOI 10.1037/h0024963; TORANALLERAND CD, 1991, PSYCHONEUROENDOCRINO, V16, P7, DOI 10.1016/0306-4530(91)90068-5; Verma RS, 1989, HUMAN CHROMOSOMES MA, p[5, 47]; WATSON C, 1992, NEUROLOGY, V42, P1743, DOI 10.1212/WNL.42.9.1743; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; 1985, SAS USERS GUIDE BASI	17	156	156	0	10	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1197	1200		10.1016/0140-6736(93)92184-U	http://dx.doi.org/10.1016/0140-6736(93)92184-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901528				2022-12-28	WOS:A1993MG27400008
J	TAKAHASHI, T; MOMIYAMA, A				TAKAHASHI, T; MOMIYAMA, A			DIFFERENT TYPES OF CALCIUM CHANNELS MEDIATE CENTRAL SYNAPTIC TRANSMISSION	NATURE			English	Article							METABOTROPIC GLUTAMATE RECEPTOR; OMEGA-AGA-IVA; SELECTIVE MODULATION; NERVE-TERMINALS; NEURONS; CONOTOXIN; HIPPOCAMPUS; RELEASE; INVITRO	SYNAPTIC transmission is mediated by calcium entry through voltage-dependent calcium channels in presynaptic nerve terminals1,2. Various types of calcium channel have been characterized in neuronal somata3-6, but it is not clear which subtypes induce transmitter release at central synapses. The N-type Ca2+ channel blocker omega-conotoxin GVIA (omega-CgTx) suppresses the excitatory postsynaptic responses only partially7,8, whereas potassium-induced release of glutamate from brain synaptosomes can be blocked by omega-Aga-VIA (ref. 9), a blocker of P-type calcium channels5,10 and possibly of other types of calcium channels11,12. Here we test type-specific calcium-channel blockers on postsynaptic currents recorded from neurons in thin slices of rat central nervous system13. Inhibitory postsynaptic currents in cerebellar and spinal neurons and excitatory postsynaptic currents in hippocampal neurons are markedly suppressed by omega-Aga-IVA and reduced to a lesser extent by omega-CgTx. The L-type calcium channel blocker nicardipine had no effect. Our results indicate that at least two types of calcium channel mediate synaptic transmission in the mammalian central nervous system.	KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 606,JAPAN	Kyoto University			Takahashi, Tomoyuki/G-5951-2015	Takahashi, Tomoyuki/0000-0002-8771-7666				AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; AUGUSTINE GJ, 1986, J PHYSIOL-LONDON, V381, P619, DOI 10.1113/jphysiol.1986.sp016347; COX DH, 1992, J NEUROSCI, V12, P906; DODGE FA, 1967, J PHYSIOL-LONDON, V193, P419, DOI 10.1113/jphysiol.1967.sp008367; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; HORNE AL, 1991, BRIT J PHARMACOL, V103, P1733, DOI 10.1111/j.1476-5381.1991.tb09855.x; KAMIYA H, 1988, NEUROSCI LETT, V91, P84, DOI 10.1016/0304-3940(88)90253-4; Katz B., 1969, RELEASE NEURAL TRANS; LEMOS JR, 1989, NEURON, V2, P1419, DOI 10.1016/0896-6273(89)90187-6; LLINAS R, 1989, P NATL ACAD SCI USA, V86, P1689, DOI 10.1073/pnas.86.5.1689; MAGLEBY KL, 1987, SYNAPTIC FUNCTION, P21; MCCLESKEY EW, 1987, P NATL ACAD SCI USA, V84, P4327, DOI 10.1073/pnas.84.12.4327; MILLER RJ, 1987, SCIENCE, V235, P46, DOI 10.1126/science.2432656; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; Sather W. A., 1992, Society for Neuroscience Abstracts, V18, P10; SAYER RJ, 1992, J NEUROPHYSIOL, V68, P833, DOI 10.1152/jn.1992.68.3.833; SOONG TW, 1993, SCIENCE, V260, P1133, DOI 10.1126/science.8388125; SWANDULLA D, 1991, NEURON, V7, P915, DOI 10.1016/0896-6273(91)90337-Y; SWARTZ KJ, 1992, J NEUROSCI, V12, P4358; TAKAHASHI T, 1992, J PHYSIOL-LONDON, V450, P593, DOI 10.1113/jphysiol.1992.sp019145; TSIEN RW, 1988, TRENDS NEUROSCI, V11, P431, DOI 10.1016/0166-2236(88)90194-4; TURNER TJ, 1992, SCIENCE, V258, P310, DOI 10.1126/science.1357749; USOWICZ MM, 1992, NEURON, V9, P1185, DOI 10.1016/0896-6273(92)90076-P	25	643	657	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					156	158		10.1038/366156a0	http://dx.doi.org/10.1038/366156a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	7901765				2022-12-28	WOS:A1993MG21600057
J	BONADONNA, G; VALAGUSSA, P; MOLITERNI, A; ZAMBETTI, M; BRAMBILLA, C				BONADONNA, G; VALAGUSSA, P; MOLITERNI, A; ZAMBETTI, M; BRAMBILLA, C			CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT CHEMOTHERAPY; AXILLARY NODES; DOXORUBICIN; INTERVAL; THERAPY; TUMORS	Background. Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil was administered after radical mastectomy for primary breast cancer with histologically positive axillary lymph nodes to assess whether it would improve treatment outcome as compared with surgery alone. Here we report a 20-year follow-up of this investigation. Methods. In 1973 we began a trial involving 386 women who were randomly assigned to receive either no further treatment after radical mastectomy (179 women) or 12 monthly cycles of adjuvant combination chemotherapy (207 women). All patients were admitted to the Istituto Nazionale Tumori in Milan, Italy. Adjuvant chemotherapy was delivered in the outpatient clinic of the Division of Medical Oncology. Results. After a median follow-up of 19.4 years, the patients given adjuvant combination chemotherapy had significantly better rates of relapse-free survival (unadjusted relative risk of relapse, 0.71; 95 percent confidence interval, 0.56 to 0.90; P=0.004; adjusted relative risk, 0.65; 95 percent confidence interval, 0.51 to 0.83; P<0.001) and total survival (unadjusted relative risk of death, 0.78; 95 percent confidence interval, 0.62 to 0.99; P=0.04; adjusted relative risk, 0.76; 95 percent confidence interval, 0.60 to 0.97; P=0.03). With the exception of postmenopausal women, a benefit from adjuvant chemotherapy was evident in all subgroups of patients. Conclusions. The long-term results of this trial of adjuvant combination chemotherapy confirm our preliminary observations of the effectiveness of the treatment in women with node-positive breast cancer.			BONADONNA, G (corresponding author), IST NAZL TUMORI,DIV MED ONCOL,VIA VENEZIAN 1,I-20133 MILAN,ITALY.				NCI NIH HHS [N01-CM-33714] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONADON G, 1975, P AM ASSOC CANC RES, V16, P254; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; BONADONNA G, 1977, CANCER-AM CANCER SOC, V39, P2904, DOI 10.1002/1097-0142(197706)39:6<2904::AID-CNCR2820390677>3.0.CO;2-8; BONADONNA G, IN PRESS CA CANCER J; BONADONNA G, 1981, MED ONCOLOGY CONTROV, P100; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; FISHER B, 1975, NEW ENGL J MED, V292, P117, DOI 10.1056/NEJM197501162920301; GOLDHIRSCH A, 1990, ANN ONCOL, V1, P183, DOI 10.1093/oxfordjournals.annonc.a057718; GOLDHIRSCH A, 1994, LANCET, V343, P377, DOI 10.1016/S0140-6736(94)91221-1; HENDERSON IC, 1990, CANCER, V65, P2132, DOI 10.1002/1097-0142(19900501)65:9+<2132::AID-CNCR2820651410>3.0.CO;2-4; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Miller R. G., 1981, SURVIVAL ANAL; MOLITERNI A, 1991, J CLIN ONCOL, V9, P1124, DOI 10.1200/JCO.1991.9.7.1124; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; VALAGUSSA P, 1994, ANN ONCOL, V5, P803, DOI 10.1093/oxfordjournals.annonc.a059008; Valagussa P, 1989, Recent Results Cancer Res, V115, P69; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; 1992, LANCET, V399, P71; 1992, LANCET, V399, P1	22	756	785	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					901	906		10.1056/NEJM199504063321401	http://dx.doi.org/10.1056/NEJM199504063321401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877646	Bronze			2022-12-28	WOS:A1995QP89300001
J	WILLIAMS, JW; HOLLEMAN, DR; SAMSA, GP; SIMEL, DL				WILLIAMS, JW; HOLLEMAN, DR; SAMSA, GP; SIMEL, DL			RANDOMIZED CONTROLLED TRIAL OF 3 VS 10 DAYS OF TRIMETHOPRIM-SULFAMETHOXAZOLE FOR ACUTE MAXILLARY SINUSITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIMICROBIAL RESISTANCE; AMOXICILLIN-CLAVULANATE; HAEMOPHILUS-INFLUENZAE; COMPARATIVE EFFICACY; CEFUROXIME AXETIL; THERAPY; CLARITHROMYCIN; EQUIVALENCE; AMOXYCILLIN; BOOTSTRAP	Objective.-To compare 14-day outcomes and relapse and recurrence rates among patients with acute maxillary sinusitis randomized to 3-day (3D) vs 10-day (10D) treatment with trimethoprim/sulfamethoxazole (TMP/SMX). Setting.-University-affiliated Veterans Affairs general medical and acute care clinics. Patients.-Consecutive patients with sinus symptoms and radiographic evidence of maxillary sinusitis (complete opacity, air-fluid level, or greater than or equal to 6 mm of mucosal thickening). Patients were excluded for antibiotic use within the past week, TMP/ SMX allergy, symptoms for more than 30 days, or previous sinus surgery. Methods.-All subjects (n=80) received oxymetazoline nasal spray 0.05%, two sprays twice daily for 3 days. Subjects were randomly assigned to TMP/SMX double strength: one tablet twice daily for 10 days or one tablet twice daily for 3 days followed by 7 days of placebo, At 7 and 14 days, patients rated their overall sinus symptoms on a Likert scale. Radiographs were scored at baseline and 14 days by radiologists masked to clinical symptoms and treatment assignment. The primary outcome was number of days to ''cure'' or ''much improvement'' in sinus symptoms. Patients who were clinical successes by day 14 were assessed for symptomatic relapse or recurrence at 30 and 60 days, respectively, Results.-Groups were comparable at randomization: male, 100%; black, 53%; median age, 48 years (interquartile range, 41 to 63 years); symptom duration, 10 days (interquartile range, 6 to 17 days); bilateral maxillary disease, 51%; and radiograph score, 4 (interquartile range, 2 to 4). Outcome assessment was completed in 95% of patients at day 14(n=76). Medication side effects and use of nonstudy sinus medications were equal between groups. By 14 days, 77% of 3D subjects and 76% of 10D subjects rated their sinus symptoms as cured or much improved (95% confidence interval for difference, -15% to 17%). Median days to cure/much improvement were 5.0 and 4.5 for the 3D and 10D groups, respectively; distributions of time to cure were not different (P=.34). Radiograph scores improved in both groups compared with baseline (2 points; P<.001), but improvement did not differ between groups (P=.31). Eight percent of 3D subjects and 13% of 10D subjects missed work due to sinus symptoms. Of the 52 patients who were clinical successes at 14 days and completed follow-up, three (11%) of 27 3D subjects and one (4%) of 25 10D subjects relapsed symptomatically by day 30; one (4%) of 27 3D subjects and one (4%) of 25 10D subjects suffered symptomatic recurrence between days 30 and 60 (P=.45 for the relapse and recurrence rates combined). Conclusion.-At the 2-week follow-up, clinical symptoms and radiograph scores improved equally following 3 or 10 days of TMP/SMX plus oxymetazoline nasal spray. Symptomatic relapse and recurrence were similar between groups. Three days of antibiotics were as effective as 10 days and, because of the high disease prevalence, hold the potential for substantial cost savings.	AUDIE L MURPHY MEM VET ADM MED CTR,DIV GEN INTERNAL MED,SAN ANTONIO,TX; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX; LEXINGTON VET HOSP,MED SERV,LEXINGTON,KY; LEXINGTON VET HOSP,DIV GEN INTERNAL MED,LEXINGTON,KY; UNIV KENTUCKY,LEXINGTON,KY; VET AFFAIRS MED CTR,HLTH SERV RES FIELD PROGRAM,DURHAM,NC; VET AFFAIRS MED CTR,DIV GEN INTERNAL MED,DURHAM,NC; DUKE UNIV,MED CTR,DURHAM,NC	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University	WILLIAMS, JW (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR,AMBULATORY CARE SERV 11C,7400 MERTON MINTON BLVD,SAN ANTONIO,TX 78284, USA.		Williams, John/AAM-4572-2020; Williams, John W/A-3696-2008	Williams, John/0000-0002-5267-5558; Williams, John W/0000-0002-5267-5558				ALTMAN DG, 1989, STAT MED, V8, P771, DOI 10.1002/sim.4780080702; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V70, P71, DOI 10.3109/00016487009181861; AXELSSON A, 1988, ANN OTO RHINOL LARYN, V92, P75; AXELSSON A, 1970, ACTA OTOLARYNGOL STO, V69, P802; BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CAMACHO AE, 1992, AM J MED, V93, P271, DOI 10.1016/0002-9343(92)90232-Z; CASIANO RR, 1991, AM J MED, V91, pS27, DOI 10.1016/0002-9343(91)90398-H; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; Fascenelli F W, 1969, Arch Otolaryngol, V90, P190; Fleiss JL, 1981, STAT METHODS RATES P; GARLASCHI ML, 1993, EUR J EPIDEMIOL, V9, P64, DOI 10.1007/BF00463092; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; KARMA P, 1991, J ANTIMICROB CHEMOTH, V27, P83, DOI 10.1093/jac/27.suppl_A.83; KAYSER FH, 1990, EUR J CLIN MICROBIOL, V9, P810, DOI 10.1007/BF01967379; KIRSHNER B, 1991, J CLIN EPIDEMIOL, V44, P839, DOI 10.1016/0895-4356(91)90139-Z; MARCHI E, 1990, CURR MED RES OPIN, V12, P19, DOI 10.1185/03007999009111487; MATTHEWS BL, 1993, SOUTHERN MED J, V86, P329, DOI 10.1097/00007611-199303000-00016; MATTUCCI KF, 1986, ARCH OTOLARYNGOL, V112, P73; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; MOSS AJ, 1986, VITAL HLTH STAT 10, V160, P66; NIELSEN RW, 1992, AM J MED, V92, pS70, DOI 10.1016/0002-9343(92)90611-E; NYFFENEGGER R, 1991, CLIN THER, V13, P589; ROVNER S, 1993, WASHINGTON POST 1130, P10; RUBIN RH, 1980, NEW ENGL J MED, V303, P426, DOI 10.1056/NEJM198008213030804; SANFORD JP, 1993, GUIDE ANTIMICROBIAL, P29; SCHELD WM, 1986, ANTIMICROB AGENTS CH, V30, P350, DOI 10.1128/AAC.30.3.350; SYDNOR A, 1989, ARCH OTOLARYNGOL, V115, P1430; VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684; WALD ER, 1986, PEDIATRICS, V77, P795; WILLIAMS JW, 1992, J GEN INTERN MED, V7, P481, DOI 10.1007/BF02599447; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILLIAMS JW, 1993, CLIN RES, V41, pA566; WINTHER B, 1990, OTOLARYNG HEAD NECK, V103, P876, DOI 10.1177/01945998901030S507; [No title captured]; 1989, NATIONAL DISEASE THE, P487; 1993, J ANTIMICROB CHEMOTH, V31, P949; 1990, SAS STAT USERS GUIDE, P1027; 1992, P229 SAS I INC TECHN, P435; 1995, JAMA-J AM MED ASSOC, V273, P776; 1994, JAMA-J AM MED ASSOC, V272, P1926; 1994, REDBOOK DRUG TOPICS	48	96	94	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1015	1021		10.1001/jama.273.13.1015	http://dx.doi.org/10.1001/jama.273.13.1015			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897784				2022-12-28	WOS:A1995QP89000031
J	VANBUREN, M; HENE, RJ; VERDONCK, LF; VERZIJLBERGEN, FJ; LOKHORST, HM				VANBUREN, M; HENE, RJ; VERDONCK, LF; VERZIJLBERGEN, FJ; LOKHORST, HM			CLINICAL REMISSION AFTER SYNGENEIC BONE-MARROW TRANSPLANTATION IN A PATIENT WITH AL AMYLOIDOSIS	ANNALS OF INTERNAL MEDICINE			English	Note						AORTIC ANEURYSM; ANEURYSM, DISSECTING; TEMPORAL ARTERITIS; VASCULITIS	SYSTEMIC AMYLOIDOSIS; MULTIPLE-MYELOMA; P COMPONENT		UNIV UTRECHT HOSP, DEPT HEMATOL, 3584 CX UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center			Verzijlbergen, Fred/E-8951-2018; Verzijlbergen, Fred/E-7848-2016	Verzijlbergen, Fred/0000-0002-4776-816X; Verzijlbergen, Fred/0000-0002-4776-816X; van Buren, Marjolijn/0000-0002-1822-6863				EWING DJ, 1985, DIABETES CARE, V8, P491, DOI 10.2337/diacare.8.5.491; GAHRTON G, 1991, NEW ENGL J MED, V325, P1267, DOI 10.1056/NEJM199110313251802; GERTZ MA, 1991, BLOOD, V77, P257; HAWKINS PN, 1988, LANCET, V1, P1413; HAWKINS PN, 1990, NEW ENGL J MED, V323, P508, DOI 10.1056/NEJM199008233230803; LOKHORST HM, 1993, CANCER TREAT REV, V19, P113, DOI 10.1016/0305-7372(93)90030-U; LOWENSTEIN J, 1970, NEW ENGL J MED, V282, P128, DOI 10.1056/NEJM197001152820304; RICHTER GW, 1954, AM J PATHOL, V30, P239	8	52	52	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					508	510		10.7326/0003-4819-122-7-199504010-00005	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872585				2022-12-28	WOS:A1995QP00800005
J	ATEENYIAGABA, C				ATEENYIAGABA, C			CONJUNCTIVAL SQUAMOUS-CELL CARCINOMA-ASSOCIATED WITH HIV-INFECTION IN KAMPALA, UGANDA	LANCET			English	Note								The incidence of conjunctival squamous-cell carcinoma in Kampala, Uganda, was steady at around 6 per million per year from 1970 until 1988, but has increased six-fold since then to 35 per million per year in 1992. Among 48 patients with conjunctival tumours seen at the ophthalmology clinic of the New Mulago Hospital from 1990 to 1991, 75% were HIV seropositive, compared with a 19% seropositivity rate among 48 matched controls (relative risk 13.0, 95% Cl 4.5-39.4, p<0.0001). The recent epidemic of conjunctival tumours in Uganda (and in neighbouring countries) appears to be largely due to the epidemic of HIV infection. Other factors that may contribute to the high incidence of these tumours in equatorial Africa may be exposure to ultraviolet light and conjunctival papillomavirus infection.			ATEENYIAGABA, C (corresponding author), MAKERERE UNIV,SCH MED,DEPT OPHTHALMOL,POB 7022,KAMPALA,UGANDA.							KESTELYN P, 1990, LANCET, V336, P51, DOI 10.1016/0140-6736(90)91562-O; KIM RY, 1990, AM J OPHTHALMOL, V109, P231, DOI 10.1016/S0002-9394(14)75997-5; TEMPLETON A, 1973, RECENT RESULTS CANC, V43, P203; TRITTEN JJ, 1994, KLIN MONATSBL AUGENH, V204, P453, DOI 10.1055/s-2008-1045463; WINWARD KE, 1989, AM J OPHTHALMOL, V107, P554, DOI 10.1016/0002-9394(89)90508-4	5	113	118	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					695	696		10.1016/S0140-6736(95)90870-6	http://dx.doi.org/10.1016/S0140-6736(95)90870-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885126				2022-12-28	WOS:A1995QM73200011
J	MARCHETTI, M; ARICO, B; BURRONI, D; FIGURA, N; RAPPUOLI, R; GHIARA, P				MARCHETTI, M; ARICO, B; BURRONI, D; FIGURA, N; RAPPUOLI, R; GHIARA, P			DEVELOPMENT OF A MOUSE MODEL OF HELICOBACTER-PYLORI INFECTION THAT MIMICS HUMAN-DISEASE	SCIENCE			English	Article							PEPTIC-ULCERATION; CHRONIC GASTRITIS; IMMUNE-RESPONSE; PROTEIN	The human pathogen Helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer. The pathogenesis of H. pylori infection in vivo was studied by adapting fresh clinical isolates of bacteria to colonize the stomachs of mice. A gastric pathology resembling human disease was observed in infections With cytotoxin-producing strains but not with noncytotoxic strains. Oral immunization with purified H. pylori antigens protected mice from bacterial infection. This mouse model will allow the development of therapeutic agents and vaccines against H. pylori infection in humans.	BIOCINE SPA,IMMUNOBIOL RES INST SIENA,I-53100 SIENA,ITALY; UNIV SIENA,IST PATOL SPECIALE MED,I-53100 SIENA,ITALY	University of Siena				Figura, Natale/0000-0003-0318-4565				CANTORNA MT, 1990, CAN J MICROBIOL, V36, P237, DOI 10.1139/m90-041; CHEN M, 1994, INT J MED MICROBIOL, V280, P155; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; CRABTREE JE, 1991, LANCET, V338, P332, DOI 10.1016/0140-6736(91)90477-7; DOUCE G, 1995, P NATL ACAD SCI USA, V92, P1644, DOI 10.1073/pnas.92.5.1644; DUNN BE, 1990, J BIOL CHEM, V265, P2659; EULER AR, 1990, J CLIN MICROBIOL, V28, P2285, DOI 10.1128/JCM.28.10.2285-2290.1990; FERRERO RL, 1994, INFECT IMMUN, V62, P4981, DOI 10.1128/IAI.62.11.4981-4989.1994; FIOCCA R, 1989, ACTA GASTRO-ENT BELG, V52, P324; FOX JG, 1991, REV INFECT DIS, V13, pS671; GHIARA P, UNPUB; KARITA M, 1994, AM J GASTROENTEROL, V89, P208; KRAKOWKA S, 1987, INFECT IMMUN, V55, P2789, DOI 10.1128/IAI.55.11.2789-2796.1987; LEE A, 1993, LANCET, V341, P280, DOI 10.1016/0140-6736(93)92624-3; LEE A, 1990, GASTROENTEROLOGY, V99, P1315, DOI 10.1016/0016-5085(90)91156-Z; MACCHIA G, 1993, MOL MICROBIOL, V9, P645, DOI 10.1111/j.1365-2958.1993.tb01724.x; MEGRAUD F, 1993, GASTROENTEROL CLIN N, V22, P73; MICHETTI P, 1994, GASTROENTEROLOGY, V107, P1002, DOI 10.1016/0016-5085(94)90224-0; PARSONNET J, 1994, NEW ENGL J MED, V330, P1267, DOI 10.1056/NEJM199405053301803; SOBALA GM, 1991, GUT, V32, P1415, DOI 10.1136/gut.32.11.1415; TELFORD JL, 1994, J EXP MED, V179, P1653, DOI 10.1084/jem.179.5.1653; TSUDA M, 1994, INFECT IMMUN, V62, P3586, DOI 10.1128/IAI.62.8.3586-3589.1994; WARREN JR, 1983, LANCET, V2, P1273; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995; 1994, JAMA-J AM MED ASSOC, V272, P65	25	513	545	2	23	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1655	1658		10.1126/science.7886456	http://dx.doi.org/10.1126/science.7886456			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886456				2022-12-28	WOS:A1995QM39700040
J	BURGE, MR; BOYLE, PJ				BURGE, MR; BOYLE, PJ			DIETARY THERAPY IN TYPE-II DIABETES-MELLITUS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											BURGE, MR (corresponding author), UNIV NEW MEXICO,SCH MED,ALBUQUERQUE,NM 87131, USA.							BANTLE JP, 1993, DIABETES CARE, V16, P1301, DOI 10.2337/diacare.16.9.1301; CRAPO PA, 1994, JOSLINS DIABETES MEL, P415; FREEMAN WL, 1988, PRIMARY CARE, V15, P327; HANSEN BC, 1988, DIABETES CARE, V11, P183, DOI 10.2337/diacare.11.2.183; HUGHES TA, 1984, AM J MED, V77, P7, DOI 10.1016/0002-9343(84)90429-7; REAVEN GM, 1980, DIABETOLOGIA, V19, P409, DOI 10.1007/BF00281817; 1994, DIABETES CARE, V17, P519; 1987, DIABETES CARE, V10, P639	8	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					898	898		10.1001/jama.273.11.898	http://dx.doi.org/10.1001/jama.273.11.898			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869567				2022-12-28	WOS:A1995QL40200035
J	BROWN, K; GERSTBERGER, S; CARLSON, L; FRANZOSO, G; SIEBENLIST, U				BROWN, K; GERSTBERGER, S; CARLSON, L; FRANZOSO, G; SIEBENLIST, U			CENTRAL OF I-KAPPA-B-ALPHA PROTEOLYSIS BY SITE-SPECIFIC, SIGNAL-INDUCED PHOSPHORYLATION	SCIENCE			English	Article							ONCOPROTEIN BCL-3; INHIBITION; PROTEINS; COMMON	I kappa B-alpha inhibits transcription factor NF-kappa B by retaining it in the cytoplasm. Various stimuli, typically those associated with stress or pathogens, rapidly inactivate I kappa B-alpha. This liberates NF-kappa B to translocate to the nucleus and initiate transcription of genes important for the defense of the organism. Activation of NF-kappa B correlates with phosphorylation of I kappa B-alpha and requires the proteolysis of this inhibitor. When either serine-32 or serine-36 of I kappa B-alpha was mutated, the protein did not undergo signal-induced phosphorylation or degradation, and NF-kappa B could not be activated. These results suggest that phosphorylation at one or both of these residues is critical for activation of NF-kappa B.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Franzoso, Guido/GRR-8628-2022	Franzoso, Guido/0000-0002-0778-988X				BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BRESSLER P, 1993, J VIROL, V67, P288, DOI 10.1128/JVI.67.1.288-293.1993; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; BROWN KS, UNPUB; DEMARTIN R, 1994, EMBO J, V12, P2773; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; HATADA EN, 1993, EMBO J, V12, P2781, DOI 10.1002/j.1460-2075.1993.tb05939.x; LIN YC, 1995, P NATL ACAD SCI USA, V92, P552, DOI 10.1073/pnas.92.2.552; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; SUN SC, 1994, MOL CELL BIOL, V14, P7377, DOI 10.1128/MCB.14.11.7377; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x	19	1324	1365	1	19	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1485	1488		10.1126/science.7878466	http://dx.doi.org/10.1126/science.7878466			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878466				2022-12-28	WOS:A1995QL49700034
J	KIRCHNER, J; CONNOLLY, CM; SANDMEYER, SB				KIRCHNER, J; CONNOLLY, CM; SANDMEYER, SB			REQUIREMENT OF RNA-POLYMERASE-III TRANSCRIPTION FACTORS FOR IN-VITRO POSITION-SPECIFIC INTEGRATION OF A RETROVIRUS-LIKE ELEMENT	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TY1 TRANSPOSITION; DNA; INVITRO; GENES; SEQUENCE; REGION; ENDONUCLEASE; NONRANDOM; HOTSPOTS	The yeast retroviruslike element Ty3 inserts at the transcription initiation sites of genes transcribed by RNA polymerase III (Pol III). An in vitro integration assay was developed with the use of Ty3 viruslike particles and a modified SUP2 tyrosine transfer RNA (tRNA(Tyr)) gene target. Integration was position-specific and required Ty3 integrase, Pol III transcription extract, and a transcriptionally competent tRNA gene. Use of individual transcription factor (TF) IIIB-, TFIIIC-, and Pol III-containing fractions showed that TFIIIB and TFIIIC, together, were sufficient for position-specific Ty3 integration, but not for transcription. This report demonstrates that in vitro integration of a retroelement can be targeted by cellular proteins.	UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717	University of California System; University of California Irvine					PHS HHS [33281] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALLISON DS, 1983, CELL, V34, P655, DOI 10.1016/0092-8674(83)90398-7; BAKER RE, 1986, J BIOL CHEM, V261, P5275; CANNON PM, 1994, J VIROL, V68, P4768, DOI 10.1128/JVI.68.8.4768-4775.1994; CHALKER DL, 1992, GENE DEV, V6, P117, DOI 10.1101/gad.6.1.117; CHALKER DL, 1990, GENETICS, V126, P837; CRAIGIE R, 1992, TRENDS GENET, V8, P187, DOI 10.1016/0168-9525(92)90223-Q; DRELICH M, 1992, VIROLOGY, V188, P459, DOI 10.1016/0042-6822(92)90499-F; EIBEL H, 1984, NATURE, V307, P386, DOI 10.1038/307386a0; ENGLEMAN A, 1992, J VIROL, V66, P6361; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1994, RNA POLYM, V3, pCH5; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; JI H, 1993, CELL, V73, P1007, DOI 10.1016/0092-8674(93)90278-X; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KIRCHNER J, 1993, J VIROL, V67, P19, DOI 10.1128/JVI.67.1.19-28.1993; Kirchner J., UNPUB; KITAMURA Y, 1992, P NATL ACAD SCI USA, V89, P5532, DOI 10.1073/pnas.89.12.5532; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LEAVITT AD, 1993, J BIOL CHEM, V268, P2113; LEVEILLARD T, 1991, J BIOL CHEM, V266, P5162; LIEBMAN SW, 1993, GENETICS, V133, P499; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MENEES TM, 1994, MOL CELL BIOL, V14, P8229, DOI 10.1128/MCB.14.12.8229; MILOT E, 1994, VIROLOGY, V201, P408, DOI 10.1006/viro.1994.1310; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; NATSOULIS G, 1989, GENETICS, V123, P269; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRYCIAK PM, 1992, EMBO J, V11, P291, DOI 10.1002/j.1460-2075.1992.tb05052.x; PRYCIAK PM, 1992, CELL, V69, P769, DOI 10.1016/0092-8674(92)90289-O; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHWARTZ CJE, 1989, J MOL BIOL, V205, P647, DOI 10.1016/0022-2836(89)90310-0; SHIN CG, 1994, J VIROL, V68, P1633, DOI 10.1128/JVI.68.3.1633-1642.1994; TADDEO B, 1994, J VIROL, V68, P8401, DOI 10.1128/JVI.68.12.8401-8405.1994; VANGENT DC, 1992, P NATL ACAD SCI USA, V89, P9598, DOI 10.1073/pnas.89.20.9598; WIKERCHEN M, 1995, J VIROL, V69, P376; WITHERSWARD ES, 1994, GENE DEV, V8, P1473, DOI 10.1101/gad.8.12.1473	37	182	188	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1488	1491		10.1126/science.7878467	http://dx.doi.org/10.1126/science.7878467			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878467	Green Submitted			2022-12-28	WOS:A1995QL49700035
J	STELLER, H				STELLER, H			MECHANISMS AND GENES OF CELLULAR SUICIDE	SCIENCE			English	Article							INTERLEUKIN-1-BETA CONVERTING ENZYME; CAENORHABDITIS-ELEGANS; INDUCED APOPTOSIS; NERVOUS-SYSTEM; NEURONAL DEATH; THYMOCYTE APOPTOSIS; SERINE PROTEASES; IMMUNE-SYSTEM; RNA-SYNTHESIS; C-MYC	Apoptosis is a morphologically distinct form of programmed cell death that plays a major role during development, homeostasis, and in many diseases including cancer, acquired immunodeficiency syndrome, acid neurodegenerative disorders. Apoptosis occurs through the activation of a cell-intrinsic suicide program. The basic machinery to carry out apoptosis appears to be present in essentially all mammalian cells at all times, but the activation of the suicide program is regulated by many different signals that originate from both the intracellular and the extracellular milieu. Genetic studies in the nematode Caenorhabditis elegans and in the fruit fly Drosophila melanogaster have led to the isolation of genes that are specifically required for the induction of programmed cell death. At least some components of the apoptotic program have been conserved among worms, insects, and vertebrates.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	STELLER, H (corresponding author), MIT, HOWARD HUGHES MED INST, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA.							ABRAMS JM, UNPUB; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; ASKEW DS, 1991, ONCOGENE, V6, P1915; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; COHEN JJ, 1984, J IMMUNOL, V132, P38; DARMON AJ, 1994, J BIOL CHEM, V269, P32043; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GLUCKSMANN A, 1951, BIOL REV, V26, P59, DOI 10.1111/j.1469-185X.1951.tb00774.x; GOLSTEIN P, 1991, IMMUNOL REV, V121, P29, DOI 10.1111/j.1600-065X.1991.tb00822.x; HAMMAR SP, 1971, J CELL SCI, V8, P229; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENGARTNER MO, 1994, PHILOS T R SOC B, V345, P243, DOI 10.1098/rstb.1994.0100; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOWARD AD, 1991, J IMMUNOL, V147, P2964; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; JACOBSON MD, 1993, NATURE, V361, P365, DOI 10.1038/361365a0; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; KUMAR S, 1992, BIOCHEM BIOPH RES CO, V185, P1155, DOI 10.1016/0006-291X(92)91747-E; LANE DP, 1994, PHILOS T ROY SOC B, V345, P277, DOI 10.1098/rstb.1994.0106; LAURENTCRAWFORD AG, 1991, VIROLOGY, V185, P829, DOI 10.1016/0042-6822(91)90554-O; LAZEBNIK YA, 1993, J CELL BIOL, V123, P7, DOI 10.1083/jcb.123.1.7; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LINDSAY RM, 1994, TRENDS NEUROSCI, V17, P182, DOI 10.1016/0166-2236(94)90099-X; LOCKSHIN RA, 1969, J INSECT PHYSIOL, V15, P1505, DOI 10.1016/0022-1910(69)90172-3; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NEWMEYER DD, 1994, CELL, V79, P353, DOI 10.1016/0092-8674(94)90203-8; ODAKE S, 1991, BIOCHEMISTRY-US, V30, P2217, DOI 10.1021/bi00222a027; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Purves D., 1988, P1; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; ROBINOW S, 1993, DEVELOPMENT, V119, P1251; ROY C, 1992, EXP CELL RES, V200, P416, DOI 10.1016/0014-4827(92)90190-J; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SCHWARTZ LM, 1990, P NATL ACAD SCI USA, V87, P6594, DOI 10.1073/pnas.87.17.6594; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SLEATH PR, 1990, J BIOL CHEM, V265, P14526; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; SNIDER WD, 1994, CELL, V77, P627, DOI 10.1016/0092-8674(94)90048-5; STELLER H, 1994, NEURON, V13, P1269, DOI 10.1016/0896-6273(94)90413-8; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TATA JR, 1966, DEV BIOL, V13, P77, DOI 10.1016/0012-1606(66)90050-9; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TRUMAN JW, 1984, J NEUROSCI, V4, P274; TSUBATA T, 1994, PHILOS T ROY SOC B, V345, P297, DOI 10.1098/rstb.1994.0109; UCKER DS, 1991, NEW BIOL, V3, P103; UMANSKY SR, 1982, J THEOR BIOL, V97, P591, DOI 10.1016/0022-5193(82)90360-5; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WHITE E, 1993, GENE DEV, V7, P2277, DOI 10.1101/gad.7.12a.2277; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WHITE K, UNPUB; WILLIAMS GT, 1991, CELL, V65, P1097, DOI 10.1016/0092-8674(91)90002-G; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; YUAN JY, 1992, DEVELOPMENT, V116, P309; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; YUAN JY, 1990, DEV BIOL, V138, P33, DOI 10.1016/0012-1606(90)90174-H	90	2350	2557	32	303	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1445	1449		10.1126/science.7878463	http://dx.doi.org/10.1126/science.7878463			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878463				2022-12-28	WOS:A1995QL49700024
J	WANG, Q; SHEN, JX; SPLAWSKI, I; ATKINSON, D; LI, ZZ; ROBINSON, JL; MOSS, AJ; TOWBIN, JA; KEATING, MT				WANG, Q; SHEN, JX; SPLAWSKI, I; ATKINSON, D; LI, ZZ; ROBINSON, JL; MOSS, AJ; TOWBIN, JA; KEATING, MT			SCN5A MUTATIONS ASSOCIATED WITH AN INHERITED CARDIAC-ARRHYTHMIA, LONG QT SYNDROME	CELL			English	Article							HYPERKALEMIC PERIODIC PARALYSIS; MUSCLE SODIUM-CHANNEL; ALPHA-SUBUNIT; PARAMYOTONIA-CONGENITA; HUMAN CHROMOSOME-3; GENE; INACTIVATION; LINKAGE; FAMILIES; CLONING	Long QT syndrome (LQT) is an inherited disorder that causes sudden death from cardiac arrhythmias, specifically torsade de pointes and ventricular fibrillation. We previously mapped three LQT loci: LQT1 on chromosome 11p15.5, LQT2 on 7q35-36, and LQT3 on 3p21-24. Here we report genetic linkage between LQT3 and polymorphisms within SCN5A, the cardiac sodium channel gene. Single strand conformation polymorphism and DNA sequence analyses reveal identical intragenic deletions of SCN5A in affected members of two unrelated LQT families. The deleted sequences reside in a region that is important for channel inactivation. These data suggest that mutations in SCN5A cause chromosome 3-linked LQT and indicate a likely cellular mechanism for this disorder.	UNIV UTAH, HLTH SCI CTR, DEPT HUMAN GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, ECCLES PROGRAM HUMAN MOLEC BIOL & GENET, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, HLTH SCI CTR, DIV CARDIOL, SALT LAKE CITY, UT 84112 USA; UNIV ROCHESTER, MED CTR, DEPT COMMUNITY & PREVENT MED, ROCHESTER, NY 14627 USA; UNIV ROCHESTER, MED CTR, DEPT MED, ROCHESTER, NY 14627 USA; BAYLOR COLL MED, DEPT PEDIAT, HOUSTON, TX 77030 USA; BAYLOR COLL MED, DEPT MOLEC & HUMAN GENET, HOUSTON, TX 77030 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; University of Rochester; University of Rochester; Baylor College of Medicine; Baylor College of Medicine	WANG, Q (corresponding author), UNIV UTAH, HLTH SCI CTR, HOWARD HUGHES MED INST, SALT LAKE CITY, UT 84112 USA.		Towbin, Jeffrey A./J-5595-2019	Towbin, Jeffrey A./0000-0002-6585-714X	NHLBI NIH HHS [R01-HL48074, R01-HL51618, R01-HL33843] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051618, R01HL033843] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; ATTWELL D, 1979, PFLUG ARCH EUR J PHY, V379, P137, DOI 10.1007/BF00586939; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; CHIN H, 1991, GENOMICS, V11, P914, DOI 10.1016/0888-7543(91)90014-6; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; EBERS GC, 1991, ANN NEUROL, V30, P810, DOI 10.1002/ana.410300610; FONTAINE B, 1990, SCIENCE, V250, P1000, DOI 10.1126/science.2173143; GELLENS ME, 1992, P NATL ACAD SCI USA, V89, P554, DOI 10.1073/pnas.89.2.554; GEORGE AL, 1995, CYTOGENET CELL GENET, V68, P67; HONERJAGER P, 1981, REV PHYSIOL BIOCH P, V92, P1; JERVELL A, 1957, AM HEART J, V54, P59, DOI 10.1016/0002-8703(57)90079-0; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LERCHE H, 1993, J PHYSIOL-LONDON, V470, P13, DOI 10.1113/jphysiol.1993.sp019843; MAGOVCEVIC I, 1992, GENOMICS, V12, P125, DOI 10.1016/0888-7543(92)90414-N; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MCCLATCHEY AI, 1992, HUM MOL GENET, V1, P521; MCCLATCHEY AI, 1992, CELL, V68, P769, DOI 10.1016/0092-8674(92)90151-2; MCCLATCHEY AI, 1992, NAT GENET, V2, P148, DOI 10.1038/ng1092-148; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PTACEK LJ, 1991, CELL, V67, P1021; PTACEK LJ, 1992, NEURON, V8, P891; ROJAS CV, 1991, NATURE, V354, P387, DOI 10.1038/354387a0; ROMANO C, 1965, LANCET, V1, P658; RUDOLPH JA, 1992, NAT GENET, V2, P144, DOI 10.1038/ng1092-144; SCHWARTZ PJ, 1975, AM HEART J, V89, P378, DOI 10.1016/0002-8703(75)90089-7; SEINO S, 1992, GENOMICS, V13, P1375, DOI 10.1016/0888-7543(92)90078-7; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WANG Q, 1994, BIOTECHNIQUES, V17, P282; WARD O C, 1964, J Ir Med Assoc, V54, P103; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WEST JW, 1992, P NATL ACAD SCI USA, V89, P10910, DOI 10.1073/pnas.89.22.10910; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7; YANG NB, 1994, P NATL ACAD SCI USA, V91, P12785, DOI 10.1073/pnas.91.26.12785; ZIPES DP, 1987, AM J CARDIOL, V59, pE26, DOI 10.1016/0002-9149(87)90198-6	42	1312	1366	1	44	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					805	811		10.1016/0092-8674(95)90359-3	http://dx.doi.org/10.1016/0092-8674(95)90359-3			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889574	Bronze			2022-12-28	WOS:A1995QM39900017
J	LIAO, SM; ZHANG, JH; JEFFREY, DA; KOLESKE, AJ; THOMPSON, CM; CHAO, DM; VILJOEN, M; VANVUUREN, HJJ; YOUNG, RA				LIAO, SM; ZHANG, JH; JEFFREY, DA; KOLESKE, AJ; THOMPSON, CM; CHAO, DM; VILJOEN, M; VANVUUREN, HJJ; YOUNG, RA			A KINASE-CYCLIN PAIR IN THE RNA-POLYMERASE-II HOLOENZYME	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TERMINAL DOMAIN; YEAST; PROTEIN; BINDING; CTD; PURIFICATION; ACTIVATION; SYSTEM; RESCUE	THE RNA polymerase II holoenzyme consists of RNA polymerase II, a subset of general transcription factors, and regulatory proteins known as SRB proteins(1,2). The genes encoding SRB proteins were isolated as suppressors of mutations in the RNA polymerase II carboxy-terminal domain (CTD3,4). The CTD and SRB proteins have been implicated in the response to transcriptional regulators(1-11). We report here the isolation of two new SRB genes, SRB10 and SRB11, which encode kinase- and cyclin-like proteins, respectively, Genetic and biochemical evidence indicates that the SRB10 and SRB11 proteins form a kinase-cyclin pair in the holoenzyme, The SRB10/11 kinase is essential for a normal transcriptional response to galactose induction in vivo. Holoenzymes lacking SRB10/11 kinase function are strikingly deficient in CTD phosphorylation, Although defects in the kinase substantially affect transcription in vivo, purified holoenzymes lacking SRB10/11 kinase function do not show defects in defined in vitro transcription systems, suggesting that the factors necessary to elicit the regulatory role of the SRB10/11 kinase are missing in these systems, These results indicate that the SRB10/11 kinase is involved in CTD phosphorylation and suggest that this modification has a role in the response to transcriptional regulators in vivo.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; UNIV STELLENBOSCH, DEPT MICROBIOL, STELLENBOSCH 7600, SOUTH AFRICA	Massachusetts Institute of Technology (MIT); Stellenbosch University	LIAO, SM (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		zhang, jianhua/D-3404-2009; Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Zhang, Jianhua/0000-0002-2128-9574; Chao, David/0000-0001-9198-337X; Viljoen-Bloom, Marinda/0000-0002-4825-2392				ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; DAHMUS ME, 1992, TRANSCRIPTIONAL REGU, P109; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1994, CELL, V79, P1103, DOI 10.1016/0092-8674(94)90040-X; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; KIM TK, 1994, NATURE, V369, P252, DOI 10.1038/369252a0; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEES JM, 1991, GENE EXPRESSION, V1, P149; LEOPOLD P, 1991, CELL, V66, P1207, DOI 10.1016/0092-8674(91)90043-X; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LI Y, 1994, P NATL ACAD SCI USA, V91, P2362, DOI 10.1073/pnas.91.6.2362; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; OBRIEN T, 1994, NATURE, V370, P75, DOI 10.1038/370075a0; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SIMON M, 1986, EMBO J, V5, P2697, DOI 10.1002/j.1460-2075.1986.tb04553.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SUROSKY RT, 1994, MOL CELL BIOL, V14, P3446, DOI 10.1128/MCB.14.5.3446; THOMPSON CM, 1993, CELL, V73, P1361, DOI 10.1016/0092-8674(93)90362-T; UESONO Y, 1987, NUCLEIC ACIDS RES, V15, P10299, DOI 10.1093/nar/15.24.10299; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689	30	369	376	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 9	1995	374	6518					193	196		10.1038/374193a0	http://dx.doi.org/10.1038/374193a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877695				2022-12-28	WOS:A1995QL39700068
J	WEAVER, HA; AHEARN, MF; ARPIGNY, C; BOICE, DC; FELDMAN, PD; LARSON, SM; LAMY, P; LEVY, DH; MARSDEN, BG; MEECH, KJ; NOLL, KS; SCOTTI, JV; SEKANINA, Z; SHOEMAKER, CS; SHOEMAKER, EM; SMITH, TE; STERN, SA; STORRS, AD; TRAUGER, JT; YEOMANS, DK; ZELLNER, B				WEAVER, HA; AHEARN, MF; ARPIGNY, C; BOICE, DC; FELDMAN, PD; LARSON, SM; LAMY, P; LEVY, DH; MARSDEN, BG; MEECH, KJ; NOLL, KS; SCOTTI, JV; SEKANINA, Z; SHOEMAKER, CS; SHOEMAKER, EM; SMITH, TE; STERN, SA; STORRS, AD; TRAUGER, JT; YEOMANS, DK; ZELLNER, B			THE HUBBLE-SPACE-TELESCOPE (HST) OBSERVING CAMPAIGN ON COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article								The Hubble Space Telescope made systematic observations of the split comet P/Shoemaker-Levy 9 (SL9) (P designates a periodic comet) starting in July 1993 and continuing through mid-July 1994 when the fragments plunged into Jupiter's atmosphere. Deconvolutions of Wide Field Planetary Camera images indicate that the diameters of some fragments may have been as large as similar to 2 to 4 kilometers, assuming a geometric albedo of 4 percent, but significantly smaller values (that is, <1 kilometer) cannot be ruled out. Most of the fragments (or nuclei) were embedded in circularly symmetric inner comae from July 1993 until late June 1994, implying that there was continuous, but weak, cometary activity. At least a few nuclei fragmented into separate, condensed objects well after the breakup of the SL9 parent body, which argues against the hypothesis that the SL9 fragments were swarms of debris with no dominant, central bodies. Spectroscopic observations taken on 14 July 1994 showed an outburst in magnesium ion emission that was followed closely by a threefold increase in continuum emission, which may have been caused by the electrostatic charging and subsequent explosion of dust as the comet passed from interplanetary space into the jovian magnetosphere. No OH emission was detected, but the derived upper limit on the H2O production rate of similar to 10(27) molecules per second does not necessarily imply that the object was water-poor.	UNIV MARYLAND,DEPT ASTRON,COLLEGE PK,MD 20742; UNIV LIEGE,INST ASTROPHYS,B-4000 LIEGE,BELGIUM; SW RES INST,DIV 15,SAN ANTONIO,TX 78228; JOHNS HOPKINS UNIV,DEPT PHYS & ASTRON,BALTIMORE,MD 21218; UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85721; LAB ASTRON SPATIALE TRAVERSE SIPHON,F-13376 MARSEILLE 12,FRANCE; HARVARD SMITHSONIAN CTR ASTROPHYS,CAMBRIDGE,MA 02138; UNIV HAWAII,INST ASTRON,HONOLULU,HI 96822; JET PROPULS LAB,PASADENA,CA 91109; NO ARIZONA UNIV,DEPT PHYS & ASTRON,FLAGSTAFF,AZ 86011; US GEOL SURVEY,FLAGSTAFF,AZ 86001; SW RES INST,DIV 15,BOULDER EXTENS OFF,BOULDER,CO 80302; GEORGIA SO UNIV,DEPT PHYS,STATESBORO,GA 30460	University System of Maryland; University of Maryland College Park; University of Liege; Southwest Research Institute; Johns Hopkins University; University of Arizona; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; University of Hawaii System; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Northern Arizona University; United States Department of the Interior; United States Geological Survey; University System of Georgia; Georgia Southern University	WEAVER, HA (corresponding author), SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218, USA.		Noll, Keith/C-8447-2012; Weaver, Harold A/D-9188-2016; Meech, Karen/CAH-1412-2022; Levy, David/GPS-4945-2022; Boice, Daniel/C-4831-2018	Weaver, Harold A/0000-0003-0951-7762; Boice, Daniel/0000-0001-6423-3768				Acuna M. H., 1983, PHYSICS JOVIAN MAGNE, P1, DOI [10. 1017/cbo9780511564574. 003, DOI 10.1017/CBO9780511564574.003]; ALLEN CW, 1976, ASTROPHYSICAL QUANTI, P162; Bobrovnikoff N. T., 1954, ASTRON J, V59, P357; BROWN WL, 1982, SCIENCE, V218, P525, DOI 10.1126/science.218.4572.525; COCHRAN AL, IN PRESS ICARUS; DEISEMME AH, 1982, COMETS, P85; DESSLER AJ, 1994, GEOPHYS RES LETT, V21, P1043, DOI 10.1029/94GL01294; FULLE M, 1990, NATURE, V359, P42; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; JEWITT D, 1986, ASTROPHYS J, V310, P937, DOI 10.1086/164745; JEWITT D, 1994, 5999 INT STR UN CIRC; LANDOLT AU, 1983, ASTRON J, V88, P439, DOI 10.1086/113329; MEECH KJ, 1993, ASTRON J, V106, P1222, DOI 10.1086/116721; SEKANINA Z, 1994, ASTRON ASTROPHYS, V289, P607; SEKANINA Z, 1994, HYPERVELOCITY IMPACT; SEKANINA Z, 1994, 6020 INT ASTR UN CIR; WALLACE LV, 1958, ASTRON J, V63, P213, DOI 10.1086/107729; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; WEISSMAN P, COMMUNICATION; WYCKOFF S, 1985, NATURE, V316, P241, DOI 10.1038/316241a0	20	75	75	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1282	1288		10.1126/science.7871424	http://dx.doi.org/10.1126/science.7871424			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871424				2022-12-28	WOS:A1995QK06800029
J	GIBSON, F; WALSH, J; MBURU, P; VARELA, A; BROWN, KA; ANTONIO, M; BEISEL, KW; STEEL, KP; BROWN, SDM				GIBSON, F; WALSH, J; MBURU, P; VARELA, A; BROWN, KA; ANTONIO, M; BEISEL, KW; STEEL, KP; BROWN, SDM			A TYPE-VII MYOSIN ENCODED BY THE MOUSE DEAFNESS GENE SHAKER-1	NATURE			English	Article							SYNDROME TYPE-I; ARTIFICIAL CHROMOSOME LIBRARY; YEAST; RECOMBINATION; CONSTRUCTION; LINKAGE; MAPS	GENETIC deafness is common, affecting about 1 in 2,000 births(1). Many of these show primary abnormalities of the sensory neuroepithelia of the inner ear, as do several hearing-impaired mouse mutants, suggesting that genes involved in sensory transduction could be affected. Here we report the identification of one such gene, the mouse shaker-1 (sh1) gene. Shaker-1 homozygotes show hyperactivity, head-tossing and circling due to vestibular dysfunction, together with typical neuroepithelial-type cochlear defects involving dysfunction and progressive degeneration of the organ of Corti(2-7). The sh1 gene encodes an unconventional myosin molecule of the type VII family. Three mutations are described, two missense mutations and a splice acceptor site mutation, all in the region encoding the myosin head. The myosin type VII molecule encoded by sh1 is the first molecule to be identified that is known, by virtue of its mutations, to be involved in auditory transduction.	UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT BIOCHEM & MOLEC GENET, LONDON W2 1PG, ENGLAND; BOYS TOWN NATL RES HOSP, OMAHA, NE 68131 USA; MRC, INST HEARING RES, NOTTINGHAM NG7 2RD, ENGLAND	Imperial College London; Boys Town National Research Hospital								BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BROWN KA, 1992, GENOMICS, V13, P189, DOI 10.1016/0888-7543(92)90219-I; BURKE DT, 1991, MAMM GENOME, V1, P65, DOI 10.1007/BF00350849; CHARTIER FL, 1992, NAT GENET, V1, P132, DOI 10.1038/ng0592-132; DEOL MS, 1956, PROC R SOC SER B-BIO, V145, P206, DOI 10.1098/rspb.1956.0028; DIBB NJ, 1985, J MOL BIOL, V183, P543, DOI 10.1016/0022-2836(85)90170-6; EVANS KL, 1993, HUM MOL GENET, V2, P115, DOI 10.1093/hmg/2.2.115; Fraser G. R, 1976, BIG 4 CAUSES POVERTY; GIBSON F, 1994, BIOTECHNIQUES, V16, P453; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GREENFIELD A J, 1987, Genomics, V1, P153, DOI 10.1016/0888-7543(87)90007-3; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; HERMANSON GG, 1991, NUCLEIC ACIDS RES, V19, P4943, DOI 10.1093/nar/19.18.4943; HUDSPETH AJ, 1994, NEURON, V12, P1, DOI 10.1016/0896-6273(94)90147-3; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KIKUCHI K, 1965, ACTA OTOLARYNG STOCK, V60, P287; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LETTS VA, 1994, MOUSE GENOME, V92, P116; Lord EM, 1929, AM NAT, V63, P435, DOI 10.1086/280276; MIKAELIAN DO, 1964, ARCHIV OTOLARYNGOL, V80, P418; MOOSEKER M, 1993, CURR BIOL, V3, P245, DOI 10.1016/0960-9822(93)90346-P; RINCHIK EM, 1990, P NATL ACAD SCI USA, V87, P896, DOI 10.1073/pnas.87.3.896; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SOLC CF, IN PRESS AUD NEUROSC; STEEL KP, 1983, ARCH OTOLARYNGOL, V109, P22; STEEL KP, 1992, DEV AUDITORY VESTIBU, V2, P221; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0	28	521	529	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	1995	374	6517					62	64		10.1038/374062a0	http://dx.doi.org/10.1038/374062a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870172				2022-12-28	WOS:A1995QK07900052
J	CRUMP, BJ; PANTON, R; DRUMMOND, MF; MARCHMENT, M; HAWKES, RA				CRUMP, BJ; PANTON, R; DRUMMOND, MF; MARCHMENT, M; HAWKES, RA			TRANSFERRING THE COSTS OF EXPENSIVE TREATMENTS FROM SECONDARY TO PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article								General practitioners, especially fundholders, are becoming increasingly concerned about being asked to prescribe treatments for their patients that are outside their therapeutic experience. They are concerned about the clinical responsibility for such prescribing and the effects on their budgets. In some specialties transferring the costs of expensive treatments from secondary to primary care (cost shifting) has become partly institutionalised because of the separate sources of funding for drugs prescribed in the two sectors. With increased efforts to control the rising costs of the drugs budget and the emergence of new expensive treatments, cost shifting will be a challenge to clinicians and purchasers as they strive for rational, cost effective prescribing. A review of the funding mechanisms for drugs prescribing and of the relation between the licensing process and the decision to support the use of a treatment in primary or secondary care is needed.	KEELE UNIV,NEWCASTLE LYME ST5 5BC,STAFFS,ENGLAND; UNIV YORK,YORK YO1 5DD,N YORKSHIRE,ENGLAND; PREMIER HLTH TRUST,BURTON TRENT DE14 2AU,STAFFS,ENGLAND	Keele University; University of York - UK	CRUMP, BJ (corresponding author), S BIRMINGHAM HLTH AUTHOR,BIRMINGHAM B15 3DP,W MIDLANDS,ENGLAND.							DRUMMOND M, 1993, PHARMACOECONOMICS, V4, P173, DOI 10.2165/00019053-199304030-00003; 1993, CRDC1 STAND GROUP HL	2	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					509	512		10.1136/bmj.310.6978.509	http://dx.doi.org/10.1136/bmj.310.6978.509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888896	Green Published			2022-12-28	WOS:A1995QJ59800030
J	ESMAIL, A; NELSON, P; PRIMAROLO, D; TOMA, T				ESMAIL, A; NELSON, P; PRIMAROLO, D; TOMA, T			ACCEPTANCE INTO MEDICAL-SCHOOL AND RACIAL-DISCRIMINATION	BRITISH MEDICAL JOURNAL			English	Article									HOUSE COMMONS,LONDON,ENGLAND		ESMAIL, A (corresponding author), UNIV MANCHESTER,RUSHOLME HLTH CTR,DEPT GEN PRACTICE,MANCHESTER M14 5NP,LANCS,ENGLAND.		Esmail, Aneez/I-6903-2013					ANDERSON J, 1980, BRIT MED J, V280, P1216, DOI 10.1136/bmj.280.6225.1216; FLEISS JL, 1981, STATISTICAL METHODS, P173; VELLINS S, 1985, NEW COMMUNITY, V10, P206	3	25	25	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					501	502		10.1136/bmj.310.6978.501	http://dx.doi.org/10.1136/bmj.310.6978.501			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ598	7888889	Green Published			2022-12-28	WOS:A1995QJ59800022
J	HENRIKSEN, TB; BEK, KM; HEDEGAARD, M; SECHER, NJ				HENRIKSEN, TB; BEK, KM; HEDEGAARD, M; SECHER, NJ			METHODS AND CONSEQUENCES OF CHANGES IN USE OF EPISIOTOMY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PERINEAL MANAGEMENT TRIAL; INFORMATION; DELIVERY; RATES	Objectives-To evaluate the use of feedback by graphical profiles of rates of episiotomy and the impact on clinical practice and perineal state after spontaneous vaginal deliveries assisted by midwives with different attitudes towards episiotomy. Design-Observation period in labour ward followed by feedback to midwives about their own and other midwives' use of episiotomies. The periods before and after the intervention were compared. Subjects-All women (n = 3919) delivering during the two periods who had been assisted by one of 30 midwives; each midwife supervised at least 20 deliveries during each period. Main outcome measures-Overall rates of episiotomies and indications, incidence of intact perineums, perineal lacerations, and tears of anal sphincter. Results-The overall rate of episiotomy during the observation period was 37.1% (615). During the second period the rate was 6.6% lower (95% confidence interval 3.6% to 9.6%), corresponding to a relative decrease of 17.8% (10.1% to 24.7%). Higher rates of episiotomy during the observation period were associated with larger reductions in the second period. The decrease could be explained by less use of episiotomy in deliveries with rigid perineum or impending perineal tear. Compared with the observation period, in the second period 3.2% more women (0.3% to 6.3%) had an intact perineum after delivery and 3.4% (0.4% to 6.2%) experienced perineal tears. The overall incidence of tears of the anal sphincter remained unchanged. Women had a slightly reduced incidence of tears of the anal sphincter, however, if they were delivered by midwives who reduced a medium or high initial rate of episiotomy and a tendency towards an increased incidence of tears if they were assisted by midwives who reduced low initial rates (around 20%) of episiotomy. Conclusions-Changes in the use of episiotomy induced by awareness of clinical practice among midwives seem to increase the incidence of parturients with intact perineum without a concomitant rise in tears of the anal sphincter. To avoid the increase of such tears these changes should probably be restricted to midwives with rates of episiotomies above 30%.			HENRIKSEN, TB (corresponding author), AARHUS UNIV HOSP, DEPT OBSTET & GYNAECOL, PERINATAL EPIDEMIOL RES UNIT, DK-8000 AARHUS C, DENMARK.							BUEKENS P, 1985, BRIT J OBSTET GYNAEC, V92, P820, DOI 10.1111/j.1471-0528.1985.tb03052.x; BUEKENS P, 1993, BRIT MED J, V306, P623, DOI 10.1136/bmj.306.6878.623; Elwood JM, 1988, CAUSAL RELATIONSHIPS, Vxi, P332; GLEICHER N, 1984, Journal of the American Medical Association, V252, P3273, DOI 10.1001/jama.252.23.3273; HARRISON RF, 1984, BRIT MED J, V288, P1971, DOI 10.1136/bmj.288.6435.1971; Hemminki E, 1992, Qual Assur Health Care, V4, P133; HENRIKSEN TB, 1992, BRIT J OBSTET GYNAEC, V99, P950, DOI 10.1111/j.1471-0528.1992.tb13695.x; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MANTEL N, 1959, J NATL CANCER I, V22, P719; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; MYERS SA, 1988, NEW ENGL J MED, V319, P1511, DOI 10.1056/NEJM198812083192304; SCHULTZ WCMW, 1990, J PSYCHOSOM OBST GYN, V11, P119, DOI 10.3109/01674829009084408; SHIONO P, 1990, OBSTET GYNECOL, V75, P765; SLEEP J, 1987, BRIT MED J, V295, P749, DOI 10.1136/bmj.295.6601.749; SLEEP J, 1984, BRIT MED J, V289, P587, DOI 10.1136/bmj.289.6445.587; SZCZEPURA A, 1987, BRIT MED J, V294, P875, DOI 10.1136/bmj.294.6576.875; Thacker S B, 1983, Obstet Gynecol Surv, V38, P322, DOI 10.1097/00006254-198306000-00003; THRANOV I, 1990, ACTA OBSTET GYN SCAN, V69, P11, DOI 10.3109/00016349009021032; YATES JM, 1984, BRIT MED J, V288, P1335; 1993, LANCET, V342, P1517; 1990, SPSS PC PLUS ADV STA, pB39	22	38	39	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	1994	309	6964					1255	1258		10.1136/bmj.309.6964.1255	http://dx.doi.org/10.1136/bmj.309.6964.1255			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888844	Green Published			2022-12-28	WOS:A1994PT03300017
J	EDDY, DM				EDDY, DM			HEALTH SYSTEM REFORM - WILL CONTROLLING COSTS REQUIRE RATIONING SERVICES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									DUKE UNIV,DURHAM,NC	Duke University								Burner S T, 1992, Health Care Financ Rev, V14, P1; Cowan C A, 1993, Health Care Financ Rev, V14, P227; EDDY DM, 1992, JAMA-J AM MED ASSOC, V268, P2575, DOI 10.1001/jama.268.18.2575; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P105, DOI 10.1001/jama.265.1.105; Letsch S W, 1992, Health Care Financ Rev, V14, P1; LETSCH SW, 1993, HEALTH AFFAIR, V12, P94, DOI 10.1377/hlthaff.12.1.94; 1992, ANN REPORT BOARD TRU; 1994, HLTH NEWS DAILY, V6, P1	8	46	46	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 27	1994	272	4					324	328		10.1001/jama.272.4.324	http://dx.doi.org/10.1001/jama.272.4.324			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NX806	7888005				2022-12-28	WOS:A1994NX80600038
J	MATCHAR, DB; MCCRORY, DC; BARNETT, HJM; FEUSSNER, JR				MATCHAR, DB; MCCRORY, DC; BARNETT, HJM; FEUSSNER, JR			MEDICAL-TREATMENT FOR STROKE PREVENTION	ANNALS OF INTERNAL MEDICINE			English	Review							TRANSIENT ISCHEMIC ATTACKS; NONVALVULAR ATRIAL-FIBRILLATION; ASYMPTOMATIC CAROTID STENOSIS; CORONARY HEART-DISEASE; CEREBRAL-ISCHEMIA; RANDOMIZED TRIAL; SECONDARY PREVENTION; THROMBOEMBOLIC STROKE; MYOCARDIAL-INFARCTION; BLOOD-PRESSURE	Purpose: To review the effectiveness of medical treatments for stroke prevention in patients at elevated risk for stroke. Data Sources: English-language articles published after 1977 and indexed in MEDLINE under the following Medical Subject Heading terms: anticoagulants, aspirin, dipyridamole, ticlopidine, or sulfinpyrazone, combined with cerebrovascular disorders. Study Selection: Randomized controlled trials of anticoagulant or platelet antiaggregant treatment reporting subsequent stroke and myocardial infarction, death, or complications in persons with asymptomatic carotid stenosis or bruit, transient ischemic attack (TIA), previous stroke, nonvalvular atrial fibrillation, or other vascular diseases. Data Extraction: Of 900 articles identified, 33 were selected by two independent reviewers and abstracted for outcome events and person-years of follow-up. Results: In patients with nonvalvular atrial fibrillation, warfarin is highly effective in reducing stroke and death but may result in more complications. Aspirin appears to be less effective and less risky than anticoagulation. In patients with TIA or minor stroke, both aspirin and ticlopidine reduce the risk for stroke. In patients who have had myocardial infarction, warfarin is effective but had high complication rates in the reviewed studies. Aspirin slightly reduces the risk for stroke. Conclusions: Warfarin is strongly recommended for persons with nonvalvular atrial fibrillation who are older than 60 years or who have additional risk factors for stroke. Aspirin is recommended for persons at elevated risk for bleeding while receiving anticoagulants. For persons with TIA or minor stroke, aspirin should be used first. Patients who do not respond to or tolerate aspirin or who have had a major stroke are reasonable candidates for ticlopidine. For patients who have had myocardial infarction, aspirin is recommended for the prevention of secondary myocardial infarction but not of stroke.	DUKE UNIV, MED CTR, DURHAM, NC 27710 USA; JOHN P ROBARTS RES INST, LONDON N6A 5K8, ON, CANADA; VET AFFAIRS MED CTR, CTR HLTH SERV RES PRIMARY CARE 152, DURHAM, NC 27705 USA; UNIV WESTERN ONTARIO, LONDON, ON, CANADA	Duke University; Western University (University of Western Ontario); US Department of Veterans Affairs; Veterans Health Administration (VHA); Western University (University of Western Ontario)	MATCHAR, DB (corresponding author), DUKE UNIV, CTR HLTH POLICY RES & EDUC, POB 90253, DURHAM, NC 27708 USA.		Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108				ACHESON J, 1969, BMJ-BRIT MED J, V1, P614, DOI 10.1136/bmj.1.5644.614; ALBERS GW, 1991, ANN INTERN MED, V115, P727, DOI 10.7326/0003-4819-115-9-727; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; ANDERSON DC, 1992, ANN INTERN MED, V116, P6; [Anonymous], 1989, Stroke, V20, P844; [Anonymous], 1990, Stroke, V21, P1122; [Anonymous], 1985, Stroke, V16, P406; [Anonymous], 1988, BRIT MED J, V296, P320; [Anonymous], 1991, Lancet, V338, P1345; [Anonymous], 1982, Lancet, V1, P237; [Anonymous], 1980, Circulation, V62, P449; APOLLONIO A, 1989, J INT MED RES, V17, P28, DOI 10.1177/030006058901700104; BALSANO F, 1990, CIRCULATION, V82, P17, DOI 10.1161/01.CIR.82.1.17; BILLER J, 1982, EUR NEUROL, V21, P98, DOI 10.1159/000115462; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BOYSEN G, 1988, STROKE, V19, P1211, DOI 10.1161/01.STR.19.10.1211; BRAND FN, 1985, JAMA-J AM MED ASSOC, V254, P3449, DOI 10.1001/jama.254.24.3449; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; CANDELISE L, 1982, STROKE, V13, P175, DOI 10.1161/01.STR.13.2.175; CARTLIDGE NEF, 1977, MAYO CLIN PROC, V52, P117; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; COOK DJ, 1992, CHEST, V102, pS305; EASTON JD, 1991, PREVENTION STROKE, P139; ECKMAN MH, 1992, CHEST, V102, pS538, DOI 10.1378/chest.102.4_Supplement.538S; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; FEINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P428; FIELDS WS, 1977, STROKE, V8, P301, DOI 10.1161/01.STR.8.3.301; FIELDS WS, 1980, CIRCULATION, V62, P90; FIELDS WS, 1978, STROKE, V9, P309, DOI 10.1161/01.STR.9.4.309; FIHN SD, 1993, ANN INTERN MED, V118, P511, DOI 10.7326/0003-4819-118-7-199304010-00005; GARDE A, 1983, STROKE, V14, P677, DOI 10.1161/01.STR.14.5.677; GENT M, 1985, STROKE, V16, P416, DOI 10.1161/01.STR.16.3.416; GENT M, 1989, LANCET, V1, P1215, DOI 10.1016/S0140-6736(89)92327-1; GROTTA JC, 1992, NEUROLOGY, V42, P111, DOI 10.1212/WNL.42.1.111; GUSTAFSSON C, 1987, STROKE, V18, P299; HARBISON JW, 1992, STROKE, V23, P1723, DOI 10.1161/01.STR.23.12.1723; Hart R G, 1983, Curr Probl Cardiol, V8, P1; HASS WK, 1989, NEW ENGL J MED, V321, P501, DOI 10.1056/NEJM198908243210804; HERSHEY LA, 1991, AM J MED, V91, P288, DOI 10.1016/0002-9343(91)90130-P; HERSKOVITS E, 1989, ACTA NEUROL SCAND, V80, P31, DOI 10.1111/j.1600-0404.1989.tb01808.x; HIRSH J, 1988, THROMB HAEMOSTASIS, V59, P129; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; JANZON L, 1990, J INTERN MED, V227, P301, DOI 10.1111/j.1365-2796.1990.tb00164.x; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KLIMT CR, 1986, J AM COLL CARDIOL, V7, P251, DOI 10.1016/S0735-1097(86)80489-2; LANDEFELD CS, 1989, AM J MED, V87, P144; LOELIGER EA, 1982, LANCET, V1, P64; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MAYBERG MR, 1991, JAMA-J AM MED ASSOC, V266, P3289, DOI 10.1001/jama.266.23.3289; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; NAGLIE IG, 1992, MED DECIS MAKING, V12, P239, DOI 10.1177/0272989X9201200401; NORRIS JW, 1991, STROKE, V22, P1485, DOI 10.1161/01.STR.22.12.1485; NORRIS JW, 1992, STROKE, V23, P483, DOI 10.1161/01.STR.23.4.483; OLSSON JE, 1980, STROKE, V11, P4, DOI 10.1161/01.STR.11.1.4; PETERSEN P, 1989, LANCET, V1, P175; PICKERING G, 1978, AM J MED, V65, P561, DOI 10.1016/0002-9343(78)90839-2; REUTHER R, 1978, ACETYLSALICYLIC ACID, P97; ROOS J, 1980, LANCET, V2, P989; ROTHROCK JF, 1991, ANN INTERN MED, V115, P885, DOI 10.7326/0003-4819-115-11-885; SACCO RL, 1982, STROKE, V13, P290, DOI 10.1161/01.STR.13.3.290; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SCHOENBERGER JA, 1980, JAMA-J AM MED ASSOC, V243, P661; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; SZE PC, 1988, STROKE, V19, P436, DOI 10.1161/01.STR.19.4.436; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707; WIEBERS DO, 1992, MAYO CLIN PROC, V67, P513; WOLF PA, 1992, STROKE PATHOPHYSIOLO, P3; 1976, J CHRON DIS, V29, P625; 1991, STROKE, V22, P147; 1992, SOFTWARE META ANAL C	77	81	82	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1994	121	1					41	53		10.7326/0003-4819-121-1-199407010-00008	http://dx.doi.org/10.7326/0003-4819-121-1-199407010-00008			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PN271	7880225				2022-12-28	WOS:A1994PN27100008
J	PLOWMAN, GD; GREEN, JM; CULOUSCOU, JM; CARLTON, GW; ROTHWELL, VM; BUCKLEY, S				PLOWMAN, GD; GREEN, JM; CULOUSCOU, JM; CARLTON, GW; ROTHWELL, VM; BUCKLEY, S			HEREGULIN INDUCES TYROSINE PHOSPHORYLATION OF HER4/P180(ERBB4)	NATURE			English	Article							GROWTH-FACTOR; EGF RECEPTOR; P185ERBB2; CLONING	THE HER4/ERBB4 gene encodes a 180K transmembrane protein (HER4/p180erbB4) that is structurally related to the 185K product (HER2/p185erbB2) of the HER2/ERBB2 proto-oncogene1. A 45K heparin-binding glycoprotein (p45) has been characterized that specifically activates the intrinsic tyrosine kinase activity of HER4 (ref. 2). This HER4 ligand shares several features with the heregulin family of proteins, including molecular mass, ability to induce differentiation of breast cancer cells, activation of tyrosine phosphorylation in MDA-MB453 cells, and amino-terminal protein sequence. Heregulin exists as multiple isoforms and all are presumed to interact directly with HER2 (refs 3-6). We have used binding and phosphorylation studies with recombinant ligand on cell lines expressing recombinant receptors, and report here that heregulin, like p45, is a specific ligand for HER4. Furthermore, heregulin fails to induce phosphorylation of HER2 in the absence of HER4. These findings suggest that activation of the HER4 receptor is involved in signal transduction by heregulin.			PLOWMAN, GD (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,3005 1ST AVE,SEATTLE,WA 98121, USA.		PLOWMAN, Greg D/E-2012-2011					CULOUSCOU JM, 1993, J BIOL CHEM, V268, P18407; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; LUPU R, 1990, SCIENCE, V249, P1552, DOI 10.1126/science.2218496; LUPU R, 1992, P NATL ACAD SCI USA, V89, P2287, DOI 10.1073/pnas.89.6.2287; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; PELES E, 1993, EMBO J, V12, P961, DOI 10.1002/j.1460-2075.1993.tb05737.x; PLOWMAN GD, 1990, MOL CELL BIOL, V10, P1969, DOI 10.1128/MCB.10.5.1969; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; STANCOVSKI I, 1991, P NATL ACAD SCI USA, V88, P8691, DOI 10.1073/pnas.88.19.8691; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	13	467	520	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 2	1993	366	6454					473	475		10.1038/366473a0	http://dx.doi.org/10.1038/366473a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MK098	7902537				2022-12-28	WOS:A1993MK09800067
J	SUNDNES, KO; HAIMANOT, AT				SUNDNES, KO; HAIMANOT, AT			EPIDEMIC OF LOUSE-BORNE RELAPSING FEVER IN ETHIOPIA	LANCET			English	Article							TETRACYCLINE; PENICILLIN	During summer 1991 an outbreak of louse-borne relapsing fever occurred simultaneously in two transit camps established for prisoners of war being returned from Eritrea at the end of the Ethiopian civil war. Only antibiotic treatment was given at the Bahr Dar camp where the frequency of cases increased for 20 days. Vector control by delousing in addition to antibiotics was given at Mekele camp where the frequency of cases fell over a similar period. This difference was significant (p < 0.001). Furthermore, there was a significant correlation between the decreasing proportion of camp inhabitants that had not been deloused at Mekele camp each day and the numbers of patients with fever (r = 0.89, p < 0.001). Taken together, these results confirm that effective control of an epidemic of louse-borne relapsing fever is dependent on efficient vector control in addition to antibiotic treatment.	INT COMM RED CROSS,MEKELE DELEGAT,ADDIS ABABA,ETHIOPIA; WHO,MALARIA UNIT,CH-1211 GENEVA 27,SWITZERLAND	World Health Organization								BRYCESON AD, 1970, Q J MED, V39, P129; GEBREHIWOT T, 1992, ETHIOPIAN MED J, V30, P175; MEKASHA A, 1992, J TROP MED HYG, V95, P206; PERINE PL, 1983, AM J TROP MED HYG, V32, P1096, DOI 10.4269/ajtmh.1983.32.1096; RIJKELS DF, 1971, TROP GEOGR MED, V23, P335; WARRELL DA, 1983, J INFECT DIS, V147, P898, DOI 10.1093/infdis/147.5.898	6	42	42	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1213	1215		10.1016/0140-6736(93)92190-5	http://dx.doi.org/10.1016/0140-6736(93)92190-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901534				2022-12-28	WOS:A1993MG27400014
J	VERDONCK, LF; VANPUTTEN, WLJ; HAGENBEEK, A; SCHOUTEN, HC; SONNEVELD, P; VANIMHOFF, GW; KLUINNELEMANS, HC; RAEMAEKERS, JMM; VANOERS, RHJ; HAAK, HL; SCHOTS, R; DEKKER, AW; DEGAST, GC; LOWENSBERG, B				VERDONCK, LF; VANPUTTEN, WLJ; HAGENBEEK, A; SCHOUTEN, HC; SONNEVELD, P; VANIMHOFF, GW; KLUINNELEMANS, HC; RAEMAEKERS, JMM; VANOERS, RHJ; HAAK, HL; SCHOTS, R; DEKKER, AW; DEGAST, GC; LOWENSBERG, B			COMPARISON OF CHOP CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW TRANSPLANTATION FOR SLOWLY RESPONDING PATIENTS WITH AGGRESSIVE NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARGE-CELL LYMPHOMA; STANDARD REGIMEN CHOP; COMBINATION CHEMOTHERAPY; M-BACOD; MALIGNANT-LYMPHOMA; DOSE THERAPY; SURVIVAL; PROGNOSIS; PROTOCOL; PROMACE	Background. High-dose chemoradiotherapy combined with autologous bone marrow transplantation can cure patients with disseminated, aggressive non-Hodgkin's lymphoma in whom first-line chemotherapy has failed. In contrast, cure is rare with second-line chemotherapy. It has been suggested that patients with slow responses to the initial phase of first-line chemotherapy are at high risk for relapse. Therefore, such patients are potential candidates for early bone marrow transplantation. Methods. To investigate whether patients with slow responses, defined as only a partial response after three courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), would benefit from early transplantation, we conducted a prospective, randomized trial. The early application of high-dose chemoradiotherapy and autologous bone marrow transplantation was compared with the continuation of CHOP therapy for another five courses. Patients with complete responses after three courses of CHOP (fast responses) and patients who responded partially but still had tumor-positive marrow continued with another five courses of CHOP. The study end points were the response rate, overall survival, disease-free survival, and event-free survival. Results. Of 286 patients who could be evaluated for the rapidity of their response after three courses of CHOP, 38 percent had fast responses, 47 percent had slow responses, and 15 percent had no response. Among 106 patients with slow responses who had lymphoma-negative marrow, 69 patients (65 percent) were randomized. Seventy-four percent of the CHOP group and 68 percent of the transplantation group had complete remissions (P=0.54). At four years the rates of overall, disease-free, and event-free survival were 85, 72, and 53 percent, respectively, in the CHOP group and 56, 60 and 41 percent in the transplantation group (P>0.10). The disease-free survival in both groups did not differ significantly from that of nonrandomized patients with fast responses (54 percent at four years). Conclusions. The early application of high-dose, marrow-ablative chemoradiotherapy with autologous bone marrow transplantation does not improve the outcome in patients with aggressive non-Hodgkin's lymphoma that responds slowly to first-line CHOP chemotherapy.	DR DANIEL DEN HOED CANC CTR, ROTTERDAM, NETHERLANDS; UNIV LIMBURG HOSP, DEPT HEMATOL & ONCOL, MAASTRICHT, NETHERLANDS; UNIV ROTTERDAM HOSP, DEPT HEMATOL, ROTTERDAM, NETHERLANDS; UNIV GRONINGEN HOSP, DEPT HEMATOL, GRONINGEN, NETHERLANDS; UNIV LEIDEN HOSP, DEPT HEMATOL, LEIDEN, NETHERLANDS; UNIV NIJMEGEN HOSP, DEPT HEMATOL, NIJMEGEN, NETHERLANDS; UNIV AMSTERDAM, ACAD MED CTR, DEPT HEMATOL, 1105 AZ AMSTERDAM, NETHERLANDS; LEYENBURG HOSP, DEPT HEMATOL, THE HAGUE, NETHERLANDS; FREE UNIV BRUSSELS, DEPT HEMATOL & ONCOL, BRUSSELS, BELGIUM	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute; Maastricht University; Maastricht University Medical Centre (MUMC); Erasmus University Rotterdam; Erasmus MC; University of Groningen; Leiden University; Leiden University Medical Center (LUMC); Radboud University Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam; Universite Libre de Bruxelles; Vrije Universiteit Brussel	VERDONCK, LF (corresponding author), UNIV UTRECHT HOSP, DEPT HEMATOL G03647, POB 85500, 3508 GA UTRECHT, NETHERLANDS.		Kluin-Nelemans, Johanna C/F-8658-2018	Kluin-Nelemans, Johanna C/0000-0003-2617-9427				ARMITAGE JO, 1986, J CLIN ONCOL, V4, P160, DOI 10.1200/JCO.1986.4.2.160; ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BOSLY A, 1992, J CLIN ONCOL, V10, P1615, DOI 10.1200/JCO.1992.10.10.1615; COIFFIER B, 1986, J CLIN ONCOL, V4, P147, DOI 10.1200/JCO.1986.4.2.147; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; GRIBBEN JG, 1989, J CLIN ONCOL, V7, P1621, DOI 10.1200/JCO.1989.7.11.1621; HAIOUN C, 1993, BLOOD, V82, P334; HAQ R, 1994, J CLIN ONCOL, V12, P1074, DOI 10.1200/JCO.1994.12.5.1074; HOELZER D, 1984, BLOOD, V64, P38; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; LAURENCE J, 1982, ANN INTERN MED, V97, P190, DOI 10.7326/0003-4819-97-2-190; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1986, J CLIN ONCOL, V4, P1295, DOI 10.1200/JCO.1986.4.9.1295; MCKELVEY EM, 1976, CANCER, V38, P1484, DOI 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I; PHILIP T, 1987, NEW ENGL J MED, V316, P1493, DOI 10.1056/NEJM198706113162401; PHILIP T, 1991, BLOOD, V77, P1587; PHILLIPS GL, 1984, NEW ENGL J MED, V310, P1557, DOI 10.1056/NEJM198406143102403; ROSENBERG SA, 1982, CANCER, V49, P2112; SALLES G, 1994, SEMIN HEMATOL, V31, P46; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91; TAKVORIAN T, 1987, NEW ENGL J MED, V316, P1499, DOI 10.1056/NEJM198706113162402; TURA S, 1992, BLOOD, V80, P719; VERDONCK LF, 1992, J CLIN ONCOL, V10, P1949, DOI 10.1200/JCO.1992.10.12.1949; VERDONCK LF, 1985, BLOOD, V65, P984	28	250	255	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1045	1051		10.1056/NEJM199504203321601	http://dx.doi.org/10.1056/NEJM199504203321601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898521	Green Published			2022-12-28	WOS:A1995QT18700001
J	KNOX, TA; KAPLAN, MM; GELFAND, JA; WOLFF, SM				KNOX, TA; KAPLAN, MM; GELFAND, JA; WOLFF, SM			METHOTREXATE TREATMENT OF IDIOPATHIC GRANULOMATOUS HEPATITIS	ANNALS OF INTERNAL MEDICINE			English	Note							UNKNOWN ORIGIN; SARCOIDOSIS; THERAPY; INTERLEUKIN-1; AGENTS	Objective: To test the efficacy and safety of low-dose oral pulse methotrexate therapy in patients with idiopathic granulomatous hepatitis who had complications of, did not respond to, or refused glucocorticoid therapy. Design: Prospective case study. Setting: Academic medical center hospital. Patients: Seven patients with biopsy-proven, idiopathic granulomatous hepatitis who could not tolerate or were unresponsive to glucocorticoid therapy. Intervention: Low-dose oral pulse methotrexate, 15 mg/wk. Measurements: Temperature, symptoms, dose of concurrent glucocorticoids, biochemical tests of liver function, side effects of methotrexate, and assessment of liver biopsy specimens. Results: All six febrile patients became afebrile within 3 months of starting methotrexate. Fatigue and anorexia improved in all patients. Glucocorticoid therapy was successfully discontinued within 6 months of starting methotrexate in four patients receiving prednisone at entry. Liver biopsy specimens were obtained again after methotrexate therapy and showed absence of granulomas in four of four patients. The minimum effective dose of methotrexate was 0.20 mg/kg body weight per week. No serious adverse effects and no failures to respond to methotrexate therapy were noted in this group of patients. In three patients, methotrexate therapy has been successfully tapered without signs or symptoms of recurrent disease. Conclusions: Low-dose oral pulse methotrexate was effective in treating patients with granulomatous hepatitis.	TUFTS UNIV NEW ENGLAND MED CTR, BOSTON, MA USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Tufts Medical Center; Tufts University			Gelfand, Jeffrey A/G-1885-2018	Gelfand, Jeffrey A/0000-0002-4118-5676				BERK PD, 1981, NEW ENGL J MED, V304, P441, DOI 10.1056/NEJM198102193040801; DINARELLO CA, 1993, NEW ENGL J MED, V328, P106; FRIEDLAND JS, 1990, MEDICINE, V69, P325, DOI 10.1097/00005792-199011000-00001; ISRAEL HL, 1984, DIGEST DIS SCI, V29, P353, DOI 10.1007/BF01318522; ISRAEL HL, 1973, ANN INTERN MED, V79, P669, DOI 10.7326/0003-4819-79-5-669; KAPLAN MM, 1988, ANN INTERN MED, V109, P429, DOI 10.7326/0003-4819-109-5-429; KAPLAN MM, 1991, GASTROENTEROLOGY, V101, P1332, DOI 10.1016/0016-5085(91)90085-Y; KAPLAN SR, 1973, NEW ENGL J MED, V289, P952, DOI 10.1056/NEJM197311012891806; KEVAT S, 1988, MED TOXICOL ADV DRUG, V3, P197, DOI 10.1007/BF03259882; KNOX TA, 1991, AM J GASTROENTEROL, V86, P546; KOBAYASHI K, 1985, J IMMUNOL, V134, P358; LOWER EE, 1990, AM J MED SCI, V299, P153, DOI 10.1097/00000441-199003000-00002; MILLER LC, 1986, ARTHRITIS RHEUM, V29, pS86; PENCHAS S, 1978, DIGESTION, V17, P46, DOI 10.1159/000198093; SARTIN JS, 1991, MAYO CLIN PROC, V66, P914, DOI 10.1016/S0025-6196(12)61578-X; SIMON HB, 1973, MEDICINE, V52, P1; SIMON HB, 1974, ANN INTERN MED, V80, P560, DOI 10.7326/0003-4819-80-4-560_2; WEISS HD, 1974, NEW ENGL J MED, V291, P127, DOI 10.1056/NEJM197407182910305	18	26	27	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					592	595		10.7326/0003-4819-122-8-199504150-00006	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887553				2022-12-28	WOS:A1995QR52500006
J	SINGH, N; GAYOWSKI, T; YU, VL; WAGENER, MM				SINGH, N; GAYOWSKI, T; YU, VL; WAGENER, MM			TRIMETHOPRIM-SULFAMETHOXAZOLE FOR THE PREVENTION OF SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOSIS - A RANDOMIZED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Note							PROPHYLAXIS; INFECTION; ANTIBIOTICS; NORFLOXACIN; CIRRHOTICS	Objective: To assess the efficacy and safety of trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Design: A randomized controlled trial. Setting: University-affiliate Veterans Affairs medical center. Patients: 60 consecutive patients with cirrhosis and ascites. Interventions: Consecutive patients were randomly assigned to receive either no prophylaxis or trimethoprim-sulfamethoxazole, one double-strength tablet daily, five times a week (Monday through Friday). Patient entry was stratified by serum bilirubin (>51 mu mol/L [>3 mg/dL]), ascitic fluid protein (<1 g/dL), and serum creatinine (>177 mu mol/L [>2 mg/dL]) levels to ensure that high-risk patients would be similarly distributed in the two groups. The median duration of follow-up for the study patients was 90 days. Main Outcome Measures: Spontaneous bacterial peritonitis or spontaneous bacteremia as defined by objective criteria. Results: Spontaneous bacterial peritonitis or spontaneous bacteremia developed in 27% (8 of 30) of patients who did not receive prophylaxis compared with 3% (1 of 30) of patients receiving trimethoprim-sulfamethoxazole (P = 0.025). Overall, infections developed in 9 of 30 patients (30%) not receiving prophylaxis and in 1 of 30 patients (3%) receiving trimethoprim-sulfamethoxazole (P = 0.012). Death occurred in 6 of 30 patients (20%) who did not receive prophylaxis and in 2 of 30 patients (7%) who received trimethoprim-sulfamethoxazole (P = 0.15). Side effects-particularly, hematologic toxicity-could not be attributed to trimethoprim-sulfamethoxazole in any patient. Conclusions: Trimethoprim-sulfamethoxazole was efficacious, safe, and cost-effective for the prevention of spontaneous bacterial peritonitis in patients with cirrhosis.	VET AFFAIRS MED CTR, INFECT DIS SECT, PITTSBURGH, PA 15240 USA; UNIV PITTSBURGH, PITTSBURGH, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BOCHUD PY, 1994, CLIN INFECT DIS, V18, P25, DOI 10.1093/clinids/18.1.25; BONTEN MJM, 1993, NEW ENGL J MED, V328, P209, DOI 10.1056/NEJM199301213280311; BOW EJ, 1988, AM J MED, V84, P847, DOI 10.1016/0002-9343(88)90062-9; COMETTA A, 1994, NEW ENGL J MED, V330, P1240, DOI 10.1056/NEJM199404283301717; DUPEYRON C, 1994, ANTIMICROB AGENTS CH, V38, P340, DOI 10.1128/AAC.38.2.340; FUNGTOMC J, 1993, ANTIMICROB AGENTS CH, V37, P1289, DOI 10.1128/AAC.37.6.1289; GINES P, 1990, HEPATOLOGY, V12, P716, DOI 10.1002/hep.1840120416; HOEFS JC, 1982, HEPATOLOGY, V2, P399; LLOVET JM, 1993, AM J GASTROENTEROL, V88, P388; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RIMOLA A, 1985, HEPATOLOGY, V5, P463, DOI 10.1002/hep.1840050320; RIMOLA A, 1988, J HEPATOL, V7, P72; RUNYON BA, 1988, HEPATOLOGY, V8, P171, DOI 10.1002/hep.1840080131; RUNYON BA, 1991, GASTROENTEROLOGY, V100, P1737, DOI 10.1016/0016-5085(91)90677-D; RUNYON BA, 1986, GASTROENTEROLOGY, V91, P1343, DOI 10.1016/0016-5085(86)90185-X; Schubert M L, 1991, Gastroenterology, V101, P550; SINGH N, 1994, DIAGN MICR INFEC DIS, V19, P1, DOI 10.1016/0732-8893(94)90042-6; SORIANO G, 1991, GASTROENTEROLOGY, V100, P477, DOI 10.1016/0016-5085(91)90219-B; TOLKOFFRUBIN NE, 1982, REV INFECT DIS, V4, P614	20	148	153	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					595	598		10.7326/0003-4819-122-8-199504150-00007	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887554				2022-12-28	WOS:A1995QR52500007
J	HABER, DA				HABER, DA			TELOMERES, CANCER, AND IMMORTALITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN FIBROBLASTS				HABER, DA (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02129, USA.							ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428	7	25	30	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					955	956		10.1056/NEJM199504063321412	http://dx.doi.org/10.1056/NEJM199504063321412			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877656				2022-12-28	WOS:A1995QP89300012
J	GLANTZ, SA; PARMLEY, WW				GLANTZ, SA; PARMLEY, WW			PASSIVE SMOKING AND HEART-DISEASE - MECHANISMS AND RISK	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; CIGARETTE-SMOKE; CARBON-MONOXIDE; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; EXERCISE PERFORMANCE; PLATELET SENSITIVITY; TOBACCO-SMOKE; LUNG-CANCER; ENDOTHELIUM	Objective.-Recent clinical, laboratory, and epidemiological evidence that passive smoking causes heart disease was reviewed, with particular emphasis on understanding the underlying physiological and biochemical mechanisms. Data Sources.-Publications in the peer-reviewed literature were located via MEDLINE, citation in other relevant articles, and appropriate reports by scientific agencies, Greatest emphasis was given to work published since 1990. Conclusions.-Passive smoking reduces the blood's ability to deliver oxygen to the heart and compromises the myocardium's ability to use oxygen to create adenosine triphosphate. These effects are manifest as reduced exercise capability in people breathing secondhand smoke, Secondhand smoke increases platelet activity, accelerates atherosclerotic lesions, and increases tissue damage following ischemia or myocardial infarction. The effects of secondhand tobacco smoke on the cardiovascular system are not caused by a single component of the smoke, but rather are caused by the effects of many elements, including carbon monoxide, nicotine, polycyclic aromatic hydrocarbons, and other, not fully specified elements in the smoke. Nonsmokers exposed to secondhand smoke in everyday life exhibit an increased risk of both fatal and nonfatal cardiac events.			GLANTZ, SA (corresponding author), UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED, DIV CARDIOL, SAN FRANCISCO, CA 94143 USA.							ALLRED EN, 1989, NEW ENGL J MED, V321, P1426, DOI 10.1056/NEJM198911233212102; ANDERSON R, 1991, AM REV RESPIR DIS, V144, P570, DOI 10.1164/ajrccm/144.3_Pt_1.570; [Anonymous], 1986, ENV TOBACCO SMOKE ME; ARONOW WS, 1978, NEW ENGL J MED, V299, P21, DOI 10.1056/NEJM197807062990105; BENOWITZ NL, 1993, J AM COLL CARDIOL, V22, P1159, DOI 10.1016/0735-1097(93)90431-Y; BENOWITZ NL, 1991, TRENDS CARDIOVAS MED, V1, P315, DOI 10.1016/1050-1738(91)90068-P; BERO LA, 1994, JAMA-J AM MED ASSOC, V272, P133, DOI 10.1001/jama.272.2.133; BURGHUBER OC, 1986, CHEST, V90, P34, DOI 10.1378/chest.90.1.34; BUTLER TL, 1988, RELATIONSHIP PASSIVE; BUTLER TL, 1990, 7TH WORLD C TOB HLTH; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111, DOI 10.2307/3430003; DAVIS JW, 1985, CLIN PHARMACOL THER, V37, P529, DOI 10.1038/clpt.1985.83; DAVIS JW, 1987, HAEMOSTASIS, V17, P66; DAVIS JW, 1989, ARCH INTERN MED, V149, P386, DOI 10.1001/archinte.149.2.386; DAVIS JW, 1986, BRIT J EXP PATHOL, V67, P765; DAVIS JW, 1985, J LAB CLIN MED, V105, P479; DOBSON AJ, 1991, MED J AUSTRALIA, V154, P793, DOI 10.5694/j.1326-5377.1991.tb121366.x; DWYER EM, 1989, NEW ENGL J MED, V321, P1474, DOI 10.1056/NEJM198911233212110; FELDMAN J, 1991, PEDIATRICS, V88, P259; FENTON RA, 1985, AM J PHYSIOL, V249, pH463, DOI 10.1152/ajpheart.1985.249.3.H463; FERRARI R, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90291-5; GARLAND C, 1985, AM J EPIDEMIOL, V121, P645, DOI 10.1093/aje/121.5.645; GIDDING SS, 1994, CIRCULATION, V90, P2581; GLANTZ SA, 1991, CIRCULATION, V83, P1, DOI 10.1161/01.CIR.83.1.1; GLANTZ SA, 1994, JAMA-J AM MED ASSOC, V271, P660, DOI 10.1001/jama.1994.03510330037022; Gvozdjak J, 1987, Czech Med, V10, P47; GVOZDJAKOVA A, 1992, CARDIOLOGY, V81, P81, DOI 10.1159/000175780; HE Y, 1994, BRIT MED J, V308, P380, DOI 10.1136/bmj.308.6925.380; HE Y, 1989, CHIN J PREV MED, V23, P19; HELSING KJ, 1988, AM J EPIDEMIOL, V127, P915, DOI 10.1093/oxfordjournals.aje.a114894; HIRAYAMA T, 1990, NEW ZEAL MED J, V103, P54; HOLE DJ, 1989, BRIT MED J, V299, P423, DOI 10.1136/bmj.299.6696.423; HOWARD G, 1994, ARCH INTERN MED, V154, P1277; HUMBLE C, 1990, AM J PUBLIC HEALTH, V80, P599, DOI 10.2105/AJPH.80.5.599; HUNT SC, 1986, ANN AM PUBLIC HLTH A; JACKSON RT, 1989, AUCKLAND HEART STUDY; KHAIFEN ES, 1987, ARKH, V59, P112; KOOL MJF, 1993, J AM COLL CARDIOL, V22, P1881, DOI 10.1016/0735-1097(93)90773-T; Lamb DH., 1984, PHYSL EXERCISE RESPO; LAVECCHIA C, 1993, LANCET, V341, P505, DOI 10.1016/0140-6736(93)90271-H; LEE PN, 1989, NEW ZEAL MED J, V102, P448; LEONE A, 1992, Journal of the American College of Cardiology, V19, p256A; LEONE A, 1993, INT J CARDIOL, V38, P113, DOI 10.1016/0167-5273(93)90169-H; MARTIN JF, 1991, LANCET, V338, P1409, DOI 10.1016/0140-6736(91)92719-I; MCCUSKER K, 1990, AM REV RESPIR DIS, V141, P678, DOI 10.1164/ajrccm/141.3.678; MCMURRAY RG, 1985, EUR J APPL PHYSIOL O, V54, P196, DOI 10.1007/BF02335929; MIYAURA S, 1992, CIRC RES, V70, P341, DOI 10.1161/01.RES.70.2.341; MOSKOWITZ WB, 1990, CIRCULATION, V81, P586, DOI 10.1161/01.CIR.81.2.586; MOSKOWITZ WB, 1993, PEDIATR RES, V33, P645, DOI 10.1203/00006450-199306000-00022; Ott W., 1992, J EXPO ANAL ENV EPID, V2, P175; Palmer JR, 1988, CVD EPIDEMIOL NEWSLE, V43, P29; PENN A, 1993, CIRCULATION, V88, P1820, DOI 10.1161/01.CIR.88.4.1820; PENN A, 1994, CIRCULATION, V90, P1363, DOI 10.1161/01.CIR.90.3.1363; PENN A, 1992, EUR J PHARM-ENVIRON, V228, P155, DOI 10.1016/0926-6917(92)90025-8; Pierce JP, 1994, TOBACCO USE CALIFORN; Pierce JP, 1994, TOB CONTROL, V3, P15, DOI DOI 10.1136/TC.3.1.15; PITTILO RM, 1982, THROMB HAEMOSTASIS, V48, P173; POMREHN P, 1990, CIRCULATION, V81, P726; PRENTICE R C, 1989, Journal of the American College of Cardiology, V13, p124A; PREROVSKY I, 1979, BLOOD VESSELS, V16, P239; PRZYKLENK K, 1994, CIRCULATION, V89, P1272, DOI 10.1161/01.CIR.89.3.1272; QUILLEN JE, 1993, J AM COLL CARDIOL, V22, P642, DOI 10.1016/0735-1097(93)90170-6; RENNIE D, 1993, JAMA-J AM MED ASSOC, V270, P1742, DOI 10.1001/jama.270.14.1742; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P1575, DOI 10.1001/jama.1994.03510440035021; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; SANDLER DP, 1989, AM J PUBLIC HEALTH, V79, P163, DOI 10.2105/AJPH.79.2.163; SHEPS DS, 1990, ANN INTERN MED, V113, P343, DOI 10.7326/0003-4819-113-5-343; SIEGEL M, 1993, JAMA-J AM MED ASSOC, V270, P490, DOI 10.1001/jama.270.4.490; SINZINGER H, 1989, WIEN KLIN WOCHENSCHR, V101, P694; SINZINGER H, 1982, LANCET, V2, P392; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V267, P94, DOI 10.1001/jama.267.1.94; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STILLMAN FA, 1990, JAMA-J AM MED ASSOC, V264, P1565, DOI 10.1001/jama.264.12.1565; SUN YP, 1994, CIRCULATION, V89, P2260, DOI 10.1161/01.CIR.89.5.2260; SVENDSEN KH, 1987, AM J EPIDEMIOL, V126, P783, DOI 10.1093/oxfordjournals.aje.a114715; TAYLOR AE, 1992, CIRCULATION, V86, P1; VANJAARSVELD H, 1992, FREE RADICAL RES COM, V17, P263, DOI 10.3109/10715769209079518; VANJAARSVELD H, 1992, BASIC RES CARDIOL, V87, P393; WALD NJ, 1986, BMJ-BRIT MED J, V293, P1217, DOI 10.1136/bmj.293.6556.1217; WELLS AJ, 1994, J AM COLL CARDIOL, V24, P546, DOI 10.1016/0735-1097(94)90315-8; WELLS AJ, 1988, ENVIRON INT, V14, P249; WHITE JR, 1992, 8TH WORLD C TOB HLTH; WOODRUFF TJ, 1993, ARCH INTERN MED, V153, P1485, DOI 10.1001/archinte.153.12.1485; WU JM, 1993, J AM COLL CARDIOL, V22, P1751, DOI 10.1016/0735-1097(93)90611-4; WUWILLIAMS AH, 1990, RISK ANAL, V10, P39, DOI 10.1111/j.1539-6924.1990.tb01018.x; ZHU BQ, 1993, J AM COLL CARDIOL, V21, P225, DOI 10.1016/0735-1097(93)90741-I; ZHU BQ, 1994, CIRCULATION, V89, P1282, DOI 10.1161/01.CIR.89.3.1282; ZHU BQ, 1993, J AM COLL CARDIOL, V22, P1752, DOI 10.1016/0735-1097(93)90612-5; 1994, CARDIOVASCULAR HLTH; 1983, DHHS PHS8450204 US D; 1990, UESPA600890045A DOC; 1995, CONSUM REP, V60, P27; 1986, DHHS CDC878398 CTR D; 1994, FED REG         0405, V59, P15968; 1992, EPA600690006F DOC; 1991, CURRENT INTELLIGENCE, V54; 1990, PHS DHHS CDC908416 U	97	336	343	1	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1047	1053		10.1001/jama.273.13.1047	http://dx.doi.org/10.1001/jama.273.13.1047			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897790				2022-12-28	WOS:A1995QP89000037
J	HALDER, G; CALLAERTS, P; GEHRING, WJ				HALDER, G; CALLAERTS, P; GEHRING, WJ			INDUCTION OF ECTOPIC EYES BY TARGETED EXPRESSION OF THE EYELESS GENE IN DROSOPHILA	SCIENCE			English	Article							MEDIATED ENHANCER DETECTION; HOMEOBOX-CONTAINING GENE; BASE-PAIRS; HOX CODES; MELANOGASTER; ANTENNAPEDIA; REGION; TRANSFORMATIONS; CHROMOSOME; VERTEBRAE	The Drosophila gene eyeless (ey) encodes a transcription factor with both a paired domain and a homeodomain. It is homologous to the mouse Small eye (Pax-6) gene and to the Aniridia gene in humans. These genes share extensive sequence identity, the position of three intron splice sites is conserved, and these genes are expressed similarly in the developing nervous system and in the eye during morphogenesis. Loss-of-function mutations in both the insect and in the mammalian genes have been shown to lead to a reduction or absence of eye structures, which suggests that ey functions in eye morphogenesis. By targeted expression of the ey com plementary DNA in various imaginal disc primordia of Drosophila, ectopic eye structures were induced on the wings, the legs, and on the antennae. The ectopic eyes appeared morphologically normal and consisted of groups of fully differentiated ommatidia with a complete set of photoreceptor cells. These results support the proposition that ey is the master control gene for eye morphogenesis, Because homologous genes are present in vertebrates, ascidians, insects, cephalopods, and nemerteans, ey may function as a master control gene throughout the metazoa.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel			Halder, Georg/F-2966-2015; Callaerts, Patrick/I-8118-2013	Halder, Georg/0000-0001-7580-3236; Callaerts, Patrick/0000-0003-4530-4561				[Anonymous], COMMUNICATION; ASHBURNER M, 1989, LABORATORY MANUAL; BACHILLER D, 1994, EMBO J, V13, P1930, DOI 10.1002/j.1460-2075.1994.tb06462.x; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BOSSY B, 1984, EMBO J, V3, P2537, DOI 10.1002/j.1460-2075.1984.tb02169.x; Botas J, 1993, CURR OPIN CELL BIOL, V5, P1015, DOI 10.1016/0955-0674(93)90086-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRIDGES CB, 1935, Z BIOL, V4, P401; CALLAERTS P, UNPUB; CASTELLIGAIR J, 1994, DEVELOPMENT, V120, P1983; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; Dickson Barry, 1993, P1327; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; GAUSZ J, 1986, GENETICS, V112, P65; GEHRING WJ, 1987, SCIENCE, V236, P1245, DOI 10.1126/science.2884726; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; GIBSON G, 1988, DEVELOPMENT, V102, P657; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GONZALEZREYES A, 1990, NATURE, V344, P78, DOI 10.1038/344078a0; GONZALEZREYES A, 1990, CELL, V61, P515, DOI 10.1016/0092-8674(90)90533-K; HALL LMC, 1983, J MOL BIOL, V169, P83, DOI 10.1016/S0022-2836(83)80176-4; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOCHMANN B, 1971, GENETICS, V62, P235; Hoge MA, 1915, AM NAT, V49, P47, DOI 10.1086/279455; HUNT P, 1992, ANNU REV CELL BIOL, V8, P227, DOI 10.1146/annurev.cb.08.110192.001303; HUNT P, 1991, NATURE, V353, P861, DOI 10.1038/353861a0; KESSEL M, 1990, CELL, V61, P301, DOI 10.1016/0092-8674(90)90810-2; KESSEL M, 1991, CELL, V67, P89, DOI 10.1016/0092-8674(91)90574-I; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAMKA M, 1992, DEVELOPMENT, V116, P8412; LEWIS EB, 1978, NATURE, V276, P565, DOI 10.1038/276565a0; Lindsley D.L., 1992, GENOME DROSOPHILA ME, P1133; MALICKI J, 1990, CELL, V63, P961, DOI 10.1016/0092-8674(90)90499-5; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; Meinertzhagen Ian A., 1993, P1363; MIRKOVITCH J, 1986, J MOL BIOL, V190, P255, DOI 10.1016/0022-2836(86)90296-2; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; Pirrotta V, 1988, VECTORS SURVEY MOL C, P437; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SERIKAKU MA, 1994, GENETICS, V138, P1137; Spemann H., 1938, EMBRYONIC DEV INDUCT; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; WOLFF R, 1993, DEV DROSOPHILA MELAN, P1277; ZHAO JJ, 1993, GENE DEV, V7, P343, DOI 10.1101/gad.7.3.343; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	53	1155	1198	3	167	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1788	1792		10.1126/science.7892602	http://dx.doi.org/10.1126/science.7892602			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892602				2022-12-28	WOS:A1995QN70200029
J	JO, K; TOPAL, MD				JO, K; TOPAL, MD			DNA TOPOISOMERASE AND RECOMBINASE ACTIVITIES IN NAE-I RESTRICTION-ENDONUCLEASE	SCIENCE			English	Article							SITE-SPECIFIC RECOMBINATION; RECOGNITION SITES; ECORII; CONFORMATION; INTEGRATION; SPERMIDINE; ACTIVATION; MECHANISM; CLEAVAGE; BINDING	Nae I endonuclease must bind to two DNA sequences for cleavage. Examination of the amino acid sequence of Nae I uncovered similarity to the active site of human DNA ligase I, except for leucine 43 in Nae I instead of the lysine essential for ligase activity. Changing leucine 43 to lysine 43 (L43K) changed Nae I activity: Nae I-L43K relaxed supercoiled DNA to yield DNA topoisomers and recombined DNA to give dimeric molecules. Interruption of the reactions of Nae I and Nae I-L43K with DNA demonstrated transient protein-DNA covalent complexes. These findings imply coupled endonuclease and ligase domains and link Nae I endonuclease to the topoisomerase and recombinase protein families.	UNIV N CAROLINA, SCH MED, DEPT BIOCHEM & BIOPHYS, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, SCH MED, DEPT PATHOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARBER W, 1990, J STRUCT BIOL, V104, P107, DOI 10.1016/1047-8477(90)90064-J; BAXTER BK, 1993, BIOCHEMISTRY-US, V32, P8291, DOI 10.1021/bi00083a033; CHANG S, 1977, P NATL ACAD SCI USA, V74, P4811, DOI 10.1073/pnas.74.11.4811; COLUMNA EA, 1993, ENVIRON MOL MUTAGEN, V22, P26, DOI 10.1002/em.2850220106; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; CRAIG NL, 1988, ANNU REV GENET, V22, P77; GABBARA S, 1992, J BIOL CHEM, V267, P18623; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; HOLTZ JK, 1994, J BIOL CHEM, V269, P27286; Kornberg A., 1991, DNA REPLICATION; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; LINDAHL T, 1992, ANNU REV BIOCHEM, V61, P251, DOI 10.1146/annurev.bi.61.070192.001343; OGORMAN S, 1991, SCIENCE, V251, P1351, DOI 10.1126/science.1900642; OLLER AR, 1991, BIOCHEMISTRY-US, V30, P2543, DOI 10.1021/bi00223a035; PICHEL JG, 1993, ONCOGENE, V8, P3333; REUTER M, 1993, ANAL BIOCHEM, V209, P232, DOI 10.1006/abio.1993.1113; ROBERTS RJ, 1976, CRC CR REV BIOCH MOL, V4, P123, DOI 10.3109/10409237609105456; SAUER B, 1990, New Biologist, V2, P441; SCHIESTL RH, 1991, P NATL ACAD SCI USA, V88, P7585, DOI 10.1073/pnas.88.17.7585; THRESHER R, 1992, METHOD ENZYMOL, V211, P481; TOPAL MD, 1993, NUCLEIC ACIDS RES, V21, P2599, DOI 10.1093/nar/21.11.2599; TOPAL MD, 1991, BIOCHEMISTRY-US, V30, P2006, DOI 10.1021/bi00221a038; VOSBERG HP, 1985, CURR TOP MICROBIOL, V114, P19; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019; YANG CC, 1994, BIOCHEMISTRY-US, V33, P14918, DOI 10.1021/bi00253a031	27	54	55	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1817	1820		10.1126/science.7892605	http://dx.doi.org/10.1126/science.7892605			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892605				2022-12-28	WOS:A1995QN70200038
J	KUMAR, J; YU, H; SHEETZ, MP				KUMAR, J; YU, H; SHEETZ, MP			KINECTIN, AN ESSENTIAL ANCHOR FOR KINESIN-DRIVEN VESICLE MOTILITY	SCIENCE			English	Article							CYTOPLASMIC DYNEIN; AXONAL-TRANSPORT; MOTOR; MICROTUBULES; CELLS; ORGANELLES; PROTEINS; MOVEMENT; GRANULES; INVITRO	The membrane anchor for the molecular motor kinesin is a critical site involved in intracellular membrane trafficking. Monoclonal antibodies specific for the; cytoplasmic surface of chick brain microsomes were used to define proteins involved in microtubule-dependent transport. One of four antibodies tested inhibited plus-end-directed vesicle motility by approximately 90 percent even as a monovalent Fab fragment and reduced kinesin binding to vesicles. This antibody bound to the cytoplasmic domain of kinectin, an integral membrane protein of the endoplasmic reticulum that binds to kinesin. Thus, kinectin acted as a membrane anchor protein for kinesin-driven vesicle motility.	DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA	Duke University			Yu, Hanry/C-7375-2011; Yu, Hanry/C-1031-2013; Yu, Hanry/L-6050-2019	Yu, Hanry/0000-0002-0339-3685; Yu, Hanry/0000-0002-0339-3685	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023345] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 23345] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; BOMSEL M, 1990, CELL, V62, P719, DOI 10.1016/0092-8674(90)90117-W; BRADY ST, 1990, P NATL ACAD SCI USA, V87, P1061, DOI 10.1073/pnas.87.3.1061; BRADY ST, 1991, NEURON, V7, P521, DOI 10.1016/0896-6273(91)90365-7; BURKHARDT JK, 1993, J CELL SCI, V104, P151; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; HARLOW E, 1988, ANTIBODIES LABORATOR; HOLLENBECK PJ, 1990, NATURE, V346, P864, DOI 10.1038/346864a0; HYMAN A, 1991, METHOD ENZYMOL, V196, P478; KUMAR J, UNPUB; LACEY ML, 1994, CELL MOTIL CYTOSKEL, V28, P205, DOI 10.1002/cm.970280304; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCILVAIN JM, 1994, J BIOL CHEM, V269, P19176; RODIONOV VI, 1993, J CELL BIOL, V123, P1811, DOI 10.1083/jcb.123.6.1811; RODIONOV VI, 1991, P NATL ACAD SCI USA, V88, P4956, DOI 10.1073/pnas.88.11.4956; SCHNAPP BJ, 1989, P NATL ACAD SCI USA, V86, P1548, DOI 10.1073/pnas.86.5.1548; SCHROER TA, 1988, J CELL BIOL, V107, P1785, DOI 10.1083/jcb.107.5.1785; SCHROER TA, 1989, CELL, V56, P937, DOI 10.1016/0092-8674(89)90627-2; SCHROER TA, 1991, J CELL BIOL, V115, P1309, DOI 10.1083/jcb.115.5.1309; SCHROER TA, 1991, ANNU REV PHYSIOL, V53, P629, DOI 10.1146/annurev.ph.53.030191.003213; SHEETZ MP, 1986, J CELL SCI, P181; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; STEUER ER, 1990, NATURE, V345, P266, DOI 10.1038/345266a0; TOYOSHIMA I, 1992, J CELL BIOL, V118, P1121, DOI 10.1083/jcb.118.5.1121; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; YU H, 1992, J BIOL CHEM, V267, P20457; YU H, IN PRESS MOL BIOL CE	29	135	137	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1834	1837		10.1126/science.7892610	http://dx.doi.org/10.1126/science.7892610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892610				2022-12-28	WOS:A1995QN70200043
J	MATZUK, MM; KUMAR, TR; BRADLEY, A				MATZUK, MM; KUMAR, TR; BRADLEY, A			DIFFERENT PHENOTYPES FOR MICE DEFICIENT IN EITHER ACTIVINS OR ACTIVIN RECEPTOR-TYPE-II	NATURE			English	Article							EXPRESSION; GENE; RAT; INHIBIN	ACTIVINS are believed to initiate a signal transduction cascade by binding to serine/threonine kinase receptors types I and II1-3. Activins(4) bind to several different receptors in vitro(1-3), but the significance of this interaction in vivo has not been confirmed. To test the function of the type II activin receptor (ActRcII) in mammalian development and reproduction, we generated a null mutation in the ActRcII gene in mice using embryonic stem cell technology. We expected ActRcII-deficient mice to phenocopy activin-deficient mice. A few ActRcII-deficient mice had skeletal and facial abnormalities reminiszzcent of the Pierre-Robin syndrome in humans(5,6), but most lacked these defects and developed into adults; their follicle-stimulating hormone was suppressed, and their reproductive performance was defective. These findings confirm a role of ActRcII in activin signalling in pituitary gonadotrophs. The striking lack of overlap between phenotypes of ActRcII-deficient and activin-deficient mice suggests that the ligands that signal through ActRcII during embryonic development are not activins.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Howard Hughes Medical Institute	MATZUK, MM (corresponding author), BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030, USA.			Bradley, Allan/0000-0002-2349-8839				Bradley A, 1987, TERATOCARCINOMAS EMB, P113; CAMERON VA, 1994, ENDOCRINOLOGY, V134, P799, DOI 10.1210/en.134.2.799; CAOUETTELABERGE L, 1994, PLAST RECONSTR SURG, V93, P934, DOI 10.1097/00006534-199404001-00006; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CLARKE L, 1988, TERATOLOGY, V38, P565, DOI 10.1002/tera.1420380604; DEWINTER JP, 1992, MOL CELL ENDOCRINOL, V83, pR1, DOI 10.1016/0303-7207(92)90201-G; FEIJEN A, 1994, DEVELOPMENT, V120, P3621; FENG ZM, 1993, ENDOCRINOLOGY, V132, P2593, DOI 10.1210/en.132.6.2593; HEMMATIBRIVANLO.A, 1994, CELL, V77, P273; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; KAIPIA A, 1994, ENDOCRINOLOGY, V134, P2165, DOI 10.1210/en.134.5.2165; KUMAR TR, 1992, MOL ENDOCRINOL, V6, P81, DOI 10.1210/me.6.1.81; MATHER JP, 1990, ENDOCRINOLOGY, V127, P3206, DOI 10.1210/endo-127-6-3206; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1992, BIOCHEM BIOPH RES CO, V185, P404, DOI 10.1016/S0006-291X(05)81000-9; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; RAMIREZSOLIS R, 1993, CELL, V83, P279; RITZEN EM, 1989, TESTIS, P269; ROBERTS VJ, 1994, ENDOCRINOLOGY, V134, P914, DOI 10.1210/en.134.2.914; SCHULTEMERKER S, 1994, EMBO J, V13, P3533, DOI 10.1002/j.1460-2075.1994.tb06660.x; SHIKONE T, 1994, MOL ENDOCRINOL, V8, P983, DOI 10.1210/me.8.8.983; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; VALE W, 1990, PEPTIDE GROWTH FACTO, V2, P211; VASSALLI A, 1994, GENE DEV, V8, P414, DOI 10.1101/gad.8.4.414; WOODRUFF TK, 1990, ENDOCRINOLOGY, V127, P3196, DOI 10.1210/endo-127-6-3196	28	480	515	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					356	360		10.1038/374356a0	http://dx.doi.org/10.1038/374356a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885474				2022-12-28	WOS:A1995QN63000059
J	PAUL, DB; SPENCER, HG				PAUL, DB; SPENCER, HG			THE HIDDEN SCIENCE OF EUGENICS	NATURE			English	Editorial Material							GENETICS		UNIV OTAGO,DEPT ZOOL,DUNEDIN,NEW ZEALAND	University of Otago	PAUL, DB (corresponding author), UNIV MASSACHUSETTS,DEPT POLIT SCI,BOSTON,MA 02125, USA.		Spencer, Hamish G/B-9637-2008	Spencer, Hamish G/0000-0001-7531-597X; Paul, Diane/0000-0003-4053-0121				BARKER D, 1989, BRIT J HIST SCI, V22, P347, DOI 10.1017/S0007087400026200; Brigham C.C., 1923, STUDY AM INTELLIGENC; BROBERG G, IN PRESS EUGENICS WE; CAPLAN AL, 1993, PRESCRIBING OUR FUTU, P149; CONKLIN EG, 1930, HUMAN BIOL POPULATIO, P577; CUMMINGS MR, 1991, HUMAN HEREDITY PRINC, P436; CURTIS H, 1989, BIOLOGY, P987; DAVENPORT CB, 1912, HEREDITY EUGENICS, P286; Deichmann U., 1994, SCI TECHNOLOGY NATL, P160; East EM, 1917, J HERED, V8, P215, DOI 10.1093/oxfordjournals.jhered.a111772; EMERY AEH, 1992, ELEMENTS MED GENETIC; FISHER RA, 1924, EUGEN REV, V26, P114; GRIFFITHS AJF, 1993, INTRO GENETIC ANAL, P759; HALDANE JBS, 1938, HEREDITY POLITICS, P80; HARWOOD J, 1989, BRIT J HIST SCI, V22, P257, DOI 10.1017/S0007087400026145; HOGBEN L, 1931, GENETIC PRINCIPLES M, P207; Jennings HS, 1927, J HERED, V18, P271, DOI 10.1093/oxfordjournals.jhered.a102871; JENNINGS HS, 1930, BIOL BASIS HUMAN NAT, P238; LAUGHLIN HH, 1914, EUGENICS RECORD OF A, V10; MORGAN TH, 1925, EVOLUTION GENETICS, P201; PAUL DB, 1988, AM J HUM GENET, V43, P344; Penrose Lionel, 1949, BIOL MENTAL DEFECT; POPENOE P, 1918, APPLIED EUGENICS, V105, P170; Popenoe Paul, 1915, J HERED, V6, P32; PROVINE WB, 1971, ORIGINS THEORETICAL, P137; Punnett, 1925, 19TH CENTURY, V97, P697; Punnett RC, 1917, J HERED, V8, P464, DOI 10.1093/oxfordjournals.jhered.a111653; STERN C, 1949, PRINCIPLES HUMAN GEN, P538; STRICKBERGER MW, 1985, GENETICS, P693; 1990, J MED GENET, V27, P34	30	32	33	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					302	304		10.1038/374302a0	http://dx.doi.org/10.1038/374302a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885463				2022-12-28	WOS:A1995QN63000025
J	MARTENSEN, RL				MARTENSEN, RL			CARING FOR THE CHRONICALLY MENTALLY-ILL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									HARVARD UNIV,SCH MED,DEPT SOCIAL MED,BOSTON,MA 02125	Harvard University; Harvard Medical School	MARTENSEN, RL (corresponding author), BRIGHAM & WOMENS HOSP,DEPT EMERGENCY MED,641 HUNTINGTON AVE,BOSTON,MA 01225, USA.							ALZHEIMER A, 1969, ARCH NEUROL-CHICAGO, V21, P109; BROWNE JC, 1874, BMJ             0516, P640; BROWNE JC, 1974, BMJ             0516, P601; COWLES E, 1897, BOSTON MED SURG J, V137, P277; Digby, 1985, MADNESS MORALITY MED; DIX D, 1943, MEMORIAL LEGISLATURE, P4; Grob Gerald N., 1994, MAD US; RIGGS DE, 1895, AM J INSANITY, V51, P318; Tomes N., 1984, GENEROUS CONFIDENCE, V1st ed.	9	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					923	923						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884949				2022-12-28	WOS:A1995QM17300025
J	ALLANDER, T; GRUBER, A; NAGHAVI, M; BEYENE, A; SODERSTROM, T; BJORKHOLM, M; GRILLNER, L; PERSSON, MAA				ALLANDER, T; GRUBER, A; NAGHAVI, M; BEYENE, A; SODERSTROM, T; BJORKHOLM, M; GRILLNER, L; PERSSON, MAA			FREQUENT PATIENT-TO-PATIENT TRANSMISSION OF HEPATITIS-C VIRUS IN A HEMATOLOGY WARD	LANCET			English	Article							POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; NON-A; REGION; INFECTION; ANTIBODY; GENOME; RNA	Blood transfusion is a well-documented route of transmission of hepatitis C virus (HCV). However, a persisting high frequency of HCV infections was recorded in our haematology ward even after screening of blood donors had been introduced. We investigated the viral strains in 37 patients with haematological malignant diseases who had developed hepatitis C when treated in the ward during 1990-93. 17 of the patients acquired hepatitis C despite being transfused only with blood components screened by second-generation anti-HCV tests. The viral strains were characterised by PCR genotyping and nucleotide sequencing of the hypervariable region of the E2 gene. Five clusters of closely related or identical viruses were found involving 2, 3, 4, 6, and 15 patients, respectively. Blood components could be ruled out as the common source of infection because no donor had given blood to all patients sharing a specific strain, and even donors whose blood had been given to several patients were negative for HCV RNA. All patients in each cluster had been treated in the ward during overlapping periods. These findings suggest that despite strict hygienic control, HCV transmission occurred between patients treated in the same hospital setting, as has previously been reported in a smaller group of haemodialysis patients.	KAROLINSKA INST,KAROLINSKA HOSP,DEPT MED,S-17176 STOCKHOLM,SWEDEN; KAROLINSKA INST,KAROLINSKA HOSP,DEPT LAB MED,S-17176 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital				Persson, Mats/0000-0002-5118-6584				ALLANDER T, 1994, J MED VIROL, V43, P415, DOI 10.1002/jmv.1890430417; ALTER HJ, 1989, NEW ENGL J MED, V321, P1494, DOI 10.1056/NEJM198911303212202; ALTER MJ, 1990, JAMA-J AM MED ASSOC, V264, P2231, DOI 10.1001/jama.264.17.2231; ARICO M, 1994, BLOOD, V84, P2919; CHANT K, 1994, NEW S WALES PUBLIC H, V5, P47; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FEUCHT HH, 1994, MICROBIOL IMMUNOL, V38, P157, DOI 10.1111/j.1348-0421.1994.tb01758.x; GRUBER A, 1993, ANN ONCOL, V4, P229, DOI 10.1093/oxfordjournals.annonc.a058462; HIGASHI Y, 1993, VIROLOGY, V197, P659, DOI 10.1006/viro.1993.1641; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; OKADA S, 1992, HEPATOLOGY, V16, P619, DOI 10.1002/hep.1840160302; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; TAKAMATSU K, 1990, LANCET, V336, P1515, DOI 10.1016/0140-6736(90)93229-I; WIDELL A, 1994, J MED VIROL, V44, P272, DOI 10.1002/jmv.1890440311; WIDELL A, 1991, J MED VIROL, V35, P253, DOI 10.1002/jmv.1890350409	17	188	189	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					603	607		10.1016/S0140-6736(95)90518-9	http://dx.doi.org/10.1016/S0140-6736(95)90518-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898176				2022-12-28	WOS:A1995QM07500006
J	RIMM, EB; CHAN, J; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC				RIMM, EB; CHAN, J; STAMPFER, MJ; COLDITZ, GA; WILLETT, WC			PROSPECTIVE-STUDY OF CIGARETTE-SMOKING, ALCOHOL-USE, AND THE RISK OF DIABETES IN MEN	BRITISH MEDICAL JOURNAL			English	Article							BODY-FAT DISTRIBUTION; MIDDLE-AGED MEN; GLUCOSE-TOLERANCE; INSULIN RESISTANCE; PHYSICAL-ACTIVITY; FOLLOW-UP; MELLITUS; WOMEN; CONSUMPTION; POPULATION	Objective-To examine the association between smoking, alcohol consumption, and the incidence of non-insulin dependent diabetes mellitus in men of middle years and older. Design-Cohort questionnaire study of men followed up for six years from 1986. Setting-The health professionals' follow up study being conducted across the United States. Subjects-41 810 male health professionals aged 40-75 years and free of diabetes, cardiovascular disease, and cancer in 1986 and followed up for six years. Main outcome meausre-Incidence of non-insulin dependent diabetes mellitus diagnosed in the six years. Results-During 230 769 person years of follow up 509 men were newly diagnosed with diabetes. After controlling for known risk factors men who smoked 25 or more cigarettes daily had a relative risk of diabetes of 1 . 94 (95% confidence interval 1 . 25 to 3 . 03) compared with non-smokers. Men who consumed higher amounts of alcohol had a reduced risk of diabetes (P for trend <0 . 001). Compared with abstainers men who drank 30 . 0-49 . 9 g of alcohol daily had a relative risk of diabetes of 0 . 61 (95% confidence interval 0 . 44 to 0 . 91). Conclusions-Cigarette smoking may be an independent, modifiable risk factor for non-insulin dependent diabetes mellitus. Moderate alcohol consumption among healthy people may be associated with increased insulin sensitivity and a reduced risk of diabetes.			RIMM, EB (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; Chan, June/0000-0002-7620-569X	NCI NIH HHS [CA 55075] Funding Source: Medline; NHLBI NIH HHS [HL 35464] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBANES D, 1987, AM J PUBLIC HEALTH, V77, P439, DOI 10.2105/AJPH.77.4.439; ALDOORI WH, IN PRESS GUT; ARKY RA, 1989, ENDOCRIN METAB CLIN, V18, P75, DOI 10.1016/S0889-8529(18)30389-X; BALKAU B, 1991, J CLIN EPIDEMIOL, V44, P465, DOI 10.1016/0895-4356(91)90209-R; BALKAU B, 1991, AM J EPIDEMIOL, V134, P1469, DOI 10.1093/oxfordjournals.aje.a116056; BARRETTCONNOR E, 1989, EPIDEMIOL REV, V11, P172, DOI 10.1093/oxfordjournals.epirev.a036035; Boffetta P, 1990, Epidemiology, V1, P342, DOI 10.1097/00001648-199009000-00003; BUTLER WJ, 1982, AM J EPIDEMIOL, V116, P971, DOI 10.1093/oxfordjournals.aje.a113499; CHAN JM, 1994, DIABETES CARE, V17, P1; CHRISTIANSEN C, 1994, BRIT J NUTR, V71, P449, DOI 10.1079/BJN19940151; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; EISEN SA, 1993, ARCH INTERN MED, V153, P2457, DOI 10.1001/archinte.153.21.2457; FACCHINI F, 1994, DIABETES CARE, V17, P115, DOI 10.2337/diacare.17.2.115; FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; GIN H, 1992, DIABETES CARE, V15, P546, DOI 10.2337/diacare.15.4.546; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; HARRIS MI, 1985, DIABETES AM DIABETES, V6; HARTZ AJ, 1984, AM J EPIDEMIOL, V119, P71, DOI 10.1093/oxfordjournals.aje.a113727; HODGE AM, 1993, AM J EPIDEMIOL, V137, P178, DOI 10.1093/oxfordjournals.aje.a116658; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; JANZON L, 1983, DIABETOLOGIA, V25, P86; JARRETT RJ, 1989, EPIDEMIOL REV, V11, P151, DOI 10.1093/oxfordjournals.epirev.a036034; KROTKIEWSKI M, 1983, J CLIN INVEST, V72, P1150, DOI 10.1172/JCI111040; KUUSISTO J, 1994, DIABETES, V43, P960, DOI 10.2337/diabetes.43.8.960; MACMAHON B, 1982, CANCER-AM CANCER SOC, V50, P2676; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MAYER EJ, 1993, CIRCULATION, V88, P2190, DOI 10.1161/01.CIR.88.5.2190; MEDALIE JH, 1975, ARCH INTERN MED, V135, P811, DOI 10.1001/archinte.135.6.811; OHLSON LO, 1985, DIABETES, V34, P1055, DOI 10.2337/diabetes.34.10.1055; PYORALA K, 1985, ACTA MED SCAND S, V701, P38; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211; Rothman K, 1986, MODERN EPIDEMIOLOGY; SEIDELL JC, 1991, AM J EPIDEMIOL, V133, P257, DOI 10.1093/oxfordjournals.aje.a115870; SHAPER AG, 1988, LANCET, V2, P1267; SHIMOKATA H, 1989, JAMA-J AM MED ASSOC, V261, P1169, DOI 10.1001/jama.261.8.1169; SPARROW D, 1986, DIABETES, V35, P411, DOI 10.2337/diabetes.35.4.411; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; WHITTEMORE AS, 1983, J CHRON DIS, V36, P251, DOI 10.1016/0021-9681(83)90059-0; WILSON PWF, 1986, AM J MED, V80, P3, DOI 10.1016/0002-9343(86)90532-2; 1989, USDA AGR HDB, V8; 1994, MONTHLY VITAL STATIS, V43	48	434	456	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					555	559		10.1136/bmj.310.6979.555	http://dx.doi.org/10.1136/bmj.310.6979.555			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888928	Green Published, Green Submitted			2022-12-28	WOS:A1995QK70000016
J	OWENS, D				OWENS, D			BENEFITS OF NEW DRUGS ARE EXAGGERATED	BRITISH MEDICAL JOURNAL			English	Article											OWENS, D (corresponding author), UNIV LEEDS,DIV PSYCHIAT & BEHAV SCI,LEEDS LS2 9LT,W YORKSHIRE,ENGLAND.							EDWARDS JG, 1992, BRIT MED J, V304, P1644, DOI 10.1136/bmj.304.6843.1644; FRADD SO, 1992, BRIT MED J, V305, P366, DOI 10.1136/bmj.305.6849.366-c; FREEMANTLE N, 1993, EFFECTIVE HLTH CARE; Henry J A, 1992, Eur J Med, V1, P343; MILNE S, 1993, BRIT MED J, V306, P1126, DOI 10.1136/bmj.306.6885.1126-b; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; Rose G., 1992, STRATEGY PREVENTIVE; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; 1993, DRUG THER B, V31, P57; 1993, BRIT NATIONAL FORMUL	10	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1281	1282		10.1136/bmj.309.6964.1281	http://dx.doi.org/10.1136/bmj.309.6964.1281			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888854	Green Published			2022-12-28	WOS:A1994PT03300029
J	FLEMING, DM; CROSS, KW				FLEMING, DM; CROSS, KW			RESPIRATORY SYNCYTIAL VIRUS OR INFLUENZA	LANCET			English	Article							INFECTION; OUTBREAK	We compared data from clinical surveillance of acute respiratory infections in elderly people reported by a network of sentinel general practitioners, virus isolate data for respiratory syncytial virus (RSV) and influenza A and B viruses, and registered deaths, during the past four winters. Cases of acute respiratory disease (ARD) and deaths (3-week moving averages) showed strong similarity in timing. Periods of high incidence of ARD and numbers of deaths were followed within 2-3 weeks by reports of high numbers of RSV or influenza virus isolates. The epidemic period in December, 1989, was followed by high numbers of both virus isolates, but in all other epidemic periods one virus predominated. The lethality of epidemics due to RSV or influenza A or B varied both within and between years. These analyses suggest that RSV is as important as influenza viruses in causing morbidity and excess deaths among elderly people. RSV was prevalent at the end of each of the past four years in the UK; its importance as a cause of excess deaths would therefore be concealed in any analysis based on several years' experience. By contrast, the inconsistency of epidemics due to influenza viruses makes excess deaths due to these viruses easily recognisable. Integrated clinical and viriological surveillance is essential if epidemics due to RSV, influenza virus, or any other virus are to be correctly interpreted.			FLEMING, DM (corresponding author), RCGP,BIRMINGHAM RES UNIT,LORDSWOOD HOUSE,54 LORDSWOOD RD,BIRMINGHAM B17 9DB,ENGLAND.							ADAMS F, 1849, GENUINE WORKS HIPPOC, P203; AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208; ALDERSON MR, 1988, MORTALITY MORBIDITY, P122; ANDERSON TW, 1970, LANCET, V1, P291; Curwen M, 1990, POPUL TRENDS, P31; Curwen M., 1990, HLTH TRENDS, V22, P169; DAB W, 1991, EUR J EPIDEMIOL, V7, P579, DOI 10.1007/BF00218667; FLEMING DM, IN PRESS EUR J EPIDE; Fleming DM, 1991, 53 ROYAL COLL GEN PR; GARVIE DG, 1980, BRIT MED J, V281, P1253, DOI 10.1136/bmj.281.6250.1253-a; Graman P S, 1989, Semin Respir Infect, V4, P253; JOSEPH CA, 1992, COMMUN DIS REV, V2, P149; KUNST AE, 1990, INT J EPIDEMIOL, V20, P971; MARTIN AJ, 1978, LANCET, V1, P1035; NOAH ND, 1989, EPIDEMIOL INFECT, V102, P175, DOI 10.1017/S0950268800029848; OSTERWEIL D, 1990, J AM GERIATR SOC, V38, P659, DOI 10.1111/j.1532-5415.1990.tb01425.x; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600, DOI 10.1164/ajrccm/145.3.600; 1988, MORTALITY STATISTICS	18	137	139	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1507	1510		10.1016/S0140-6736(05)80082-0	http://dx.doi.org/10.1016/S0140-6736(05)80082-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902899				2022-12-28	WOS:A1993MM40200009
J	ZIEGLER, JL				ZIEGLER, JL			ENDEMIC KAPOSIS-SARCOMA IN AFRICA AND LOCAL VOLCANIC SOILS	LANCET			English	Article							ELEPHANTIASIS; PATHOGENESIS; UGANDA; AIDS	Endemic Kaposi's sarcoma (KS) in Africa has been attributed to a geographically-determined environmental factor. Endemic KS, a chronic nodular condition predominantly affecting the feet and legs, is believed to arise in the lymphatic endothelium and is associated with chronic lymphoedema. As such, KS bears a resemblance to podoconiosis (non-filarial elephantiasis). The prevalence of both conditions in highland areas close to volcanoes suggests a shared pathogenetic relationship to exposure to volcanic soils. The lymphatics and lymph nodes of patients with podoconiosis contain particulate alumino-silicates in macrophages consistent with the theory that ultrafine clay minerals are absorbed through the feet. The resulting chronic lymphatic irritation, inflammation, and collagenosis causes obstruction and lymphoedema. The geographical proximity of endemic KS to areas containing volcanic clay minerals, its lympho-endothelial origin, predilection for the feet and legs, and its prevalence among rural peasants and cultivators, suggest a common aetiology. Other features point to the participation of a low-grade, possibly sexually-transmitted, infective agent that becomes more pathogenic in the presence of immunosuppression. Damage to the dermal lymphatics of the feet and legs by absorbed clays could impair local immunity to such an agent. Endemic KS would then occur in exposed individuals who harbour the KS infective agent and are susceptible to the KS phenotype (males).	UNIV LONDON LONDON SCH HYG & TROP MED,DEPT CLIN SCI,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine								ALLISON AC, 1966, J EXP MED, V124, P141, DOI 10.1084/jem.124.2.141; BAYLEY AC, 1991, CANCER SURV, V10, P53; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1991, CANCER SURV, V10, P5; BLAND JM, 1977, E AFR J MED RES, V4, P47; BRONSON DM, 1988, KAPOSIS SARCOMA TEXT, P24; BRYCESON AD, 1970, T ROY SOC TROP MED H, V64, P380, DOI 10.1016/0035-9203(70)90174-4; COLLEY MH, 1989, AM J SURG PATHOL, V13, P803, DOI 10.1097/00000478-198909000-00011; DESMONDHELLMANN SD, 1991, J ACQ IMMUN DEF SYND, V4, P647; DIGIOVANNA JJ, 1981, AM J MED, V71, P779, DOI 10.1016/0002-9343(81)90364-8; DORFMAN RF, 1988, KAPOSIS SARCOMA PATH, P71; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; FYFE NCM, 1985, T ROY SOC TROP MED H, V79, P645, DOI 10.1016/0035-9203(85)90180-4; GAAFAR S, 1969, J PATHOL, V100, P9; GIGASE PL, 1986, VIRUS ASS CANCERS AF, P549; HUTT MSR, 1984, BRIT MED BULL, V40, P355, DOI 10.1093/oxfordjournals.bmb.a072004; KALENGAYI NMR, 1986, VIRUS ASS CANCERS AF, P559; KENNEDY TP, 1989, ARCH BIOCHEM BIOPHYS, V269, P359, DOI 10.1016/0003-9861(89)90118-5; KESTENS L, 1985, INT J CANCER, V36, P49, DOI 10.1002/ijc.2910360109; Kungu A, 1981, Antibiot Chemother (1971), V29, P38; OTU AA, 1986, J ROY SOC MED, V79, P510, DOI 10.1177/014107688607900905; PETERMAN TA, 1991, CANCER SURV, V10, P23; PRICE EW, 1972, T ROY SOC TROP MED H, V66, P150, DOI 10.1016/0035-9203(72)90063-6; PRICE EW, 1976, T ROY SOC TROP MED H, V70, P288, DOI 10.1016/0035-9203(76)90078-X; Price EW, 1990, PODOCONIOSIS NONFILA; SCHMID H, 1973, TROP GEOGR MED, V25, P266; TAYLOR JF, 1972, BRIT J CANCER, V26, P483, DOI 10.1038/bjc.1972.66; TAYLOR JF, 1971, INT J CANCER, V8, P122, DOI 10.1002/ijc.2910080116; Templeton A C, 1981, Pathol Annu, V16, P315; VOGEL J, 1988, NATURE, V335, P606, DOI 10.1038/335606a0; WILSON M, 1993, IGNEOUS PETROGENESIS, P549	31	111	112	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1348	1351		10.1016/0140-6736(93)92252-O	http://dx.doi.org/10.1016/0140-6736(93)92252-O			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901641				2022-12-28	WOS:A1993MJ03900015
J	MESSERLI, FH				MESSERLI, FH			THIS DAY 50 YEARS AGO	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											MESSERLI, FH (corresponding author), ALTON OCHSNER MED FDN & OCHSNER CLIN,1516 JEFFERSON HIGHWAY,NEW ORLEANS,LA 70121, USA.		Messerli, Franz/AAR-4783-2021					Axelsson G, 1945, NY TIMES, P4; BARACH AL, 1977, NEW YORK STATE J MED, V77, P2154; BISHOP J, 1974, FDRS LAST YEAR APRIL, P620; BRUENN HG, 1970, ANN INTERN MED, V72, P579, DOI 10.7326/0003-4819-72-4-579; CALHOUN DA, 1995, NEW ENGL J MED, V332, P1029, DOI 10.1056/NEJM199504133321512; Hart J, 1989, NATIONAL REV    0915, P32; MESSERLI FH, 1985, NEW ENGL J MED, V312, P1548, DOI 10.1056/NEJM198506133122405; White P, 1937, HEART DIS, P326; 1945, NY TIMES        0413, P10; 1945, NY TIMES        0413, P1	10	44	44	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					1038	1039		10.1056/NEJM199504133321518	http://dx.doi.org/10.1056/NEJM199504133321518			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885424				2022-12-28	WOS:A1995QT73700031
J	SCHWARTZ, RS				SCHWARTZ, RS			MOLECULAR MEDICINE - JUMPING GENES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																		CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Keller E. F., 1983, FEELING ORGANISM; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0	3	9	10	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					941	944		10.1056/NEJM199504063321408	http://dx.doi.org/10.1056/NEJM199504063321408			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877653				2022-12-28	WOS:A1995QP89300008
J	HARRIS, MA; SULLIVAN, CE				HARRIS, MA; SULLIVAN, CE			SLEEP PATTERN AND SUPPLEMENTARY OXYGEN REQUIREMENTS IN INFANTS WITH CHRONIC NEONATAL LUNG-DISEASE	LANCET			English	Note							AROUSAL RESPONSES	Seven infants with chronic neonatal lung disease and baseline oxygen saturation greater than 90% were studied with overnight polysomnography in their prescribed oxygen environment, and on a second night with 0.25 L/min additional oxygen. All had sleep fragmentation and decreased rapid-eye-movement (REM) sleep, which was reversed after the increased oxygen. Sleep duration (p<0.003), percentage REM sleep (p<0.001), and mean REM sleep period length (p<0.001) were increased, and arousals in REM sleep decreased (p<0.05), with improved oxygenation. We conclude that, in infants with chronic neonatal lung disease, arousal mechanisms minimise oxygen desaturation but induce sleep disruption.	ROYAL ALEXANDRA HOSP CHILDREN,DAVID READ PAEDIAT SLEEP DISORDERS CTR,MATL SIDS COUNCIL,SYDNEY,NSW,AUSTRALIA				Harris, Margaret-Anne/G-9627-2014					COONS S, 1987, SLEEP ITS DISORDERS, P17; ISSA FG, 1987, J APPL PHYSIOL, V62, P1832, DOI 10.1152/jappl.1987.62.5.1832; SCHER MS, 1992, SLEEP, V15, P195, DOI 10.1093/sleep/15.3.195; SELL EJ, 1988, BRONCHOPULMONARY DYS, P403; VOHR BR, 1982, AM J DIS CHILD, V136, P443, DOI 10.1001/archpedi.1982.03970410061015; WARD SLD, 1992, PEDIATRICS, V89, P860; WILLIAMS GR, 1989, AUST PAEDIATR J, V25, P370	7	33	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					831	832		10.1016/S0140-6736(95)92966-5	http://dx.doi.org/10.1016/S0140-6736(95)92966-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898231				2022-12-28	WOS:A1995QQ19500011
J	SICKLES, EA; KOPANS, DB				SICKLES, EA; KOPANS, DB			MAMMOGRAPHIC SCREENING FOR WOMEN AGED 40 TO 49 YEARS - THE PRIMARY-CARE PRACTITIONERS DILEMMA	ANNALS OF INTERNAL MEDICINE			English	Article							NONPALPABLE BREAST-LESIONS; PROBABLY BENIGN LESIONS; FOLLOW-UP; CANCER; BIOPSY; MORTALITY; APPRAISAL; CARCINOMA; PROGRAM; TRIALS	The data from population-based, randomized trials of the mammographic screening of women aged 40 to 49 years are limited by retrospective subgroup analysis, low statistical power, and the use of older mammographic techniques. Nonetheless, meta-analysis involving the most recently reported data from all similarly designed trials shows a 21% mortality reduction in women who have had mammographic screening compared with those in control groups, a statistically significant difference (upper bound of 95% CI, 0.98). Evidence from modern mammography demonstration projects (which are limited by a lack of control groups and the unavailability of mortality results) also shows that the tumor size, axillary lymph node status, and stage of screening-detected breast cancers in women aged 40 to 49 years indicate that screening is at least as beneficial for these women as it is for those aged 50 to 64 years, for whom mammographic screening is widely accepted. Overall, the evidence suggests that screening will benefit women aged 40 to 49 years, but some argue that the level of proof provided is not rigorous enough to establish the efficacy of screening. In the United States, more than 10 000 deaths per year occur among women who develop breast cancer between the ages of 40 and 49. Thousands of lives are probably lost each year because women are not being screened. We believe that it is much more prudent to endorse mammographic screening now, risking the unlikely subsequent determination that the effort was ineffective, than to withhold screening until it is determined whether ''proof'' of efficacy will be obtained, risking the loss of so many lives. We urge primary care practitioners to recommend routine mammography for women aged 40 to 49 years.	MASSACHUSETTS GEN HOSP, DEPT RADIOL, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	SICKLES, EA (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT RADIOL, BOX 0628, SAN FRANCISCO, CA 94143 USA.							ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; AZAVEDO E, 1989, LANCET, V1, P1033, DOI 10.1016/S0140-6736(89)92441-0; BAINES CJ, 1994, CANCER, V74, P1207, DOI 10.1002/1097-0142(19940815)74:4<1207::AID-CNCR2820740405>3.0.CO;2-V; BAINES CJ, 1994, ANN INTERN MED, V120, P326, DOI 10.7326/0003-4819-120-4-199402150-00011; BASSETT LW, 1991, AM J ROENTGENOL, V157, P21, DOI 10.2214/ajr.157.1.1646562; BJURSTAM N, 1994, 26TH NAT C BREAST CA; BOYD NF, 1993, RADIOLOGY, V189, P661, DOI 10.1148/radiology.189.3.8234686; BROWN ML, 1992, CANCER-AM CANCER SOC, V69, P1963, DOI 10.1002/1097-0142(19920401)69:7+<1963::AID-CNCR2820691717>3.0.CO;2-0; BURHENNE LJW, 1993, AM J ROENTGENOL, V161, P761, DOI 10.2214/ajr.161.4.8372753; BURHENNE LJW, 1995, RADIOLOGY, V194, P185, DOI 10.1148/radiology.194.1.7997549; CONWAY BJ, 1994, RADIOLOGY, V191, P323, DOI 10.1148/radiology.191.2.8153301; CURPEN NB, 1995, IN PRESS AJR AM J RO; ECKHARDT S, 1994, INT J CANCER, V56, P1; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; ELWOOD JM, 1993, ONLINE J CURR CLIN T, P32; FARKOUH ME, 1994, ANN INTERN MED, V120, P886, DOI 10.7326/0003-4819-120-10-199405150-00011; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FLETCHER SW, 1994, J NATL CANCER I, V86, P558, DOI 10.1093/jnci/86.7.558-a; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; GOLDBERG K, 1993, CANCER, V37, P1; HALL FM, 1988, RADIOLOGY, V167, P353, DOI 10.1148/radiology.167.2.3282256; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KOPANS DB, 1994, CANCER, V74, P1196, DOI 10.1002/1097-0142(19940815)74:4<1196::AID-CNCR2820740403>3.0.CO;2-Y; KOPANS DB, 1990, AM J ROENTGENOL, V155, P748, DOI 10.2214/ajr.155.4.ajronline_155_4_001; KOPANS DB, 1992, J NATL CANCER I, V84, P1367, DOI 10.1093/jnci/84.17.1367; KOPANS DB, 1993, AM J ROENTGENOL, V161, P755, DOI 10.2214/ajr.161.4.8372752; LACHIN JM, 1981, CONTROL CLIN TRIALS, V2, P93, DOI 10.1016/0197-2456(81)90001-5; LOGANYOUNG WW, 1994, RADIOLOGY, V190, P313, DOI 10.1148/radiology.190.2.313-a; METTLIN CJ, 1993, CANCER, V72, P1461, DOI 10.1002/1097-0142(19930815)72:4+<1461::AID-CNCR2820721408>3.0.CO;2-S; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLER AB, 1993, CAN MED ASSOC J, V148, P880; MILLER AB, 1990, AM J ROENTGENOL, V155, P1133, DOI 10.2214/ajr.155.5.2120947; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; MOLLOY M, 1989, J SURG ONCOL, V40, P152, DOI 10.1002/jso.2930400304; MURPHY GP, 1993, CA-CANCER J CLIN, V43, P372, DOI 10.3322/canjclin.43.6.372; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PARKER SH, 1991, RADIOLOGY, V180, P403, DOI 10.1148/radiology.180.2.1648757; ROBERTS MM, 1990, LANCET, V335, P241; ROSENQUIST CJ, 1994, RADIOLOGY, V191, P647, DOI 10.1148/radiology.191.3.8184041; SHAPIRO S, 1994, CANCER, V74, P231, DOI 10.1002/cncr.2820741306; Shapiro S, 1988, PERIODIC SCREENING B; SICKLES EA, 1994, RADIOLOGY, V192, P439, DOI 10.1148/radiology.192.2.8029411; SICKLES EA, 1994, J NATL CANCER I, V86, P559, DOI 10.1093/jnci/86.7.559; SICKLES EA, 1991, RADIOLOGY, V179, P463, DOI 10.1148/radiology.179.2.2014293; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; SMART CR, 1995, IN PRESS CANCER; SMIGEL K, 1993, J NATL CANCER I, V85, P1626, DOI 10.1093/jnci/85.20.1626; SONDIK EJ, 1994, J NATL CANCER I, V86, P560, DOI 10.1093/jnci/86.7.560; SPIVEY GH, 1982, AM SURGEON, V48, P326; SULLIVAN DC, 1994, AM J ROENTGENOL, V162, P601, DOI 10.2214/ajr.162.3.8109505; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TENGS TO, 1995, IN PRESS RISK ANAL; THURFJELL EL, 1994, RADIOLOGY, V193, P351, DOI 10.1148/radiology.193.2.7972742; VARAS X, 1992, RADIOLOGY, V184, P409, DOI 10.1148/radiology.184.2.1620838; WALD N, 1993, TUMORI, V79, P371, DOI 10.1177/030089169307900601; Yaffe M.J., 1993, LETT JNCI, V85, P94; 1994, 103863 HOUS REPR COM	59	34	34	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					534	538		10.7326/0003-4819-122-7-199504010-00010	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872590				2022-12-28	WOS:A1995QP00800010
J	BARNES, PJ				BARNES, PJ			DRUG-THERAPY - INHALED GLUCOCORTICOIDS FOR ASTHMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HIGH-DOSE BECLOMETHASONE; PITUITARY-ADRENAL AXIS; LONG-TERM TREATMENT; BONE TURNOVER; AIRWAY RESPONSIVENESS; BRONCHIAL-ASTHMA; STEROID-THERAPY; CORTICOSTEROID TREATMENT; ORAL PREDNISOLONE; NEDOCROMIL SODIUM				BARNES, PJ (corresponding author), NATL HEART & LUNG INST,DEPT THORAC MED,DOVEHOUSE ST,LONDON SW3 6LY,ENGLAND.			Barnes, Peter/0000-0002-5122-4018				AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; ALI NJ, 1991, THORAX, V46, P160, DOI 10.1136/thx.46.3.160; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1, DOI 10.1164/ajrccm/148.4_Pt_2.S1; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BARNES PJ, 1990, AM REV RESPIR DIS, V141, pS70; BEL EH, 1991, AM REV RESPIR DIS, V143, P109, DOI 10.1164/ajrccm/143.1.109; BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; BISGAARD H, 1988, J ALLERGY CLIN IMMUN, V81, P1088, DOI 10.1016/0091-6749(88)90874-3; BOSCHETTO P, 1991, AM REV RESPIR DIS, V143, P605, DOI 10.1164/ajrccm/143.3.605; British Thoracic Society (BTS), 1993, THORAX, V48, pS1; Brodgen RN, 1992, DRUGS, V44, P375; BROGDEN RN, 1984, DRUGS, V28, P99, DOI 10.2165/00003495-198428020-00002; BROGDEN RN, 1993, DRUGS, V45, P693, DOI 10.2165/00003495-199345050-00007; BROWN PH, 1993, THORAX, V48, P233, DOI 10.1136/thx.48.3.233; BROWN PH, 1993, THORAX, V48, P967, DOI 10.1136/thx.48.10.967; BROWN PH, 1992, RESP MED, V86, P495, DOI 10.1016/S0954-6111(96)80009-6; Brown PH, 1990, THORAX, V95, P736; BURKE C, 1992, EUR RESPIR J, V5, P73; CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402, DOI 10.1038/clpt.1980.54; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669, DOI 10.1164/ajrccm/145.3.669; DOMPELING E, 1992, EUR RESPIR J, V5, P945; EBDEN P, 1986, THORAX, V41, P869, DOI 10.1136/thx.41.11.869; ENGEL T, 1989, ALLERGY, V44, P220, DOI 10.1111/j.1398-9995.1989.tb02266.x; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; EVANS PM, 1993, J ALLERGY CLIN IMMUN, V91, P643, DOI 10.1016/0091-6749(93)90270-P; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; GEDDES DM, 1992, THORAX, V47, P404, DOI 10.1136/thx.47.6.404; GLEESON JGA, 1988, BRIT MED J, V297, P163, DOI 10.1136/bmj.297.6642.163; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HOLLIDAY SM, 1994, DRUGS, V47, P319; HOLT PR, 1990, CLIN EXP ALLERGY, V20, P145, DOI 10.1111/j.1365-2222.1990.tb02659.x; HOSKING DJ, 1993, RESP MED, V87, P15, DOI 10.1016/S0954-6111(05)80252-5; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356, DOI 10.1136/adc.68.3.356; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; JENNINGS BH, 1991, EUR J CLIN PHARMACOL, V40, P77, DOI 10.1007/BF00315143; JONES AH, 1994, RESP MED, V88, P293, DOI 10.1016/0954-6111(94)90059-0; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832, DOI 10.1164/ajrccm/142.4.832; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; KIVIRANTA K, 1993, THORAX, V48, P974, DOI 10.1136/thx.48.10.974; KONIG P, 1993, J PEDIATR-US, V122, P219, DOI 10.1016/S0022-3476(06)80116-2; LACRONIQUE J, 1991, EUR RESPIR J, V4, P807; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LOFDAHL CG, 1989, EUR J RESPIR DI S130, V65, P69; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MAK VHF, 1992, EUR RESPIR J, V5, P1068; MALO JL, 1989, AM REV RESPIR DIS, V140, P624, DOI 10.1164/ajrccm/140.3.624; Mellis C M, 1993, Pharmacoeconomics, V3, P205, DOI 10.2165/00019053-199303030-00004; MELTZER EO, 1985, AM REV RESPIR DIS, V131, P732; MOLLMANN H, 1985, EUR J CLIN PHARMACOL, V29, P85, DOI 10.1007/BF00547374; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; NICOLAIZIK WH, 1994, AM J RESP CRIT CARE, V150, P624, DOI 10.1164/ajrccm.150.3.8087329; NINAN TK, 1992, ARCH DIS CHILD, V67, P703, DOI 10.1136/adc.67.6.703; PACKE GE, 1992, THORAX, V47, P414, DOI 10.1136/thx.47.6.414; PEDERSEN S, 1988, EUR RESPIR J, V1, P433; PHILLIP M, 1992, PEDIATR PULM, V12, P84, DOI 10.1002/ppul.1950120205; PIACENTINI GL, 1990, ALLERGY, V45, P612, DOI 10.1111/j.1398-9995.1990.tb00947.x; POUW EM, 1991, BRIT MED J, V302, P627, DOI 10.1136/bmj.302.6777.627; PRAHL P, 1991, CLIN EXP ALLERGY, V21, P145, DOI 10.1111/j.1365-2222.1991.tb00817.x; Reed CE, 1990, AM REV RESPIR DIS, V140, pS82; RUSSELL G, 1993, ARCH DIS CHILD, V69, P695, DOI 10.1136/adc.69.6.695; RYRFELDT A, 1982, EUR J RESPIR DIS S, V122, P86; SALMERON S, 1989, AM REV RESPIR DIS, V140, P167, DOI 10.1164/ajrccm/140.1.167; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SELROOS O, 1991, THORAX, V46, P891, DOI 10.1136/thx.46.12.891; Selroos O., 1994, European Respiratory Journal, V7, p151S; SHAPIRO GG, 1985, PHARMACOTHERAPY, V5, P156; SHIMURA S, 1990, AM REV RESPIR DIS, V141, P1044, DOI 10.1164/ajrccm/141.4_Pt_1.1044; SIMONS FER, 1993, LANCET, V342, P776, DOI 10.1016/0140-6736(93)91541-S; SLY RM, 1978, J ALLERGY CLIN IMMUN, V62, P76, DOI 10.1016/0091-6749(78)90082-9; SVENDSEN UG, 1991, EUR RESPIR J, V4, P992; SZEFLER SJ, 1991, J ALLERGY CLIN IMMUN, V88, P147, DOI 10.1016/0091-6749(91)90323-G; THORSSON L, 1993, THORAX, V48, P434; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD JH, 1982, J ALLERGY CLIN IMMUN, V70, P288, DOI 10.1016/0091-6749(82)90065-3; TOOGOOD JH, 1993, J ALLERGY CLIN IMMUN, V91, P571, DOI 10.1016/0091-6749(93)90263-F; TOOGOOD JH, 1989, J ALLERGY CLIN IMMUN, V83, P528, DOI 10.1016/0091-6749(89)90034-1; TOOGOOD JH, 1988, AM REV RESPIR DIS, V138, P57, DOI 10.1164/ajrccm/138.1.57; TOOGOOD JH, 1991, J ALLERGY CLIN IMMUN, V88, P572, DOI 10.1016/0091-6749(91)90150-M; TOOGOOD JH, 1984, EUR J RESPIR DIS, V65, P35; TURPEINEN M, 1991, J ALLERGY CLIN IMMUN, V88, P384, DOI 10.1016/0091-6749(91)90101-S; VANESSENZANDVLI.EE, 1992, AM REV RESPIR DIS, V146, P547; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317, DOI 10.1164/ajrccm/143.6.1317; VOLOVITZ B, 1993, NEW ENGL J MED, V329, P1703, DOI 10.1056/NEJM199312023292305; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252, DOI 10.1164/ajrccm/148.5.1252; WATSON A, 1992, CHEST, V101, P350, DOI 10.1378/chest.101.2.350; WEMPE JB, 1992, J ALLERGY CLIN IMMUN, V90, P349, DOI 10.1016/S0091-6749(05)80014-4; WILLIAMS AJ, 1983, THORAX, V38, P813, DOI 10.1136/thx.38.11.813; WOLTHERS OD, 1993, PEDIATR PULM, V16, P341, DOI 10.1002/ppul.1950160604; WURTHWEIN G, 1990, BIOPHARM DRUG DISPOS, V11, P381, DOI 10.1002/bdd.2510110503; 1991, J ALLERGY CLIN IMMUN, V88, P425; 1992, CLIN EXP ALLERGY S1, V22, P1	99	521	529	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					868	875		10.1056/NEJM199503303321307	http://dx.doi.org/10.1056/NEJM199503303321307			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7870143				2022-12-28	WOS:A1995QP22800007
J	REAUME, AG; DESOUSA, PA; KULKARNI, S; LANGILLE, BL; ZHU, DG; DAVIES, TC; JUNEJA, SC; KIDDER, GM; ROSSANT, J				REAUME, AG; DESOUSA, PA; KULKARNI, S; LANGILLE, BL; ZHU, DG; DAVIES, TC; JUNEJA, SC; KIDDER, GM; ROSSANT, J			CARDIAC MALFORMATION IN NEONATAL MICE LACKING CONNEXIN43	SCIENCE			English	Article							GAP JUNCTION PROTEIN; MOUSE PREIMPLANTATION EMBRYOS; RAT-HEART; EXPRESSION; COMMUNICATION; CELLS; CHICK; MYOCARDIUM; PREGNANCY; TISSUES	Gap junctions are made up of connexin proteins, which comprise a multigene family in mammals. Targeted mutagenesis of connexin43 (Cx43), one of the most prevalent connexin proteins, showed that its absence was compatible with survival of mouse embryos to term, even though mutant cell lines showed reduced dye coupling in vitro. However, mutant embryos died at birth, as a result of a failure in pulmonary gas exchange caused by a swelling and blockage of the right ventricular outflow tract from the heart. This finding suggests that Cx43 plays an essential role in heart development but that there is functional compensation among connexins in other parts of the developing fetus.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MOLEC & MED GENET, TORONTO, ON M5S 1A8, CANADA; UNIV WESTERN ONTARIO, DEPT ZOOL, LONDON, ON N6A 5B7, CANADA; UNIV WESTERN ONTARIO, MOLEC GENET UNIT, LONDON, ON N6A 5B7, CANADA; MAX BELL RES CTR, TORONTO GEN DIV, TORONTO, ON M5G 2C4, CANADA; UNIV TORONTO, DEPT PATHOL, TORONTO, ON M5S 1A8, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto			De Sousa, Paul A/H-7416-2013	De Sousa, Paul A/0000-0003-0745-2504; Juneja, Subhash/0000-0002-8536-5724				BASTIDE B, 1993, CIRC RES, V73, P1138, DOI 10.1161/01.RES.73.6.1138; BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEVILACQUA A, 1989, P NATL ACAD SCI USA, V86, P5444, DOI 10.1073/pnas.86.14.5444; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; BISHOP SP, 1990, CIRC RES, V66, P84, DOI 10.1161/01.RES.66.1.84; BOCKMAN DE, 1987, AM J ANAT, V180, P332; BRITZCUNNINGHAM SH, 1993, MOL BIOL CELL, V4, P329; CAVENEY S, 1985, ANNU REV PHYSIOL, V47, P319; CHARLES AC, 1992, J CELL BIOL, V118, P195, DOI 10.1083/jcb.118.1.195; CLARK EB, 1989, AM J PHYSIOL, V257, pH55, DOI 10.1152/ajpheart.1989.257.1.H55; DEALY CN, 1994, DEV DYNAM, V199, P156, DOI 10.1002/aja.1001990208; DESOUSA PA, 1993, DEVELOPMENT, V117, P1355; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; FISHMAN GI, 1991, CIRC RES, V68, P782, DOI 10.1161/01.RES.68.3.782; GOURDIE RG, 1993, CIRC RES, V72, P278, DOI 10.1161/01.RES.72.2.278; GOURDIE RG, 1993, J CELL SCI, V105, P985; GOURDIE RG, 1992, ANAT EMBRYOL, V185, P363; GREEN CR, 1988, BIOESSAYS, V8, P7, DOI 10.1002/bies.950080103; GROS D, 1994, CIRC RES, V74, P839, DOI 10.1161/01.RES.74.5.839; HURLE JM, 1979, J ANAT, V129, P427; KANTER HL, 1992, CIRC RES, V70, P438, DOI 10.1161/01.RES.70.2.438; KANTER HL, 1993, CIRC RES, V73, P344, DOI 10.1161/01.RES.73.2.344; LAIRD DW, 1990, J CELL SCI, V97, P109; LANGILLE BL, 1981, CIRC RES, V48, P481, DOI 10.1161/01.RES.48.4.481; Larsen WJ, 1993, HUMAN EMBRYOLOGY; LEE S, 1987, CELL, V51, P851, DOI 10.1016/0092-8674(87)90108-5; MCLACHLIN JR, 1986, DEV BIOL, V117, P146, DOI 10.1016/0012-1606(86)90357-X; MEDA P, 1993, ENDOCRINOLOGY, V133, P2371, DOI 10.1210/en.133.5.2371; MINKOFF R, 1993, CIRC RES, V73, P71, DOI 10.1161/01.RES.73.1.71; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAUS CCG, 1992, CELL MOL NEUROBIOL, V12, P163, DOI 10.1007/BF00713370; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; NISHI M, 1991, DEV BIOL, V146, P117, DOI 10.1016/0012-1606(91)90452-9; Papaioannou V., 1993, Gene targeting: a practical approach., P107; PEXEIDER T, 1975, ADV ANAT EMBRYOL CEL, V51, P6; RISEK B, 1990, J CELL BIOL, V110, P269, DOI 10.1083/jcb.110.2.269; RISEK B, 1991, DEVELOPMENT, V113, P165; RISEK B, 1992, DEVELOPMENT, V116, P639; RUANGVORAVAT CP, 1992, DEV DYNAM, V194, P261, DOI 10.1002/aja.1001940403; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SAEZ JC, 1993, ADV SEC MESS PHOSPH, V27, P163; SAFFITZ JE, 1994, CIRC RES, V74, P1065, DOI 10.1161/01.RES.74.6.1065; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; VALDIMARSSON G, 1993, MOL REPROD DEV, V36, P7, DOI 10.1002/mrd.1080360103; VALDIMARSSON G, 1991, MOL REPROD DEV, V30, P18, DOI 10.1002/mrd.1080300103; VANKEMPEN MJA, 1991, CIRC RES, V68, P1638, DOI 10.1161/01.RES.68.6.1638; VUILLEMIN M, 1989, AM J ANAT, V184, P114, DOI 10.1002/aja.1001840203; WERNER R, 1989, P NATL ACAD SCI USA, V86, P5380, DOI 10.1073/pnas.86.14.5380; WURST W, 1993, GENE TARGETING PRACT, P31	52	1040	1080	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1831	1834		10.1126/science.7892609	http://dx.doi.org/10.1126/science.7892609			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892609				2022-12-28	WOS:A1995QN70200042
J	MUSTARD, JF; SUNSHINE, JM				MUSTARD, JF; SUNSHINE, JM			SEEING THROUGH THE DUST - MARTIAN CRUSTAL HETEROGENEITY AND LINKS TO THE SNC METEORITES	SCIENCE			English	Article							REFLECTANCE SPECTRA; SURFACE	Through the application of new analytical techniques to high spatial resolution imaging spectrometer data, the ferrous mineralogy of major volcanic terrains on Mars is shown to consist of significant fractions of both low- and high-calcium pyroxene. Changes in the relative abundances of these pyroxenes are observed for units of different age and morphology, even in regions with higher degrees of alteration and contamination from dust. Volcanic rocks with these characteristics are uncommon on Earth but are typical of the basaltic SNC meteorites (shergottites, nakhlites, and chassignites) thought to be from Mars, Thus, it is possible to infer, even through the veil of dust, that the SNC meteorites have mineralogic affinities to major volcanic provinces on Mars and are therefore truly representative of the heterogeneity observed on the surface of the ''red planet.''	SETS TECHNOL,MILILANI,HI 96789		MUSTARD, JF (corresponding author), BROWN UNIV,DEPT GEOL SCI,BOX 1846,PROVIDENCE,RI 02912, USA.			Sunshine, Jessica/0000-0002-9413-8785				ADAMS JB, 1974, J GEOPHYS RES, V79, P4829, DOI 10.1029/JB079i032p04829; BIBRING JP, 1989, NATURE, V341, P591, DOI 10.1038/341591a0; BURNS RG, 1993, MINERALOGICAL APPLIC; CLARK BC, 1982, J GEOPHYS RES, V87, P59, DOI 10.1029/JB087iB12p10059; CLOUTIS EA, 1991, J GEOPHYS RES, V96, P18819; ERARD S, 1991, P LUNAR PLANET C, V21, P461; LONGHI J, 1991, P LUNAR PLANET SCI C, V19, P451; LONGHI J, 1992, MARS, pCH6; MCGETCHIN TR, 1978, ICARUS, V34, P512, DOI 10.1016/0019-1035(78)90042-8; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MCSWEEN HY, 1983, GEOCHIM COSMOCHIM AC, V47, P1501, DOI 10.1016/0016-7037(83)90309-5; MOUGINISMARK PJ, 1992, MARS, pCH13; MUSTARD JF, 1993, J GEOPHYS RES-PLANET, V98, P3387, DOI 10.1029/92JE02682; MUSTARD JF, 1993, LUNAR PLANET SCI, V24, P1039; MUSTARD JF, 1992, AM MINERAL, P345; PINET, 1994, GEOPHYS RES LETT, V21, P887; PINET P, 1990, J GEOPHYS RES-SOLID, V95, P14435, DOI 10.1029/JB095iB09p14435; Roush T.L., 1993, REMOTE GEOCHEMICAL A, P367; SCHUBERG G, 1992, MARS, pCH5; SINGER RB, 1993, RESOURCES NEAR EARTH, P709; SODERBLOM LA, 1992, MARS, pCH17; SUNSHINE JM, 1993, J GEOPHYS RES-PLANET, V98, P9075, DOI 10.1029/93JE00677; SUNSHINE JM, 1990, J GEOPHYS RES-SOLID, V95, P6955, DOI 10.1029/JB095iB05p06955; SUNSHINE JM, 1993, ICARUS, V105, P79, DOI 10.1006/icar.1993.1112; SUNSHINE JM, 1993, LUNAR PLANET SCI, V24, P1379; TARANTOLA A, 1982, REV GEOPHYS, V20, P219, DOI 10.1029/RG020i002p00219	26	96	96	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1623	1626		10.1126/science.7886449	http://dx.doi.org/10.1126/science.7886449			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886449				2022-12-28	WOS:A1995QM39700029
J	ALLMAN, RM; GOODE, PS; PATRICK, MM; BURST, N; BARTOLUCCI, AA				ALLMAN, RM; GOODE, PS; PATRICK, MM; BURST, N; BARTOLUCCI, AA			PRESSURE ULCER RISK-FACTORS AMONG HOSPITALIZED-PATIENTS WITH ACTIVITY LIMITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SORES; SUPPORT; COHORT	Objective.-To identify specific demographic, medical, functional status, and nutritional characteristics that predict the development of stage 2 or greater pressure ulcers among patients whose activity is limited to bed or chair. Design.-Prospective inception cohort study. Setting.-Tertiary care, urban, university teaching hospital. Patients.-A total of 286 patients fulfilling the following criteria: admitted to the hospital within the previous 3 days, age 55 years or more, expected to be confined to bed or chair for at least 5 days or had a hip fracture, and without a stage 2 or greater pressure ulcer. Main Outcome Measure.-Time to in-hospital development of a stage 2 or greater pressure ulcer. Results.-Total cumulative incidence of pressure ulcers was 12.9% (n=37) after a median time of 9 days from admission to final skin examination. Age of 75 years or more, dry skin, nonblanchable erythema (a stage 1 pressure ulcer), previous pressure ulcer history, immobility, fecal incontinence, depleted triceps skinfold, lymphopenia (lymphocyte count <1.50x10(9)/L), and decreased body weight (<58 kg) were significantly associated with pressure ulcer development by univariate Kaplan-Meier survival analyses (P<.05 by log-rank test). Risk ratios (and 95% confidence intervals) for predictors (P less than or equal to.05) of pressure ulcer development after multivariable Cox regression analysis included the following: nonblanchable erythema, 7.52 (1.00 to 59.12); lymphopenia, 4.86 (1.70 to 13.89); immobility, 2.36 (1.14 to 4.85); dry skin, 2.31 (1.02 to 5.21); and decreased body weight, 2.18 (1.05 to 4.52). The 3-week cumulative incidence of pressure ulcers with none, one, two, or three or more of these characteristics was 0%, 11.4%, 39.6%, and 67.9%, respectively (P<.001 by log-rank test). Conclusions.-These results suggest that nonblanchable erythema, lymphopenia, immobility, dry skin, and decreased body weight are independent and significant risk factors for pressure ulcers in hospitalized patients whose activity is limited to bed or chair.	UNIV ALABAMA, DEPT MED, DIV GERONTOL & GERIATR MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT BIOSTAT, BIRMINGHAM, AL 35294 USA; DEPT VET AFFAIRS MED CTR, BIRMINGHAM, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	ALLMAN, RM (corresponding author), UNIV ALABAMA, CTR AGING, 933 S 19TH ST, 201 CH-19, BIRMINGHAM, AL 35294 USA.		Allman, Richard M/D-5964-2011; Allman, Richard M./O-1693-2019	Allman, Richard M./0000-0002-1850-6515	NIA NIH HHS [5-R01-AG07178-03] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007178] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Allman R M, 1989, Decubitus, V2, P30; ALLMAN RM, 1987, ANN INTERN MED, V107, P641, DOI 10.7326/0003-4819-107-5-641; ALLMAN RM, 1986, ANN INTERN MED, V105, P337, DOI 10.7326/0003-4819-105-3-337; ALLMAN RM, 1989, NEW ENGL J MED, V320, P850; ANDERSEN KE, 1982, BMJ-BRIT MED J, V284, P1370, DOI 10.1136/bmj.284.6326.1370; [Anonymous], 1989, Decubitus, V2, P24; BERGSTROM N, 1992, J AM GERIATR SOC, V40, P747, DOI 10.1111/j.1532-5415.1992.tb01845.x; BERLOWITZ DR, 1989, J AM GERIATR SOC, V37, P1043, DOI 10.1111/j.1532-5415.1989.tb06918.x; Braden B J, 1989, Decubitus, V2, P44; Braden BJ, 1989, DECUB J SKIN ULCERS, V2, P50; BRANDEIS GH, 1994, J AM GERIATR SOC, V42, P388, DOI 10.1111/j.1532-5415.1994.tb07486.x; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; EXTONSMITH A, 1961, LANCET, V2, P1124; Gilchrest BA., 1984, SKIN AGING PROCESSES; Gosnell D J, 1989, Decubitus, V2, P32; GOSNELL DJ, 1973, NURS RES, V22, P55; GURALNIK JM, 1988, J AM GERIATR SOC, V36, P807, DOI 10.1111/j.1532-5415.1988.tb04264.x; KEMP MG, 1993, RES NURS HEALTH, V16, P89, DOI 10.1002/nur.4770160203; KNAUS WA, 1981, JAMA-J AM MED ASSOC, V246, P2711, DOI 10.1001/jama.246.23.2711; LAWTON MP, 1969, GERONTOLOGIST, V9, P179, DOI 10.1093/geront/9.3_Part_1.179; LOWTHIAN PT, 1976, BEDSORE BIOMECHANICS, P141; Norton D, 1975, INVESTIGATION GERIAT, P193; OKAMOTO GA, 1983, ARCH PHYS MED REHAB, V64, P20; Pennington JAT, 1985, FOOD VALUES PORTIONS; SCHLESSELMAN JJ, 1974, AM J EPIDEMIOL, V99, P381, DOI 10.1093/oxfordjournals.aje.a121625; SHURAN M, 1986, GERIATRICS, V41, P48; SMITH DM, 1991, J GEN INTERN MED, V6, P81, DOI 10.1007/BF02599399; Stotts N A, 1988, Decubitus, V1, P24; WEINSIER R, 1989, HDB CLIN NUTRITION; 1992, PHS920047 US DEP HLT; 1985, 5TH PATIENT TYPE CLA	32	223	239	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					865	870		10.1001/jama.273.11.865	http://dx.doi.org/10.1001/jama.273.11.865			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869557				2022-12-28	WOS:A1995QL40200024
J	CAMPBELL, KP				CAMPBELL, KP			3 MUSCULAR-DYSTROPHIES - LOSS OF CYTOSKELETON EXTRACELLULAR-MATRIX LINKAGE	CELL			English	Review							GLYCOPROTEIN COMPLEX; SARCOLEMMA; LAMININ				CAMPBELL, KP (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242, USA.			Campbell, Kevin/0000-0003-2066-5889				AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; ARAHATA K, 1993, P JPN ACAD B-PHYS, V69, P259, DOI 10.2183/pjab.69.259; BENOTHMANE K, 1992, NAT GENET, V2, P315, DOI 10.1038/ng1292-315; BUSHBY K, 1995, IN PRESS NEUROMUSC D; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; ERVASTI JM, 1993, NATUR, V345, P315; GEE SH, 1993, J BIOL CHEM, V268, P14972; GREENBERG DS, 1994, NAT GENET, V8, P340, DOI 10.1038/ng1294-340; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HILLAIRE D, 1994, HUM MOL GENET, V3, P1657, DOI 10.1093/hmg/3.9.1657; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; IBRAGHINOVBESKR, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; MATSUMURA K, 1992, NATURE, V359, P320, DOI 10.1038/359320a0; MATSUMURA K, 1994, MUSCLE NERVE, V17, P2, DOI 10.1002/mus.880170103; Mckusick V.A., 1994, MENDELIAN INHERITANC; MCNALLY EM, 1994, P NATL ACAD SCI USA, V91, P9690, DOI 10.1073/pnas.91.21.9690; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; ROBERDS SL, 1994, CELL, V78, P625, DOI 10.1016/0092-8674(94)90527-4; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUZUKI A, 1994, EUR J BIOCHEM, V220, P283, DOI 10.1111/j.1432-1033.1994.tb18624.x; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; TOME FMS, 1994, CR ACAD SCI III-VIE, V317, P351; XU H, 1994, NAT GENET, V8, P297, DOI 10.1038/ng1194-297; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276	26	729	746	1	25	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					675	679		10.1016/0092-8674(95)90344-5	http://dx.doi.org/10.1016/0092-8674(95)90344-5			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889563	Bronze			2022-12-28	WOS:A1995QM39900002
J	LERNER, RA; GUILLEMIN, R				LERNER, RA; GUILLEMIN, R			BLOOM,FLOYD - THE NEXT EDITOR-IN-CHIEF OF SCIENCE	SCIENCE			English	Biographical-Item							SEQUENCE		SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA; WHITTIER INST DIABET & ENDOCRINOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT REPROD MED, LA JOLLA, CA 92037 USA	Scripps Research Institute; University of California System; University of California San Diego	LERNER, RA (corresponding author), SCRIPPS RES INST, DEPT CHEM, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							BLOOM FE, PUBLICATION LIST; BURTON FH, 1991, NATURE, V350, P74, DOI 10.1038/350074a0; CIVELLI O, 1985, P NATL ACAD SCI USA, V82, P4291, DOI 10.1073/pnas.82.12.4291; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; MOSES AV, 1993, P NATL ACAD SCI USA, V90, P10474, DOI 10.1073/pnas.90.22.10474; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; SALMOIRAGHI GC, 1964, SCIENCE, V144, P493, DOI 10.1126/science.144.3618.493; SANNA PP, 1993, MOL BRAIN RES, V19, P241, DOI 10.1016/0169-328X(93)90035-N; SIGGINS GR, 1969, SCIENCE, V165, P1018, DOI 10.1126/science.165.3897.1018; SUTCLIFFE JG, 1983, CELL, V33, P671, DOI 10.1016/0092-8674(83)90010-7; WEISS F, 1993, J PHARMACOL EXP THER, V267, P250; YANG TT, 1994, NATURE, V368, P3	12	0	0	0	0	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1441	1442		10.1126/science.7878461	http://dx.doi.org/10.1126/science.7878461			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878461				2022-12-28	WOS:A1995QL49700022
J	CAVANAUGH, AH; HEMPEL, WM; TAYLOR, LJ; ROGALSKY, V; TODOROV, G; ROTHBLUM, LI				CAVANAUGH, AH; HEMPEL, WM; TAYLOR, LJ; ROGALSKY, V; TODOROV, G; ROTHBLUM, LI			ACTIVITY OF RNA-POLYMERASE-I TRANSCRIPTION FACTOR UBF BLOCKED BY RB GENE-PRODUCT	NATURE			English	Article							CELL DIFFERENTIATION; PROTEIN; PHOSPHORYLATION; TRANSACTIVATION; BINDING; GROWTH	THE protein encoded by the retinoblastoma susceptibility gene (Rb) functions as a tumour suppressor and negative growth regulator(1). As actively growing cells require the ongoing synthesis of ribosomal RNA, we considered that Rb might interact with the ribosomal DNA transcription apparatus, Here we report that (1) there is an accumulation of Rb protein in the nucleoli of differentiated U937 cells which correlates with inhibition of rDNA transcription; (2) addition of Rb to an in vitro transcription system inhibits transcription by RNA polymerase I; (3) this inhibition requires a functional Rb pocket(2); and (4) Rb specifically inhibits the activity of the RNA polymerase I transcription factor UBF (upstream binding factor) in vitro. This last observation was confirmed by affinity chromatography and immunoprecipitation, which demonstrated an interaction between Rb and UBF. These results indicate that there is an additional mechanism by which Rb suppresses cell growth, namely that Rb directly represses transcription of the rRNA genes.	GEISINGER MED CLIN,SIGFRIED & JANET WEIS CTR RES,DANVILLE,PA 17822; MT SINAI MED CTR,DIV NEOPLAST DIS,NEW YORK,NY 10029	Geisinger Medical Center; Icahn School of Medicine at Mount Sinai								Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; LARSON DE, 1993, P NATL ACAD SCI USA, V90, P7933, DOI 10.1073/pnas.90.17.7933; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; NEVINS JR, 1992, SCIENCE, V258, P424; OMAHONY DJ, 1992, J BIOL CHEM, V267, P35; ROGALSKY V, 1993, BIOCHEM BIOPH RES CO, V192, P1139, DOI 10.1006/bbrc.1993.1535; ROGALSKY V, 1991, ANN NY ACAD SCI, V628, P323, DOI 10.1111/j.1749-6632.1991.tb17264.x; SCHNAPP G, 1994, EMBO J, V23, P190; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Smith S. David, 1993, Gene Expression, V3, P229; SMITH SD, 1990, MOL CELL BIOL, V10, P3105, DOI 10.1128/MCB.10.6.3105; VOIT R, 1992, EMBO J, V11, P2211, DOI 10.1002/j.1460-2075.1992.tb05280.x; WAND CY, 1993, SCIENCE, V280, P1330	17	297	299	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					177	180		10.1038/374177a0	http://dx.doi.org/10.1038/374177a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877691				2022-12-28	WOS:A1995QL39700063
J	HORNE, JA; REYNER, LA				HORNE, JA; REYNER, LA			SLEEP-RELATED VEHICLE ACCIDENTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To assess the incidence, time of day, and driver morbidity associated with vehicle accidents where the most likely cause was the driver falling asleep at the wheel. Design-Two surveys were undertaken, in southwest England and the midlands, by using police databases or on the spot interviews. Subjects-Drivers involved in 679 sleep related vehicle accidents. Results-Of all vehicle accidents to which the police were summoned, sleep related vehicle accidents comprised 16% on major roads in southwest England, and over 20% on midland motorways. During the 24 hour period there were three major peaks: at around 0200, 0600, and 1600. About half these drivers were men under 30 years; few such accidents involved women. Conclusions-Sleep related vehicle accidents are largely dependent on the time of day and account for a considerable proportion of vehicle accidents, especially those on motorways and other monotonous roads. As there are no norms for the United Kingdom on road use by age and sex for time of day with which to compare these data, we cannot determine what the hourly exposure upsilon risk factors are for these subgroups. The findings are in close agreement with those from other countries.			HORNE, JA (corresponding author), LOUGHBOROUGH UNIV TECHNOL,DEPT HUMAN SCI,SLEEP RES LAB,LOUGHBOROUGH LE11 3TU,LEICS,ENGLAND.			Albery, Ian/0000-0002-5626-8677				AKERSTEDT T, 1994, J SLEEP RES, V3, P194; BRENDEL DH, 1990, PSYCHOPHYSIOLOGY, V27, P677, DOI 10.1111/j.1469-8986.1990.tb03193.x; HORNE JA, 1988, WHY WE SLEEP; LANGLOIS PH, 1986, CHRONOBIOL INT, V2, P131; LEGER D, 1994, SLEEP, V17, P84, DOI 10.1093/sleep/17.1.84; MITLER MM, 1988, SLEEP, V11, P100, DOI 10.1093/sleep/11.1.100; MONK TH, 1991, SLEEPINESS SLEEP PER, P325; PACK AM, 1994, SLEEP RES, V23, P141; ZOMER J, 1990, SLEEP 90, P448; ZULLEY J, 1994, 248 KAR I STRESS RES, P104; 1994, ROAD ACCIDENTS GB 19	11	559	575	0	19	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					565	567		10.1136/bmj.310.6979.565	http://dx.doi.org/10.1136/bmj.310.6979.565			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888930	Green Published			2022-12-28	WOS:A1995QK70000018
J	LEE, JW; RYAN, F; SWAFFIELD, JC; JOHNSTON, SA; MOORE, DD				LEE, JW; RYAN, F; SWAFFIELD, JC; JOHNSTON, SA; MOORE, DD			INTERACTION OF THYROID-HORMONE RECEPTOR WITH A CONSERVED TRANSCRIPTIONAL MEDIATOR	NATURE			English	Article							26-S PROTEASE; TRANSACTIVATION; ACTIVATION; MODULATOR; DOMAIN; YEAST	THE thyroid-hormone receptors are hormone-dependent transcription factors that control expression of many target genes(1,2). This regulation is presumably a consequence of hormone-dependent contacts between the receptors and the basal transcription machinery(3). We used the yeast two-hybrid system(4,5) to identify a candidate human transcriptional mediator that interacts with both the thyroid-hormone receptor and the retinoid-X receptor in a ligand-dependent fashion. This protein, Trip1 (for thyroid-hormone-receptor Interacting protein), shares striking sequence conservation with the yeast transcriptional mediator Sug1 (refs 6, 7). Here we show that Trip1 can functionally substitute for Sug1 in yeast, and that both proteins interact in vitro with the thyroid-hormone receptor, acid with the transcriptional activation domains of yeast GAL4 and of herpes virus VP16.	UNIV TEXAS,SW MED CTR,DEPT MED,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	LEE, JW (corresponding author), MASSACHUSETTS GEN HOSP,DEPT MOLEC BIOL,WELLMAN 9,BOSTON,MA 02114, USA.							BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BRENT GA, 1991, REV PHYSL, V53, P17; CARTER ME, 1994, MOL CELL BIOL, V14, P360; CORMACK BP, 1991, CELL, V65, P341, DOI 10.1016/0092-8674(91)90167-W; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22699; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GILL G, 1991, CELL, V65, P333, DOI 10.1016/0092-8674(91)90166-V; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOENIG RJ, 1988, P NATL ACAD SCI USA, V85, P5031, DOI 10.1073/pnas.85.14.5031; LAZAR MA, 1993, ENDOCR REV, V14, P184, DOI 10.1210/er.14.2.184; LEE JW, 1994, MOL ENDOCRINOL, V8, P1245, DOI 10.1210/me.8.9.1245; LEE JW, IN PRESS MOL ENDOCR; Moore DD, 1995, GLOB MOB SURV; SHIBUYA H, 1992, NATURE, V357, P700, DOI 10.1038/357700a0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0	20	392	404	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					91	94		10.1038/374091a0	http://dx.doi.org/10.1038/374091a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870181				2022-12-28	WOS:A1995QK07900061
J	COOK, RJ; SACKETT, DL				COOK, RJ; SACKETT, DL			THE NUMBER NEEDED TO TREAT - A CLINICALLY USEFUL MEASURE OF TREATMENT EFFECT	BRITISH MEDICAL JOURNAL			English	Article								The relative benefit of an active treatment over a control is usually expressed as the relative risk, the relative risk reduction, or the odds ratio. These measures are used extensively in both clinical and epidemiological investigations. For clinical decision making, however, it is more meaningful to use the measure ''number needed to treat.'' This measure is calculated on the inverse of the absolute risk reduction. It has the advantage that it conveys both statistical and clinical significance to the doctor. Furthermore, it can be used to extrapolate published findings to a patient at an arbitrary specified baseline risk when the relative risk reduction associated with treatment is constant for all levels of risk.	UNIV OXFORD,JOHN RADCLIFFE HOSP,NUFFIELD DEPT CLIN MED,OXFORD OX3 9DU,ENGLAND	University of Oxford	COOK, RJ (corresponding author), UNIV WATERLOO,DEPT STAT & ACTUARIAL SCI,WATERLOO,ON N2L 3G1,CANADA.			Cook, Richard/0000-0002-1414-4908				COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SNITH GD, 1992, BRIT MED J, V308, P72; 1992, JAMA-J AM MED ASSOC, V208, P2420	5	1325	1347	0	24	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					452	454		10.1136/bmj.310.6977.452	http://dx.doi.org/10.1136/bmj.310.6977.452			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873954	Green Published			2022-12-28	WOS:A1995QJ24200026
J	DENNIS, M; LANGHORNE, P				DENNIS, M; LANGHORNE, P			FORTNIGHTLY REVIEW - SO STROKE UNITS SAVE LIVES - WHERE DO WE GO FROM HERE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; REHABILITATION; MANAGEMENT; CARE				DENNIS, M (corresponding author), WESTERN GEN HOSP, DEPT CLIN NEUROSCI, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.							Aitken PD, 1993, AGE AGEING S2, V22, P4; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; CHALMERS I, 1992, BMJ-BRIT MED J, V305, P786, DOI 10.1136/bmj.305.6857.786; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DRAKE WE, 1973, STROKE, V4, P933, DOI 10.1161/01.STR.4.6.933; FELDMAN DJ, 1962, J CHRON DIS, V15, P297, DOI 10.1016/0021-9681(62)90013-9; GARRAWAY WM, 1980, BRIT MED J, V281, P827, DOI 10.1136/bmj.281.6244.827; HARNRIN E, 1982, SCAND J REHABIL MED, V14, P111; INDREDAVIK B, 1991, STROKE, V22, P1026, DOI 10.1161/01.STR.22.8.1026; KALRA L, 1993, STROKE, V24, P1462, DOI 10.1161/01.STR.24.10.1462; KALRA L, 1994, STROKE, V25, P346, DOI 10.1161/01.STR.25.2.346; KENNEDY FB, 1970, AM HEART J, V80, P188, DOI 10.1016/0002-8703(70)90166-3; LANGHORNE P, 1993, LANCET, V342, P395, DOI 10.1016/0140-6736(93)92813-9; PEACOCK PB, 1972, TRENDS EPIDEMIOLOGY, P231; Pitner SE, 1973, STROKE, V4, P737, DOI 10.1161/01.STR.4.5.737; SANDERCOCK PAG, 1993, J NEUROL NEUROSUR PS, V56, P17, DOI 10.1136/jnnp.56.1.17; SIVENIUS J, 1985, STROKE, V16, P928, DOI 10.1161/01.STR.16.6.928; STEVENS RS, 1984, AGE AGEING, V13, P65, DOI 10.1093/ageing/13.2.65; STRAND T, 1985, STROKE, V16, P29, DOI 10.1161/01.STR.16.1.29; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P; WOODDAUPHINEE S, 1984, STROKE, V15, P864, DOI 10.1161/01.STR.15.5.864; 1993, LANCET, V342, P1255; 1993, 12 NAT HLTH SERV AUD; 1991, CM1523	25	63	64	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	1994	309	6964					1273	1277		10.1136/bmj.309.6964.1273	http://dx.doi.org/10.1136/bmj.309.6964.1273			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888851	Green Published			2022-12-28	WOS:A1994PT03300026
J	HARRISON, G				HARRISON, G			CONTROVERSIES IN MANAGEMENT .9. NEW OR OLD ANTIDEPRESSANTS - NEW IS BETTER	BRITISH MEDICAL JOURNAL			English	Article											HARRISON, G (corresponding author), MAPPERLEY HOSP,ACAD DEPT PSYCHIAT,NOTTINGHAM NG3 6AA,ENGLAND.							COOKSON J, 1993, BRIT J PSYCHIAT, V163, P20, DOI 10.1192/S0007125000292325; DUNBAR GC, 1991, BRIT J PSYCHIAT, V159, P394, DOI 10.1192/bjp.159.3.394; JONSSON B, 1993, PERSPECTIVES PSYCHIA, V4, P35; Kasper S, 1992, Drugs, V43 Suppl 2, P11; KERR JS, 1992, SAFETY HLTH PRACTITI, V10, P17; OTTEVANGER EA, 1991, BRIT J CLIN RES, V2, P125; TYRER P, 1978, BRIT MED J, V2, P1008, DOI 10.1136/bmj.2.6143.1008; WEISSMAN MM, 1981, ARCH GEN PSYCHIAT, V38, P417; 1992, DRUG THER B, V30, P5	9	17	18	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1280	1281		10.1136/bmj.309.6964.1280	http://dx.doi.org/10.1136/bmj.309.6964.1280			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888853	Green Published			2022-12-28	WOS:A1994PT03300028
J	TURNER, JA; DEYO, RA; LOESER, JD; VONKORFF, M; FORDYCE, WE				TURNER, JA; DEYO, RA; LOESER, JD; VONKORFF, M; FORDYCE, WE			THE IMPORTANCE OF PLACEBO-EFFECTS IN PAIN TREATMENT AND RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-BACK-PAIN; EXPECTANCY; RESPONSES; ANALGESIA; SURGERY; MODEL	Objective.-To estimate the importance and implications of placebo effects in pain treatment and research from the existing literature, with emphasis on their magnitude and duration, the conditions influencing them, and proposed explanations. Data Sources.-English-language articles and books identified through MED-LINE (1980 through 1993) and PsycLIT (1967 through 1993) database searching, bibliography review, and expert consultation. Study Selection.-Articles were included if they pertained to the review objectives. Results.-Placebo response rates vary greatly and are frequently much higher than the often-cited one third. Placebos have time-effect curves, and peak, cumulative, and carryover effects similar to those of active medications. As with medication, surgery can produce substantial placebo effects, and this possibility is commonly overlooked in case series reports on back surgery. Individuals are not consistent in their placebo responses, and a placebo-responder personality has not been identified. Models advanced to explain placebo effects emphasize the role of anxiety, expectations, and learning. Conclusions.-Placebo effects influence patient outcomes after any treatment, including surgery, that the clinician and patient believe is effective. Placebo effects plus disease natural history and regression to the mean can result in high rates of good outcomes, which may be misattributed to specific treatment effects. The true causes of improvements in pain after treatment remain unknown in the absence of independently evaluated randomized controlled trials.	UNIV WASHINGTON, DEPT REHABIL MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT NEUROL SURG, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT ANESTHESIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, CTR MULTIDISCIPLINARY PAIN, SEATTLE, WA USA; VET AFFAIRS MED CTR, HLTH SERV RES & DEV FIELD PROGRAM, SEATTLE, WA USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Group Health Cooperative	TURNER, JA (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PSYCHIAT & BEHAV SCI RP10, SEATTLE, WA 98195 USA.			VonKorff, Michael/0000-0001-5386-8477	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006344] Funding Source: NIH RePORTER; AHRQ HHS [HS 06344] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; BLACKWELL B, 1972, LANCET, V1, P1279; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; Brody Howard, 1985, PLACEBO THEORY RES M, P37; BUCKALEW LW, 1982, J CLIN PSYCHOPHARM, V2, P245; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; DePalma A F, 1968, Clin Orthop Relat Res, V59, P113; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; DEYO RA, 1993, SPINE, V18, P2153, DOI 10.1097/00007632-199311000-00002; DEYO RA, 1991, PHYS MED REHABIL, V5, P209; DIMOND EG, 1960, AM J CARDIOL, V5, P483, DOI 10.1016/0002-9149(60)90105-3; Evans F. J., 1985, PLACEBO THEORY RES M, P215; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FLATLEY TJ, 1985, CLIN ORTHOP RELAT R, P273; FULLENLOVE TM, 1957, RADIOLOGY, V68, P572, DOI 10.1148/68.4.572; GOODMAN P, 1976, J AM DENT ASSOC, V92, P755, DOI 10.14219/jada.archive.1976.0419; Gracely R H, 1987, Anesth Prog, V34, P113; GRACELY RH, 1985, LANCET, V1, P43; GREVERT P, 1985, PLACEBO THEORY RES M, P232; HOFFMAN RM, 1993, J GEN INTERN MED, V8, P487, DOI 10.1007/BF02600110; LASAGNA L, 1954, AM J MED, V16, P770, DOI 10.1016/0002-9343(54)90441-6; LASAGNA L, 1958, J CLIN INVEST, V37, P533, DOI 10.1172/JCI103635; LASKA E, 1973, HEADACHE, V13, P1, DOI 10.1111/j.1526-4610.1973.hed1301001.x; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; LIBERMAN R, 1964, J PSYCHIAT RES, V2, P233, DOI 10.1016/0022-3956(64)90010-X; LONG DM, 1989, STEREOT FUNCT NEUROS, V53, P149, DOI 10.1159/000099531; LUPARELLO TJ, 1970, PSYCHOSOM MED, V32, P509, DOI 10.1097/00006842-197009000-00009; MAGORA A, 1976, SCAND J REHABIL MED, V8, P115; MAX MB, 1987, NEUROLOGY, V37, P589, DOI 10.1212/WNL.37.4.589; McDonald C J, 1983, Stat Med, V2, P417; MILLER NE, 1989, NONSPECIFIC ASPECTS, P39; PECK C, 1991, THEOR MED, V12, P247, DOI 10.1007/BF00489609; POGGE RC, 1963, MED TIMES, V91, P1; REISS S, 1980, BEHAV THER, V11, P380, DOI 10.1016/S0005-7894(80)80054-2; ROBERTS AH, 1993, CLIN PSYCHOL REV, V13, P375, DOI 10.1016/0272-7358(93)90010-J; ROBERTS AH, 1993, 7TH WORLD C INT ASS; ROSENZWEIG P, 1993, CLIN PHARMACOL THER, V54, P578, DOI 10.1038/clpt.1993.190; Ross S, 1985, PLACEBO THEORY RES M, P67; SCHWEIGER A, 1981, PAVLOVIAN J BIOL SCI, V16, P140; Shapiro A, 1984, BEHAV HLTH HDB HLTH, P371; SHAPIRO AP, 1954, PSYCHOSOM MED, V16, P478, DOI 10.1097/00006842-195411000-00002; SOX HC, 1981, ANN INTERN MED, V95, P680, DOI 10.7326/0003-4819-95-6-680; SPANGFORT EV, 1972, ACTA ORTHOP SCAND, P1; Spiro HM, 1986, DOCTORS PATIENTS PLA; SPLITHOFF CA, 1953, JAMA-J AM MED ASSOC, V152, P1610, DOI 10.1001/jama.1953.03690170024008; STERNBACH RA, 1964, PSYCHOPHYSIOLOGY, V1, P67; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; THOMSON R, 1982, BRIT J PSYCHIAT, V140, P64, DOI 10.1192/bjp.140.1.64; TURNER JA, 1992, JAMA-J AM MED ASSOC, V268, P907, DOI 10.1001/jama.268.7.907; TURNER JA, 1992, SPINE, V17, P1, DOI 10.1097/00007632-199201000-00001; VOUDOURIS NJ, 1990, PAIN, V43, P121, DOI 10.1016/0304-3959(90)90057-K; VOUDOURIS NJ, 1989, PAIN, V38, P109, DOI 10.1016/0304-3959(89)90080-8; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WADDELL G, 1979, J BONE JOINT SURG AM, V61, P201, DOI 10.2106/00004623-197961020-00007; WALL PD, 1993, CIBA F SYMP, V174, P187; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; WHITNEY CW, 1992, PAIN, V50, P281, DOI 10.1016/0304-3959(92)90032-7; Wickramasekera I., 1985, PLACEBO THEORY RES M, P255; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003	61	633	639	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1609	1614		10.1001/jama.271.20.1609	http://dx.doi.org/10.1001/jama.271.20.1609			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL758	7880221				2022-12-28	WOS:A1994NL75800031
J	URNOVITZ, HB; CLERICI, M; SHEARER, GM; GOTTFRIED, TD; ROBISON, DJ; LUTWICK, LI; MONTAGNIER, L; LANDERS, DV				URNOVITZ, HB; CLERICI, M; SHEARER, GM; GOTTFRIED, TD; ROBISON, DJ; LUTWICK, LI; MONTAGNIER, L; LANDERS, DV			HIV-1 ANTIBODY SERUM NEGATIVITY WITH URINE POSITIVITY	LANCET			English	Note								7 individuals who were negative for HIV-1 antibody in a licensed serum enzyme immunoassay (EIA) were positive in a urine EIA and western blot (WB). Follow-up in individuals by use of a cell-mediated immune response showed 1 positive and 1 negative for HIV-1 peptide reactivity. In a second study, 4 out of 5 subjects positive by urine EIA and indeterminate or negative by serum WB were HIV-1 peptide positive in the cell-mediated immune test. Comparison of cell-mediated responses with urine antibody responses may help to resolve discrepant HIV-1 results.	MAIMONIDES HOSP,BROOKLYN,NY 11219; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143; INST PASTEUR,F-75724 PARIS 15,FRANCE; NCI,BETHESDA,MD 20892	Maimonides Medical Center; University of California System; University of California San Francisco; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	URNOVITZ, HB (corresponding author), CALYPTE BIOMED CORP,BERKELEY,CA 94710, USA.			Clerici, Mario/0000-0001-5920-6191				BAUER G, 1992, LANCET, V340, P559, DOI 10.1016/0140-6736(92)91763-X; CAO YZ, 1988, LANCET, V1, P831; CHAMARET S, 1992, 8 INT C AIDS AMST; CHEINGSONGPOPOV R, 1993, LANCET, V341, P1659, DOI 10.1016/0140-6736(93)90789-J; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1993, IMMUNOL TODAY, V14, P107, DOI 10.1016/0167-5699(93)90208-3; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553	8	24	26	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1458	1459		10.1016/0140-6736(93)92934-L	http://dx.doi.org/10.1016/0140-6736(93)92934-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902483				2022-12-28	WOS:A1993ML21700010
J	WAAGSTEIN, F; BRISTOW, MR; SWEDBERG, K; CAMERINI, F; FOWLER, MB; SILVER, MA; GILBERT, EM; JOHNSON, MR; GOSS, FG; HJALMARSON, A				WAAGSTEIN, F; BRISTOW, MR; SWEDBERG, K; CAMERINI, F; FOWLER, MB; SILVER, MA; GILBERT, EM; JOHNSON, MR; GOSS, FG; HJALMARSON, A			BENEFICIAL-EFFECTS OF METOPROLOL IN IDIOPATHIC DILATED CARDIOMYOPATHY	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; TERM BETA-BLOCKADE; RECEPTOR BLOCKADE; DOUBLE-BLIND; EXERCISE; IMPROVEMENT; WITHDRAWAL; DISEASE; DENSITY; TRIAL	Several small studies have suggested beneficial effects of long-term beta-blocker treatment in idiopathic dilated cardiomyopathy. Our large multicentre study aimed to find out whether metoprolol improves overall survival and morbidity in this disorder. 383 subjects with heart failure from idiopathic dilated cardiomyopathy (ejection fraction < 0.40) were randomly assigned placebo or metoprolol. 94% were in New York Heart Association functional classes II and III, and 80% were receiving background treatment. A test dose of metoprolol (5 mg twice daily) was given for 2-7 days; those tolerating this dose (96%) entered randomisation. Study medication was increased slowly from 10 mg to 100-150 mg daily. There were 34% (95% CI - 6 to 62%, p = 0.058) fewer primary end points in the metoprolol than the placebo group; 2 and 19 patients, respectively, deteriorated to the point of needing transplantation and 23 and 19 died. The change in ejection fraction from baseline to 12 months was significantly greater with metoprolol than with placebo (0.13 vs 0.06, p < 0.0001). Pulmonary capillary wedge pressure decreased more from baseline to 12 months with metoprolol than with placebo (5 vs 2 mm Hg, p = 0.06). Exercise time at 12 months was significantly greater (p = 0.046) in metoprolol-treated than in placebo-treated patients. In patients with idiopathic dilated cardiomyopathy, treatment with metoprolol prevented clinical deterioration, improved symptoms and cardiac function, and was well tolerated.	GOTHENBURG UNIV, OSTRA HOSP, DEPT MED, S-41124 GOTHENBURG, SWEDEN; UNIV UTAH, SCH MED, DIV CARDIOL, SALT LAKE CITY, UT 84112 USA; OSPED MAGGIORE TRIESTE, DIV CARDIOL, TRIESTE, ITALY; STANFORD UNIV, MED CTR, DIV CARDIOL, STANFORD, CA 94305 USA; LOYOLA UNIV, MED CTR, DIV CARDIOL, MAYWOOD, IL 60153 USA; ZENT KLINIKUM, MED KLIN, AUGSBURG, GERMANY	Sahlgrenska University Hospital; University of Gothenburg; Utah System of Higher Education; University of Utah; Stanford University; Loyola University Chicago	WAAGSTEIN, F (corresponding author), GOTHENBURG UNIV, SAHLGRENS HOSP, DIV CARDIOL, S-41345 GOTHENBURG, SWEDEN.		Swedberg, Karl/B-2475-2008; bristow, michael r/G-7850-2011					ANDERSON MG, 1991, GOV PUBL REV, V18, P555; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; BRADLEY JV, 1968, DISTRIBUTION FREE ST, P68; BRISTOW MR, 1985, J MOL CELL CARDIOL, V17, P41, DOI 10.1016/0022-2828(85)90007-0; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; CURRIE PJ, 1984, J AM COLL CARDIOL, V3, P203, DOI 10.1016/S0735-1097(84)80449-0; ENGELMEIER RS, 1985, CIRCULATION, V72, P536, DOI 10.1161/01.CIR.72.3.536; FIGULLA HR, 1985, CIRCULATION, V71, P1095, DOI 10.1161/01.CIR.71.6.1095; GILBERT EM, IN PRESS CIRCULATION; HEILBRUNN SM, 1989, CIRCULATION, V79, P483, DOI 10.1161/01.CIR.79.3.483; IKRAM H, 1981, LANCET, V2, P490; MAGNUSSON Y, 1990, J CLIN INVEST, V86, P1658, DOI 10.1172/JCI114888; NEMANICH JW, 1990, AM J CARDIOL, V66, P843, DOI 10.1016/0002-9149(90)90362-5; PACKER M, 1992, LANCET, V340, P88, DOI 10.1016/0140-6736(92)90405-R; PATTERSON JA, 1972, AM J CARDIOL, V30, P757, DOI 10.1016/0002-9149(72)90151-8; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; SANO H, 1989, CIRCULATION S2, V89, P118; SPANN JF, 1967, CIRC RES, V21, P341, DOI 10.1161/01.RES.21.3.341; SWEDBERG K, 1979, LANCET, V1, P1374; SWEDBERG K, 1980, BRIT HEART J, V44, P134; SWEDBERG K, 1980, BRIT HEART J, V44, P117; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; SWEDBERG K, 1984, AM J CARDIOL, V54, P783, DOI 10.1016/S0002-9149(84)80208-8; SWEDBERG K, 1990, CIRCULATION, V82, P1730, DOI 10.1161/01.CIR.82.5.1730; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1989, CIRCULATION, V80, P551, DOI 10.1161/01.CIR.80.3.551; WAAGSTEIN F, 1983, EUR HEART J, V4, P173, DOI 10.1093/eurheartj/4.suppl_A.173; WIKLUND I, 1987, SCAND J PSYCHOL, V28, P220, DOI 10.1111/j.1467-9450.1987.tb00758.x; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	30	1014	1058	0	21	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1441	1446		10.1016/0140-6736(93)92930-R	http://dx.doi.org/10.1016/0140-6736(93)92930-R			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902479				2022-12-28	WOS:A1993ML21700006
J	GARATTINI, S; GARATTINI, L				GARATTINI, S; GARATTINI, L			PHARMACEUTICAL PRESCRIPTIONS IN 4 EUROPEAN COUNTRIES	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), MARIO NEGRI INST PHARMACOL RES,CTR ECON SANIT A VALENTI,I-20157 MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297					0	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1191	1192		10.1016/0140-6736(93)92181-R	http://dx.doi.org/10.1016/0140-6736(93)92181-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901525				2022-12-28	WOS:A1993MG27400005
J	MUERS, M				MUERS, M			UNDERSTANDING BREATHLESSNESS	LANCET			English	Editorial Material							AIR HUNGER				MUERS, M (corresponding author), KILLINGBECK HOSP,RESP UNIT,LEEDS,ENGLAND.							BANZETT RB, 1990, RESP PHYSIOL, V81, P1, DOI 10.1016/0034-5687(90)90065-7; BANZETT RB, 1989, RESP PHYSIOL, V76, P53, DOI 10.1016/0034-5687(89)90017-0; CAMPBELL EJ, 1969, CLIN SCI, V36, P323; DAVIS JN, 1967, CLIN SCI, V33, P249; FOWLER WS, 1954, J APPL PHYSIOL, V6, P539, DOI 10.1152/jappl.1954.6.9.539; GANDEVIA SC, 1993, J PHYSIOL-LONDON, V470, P85, DOI 10.1113/jphysiol.1993.sp019849; HOWELL JBL, 1990, THORAX, V45, P287, DOI 10.1136/thx.45.4.287; HOWELL JBL, 1970, HERRINGBREUER CENTEN, P287; HOWELL JBL, 1990, BREATHLESSNESS, P221; MCCLOSKEY DI, 1981, HDB PHYSL NERVOUS SY, V2, P1415; Merton P A, 1964, Symp Soc Exp Biol, V18, P387	11	8	8	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1190	1191		10.1016/0140-6736(93)92180-2	http://dx.doi.org/10.1016/0140-6736(93)92180-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901524				2022-12-28	WOS:A1993MG27400004
J	ASCHERIO, A; RIMM, EB; STAMPFER, MJ; GIOVANNUCCI, EL; WILLETT, WC				ASCHERIO, A; RIMM, EB; STAMPFER, MJ; GIOVANNUCCI, EL; WILLETT, WC			DIETARY-INTAKE OF MARINE N-3 FATTY-ACIDS, FISH INTAKE, AND THE RISK OF CORONARY-DISEASE AMONG MEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; HEART-DISEASE; MYOCARDIAL-INFARCTION; ADIPOSE-TISSUE; CONSUMPTION; MORTALITY; GREENLAND	Background. It has been hypothesized that a diet containing n-3 fatty acids from fish reduces the risk of coronary heart disease, but few large epidemiologic studies have examined this question. Methods. In 1986, 44,895 male health professionals, 40 to 75 years of age, who were free of known cardiovascular disease completed detailed and validated dietary questionnaires as part of the Health Professionals Followup Study. During six years of follow-up, we documented 1543 coronary events in this group: 264 deaths from coronary disease, 547 nonfatal myocardial infarctions, and 732 coronary-artery bypass or angioplasty procedures. Results. After controlling for age and several coronary risk factors, we observed no significant associations between dietary intake of n-3 fatty acids or fish intake and the risk of coronary disease, For men in the top fifth of the group in terms of intake of n-3 fatty acids (median, 0.58 g per day), the multivariate relative risk of coronary heart disease was 1.12 (95 percent confidence interval, 0.96 to 1.31), as compared with the men in the bottom fifth (median, 0.07 g per day). For men who consumed six or more servings of fish per week, as compared with those who consumed one serving per month or less, the multivariate relative risk of coronary disease was 1.14 (95 percent confidence interval, 0.86 to 1.51). The risk of death due to coronary disease among men who ate any amount of fish, as compared with those who ate no fish, was 0.74 (95 percent confidence interval, 0.44 to 1.23), but the risk did not decrease as fish consumption increased. Conclusions, Although the possibility of residual confounding by unmeasured factors cannot be entirely excluded, these data suggest that increasing fish intake from one to two servings per week to five to six servings per week does not substantially reduce the risk of coronary heart disease among men who are initially free of cardiovascular disease.	HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	ASCHERIO, A (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, 665 HUNTINGTON AVE, BOSTON, MA 02115 USA.				NATIONAL CANCER INSTITUTE [P01CA055075] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035464] Funding Source: NIH RePORTER; NCI NIH HHS [CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANG HO, 1980, AM J CLIN NUTR, V33, P2657, DOI 10.1093/ajcn/33.12.2657; BRR ML, 1989, LANCET, V2, P757; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; CURB JD, 1985, NEW ENGL J MED, V313, P821; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GABH Rose, 1982, WHO MONOGRAPH SERIES; GRAMENZI A, 1990, BMJ-BRIT MED J, V300, P771, DOI 10.1136/bmj.300.6727.771; GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6; HIRAI A, 1980, LANCET, V2, P1132; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; KROMANN N, 1980, ACTA MED SCAND, V208, P401; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MIETTINEN TA, 1982, BRIT MED J, V285, P993, DOI 10.1136/bmj.285.6347.993; MORRIS MC, 1992, CIRCULATION, V86, P463; NORELL SE, 1986, BRIT MED J, V293, P426, DOI 10.1136/bmj.293.6544.426; RAPER NR, 1992, 50 DEP AGR HOM EC RE; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; RIMM EB, 1992, AM J EPIDEMIOL, V135, P114; RIMM EB, 1993, NEW ENGL J MED, V328, P450; Rothman K, 1986, MODERN EPIDEMIOLOGY; SCHMIDT EB, 1994, DRUGS, V47, P405, DOI 10.2165/00003495-199447030-00003; SCHRADE W, 1961, J ATHEROSCLER RES, V1, P47, DOI 10.1016/S0368-1319(61)80053-7; SEIDELIN KN, 1992, AM J CLIN NUTR, V55, P1117, DOI 10.1093/ajcn/55.6.1117; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WOOD DA, 1984, LANCET, V2, P117, DOI 10.1016/S0140-6736(84)91044-4; WOOD DA, 1987, LANCET, V1, P117; 1963, AGR HDB DEP AGR, V8	32	427	429	0	17	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					977	982		10.1056/NEJM199504133321501	http://dx.doi.org/10.1056/NEJM199504133321501			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885425				2022-12-28	WOS:A1995QT73700001
J	SCHLITT, HJ; PICHLMAYR, R				SCHLITT, HJ; PICHLMAYR, R			INCREASING THE LONG-TERM SUCCESS OF RENAL-TRANSPLANTATION	LANCET			English	Editorial Material							LIVER-TRANSPLANTATION; DRUG-THERAPY; TRIAL				SCHLITT, HJ (corresponding author), HANNOVER MED SCH,ABDOMINAL & TRANSPLANTAT CHIRURG KLIN,HANNOVER,GERMANY.		Schlitt, Hans J./ABG-4368-2020					[Anonymous], 1983, LANCET, V2, P986; BRINKER KR, 1990, TRANSPLANTATION, V50, P43, DOI 10.1097/00007890-199007000-00009; BURKE JF, 1994, NEW ENGL J MED, V331, P358, DOI 10.1056/NEJM199408113310604; FONTES P, 1994, LANCET, V344, P151, DOI 10.1016/S0140-6736(94)92756-1; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; NEUHAUS P, 1993, TRANSPLANTATION, V55, P1320, DOI 10.1097/00007890-199306000-00021; OPELZ G, 1994, TRANSPLANTATION, V58, P443, DOI 10.1097/00007890-199408270-00009; REYES J, 1993, TRANSPL P, V25, P3315; SCHLITT HJ, 1994, LANCET, V343, P1469, DOI 10.1016/S0140-6736(94)92584-4; SOLLINGER HW, 1992, TRANSPLANTATION, V53, P428, DOI 10.1097/00007890-199202010-00031; VANROOD JJ, 1994, CLIN TRANSPLANTS 199, P285	11	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					600	601		10.1016/S0140-6736(95)90515-4	http://dx.doi.org/10.1016/S0140-6736(95)90515-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898173				2022-12-28	WOS:A1995QM07500003
J	SHABAT, D; ITZHAKY, H; REYMOND, JL; KEINAN, E				SHABAT, D; ITZHAKY, H; REYMOND, JL; KEINAN, E			ANTIBODY CATALYSIS OF A REACTION OTHERWISE STRONGLY DISFAVOURED IN WATER	NATURE			English	Article							HYDROLYSIS; ETHERS	SEVERAL examples have been reported recently(1) of antibody catalysis(2) of reactions that are strongly disfavoured because of the high free energy of the transition state, Here we shaw that catalytic antibodies can be used to promote a particularly useful kind of reaction from a synthetic point of view: one involving an intermediate that is highly unstable in water, We show that an antibody elicited against the quaternary ammonium ion 4a (Fig, 1) catalyses the protonation of the enol ether 1 to form, with complete enantioselectivity, an oxocarbonium intermediate. This species is highly reactive in water, and would normally react with a water molecule to give the corresponding ketone 2, But the antibody provides a hydrophobic environment that allows the oxocarbonium ion instead to undergo an intramolecular reaction to form an enantiomerically pure ketal 3, This result shows that catalytic antibodies can exclude solvent molecules entirely from crucial steps on the reaction pathway.	TECHNION ISRAEL INST TECHNOL, DEPT CHEM, IL-32000 HAIFA, ISRAEL; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Technion Israel Institute of Technology; Scripps Research Institute				Reymond, Jean-Louis/0000-0003-2724-2942				BANAIT NS, 1991, J AM CHEM SOC, V113, P7951, DOI 10.1021/ja00021a021; EVANS DA, 1982, J AM CHEM SOC, V104, P1737, DOI 10.1021/ja00370a050; JAHANGIRI GK, 1994, J AM CHEM SOC, V116, P11264, DOI 10.1021/ja00104a008; JENKS WP, 1987, CATALYSIS CHEM ENZYM, P52; LERNER RA, 1991, SCIENCE, V252, P659, DOI 10.1126/science.2024118; LEWIS C, 1993, J AM CHEM SOC, V115, P1410, DOI 10.1021/ja00057a025; POTHIER N, 1992, HELV CHIM ACTA, V75, P604, DOI 10.1002/hlca.19920750217; REYMOND JL, 1994, ANGEW CHEM INT EDIT, V33, P475, DOI 10.1002/anie.199404751; REYMOND JL, 1993, J AM CHEM SOC, V115, P3909, DOI 10.1021/ja00063a009; REYMOND JL, 1991, ANGEW CHEM INT EDIT, V30, P1711, DOI 10.1002/anie.199117111; SCHMIR GL, 1965, J AM CHEM SOC, V87, P5692, DOI 10.1021/ja00952a030; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SCHUSTER M, 1994, J AM CHEM SOC, V116, P1135, DOI 10.1021/ja00082a047; SINHA SC, 1993, J AM CHEM SOC, V115, P4893, DOI 10.1021/ja00064a061; SINHA SC, 1993, P NATL ACAD SCI USA, V90, P11910, DOI 10.1073/pnas.90.24.11910	15	39	39	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					143	146		10.1038/374143a0	http://dx.doi.org/10.1038/374143a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	QL397	7877686				2022-12-28	WOS:A1995QL39700052
J	ARANY, Z; NEWSOME, D; OLDREAD, E; LIVINGSTON, DM; ECKNER, R				ARANY, Z; NEWSOME, D; OLDREAD, E; LIVINGSTON, DM; ECKNER, R			A FAMILY OF TRANSCRIPTIONAL ADAPTER PROTEINS TARGETED BY THE E1A ONCOPROTEIN	NATURE			English	Article							TISSUE-SPECIFIC EXTINGUISHER; REGULATORY SUBUNIT; TSE1 ENCODES; CYCLIC-AMP; ACTIVATION; KINASE; GENE	THE cellular protein p300 is a target of the adenoviral E1A oncoprotein and is thought to participate in preventing the G0/G1 transition in the cell cycle, activating certain enhancers and stimulating differentiation pathways(1). CBP is a protein that is associated with and coactivates the transcription factor CREB, mediating the induction by cyclic AMP of certain responsive promoters(2-4). The sequences of p300 and CBP are highly related(4,5). We show here that p300, like CBP2, can stimulate transcription, This activity is directly aml specifically inhibited by E1A. We also find that CBP exists in a DNA-bound complex containing a member of the CREB family and that E1A and CBP interact with one another in vivo. In keeping with the idea that E1A functionally targets CBP, cAMP-dependent transcription is repressed by E1A. Thus, p300 and CBP define a family of transcriptional adaptor proteins that are specifically targeted by the E1A oncoprotein.			ARANY, Z (corresponding author), HARVARD UNIV,SCH MED,DANA FARBER CANC INST,44 BINNEY ST,BOSTON,MA 02115, USA.							ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V30, P226; BARBEAU D, 1994, ONCOGENE, V9, P359; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOSHART M, 1991, CELL, V66, P849, DOI 10.1016/0092-8674(91)90432-X; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; JANASWAMI PM, 1992, J BIOL CHEM, V267, P24886; JONES KW, 1991, CELL, V66, P861, DOI 10.1016/0092-8674(91)90433-Y; KALVAKOLANU DVR, 1992, J BIOL CHEM, V267, P2530; KATO J, 1994, J CELL SCI, V79, P487; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; VAIRO G, 1990, J BIOL CHEM, V265, P2692; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	16	507	513	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					81	84		10.1038/374081a0	http://dx.doi.org/10.1038/374081a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870178				2022-12-28	WOS:A1995QK07900058
J	JARMAN, PR; WALPORT, MJ; PRIDE, NB; HUGHES, JMB; SCADDING, JG; FRACKOWIAK, RS; PETERS, AM				JARMAN, PR; WALPORT, MJ; PRIDE, NB; HUGHES, JMB; SCADDING, JG; FRACKOWIAK, RS; PETERS, AM			GRAND ROUNDS - HAMMERSMITH-HOSPITAL - MENINGEAL GRANULOMAS - SARCOIDOSIS OR TUBERCULOSIS	BRITISH MEDICAL JOURNAL			English	Discussion							NEUROSARCOIDOSIS; MANIFESTATIONS; DNA				JARMAN, PR (corresponding author), HAMMERSMITH HOSP,DEPT MED,LONDON W12 0NN,ENGLAND.		Frackowiak, Richard/H-4383-2011; Frackowiak, Richard S/I-1809-2013	Frackowiak, Richard/0000-0002-3151-822X; 				BOCART D, 1992, AM REV RESPIR DIS, V145, P1142, DOI 10.1164/ajrccm/145.5.1142; DELANEY P, 1977, ANN INTERN MED, V87, P336, DOI 10.7326/0003-4819-87-3-336; FIDLER HM, 1993, BRIT MED J, V306, P546, DOI 10.1136/bmj.306.6877.546; KETONEN L, 1987, NEURORADIOLOGY, V29, P127, DOI 10.1007/BF00327536; KHAW KT, 1991, J NEUROL NEUROSUR PS, V54, P499, DOI 10.1136/jnnp.54.6.499; MILLER DH, 1988, NEUROLOGY, V38, P378, DOI 10.1212/WNL.38.3.378; MITCHELL DN, 1977, J CLIN PATHOL, V30, P395, DOI 10.1136/jcp.30.5.395; OKSANEN V, 1986, ACTA NEUROL SCAND, V73, P283; OKSANEN V, 1985, NEUROLOGY, V35, P1220, DOI 10.1212/WNL.35.8.1220; RANOUX D, 1992, J NEUROL NEUROSUR PS, V55, P30; RICKER W, 1949, AM J CLIN PATHOL, V19, P724; SCADDING JG, 1985, SARCOIDOSIS; STERN BJ, 1985, ARCH NEUROL-CHICAGO, V42, P909, DOI 10.1001/archneur.1985.04060080095022; WINTERBAUER RH, 1976, ARCH INTERN MED, V136, P1356, DOI 10.1001/archinte.136.12.1356; 1990, NEW ENGL J MED, V322, P1728	15	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					517	520						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888899				2022-12-28	WOS:A1995QJ59800033
J	WINDELER, J; LANGE, S				WINDELER, J; LANGE, S			EVENTS PER PERSON YEAR - A DUBIOUS CONCEPT	BRITISH MEDICAL JOURNAL			English	Article							POSTMENOPAUSAL OSTEOPOROSIS; CLINICAL-TRIALS; FRACTURE RATE; CALCIUM; THERAPY; WOMEN	In 1982 a new measure was introduced in research into osteoporosis and is now used everywhere in the literature. The so called ''fracture rate'' relates the number of fractures (single in some patients, multiple in others) to the cumulative time of observation of all patients. This concept, however, has no sound basis. Counting events instead of patients usually violates basic statistical assumptions and invalidates the use of common statistical tests and estimators. Its clinical interpretation is rather dubious. The use of such a measure impedes the search for valid and clinically meaningful outcome criteria and should be abandoned.	RUHR UNIV BOCHUM,MED INFORMAT & BIOMATH ABT,BOCHUM,GERMANY	Ruhr University Bochum	WINDELER, J (corresponding author), UNIV HEIDELBERG,INST MED BIOMETRIE,NEUENHEIMER FELD 305,D-69120 HEIDELBERG,GERMANY.							ANDERSEN B, 1990, METHODOLOGICAL ERROR, P152; ARMITAGE P, 1987, STATISTICAL METHODS; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; Kleerekoper M, 1991, Osteoporos Int, V1, P155, DOI 10.1007/BF01625446; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LUFKIN EG, 1992, ANN INTERN MED, V117, P1, DOI 10.7326/0003-4819-117-1-1; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; NEWELL DJ, 1992, INT J EPIDEMIOL, V21, P837, DOI 10.1093/ije/21.5.837; PAK C Y C, 1990, Journal of Bone and Mineral Research, V5, pS149; PALMIERI GMA, 1989, CALCIFIED TISSUE INT, V45, P137, DOI 10.1007/BF02556055; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; RIGGS BL, 1982, NEW ENGL J MED, V306, P446, DOI 10.1056/NEJM198202253060802; RYAN PJ, 1992, ANN RHEUM DIS, V51, P1063, DOI 10.1136/ard.51.9.1063; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; STORM T, 1990, NEW ENGL J MED, V323, P1210; STORM T, 1990, NEW ENGL J MED, V322, P1265, DOI 10.1056/NEJM199005033221803; TILYARD MW, 1992, NEW ENGL J MED, V326, P357, DOI 10.1056/NEJM199202063260601; WATTS NB, 1990, NEW ENGL J MED, V323, P73, DOI 10.1056/NEJM199007123230201	19	68	68	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					454	456		10.1136/bmj.310.6977.454	http://dx.doi.org/10.1136/bmj.310.6977.454			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873955	Green Published			2022-12-28	WOS:A1995QJ24200027
J	NATAZUKA, T; MANABE, Y; KONO, M; MURAYAMA, T; MATSUI, T; CHIHARA, K				NATAZUKA, T; MANABE, Y; KONO, M; MURAYAMA, T; MATSUI, T; CHIHARA, K			ASSOCIATION BETWEEN NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND NON-HODGKINS-LYMPHOMA	BRITISH MEDICAL JOURNAL			English	Article									KOBE UNIV,SCH MED,DEPT MED,CHUO KU,KOBE 650,JAPAN; KOBE UNIV,SCH MED,DEPT RADIOL,KOBE 650,JAPAN; FUKUI MED SCH,DEPT OTOLARYNGOL,FUKUI,JAPAN	Kobe University; Kobe University; University of Fukui			Matsui, Toshimitsu/E-8065-2010	Matsui, Toshimitsu/0000-0002-2536-7584				BIERMAN PJ, 1991, HEMATOLOGY BASIC PRI, P963; JACKSON RM, 1987, OTOLARYNG HEAD NECK, V97, P469, DOI 10.1177/019459988709700507; OTTER R, 1989, EUR J CANCER CLIN ON, V25, P1203, DOI 10.1016/0277-5379(89)90416-1; RAGOZZINO MW, 1983, J CHRON DIS, V36, P363, DOI 10.1016/0021-9681(83)90167-4; STOWENS D, 1981, LANCET, V2, P989	5	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1269	1269		10.1136/bmj.309.6964.1269	http://dx.doi.org/10.1136/bmj.309.6964.1269			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888850	Green Published			2022-12-28	WOS:A1994PT03300023
J	CATALONA, WJ				CATALONA, WJ			MANAGEMENT OF CANCER OF THE PROSTATE	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXTERNAL BEAM RADIATION; RADICAL RETROPUBIC PROSTATECTOMY; GONADOTROPIN-RELEASING-HORMONE; LYMPH-NODE DISSECTION; TERM FOLLOW-UP; ANTIGEN LEVELS; PHASE-II; LOCALIZED ADENOCARCINOMA; DEFINITIVE RADIOTHERAPY; CLINICAL-TRIAL				CATALONA, WJ (corresponding author), WASHINGTON UNIV, SCH MED, DEPT SURG, DIV UROL SURG, 4960 CHILDRENS PL, ST LOUIS, MO 63110 USA.							ADOLFSSON J, 1993, J UROLOGY, V149, P326, DOI 10.1016/S0022-5347(17)36071-8; ANSCHER MS, 1992, INT J RADIAT ONCOL, V24, P489, DOI 10.1016/0360-3016(92)91064-T; Bagshaw M A, 1988, NCI Monogr, P47; BELAND G, 1991, UROL CLIN N AM, V18, P75; BIGG SW, 1990, J UROLOGY, V144, P1420, DOI 10.1016/S0022-5347(17)39758-6; BLUTE ML, 1989, J UROLOGY, V142, P1262, DOI 10.1016/S0022-5347(17)39051-1; BLUTE ML, 1986, J UROLOGY, V136, P840, DOI 10.1016/S0022-5347(17)45098-1; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; BRAWER MK, 1992, J UROLOGY, V147, P841, DOI 10.1016/S0022-5347(17)37401-3; BROSMAN SA, 1991, UROLOGY, V38, P372, DOI 10.1016/0090-4295(91)80157-3; Byar D P, 1988, NCI Monogr, P165; BYRNE TN, 1992, NEW ENGL J MED, V327, P614; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; CATALONA WJ, 1993, JAMA-J AM MED ASSOC, V270, P948, DOI 10.1001/jama.270.8.948; CATALONA WJ, 1990, J UROLOGY, V143, P538, DOI 10.1016/S0022-5347(17)40013-9; CATALONA WJ, 1992, J UROLOGY, V147, P916, DOI 10.1016/S0022-5347(17)37421-9; CATALONA WJ, 1993, J UROLOGY, V150, P905, DOI 10.1016/S0022-5347(17)35645-8; CATALONA WJ, 1991, NEW ENGL J MED, V325, P1324; CATALONA WJ, 1989, J UROLOGY, V142, P1302, DOI 10.1016/S0022-5347(17)39066-3; CATALONA WJ, 1992, JAMA-J AM MED ASSOC, V268, P3198, DOI 10.1001/jama.1992.03490220040016; CHODAK GW, 1994, NEW ENGL J MED, V330, P242, DOI 10.1056/NEJM199401273300403; COLEMAN CN, 1992, INT J RADIAT ONCOL, V22, P565; CONN PM, 1991, NEW ENGL J MED, V324, P93; CRAWFORD E D, 1992, Journal of Urology, V147, p417A; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P419, DOI 10.1056/NEJM198908173210702; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P1420; DENIS L, 1990, CANCER-AM CANCER SOC, V66, P1086; DENIS LJ, 1993, UROLOGY, V42, P119, DOI 10.1016/0090-4295(93)90634-M; EISENBERGER M A, 1988, NCI (National Cancer Institute) Monographs, P151; EPSTEIN BE, 1992, CA-CANCER J CLIN, V42, P223, DOI 10.3322/canjclin.42.4.223; EPSTEIN JI, 1986, J UROLOGY, V136, P837, DOI 10.1016/S0022-5347(17)45097-X; FLEMING C, 1993, JAMA-J AM MED ASSOC, V269, P2650, DOI 10.1001/jama.269.20.2650; Fleshner Neil, 1993, Journal of Urology, V149, p258A; FRAZIER HA, 1993, J UROLOGY, V149, P516, DOI 10.1016/S0022-5347(17)36132-3; GELLER J, 1991, J ANDROL, V12, P364; GIBBONS R P, 1988, NCI (National Cancer Institute) Monographs, P123; GIBBONS RP, 1986, J UROLOGY, V135, P65, DOI 10.1016/S0022-5347(17)45519-4; Gleason DF, 1977, UROLOGIC PATHOLOGY P, P171; GOFFINET DR, 1980, CANCER, V45, P2717, DOI 10.1002/1097-0142(19800601)45:11<2717::AID-CNCR2820451104>3.0.CO;2-#; HANKS GE, 1991, INT J RADIAT ONCOL, V21, P1099, DOI 10.1016/0360-3016(91)90757-U; HANKS GE, 1988, INT J RADIAT ONCOL, V14, P1053, DOI 10.1016/0360-3016(88)90033-8; HOLZMAN M, 1991, J UROLOGY, V146, P1578, DOI 10.1016/S0022-5347(17)38171-5; HUDES GR, 1992, J CLIN ONCOL, V10, P1754, DOI 10.1200/JCO.1992.10.11.1754; HUDSON MA, 1989, J UROLOGY, V142, P1011, DOI 10.1016/S0022-5347(17)38972-3; JANKNEGT RA, 1993, J UROLOGY, V149, P77, DOI 10.1016/S0022-5347(17)36003-2; JOHANSSON JE, 1992, JAMA-J AM MED ASSOC, V267, P2191, DOI 10.1001/jama.267.16.2191; KABALIN JN, 1992, J UROLOGY, V148, P1565; KAPLAN ID, 1993, J UROLOGY, V149, P519, DOI 10.1016/S0022-5347(17)36133-5; KAVOUSSI LR, 1993, J UROLOGY, V149, P322, DOI 10.1016/S0022-5347(17)36069-X; KELLY WK, 1993, J UROLOGY, V149, P607; KOPROWSKI CD, 1991, INT J RADIAT ONCOL, V21, P955, DOI 10.1016/0360-3016(91)90735-M; KOZLOWSKI JM, 1991, UROL CLIN N AM, V18, P15; KUBAN DA, 1989, CANCER, V63, P2415, DOI 10.1002/1097-0142(19890615)63:12<2415::AID-CNCR2820631207>3.0.CO;2-U; KUBAN DA, 1991, UROL CLIN N AM, V18, P131; KUHN JM, 1989, NEW ENGL J MED, V321, P413, DOI 10.1056/NEJM198908173210701; Lange P H, 1988, NCI Monogr, P141; LANGE PH, 1990, J UROLOGY, V144, P927, DOI 10.1016/S0022-5347(17)39624-6; LANGE PH, 1993, JAMA-J AM MED ASSOC, V269, P2212, DOI 10.1001/jama.1993.03500170042025; LARAMORE GE, 1993, AM J CLIN ONCOL-CANC, V16, P164, DOI 10.1097/00000421-199304000-00018; LAWTON CA, 1991, INT J RADIAT ONCOL, V21, P935, DOI 10.1016/0360-3016(91)90732-J; LEPOR H, 1988, NATL CANCER I MONOGR, V7, P117; LIGHTNER DJ, 1990, J UROLOGY, V144, P921, DOI 10.1016/S0022-5347(17)39623-4; LINK P, 1991, J UROLOGY, V145, P532, DOI 10.1016/S0022-5347(17)38388-X; LITTRUP PJ, 1993, CA-CANCER J CLIN, V43, P134, DOI 10.3322/canjclin.43.3.134; MARINELLI D, 1992, J UROLOGY, V147, P922, DOI 10.1016/S0022-5347(17)37423-2; MARTINEZ A, 1985, INT J RADIAT ONCOL, V11, P391, DOI 10.1016/0360-3016(85)90163-4; McCarthy John, 1993, Journal of Urology, V149, p430A; MILLER JI, 1992, J UROLOGY, V147, P956, DOI 10.1016/S0022-5347(17)37432-3; MORGAN WR, 1993, UROLOGY, V41, P113, DOI 10.1016/0090-4295(93)90159-8; MORTON RA, 1991, J UROLOGY, V145, P1197, DOI 10.1016/S0022-5347(17)38574-9; MYERS C, 1992, J CLIN ONCOL, V10, P881, DOI 10.1200/JCO.1992.10.6.881; MYERS RP, 1992, J UROLOGY, V147, P910, DOI 10.1016/S0022-5347(17)37420-7; NEERHUT GJ, 1988, J UROLOGY, V140, P544, DOI 10.1016/S0022-5347(17)41714-9; OESTERLING JE, 1993, J UROLOGY, V149, P779, DOI 10.1016/S0022-5347(17)36206-7; PARMAR H, 1985, LANCET, V2, P1201; PAULSON D F, 1988, NCI (National Cancer Institute) Monographs, P127; PAULSON DF, 1990, J UROLOGY, V143, P1178, DOI 10.1016/S0022-5347(17)40219-9; PILEPICH MV, 1990, AM J CLIN ONCOL-CANC, V13, P461, DOI 10.1097/00000421-199012000-00001; PONTES JE, 1993, CANCER, V71, P976, DOI 10.1002/1097-0142(19930201)71:3+<976::AID-CNCR2820711413>3.0.CO;2-M; PRESTI JC, 1992, J UROLOGY, V148, P1201, DOI 10.1016/S0022-5347(17)36860-X; QUINLAN DM, 1991, J UROLOGY, V145, P998, DOI 10.1016/S0022-5347(17)38512-9; RUSSELL KJ, 1991, J UROLOGY, V146, P1046, DOI 10.1016/S0022-5347(17)37998-3; SCHELLHAMMER PF, 1993, UROLOGY, V42, P13, DOI 10.1016/0090-4295(93)90325-5; SEIDMAN AD, 1992, J UROLOGY, V147, P931, DOI 10.1016/S0022-5347(17)37426-8; SHEARER R J, 1973, British Journal of Urology, V45, P668, DOI 10.1111/j.1464-410X.1973.tb12238.x; Shipley W U, 1988, NCI Monogr, P67; Simpson K. N., 1993, J UROL S, V149, p413A; SMITH JA, 1984, J UROLOGY, V131, P705, DOI 10.1016/S0022-5347(17)50590-X; SOFFEN EM, 1992, INT J RADIAT ONCOL, V24, P485, DOI 10.1016/0360-3016(92)91063-S; STAMEY TA, 1990, J UROLOGY, V143, P1166; STEIN A, 1992, J UROLOGY, V147, P942, DOI 10.1016/S0022-5347(17)37429-3; STEINBERG GD, 1990, J UROLOGY, V144, P1425, DOI 10.1016/S0022-5347(17)39759-8; WHITMORE WF, 1991, CANCER, V67, P1091, DOI 10.1002/1097-0142(19910215)67:4<1091::AID-CNCR2820670437>3.0.CO;2-J; ZAGARS GK, 1987, CANCER, V60, P1489, DOI 10.1002/1097-0142(19871001)60:7<1489::AID-CNCR2820600715>3.0.CO;2-9; ZAGARS GK, 1991, CANCER-AM CANCER SOC, V67, P412, DOI 10.1002/1097-0142(19910115)67:2<412::AID-CNCR2820670216>3.0.CO;2-R; 1992, MANUAL CANCER STAGIN, P181; 1984, NEW ENGL J MED, V311, P1281	97	263	277	0	5	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 13	1994	331	15					996	1004						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PK504	7880240				2022-12-28	WOS:A1994PK50400007
J	DOHN, MN; WEINBERG, WG; TORRES, RA; FOLLANSBEE, SE; CALDWELL, PT; SCOTT, JD; GATHE, JC; HAGHIGHAT, DP; SAMPSON, JH; SPOTKOV, J; DERESINSKI, SC; MEYER, RD; LANCASTER, DJ; FRAME, PT; MOHSENIFAR, Z; BUCKLEY, RM; CHEUNG, T; HYLAND, R; CHAN, C; LANG, W; MILDVAN, D; GREENBERG, SB; CRAVEN, D; HIRSCH, M; ELSADR, W; JOSEPH, P; HARDY, D; BROWN, N; ROGERS, M				DOHN, MN; WEINBERG, WG; TORRES, RA; FOLLANSBEE, SE; CALDWELL, PT; SCOTT, JD; GATHE, JC; HAGHIGHAT, DP; SAMPSON, JH; SPOTKOV, J; DERESINSKI, SC; MEYER, RD; LANCASTER, DJ; FRAME, PT; MOHSENIFAR, Z; BUCKLEY, RM; CHEUNG, T; HYLAND, R; CHAN, C; LANG, W; MILDVAN, D; GREENBERG, SB; CRAVEN, D; HIRSCH, M; ELSADR, W; JOSEPH, P; HARDY, D; BROWN, N; ROGERS, M			ORAL ATOVAQUONE COMPARED WITH INTRAVENOUS PENTAMIDINE FOR PNEUMOCYSTIS-CARINII PNEUMONIA IN PATIENTS WITH AIDS	ANNALS OF INTERNAL MEDICINE			English	Article						PENTAMIDINE; ATOVAQUONE; PNEUMONIA, PNEUMOCYSTIS CARINII; ACQUIRED IMMUNODEFICIENCY SYNDROME	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; TRIMETHOPRIM-SULFAMETHOXAZOLE; CLINDAMYCIN PRIMAQUINE; RANDOMIZED TRIAL; 566C80; EFFICACY; THERAPY; DAPSONE	Objective: To test the hypothesis that the therapeutic success rate of oral atovaquone is not worse than that of intravenous pentamidine in the primary treatment of mild and moderate Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome and to detect differences in the toxicity rates of the two treatments. Design: Patients were randomly assigned to receive 21 days of open-label therapy with either atovaquone, 750 mg orally with meals three times daily, or intravenous pentamidine, 3 to 4 mg per kg body weight once daily. Setting: Multicenter study including university and community treatment facilities. Patients: Patients with human immunodeficiency virus infection and clinical presentations consistent with mild or moderate P. carinii pneumonia were eligible. For efficacy and safety analyses, patients with histologically confirmed P. carinii pneumonia were emphasized. Measurements: Patients were monitored by clinical and laboratory evaluations for therapeutic efficacy and adverse events during the acute treatment phase and for 8 weeks after therapy was discontinued.	INFECT DIS RES CONSORTIUM GEORGIA, ATLANTA, GA USA; ST VINCENTS HOSP & MED CTR, NEW YORK, NY 10011 USA; DAVIES MED CTR, INST HIV RES & TREATMENT, SAN FRANCISCO, CA USA; BURROUGHS WELLCOME CO, RES TRIANGLE PK, NC 27709 USA; PK PLAZA MED CTR, HOUSTON, TX USA; UNIV CALIF IRVINE, IRVINE MED CTR, ORANGE, CA 92668 USA; RES & EDUC GRP, PORTLAND, OR USA; KAISER FDN HOSP, HARBOR CITY, CA USA; AIDS CLIN RES CONSORTIUM, REDWOOD CITY, CA USA; CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA; REG MED CTR, MEMPHIS, TN USA; PENN HOSP, PHILADELPHIA, PA 19107 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA; WELLESLEY COLL HOSP, TORONTO M4Y 1J3, ON, CANADA; VIRX INC, SAN FRANCISCO, CA USA; BETH ISRAEL MED CTR, NEW YORK, NY 10003 USA; BAYLOR COLL MED, HOUSTON, TX 77030 USA; BOSTON CITY HOSP, BOSTON, MA 02118 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; HARLEM HOSP MED CTR, NEW YORK, NY 10037 USA; SUMMIT MED CTR, OAKLAND, CA USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA USA	Saint Vincents Hospital Manhattan; California Pacific Medical Center; Burroughs Wellcome Fund; University of California System; University of California Irvine; Kaiser Permanente; Cedars Sinai Medical Center; University of Pennsylvania; Pennsylvania Medicine; Icahn School of Medicine at Mount Sinai; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Harvard University; Beth Israel Deaconess Medical Center; Baylor College of Medicine; Boston Medical Center; Harvard University; Massachusetts General Hospital; University of California System; University of California Los Angeles	DOHN, MN (corresponding author), UNIV CINCINNATI, COLL MED, DEPT INTERNAL MED, DIV PULM CRIT CARE, POB 670564, CINCINNATI, OH 45267 USA.							BLACK JR, 1991, EUR J CLIN MICROBIOL, V10, P204, DOI 10.1007/BF01964465; CONTE JE, 1990, ANN INTERN MED, V113, P203, DOI 10.7326/0003-4819-113-3-203; DOHN MN, 1992, ARCH INTERN MED, V152, P2465, DOI 10.1001/archinte.152.12.2465; DOHN MN, 1991, J PROTOZOOL, V38, pS220; FALLOON J, 1991, NEW ENGL J MED, V325, P1534, DOI 10.1056/NEJM199111283252202; Fleiss JL, 1981, STAT METHODS RATES P; FREIMAN JA, 1992, MED USES STATISTICS; HAMMOND DJ, 1985, MOL BIOCHEM PARASIT, V164, P170; HUGHES W, 1993, NEW ENGL J MED, V328, P1521, DOI 10.1056/NEJM199305273282103; HUGHES WT, 1990, ANTIMICROB AGENTS CH, V34, P225, DOI 10.1128/AAC.34.2.225; KLEIN NC, 1992, AIDS, V6, P301, DOI 10.1097/00002030-199203000-00007; LEE BL, 1989, ANN INTERN MED, V110, P606, DOI 10.7326/0003-4819-110-8-606; LEOUNG GS, 1986, ANN INTERN MED, V105, P45, DOI 10.7326/0003-4819-105-1-45; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; NOSKIN GA, 1992, CLIN INFECT DIS, V14, P183, DOI 10.1093/clinids/14.1.183; RUF B, 1989, LANCET, V2, P626; RUF B, 1991, EUR J CLIN MICROBIOL, V10, P207, DOI 10.1007/BF01964466; TOMA E, 1989, LANCET, V1, P1046, DOI 10.1016/S0140-6736(89)92446-X; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; 1981, MMWR MORB REP, V30, P305; 1981, MMWR MORB REP, V30, P250	23	76	78	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1994	121	3					174	180		10.7326/0003-4819-121-3-199408010-00003	http://dx.doi.org/10.7326/0003-4819-121-3-199408010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NY338	7880228				2022-12-28	WOS:A1994NY33800003
J	HOOVER, DR; SAAH, AJ; BACELLAR, H; PHAIR, J; DETELS, R; ANDERSON, R; KASLOW, RA				HOOVER, DR; SAAH, AJ; BACELLAR, H; PHAIR, J; DETELS, R; ANDERSON, R; KASLOW, RA			CLINICAL MANIFESTATIONS OF AIDS IN THE ERA OF PNEUMOCYSTIS PROPHYLAXIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARINII PNEUMONIA; TRIMETHOPRIM-SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; CONTROLLED TRIAL; ZIDOVUDINE; INFECTION	Background. Among patients infected with human immunodeficiency virus type 1 (HIV-1), early and widespread use of prophylactic regimens against Pneumocystis carinii is changing the pattern of illnesses related to the acquired immunodeficiency syndrome (AIDS). Methods. We conducted a subcohort analysis of 844 men with AIDS (87 percent of whom have since died) from a prospectively followed cohort of 2592 HIV-1-infected homosexual men. Results. A total of 138 men received prophylaxis before the diagnosis of AIDS, but 39 (28 percent) nevertheless had P. carinii pneumonia at some time. Only four illnesses occurred more frequently in men who received P. carinii prophylaxis before the onset of AIDS: Mycobacterium avium complex disease, which developed in 33.4 percent, as compared with 17.3 percent of the 706 men who did not receive early prophylaxis; wasting syndrome (18.4 percent vs. 6.4 percent); cytomegalovirus disease (44.9 percent vs. 24.8 percent); and esophageal candidiasis (21.3 percent vs. 12.8 percent). Collectively, these four diseases accounted for the initial AIDS-related illness in 42.7 percent of those who received prophylaxis before the onset of AIDS, as compared with 10.7 percent of those who did not. During the three 6-month periods before the diagnosis of AIDS (0 to 6, >6 to 12, and >12 to 18 months), the geometric mean CD4+ cell counts were 48, 87, and 147 per cubic millimeter, respectively, in men who received prophylaxis against P. carinii, as compared with 118, 211, and 279 per cubic millimeter in those who did not. Conclusions. M. avium complex disease, esophageal candidiasis, wasting syndrome, and cytomegalovirus disease are more common in HIV-infected patients who have received prophylaxis against P. carinii than in those who have not. Prophylaxis may delay the first AIDS illness for 6 to 12 months.	NORTHWESTERN UNIV, SCH MED, DIV INFECT DIS, EVANSTON, IL 60201 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, LOS ANGELES, CA USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT BIOSTAT, BALTIMORE, MD 21205 USA; UNIV PITTSBURGH, GRAD SCH PUBL HLTH, PITTSBURGH, PA 15260 USA; NIAID, BETHESDA, MD 20892 USA	Northwestern University; University of California System; University of California Los Angeles; Johns Hopkins University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	HOOVER, DR (corresponding author), JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT EPIDEMIOL, 624 N BROADWAY, SUITE 784, BALTIMORE, MD 21205 USA.				NIAID NIH HHS [N01-AI-72634, N01-AI-32535, N01-AI-72676] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072676, N01AI072634, N01AI032535] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BENSON CA, 1993, CLIN INFECT DIS, V17, P7, DOI 10.1093/clinids/17.1.7; BERAL V, 1991, CANCER SURV, V10, P5; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CLERICI M, 1992, J INFECT DIS, V166, P723, DOI 10.1093/infdis/166.4.723; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRUNFELD C, 1992, NEW ENGL J MED, V327, P329, DOI 10.1056/NEJM199207303270506; HAY JW, 1988, J ACQ IMMUN DEF SYND, V1, P466; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; ISRAELSKI DM, 1993, J ACQ IMMUN DEF SYND, V6, P414; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; 1989, MMWR MORB MORTAL S5, V38, P1; 1987, MMWR MORB MORTAL WKL, V36, P522; 1990, CLIN COURIER, V8, P1; 1981, MMWR MORB MORTAL WKL, V30, P250; 1992, NEW ENGL J MED, V326, P213; 1991, SAS USERS GUIDE STAT	22	425	431	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 23	1993	329	26					1922	1926		10.1056/NEJM199312233292604	http://dx.doi.org/10.1056/NEJM199312233292604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM885	7902536				2022-12-28	WOS:A1993MM88500004
J	ERKELENS, DW; DEBRUIN, TWA; CABEZAS, MC				ERKELENS, DW; DEBRUIN, TWA; CABEZAS, MC			TULP SYNDROME	LANCET			English	Editorial Material							DISEASE				ERKELENS, DW (corresponding author), UNIV HOSP UTRECHT,POB 85500,3508 GA UTRECHT,NETHERLANDS.							BEIJER T, 1991, 6 ART PROMOTIONS, P1; BEYER T, 1991, 6 ART PROMOTIONS, P139; CASTRO CM, 1993, J CLIN INVEST, V92, P160; CRIQUI MH, 1993, NEW ENGL J MED, V328, P1220, DOI 10.1056/NEJM199304293281702; FREDRICK.DS, 1967, NEW ENGL J MED, V276, P148, DOI 10.1056/NEJM196701192760305; FREDRICK.DS, 1967, NEW ENGL J MED, V276, P273, DOI 10.1056/NEJM196702022760507; FREDRICKSON DONALD S., 1967, N ENGL J MED, V276, P34, DOI 10.1056/NEJM196701052760107; FREDRICKSON DS, 1967, NEW ENGL J MED, V276, P94, DOI 10.1056/NEJM196701122760206; FREDRICKSON DS, 1967, NEW ENGL J MED, V276, P215, DOI 10.1056/NEJM196701262760406; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; VAGUE J, 1947, PRESSE MED, V55, P339	12	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1536	1537		10.1016/S0140-6736(05)80093-5	http://dx.doi.org/10.1016/S0140-6736(05)80093-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902909				2022-12-28	WOS:A1993MM40200020
J	PATRIARCA, PA; FOEGE, WH; SWARTZ, TA				PATRIARCA, PA; FOEGE, WH; SWARTZ, TA			PROGRESS IN POLIO ERADICATION	LANCET			English	Article							PARALYTIC POLIOMYELITIS; VACCINE; STRATEGIES; OUTBREAK		NATL VACCINE PROGRAM OFF, ROCKVILLE, MD USA; TASK FORCE CHILD SURVIVAL & DEV, ATLANTA, GA USA; TEL AVIV UNIV, SACKLER SCH MED, DEPT EPIDEMIOL & PREVENT MED, TEL AVIV, ISRAEL	Tel Aviv University; Sackler Faculty of Medicine								BART K, 1992, P WORLD C POLIOMYELI; BOTTIGER M, 1984, REV INFECT DIS, V6, pS548; CREESE AL, 1984, REV INFECT DIS S, V6; CREESE AL, 1987, PAHO B, V21, P377; DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239; FISHBEIN M, 1961, 5TH INT POL C COP; HOVI T, 1986, LANCET, V1, P1427; MORINIERE BJ, 1993, LANCET, V341, P1545, DOI 10.1016/0140-6736(93)90693-B; OTTEN MW, 1992, AM J EPIDEMIOL, V135, P381, DOI 10.1093/oxfordjournals.aje.a116299; PATRIARCA PA, 1991, REV INFECT DIS, V13, P926; REICHLER MR, 1992, 32ND INT C ANT AG CH, P398; SHEPARD DS, 1989, B WORLD HEALTH ORGAN, V67, P649; SIMOES EAF, 1985, AM J DIS CHILD, V139, P977, DOI 10.1001/archpedi.1985.02140120023021; SLATER PE, 1990, LANCET, V335, P1192, DOI 10.1016/0140-6736(90)92705-M; STREBEL PM, 1992, CLIN INFECT DIS, V14, P568, DOI 10.1093/clinids/14.2.568; SUTTER RW, 1991, LANCET, V338, P715, DOI 10.1016/0140-6736(91)91442-W; SUTTER RW, 1993, POLIOMYELITIS VACCIN, P279; SWARTZ TA, 1989, EUR J EPIDEMIOL, V5, P143, DOI 10.1007/BF00156819; SWARTZ TA, 1992, VACCINE, V10, P904, DOI 10.1016/0264-410X(92)90322-B; TULCHINSKY T, 1989, AM J PUBLIC HEALTH, V79, P1648, DOI 10.2105/AJPH.79.12.1648; 1993, PLAN ACTION GLOBAL E; 1992, WEEKLY EPIDEMIOL REC, V45, P336; 1992, MMWR, V41, P979; 1993, 1993 EUR M INT EP AS	24	24	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1461	1464		10.1016/0140-6736(93)92936-N	http://dx.doi.org/10.1016/0140-6736(93)92936-N			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902485				2022-12-28	WOS:A1993ML21700012
J	SACKS, NPM; BAUM, M				SACKS, NPM; BAUM, M			PRIMARY MANAGEMENT OF CARCINOMA OF THE BREAST	LANCET			English	Article							RANDOMIZED TRIAL; CLINICAL-TRIAL; RADICAL MASTECTOMY; CANCER PATIENTS; RADIOTHERAPY; THERAPY; CONSERVATION; LUMPECTOMY; RECURRENCE; MORTALITY		ROYAL MARSDEN HOSP, ACAD DEPT SURG, LONDON SW3 6JJ, ENGLAND	Royal Marsden NHS Foundation Trust								ABE O, 1992, LANCET, V339, P71; [Anonymous], 1992, Lancet, V339, P1; BARR LC, 1992, LANCET, V339, P915, DOI 10.1016/0140-6736(92)90941-U; BLICHERTTOFT M, 1988, ACTA ONCOL, V27, P671, DOI 10.3109/02841868809091767; BONADONNA G, 1990, J NATL CANCER I, V82, P1539, DOI 10.1093/jnci/82.19.1539; Bostwick J, 1990, PLASTIC RECONSTRUCTI, VII, P1369; CIATTO S, 1988, CANCER, V61, P1038, DOI 10.1002/1097-0142(19880301)61:5<1038::AID-CNCR2820610530>3.0.CO;2-Z; CLARK RM, 1992, JNCI-J NATL CANCER I, V84, P683, DOI 10.1093/jnci/84.9.683; CUZICK J, 1987, CANCER TREAT REP, V71, P15; CUZICK J, IN PRESS J CLIN ONCO; DAVIES GC, 1980, ANN SURG, V192, P148, DOI 10.1097/00000658-198008000-00002; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FALLOWFIELD LJ, 1991, BRIT MED BULL, V47, P388, DOI 10.1093/oxfordjournals.bmb.a072478; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1970, ANN SURG, V172, P711, DOI 10.1097/00000658-197010000-00016; FISHER B, 1985, NEW ENGL J MED, V312, P674, DOI 10.1056/NEJM198503143121102; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FISHER B, 1992, CANCER RES, V52, P2371; FORREST APM, 1982, ANN SURG, V196, P371, DOI 10.1097/00000658-198209000-00017; HANDLEY RS, 1975, ANN ROY COLL SURG, V57, P59; HAYBITTLE JL, 1989, BMJ-BRIT MED J, V298, P1161; HAYWARD J, 1987, ARCH SURG-CHICAGO, V122, P1244; HOLLAND R, 1990, J CLIN ONCOL, V8, P113, DOI 10.1200/JCO.1990.8.1.113; HOLMBERG L, 1990, J NATL CANCER I, V82, P277; HOUGHTON J, 1980, LANCET, V2, P55; JONES JM, 1989, CLIN RADIOL, V40, P204, DOI 10.1016/S0009-9260(89)80099-6; Keynes G, 1937, BRIT MED J, V1937, P643, DOI 10.1136/bmj.2.4004.643; KURTZ JM, 1992, EUR J CANCER, V28A, P660, DOI 10.1016/S0959-8049(05)80121-2; LICHTER AS, 1992, J CLIN ONCOL, V10, P976, DOI 10.1200/JCO.1992.10.6.976; LOCKER AP, 1989, BRIT J SURG, V76, P890, DOI 10.1002/bjs.1800760906; MAGUIRE GP, 1978, BMJ-BRIT MED J, V1, P963, DOI 10.1136/bmj.1.6118.963; MCGUIRE WL, 1992, NEW ENGL J MED, V326, P1756; MORRIS T, 1977, CANCER-AM CANCER SOC, V40, P2381, DOI 10.1002/1097-0142(197711)40:5<2381::AID-CNCR2820400555>3.0.CO;2-B; OVERGAARD M, 1990, INT J RADIAT ONCOL, V19, P1121, DOI 10.1016/0360-3016(90)90214-5; RAGAZ J, 1990, P AACR, V10; RUTQVIST LE, 1989, INT J RADIAT ONCOL, V16, P629, DOI 10.1016/0360-3016(89)90478-1; RUTQVIST LE, 1992, INT J RADIAT ONCOL, V22, P887, DOI 10.1016/0360-3016(92)90784-F; SACKS NPM, 1992, BREAST, V1, P41; SARRAZIN D, 1989, RADIOTHER ONCOL, V14, P177, DOI 10.1016/0167-8140(89)90165-5; SUESSAN WE, 1991, CLIN RADIOL, V44, P249; VALAGUSSA P, 1978, CANCER, V41, P1170, DOI 10.1002/1097-0142(197803)41:3<1170::AID-CNCR2820410355>3.0.CO;2-I; VERONESI U, 1990, EUR J SURG ONCOL, V16, P127; VERONESI U, 1990, EUR J CANCER, V26, P668, DOI 10.1016/0277-5379(90)90113-8; 1993, LANCET, V341, P343	44	21	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1993	342	8884					1402	1408		10.1016/0140-6736(93)92759-M	http://dx.doi.org/10.1016/0140-6736(93)92759-M			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901688				2022-12-28	WOS:A1993MK09500016
J	BRAHAMS, D				BRAHAMS, D			RELIGIOUS OBJECTION VERSUS PARENTAL DUTY	LANCET			English	Editorial Material																		BRAHAMS D, 1990, LANCET, V336, P107, DOI 10.1016/0140-6736(90)91612-E	1	3	3	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1189	1190		10.1016/0140-6736(93)92179-W	http://dx.doi.org/10.1016/0140-6736(93)92179-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MG274	7901523				2022-12-28	WOS:A1993MG27400003
J	RIORDAN, AM; HUNTER, JO; COWAN, RE; CRAMPTON, JR; DAVIDSON, AR; DICKINSON, RJ; DRONFIELD, MW; FELLOWS, IW; HISHON, S; KERRIGAN, GNW; KENNEDY, HJ; MCGOURAN, RCM; NEALE, G; SAUNDERS, JHB				RIORDAN, AM; HUNTER, JO; COWAN, RE; CRAMPTON, JR; DAVIDSON, AR; DICKINSON, RJ; DRONFIELD, MW; FELLOWS, IW; HISHON, S; KERRIGAN, GNW; KENNEDY, HJ; MCGOURAN, RCM; NEALE, G; SAUNDERS, JHB			TREATMENT OF ACTIVE CROHNS-DISEASE BY EXCLUSION DIET - EAST ANGLIAN MULTICENTER CONTROLLED TRIAL	LANCET			English	Article							ELEMENTAL DIET; ENTERAL NUTRITION	Elemental diet is as effective in producing remission of Crohn's disease (CD) as is corticosteroid treatment, but most patients relapse soon after resumption of a normal diet. We have investigated the efficacies of dietary modification and oral corticosteroids in maintaining remission achieved with elemental diet. In a multicentre trial, 136 patients with active CD were started on elemental diet and other treatment was withdrawn. 43 (31%) declined to continue elemental diet for 14 days, but 78 (84%) of the remaining 93 achieved remission and were randomly assigned corticosteroids (38) or diet (40). Corticosteroid treatment started at 40 mg prednisolone daily, which was tapered and stopped after 12 weeks; that group received dietary advice on healthy eating. The diet group received ''tapered'' placebo and were instructed to introduce one new food daily, excluding any that precipitated symptoms. Assessment of progress for up to 2 years was made by physicians unaware of group assignment. Intention-to-treat analysis showed median lengths of remission of 3.8 (interquartile range 5.0) months in the corticosteroid group and 7.5 (15.3) months on diet, and relapse rates at 2 years, adjusted for withdrawals, of 79% and 62%, respectively (p=0.048). Clinical improvement in the diet group was associated with significant changes in plasma albumin and alpha1-antichymotrypsin concentrations and erythrocyte sedimentation rate. Food intolerances discovered were predominantly to cereals, dairy products, and yeast. Diet provides a further therapeutic strategy in active Crohn's disease.	ADDENBROOKES HOSP,DEPT GASTROENTEROL,GASTROENTEROL RES UNIT,CAMBRIDGE CB2 2QQ,ENGLAND; COLCHESTER GEN HOSP,COLCHESTER,ENGLAND; KETTERING & DIST GEN HOSP,KETTERING NN16 8UZ,NORTHANTS,ENGLAND; HINCHINGBROOKE HOSP,HUNTINGDON,ENGLAND; PETERBOROUGH DIST GEN HOSP,PETERBOROUGH PE3 6DA,ENGLAND; NORFOLK & NORWICH HOSP,NORWICH NR1 3SR,NORFOLK,ENGLAND; JAMES PAGET HOSP,GORLESTON,ENGLAND; W SUFFOLK HOSP,BURY ST EDMUNDS,ENGLAND; QUEEN ELIZABETH HOSP,KINGS LYNN,ENGLAND; BEDFORD HOSP,BEDFORD,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Norfolk & Norwich University Hospitals NHS Foundation Trust; Norfolk & Norwich University Hospital								GIAFFER MH, 1990, LANCET, V335, P816, DOI 10.1016/0140-6736(90)90936-Y; HARVEY RF, 1980, LANCET, V1, P514; JONES VA, 1985, LANCET, V2, P177; KELLY SM, 1989, SCAND J GASTR   S158, V24, P149; LOCHS H, 1991, GASTROENTEROLOGY, V101, P881, DOI 10.1016/0016-5085(91)90711-S; MALCHOW H, 1990, SCAND J GASTROENTERO, V25, P235, DOI 10.1080/00365521.1990.12067097; MIDDLETON SJ, 1991, GUT, V32, pA578; OMORAIN C, 1984, BRIT MED J, V288, P1859, DOI 10.1136/bmj.288.6434.1859; RIGAUD D, 1991, GUT, V32, P1492, DOI 10.1136/gut.32.12.1492; SANDERSON IR, 1987, GUT, V28, P1073, DOI 10.1136/gut.28.9.1073; SAVERYMUTTU S, 1985, GUT, V26, P994, DOI 10.1136/gut.26.10.994; TEAHON K, 1990, GUT, V31, P1133, DOI 10.1136/gut.31.10.1133; WORKMAN EM, 1984, HUM NUTR-APPL NUTR, V38A, P469	13	144	147	0	15	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1131	1134		10.1016/0140-6736(93)92121-9	http://dx.doi.org/10.1016/0140-6736(93)92121-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901473				2022-12-28	WOS:A1993MF19800007
J	DAVIS, PJ; GREGERMAN, RI				DAVIS, PJ; GREGERMAN, RI			PARSE ANALYSIS .2. A REVISED MODEL THAT ACCOUNTS FOR PHI	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX 78284; AUDIE L MURPHY MEM VET ADM MED CTR,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital	DAVIS, PJ (corresponding author), ALBANY MED COLL,ALBANY,NY 12208, USA.							DAVIS PJ, 1969, NEW ENGL J MED, V281, P989, DOI 10.1056/NEJM196910302811805	1	5	5	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					965	966		10.1056/NEJM199504063321421	http://dx.doi.org/10.1056/NEJM199504063321421			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877668				2022-12-28	WOS:A1995QP89300034
J	MCCUE, JD				MCCUE, JD			THE NATURALNESS OF DYING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LIFE-SUPPORT; FUNCTIONAL STATUS; TERMINALLY ILL; DEATH ANXIETY; BODY-WEIGHT; BRAIN-DEATH; PHYSICIANS; MORTALITY; DEPRESSION; CARE	Evidence that dying occurs as a natural, final event in the wholeness of human life is culturally, artistically, and scientifically persuasive. Very elderly patients eventually undergo a process of functional declines, progressive apathy, and loss of willingness to eat and drink that culminates in death, even in the absence of acute illness or severe chronic disease. Despite clinical resemblances to depression and dementia, aging itself and a loss of will to live are the most probable explanations for natural dying. Acceptance of the naturalness of dying, however, directly conflicts with the medicalization and legalization of death that characterizes modern society's treatment of dying elderly patients. We prefer instead to believe that dying results from disease and injury, which may yield to advances in medical technology. The progressive move of the dying out of the home and into acute and long-term care facilities suggests that medicalization may be an irreversible process. Viewing dying as an independent diagnosis in patients who are obviously undergoing terminal declines from aging and chronic diseases can facilitate communication about spiritual and palliative care needs, which tend to be neglected in the medicalized view of dying. Physicians and nurses may need to assume the role of medical stewardship to help prevent the overtreatment and overtesting of modern medicine's approach to the dying. The emotional burdens of caring for the dying elderly, however, must be addressed openly through collaborative work, institutional policies on limitation of treatment, and support building among physicians and other caregivers.	UNIV MASSACHUSETTS, SCH MED, DEPT MED, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	MCCUE, JD (corresponding author), BERKSHIRE MED CTR, 725 NORTH ST, PITTSFIELD, MA 01201 USA.							Aries Philippe, 2008, HOUR OUR DEATH; ARTISS KL, 1973, NEW ENGL J MED, V288, P1210, DOI 10.1056/NEJM197306072882305; AURELIUS M, MEDITATIONS MA ANTON; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; BEAUVOIR SD, 1972, COMING OF AGE; BERLINGER WG, 1991, J AM GERIATR SOC, V39, P973, DOI 10.1111/j.1532-5415.1991.tb04043.x; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BLAZER D, 1989, NEW ENGL J MED, V320, P164, DOI 10.1056/NEJM198901193200306; BOCQUET H, 1987, REV EPIDEMIOL SANTE, V35, P151; BORTZ WM, 1990, J AM GERIATR SOC, V38, P146, DOI 10.1111/j.1532-5415.1990.tb03476.x; BOTWINICK J, 1978, J GERONTOL, V33, P755, DOI 10.1093/geronj/33.5.755; BRAITHWAITE S, 1986, ANN INTERN MED, V104, P711, DOI 10.7326/0003-4819-104-5-711; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BRANCH WT, 1990, AM J MED, V88, P56, DOI 10.1016/0002-9343(90)90128-Z; BRURERA E, 1993, LANCET, V342, P13; BURGESS MM, 1993, J MED PHILOS, V18, P269, DOI 10.1093/jmp/18.3.269; CALLAHAN D, 1977, HASTINGS CENT REP, V7, P32, DOI 10.2307/3560692; CALLAHAN D, 1983, HASTINGS CENT REP, V13, P22, DOI 10.2307/3560573; Callahan D., 1987, MED GOALS AGEING SOC; Callahan Daniel, 1993, TROUBLED DREAM LIFE; Callanan M, 1992, FINAL GIFTS; CHAMBERS CV, 1994, ARCH INTERN MED, V154, P541, DOI 10.1001/archinte.154.5.541; CLARK LP, 1990, J AM GERIATR SOC, V38, P967, DOI 10.1111/j.1532-5415.1990.tb04417.x; COOK ML, 1993, ARCH INTERN MED, V153, P2718, DOI 10.1001/archinte.153.24.2718; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; DONTAS AS, 1991, J AM GERIATR SOC, V39, P641, DOI 10.1111/j.1532-5415.1991.tb03616.x; Dozor R B, 1992, Fam Med, V24, P538; Durand R P, 1990, Fam Pract Res J, V9, P123; DWYER JT, 1987, J GERONTOL, V42, P246, DOI 10.1093/geronj/42.3.246; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EMANUEL EJ, 1988, LANCET, V1, P106; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; ERIKSON EH, 1982, LIFE CYCLE COMPLETED, P60; FEIFEL H, 1973, J ABNORM PSYCHOL, V49, P278; FEIFEL H, 1967, 75TH P ANN CONV AM P, V2, P201; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; FORBES WF, 1993, J AM GERIATR SOC, V41, P1267, DOI 10.1111/j.1532-5415.1993.tb07313.x; FRIEDLAND RP, 1988, ANN INTERN MED, V109, P298, DOI 10.7326/0003-4819-109-4-298; GARLAND J, 1985, BRIT J MED PSYCHOL, V58, P267, DOI 10.1111/j.2044-8341.1985.tb02644.x; Gates M F, 1992, Hosp J, V8, P17; GLICK HR, 1992, RIGHT DIE; GRAHAM H, 1983, LANCET, V2, P670; Gruman G J, 1978, Omega (Westport), V9, P203, DOI 10.2190/1HPQ-G1GQ-TWVB-BWW5; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; HALEVY A, 1993, ANN INTERN MED, V119, P519, DOI 10.7326/0003-4819-119-6-199309150-00013; HILFIKER D, 1983, NEW ENGL J MED, V308, P716, DOI 10.1056/NEJM198303243081210; HOWELLS K, 1986, MED EDUC, V20, P502, DOI 10.1111/j.1365-2923.1986.tb01390.x; HULL FM, 1991, MED EDUC, V25, P491, DOI 10.1111/j.1365-2923.1991.tb00103.x; JARVIK LF, 1988, GERONTOLOGIST, V28, P739, DOI 10.1093/geront/28.6.739; Jennings B, 1988, Hastings Cent Rep, V18, P1; JOHANSSON B, 1989, J GERONTOL, V44, pP184, DOI 10.1093/geronj/44.6.P184; JONAS H, 1992, HASTINGS CENT REP, V22, P34, DOI 10.2307/3562722; KANE AC, 1985, OMEGA-J DEATH DYING, V16, P11; KAOTONA CLE, 1991, J MED GERONTOL, V1, P371; KELLER HH, 1993, J AM GERIATR SOC, V41, P1212, DOI 10.1111/j.1532-5415.1993.tb07305.x; KINSELLA TD, 1989, AM J MED, V86, P643, DOI 10.1016/0002-9343(89)90435-X; KITCHEN AD, 1986, J MED EDUC, V61, P760; KLONOFFCOHEN H, 1992, J CLIN EPIDEMIOL, V45, P207, DOI 10.1016/0895-4356(92)90080-7; KOENIG HG, 1990, ARCH INTERN MED, V150, P1349, DOI 10.1001/archinte.1990.00390180147035; KOENIG HG, 1989, J GEN INTERN MED, V4, P498, DOI 10.1007/BF02599548; KOENIG HG, 1989, J AM GERIATR SOC, V37, P599, DOI 10.1111/j.1532-5415.1989.tb01249.x; KRAKOWSKI AJ, 1982, PSYCHOTHER PSYCHOSOM, V38, P11, DOI 10.1159/000287609; KRAKOWSKI AJ, 1982, J PSYCHOSOM RES, V26, P91, DOI 10.1016/0022-3999(82)90068-X; Kubler-Ross E., 1975, DEATH FINAL STAGE GR; Larrabee GJ, 1986, DEV NEUROPSYCHOL, V2, P373, DOI 10.1080/87565648609540355; LASCH C, 1978, CULTURE NARCISSISM A, P207; LAUNER LJ, 1994, JAMA-J AM MED ASSOC, V271, P1093, DOI 10.1001/jama.271.14.1093; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LEE MA, 1990, J AM GERIATR SOC, V38, P710, DOI 10.1111/j.1532-5415.1990.tb01433.x; LO B, 1980, ANN INTERN MED, V93, P764, DOI 10.7326/0003-4819-93-5-764; LUDDINGTON AV, 1993, GERIATRICS, V48, P72; LYNN J, 1986, BY NO EXTRAORDINARY; MACKLIN R, 1993, ENEMIES PATIENTS; MAKSOUD A, 1993, ARCH INTERN MED, V153, P1249, DOI 10.1001/archinte.153.10.1249; MARTIN CA, 1987, STRESS BURNOUT PROVI, P121; MARTIN CA, 1987, STRESS BURNOUT PROVI; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; MENDEZ OE, 1993, CRIT CARE CLIN, V9, P613, DOI 10.1016/S0749-0704(18)30189-1; MERMANN AC, 1992, YALE J BIOL MED, V65, P137; MILES SH, 1989, NEW ENGL J MED, V321, P48, DOI 10.1056/NEJM198907063210110; Miller R. A., 1994, PRINCIPLES GERIATRIC, P3; MOEHLE KA, 1989, J GERONTOL, V44, pP176, DOI 10.1093/geronj/44.6.P176; MONMEYER RW, 1988, CONFRONTING DEATH; Mortimer J A, 1990, Adv Neurol, V51, P27; MOUNT BM, 1986, J CLIN ONCOL, V4, P1127, DOI 10.1200/JCO.1986.4.7.1127; MURPHY E, 1988, BRIT J PSYCHIAT, V152, P347, DOI 10.1192/bjp.152.3.347; MURPHY E, 1983, BRIT J PSYCHIAT, V142, P111, DOI 10.1192/bjp.142.2.111; Nuland S.B., 1994, HOW WE DIE; PALMORE E, 1976, J GERONTOL, V31, P76, DOI 10.1093/geronj/31.1.76; PAYER L, 1988, MED CULTURE; PERKINS HS, 1990, AM J MED, V89, P185, DOI 10.1016/0002-9343(90)90298-R; PERLS TT, 1993, J AM GERIATR SOC, V41, P1193, DOI 10.1111/j.1532-5415.1993.tb07302.x; PETERS AL, 1990, AM J MED, V89, P81, DOI 10.1016/0002-9343(90)90102-J; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; QUILL T, 1994, DEATH DIGNITY; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1989, ANN INTERN MED, V111, P51, DOI 10.7326/0003-4819-111-1-51; REED HBC, 1963, J GERONTOL, V18, P271, DOI 10.1093/geronj/18.3.271; REUBEN DB, 1992, AM J MED, V93, P663, DOI 10.1016/0002-9343(92)90200-U; ROSENGREN A, 1993, BRIT MED J, V307, P1102, DOI 10.1136/bmj.307.6912.1102; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; RUDMAN D, 1987, J AM GERIATR SOC, V35, P496, DOI 10.1111/j.1532-5415.1987.tb01394.x; SAGER M, 1990, ARCH INTERN MED, V150, P1091, DOI 10.1001/archinte.150.5.1091; SANDMAN PO, 1987, J AM GERIATR SOC, V35, P31, DOI 10.1111/j.1532-5415.1987.tb01316.x; SCHMITZ P, 1994, PRINCIPLES GERIATRIC, P383; SCHNEIDERMAN ES, 1970, PSYCHOL TODAY, V5, P43; SCHNEIDERMAN ES, 1970, PSYCHOL TODAY, V4, P67; SCHULZ R, 1978, OMEGA, V9, P327; SERAVALLI EP, 1988, NEW ENGL J MED, V319, P1728, DOI 10.1056/NEJM198812293192609; SLOMKA J, 1992, SOC SCI MED, V35, P251, DOI 10.1016/0277-9536(92)90021-H; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SOUTHWICK F, 1993, ANN INTERN MED, V118, P146, DOI 10.7326/0003-4819-118-2-199301150-00011; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; TAYBACK M, 1990, ARCH INTERN MED, V150, P1065, DOI 10.1001/archinte.150.5.1065; THOMPSON MP, 1991, J AM GERIATR SOC, V39, P497, DOI 10.1111/j.1532-5415.1991.tb02496.x; TOLLE SW, 1983, ARCH INTERN MED, V143, P1447, DOI 10.1001/archinte.143.7.1447; Tolstoy L, 1981, DEATH I ILYICH; UEDA K, 1990, J AM GERIATR SOC, V38, P1332, DOI 10.1111/j.1532-5415.1990.tb03457.x; UHLMANN RF, 1987, ANN INTERN MED, V106, P879, DOI 10.7326/0003-4819-106-6-879; VICKIO CJ, 1985, J GERONTOL, V40, P347, DOI 10.1093/geronj/40.3.347; VONDRAS DD, 1992, J AM GERIATR SOC, V40, P285; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WARREN WG, 1989, DEATH ED RES CLIN PE; WHITE N, 1988, J GERONTOL, V43, pP141, DOI 10.1093/geronj/43.6.P141; YARBOROUGH M, 1988, J AM GERIATR SOC, V36, P63, DOI 10.1111/j.1532-5415.1988.tb03435.x; YOUNGNER SJ, 1989, JAMA-J AM MED ASSOC, V261, P2205, DOI 10.1001/jama.261.15.2205; YOUNGNER SJ, 1983, ANN INTERN MED, V99, P252, DOI 10.7326/0003-4819-99-2-252	131	134	135	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1039	1043		10.1001/jama.273.13.1039	http://dx.doi.org/10.1001/jama.273.13.1039			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP890	7897788				2022-12-28	WOS:A1995QP89000035
J	GLYNN, RJ; FIELD, TS; ROSNER, B; HEBERT, PR; TAYLOR, JO; HENNEKENS, CH				GLYNN, RJ; FIELD, TS; ROSNER, B; HEBERT, PR; TAYLOR, JO; HENNEKENS, CH			EVIDENCE FOR A POSITIVE LINEAR RELATION BETWEEN BLOOD-PRESSURE AND MORTALITY IN ELDERLY PEOPLE	LANCET			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; HYPERTENSION; RISK; REDUCTION; SURVIVAL	Many studies of blood pressure in the elderly have found higher death rates in groups with the lowest blood pressure than in those with intermediate values. In a large community study, we examined whether these findings are real or artifacts of short follow-up, co-morbidity, or low blood pressure in people near death. In 1982-83, we assessed drug use, medical history, disability, physical function, and blood pressure in 3657 residents of East Boston, Massachusetts, aged 65 and older. We identified all deaths (1709) up to 1992 and followed up survivors for an average of 10.5 (range 9.5-11.0) years. After adjustment for confounding variables (including frailty and disorders such as congestive heart failure and myocardial infarction) and exclusion of deaths within the first 3 years of follow-up, higher systolic pressure predicted linear increases in cardiovascular (p<0.0001) and total (p<0.0007) mortality. Higher diastolic pressure predicted increases in cardiovascular (p=0.006) but not total (p=0.48) mortality. These results differed from those for the first 3 years, during which groups with the lowest systolic and diastolic pressures had the highest death rates. In the long term, lower blood pressure in old age, as in middle age, is associated with better survival. Short-term findings may differ because of associations of co-morbidity and frailty with blood pressure near death. Overall, the findings support recommendations to treat high blood pressure in elderly people.	BRIGHAM & WOMENS HOSP, E BOSTON NEIGHBOURHOOD HLTH CTR, BOSTON, MA 02215 USA; BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	GLYNN, RJ (corresponding author), BRIGHAM & WOMENS HOSP, DIV PREVENT MED, BOSTON, MA 02215 USA.				NIA NIH HHS [AG12106, AG02107] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; [Anonymous], 1991, JAMA, V265, P3255; Benfante R, 1992, Ann Epidemiol, V2, P273; BISHOP YM, 1980, DISCRETE MULTIVARIAT, P492; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BULPITT CJ, 1992, J HYPERTENSION S7, V10, P545; COOPE J, 1988, J HUM HYPERTENS, V2, P79; COOPE J, 1987, LANCET, V1, P1380; CORNONIHUNTLEY JC, 1986, NIH862443 PUBL; CRUICKSHANK JM, 1988, BMJ-BRIT MED J, V297, P1227, DOI 10.1136/bmj.297.6658.1227; CRUICKSHANK JM, 1987, LANCET, V1, P581; DAGOSTINO RB, 1991, BRIT MED J, V303, P385, DOI 10.1136/bmj.303.6799.385; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; FLETCHER AE, 1992, NEW ENGL J MED, V326, P251; FRY J, 1974, LANCET, V2, P431; GLYNN RJ, 1993, AM J EPIDEMIOL, V138, P365, DOI 10.1093/oxfordjournals.aje.a116869; HARRIS T, 1985, HYPERTENSION, V7, P118, DOI 10.1161/01.HYP.7.1.118; HEBERT PR, 1993, ARCH INTERN MED, V153, P578, DOI 10.1001/archinte.153.5.578; HUGHES MD, 1993, BIOMETRICS, V49, P1056, DOI 10.2307/2532247; LANGER RD, 1989, BRIT MED J, V298, P1356, DOI 10.1136/bmj.298.6684.1356; LINDHOLM L, 1986, FAM PRACT, V3, P3, DOI 10.1093/fampra/3.1.3; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; MATTILA K, 1988, BRIT MED J, V296, P887, DOI 10.1136/bmj.296.6626.887; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; SIEGEL D, 1987, AM J EPIDEMIOL, V126, P385, DOI 10.1093/oxfordjournals.aje.a114670; STAESSEN J, 1989, BMJ-BRIT MED J, V298, P1552, DOI 10.1136/bmj.298.6687.1552; TAYLOR JO, 1991, AM J EPIDEMIOL, V134, P489, DOI 10.1093/oxfordjournals.aje.a116121; 1994, HLTH US 1993; 1978, J CHRON DIS, V31, P651	30	148	150	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	1995	345	8953					825	829		10.1016/S0140-6736(95)92964-9	http://dx.doi.org/10.1016/S0140-6736(95)92964-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898229				2022-12-28	WOS:A1995QQ19500009
J	SAKAMOTO, J; YASUE, M				SAKAMOTO, J; YASUE, M			EXTENSIVE LYMPHADENECTOMY FOR GASTRIC-CANCER PATIENTS - WHAT CAN THE RESULTS OF ONE-TRIAL TELL US	LANCET			English	Editorial Material											SAKAMOTO, J (corresponding author), AICHI PREFECTURAL HOSP,DEPT SURG,OKAZAKI,AICHI,JAPAN.							BONENKAMP JJ, 1995, LANCET, V345, P745, DOI 10.1016/S0140-6736(95)90637-1; BUNT AMG, 1994, J CLIN ONCOL, V12, P417, DOI 10.1200/JCO.1994.12.2.417; BUYSE M, 1991, EUR J SURG ONCOL, V17, P421; ROTHENBERG ML, 1994, J CANCER RES CLIN, V120, P747, DOI 10.1007/BF01194276; SASAKO M, 1992, JPN J CLIN ONCOL, V22, P41; SIEWERT JR, 1993, BRIT J SURG, V80, P1015, DOI 10.1002/bjs.1800800829	6	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					742	743		10.1016/S0140-6736(95)90633-9	http://dx.doi.org/10.1016/S0140-6736(95)90633-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891480				2022-12-28	WOS:A1995QN70100004
J	ABRAHAM, E; WUNDERINK, R; SILVERMAN, H; PERL, TM; NASRAWAY, S; LEVY, H; BONE, R; WENZEL, RP; BALK, R; ALLRED, R; PENNINGTON, JE; WHERRY, JC				ABRAHAM, E; WUNDERINK, R; SILVERMAN, H; PERL, TM; NASRAWAY, S; LEVY, H; BONE, R; WENZEL, RP; BALK, R; ALLRED, R; PENNINGTON, JE; WHERRY, JC			EFFICACY AND SAFETY OF MONOCLONAL-ANTIBODY TO HUMAN TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH SEPSIS SYNDROME - A RANDOMIZED, CONTROLLED, DOUBLE-BLIND, MULTICENTER CLINICAL-TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GRAM-NEGATIVE SEPSIS; SEPTIC SHOCK; LETHAL BACTEREMIA; ENDOTOXIN; DYSFUNCTION; THERAPY; DISEASE; CANCER; SYSTEM	Objective.-To evaluate the efficacy and safety of anti-tumor necrosis factor alpha monoclonal antibody (TNF-alpha MAb) in the treatment of patients with sepsis syndrome. Design.-Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial. Setting.-A total of 31 hospitals in the United States and Canada. Patients.-There were 994 patients with sepsis syndrome enrolled in this clinical trial, and 971 patients were infused with the study drug. Intervention.-Patients were prospectively stratified into shock or nonshock groups and then randomized to receive a single infusion of 15 mg/kg of TNF-alpha MAb, 7.5 mg/kg of TNF-alpha MAb, or placebo, Patients received standard aggressive medical and surgical care during the 28-day postinfusion period. Outcome Measure.-Twenty-eight-day all-cause mortality. Results.-The distribution of variables describing demographics, organ system dysfunction or failure, preinfusion Acute Physiology and Chronic Health Evaluation II score, number of organs failing at baseline, initial sites of infection, infecting microorganisms, antimicrobials used, and initial invasive procedures was similar among patients in the TNF-alpha MAb and placebo treatment arms. Among all infused patients, there was no difference in all-cause mortality in patients who received placebo as compared with those who received TNF-alpha MAb. In septic patients with shock (n=478), there was a trend toward a reduction in all-cause mortality, which was most evident 3 days after infusion: 25 of 162 patients treated with 15 mg/kg of TNF-alpha MAb died, 22 of 156 patients treated with 7.5 mg/kg of TNF-alpha MAb died, and 44 of 160 patients in the placebo group died (15 mg/kg: 44% reduction vs placebo, P=.01; 7.5 mg/kg: 48.7% reduction vs placebo, P=.004). At day 28, the reduction in mortality for shock patients was not significant for either dose of TNF-alpha MAb relative to placebo (15 mg/kg, 61 deaths among 162 patients [37.7% mortality], 7.5 mg/kg, 59 deaths among 156 patients [37.8% mortality], placebo, 73 deaths among 160 patients [45.6% mortality]; P=.20 for 7.5 mg/kg and P=.15 for 15 mg/kg), Serious adverse events were reported in 4.6% of all infused patients. No immediate hypersensitivity allergic reactions due to TNF-alpha MAb were reported. Serum sickness-like reactions were seen in 2.5% of patients receiving TNF-alpha MAb. Conclusions.-There was no decrease in mortality between placebo and TNF-alpha MAb in all infused patients, In septic shock patients who received TNF-alpha MAb, a significant reduction in mortality was present 3 days after infusion. Although a trend toward reduced mortality continued at 28 days following treatment with TNF-alpha MAb, the difference in mortality among shock patients treated with placebo or TNP-alpha. MAb was not significant.	UNIV TENNESSEE, DEPT MED, DIV PULM, MEMPHIS, TN USA; UNIV MARYLAND, DIV PULM & CRIT CARE MED, BALTIMORE, MD USA; UNIV IOWA, COLL MED, DIV GEN MED CLIN EPIDEMIOL & HLTH SERV RES, IOWA CITY, IA USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT ANESTHESIOL, BOSTON, MA USA; UNIV NEW MEXICO, DEPT MED, ALBUQUERQUE, NM USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT MED, CHICAGO, IL USA; MILES INC, DEPT CLIN RES, BERKELEY, CA USA	University of Tennessee System; University of Tennessee Health Science Center; University System of Maryland; University of Maryland Baltimore; University of Iowa; Tufts Medical Center; University of New Mexico; Rush University	ABRAHAM, E (corresponding author), UNIV COLORADO, HLTH SCI CTR,DEPT MED, DIV PULM SCI & CRIT CARE MED,BOX C272, 4200 E 9TH AVE, DENVER, CO 80262 USA.			Wunderink, Richard/0000-0002-8527-4195				BONE RC, 1987, NEW ENGL J MED, V317, P653, DOI 10.1056/NEJM198709103171101; BONE RC, 1989, CRIT CARE MED, V17, P389, DOI 10.1097/00003246-198905000-00002; CANNON JG, 1990, J INFECT DIS, V161, P79, DOI 10.1093/infdis/161.1.79; CHAPMAN PB, 1987, J CLIN ONCOL, V5, P1942, DOI 10.1200/JCO.1987.5.12.1942; COLLINS MS, 1991, 31ST INT C ANT AG CH; DUERR ML, 1991, 31ST INT C ANT AG CH; EMERSON TE, 1992, CIRC SHOCK, V38, P75; FIEDLER VB, 1992, J LAB CLIN MED, V120, P574; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V271, P1836, DOI 10.1001/jama.271.23.1836; FISHER CJ, 1994, JAMA-J AM MED ASSOC, V272, P1170; FONG YM, 1989, J EXP MED, V170, P1627, DOI 10.1084/jem.170.5.1627; GALLOWAY CJ, 1991, J IMMUNOL METHODS, V140, P37, DOI 10.1016/0022-1759(91)90124-X; GREENMAN RL, 1991, JAMA-J AM MED ASSOC, V266, P1097, DOI 10.1001/jama.266.8.1097; HAVELL EA, 1989, J IMMUNOL, V143, P2894; HINSHAW LB, 1992, J TRAUMA, V33, P568, DOI 10.1097/00005373-199210000-00013; HINSHAW LB, 1990, CIRC SHOCK, V30, P279; ISPAHANI P, 1987, Q J MED, V63, P427; JESMOK G, 1992, AM J PATHOL, V141, P1197; JESMOK GJ, 1991, 31ST INT C ANT AG CH; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LINDSEY DC, 1991, 31ST INT C ANT AG CH; LUCE JM, 1993, CRIT CARE MED, V21, P1233, DOI 10.1097/00003246-199308000-00026; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OPAL SM, 1990, J INFECT DIS, V161, P1148, DOI 10.1093/infdis/161.6.1148; PARRILLO JE, 1990, ANN INTERN MED, V113, P227, DOI 10.7326/0003-4819-113-3-227; PARRILLO JE, 1991, ANN INTERN MED, V115, P491, DOI 10.7326/0003-4819-115-6-491; PAULI U, 1994, J IMMUNOL METHODS, V171, P263, DOI 10.1016/0022-1759(94)90047-7; PEDUZZI P, 1987, NEW ENGL J MED, V317, P659; SARAVOLATZ LD, 1994, J INFECT DIS, V169, P214, DOI 10.1093/infdis/169.1.214; SCHLAG G, 1991, 2ND INT C SHOCK VIEN; SELBY P, 1987, BRIT J CANCER, V56, P803, DOI 10.1038/bjc.1987.294; SHERMAN ML, 1988, J CLIN ONCOL, V6, P344, DOI 10.1200/JCO.1988.6.2.344; TOMPKINS RG, 1994, CRIT CARE MED, V22, P3, DOI 10.1097/00003246-199401000-00002; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; TRAN DD, 1990, CRIT CARE MED, V18, P474, DOI 10.1097/00003246-199005000-00002; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; WALSH C, 1991, 17TH INT C CHEM BERL; WALSH CJ, 1992, ARCH SURG-CHICAGO, V127, P138; WENZEL RP, 1992, NEW ENGL J MED, V326, P1151, DOI 10.1056/NEJM199204233261710; Young LS, 1990, PRINCIPLES PRACTICE, P611; 1991, NEW ENGL J MED, V824, P429	42	660	724	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					934	941		10.1001/jama.273.12.934	http://dx.doi.org/10.1001/jama.273.12.934			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884952				2022-12-28	WOS:A1995QM17300028
J	MENDEL, JE; KORSWAGEN, HC; LIU, KS; HAJDUCRONIN, YM; SIMON, MI; PLASTERK, RHA; STERNBERG, PW				MENDEL, JE; KORSWAGEN, HC; LIU, KS; HAJDUCRONIN, YM; SIMON, MI; PLASTERK, RHA; STERNBERG, PW			PARTICIPATION OF THE PROTEIN G(O) IN MULTIPLE ASPECTS OF BEHAVIOR IN C-ELEGANS	SCIENCE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; NUCLEOTIDE-BINDING PROTEIN; ESCHERICHIA-COLI; ALPHA-SUBUNITS; GS-ALPHA; EXPRESSION; MUTANTS; G0; GO; RECEPTORS	The goa-1 gene encoding the alpha subunit of the heterotrimeric guanosine triphosphate-binding protein (G protein) G(o) from Caenorhabditis elegans is expressed in most neurons, and in the muscles involved in egg laying and male mating, Reduction-of-function mutations in goa-1 caused a variety of behavioral defects including hyperactive movement, premature egg laying, and male impotence, Expression of the activated G(o) alpha subunit (G alpha(o)) in transgenic nematodes resulted in lethargic movement, delayed egg laying, and reduced mating efficiency, Induced expression of activated G alpha(o) in adults was sufficient to cause these phenotypes, indicating that G alpha(o) mediates behavior through its role in neuronal function and the functioning of specialized muscles.	CALTECH,HOWARD HUGHES MED INST,PASADENA,CA 91125; CALTECH,DIV BIOL,PASADENA,CA 91125; NETHERLANDS CANC INST,DIV MOLEC BIOL,1066 CX AMSTERDAM,NETHERLANDS	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; Netherlands Cancer Institute			Korswagen, Hendrik/I-8782-2012	Sternberg, Paul/0000-0002-7699-0173				BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1985, J NEUROSCI, V5, P956; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; COUPRY I, 1992, J BIOL CHEM, V267, P9852; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HODGKIN J, 1979, GENETICS, V91, P67; HODGKIN J, 1983, GENETICS, V103, P43; HUFF RM, 1985, J BIOL CHEM, V260, P864; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; LOCHRIE MA, 1991, CELL REGUL, V2, P135, DOI 10.1091/mbc.2.2.135; LOER CM, 1993, J NEUROSCI, V13, P5407, DOI 10.1523/JNEUROSCI.13-12-05407.1993; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MELLO CC, 1995, IN PRESS METHODS CEL; MORIARTY TM, 1990, NATURE, V343, P79, DOI 10.1038/343079a0; SCHMIDT CJ, 1989, CELL REGUL, V1, P125, DOI 10.1091/mbc.1.1.125; SLEPAK VZ, 1993, J BIOL CHEM, V268, P1414; STRETTON AOW, 1985, TRENDS NEUROSCI, V8, P294, DOI 10.1016/0166-2236(85)90105-5; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; STRITTMATTER SM, 1994, J NEUROSCI, V14, P2327; STRITTMATTER SM, 1990, NATURE, V344, P836, DOI 10.1038/344836a0; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; TRENT C, 1983, GENETICS, V104, P619; WAY JC, 1991, GENE DEV, V5, P2199, DOI 10.1101/gad.5.12a.2199; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; WORLEY PF, 1986, P NATL ACAD SCI USA, V83, P4561, DOI 10.1073/pnas.83.12.4561; ZWAAL RR, 1993, P NATL ACAD SCI USA, V90, P7431, DOI 10.1073/pnas.90.16.7431	33	204	210	0	9	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1652	1655		10.1126/science.7886455	http://dx.doi.org/10.1126/science.7886455			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886455				2022-12-28	WOS:A1995QM39700039
J	SCHOTLAND, J; SHUPLIAKOV, O; WIKSTROM, M; BRODIN, L; SRINIVASAN, M; YOU, ZB; HERRERAMARSCHITZ, M; ZHANG, WQ; HOKFELT, T; GRILLNER, S				SCHOTLAND, J; SHUPLIAKOV, O; WIKSTROM, M; BRODIN, L; SRINIVASAN, M; YOU, ZB; HERRERAMARSCHITZ, M; ZHANG, WQ; HOKFELT, T; GRILLNER, S			CONTROL OF LAMPREY LOCOMOTOR NEURONS BY COLOCALIZED MONOAMINE TRANSMITTERS	NATURE			English	Article							SPINAL-CORD; RAT STRIATUM; 5-HYDROXYTRYPTAMINE; SEROTONIN; DOPAMINE; AFTERHYPERPOLARIZATION; INVIVO	NEURONS in the central nervous system (CNS) often store more than one neurotransmitter(1,2), but as yet the functional significance of this type of coexistence is poorly understood. 5-Hydroxytryptamine (5-HT) modulates calcium-dependent K+ channels (K-Ca) responsible for the postspike afterhyperpolarization in different regions of the CNS3,4. In lamprey, 5-HT neurons control apamine-sensitive K-Ca channels in spinal locomotor network interneurons(4-6), thereby in addition regulating the duration of locomotor bursts(7,8). We report here that these spinal 5-HT neurons also contain dopamine. Like 5-HT, dopamine causes a reduction of the afterhyperpolarization, but in this case it is due to a reduction of calcium entry during the action potential, which results in a reduced activation of Kc,. 5-HT and dopamine are both released from these midline neurons, and both reduce the afterhyperpolarization through two distinctly different, but complementary cellular mechanisms. The net effect of dopamine (10-100 mu M) on the locomotor network is similar to that of 5-HT, and the effects of dopamine and 5-HT are additive at the network level.	KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,DEPT NEUROPHYSIOL,S-17177 STOCKHOLM,SWEDEN; KAROLINSKA INST,NOBEL INST NEUROPHYSIOL,DEPT PHARMACOL,S-17177 STOCKHOLM,SWEDEN	Karolinska Institutet; Karolinska Institutet			Shupliakov, Oleg/R-9148-2016	Shupliakov, Oleg/0000-0001-5352-6848				BRODIN L, 1990, BRAIN RES, V508, P172, DOI 10.1016/0006-8993(90)91134-3; BRODIN L, 1986, NEUROSCI LETT, V67, P53, DOI 10.1016/0304-3940(86)90207-7; CHRISTENSON J, 1989, NEUROSCI LETT, V100, P188, DOI 10.1016/0304-3940(89)90682-4; CHURCH PJ, 1993, J NEUROSCI, V13, P2790; Cuello A. C., 1982, COTRANSMISSION; CUMMING P, 1992, J NEUROCHEM, V59, P1905, DOI 10.1111/j.1471-4159.1992.tb11026.x; DEDEK J, 1979, J NEUROCHEM, V33, P687, DOI 10.1111/j.1471-4159.1979.tb05213.x; HARRISWARRICK RM, 1985, J EXP BIOL, V116, P27; HARRISWARRICK RM, 1985, NEUROSCIENCE, V14, P1127, DOI 10.1016/0306-4522(85)90282-9; HERRERAMARSCHIT.M, 1992, AMINO ACIDS, V2, P157; HILL RH, 1985, BRAIN RES, V358, P40, DOI 10.1016/0006-8993(85)90946-1; HOKFELT T, 1987, SYNAPTIC FUNCTION, P179; MATSUSHIMA T, 1992, J NEUROPHYSIOL, V67, P1683, DOI 10.1152/jn.1992.67.6.1683; NOMIKOS GG, 1992, NEUROPSYCHOPHARMACOL, V7, P7; SCHOTLAND JL, 1993, EXP BRAIN RES, V93, P391; SCHWINDT PC, 1992, J NEUROPHYSIOL, V67, P216, DOI 10.1152/jn.1992.67.1.216; SHARP T, 1986, J NEUROCHEM, V47, P113; STEINBUSCH HWM, 1991, NATO ASI SERIES, V58; VANDONGEN PAM, 1986, BRAIN RES, V366, P320; VANDONGEN PAM, 1985, J COMP NEUROL, V234, P501, DOI 10.1002/cne.902340408; VERHOFSTAD AAJ, 1983, CYTOCHEMISTRY PRACTI; VIGH B, 1983, CELL TISSUE RES, V231, P615, DOI 10.1007/BF00218119; WALLEN P, 1989, J NEUROPHYSIOL, V61, P759, DOI 10.1152/jn.1989.61.4.759	23	87	89	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					266	268		10.1038/374266a0	http://dx.doi.org/10.1038/374266a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885446				2022-12-28	WOS:A1995QM38700051
J	CHIBA, A; SNOW, P; KESHISHIAN, H; HOTTA, Y				CHIBA, A; SNOW, P; KESHISHIAN, H; HOTTA, Y			FASCICLIN-III AS A SYNAPTIC TARGET RECOGNITION MOLECULE IN DROSOPHILA	NATURE			English	Article							CELL-ADHESION MOLECULE; GROWTH CONE GUIDANCE; NEURONAL RECOGNITION; GENETIC-ANALYSIS; MOTONEURONS; MUSCLES; MELANOGASTER; MUTATIONS; COLLAPSE; PROTEIN	FASCICLIN III, a cell adhesion molecule of the immunoglobulin superfamily(1-3), is expressed by motor neuron RP3 and its synaptic targets (muscle cells 6 and 7) during embryonic neuromuscular development of Drosophila(4). We report here that RP3 often incorrectly innervates neighbouring non-target muscle cells when these cells misexpress fasciclin In, but still innervates normal targets in the fasciclin III null mutant, Fasciclin III manipulations do not influence target selections by other motor neurons, including fasciclin III-expressing RP1, We propose that fasciclin III acts as a synaptic target recognition molecule for motor neuron RP3, and also that its absence can be compensated for by other molecule(s).	UNIV TOKYO,GRAD SCH SCI,DEPT PHYS,TOKYO 113,JAPAN; NATL INST BASIC BIOL,CELLULAR COMMUN LAB,OKAZAKI,AICHI 444,JAPAN; SUNY ALBANY,DEPT BIOL SCI,ALBANY,NY 12222; YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06520	University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); State University of New York (SUNY) System; State University of New York (SUNY) Albany; Yale University								BROADIE K, 1993, NATURE, V361, P350, DOI 10.1038/361350a0; CASH S, 1992, J NEUROSCI, V12, P2051; CHIBA A, 1993, J NEUROSCI, V13, P714; CRIPPS RM, 1994, J CELL BIOL, V126, P689, DOI 10.1083/jcb.126.3.689; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SH Q B, V55, P327; HALPERN ME, 1991, J NEUROSCI, V11, P3227; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; KANIA A, 1993, NEURON, V11, P673, DOI 10.1016/0896-6273(93)90078-6; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KESHISHIAN H, 1993, TRENDS NEUROSCI, V16, P278, DOI 10.1016/0166-2236(93)90182-L; KESHISHIAN H, 1993, J NEUROBIOL, V24, P757, DOI 10.1002/neu.480240606; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; MCALLISTER L, 1992, DEVELOPMENT, V115, P267; NOSE A, 1992, CELL, V70, P553, DOI 10.1016/0092-8674(92)90426-D; NOSE A, 1994, NEURON, V13, P525, DOI 10.1016/0896-6273(94)90023-X; PATEL NH, 1987, CELL, V48, P975, DOI 10.1016/0092-8674(87)90706-9; RUBIN GM, 1982, SCIENCE, V218, P341; RUTISHAUSER U, 1988, SCIENCE, V240, P53, DOI 10.1126/science.3281256; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SINK H, 1991, DEVELOPMENT, V113, P701; SINK H, 1991, J NEUROBIOL, V22, P298, DOI 10.1002/neu.480220309; SNOW PM, 1989, CELL, V59, P313, DOI 10.1016/0092-8674(89)90293-6; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; VANVACTOR D, 1993, CELL, V73, P1137, DOI 10.1016/0092-8674(93)90643-5; WASSENBERG DR, 1987, J BIOL CHEM, V262, P10741; WHITLOCK KE, 1993, DEVELOPMENT, V117, P1251; ZHENG JQ, 1994, NATURE, V368, P140, DOI 10.1038/368140a0	29	110	110	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					166	168		10.1038/374166a0	http://dx.doi.org/10.1038/374166a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877688				2022-12-28	WOS:A1995QL39700060
J	KOBE, B; DEISENHOFER, J				KOBE, B; DEISENHOFER, J			A STRUCTURAL BASIS OF THE INTERACTIONS BETWEEN LEUCINE-RICH REPEATS AND PROTEIN LIGANDS	NATURE			English	Article							PORCINE RIBONUCLEASE INHIBITOR; CRYSTAL-STRUCTURE; MOTIF	THE leucine-rich repeat is a recently characterized structural motif(1) used in molecular recognition processes as diverse as signal transduction, cell adhesion, cell development, DNA repair and RNA processing(2). We present here the crystal structure at 2.5 Angstrom resolution of the complex between ribonuclease A and ribonculease inhibitor, a protein built entirely of leucine-rich repeats, The unusual non-globular structure of ribonuclease inhibitor, its solvent-exposed parallel beta-sheet and the conformational flexibility of the structure are used in the interaction; they appear to be the principal reasons for the effectiveness of leucine-rich repeats as protein-binding motifs, The structure can serve as a model for the interactions of other proteins containing leucine-rich repeats with their ligands.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Kobe, Bostjan/D-1292-2009	Kobe, Bostjan/0000-0001-9413-9166				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; AVEY HP, 1967, NATURE, V11, P557; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BIRDSALL DL, 1992, J BIOL CHEM, V267, P22230; BORKAKOTI N, 1983, EUR J BIOCHEM, V132, P89, DOI 10.1111/j.1432-1033.1983.tb07329.x; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; DAVIES D R, 1992, Current Biology, V2, P254, DOI 10.1016/0960-9822(92)90369-L; FOMINAYA JM, 1992, J BIOL CHEM, V267, P24655; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; JANIN J, 1990, J BIOL CHEM, V265, P16027; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KARTHA G, 1967, NATURE, V213, P862, DOI 10.1038/213862a0; KOBE B, 1994, J MOL BIOL, V241, P288, DOI 10.1006/jmbi.1994.1502; KOBE B, 1993, J MOL BIOL, V231, P137, DOI 10.1006/jmbi.1993.1263; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NACHMAN J, 1990, BIOCHEMISTRY-US, V29, P928, DOI 10.1021/bi00456a012; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; ROTH JS, 1956, BIOCHIM BIOPHYS ACTA, V21, P34, DOI 10.1016/0006-3002(56)90091-9; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; VOCENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827; WLODAWER A, 1988, BIOCHEMISTRY-US, V27, P2705, DOI 10.1021/bi00408a010; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994	30	565	604	3	38	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					183	186		10.1038/374183a0	http://dx.doi.org/10.1038/374183a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877692				2022-12-28	WOS:A1995QL39700065
J	MCGRATH, MA; HALL, DT; MATHESON, PL; WEAVER, HA; TRAUGER, JT; SMITH, TE; THOMAS, N; GLADSTONE, R; SCHNEIDER, NM; HARRIS, WM; LIVENGOOD, TA; PRANGE, R; FESTOU, MC				MCGRATH, MA; HALL, DT; MATHESON, PL; WEAVER, HA; TRAUGER, JT; SMITH, TE; THOMAS, N; GLADSTONE, R; SCHNEIDER, NM; HARRIS, WM; LIVENGOOD, TA; PRANGE, R; FESTOU, MC			RESPONSE OF THE IO-PLASMA TORUS TO COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article								Spectroscopic and imaging observations of the lo plasma torus were made in June and July 1994 in conjunction with the encounter of periodic comet Shoemaker-Levy 9 with Jupiter, Characteristic emissions from sulfur and oxygen ions showed a decline of about 30 percent in the extreme ultraviolet and an increase of about 40 percent in the far ultraviolet relative to preimpact observations. Changes in the extreme ultraviolet may be indicative of small changes in the torus electron temperature as a result of quenching of electrons by dust associated with the comet passage. However, no new emission features indicative of fragment dust within the torus were detected. The characteristic torus morphology seen in ground-based imaging was typical of that observed in the past.	JOHNS HOPKINS UNIV,DEPT PHYS & ASTRON,BALTIMORE,MD 21218; UNIV SO CALIF,DEPT AEROSP ENGN,LOS ANGELES,CA 90089; JET PROPULS LAB,PASADENA,CA 91109; MAX PLANCK INST AERON,W-3411 KATLENBURG DUHM,GERMANY; SW RES INST,SAN ANTONIO,TX 78238; UNIV COLORADO,ASTRON & SPACE PHYS LAB,BOULDER,CO 80309; UNIV MICHIGAN,SPACE PHYS RES LAB,ANN ARBOR,MI 48109; NASA,GODDARD SPACE FLIGHT CTR,GREENBELT,MD 20771; INST ASTROPHYS SPATIALE,ORSAY,FRANCE; OBSERV MIDI PYRENEES,NATL CTR SCI RES,F-31400 TOULOUSE,FRANCE	Johns Hopkins University; University of Southern California; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Max Planck Society; Southwest Research Institute; University of Colorado System; University of Colorado Boulder; University of Michigan System; University of Michigan; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Universite de Toulouse; Universite Toulouse III - Paul Sabatier	MCGRATH, MA (corresponding author), SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218, USA.		Weaver, Harold A/D-9188-2016; Livengood, Timothy A/C-8512-2012	Weaver, Harold A/0000-0003-0951-7762; SCHNEIDER, NICHOLAS/0000-0001-6720-5519				CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; DEPATER I, 1994, B AM ASTRON SOC, V26, P4; DESSLER AJ, 1994, GEOPHYS RES LETT, V21, P1043, DOI 10.1029/94GL01294; GRUN E, 1994, GEOPHYS RES LETT, V21, P1035, DOI 10.1029/94GL00701; Grun E., 1984, PLANETARY RINGS; HALL DT, 1994, ASTROPHYS J, V426, pL51, DOI 10.1086/187337; HERBERT F, 1994, GEOPHYS RES LETT, V21, P1047, DOI 10.1029/94GL00884; HORANYI M, 1994, GEOPHYS RES LETT, V21, P1039, DOI 10.1029/94GL01326; MCGRATH MA, 1993, ASTROPHYS J, V415, pL55, DOI 10.1086/187031; MOOS HW, 1985, ASTROPHYS J, V294, P369, DOI 10.1086/163304; MORFILL GE, 1993, J GEOPHYS RES-SPACE, V98, P1435, DOI 10.1029/92JA01951; SCHNEIDER NM, 1991, SCIENCE, V253, P1394, DOI 10.1126/science.253.5026.1394; SCHNEIDER NM, UNPUB; SEKANINA Z, 1994, ASTRON ASTROPHYS, V289, P607; THOMAS N, 1993, J GEOPHYS RES-PLANET, V98, P18737, DOI 10.1029/93JE01461; TRAUGER JT, 1984, SCIENCE, V226, P337, DOI 10.1126/science.226.4672.337; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424	17	10	10	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1313	1317		10.1126/science.7871429	http://dx.doi.org/10.1126/science.7871429			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871429				2022-12-28	WOS:A1995QK06800034
J	DALL, JLC				DALL, JLC			MEDICINE IN EUROPE .10. THE GRAYING OF EUROPE	BRITISH MEDICAL JOURNAL			English	Article								About a quarter of the population of Europe is now of pensionable age. Facilities for caring for very old or disabled people differ throughout Europe in scope and means of funding, and the countries of the European Union are far from equity in the status of pensioners. Health expectations have increased in older people-most of the calculated gain in life expectancy is likely to be without disability. Most countries now have specialist geriatric medicine facilities, and international research programmes are under way.			DALL, JLC (corresponding author), VICTORIA INFIRM,NATL HLTH TRUST,GLASGOW G42 9TT,LANARK,SCOTLAND.							ANDERSON R, 1992, COMING AGE EUROPE OL; BOUMA H, 1992, GEROTECHNOLOGY; GUILLEMARD AM, 1992, VIEILLESE POLITIQUE; SCHROLL M, 1994, SANDOZ LECTURES GERO; 1992, AGE ATTITUDES MAIN R; 1993, OLDER PEOPLE EUROPE; 1992, 9 NUFF DEP CLIN MED; 1992, BIOMEDICAL HLTH RES, V3	8	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1282	1285		10.1136/bmj.309.6964.1282	http://dx.doi.org/10.1136/bmj.309.6964.1282			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888855	Green Published			2022-12-28	WOS:A1994PT03300031
J	GRIMSHAW, JM; RUSSELL, IT				GRIMSHAW, JM; RUSSELL, IT			EFFECT OF CLINICAL GUIDELINES ON MEDICAL-PRACTICE - A SYSTEMATIC REVIEW OF RIGOROUS EVALUATIONS	LANCET			English	Review							CRITICAL-APPRAISAL; QUALITY ASSURANCE; SMOKING CESSATION; RANDOMIZED TRIAL; PRIMARY CARE; NEW-MEXICO; IMPACT; PHYSICIANS; EDUCATION; REMINDERS	Although interest in clinical guidelines has never been greater, uncertainty persists about whether they are effective. The debate has been hampered by the lack of a rigorous overview. We have identified 59 published evaluations of clinical guidelines that met defined criteria for scientific rigour; 24 investigated guidelines for specific clinical conditions, 27 studied preventive care, and 8 looked at guidelines for prescribing or for support services. All but 4 of these studies detected significant improvements in the process of care after the introduction of guidelines and all but 2 of the 11 studies that assessed the outcome of care reported significant improvements. We conclude that explicit guidelines do improve clinical practice, when introduced in the context of rigorous evaluations. However, the size of the improvements in performance varied considerably.	UNIV ABERDEEN,HLTH SERV RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen	GRIMSHAW, JM (corresponding author), UNIV ABERDEEN,FORESTERHILL HLTH CTR,DEPT GEN PRACTICE,WESTBURN RD,ABERDEEN AB9 2ZD,SCOTLAND.		Grimshaw, Jeremy/D-8726-2013; Russell, Ian T/H-1181-2012	Grimshaw, Jeremy/0000-0001-8015-8243	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BARNETT GO, 1983, MED CARE, V21, P400, DOI 10.1097/00005650-198304000-00003; BROOK RH, 1976, ANN INTERN MED, V85, P509, DOI 10.7326/0003-4819-85-4-509; BUNTINX F, 1993, FAM PRACT, V10, P219, DOI 10.1093/fampra/10.2.219; COHEN DI, 1982, MED CARE, V20, P1040, DOI 10.1097/00005650-198210000-00006; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; COHEN SJ, 1985, SOC SCI MED, V21, P909, DOI 10.1016/0277-9536(85)90147-9; COHEN SJ, 1989, ANN INTERN MED, V110, P686; CUMMINGS SR, 1989, ANN INTERN MED, V110, P640, DOI 10.7326/0003-4819-110-8-640; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; Field MJ, 1990, CLIN PRACTICE GUIDEL; Grol R, 1992, Qual Health Care, V1, P184, DOI 10.1136/qshc.1.3.184; HAINES A, 1992, BMJ-BRIT MED J, V305, P785, DOI 10.1136/bmj.305.6857.785; HAYNES RB, 1987, ARCH INTERN MED, V147, P1297, DOI 10.1001/archinte.147.7.1297; HAYNES RB, 1984, JAMA-J AM MED ASSOC, V251, P61, DOI 10.1001/jama.251.1.61; HOPKINS JA, 1980, ARCH SURG-CHICAGO, V115, P745, DOI 10.1001/archsurg.1980.01380060043011; IRVINE D, 1991, MANAGING QUALITY GEN; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LINN BS, 1980, JAMA-J AM MED ASSOC, V244, P565, DOI 10.1001/jama.244.6.565; LOHR KN, 1980, ANN INTERN MED, V92, P99, DOI 10.7326/0003-4819-92-1-99; LOMAS J, 1991, ANNU REV PUBL HEALTH, V12, P41, DOI 10.1146/annurev.pu.12.050191.000353; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; LOMAS J, 1988, American Journal of Preventive Medicine, V4, P77; MCALISTER NH, 1986, BRIT MED J, V293, P670, DOI 10.1136/bmj.293.6548.670; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130, DOI 10.7326/0003-4819-100-1-130; MUGFORD M, 1991, BRIT MED J, V303, P398, DOI 10.1136/bmj.303.6799.398; NORTON PG, 1985, J FAM PRACTICE, V21, P289; PUTNAM RW, 1985, CAN MED ASSOC J, V132, P1025; Russell IT GJ, 1992, HOSP REFERRALS, P179; SANAZARO PJ, 1978, NEW ENGL J MED, V298, P1171, DOI 10.1056/NEJM197805252982104; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; Thomas J C, 1983, J Med Syst, V7, P307, DOI 10.1007/BF00993294; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570; 1992, LANCET, V339, P1197; 1992, BMJ, V304, P1480	34	1969	1994	1	67	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1317	1322		10.1016/0140-6736(93)92244-N	http://dx.doi.org/10.1016/0140-6736(93)92244-N			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901634				2022-12-28	WOS:A1993MJ03900007
J	IMPERATO, PJ				IMPERATO, PJ			DEMISE OF A PEER-REVIEWED JOURNAL	LANCET			English	Editorial Material							OF-MEDICINE				IMPERATO, PJ (corresponding author), SUNY HLTH SCI CTR,DEPT PREVENT MED & COMMUNITY HLTH,450 CLARKSON AVE,BOX 43,BROOKLYN,NY 11203, USA.							GARFIELD E, 1986, ANN INTERN MED, V105, P313, DOI 10.7326/0003-4819-105-2-313; GORDON M, 1993, NEW YORK STATE J MED, V93, P7; GORDON M, 1992, NEW YORK STATE J MED, V92, P294; IMPERATO PJ, 1987, NEW YORK STATE J MED, V87, P606; OBERMAN L, 1993, AM MED NEWS     0222, P35; POUND R, 1949, NEW ENGL J MED, V241, P351, DOI 10.1056/NEJM194909082411001; ROBACK G, 1993, PHYSICIAN CHARACTERI, P8; SHERMAN C, 1993, NEWS NY, V48, P5; 1991, BY LAWS MED SOC STAT, pA2	9	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1160	1161		10.1016/0140-6736(93)92132-D	http://dx.doi.org/10.1016/0140-6736(93)92132-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901484				2022-12-28	WOS:A1993MF19800018
J	KING, GN; HEALY, CM; GLOVER, MT; KWAN, JTC; WILLIAMS, DM; LEIGH, IM; WORTHINGTON, HV; THORNHILL, MH				KING, GN; HEALY, CM; GLOVER, MT; KWAN, JTC; WILLIAMS, DM; LEIGH, IM; WORTHINGTON, HV; THORNHILL, MH			INCREASED PREVALENCE OF DYSPLASTIC AND MALIGNANT LIP LESIONS IN RENAL-TRANSPLANT RECIPIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALLOGRAFT RECIPIENTS; SKIN-CANCER; CARCINOMA; TUMORS	Background. Renal-transplant recipients are known to have increased rates of skin cancer associated with exposure to the sun. Little is known, however, about the prevalence and histologic features of lesions of the lips in these patients, or about risk factors for such lesions. Methods. We examined the lips of 160 renal-transplant recipients (105 men and 55 women; mean [+/-SD] age, 48+/-13 years) and 160 normal subjects matched with the transplant recipients for age, sex, and skin type. The mean length of time between transplantation and the examination was 69+/-52 months; 58 percent of the recipients had received their grafts more than 60 months earlier. Results. Among the 160 renal-transplant recipients, 21 (13 percent) had leukoplakia; in 2 (1.2 percent) the leukoplakia contained squamous-cell carcinoma. In contrast, only one normal subject (0.6 percent) had leukoplakia. Histologically, 13 of the 21 leukoplakias (62 percent) in the renal-transplant recipients who underwent biopsy were dysplastic, and 2 (10 percent) contained squamous-cell carcinoma. Actinic change was evident in 91 percent of the dysplastic lesions but not in the nondysplastic lesions (P<0.001). Exposure to the sun and smoking were risk factors for dysplastic and malignant lip lesions in the renal-transplant recipients (P<0.001 and P=0.003, respectively). Among these recipients, only men had dysplastic or malignant lip lesions (P=0.006); lipstick was used frequently by 73 percent of the women. The clinical appearance of lip lesions did not predict the presence of dysplasia or cancer. Conclusions. Renal-transplant recipients have an increased prevalence of leukoplakia, dysplasia, and cancer of the lip.	UNIV LONDON LONDON HOSP,COLL MED,DEPT DERMATOL,LONDON E1 2AD,ENGLAND; UNIV LONDON LONDON HOSP,COLL MED,DEPT NEPHROL,LONDON E1 2AD,ENGLAND; UNIV LONDON LONDON HOSP,COLL MED,INST DENT SURG,JOINT DEPT ORAL PATHOL,LONDON E1 2AD,ENGLAND; UNIV MANCHESTER,DEPT ORAL HLTH,MANCHESTER,LANCS,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London; University of Manchester	KING, GN (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,DEPT ORAL MED & PERIODONTOL,LONDON E1 2AD,ENGLAND.		Healy, Claire M/AGL-9755-2022; Worthington, Helen/U-8971-2019	Healy, Claire M/0000-0003-0583-6360; Worthington, Helen/0000-0002-4851-7469; Thornhill, Martin/0000-0003-0681-4083; Healy, Claire M/0000-0001-7940-4611				BARR BBB, 1989, LANCET, V1, P124; BLESSING K, 1989, HISTOPATHOLOGY, V14, P129, DOI 10.1111/j.1365-2559.1989.tb02123.x; BLOHME I, 1985, TRANSPLANTATION, V39, P23; BLOHME I, 1984, TRANSPLANTATION, V37, P165, DOI 10.1097/00007890-198402000-00010; Bouquot J E, 1987, Quintessence Int, V18, P277; BOYLE J, 1984, LANCET, V1, P702; BUNNEY MH, 1987, LANCET, V2, P151; DOUGLASS CW, 1984, ORAL SURG ORAL MED O, V57, P631, DOI 10.1016/0030-4220(84)90286-X; HARDIE IR, 1980, SURGERY, V87, P177; HOXTELL EO, 1977, ARCH DERMATOL, V113, P436, DOI 10.1001/archderm.113.4.436; KINLEN LJ, 1979, BRIT MED J, V2, P1461, DOI 10.1136/bmj.2.6203.1461; KRAMER I R H, 1978, Oral Surgery Oral Medicine Oral Pathology, V46, P518; LINDQVIST C, 1981, COMMUNITY DENT ORAL, V9, P247, DOI 10.1111/j.1600-0528.1981.tb00339.x; LUTZNER M, 1980, J INVEST DERMATOL, V75, P353, DOI 10.1111/1523-1747.ep12531131; MARSHALL V, 1974, TRANSPLANTATION, V17, P272, DOI 10.1097/00007890-197403000-00006; PATHAK MA, 1987, DERMATOLOGY GENERAL, V1, P1507; PENN I, 1980, CLIN PLAST SURG, V7, P361; PENN I, 1993, HEMATOL ONCOL CLIN N, V7, P431, DOI 10.1016/S0889-8588(18)30250-8; ROGERS GS, 1988, J AM ACAD DERMATOL, V18, P1039, DOI 10.1016/S0190-9622(88)70101-2	19	94	96	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1052	1057		10.1056/NEJM199504203321602	http://dx.doi.org/10.1056/NEJM199504203321602			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898522				2022-12-28	WOS:A1995QT18700002
J	KHAMASHTA, MA; CUADRADO, MJ; MUJIC, F; TAUB, NA; HUNT, BJ; HUGHES, GRV				KHAMASHTA, MA; CUADRADO, MJ; MUJIC, F; TAUB, NA; HUNT, BJ; HUGHES, GRV			THE MANAGEMENT OF THROMBOSIS IN THE ANTIPHOSPHOLIPID-ANTIBODY SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTICARDIOLIPIN ANTIBODIES; DIFFERENT INTENSITIES; VENOUS THROMBOSIS; ANTICOAGULANT; WARFARIN; FEATURES; TRIAL	Background. The anti phospholipid-anti body syndrome is a thrombophilic disorder in which venous or arterial thrombosis, or both, may occur in patients with antiphospholipid antibodies. The optimal treatment of these patients is unclear. We assessed the efficacy of warfarin, low-dose aspirin, or both in the secondary prevention of thrombosis in patients with the syndrome. Methods. One hundred forty-seven patients (124 [84 percent] of whom were female) with the antiphospholipid-antibody syndrome and a history of thrombosis were studied retrospectively. The syndrome was primary in 62 patients and was associated with systemic lupus erythematosus in 66 patients and lupus-like disease in 19. Each patient's history was reviewed. Results. One hundred one patients (69 percent) had a total of 186 recurrences of thrombosis. The median time between the initial thrombosis and the first recurrence was 12 months (range, 0.5 to 144 months). Treatment with high-intensity warfarin (producing an international normalized ratio of greater than or equal to 3) with or without law-dose aspirin (75 mg per day) was significantly more effective (P<0.001 by the log-rank test) than treatment with low-intensity warfarin (producing an international normalized ratio of <3) with or without low-dose aspirin or treatment with aspirin alone in preventing further thrombotic events (recurrence rates per patient-year, 0.013, 0.23, and 0.18, respectively). The rate of recurrence of thrombosis was highest (1.30 per patient-year) during the first six months after the cessation of warfarin therapy. Complications involving bleeding occurred in 29 patients during warfarin therapy and were severe in 7 (0.071 and 0.017 occurrence per patient-year, respectively). Conclusions. The risk of recurrent thrombosis in patients with the antiphospholipid-antibody syndrome is high. Long-term anticoagulation therapy in which the international normalized ratio is maintained at or above 3 is advisable in these patients.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, RAYNE INST, LUPUS & ARTHRITIS RES UNIT, LONDON SE1 7EH, ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMASS HOSP, DEPT PUBL HLTH MED, LONDON SE1 7EH, ENGLAND; ST THOMAS HOSP, CTR HEMOPHILIA, LONDON, ENGLAND	University of London; King's College London; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust								ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P1014; ALARCONSEGOVIA D, 1989, J RHEUMATOL, V16, P482; ARMITAGE P, 1994, STATISTICAL METHODS, P144; ASHERSON RA, 1989, MEDICINE, V68, P366, DOI 10.1097/00005792-198911000-00004; ASHERSON RA, 1991, ANN RHEUM DIS, V50, P805, DOI 10.1136/ard.50.11.805; ASHERSON RA, 1985, ANN RHEUM DIS, V44, P823, DOI 10.1136/ard.44.12.823; BARBUI T, 1994, LUPUS, V3, P303, DOI 10.1177/096120339400300419; BERN MM, 1990, ANN INTERN MED, V112, P423, DOI 10.7326/0003-4819-76-3-112-6-423; COX DR, 1972, J R STAT SOC B, V34, P187; DERKSEN RHWM, 1993, ANN RHEUM DIS, V52, P689, DOI 10.1136/ard.52.9.689; EXNER T, 1975, PATHOLOGY, V7, P319, DOI 10.3109/00313027509081688; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; HARRIS E N, 1987, British Journal of Rheumatology, V26, P19; HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215; HIRSH J, 1994, CIRCULATION, V89, P1469, DOI 10.1161/01.CIR.89.3.1469; HUGHES GRV, 1983, BRIT MED J, V287, P1088, DOI 10.1136/bmj.287.6399.1088; HUGHES GRV, 1993, LANCET, V342, P341, DOI 10.1016/0140-6736(93)91477-4; HULL R, 1982, NEW ENGL J MED, V307, P1676, DOI 10.1056/NEJM198212303072704; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEVINE M, 1994, LANCET, V343, P886, DOI 10.1016/S0140-6736(94)90008-6; LEVINE SR, 1992, STROKE S1, V23, P29; LIE JT, 1989, J RHEUMATOL, V16, P713; LOCKSHIN MD, 1993, RHEUM DIS CLIN N AM, V19, P235; MACHIN SJ, 1991, J CLIN PATHOL, V44, P885; MACKWORTHYOUNG CG, 1989, ANN RHEUM DIS, V48, P362, DOI 10.1136/ard.48.5.362; POLLER L, 1987, BRIT MED J, V295, P1309, DOI 10.1136/bmj.295.6609.1309; RIVIER G, 1994, LUPUS, V3, P85, DOI 10.1177/096120339400300205; ROSOVE MH, 1992, ANN INTERN MED, V117, P303, DOI 10.7326/0003-4819-117-4-303; SAOUR JN, 1990, NEW ENGL J MED, V322, P428, DOI 10.1056/NEJM199002153220703; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; VIANNA JL, 1994, AM J MED, V96, P3, DOI 10.1016/0002-9343(94)90108-2; VLACHOYIANNOPOULOS PG, 1994, LUPUS, V3, P91, DOI 10.1177/096120339400300206; WHISNANT JP, 1990, STROKE, V21, P707, DOI 10.1161/01.STR.21.5.707	33	1130	1153	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					993	997		10.1056/NEJM199504133321504	http://dx.doi.org/10.1056/NEJM199504133321504			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885428	Bronze			2022-12-28	WOS:A1995QT73700004
J	IGLEHART, JK				IGLEHART, JK			REPUBLICANS AND THE NEW POLITICS OF HEALTH-CARE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Altman Lawrence K, 1995, N Y Times Web, pC3; Balz Dan, 1994, WASH POST, pA1; CALMES J, 1995, WALL STREET J   0127, P4; CALMES J, 1995, WALL STREET J   0127, pA1; FREUDENHEIM M, 1995, NY TIMES        0414, pA1; FREUDENHEIM M, 1995, NY TIMES        0214, pD9; FRISBY MK, 1995, WALL STREET J   0207, pA24; HUSKAMP HA, 1994, HEALTH AFFAIR, V13, P32, DOI 10.1377/hlthaff.13.5.32; IGLEHART JK, 1985, NEW ENGL J MED, V313, P1552, DOI 10.1056/NEJM198512123132429; KING G, 1994, HEALTH AFFAIR, V13, P39, DOI 10.1377/hlthaff.13.5.39; SCHICK A, 1995, FEDERAL BUDGET POLIC; WINSLOW R, 1995, WALL STREET J   0412, pA1; 1995, SOURCES HLTH INSURAN; 1994, POST ELECTION SURVEY	14	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					972	975		10.1056/NEJM199504063321425	http://dx.doi.org/10.1056/NEJM199504063321425			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP893	7877669				2022-12-28	WOS:A1995QP89300035
J	OLIVIERI, NF; BRITTENHAM, GM; MATSUI, D; BERKOVITCH, M; BLENDIS, LM; CAMERON, RG; MCCLELLAND, RA; LIU, PP; TEMPLETON, DM; KOREN, G				OLIVIERI, NF; BRITTENHAM, GM; MATSUI, D; BERKOVITCH, M; BLENDIS, LM; CAMERON, RG; MCCLELLAND, RA; LIU, PP; TEMPLETON, DM; KOREN, G			IRON-CHELATION THERAPY WITH ORAL DEFERIPRONE IN PATIENTS WITH THALASSEMIA MAJOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE L1; SUBCUTANEOUS DEFEROXAMINE; EFFICACY; STORES; ANEMIA; TRIAL; DESFERRIOXAMINE; FERRITIN; TOXICITY; MICE	Background. To determine whether the orally active iron chelator deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) is efficacious in the treatment of iron overload in patients with thalassemia major, we conducted a prospective trial of deferiprone in 21 patients unable or unwilling to use standard chelation therapy with parenteral deferoxamine. Methods. Hepatic iron stores were determined yearly by chemical analysis of liver-biopsy specimens or magnetic-susceptibility measurements. Detailed clinical and laboratory studies were used to monitor safety and compliance. Results. The patients received deferiprone therapy for a mean (+/-SE) of 3.1+/-0.3 years. Ten patients in whom previous chelation therapy with deferoxamine had been ineffective had initial hepatic iron concentrations of at least 80 mu mol per gram of liver, wet weight - values associated with complications of iron overload. Hepatic iron concentrations decreased in all 10 patients, from 125.3+/-11.5 to 60.3+/-9.6 mu mol per gram (P<0.005), with values that were less than 80 mu mol per gram in 8 of the 10 patients (P<0.005). In all 11 patients in whom deferoxamine therapy had previously been effective, deferiprone maintained hepatic iron concentrations below 80 mu mol of iron per gram. Conclusions. Oral deferiprone induces sustained decreases in body iron to concentrations compatible with the avoidance of complications from iron overload. The risk of agranulocytosis associated with deferiprone may restrict its administration to patients who are unable or unwilling to use deferoxamine.	TORONTO HOSP,DEPT MED,TORONTO,ON M5T 2S8,CANADA; TORONTO HOSP,DEPT PATHOL,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT CHEM,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON,CANADA; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; METROHLTH MED CTR,DEPT MED,CLEVELAND,OH	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Case Western Reserve University; MetroHealth System	OLIVIERI, NF (corresponding author), HOSP SICK CHILDREN,DEPT PEDIAT,HEMOGLOBINOPATHY PROGRAM,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		Olivieri, Nancy/AAI-2250-2020	Templeton, Douglas/0000-0003-0693-662X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL042824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035827] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42824] Funding Source: Medline; NIAID NIH HHS [AI 35827] Funding Source: Medline; FDA HHS [FD-R-000532] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FDA HHS		AGARWAL MB, 1992, BRIT J HAEMATOL, V82, P460, DOI 10.1111/j.1365-2141.1992.tb06445.x; ALREFAIE FN, 1992, BLOOD, V80, P593; BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; BERGERON RJ, 1992, BLOOD, V79, P1882; BERKOVITCH M, 1994, LANCET, V343, P1471, DOI 10.1016/S0140-6736(94)92585-2; BIESEMEIER JA, 1991, 14 DAY ORAL TOXICITY; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRONSPIEGELWEIN.N, 1990, NEW ENGL J MED, V323, P713; Cohen A, 1987, Hematol Oncol Clin North Am, V1, P521; COHEN A, 1984, BRIT J HAEMATOL, V58, P369, DOI 10.1111/j.1365-2141.1984.tb06096.x; COLLINS AF, 1994, BLOOD, V83, P2329; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V262, P1472; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; ENGLE MA, 1964, CIRCULATION, V30, P698, DOI 10.1161/01.CIR.30.5.698; FOSBURG MT, 1990, BLOOD, V76, P435; HOFFBRAND AV, 1989, LANCET, V2, P457; KONTOGHIORGHES GJ, 1987, INORG CHIM A-BIOINOR, V136, pL11, DOI 10.1016/S0020-1693(00)85549-8; KONTOGHIORGHES GJ, 1987, LANCET, V1, P1294; KONTOGHIORGHES GJ, 1990, BRIT J HAEMATOL, V76, P295, DOI 10.1111/j.1365-2141.1990.tb07887.x; MATSUI D, 1991, CLIN PHARMACOL THER, V50, P294, DOI 10.1038/clpt.1991.139; MEHTA J, 1991, INDIAN J HEMATOL BLO, V9, P33; OLIVIERI NF, 1992, AM J PEDIAT HEMATOL, V14, P48; OLIVIERI NF, 1986, NEW ENGL J MED, V314, P869, DOI 10.1056/NEJM198604033141402; OLIVIERI NF, 1990, SEMIN HEMATOL, V27, P101; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; OLIVIERI NF, 1994, BLOOD, V84, pA363; OLIVIERI NF, 1992, BLOOD, V79, P2741; OLIVIERI NF, 1990, LANCET, V336, P1275, DOI 10.1016/0140-6736(90)92962-H; Porter J B, 1989, Baillieres Clin Haematol, V2, P459, DOI 10.1016/S0950-3536(89)80027-7; PORTER JB, 1990, BLOOD, V76, P2389; PORTER JB, 1991, BLOOD, V78, P2727; SCHNEBLI HP, 1993, ERS6293 CEIB GEIG BI, P30; TONDURY P, 1990, BRIT J HAEMATOL, V76, P550; VREUGDENHIL G, 1990, ANN RHEUM DIS, V49, P956, DOI 10.1136/ard.49.11.956-b; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	38	257	268	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					918	922		10.1056/NEJM199504063321404	http://dx.doi.org/10.1056/NEJM199504063321404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877649				2022-12-28	WOS:A1995QP89300004
J	JADHAV, S				JADHAV, S			THE GHOSTBUSTERS OF PSYCHIATRY	LANCET			English	Editorial Material											JADHAV, S (corresponding author), UCL, DEPT PSYCHIAT, LONDON, ENGLAND.		jadhav, sushrut/B-8249-2009	jadhav, sushrut/0000-0001-5325-8687				BLUE I, 1994, BRIT J PSYCHIAT, V165, P9, DOI 10.1192/bjp.165.1.9; COLEMAN J, 1994, TREATING SURVIVORS S; Good B, 1994, MED RATIONALITY EXPE; HALE AS, 1994, BRIT J PSYCHIAT, V165, P386, DOI 10.1192/bjp.165.3.386; JADHAV S, 1994, PSYCHIATR B, V18, P572; Kakar Sudhir., 1982, SHAMANS MYSTICS DOCT; LEWIS IM, 1966, MAN, V1, P307, DOI 10.2307/2796794; LITTLEWOOD R, 1991, LANCET, V337, P1013, DOI 10.1016/0140-6736(91)92668-R; MULHERN S, 1991, PSYCHIAT CLIN N AM, V14, P769; Turner V.W., 1964, MAGIC FAITH HEALING; Vitebsky, 1993, DIALOGUES DEAD DISCU; WEISS MG, 1992, BRIT J PSYCHIAT, V160, P819, DOI 10.1192/bjp.160.6.819	12	7	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 1	1995	345	8953					808	810		10.1016/S0140-6736(95)92959-2	http://dx.doi.org/10.1016/S0140-6736(95)92959-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QQ195	7898225				2022-12-28	WOS:A1995QQ19500004
J	COOPER, C; KANIS, JA; COMPSTON, J				COOPER, C; KANIS, JA; COMPSTON, J			HOW TO ASSESS DRUG EFFICACY IN OSTEOPOROSIS	LANCET			English	Editorial Material							POPULATION		UNIV SHEFFIELD,SCH MED,DEPT HUMAN METAB & CLIN BIOCHEM,WHO COLLABORATING CTR METAB BONE DIS,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND; UNIV CAMBRIDGE,SCH MED,DEPT MED,CAMBRIDGE,ENGLAND	University of Sheffield; World Health Organization; University of Cambridge	COOPER, C (corresponding author), SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							COOPER C, 1992, J BONE MINER RES, V7, P221, DOI 10.1002/jbmr.5650070214; COOPER C, 1992, TRENDS ENDOCRIN MET, V3, P224, DOI 10.1016/1043-2760(92)90032-V; KANIS JA, 1993, DRUG AGING, V3, P391, DOI 10.2165/00002512-199303050-00001; KLEEREKOPER M, 1990, OSTEOPOROSIS INT, V1, P155; MCCLOSKEY EV, 1993, OSTEOPOROSIS INT, V3, P138, DOI 10.1007/BF01623275; RIGGS BL, 1990, NEW ENGL J MED, V322, P802, DOI 10.1056/NEJM199003223221203; 1994, GUIDELINES PRECLINIC; 1994, WHO TECH REPORT SERI, V843	8	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					743	744		10.1016/S0140-6736(95)90635-5	http://dx.doi.org/10.1016/S0140-6736(95)90635-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891482				2022-12-28	WOS:A1995QN70100006
J	EVANS, I; FOX, R				EVANS, I; FOX, R			CURSE OF THE EXAMINATION INCUBUS	LANCET			English	Editorial Material																		GODFREY RC, 1995, LANCET, V345, P765, DOI 10.1016/S0140-6736(95)90644-4; Godlee RJ, 1913, LANCET, V2, P1155; Shaw LE, 1913, LANCET, V2, P1287	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					744	744		10.1016/S0140-6736(95)90636-3	http://dx.doi.org/10.1016/S0140-6736(95)90636-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891483				2022-12-28	WOS:A1995QN70100007
J	BABA, TW; JEONG, YS; PENNINCK, D; BRONSON, R; GREENE, MF; RUPRECHT, RM				BABA, TW; JEONG, YS; PENNINCK, D; BRONSON, R; GREENE, MF; RUPRECHT, RM			PATHOGENICITY OF LIVE, ATTENUATED SIV AFTER MUCOSAL INFECTION OF NEONATAL MACAQUES	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; INDEPENDENT DOWN-REGULATION; VIRION-ASSOCIATED PROTEIN; CELL-SURFACE CD4; MUTATIONAL ANALYSIS; NEF-PROTEIN; THROMBOCYTOPENIC PURPURA; RHESUS MACAQUES; HOMOSEXUAL MEN	Adult macaques do not develop disease after infection with a nef deletion mutant of the simian immunodeficiency virus (SIV) and are protected against challenge with pathogenic virus. This finding led to the proposal to use nef-deleted viruses as live, attenuated vaccines to prevent human acquired immunodeficiency syndrome (AIDS). In contrast, neonatal macaques developed persistently high levels of viremia after oral exposure to an SIV nef, vpr, and negative regulatory element (NRE) deletion mutant. Severe hemolytic anemia, thrombocytopenia, and CD4(+) T cell depletion were observed, indicating that neither nef nor vpr determine pathogenicity in neonates. Because such constructs have retained their pathogenic potential, they should not be used as candidate live, attenuated virus vaccines against human AIDS.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,VIRAL PATHOGENESIS LAB,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; TUFTS UNIV,SCH MED,DEPT PEDIAT,DIV NEWBORN MED,BOSTON,MA 02111; MASSACHUSETTS GEN HOSP,DEPT OBSTET & GYNECOL,BOSTON,MA 02114; TUFTS UNIV,SCH VET MED,DEPT RADIOL,GRAFTON,MA 01536; TUFTS UNIV,SCH VET MED,DEPT VET PATHOL,BOSTON,MA 02111	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Tufts University; Harvard University; Massachusetts General Hospital; Tufts University; Tufts University			Abrams, William R/A-5782-2008		PHS HHS [R01-A135533, R01-A132330] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AHMAD N, 1988, SCIENCE, V241, P1481, DOI 10.1126/science.3262235; AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; AYEHUNIE S, UNPUB; BABA T, UNPUB; BABA TW, 1994, AIDS RES HUM RETROV, V10, P351, DOI 10.1089/aid.1994.10.351; BABA TW, 1993, J WOMENS HEALTH, V2, P231; BACHELERIE F, 1990, J VIROL, V64, P3059, DOI 10.1128/JVI.64.6.3059-3062.1990; BARRY PA, 1990, J MED PRIMATOL, V19, P327; BOLOGNESI DP, 1994, J NIH RES, V6, P55; CHENGMAYER C, 1989, SCIENCE, V246, P1629, DOI 10.1126/science.2531920; CHINNECK JW, 1994, COMPUT OPER RES, V21, P1, DOI 10.1016/0305-0548(94)90057-4; COHEN EA, 1990, J VIROL, V64, P3097, DOI 10.1128/JVI.64.6.3097-3099.1990; DANIEL MD, 1985, SCIENCE, V228, P1201, DOI 10.1126/science.3159089; DANIEL MD, 1992, SCIENCE, V258, P1938, DOI 10.1126/science.1470917; DENNY TN, 1990, PEDIATR RES, V27, pA155; Desrosiers R.C., 1994, J NIH RES, V6, P54; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P1457, DOI 10.1089/aid.1992.8.1457; DESROSIERS RC, 1990, ANNU REV IMMUNOL, V8, P557, DOI 10.1146/annurev.iy.08.040190.003013; DESROSIERS RC, 1994, AIDS RES HUM RETROV, V10, P221; DESROSIERS RC, 1994, 7TH ANN M NAT COOP V; FAZELY F, 1993, J ACQ IMMUN DEF SYND, V6, P107; FERNIE S, 1994, J TOXICOL ENV HLTH, V45, P53; FORSTER SM, 1987, AIDS, V1, P235; FOX CH, 1993, CURRENT PROTOCOLS IM; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; GIBBS JS, 1994, AIDS RES HUM RETROV, V10, P607, DOI 10.1089/aid.1994.10.607; GOLDSWEIG HG, 1986, AM J HEMATOL, V21, P243, DOI 10.1002/ajh.2830210303; HAMMES SR, 1989, P NATL ACAD SCI USA, V86, P9549, DOI 10.1073/pnas.86.23.9549; HU SL, 1993, HIV MOL ORG PATHOGEN; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; KIM SY, 1989, P NATL ACAD SCI USA, V86, P9544, DOI 10.1073/pnas.86.23.9544; KLEGANOFF SJ, 1994, P NATL ACAD SCI USA, V91, P10615; KOPELMAN RG, 1988, AM J MED, V84, P82, DOI 10.1016/0002-9343(88)90012-5; LAIRMORE MD, 1990, AIDS RES HUM RETROV, V6, P1233, DOI 10.1089/aid.1990.6.1233; LAIRMORE MD, 1993, AIDS RES HUM RETROV, V9, P565, DOI 10.1089/aid.1993.9.565; LETVIN NL, 1985, SCIENCE, V230, P71, DOI 10.1126/science.2412295; LITTMAN DR, 1994, CURR BIOL, V4, P618, DOI 10.1016/S0960-9822(00)00135-4; LU YC, 1989, J VIROL, V63, P4115, DOI 10.1128/JVI.63.9.4115-4119.1989; LUCIW PA, 1987, P NATL ACAD SCI USA, V84, P1434, DOI 10.1073/pnas.84.5.1434; Mann J., 1992, AIDS WORLD GLOBAL RE; MILLER CJ, 1989, J VIROL, V63, P4277, DOI 10.1128/JVI.63.10.4277-4284.1989; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MORRIS L, 1982, ANN INTERN MED, V96, P714, DOI 10.7326/0003-4819-96-6-714; NIEDERMAN TMJ, 1989, P NATL ACAD SCI USA, V86, P1128, DOI 10.1073/pnas.86.4.1128; OGAWA K, 1989, J VIROL, V63, P4110, DOI 10.1128/JVI.63.9.4110-4114.1989; OHKAWA S, 1990, FASEB J, V4, pA2264; PAGE JB, 1990, LANCET, V335, P1439, DOI 10.1016/0140-6736(90)91456-K; PAUZA CD, 1993, J MED PRIMATOL, V22, P154; RASZKA WV, 1994, PEDIATR INFECT DIS J, V13, P70, DOI 10.1097/00006454-199401000-00015; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; RUPRECHT RM, 1990, J ACQ IMMUN DEF SYND, V3, P591; RUPRECHT RM, 1990, P NATL ACAD SCI USA, V87, P5558, DOI 10.1073/pnas.87.14.5558; RUPRECHT RM, 1994, DNA CELL BIOL, V13, P59, DOI 10.1089/dna.1994.13.59; SAVONA S, 1985, ANN INTERN MED, V102, P737, DOI 10.7326/0003-4819-102-6-737; SCHREIBNER ZA, 1983, BLOOD S, V92, pA117; SHIBATA R, 1990, J MED PRIMATOL, V19, P217; SHIBATA R, 1990, J VIROL, V64, P742, DOI 10.1128/JVI.64.2.742-747.1990; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SOSA MAG, 1991, AIDS RES HUM RETROV, V7, P859, DOI 10.1089/aid.1991.7.859; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TOY PTCY, 1985, AM J HEMATOL, V19, P145, DOI 10.1002/ajh.2830190206; TRAINADORGE V, 1992, AIDS RES HUM RETROV, V8, P97, DOI 10.1089/aid.1992.8.97; VIGLIANTI GA, 1988, J VIROL, V62, P4523, DOI 10.1128/JVI.62.12.4523-4532.1988; WALSH C, 1985, ANN INTERN MED, V103, P542, DOI 10.7326/0003-4819-103-4-542; WEBER JN, 1987, LANCET, V1, P121; WEISS R, 1984, RNA TUMOR VIRUSES; WILLIAMSHERMAN D, 1993, 9TH INT C AIDS BERL; WYAND MS, 1994, 1994 C ADV AIDS VACC; YU M, 1994, J NIH RES, V6, P20; YU XF, 1988, NATURE, V335, P262, DOI 10.1038/335262a0; YUAN X, 1990, AIDS RES HUM RETROV, V6, P1265, DOI 10.1089/aid.1990.6.1265; ZACK JA, 1988, SCIENCE, V240, P1026, DOI 10.1126/science.2835813	72	453	466	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1820	1825		10.1126/science.7892606	http://dx.doi.org/10.1126/science.7892606			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892606				2022-12-28	WOS:A1995QN70200039
J	KLINGMULLER, U; LORENZ, U; CANTLEY, LC; NEEL, BG; LODISH, HF				KLINGMULLER, U; LORENZ, U; CANTLEY, LC; NEEL, BG; LODISH, HF			SPECIFIC RECRUITMENT OF SH-PTP1 TO THE ERYTHROPOIETIN RECEPTOR CAUSES INACTIVATION OF JAK2 AND TERMINATION OF PROLIFERATIVE SIGNALS	CELL			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; MOTH-EATEN; KINASE; PHOSPHORYLATION; DOMAIN; CELLS; SH2; DIFFERENTIATION; TRANSDUCTION; SUPERFAMILY	The binding of erythropoietin (EPO) to its receptor (EPO-R) activates the protein tyrosine kinase JAK2. The mechanism of JAK2 inactivation has been unclear. We show that the hematopoietic protein tyrosine phosphatase SH-PTP1 (also called HCP and PTP1C) associates via its SH2 domains with the tyrosine-phosphorylated EPO-R. In vitro binding studies suggest that Y429 in the cytoplasmic domain of the EPO-R is the binding site for SH-PTP1. Mutant EPO-Rs lacking Y429 are unable to bind SH-PTP1; cells expressing such mutants are hypersensitive to EPO and display prolonged EPO-induced autophosphorylation of JAK2. Our results suggest that activation of SH-PTP1 by binding to the EPO-R plays a major role in terminating proliferative signals.	BETH ISRAEL HOSP, MOLEC MED UNIT, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02215 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02138 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	KLINGMULLER, U (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Cantley, Lewis C/D-1800-2014; Klingmüller, Ursula/G-8477-2013	Cantley, Lewis C/0000-0002-1298-7653; Klingmüller, Ursula/0000-0001-9845-3099; Lorenz, Ulrike/0000-0002-7933-6855	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL032262] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32262] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CASE RD, 1994, J BIOL CHEM, V269, P10467; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DECHERT U, 1994, J BIOL CHEM, V269, P5602; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HILTON DJ, 1988, P NATL ACAD SCI USA, V85, P5971, DOI 10.1073/pnas.85.16.5971; LEDBETTER JA, 1993, CURR OPIN IMMUNOL, V5, P334, DOI 10.1016/0952-7915(93)90050-3; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; LONGMORE GD, 1991, CELL, V67, P1089, DOI 10.1016/0092-8674(91)90286-8; LORENZ U, 1994, MOL CELL BIOL, V14, P1824, DOI 10.1128/MCB.14.3.1824; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MIGLIACCIO G, 1989, J CELL BIOL, V109, P833, DOI 10.1083/jcb.109.2.833; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; QUELLE FW, 1991, J BIOL CHEM, V266, P609; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1987, ANNU REV IMMUNOL, V5, P367, DOI 10.1146/annurev.iy.05.040187.002055; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SKODA RC, 1993, EMBO J, V12, P2645, DOI 10.1002/j.1460-2075.1993.tb05925.x; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; TAKAHASHI T, 1994, FEBS LETT, V342, P124, DOI 10.1016/0014-5793(94)80485-0; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; VANZANT G, 1989, EXP HEMATOL, V17, P81; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; YI TL, 1993, MOL CELL BIOL, V13, P7577, DOI 10.1128/MCB.13.12.7577; YI TL, 1993, MOL CELL BIOL, V13, P3350, DOI 10.1128/MCB.13.6.3350; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	46	843	871	0	14	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					729	738		10.1016/0092-8674(95)90351-8	http://dx.doi.org/10.1016/0092-8674(95)90351-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889566	Bronze			2022-12-28	WOS:A1995QM39900009
J	MYNORSWALLIS, LM; GATH, DH; LLOYDTHOMAS, AR; TOMLINSON, D				MYNORSWALLIS, LM; GATH, DH; LLOYDTHOMAS, AR; TOMLINSON, D			RANDOMIZED CONTROLLED TRIAL COMPARING PROBLEM-SOLVING TREATMENT WITH AMITRIPTYLINE AND PLACEBO FOR MAJOR DEPRESSION IN PRIMARY-CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; COGNITIVE THERAPY; COMBINATION; IMIPRAMINE; MANAGEMENT; DISORDER	Objective-To determine whether, in the treatment of major depression in primary care, a brief psychological treatment (problem solving) was (a) as effective as antidepressant drugs and more effective than placebo; (b) feasible in practice; and (c) acceptable to patients. Design-Randomised controlled trial of problem solving treatment, amitriptyline plus standard clinical management, and drug placebo plus standard clinical management. Each treatment was delivered in six sessions over 12 weeks. Setting-Primary care in Oxfordshire. Subjects-91 patients in primary care who had major depression. Main outcome measures-Observer and self reported measures of severity of depression, self reported measure of social outcome, and observer measure of psychological symptoms at six and 12 weeks; self reported measure of patient satisfaction at 12 weeks. Numbers of patients recovered at six and 12 weeks. Results-At six and 12 weeks the difference in score on the Hamilton rating scale for depression between problem solving and placebo treatments was significant (5.3 (95% confidence interval 1.6 to 9.0) and 4.7 (0.4 to 9.0) respectively), but the difference between problem solving and amitriptyline was not significant (1.8 (-1.8 to 5.5) and 0.9 (-3.3 to 5.2) respectively). At 12 weeks 60% (18/30) of patients given problem solving treatment had recovered on the Hamilton scale compared with 52% (16/31) given amitriptyline and 27% (8/30) given placebo. Patients were satisfied with problem solving treatment; all patients who completed treatment (28/30) rated the treatment as helpful or very helpful. The six sessions of problem solving treatment totalled a mean therapy time of 31/2 hours. Conclusions-As a treatment for major depression in primary care, problem solving treatment is effective, feasible, and acceptable to patients.			MYNORSWALLIS, LM (corresponding author), UNIV OXFORD, WARNEFORD HOSP, DEPT PSYCHIAT, OXFORD OX3 7JX, ENGLAND.							BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLACKBURN IM, 1981, BRIT J PSYCHIAT, V139, P181, DOI 10.1192/bjp.139.3.181; BLACKER CVR, 1988, PSYCHOPHARMACOLOGY, V95, pS14; BLASHKI TG, 1971, BMJ-BRIT MED J, V1, P133, DOI 10.1136/bmj.1.5741.133; CATALAN J, 1991, PSYCHOL MED, V21, P1013, DOI 10.1017/S0033291700030002; COOPER P, 1982, BRIT J PSYCHIAT, V141, P68, DOI 10.1192/bjp.141.1.68; CORNEY RH, 1981, PSYCHOL MED, V11, P417, DOI 10.1017/S0033291700052247; DUNN G, 1981, PSYCHOL MED, V11, P755, DOI 10.1017/S003329170004126X; FAWCETT J, 1987, PSYCHOPHARMACOL BULL, V23, P309; FRANK E, 1991, ARCH GEN PSYCHIAT, V48, P851, DOI 10.1001/archpsyc.1991.01810330075011; Hamilton M., 1967, BRIT J SOC CLIN PSYC, V6, P278, DOI [10.1111/j.2044-8260.1967.tb00530.x, DOI 10.1111/J.2044-8260.1967.TB00530.X]; Hawton K., 1989, COGNITIVE BEHAV THER, P406; Johnson D A, 1977, J R Coll Gen Pract, V27, P419; JOHNSON DAW, 1981, ACTA PSYCHIAT SCAND, V63, P447, DOI 10.1111/j.1600-0447.1981.tb00751.x; PAYKEL ES, 1988, J AFFECT DISORDERS, V14, P83, DOI 10.1016/0165-0327(88)90075-4; PORTER AMW, 1970, BMJ-BRIT MED J, V1, P773, DOI 10.1136/bmj.1.5699.773; RICKELS K, 1970, DIS NERV SYST, V31, P30; ROSS M, 1985, J ROY COLL GEN PRACT, V35, P239; SCOTT AIF, 1992, BRIT MED J, V304, P883, DOI 10.1136/bmj.304.6831.883; SPITZER RL, 1978, ARCH GEN PSYCHIAT, V35, P773, DOI 10.1001/archpsyc.1978.01770300115013; TEASDALE JD, 1984, BRIT J PSYCHIAT, V144, P400, DOI 10.1192/bjp.144.4.400; THOMSON J, 1982, PSYCHOL MED, V12, P741, DOI 10.1017/S0033291700049047; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; 1993, DEPRESSION PRIMARY C, V2; 1978, LANCET, V2, P1347	26	378	382	0	16	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	1995	310	6977					441	445		10.1136/bmj.310.6977.441	http://dx.doi.org/10.1136/bmj.310.6977.441			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ242	7873952	Green Published			2022-12-28	WOS:A1995QJ24200022
J	LYKETSOS, CG; HOOVER, DR; GUCCIONE, M; SENTERFITT, W; DEW, MA; WESCH, J; VANRADEN, MJ; TREISMAN, GJ; MORGENSTERN, H				LYKETSOS, CG; HOOVER, DR; GUCCIONE, M; SENTERFITT, W; DEW, MA; WESCH, J; VANRADEN, MJ; TREISMAN, GJ; MORGENSTERN, H			DEPRESSIVE SYMPTOMS AS PREDICTORS OF MEDICAL OUTCOMES IN HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; 500 PSYCHIATRIC OUTPATIENTS; MULTICENTER AIDS COHORT; FOLLOW-UP; LYMPHOCYTE SUBSETS; HOMOSEXUAL MEN; RISK; MORTALITY; CANCER; HEALTH	Objective.-To ascertain whether depressive symptoms as determined by the Center for Epidemiologic Studies-Depression scale (CES-D) predict accelerated mortality and worse medical outcomes in patients infected with human immunodeficiency virus (HIV). Design.-Eight-year cohort study with semiannual follow-up. Setting.-Community volunteers. Participants.-A total of 1809 HIV-seropositive homosexual men without the acquired immunodeficiency syndrome (AIDS) who entered the Multicenter AIDS Cohort Study in 1984 or 1985. Eight-year follow-up data were available on 75% of eligible participants. Outcome Measures.-Times to AIDS, death, and prophylactic treatment, and slopes describing the decline in CD4 count for each individual participant. Results.-Using a conventional definition of depression (CES-D greater-than-or-equal-to 16 at the first study visit), 21.3% of participants were classified as depressed. Depressed participants had lower CD4 counts and reported more AIDS-related symptoms. There were no significant differences between depressed and nondepressed participants on any of the outcome measures (P>.05 in all cases). In contrast, men reporting AIDS-related symptoms had shorter times to AIDS and to death even after adjusting for CD4 counts (P<.01). The analyses were repeated, with similar results, using different definitions of depression based on the CES-D. Conclusions.-We find no evidence that depressive symptoms independently prognosticate worse outcomes in HIV infection. Because of associations of depression with symptom reports, CD4 counts, and indicators of socioeconomic status, future studies of the relationship between depression and HIV outcome should consider these variables as confounders.	JOHNS HOPKINS UNIV, SCH MED, DEPT PSYCHIAT & BEHAV SCI, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MENTAL HYG, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT EPIDEMIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH PUBL HLTH, BALTIMORE, MD 21218 USA; UNIV CALIF LOS ANGELES, SCH PUBL HLTH, DEPT EPIDEMIOL, LOS ANGELES, CA USA; UNIV PITTSBURGH, SCH MED, DEPT PSYCHIAT, PITTSBURGH, PA 15261 USA; UNIV PITTSBURGH, SCH PUBL HLTH, DEPT EPIDEMIOL, PITTSBURGH, PA 15260 USA; NORTHWESTERN UNIV, HOWARD BROWN MEM CLIN, CHICAGO, IL 60611 USA; NIAID, BETHESDA, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene; Johns Hopkins University; Johns Hopkins University; University of California System; University of California Los Angeles; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)					NIAID NIH HHS [N01-AI-72631, N01-AI-32535, N01-AI-72634] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI072631, N01AI032535, N01AI072634] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLACK D, 1985, ARCHIT DIGEST, V42, P82; BLACK DW, 1985, ARCH GEN PSYCHIAT, V42, P71; BRESLAU N, 1985, PSYCHIAT RES, V15, P219, DOI 10.1016/0165-1781(85)90079-4; BURACK JH, 1992, 8TH INT C AIDS ABSTR; CASSIDY WL, 1957, JAMA-J AM MED ASSOC, V164, P1535, DOI 10.1001/jama.1957.02980140011003; EVANS DL, 1992, ARCH GEN PSYCHIAT, V49, P388; GOODWIN FK, 1990, MANIC DEPRESSIVE ILL, P38; GORMAN JM, 1991, ARCH GEN PSYCHIAT, V48, P120; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN HI, 1989, COMPREHENSIVE TXB PS, P913; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; LIPOWSKI ZJ, 1975, COMPR PSYCHIAT, V16, P105, DOI 10.1016/0010-440X(75)90056-5; LYKETSOS CG, 1993, 146TH AM PSYCH ASS A; MARTIN RL, 1985, ARCH GEN PSYCHIAT, V42, P47; MARTIN RL, 1985, ARCH GEN PSYCHIAT, V42, P58; MAYOU R, 1986, BRIT J PSYCHIAT, V149, P172, DOI 10.1192/bjp.149.2.172; OSTROW DG, 1989, AM J PSYCHIAT, V146, P737; PERRY S, 1992, ARCH GEN PSYCHIAT, V49, P396; PERSKY VW, 1987, PSYCHOSOM MED, V49, P435, DOI 10.1097/00006842-198709000-00001; RABKIN JG, 1991, ARCH GEN PSYCHIAT, V48, P111; Radloff L. S., 1977, APPL PSYCH MEAS, V1, P386; SAAH AJ, 1992, AM J EPIDEMIOL, V135, P1147, DOI 10.1093/oxfordjournals.aje.a116215; SHEKELLE RB, 1981, PSYCHOSOM MED, V43, P117, DOI 10.1097/00006842-198104000-00003; STEIN M, 1991, ARCH GEN PSYCHIAT, V48, P171; STRAIN JJ, 1991, AM J PSYCHIAT, V148, P1044; TAYLOR JMG, 1989, J ACQ IMMUN DEF SYND, V2, P114; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; WESSIMAN MM, 1975, COMPARISON CESD STAN; ZONDERMAN AB, 1989, JAMA-J AM MED ASSOC, V262, P1191, DOI 10.1001/jama.262.9.1191; 1987, MMWR MORB MORTAL S1S, V36, pS3	31	210	215	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2563	2567		10.1001/jama.270.21.2563	http://dx.doi.org/10.1001/jama.270.21.2563			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	7901432				2022-12-28	WOS:A1993MJ26600022
J	KOUDSTAAL, PJ; DEHAENE, I; DHOOGHE, M; MARCHAU, M; VANZANDIJCKE, M; DELWAIDE, C; DEPRE, A; LATERRE, EC; VANBUGGENHOUT, E; SCHURMANS, J; DESMET, E; SWERTS, L; VANDENABEELE, G; CARTON, H; VERDRU, PMA; INDEKEU, PA; LAM, D; VANDENBERGH, V; VANLANDEGEM, W; STRAUVEN, T; BOYSEN, G; GYRING, J; PETERSEN, P; WURTZENNIELSEN, P; CREPINLEBLOND, T; MOULIN, T; AURIACOMBE, S; ORGOGOZO, JM; BOULLIAT, J; GOAS, JY; MOCQUARD, Y; BESSON, G; HOMMEL, M; ADNETBONTE, C; JOSIEN, E; CHEDRU, F; EVRARD, S; LEVASSEUR, M; MAS, JL; MEYNIARD, O; ZUBER, M; AMARENCO, P; BOUSSER, MG; ROULLET, E; PINEL, JF; MASSARDIER, E; MIHOUT, B; CHOLLET, F; RASCOL, A; AUTRET, A; SAUDEAU, D; BUTTNER, T; NIEMCZYK, W; BOHM, KD; HORNIG, C; HACKE, W; HEISS, C; REUTHER, R; HAASS, A; STOLL, M; KRAMER, G; ROTHACHER, G; BAUER, M; BUSSE, O; KOCHROSE, S; MUEFFELMANN, B; DICHGANS, J; THOMAS, C; HENNEN, OAD; JORG, J; SCHWAN, H; SIEPEN, R; BORNSTEIN, NM; CENSORI, B; CERAVOLO, M; PROVINCIALI, L; DALESSANDRO, G; BOTTACCHI, E; CARENINI, L; DUC, E; FEDERICO, F; FIORE, A; LAMBERTI, P; LATTANZI, P; CAMERLINGO, M; CASTO, L; MAMOLI, A; BENEMIO, G; BOLDRINI, F; GATTESCHI, C; SCHILLACI, G; VERDECCHIA, P; VIGNAI, E; ARCELLI, G; BRAVI, S; COLI, L; GIRELLI, L; PURRO, A; DELFAVERO, C; GUIDOTTI, M; PELLEGRINI, G; SANTARONE, M; TADEO, G; BOTTINI, G; CANEPARI, C; STERZI, R; BINDA, A; CANDELISE, L; NADOR, F; PINARDI, G; OLIVA, L; MOMBELLONI, A; PONARI, O; SQUERI, M; BARZIZZA, F; CAVALLINI, A; MICIELI, G; NAPPI, G; RICHICHI, I; CASELLI, P; MORETTI, E; AISA, G; BOSCHETTI, E; CAPUTO, N; CELANI, MG; DELFAVERO, A; NENCI, G; RICCI, S; RIGHETTI, E; SENIN, U; BIOTTI, M; DETTORE, M; FABRIZI, G; GRASSELLI, S; PEZZELLA, F; ANTONUTTI, L; GRANDI, FC; GUERRINI, D; MARZALLI, A; PINAMONTI, B; SALVI, R; SAMMARTINI, C; DUDINE, P; MILONE, FF; VICENZI, M; TERBERG, JWM; GELMERS, HJ; HAAS, JA; LINDEBOOM, SF; HERDERSCHEE, D; HIJDRA, A; VERMEULEN, M; BERTELSMANN, FW; HAZENBERG, GJ; KOETSIER, JC; BERNTSEN, PJIM; GEBBINK, TB; SLEEGERS, FM; VANBEECK, JA; FEIKEMA, WJ; VANGASTEREN, JHM; VELTEMA, AN; VREDEVELD, CJM; CARBAAT, PAT; HERTZBERGER, LI; KLEYWEG, RP; BOON, AM; LIEUWENS, WHG; VISSCHER, F; ARTS, WFM; BOON, A; MOLL, LCM; PERQUIN, WVM; TANS, JTJ; TONK, R; DEWEERD, AW; HAAXMAREICHE, H; OOSTERHUIS, HJGH; SNOEK, JW; FRANKE, CL; MIRANDOLLE, JF; KOEHLER, PJJ; BRIET, PE; VANROSSUM, J; BOITEN, J; BOON, AE; LODDER, J; NIHOM, J; MAUSER, HW; FRENKEN, CWGM; POELS, EFJ; PRICK, MJJ; VERHAGEN, WIM; HOPPENBROUWERS, WJJF; KOUUDSTAAL, PJ; STAAL, A; BENEDER, PR; BULENS, C; DEVRIESBOS, LHP; DECOUL, AAWO; LEYTEN, ACM; TIJSSEN, CC; SCHELLENS, RLLA; CILLESSEN, JPM; VANGIJN, J; KAPPELLE, LJ; DRIESEN, JJM; VANOUDENAARDEN, WF; VERHEY, JCB; FRISVOLD, OJ; HOLE, T; SKOGEN, OR; ASLAKSEN, B; GALLEFOSS, F; LAAKE, KO; BERG, LK; BALSLIEMKE, S; RITLAND, S; HVEEM, K; DEHLI, O; ABILDGAARD, U; DAHL, T; WELUND; GONCALVES, JAG; MAIA, R; PALMEIRO, JF; AMARAL, R; MACHADO, C; MESTRE, A; RIBEIRO, F; SOUSA, L; SALGADO, AV; BAPTISTA, A; CANDIDO, JM; MORGADO, AV; RAMIRES, IMV; CRESPO, M; FERRO, JM; FRANCO, AS; MELO, TMP; OLIVEIRA, V; LIMA, AFB; CORREIA, MM; LOPEZ, JC; MORGADO, R; SANTOS, M; GRAU, G; LOPEZ, J; MARTIN, R; MATIASGUIU, J; ALIO, J; CALOPA, M; MIRALLES, F; RUBIO, F; FUEYO, J; GOMEZ, C; MOLINA, L; DOLHABERRIAGUE, L; SOLERSINGLA, L; DAVALOS, A; GENIS, D; BASSAGANYAS, J; BARREIRO, P; DIEZTEJEDOR, E; FRANK, A; COSTA, J; MARES, R; LAINEZ, L; SANCHO, J; HENNERDAL, KH; RUDBACK, N; SAMUELSSON, M; SIGFRIDSON, P; HEDENUS, M; BOGOUSSLAVSKY, J; GHIKA, J; MARIANI, L; NATER, B; SCHMID, F; KNIGHT, R; HAMILTON, SJC; KANE, J; BELL, R; FOOTE, CK; CASSIDY, T; GRAY, CS; SANDERCOCK, PAG; SELLAR, R; WARLOW, CP; HOWE, JG; MCGOURTY, JC; BAMFORD, J; JOHNSON, M; CASTLEDEN, CM; HARPER, GD; PANAYIOTOU, BN; ROBINSON, T; BARER, D; HUMPHREY, P; KAFETZ, K; MCELLIGOTT, G; BATES, D; CARTLIDGE, NEF; VENABLES, GS; MONRO, P; VANLATUM, JC; VERMEULEN, PC; DENOUDEN, A; MAST, B; KOUDSTAAL, PJ; BOGOUSSLAVSKY, J; BOYSEN, G; BORNSTEIN, N; CANDELISE, L; DAHL, T; DEHAENE, I; FERRO, J; VANGIJN, J; GUSTAFSSON, C; HEDENUS, M; HIJDRA, A; KOUDSTAAL, PJ; KRAMER, G; LODDER, J; MAS, JL; MATIASGUIU, J; RICCI, S; SANDERCOCK, PAG; SCHOBBEN, AFAM; STAAL, A; VENABLES, GS; VERMEULEN, M; COLLINS, R; HARRISON, MJG; HILL, C; ALGRA, A; BAARSMA, GS; BANGA, JD; BROWER, RW; KAPPELLE, LJ; LOELIGER, EA; LUBSEN, J; POP, GAM; VANSWIETEN, JC; TIJSSEN, JGP; VANURK, H; VERHEUGT, FWA				KOUDSTAAL, PJ; DEHAENE, I; DHOOGHE, M; MARCHAU, M; VANZANDIJCKE, M; DELWAIDE, C; DEPRE, A; LATERRE, EC; VANBUGGENHOUT, E; SCHURMANS, J; DESMET, E; SWERTS, L; VANDENABEELE, G; CARTON, H; VERDRU, PMA; INDEKEU, PA; LAM, D; VANDENBERGH, V; VANLANDEGEM, W; STRAUVEN, T; BOYSEN, G; GYRING, J; PETERSEN, P; WURTZENNIELSEN, P; CREPINLEBLOND, T; MOULIN, T; AURIACOMBE, S; ORGOGOZO, JM; BOULLIAT, J; GOAS, JY; MOCQUARD, Y; BESSON, G; HOMMEL, M; ADNETBONTE, C; JOSIEN, E; CHEDRU, F; EVRARD, S; LEVASSEUR, M; MAS, JL; MEYNIARD, O; ZUBER, M; AMARENCO, P; BOUSSER, MG; ROULLET, E; PINEL, JF; MASSARDIER, E; MIHOUT, B; CHOLLET, F; RASCOL, A; AUTRET, A; SAUDEAU, D; BUTTNER, T; NIEMCZYK, W; BOHM, KD; HORNIG, C; HACKE, W; HEISS, C; REUTHER, R; HAASS, A; STOLL, M; KRAMER, G; ROTHACHER, G; BAUER, M; BUSSE, O; KOCHROSE, S; MUEFFELMANN, B; DICHGANS, J; THOMAS, C; HENNEN, OAD; JORG, J; SCHWAN, H; SIEPEN, R; BORNSTEIN, NM; CENSORI, B; CERAVOLO, M; PROVINCIALI, L; DALESSANDRO, G; BOTTACCHI, E; CARENINI, L; DUC, E; FEDERICO, F; FIORE, A; LAMBERTI, P; LATTANZI, P; CAMERLINGO, M; CASTO, L; MAMOLI, A; BENEMIO, G; BOLDRINI, F; GATTESCHI, C; SCHILLACI, G; VERDECCHIA, P; VIGNAI, E; ARCELLI, G; BRAVI, S; COLI, L; GIRELLI, L; PURRO, A; DELFAVERO, C; GUIDOTTI, M; PELLEGRINI, G; SANTARONE, M; TADEO, G; BOTTINI, G; CANEPARI, C; STERZI, R; BINDA, A; CANDELISE, L; NADOR, F; PINARDI, G; OLIVA, L; MOMBELLONI, A; PONARI, O; SQUERI, M; BARZIZZA, F; CAVALLINI, A; MICIELI, G; NAPPI, G; RICHICHI, I; CASELLI, P; MORETTI, E; AISA, G; BOSCHETTI, E; CAPUTO, N; CELANI, MG; DELFAVERO, A; NENCI, G; RICCI, S; RIGHETTI, E; SENIN, U; BIOTTI, M; DETTORE, M; FABRIZI, G; GRASSELLI, S; PEZZELLA, F; ANTONUTTI, L; GRANDI, FC; GUERRINI, D; MARZALLI, A; PINAMONTI, B; SALVI, R; SAMMARTINI, C; DUDINE, P; MILONE, FF; VICENZI, M; TERBERG, JWM; GELMERS, HJ; HAAS, JA; LINDEBOOM, SF; HERDERSCHEE, D; HIJDRA, A; VERMEULEN, M; BERTELSMANN, FW; HAZENBERG, GJ; KOETSIER, JC; BERNTSEN, PJIM; GEBBINK, TB; SLEEGERS, FM; VANBEECK, JA; FEIKEMA, WJ; VANGASTEREN, JHM; VELTEMA, AN; VREDEVELD, CJM; CARBAAT, PAT; HERTZBERGER, LI; KLEYWEG, RP; BOON, AM; LIEUWENS, WHG; VISSCHER, F; ARTS, WFM; BOON, A; MOLL, LCM; PERQUIN, WVM; TANS, JTJ; TONK, R; DEWEERD, AW; HAAXMAREICHE, H; OOSTERHUIS, HJGH; SNOEK, JW; FRANKE, CL; MIRANDOLLE, JF; KOEHLER, PJJ; BRIET, PE; VANROSSUM, J; BOITEN, J; BOON, AE; LODDER, J; NIHOM, J; MAUSER, HW; FRENKEN, CWGM; POELS, EFJ; PRICK, MJJ; VERHAGEN, WIM; HOPPENBROUWERS, WJJF; KOUUDSTAAL, PJ; STAAL, A; BENEDER, PR; BULENS, C; DEVRIESBOS, LHP; DECOUL, AAWO; LEYTEN, ACM; TIJSSEN, CC; SCHELLENS, RLLA; CILLESSEN, JPM; VANGIJN, J; KAPPELLE, LJ; DRIESEN, JJM; VANOUDENAARDEN, WF; VERHEY, JCB; FRISVOLD, OJ; HOLE, T; SKOGEN, OR; ASLAKSEN, B; GALLEFOSS, F; LAAKE, KO; BERG, LK; BALSLIEMKE, S; RITLAND, S; HVEEM, K; DEHLI, O; ABILDGAARD, U; DAHL, T; WELUND; GONCALVES, JAG; MAIA, R; PALMEIRO, JF; AMARAL, R; MACHADO, C; MESTRE, A; RIBEIRO, F; SOUSA, L; SALGADO, AV; BAPTISTA, A; CANDIDO, JM; MORGADO, AV; RAMIRES, IMV; CRESPO, M; FERRO, JM; FRANCO, AS; MELO, TMP; OLIVEIRA, V; LIMA, AFB; CORREIA, MM; LOPEZ, JC; MORGADO, R; SANTOS, M; GRAU, G; LOPEZ, J; MARTIN, R; MATIASGUIU, J; ALIO, J; CALOPA, M; MIRALLES, F; RUBIO, F; FUEYO, J; GOMEZ, C; MOLINA, L; DOLHABERRIAGUE, L; SOLERSINGLA, L; DAVALOS, A; GENIS, D; BASSAGANYAS, J; BARREIRO, P; DIEZTEJEDOR, E; FRANK, A; COSTA, J; MARES, R; LAINEZ, L; SANCHO, J; HENNERDAL, KH; RUDBACK, N; SAMUELSSON, M; SIGFRIDSON, P; HEDENUS, M; BOGOUSSLAVSKY, J; GHIKA, J; MARIANI, L; NATER, B; SCHMID, F; KNIGHT, R; HAMILTON, SJC; KANE, J; BELL, R; FOOTE, CK; CASSIDY, T; GRAY, CS; SANDERCOCK, PAG; SELLAR, R; WARLOW, CP; HOWE, JG; MCGOURTY, JC; BAMFORD, J; JOHNSON, M; CASTLEDEN, CM; HARPER, GD; PANAYIOTOU, BN; ROBINSON, T; BARER, D; HUMPHREY, P; KAFETZ, K; MCELLIGOTT, G; BATES, D; CARTLIDGE, NEF; VENABLES, GS; MONRO, P; VANLATUM, JC; VERMEULEN, PC; DENOUDEN, A; MAST, B; KOUDSTAAL, PJ; BOGOUSSLAVSKY, J; BOYSEN, G; BORNSTEIN, N; CANDELISE, L; DAHL, T; DEHAENE, I; FERRO, J; VANGIJN, J; GUSTAFSSON, C; HEDENUS, M; HIJDRA, A; KOUDSTAAL, PJ; KRAMER, G; LODDER, J; MAS, JL; MATIASGUIU, J; RICCI, S; SANDERCOCK, PAG; SCHOBBEN, AFAM; STAAL, A; VENABLES, GS; VERMEULEN, M; COLLINS, R; HARRISON, MJG; HILL, C; ALGRA, A; BAARSMA, GS; BANGA, JD; BROWER, RW; KAPPELLE, LJ; LOELIGER, EA; LUBSEN, J; POP, GAM; VANSWIETEN, JC; TIJSSEN, JGP; VANURK, H; VERHEUGT, FWA			SECONDARY PREVENTION IN NONRHEUMATIC ATRIAL-FIBRILLATION AFTER TRANSIENT ISCHEMIC ATTACK OR MINOR STROKE	LANCET			English	Article							THROMBOEMBOLIC COMPLICATIONS; INTEROBSERVER AGREEMENT; ANTITHROMBOTIC THERAPY; CEREBRAL INFARCTION; ANTICOAGULATION; WARFARIN; HANDICAP; RISK	Several studies have established the value of anticoagulation for primary prevention of thromboembolic events in patients with non-rheumatic atrial fibrillation (NRAF). However, in patients with a recent transient ischaemic attack (TIA) or minor ischaemic stroke the preventive benefit of anticoagulation or aspirin remains unclear. Physicians in 108 centres from 13 countries collaborated to study this question. 1007 NRAF patients with a recent TIA or minor ischaemic stroke were randomised to open anticoagulation or double-blind treatment with either 300 mg aspirin per day or placebo (group 1, 669). Patients with contraindications to anticoagulation were randomised to receive aspirin or placebo (group 2, 338). The measure of outcome was death from vascular disease, any stroke, myocardial infarction, or systemic embolism. During mean follow-up of 2.3 years, the annual rate of outcome events was 8% in patients assigned to anticoagulants vs 17% in placebo-treated patients in group 1 (hazard ratio [HR] 0.53; 95% confidence interval [CI] 0.36-0.79). The risk of stroke alone was reduced from 12% to 4% per year (HR 0.34; 95% CI 0.20-0.57). Among all patients assigned to aspirin (groups 1 and 2), the annual incidence of outcome events was 15%, against 19% in those on placebo (HR 0.83; 95% CI 0.65-1.05). Anticoagulation was significantly more effective than aspirin (HR 0.60; 95% CI 0.41-0.87). The incidence of major bleeding events was low, both on anticoagulation (2.8% per year) and on aspirin (0.9% per year). No intracranial bleeds were identified in patients assigned to anticoagulation. We conclude that anticoagulation is effective in reducing the risk of recurrent vascular events in NRAF patients with a recent TIA or minor ischaemic stroke. In absolute terms: 90 vascular events (mainly strokes) are prevented if 1000 patients are treated with anticoagulation for one year. Aspirin is a safe, though less effective, alternative when anticoagulation is contraindicated; it prevents 40 vascular events each year for every 1000 treated patients.			KOUDSTAAL, PJ (corresponding author), UNIV HOSP ROTTERDAM,DEPT NEUROL,DR MOLEWATERPLEIN 40,3015 GD ROTTERDAM,NETHERLANDS.		Cavallini, Anna/AAC-1895-2022; Cascinu, Stefano/AAN-1923-2020; Pop, Gheorghe/L-4582-2015; Bamford, John/ABE-6218-2021; Hveem, Kristian/AFV-4683-2022; Franco, Andrezza Serpa/V-6469-2019; AURIACOMBE, Sophie/T-5596-2019; Censori, Bruno/ABB-9273-2020; sandercock, peter/GQI-3167-2022; Grau, Georges/AGR-7139-2022; Mariani, Luigi/AAB-9464-2019; García, Ana Frank/I-5159-2015; Verheugt, F.W.A./H-8105-2014; van Gijn, Jan/A-9444-2008; Ferro, José/ABA-1779-2021; celani, maria grazia/AAF-4143-2020; Hacke, Werner/ABE-8661-2020	Cavallini, Anna/0000-0002-5227-1502; Franco, Andrezza Serpa/0000-0001-5008-1345; Censori, Bruno/0000-0001-7235-5909; sandercock, peter/0000-0001-8484-0135; Grau, Georges/0000-0002-0442-0462; García, Ana Frank/0000-0003-3858-9116; Ferro, Jose/0000-0002-2343-9097				BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BOGOUSSLAVSKY J, 1991, NEUROLOGY, V41, P855, DOI 10.1212/WNL.41.6.855; CAIRNS JA, 1991, CIRCULATION, V84, P469, DOI 10.1161/01.CIR.84.2.469; CARO JJ, 1993, LANCET, V341, P1381, DOI 10.1016/0140-6736(93)90950-L; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; DUNN M, 1989, CHEST, V95, pS118, DOI 10.1378/chest.95.2_Supplement.118S; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; HALPERIN JH, 1993, 42ND ANN SCI SESS AM; LEVINE M, 1986, STROKE, V17, P111, DOI 10.1161/01.STR.17.1.111; LOELIGER EA, 1985, ACTA HAEMATOL-BASEL, V74, P125, DOI 10.1159/000206187; LUNDSTROM T, 1989, J INTERN MED, V225, P137, DOI 10.1111/j.1365-2796.1989.tb00053.x; MILLER VT, 1993, NEUROLOGY, V43, P32, DOI 10.1212/WNL.43.1_Part_1.32; OLSEN TS, 1985, STROKE, V16, P459, DOI 10.1161/01.STR.16.3.459; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1990, NEW ENGL J MED, V323, P482; SANDERCOCK P, 1986, LANCET, V2, P788; SANDERCOCK PAG, 1993, J NEUROL NEUROSUR PS, V56, P17, DOI 10.1136/jnnp.56.1.17; SHERMAN DG, 1986, ARCH NEUROL-CHICAGO, V43, P68, DOI 10.1001/archneur.1986.00520010062024; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; WARLOW C, 1992, BRIT HEART J, V68, P547; WEINBERGER J, 1988, ARCH INTERN MED, V148, P1785, DOI 10.1001/archinte.148.8.1785; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; 1990, STROKE, V21, P538; 1987, ARCH INTERN MED, V147, P636; 1991, CIRCULATION, V84, P527; 1984, STROKE, V15, P779; 1988, BMJ, V296, P320; 1982, LANCET, V1, P64; 1989, ARCH NEUROL-CHICAGO, V46, P727; 1990, NEW ENGL J MED, V323, P1505	30	1242	1267	2	43	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1255	1262						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901582				2022-12-28	WOS:A1993MH56600008
J	ROSAHL, TW; GEPPERT, M; SPILLANE, D; HERZ, J; HAMMER, RE; MALENKA, RC; SUDHOF, TC				ROSAHL, TW; GEPPERT, M; SPILLANE, D; HERZ, J; HAMMER, RE; MALENKA, RC; SUDHOF, TC			SHORT-TERM SYNAPTIC PLASTICITY IS ALTERED IN MICE LACKING SYNAPSIN-I	CELL			English	Article							SQUID GIANT SYNAPSE; PROTEIN-KINASE-II; NEUROTRANSMITTER RELEASE; TRANSMITTER RELEASE; PHOSPHORYLATION; VESICLES; CALMODULIN; GENE; POTENTIATION; HIPPOCAMPUS	Synapsin I, the major phosphoprotein of synaptic vesicles, is thought to play a central role in neurotransmitter release. Here we introduce a null mutation into the murine synapsin I gene by homologous recombination. Mice with no detectable synapsin I manifest no apparent changes in well-being or gross nervous system function. Thus, synapsin I is not essential for neurotransmitter release. Electrophysiology reveals that mice lacking synapsin I exhibit a selective increase in paired pulse facilitation, with no major alterations in other synaptic parameters such as long-term potentiation. In addition to potential redundant functions shared with other proteins, synapsin I in normal mice may function to limit increases in neurotransmitter release elicited by residual Ca2+ after an initial stimulus.	UNIV TEXAS, HLTH SCI CTR, SW MED SCH, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA; UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV CALIF SAN FRANCISCO, DEPT PSYCHIAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ROSAHL, TW (corresponding author), UNIV TEXAS, HLTH SCI CTR, SW MED SCH, DEPT MOLEC GENET, DALLAS, TX 75235 USA.			Hammer, Robert E./0000-0001-5487-7551				BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BENNETT AF, 1991, BIOCHEM J, V276, P793, DOI 10.1042/bj2760793; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; FYKSE EM, 1993, IN PRESS J NEUROSCI; GREENE RW, 1991, PROG NEUROBIOL, V36, P329, DOI 10.1016/0301-0082(91)90005-L; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; HACKETT JT, 1990, J NEUROPHYSIOL, V63, P701, DOI 10.1152/jn.1990.63.4.701; HARLOW E, 1988, ANTIBODIES LABORATOR; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HAYES NVL, 1991, BIOCHEM J, V275, P93, DOI 10.1042/bj2750093; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; KAHLE JS, 1989, BRAIN RES, V482, P159, DOI 10.1016/0006-8993(89)90554-4; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KORN H, 1991, TRENDS NEUROSCI, V14, P439, DOI 10.1016/0166-2236(91)90042-S; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LLINAS R, 1991, J PHYSIOL-LONDON, V436, P257, DOI 10.1113/jphysiol.1991.sp018549; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MALENKA RC, 1991, NEURON, V6, P53, DOI 10.1016/0896-6273(91)90121-F; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MCGUINNESS TL, 1989, J NEUROSCI, V9, P4138; MCNAUGHTON BL, 1980, BRAIN RES, V199, P1, DOI 10.1016/0006-8993(80)90226-7; MIGNERY GA, 1989, NATURE, V342, P192, DOI 10.1038/342192a0; NICHOLS RA, 1992, J NEUROCHEM, V58, P783, DOI 10.1111/j.1471-4159.1992.tb09788.x; PETRUCCI TC, 1987, J CELL BIOL, V105, P1355, DOI 10.1083/jcb.105.3.1355; PRINCE DA, 1992, P NATL ACAD SCI USA, V89, P8586, DOI 10.1073/pnas.89.18.8586; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; Sambrook J, 1989, MOL CLONING LABORATO; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SIKORSKI AF, 1991, BRAIN RES BULL, V27, P195, DOI 10.1016/0361-9230(91)90067-T; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; STEVENS CF, 1993, CELL, V72, P55, DOI 10.1016/S0092-8674(05)80028-5; SUDHOF TC, 1990, J BIOL CHEM, V265, P7849; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; SUDHOF TC, 1991, NEUROSCI YEAR, V2, P146; YANGFENG TL, 1986, P NATL ACAD SCI USA, V83, P2238; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P175, DOI 10.1085/jgp.76.2.175; ZENGEL JE, 1980, J GEN PHYSIOL, V76, P213, DOI 10.1085/jgp.76.2.213; ZHENG H, 1990, NATURE, V344, P170, DOI 10.1038/344170a0; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	46	280	291	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 19	1993	75	4					661	670		10.1016/0092-8674(93)90487-B	http://dx.doi.org/10.1016/0092-8674(93)90487-B			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7902212	Bronze			2022-12-28	WOS:A1993MH74900012
J	MARTIN, J; MAYHEW, M; LANGER, T; HARTL, FU				MARTIN, J; MAYHEW, M; LANGER, T; HARTL, FU			THE REACTION CYCLE OF GROEL AND GROES IN CHAPERONIN-ASSISTED PROTEIN-FOLDING	NATURE			English	Article							ESCHERICHIA-COLI; RIBULOSEBISPHOSPHATE CARBOXYLASE; MOLECULAR CHAPERONE; ATP HYDROLYSIS; PURIFICATION; COOPERATIVITY; SURFACE	The reaction mechanism of protein folding by the chaperonin GroEL and its regulator GroES has been defined. GroES and substrate protein counteract each other's effects on GroEL: whereas GroES stabilizes GroEL in the ADP-bound state, binding of unfolded polypeptide within the cavity of the GroEL cylinder triggers ADP and GroES release. Upon ADP-ATP exchange, GroES reassociates with GroEL and ATP hydrolysis discharges the bound protein for folding. Partially folded protein rebinds to the chaperonin, thus perpetuating the cycle until folding is complete.	MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019	Langer, Thomas/0000-0003-1250-1462				BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P25672; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P321, DOI 10.1146/annurev.bi.60.070191.001541; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOHN T, 1979, J MOL BIOL, V129, P359, DOI 10.1016/0022-2836(79)90501-1; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P279, DOI 10.1038/366279a0; MCLENNAN NF, 1993, MOL MICROBIOL, V7, P49, DOI 10.1111/j.1365-2958.1993.tb01096.x; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; TODD MJ, 1993, BIOCHEMISTRY-US, V32, P8560, DOI 10.1021/bi00084a024; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1992, J BIOL CHEM, V267, P695; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WANG Z, 1992, PROTEIN SCI, V1, P522	31	265	268	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1993	366	6452					228	233		10.1038/366228a0	http://dx.doi.org/10.1038/366228a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	7901770				2022-12-28	WOS:A1993MH32500052
J	MARTIN, J; GEROMANOS, S; TEMPST, P; HARTL, FU				MARTIN, J; GEROMANOS, S; TEMPST, P; HARTL, FU			IDENTIFICATION OF NUCLEOTIDE-BINDING REGIONS IN THE CHAPERONIN PROTEINS GROEL AND GROES	NATURE			English	Article							ESCHERICHIA-COLI; ATP HYDROLYSIS; COOPERATIVITY; PURIFICATION; F1-ATPASE; GENES; SITE	THE chaperonin GroEL, a tetradecameric cylinder consisting of subunits of M(r) approximately 60,000 (60K), and its cofactor GroES, a heptameric ring of 10K subunits, mediate protein folding in the cytosol of Escherichia coli1-3. In the presence of nucleotide, GroES forms a 1:1 complex with GroEL which binds unfolded protein in its central cavity and releases it to allow folding upon ATP hydrolysis4-7. Using labelling with azido-ATP, we have identified a protease-stable nucleotide-binding domain of M(r) 40K in the GroEL subunits (residues 153-531). Azido-ATP is crosslinked to the highly conserved Tyr 477, indicating that this residue is close to the purine ring of the bound nucleotide. Surprisingly, GroES also binds ATP cooperatively and with an affinity comparable to that of GroEL. Azido-nucleotide labelling of GroES subunits occurs at the conserved Tyr 71 in a protease-stable 6.5K domain (starting at residue 33). Proteinase K cleavage at residue 32 is prevented when GroES is bound to GroEL. ATP binding to GroES may be important in charging the seven subunits of the interacting GroEL ring with ATP to facilitate cooperative ATP binding and hydrolysis for substrate protein release.	MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,MOLEC BIOL PROGRAM,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center			Hartl, F. Ulrich/Y-8206-2019					Beavis R C, 1989, Rapid Commun Mass Spectrom, V3, P233, DOI 10.1002/rcm.1290030708; BOCHKAREVA ES, 1992, J BIOL CHEM, V267, P6796; BRAIG K, 1993, P NATL ACAD SCI USA, V90, P3978, DOI 10.1073/pnas.90.9.3978; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; ELLIS RJ, 1991, ANNU REV BIOCHEM, V60, P327; ERDJUMENTBROMAG.H, 1993, TECHNIQUES PROTEIN C, V4, P419; FAYET O, 1986, MOL GEN GENET, V202, P435, DOI 10.1007/BF00333274; FRY DC, 1986, P NATL ACAD SCI USA, V83, P907, DOI 10.1073/pnas.83.4.907; GEROMANOS S, IN PRESS TECHNIQUES, V5; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GRAY TE, 1991, FEBS LETT, V292, P254, DOI 10.1016/0014-5793(91)80878-7; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOLLEMANS M, 1983, J BIOL CHEM, V258, P9307; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KNIGHT KL, 1985, J BIOL CHEM, V260, P185; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; MARTEL R, 1990, GENE, V94, P181, DOI 10.1016/0378-1119(90)90385-5; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; ROST B, 1993, TRENDS BIOCHEM SCI, V18, P120, DOI 10.1016/0968-0004(93)90017-H; SAIBIL H, 1991, NATURE, V353, P25, DOI 10.1038/353025b0; SAIBIL HR, 1993, CURR BIOL, V3, P265, DOI 10.1016/0960-9822(93)90176-O; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHLOMAI J, 1980, J BIOL CHEM, V255, P6789; SHOEMAKER MT, 1993, BIOCHEMISTRY-US, V32, P1883, DOI 10.1021/bi00058a023; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; TEMPST P, 1990, ELECTROPHORESIS, V11, P537, DOI 10.1002/elps.1150110704; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003	29	94	99	1	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	NOV 18	1993	366	6452					279	282		10.1038/366279a0	http://dx.doi.org/10.1038/366279a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH325	7901771				2022-12-28	WOS:A1993MH32500068
J	SHINDO, M; ARAI, K; SOKAWA, Y; OKUNO, T				SHINDO, M; ARAI, K; SOKAWA, Y; OKUNO, T			HEPATIC HEPATITIS-C VIRUS-RNA AS A PREDICTOR OF A LONG-TERM RESPONSE TO INTERFERON-ALPHA THERAPY	ANNALS OF INTERNAL MEDICINE			English	Article						HEPATITIS C VIRUSES; HEPATITIS C; RNA, VIRAL; INTERFERON-ALPHA; HEPATITIS, CHRONIC ACTIVE	POLYMERASE CHAIN-REACTION; NON-B-HEPATITIS; CONTROLLED TRIAL; VIRAL SEQUENCES; ALFA THERAPY; NON-A; SERUM; LIVER; GENOTYPES; PLACEBO	Objective: To identify predictors of a long-term response to interferon-alpha therapy in chronic hepatitis C and to determine whether hepatitis C virus (HCV) was eradicated in patients with chronic hepatitis C who had a long-term response to therapy. Design: A retrospective analysis. Setting: In- and outpatient liver clinic of a municipal hospital in Japan. Patients: 47 patients with chronic hepatitis C who responded to interferon-alpha were divided into two groups: 22 patients with a long-term response (serum aminotransferase levels remained normal for > 1 year after therapy) and 25 patients with a short-term response (serum aminotransferase levels increased again after therapy). Measurements: Genotyping of HCV, titers of HCV RNA in liver and serum samples (using the reverse transcriptase-polymerase chain reaction), histologic activity index, and liver histologic tests during and 1 year after therapy. Results: Among the 22 long-term responders, HCV RNA was no longer detectable in liver and serum samples of 21 (95%) at the end of therapy and remained undetectable in the serum of 20 (98%) and in the liver of 19 (86%) 1 year after therapy. Liver histologic tests improved substantially immediately after therapy and 1 year after therapy in the long-term responders; however, 18 (82%) of these patients still had mild, chronic hepatitis. Among the 25 short-term responders, HCV RNA was still detected in the liver of 19 (76%) and in the serum of 9 (36%) at the end of therapy. Multivariate logistic regression analysis showed that the persistent presence of hepatic HCV RNA at the end of therapy was the strongest predictor of relapse. Conclusion: These findings suggest that HCV infection was eradicated in most of the long-term responders to interferon-alpha therapy because HCV RNA could no longer be detected in their serum and liver samples and because a significant improvement gradually occurred in their liver histologic results. The persistent presence of hepatic HCV RNA at the end of therapy was the most important predictor of relapse.	KYOTO INST TECHNOL, KYOTO, JAPAN	Kyoto Institute of Technology	SHINDO, M (corresponding author), AKASHI MUNICIPAL HOSP, DEPT INTERNAL MED, 1-33 TAKASHOMACHI, AKASHI, HYOGO 673, JAPAN.							BALART LA, 1993, GASTROENTEROLOGY, V104, P1472, DOI 10.1016/0016-5085(93)90358-J; CAMPS J, 1994, J HEPATOL, V21, P4, DOI 10.1016/S0168-8278(94)80129-0; CAUSSE X, 1991, GASTROENTEROLOGY, V101, P497, DOI 10.1016/0016-5085(91)90030-O; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS GL, 1994, J HEPATOL, V21, P1, DOI 10.1016/S0168-8278(94)80128-2; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DAVIS GL, 1990, HEPATOLOGY, V12, P905; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; DIBISCEGLIE AM, 1993, GASTROENTEROLOGY, V105, P858, DOI 10.1016/0016-5085(93)90905-R; FONG TL, 1991, J CLIN INVEST, V88, P1058, DOI 10.1172/JCI115368; GARSON JA, 1990, LANCET, V335, P1419, DOI 10.1016/0140-6736(90)91446-H; HAGIWARA H, 1993, GASTROENTEROLOGY, V104, P877, DOI 10.1016/0016-5085(93)91025-D; KANAI K, 1992, LANCET, V339, P1543, DOI 10.1016/0140-6736(92)91311-U; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; OKAMOTO H, 1990, JPN J EXP MED, V60, P215; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1990, JPN J EXP MED, V60, P167; SERFATY L, 1994, J HEPATOL, V21, P12, DOI 10.1016/S0168-8278(94)80130-4; SHINDO M, 1992, J INFECT DIS, V166, P424, DOI 10.1093/infdis/166.2.424; SHINDO M, 1991, ANN INTERN MED, V115, P700, DOI 10.7326/0003-4819-115-9-700; TSUBOTA A, 1994, HEPATOLOGY, V19, P1088, DOI 10.1016/0270-9139(94)90854-0; WEINER AJ, 1990, LANCET, V335, P1, DOI 10.1016/0140-6736(90)90134-Q; YOSHIOKA K, 1992, HEPATOLOGY, V16, P293, DOI 10.1002/hep.1840160203	24	103	103	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					586	591		10.7326/0003-4819-122-8-199504150-00005	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00005			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887552				2022-12-28	WOS:A1995QR52500005
J	BRADLEY, M				BRADLEY, M			SPONTANEOUS ATHEROEMBOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											BRADLEY, M (corresponding author), VET AFFAIRS MED CTR,ROSEBURG,OR 97470, USA.								0	2	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					998	998		10.1056/NEJM199504133321505	http://dx.doi.org/10.1056/NEJM199504133321505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885429				2022-12-28	WOS:A1995QT73700005
J	MASSAD, S				MASSAD, S			WATCHERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					914	914						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884941				2022-12-28	WOS:A1995QM17300009
J	DORN, A; STOFFEL, R; MATILE, H; BUBENDORF, A; RIDLEY, RG				DORN, A; STOFFEL, R; MATILE, H; BUBENDORF, A; RIDLEY, RG			MALARIAL HAEMOZOIN BETA-HEMATIN SUPPORTS HEME POLYMERIZATION IN THE ABSENCE OF PROTEIN	NATURE			English	Article							PLASMODIUM-FALCIPARUM; HEMOGLOBIN DEGRADATION; FERRIPROTOPORPHYRIN-IX; CHLOROQUINE; PARASITES; PIGMENT; CULTURE	MALARIAL parasites growing inside erythrocytes digest up to 80% of the host cell's haemoglobin within a lysosomal organelle, the digestive vacuole(1,2). They sequester the potentially toxic haem (Fe (II) protohaematoporphyrin) that is released during this process into an insoluble pigment called haemozoin, which consists of polymerized Fe(III) protohaematoporphyrin subunits(3). We have studied this process of haem polymerization, which was previously reported to be enzyme-mediated and the target of the quinoline antimalarial drugs chloroquine and quinine(4). Here we show that, rather than being enzyme-mediated, haem polymerization is actually a chemical process, dependent only on the presence of haem-derived material associated with haemozoin and not on protein. This discovery does not invalidate haem polymerization as a target for drug intervention and the mechanism by which haemozoin formation is initiated is still not understood, but our view of this process and of the action of chloroquine must be reconsidered.	F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES SPECT,CH-4002 BASEL,SWITZERLAND	Roche Holding	DORN, A (corresponding author), F HOFFMANN LA ROCHE & CO LTD,DIV PHARMA,PRECLIN RES INFECT DIS,CH-4002 BASEL,SWITZERLAND.							ASHONG JO, 1989, T ROY SOC TROP MED H, V83, P167, DOI 10.1016/0035-9203(89)90631-7; COHEN P, 1971, J CLIN INVEST, V50, P762, DOI 10.1172/JCI106547; EGAN TJ, 1994, FEBS LETT, V352, P54, DOI 10.1016/0014-5793(94)00921-X; FITCH CD, 1982, ANTIMICROB AGENTS CH, V21, P819, DOI 10.1128/AAC.21.5.819; FITCH CD, 1987, J BIOL CHEM, V262, P15552; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; GOLDBERG DE, 1992, PARASITOL TODAY, V8, P280, DOI 10.1016/0169-4758(92)90146-S; GOMAN M, 1982, MOL BIOCHEM PARASIT, V25, P391; GUSHIMANA Y, 1993, BIOPHYS CHEM, V47, P153, DOI 10.1016/0301-4622(93)85033-E; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; SLATER AFG, 1991, P NATL ACAD SCI USA, V88, P325, DOI 10.1073/pnas.88.2.325; SLATER AFG, 1992, NATURE, V355, P167, DOI 10.1038/355167a0; SLATER AFG, 1993, PHARMACOL THERAPEUT, V57, P203, DOI 10.1016/0163-7258(93)90056-J; SLATER AFG, 1993, Patent No. 9211279; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840	15	347	351	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					269	271		10.1038/374269a0	http://dx.doi.org/10.1038/374269a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885447	Green Published			2022-12-28	WOS:A1995QM38700052
J	NOAKES, PG; GAUTAM, M; MUDD, J; SANES, JR; MERLIE, JP				NOAKES, PG; GAUTAM, M; MUDD, J; SANES, JR; MERLIE, JP			ABERRANT DIFFERENTIATION OF NEUROMUSCULAR-JUNCTIONS IN MICE LACKING S-LAMININ LAMININ BETA-2	NATURE			English	Article							ORIGINAL SYNAPTIC SITES; ACETYLCHOLINE-RECEPTOR; SKELETAL-MUSCLE; BASAL LAMINA; PROTEIN; IDENTIFICATION; INNERVATION; SYNAPSIN; REGIONS; CELLS	SYNAPSE formation requires a complex interchange of information between the pre- and postsynaptic partners. At the skeletal neuromuscular junction, some of this information is contained in the basal lamina (BL), which runs through the synaptic cleft between the motor nerve terminal and the muscle fibre. During regeneration following injury, components of synaptic BL can trigger several features of postsynaptic differentiation in the absence of the nerve terminal, and of presynaptic differentiation in the absence of the muscle fibre(1-3). One nerve-derived component of synaptic BL, agrin, is known to affect postsynaptic differentiation3, but no muscle-derived components have yet been shown to influence motor nerve terminals. A candidate for such a role is s-laminin (also called laminin beta 2), a homologue of the B1 (beta 1) chain of the widely distributed BL glycoprotein, laminin(30). s-laminin is synthesized by muscle cells(5) and concentrated in synaptic BL(4). In vitro, recombinant s-laminin fragments are selectively adhesive for motor neuron-like cells, inhibit neurite outgrowth promoted by other matrix molecules, and act as a 'stop signal' for growing neurites(6,7). By generating and characterizing mice with a targeted mutation of the s-laminin gene, we show here that s-laminin regulates formation of motor nerve terminals.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)			Noakes, Peter/X-9825-2019	Noakes, Peter/0000-0001-9821-8478; Gautam, Medha/0000-0002-5418-4322				BALICEGORDON RJ, 1993, NEURON, V11, P801, DOI 10.1016/0896-6273(93)90110-D; BALICEGORDON RJ, 1993, J NEUROSCI, V13, P834; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; BURDEN SJ, 1979, J CELL BIOL, V82, P412, DOI 10.1083/jcb.82.2.412; COVAULT J, 1986, J CELL BIOL, V102, P716, DOI 10.1083/jcb.102.3.716; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; GREEN TL, 1992, J BIOL CHEM, V267, P2014; GREENGARD P, 1993, SCIENCE, V259, P708; GU Y, 1988, NEURON, V1, P117, DOI 10.1016/0896-6273(88)90195-X; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; HIROKAWA N, 1989, J CELL BIOL, V108, P111, DOI 10.1083/jcb.108.1.111; HUNTER DD, 1989, CELL, V59, P905, DOI 10.1016/0092-8674(89)90613-2; HUNTER DD, 1989, NATURE, V338, P229, DOI 10.1038/338229a0; HUTCHINSON DO, 1993, BRAIN, V116, P633, DOI 10.1093/brain/116.3.633; INOUE A, 1992, J BIOL CHEM, V267, P10613; JIRMANOVA I, 1975, J NEUROCYTOL, V4, P141, DOI 10.1007/BF01098779; KARNOVSKY MJ, 1964, J CELL BIOL, V23, P217, DOI 10.1083/jcb.23.2.217; MATTHEW WD, 1981, J CELL BIOL, V91, P257, DOI 10.1083/jcb.91.1.257; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MERLIE JP, 1985, NATURE, V317, P66, DOI 10.1038/317066a0; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PORTER BE, IN PRESS NEURON; ROSAHL TW, 1993, CELL, V75, P661, DOI 10.1016/0092-8674(93)90487-B; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SANES JR, 1978, J CELL BIOL, V78, P176, DOI 10.1083/jcb.78.1.176; SCOTT LJC, 1988, J NEUROSCI, V8, P932; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313	30	400	406	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					258	262		10.1038/374258a0	http://dx.doi.org/10.1038/374258a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885444				2022-12-28	WOS:A1995QM38700049
J	HELM, TN				HELM, TN			EVALUATION OF ALOPECIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											HELM, TN (corresponding author), SUNY BUFFALO,BUFFALO,NY, USA.							BERGFELD WF, 1994, CONSULTANT, V34, P1390; HELM TN, 1992, INT J DERMATOL, V31, P437, DOI 10.1111/j.1365-4362.1992.tb02680.x; STECK WD, 1978, CUTIS, V21, P543; WHITING DA, 1993, J AM ACAD DERMATOL, V28, P755, DOI 10.1016/0190-9622(93)70106-4	4	1	1	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					897	898						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869566				2022-12-28	WOS:A1995QL40200034
J	MAGRATH, I				MAGRATH, I			BONE-MARROW TRANSPLANTATION FOR LEUKEMIA - A LAME STALKING HORSE FOR USE OF HIGH-TECHNOLOGY MEDICAL-CARE	LANCET			English	Editorial Material											MAGRATH, I (corresponding author), NIH, LYMPHOMA BIOL SECT, BETHESDA, MD 20892 USA.							DICKE KA, 1993, ANN ONCOL, V4, pS81, DOI 10.1093/annonc/4.suppl_1.S81; GORIN NC, 1993, ANN ONCOL, V4, pS59, DOI 10.1093/annonc/4.suppl_1.S59; HAIOUN C, 1994, J CLIN ONCOL, V12, P2543, DOI 10.1200/JCO.1994.12.12.2543; KANTARJIAN HM, 1993, BLOOD, V82, P691; SEBBAN C, 1994, J CLIN ONCOL, V12, P2580, DOI 10.1200/JCO.1994.12.12.2580; 1994, GAOPEMD9410 US GEN A	6	5	5	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 11	1995	345	8950					601	602		10.1016/S0140-6736(95)90516-2	http://dx.doi.org/10.1016/S0140-6736(95)90516-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898174	Bronze			2022-12-28	WOS:A1995QM07500004
J	BROWN, RH				BROWN, RH			AMYOTROPHIC-LATERAL-SCLEROSIS - RECENT INSIGHTS FROM GENETICS AND TRANSGENIC MICE	CELL			English	Review							MITOCHONDRIAL ENERGY-METABOLISM; CU/ZN SUPEROXIDE-DISMUTASE; MOTOR-NEURON DISEASE; NITRIC-OXIDE; BRAIN; CHROMOSOME-21; PATHOLOGY; GLUTAMATE; MUTATIONS; DEFECTS				BROWN, RH (corresponding author), MASSACHUSETTS GEN HOSP, NEUROMUSC RES NEUROL SERV, CECIL B DAY LAB, BOSTON, MA 02114 USA.							BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BENHAMIDA M, 1990, BRAIN, V113, P347; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; CHOI DW, 1993, P NATL ACAD SCI USA, V90, P9741, DOI 10.1073/pnas.90.21.9741; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DALCANTO MC, 1994, AM J PATHOL, V145, P1271; DAWSON VL, 1993, J NEUROSCI, V13, P2651; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DYKENS JA, 1994, J NEUROCHEM, V63, P584; EBADI M, 1990, ANN NY ACAD SCI, V585, P189, DOI 10.1111/j.1749-6632.1990.tb28053.x; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; GRIFFIN J, 1982, HUMAN MOTOR NEURON D, P419; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HIRANO A, 1991, ADV NEUROL, V56, P91; INCE P, 1993, NEUROPATH APPL NEURO, V19, P291, DOI 10.1111/j.1365-2990.1993.tb00443.x; KOH JY, 1988, J NEUROSCI, V8, P2164; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; LEIGH PN, 1991, ADV NEUROL, V56, P115; LEVANON D, 1985, EMBO J, V4, P77, DOI 10.1002/j.1460-2075.1985.tb02320.x; MITCHELL JD, 1987, J NEUROL NEUROSUR PS, V50, P919, DOI 10.1136/jnnp.50.7.919; PARK EC, 1986, GENETICS, V113, P821; PERRY TL, 1990, ANN NEUROL, V28, P12, DOI 10.1002/ana.410280105; PERRY TL, 1987, NEUROLOGY, V37, P1845, DOI 10.1212/WNL.37.12.1845; PRAMATAROVA A, 1994, HUM MOL GENET, V3, P2061; Price D L, 1994, Neurobiol Dis, V1, P3, DOI 10.1006/nbdi.1994.0002; RIPPS ME, 1995, IN PRESS P NATL ACAD; ROBBERECHT W, 1994, J NEUROCHEM, V62, P384; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; ROTHSTEIN JD, 1994, P NATL ACAD SCI USA, V91, P4155, DOI 10.1073/pnas.91.10.4155; ROWLAND LP, 1991, ADV NEUROL, V56, P3; Scheinbergh H., 1988, METAL NEUROTOXICITY, P55; SIDDIQUE T, 1991, NEW ENGL J MED, V324, P1381, DOI 10.1056/NEJM199105163242001; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; TSAI GC, 1993, BRAIN RES, V629, P305, DOI 10.1016/0006-8993(93)91335-P; TSUDA T, 1994, NEURON, V13, P727, DOI 10.1016/0896-6273(94)90039-6; WILLIAMS DB, 1991, MAYO CLIN PROC, V66, P54, DOI 10.1016/S0025-6196(12)61175-6; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	44	326	329	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					687	692		10.1016/0092-8674(95)90346-1	http://dx.doi.org/10.1016/0092-8674(95)90346-1			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889564	Bronze			2022-12-28	WOS:A1995QM39900004
J	HIOM, K; WEST, SC				HIOM, K; WEST, SC			BRANCH MIGRATION DURING HOMOLOGOUS RECOMBINATION - ASSEMBLY OF A RUVAB-HOLLIDAY JUNCTION COMPLEX IN-VITRO	CELL			English	Article							ESCHERICHIA-COLI RUVA; DNA-REPAIR; PHYSICAL-PROPERTIES; PROTEINS; PURIFICATION; GENES	The RuvA and RuvB proteins of E. coli promote the branch migration or movement of Holliday junctions during genetic recombination and DNA repair. Using small synthetic Holliday junctions in which the crossover point is confined near one end of the DNA molecule, we show that RuvAB-mediated branch migration occurs with a defined polarity. The assembly of RuvA and RuvB on the Holliday junction has been investigated by sedimentation analysis and by DNase I footprinting. We find that RuvA protein binds and protects all four strands of DNA at the crossover point, whereas RuvB protein binds the DNA asymmetrically. The polarity of branch migration is defined by the asymmetric assembly of the RuvAB branch migration complex relative to the junction and is consistent with a model in which RuvAB drives branch migration by passing the DNA through the hexameric rings of RuvB.			HIOM, K (corresponding author), IMPERIAL CANC RES FUND,CLARE HALL LABS,S MIMMS EN6 3LD,HERTS,ENGLAND.			West, Stephen/0000-0001-8848-9418				BENSON F, 1991, MOL GEN GENET, V225, P266, DOI 10.1007/BF00269858; BENSON FE, 1988, NUCLEIC ACIDS RES, V16, P1541, DOI 10.1093/nar/16.4.1541; IWASAKI H, 1989, J BACTERIOL, V171, P5276, DOI 10.1128/jb.171.10.5276-5280.1989; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LLOYD RG, 1984, MOL GEN GENET, V194, P303, DOI 10.1007/BF00383532; LLOYD RG, 1993, NUCLEIC ACIDS RES, V21, P1719, DOI 10.1093/nar/21.8.1719; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17185; MULLER B, 1993, J BIOL CHEM, V268, P17179; MURCHIE AIH, 1990, NUCLEIC ACIDS RES, V18, P2599, DOI 10.1093/nar/18.9.2599; PARSONS CA, 1990, NUCLEIC ACIDS RES, V18, P4377, DOI 10.1093/nar/18.15.4377; PARSONS CA, 1990, J BIOL CHEM, V265, P9285; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SAMBROOK E, 1989, MOL CLONING LABORATO; SARGENTINI NJ, 1989, MUTAT RES, V215, P115, DOI 10.1016/0027-5107(89)90224-8; SHIBA T, 1993, MOL GEN GENET, V237, P395, DOI 10.1007/BF00279443; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; SHINAGAWA H, 1988, J BACTERIOL, V170, P4322, DOI 10.1128/jb.170.9.4322-4329.1988; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1994, J BIOL CHEM, V269, P26552; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315	26	68	69	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					787	793		10.1016/0092-8674(95)90357-7	http://dx.doi.org/10.1016/0092-8674(95)90357-7			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889572	Bronze			2022-12-28	WOS:A1995QM39900015
J	SMITH, HR; DHATT, GS; MELIA, WMA; DICKINSON, JG				SMITH, HR; DHATT, GS; MELIA, WMA; DICKINSON, JG			LESSON OF THE WEEK - CYSTIC-FIBROSIS PRESENTING AS HYPONATREMIC HEAT EXHAUSTION	BRITISH MEDICAL JOURNAL			English	Article							ADULTS		QUEEN ELIZABETH MIL HOSP,LONDON SE18 4QH,ENGLAND; PRINCESS MARY HOSP,AKROTIRI,CYPRUS									ALTON EWFW, 1990, EUR RESPIR J, V3, P922; GIBSON LE, 1959, PEDIATRICS, V23, P545; HODSON ME, 1983, BMJ-BRIT MED J, V286, P1381, DOI 10.1136/bmj.286.6375.1381; KESSLER WR, 1951, PEDIATRICS, V8, P648; OCONNOR KW, 1985, ARCH INTERN MED, V145, P153, DOI 10.1001/archinte.145.1.153; QUINTON PM, 1989, CLIN CHEM, V35, P726; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; SANTAGNESE P, 1981, 1000 YEARS CYSTIC FI, P35; SANTIS G, 1990, LANCET, V335, P1426, DOI 10.1016/0140-6736(90)91448-J; 1993, NEW ENGL J MED, V329, P1308	10	39	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					579	580		10.1136/bmj.310.6979.579	http://dx.doi.org/10.1136/bmj.310.6979.579			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888936	Green Published			2022-12-28	WOS:A1995QK70000024
J	NICHOLSON, RJ; KELLY, KP; GRANT, IS				NICHOLSON, RJ; KELLY, KP; GRANT, IS			LEUKOPENIA ASSOCIATED WITH LAMOTRIGINE	BRITISH MEDICAL JOURNAL			English	Letter											NICHOLSON, RJ (corresponding author), WESTERN GEN HOSP,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							BRODIE MJ, 1992, LANCET, V339, P1397, DOI 10.1016/0140-6736(92)91207-O; LAMOTRIGINE, 1992, DRUG THER B, V30, P75	2	36	37	2	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					504	504		10.1136/bmj.310.6978.504b	http://dx.doi.org/10.1136/bmj.310.6978.504b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888892	Green Published			2022-12-28	WOS:A1995QJ59800027
J	RICHARDS, C; RICHARDS, H; PHEBY, D				RICHARDS, C; RICHARDS, H; PHEBY, D			SKIN-CANCER - HOW ACCURATE ARE LOCAL DATA	BRITISH MEDICAL JOURNAL			English	Article									BRISTOL & DIST HLTH AUTHOR,DEPT PUBL HLTH MED,BRISTOL BS2 8EE,AVON,ENGLAND; S WESTERN REG CANC REGISTRY,BRISTOL BS8 2PR,AVON,ENGLAND	University of Bristol								BENN RT, 1982, INT J EPIDEMIOL, V11, P362, DOI 10.1093/ije/11.4.362; Boyle P, 1991, CANC REGISTRATION PR, V95; 1990, REV NATIONAL CANCER; 1992, HLTH NATION SPECIFIC; 1993, PUBLIC HLTH COMMON D	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					503	503		10.1136/bmj.310.6978.503	http://dx.doi.org/10.1136/bmj.310.6978.503			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888891	Green Published			2022-12-28	WOS:A1995QJ59800024
J	SCOTT, S; DEARY, I; PELOSI, AJ				SCOTT, S; DEARY, I; PELOSI, AJ			GENERAL-PRACTITIONERS ATTITUDES TO PATIENTS WITH A SELF-DIAGNOSIS OF MYALGIC ENCEPHALOMYELITIS	BRITISH MEDICAL JOURNAL			English	Article									HAIRMYRES HOSP,GLASGOW G75 8RG,LANARK,SCOTLAND; UNIV EDINBURGH,DEPT PSYCHOL,EDINBURGH EH8 9JZ,MIDLOTHIAN,SCOTLAND	University Hospital Hairmyres; University of Edinburgh			Deary, Ian J/C-6297-2009	Deary, Ian J/0000-0002-1733-263X; Pelosi, Anthony/0000-0002-5501-2661				DAVID AS, 1991, BRIT J HOSP MED, V45, P158; LEWIS G, 1988, BRIT J PSYCHIAT, V153, P410; Schofield W., 1964, PSYCHOTHERAPY PURCHA; 1993, J ACTION MYALGIC ENC; 1994, COPING ME GUIDELINES	5	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					508	508		10.1136/bmj.310.6978.508	http://dx.doi.org/10.1136/bmj.310.6978.508			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ598	7888895	Green Published, Green Submitted			2022-12-28	WOS:A1995QJ59800029
J	MCCONNELL, J				MCCONNELL, J			MEDICINE ON THE SUPERHIGHWAY	LANCET			English	Editorial Material														McConnell, John/0000-0002-9928-6568					0	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1313	1314		10.1016/0140-6736(93)92240-T	http://dx.doi.org/10.1016/0140-6736(93)92240-T			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901630				2022-12-28	WOS:A1993MJ03900003
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSAL TO REQUIRE EVIDENCE OF EFFECTIVENESS OF SPERMICIDES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-28	WOS:A1995QP89000008
J	HARRIS, R; LEININGER, L				HARRIS, R; LEININGER, L			CLINICAL STRATEGIES FOR BREAST-CANCER SCREENING - WEIGHING AND USING THE EVIDENCE	ANNALS OF INTERNAL MEDICINE			English	Article							INTRADUCTAL CARCINOMA; FAMILY HISTORY; OLDER WOMEN; MAMMOGRAPHY; AGE; PHYSICIANS; DECISIONS; HEALTH; TRIAL; RISK	When balancing the benefits of screening women for breast cancer against the harms and costs of such screening, one needs to consider the risk far dying of breast cancer, the relative reduction in that risk that will result from screening women in different age groups, and the harms and costs associated with screening. Seven randomized controlled trials provide evidence of the relative risk reduction that results from screening women in different age groups; other studies estimate the harms and costs of screening. These studies indicate that the benefit of screening, expressed as the absolute number of lives extended per 1000 women screened, increases with age and that the harm of screening, expressed as the number of follow-up procedures per cancer detected, decreases with age. Thus, the tradeoff between the benefits and the harms and costs of screening is better for older than for younger women. Because there is no clear cut-point for determining when benefits outweigh harms and costs, it is important to involve women in discussions of breast cancer screening. The women who most need to be involved are those for whom the benefits of screening clearly outweigh the harms and costs and those for whom the benefits and the harms and costs constitute a ''close call.'' For women in both groups, the physician should routinely raise the issue of screening, first eliciting the patient's perceptions and then providing information and discussion about the risk for breast cancer and about the benefits and the harms and costs of screening. Furthermore, the physician should encourage the patient to use her own values to weigh the benefits against the harms and costs, pointing out biases in reasoning and minimizing socioeconomic barriers. Finally, when the benefits obviously outweigh the harms and costs, the physician should make a clear recommendation for screening.	UNIV N CAROLINA, SCH MED, LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	HARRIS, R (corresponding author), UNIV N CAROLINA, SCH MED,DEPT MED,CANC CONTROL PROGRAM,CB 7300, TRAILER L, CHAPEL HILL, NC 27599 USA.				NCI NIH HHS [CA5434-02] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER FE, 1994, BRIT J CANCER, V70, P542, DOI 10.1038/bjc.1994.342; BAINES CJ, 1994, ANN INTERN MED, V120, P326, DOI 10.7326/0003-4819-120-4-199402150-00011; BAINES CJ, 1989, CANCER, V63, P1816; BLACK WC, 1995, IN PRESS J NATL CANC; BROWN ML, 1992, J GERONTOL, V47, P51; CHU KC, 1988, JNCI-J NATL CANCER I, V80, P1125, DOI 10.1093/jnci/80.14.1125; Cockburn J, 1994, J Med Screen, V1, P7; COLDITZ GA, 1993, JAMA-J AM MED ASSOC, V270, P338, DOI 10.1001/jama.270.3.338; DAY NE, 1988, SCREENING BREAST CAN; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; ELLMAN R, 1989, BRIT J CANCER, V60, P781, DOI 10.1038/bjc.1989.359; FELDMAN W, 1990, Journal of General Internal Medicine, V5, pS50, DOI 10.1007/BF02600842; FEUER EJ, 1993, J NATL CANCER I, V85, P892, DOI 10.1093/jnci/85.11.892; FLETCHER SW, 1993, JNCI-J NATL CANCER I, V85, P112, DOI 10.1093/jnci/85.2.112; FLETCHER SW, 1985, JAMA-J AM MED ASSOC, V253, P2224, DOI 10.1001/jama.253.15.2224; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FOX SA, 1991, ARCH INTERN MED, V151, P50, DOI 10.1001/archinte.151.1.50; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRAM IT, 1990, BRIT J CANCER, V62, P1018, DOI 10.1038/bjc.1990.430; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; HOUN F, 1994, RADIOLOGY, V190, P209, DOI 10.1148/radiology.190.1.8259406; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KEUTER MW, 1995, IN PRESS HLTH PSYCHO; KOPANS DB, 1988, AM J ROENTGENOL, V150, P785, DOI 10.2214/ajr.150.4.785; KOPANS DB, 1993, AM J ROENTGENOL, V161, P755, DOI 10.2214/ajr.161.4.8372752; KOTTKE TE, 1995, IN PRESS JAMA; LANNIN DR, 1993, SURG GYNECOL OBSTET, V177, P457; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; MILLER AB, 1992, CAN MED ASSOC J, V147, P1477; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLER BA, 1992, NCI NIH922789 PUB; Morrison AS, 1992, SCREENING CHRONIC DI; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; PILGRIM C, 1993, J GEN INTERN MED, V8, P685, DOI 10.1007/BF02598289; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; ROSEN PP, 1980, CANCER, V46, P919, DOI 10.1002/1097-0142(19800815)46:4+<919::AID-CNCR2820461311>3.0.CO;2-Z; SCHNITT SJ, 1988, NEW ENGL J MED, V318, P898, DOI 10.1056/NEJM198804073181406; Shapiro S, 1988, PERIODIC SCREENING B; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TVERSKY A, 1981, SCIENCE, V211, P453, DOI 10.1126/science.7455683; 1989, IMPROVING RISK COMMU; 1990, JAMA-J AM MED ASSOC, V264, P54; 1985, DHHS PHS18511501 US; 1994, US 1993	47	63	64	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					539	547		10.7326/0003-4819-122-7-199504010-00011	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872591				2022-12-28	WOS:A1995QP00800011
J	LESKO, SM; MITCHELL, AA				LESKO, SM; MITCHELL, AA			AN ASSESSMENT OF THE SAFETY OF PEDIATRIC IBUPROFEN - A PRACTITIONER-BASED RANDOMIZED CLINICAL-TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; ANTIPYRETIC EFFICACY; FEBRILE CHILDREN; ACETAMINOPHEN; PARACETAMOL; PLACEBO; SUSPENSION; PYREXIA; MULTICENTER; ARTHRITIS	Objective.-To test the hypothesis that ibuprofen increases the risk of hospitalization for gastrointestinal bleeding, renal failure, or anaphylaxis among febrile children. Design.-Randomized double-blind acetaminophen-controlled trial. Setting.-Outpatient pediatric and family medicine practices. Patients.-A total of 84 192 children. Intervention.-Patients were randomly assigned to receive 12 mg/kg of acetaminophen, 5 mg/kg of ibuprofen, or 10 mg/kg of ibuprofen. Main Outcome Measures.-Hospitalizations for acute gastrointestinal bleeding, acute renal failure, and anaphylaxis. Results.-A total of 277 patients (0.3%) were unavailable for follow-up. Overall, 795 participants (1%) were hospitalized, primarily for infectious diseases; hospitalization rates did not differ according to treatment group. Four children had diagnoses of acute, nonmajor gastrointestinal bleeding (two in each ibuprofen dosage group); among ibuprofen-treated children, the observed risk of gastrointestinal bleeding, 7.2 per 100 000 (95% confidence interval, 2 to 18 per 100 000), was not significantly different from the risk among acetaminophen-treated children (P=.31). There were no hospitalizations for acute renal failure or anaphylaxis; the upper 95% confidence bound for the risk of either of these outcomes was 5.4 per 100 000 ibuprofen-treated children. Among a number of other possibly serious adverse drug events, low white blood cell count was marginally associated with ibuprofen treatment. Because this association was observed in the setting of multiple comparisons and white blood cell counts may have been low before treatment, causation is unclear. Conclusions.-The risk of hospitalization for gastrointestinal bleeding, renal failure, or anaphylaxis was not increased following short-term use of ibuprofen in children. These data, however, provide no information on the risks of less severe outcomes or the risks of prolonged ibuprofen use.			LESKO, SM (corresponding author), BOSTON UNIV,SCH MED,SCH PUBL HLTH,SLONE EPIDEMIOL UNIT,1371 BEACON ST,BROOKLINE,MA 02146, USA.			Mitchell, Allen/0000-0003-0950-6799				AMDEKAR YK, 1985, BRIT J CLIN PRACT, V39, P140; BERTIN L, 1991, J PEDIATR-US, V119, P811, DOI 10.1016/S0022-3476(05)80308-7; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; CLIVE DM, 1984, NEW ENGL J MED, V310, P563, DOI 10.1056/NEJM198403013100905; FRIEDMAN LM, 1985, FUNDAMENTALS CLIN TR, P138; GIANNINI EH, 1990, J PEDIATR-US, V117, P645, DOI 10.1016/S0022-3476(05)80708-5; HEREMANS G, 1988, BRIT J CLIN PRACT, V42, P245; HURWITZ ES, 1982, PEDIATRICS, V70, P895; KANDOTH PW, 1984, J INT MED RES, V12, P292, DOI 10.1177/030006058401200505; KAUFFMAN RE, 1992, AM J DIS CHILD, V146, P622, DOI 10.1001/archpedi.1992.02160170102024; KAUFMAN DW, 1993, CLIN PHARMACOL THER, V53, P485, DOI 10.1038/clpt.1993.55; KOTOB A, 1985, J INT MED RES, V13, P122, DOI 10.1177/030006058501300208; MANN JFE, 1993, CLIN NEPHROL, V39, P1; MARRIOTT SC, 1991, ARCH DIS CHILD, V66, P1037, DOI 10.1136/adc.66.9.1037; MCINTIRE SC, 1993, PEDIATRICS, V93, P459; MEHTA C, 1989, STATXACT STATISTICAL; Miettinen O.S., 1980, DRUG THERAPEUTICS, P201; NAHATA MC, 1992, INT J CLIN PHARM TH, V30, P94; PHADKE MA, 1985, BRIT J CLIN PRACT, V39, P437; SCHACHTEL BP, 1993, CLIN PHARMACOL THER, V53, P593, DOI 10.1038/clpt.1993.75; SHETH UK, 1980, J CLIN PHARMACOL, V20, P672, DOI 10.1002/j.1552-4604.1980.tb01685.x; STEANS A, 1990, BRIT J CLIN PRACT, V44, P172; VANBILJON G, 1989, S AFR MED J, V76, P34; WALSON PD, 1989, CLIN PHARMACOL THER, V46, P9, DOI 10.1038/clpt.1989.100; WALSON PD, 1992, AM J DIS CHILD, V146, P626, DOI 10.1001/archpedi.1992.02160170106025; WATTAD A, 1994, PEDIATRICS, V93, P693; WILSON G, 1984, J INT MED RES, V12, P250, DOI 10.1177/030006058401200405; WILSON JT, 1991, J PEDIATR-US, V119, P803, DOI 10.1016/S0022-3476(05)80307-5	28	190	201	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					929	933		10.1001/jama.273.12.929	http://dx.doi.org/10.1001/jama.273.12.929			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884951				2022-12-28	WOS:A1995QM17300027
J	CANNON, RO				CANNON, RO			THE SENSITIVE HEART - A SYNDROME OF ABNORMAL CARDIAC PAIN PERCEPTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							NORMAL CORONARY ARTERIOGRAMS; LEFT-VENTRICULAR HYPERTROPHY; ESOPHAGEAL CHEST PAIN; SYNDROME-X; ANGINA-PECTORIS; FOLLOW-UP; FLOW RESERVE; ENDOTHELIAL DYSFUNCTION; RESISTANCE VESSELS; ARTERY DISEASE				CANNON, RO (corresponding author), NHLBI, CARDIOL BRANCH, BLDG 10, ROOM 7B-15, BETHESDA, MD 20892 USA.							ARBOGAST R, 1973, AM J CARDIOL, V32, P257, DOI 10.1016/S0002-9149(73)80130-4; BASS C, 1983, LANCET, V1, P605; BEITMAN BD, 1989, AM J CARDIOL, V63, P1399, DOI 10.1016/0002-9149(89)91056-4; BORTONE AS, 1989, CIRCULATION, V79, P516, DOI 10.1161/01.CIR.79.3.516; BRAND DL, 1977, AM J DIG DIS, V22, P300, DOI 10.1007/BF01072186; BRUSH JE, 1988, NEW ENGL J MED, V319, P1302, DOI 10.1056/NEJM198811173192002; CAMICI PG, 1991, J AM COLL CARDIOL, V17, P1461, DOI 10.1016/0735-1097(91)90632-J; CANNON RO, 1990, J AM COLL CARDIOL, V16, P1359, DOI 10.1016/0735-1097(90)90377-2; CANNON RO, 1990, AM J MED, V88, P217, DOI 10.1016/0002-9343(90)90145-4; CANNON RO, 1985, CIRCULATION, V71, P218, DOI 10.1161/01.CIR.71.2.218; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CANNON RO, 1994, NEW ENGL J MED, V330, P1411, DOI 10.1056/NEJM199405193302003; CARTER C, 1992, PSYCHOSOMATICS, V33, P302, DOI 10.1016/S0033-3182(92)71969-0; CHAUHAN A, 1993, BRIT HEART J, V69, P516; CHAUHAN A, 1994, J AM COLL CARDIOL, V24, P329, DOI 10.1016/0735-1097(94)90284-4; CRAKE T, 1988, BRIT HEART J, V59, P31; CREA F, 1990, CIRCULATION, V81, P164, DOI 10.1161/01.CIR.81.1.164; Dart A M, 1980, Eur Heart J, V1, P97; DAY LJ, 1976, LANCET, V2, P334; DURATE IDG, 1990, NITRIC OXIDE L ARGIN, P165; EGASHIRA K, 1993, NEW ENGL J MED, V328, P1659, DOI 10.1056/NEJM199306103282302; EGASHIRA K, 1993, J CLIN INVEST, V91, P29, DOI 10.1172/JCI116183; GALASSI AR, 1991, AM HEART J, V122, P458, DOI 10.1016/0002-8703(91)91000-D; GILLIGAN DM, 1994, CIRCULATION, V89, P2545, DOI 10.1161/01.CIR.89.6.2545; ISNER JM, 1981, AM HEART J, V102, P645, DOI 10.1016/0002-8703(81)90088-0; JANSSENS J, 1986, GASTROENTEROLOGY, V90, P1978, DOI 10.1016/0016-5085(86)90270-2; KATON W, 1988, AM J MED, V84, P1, DOI 10.1016/0002-9343(88)90001-0; Kemp H G, 1967, Trans Assoc Am Physicians, V80, P59; KEMP HG, 1986, J AM COLL CARDIOL, V7, P479, DOI 10.1016/S0735-1097(86)80456-9; KEMP HG, 1973, AM J CARDIOL, V32, P375, DOI 10.1016/S0002-9149(73)80150-X; KEMP HG, 1973, AM J MED, V54, P735, DOI 10.1016/0002-9343(73)90060-0; LAGERQVIST B, 1992, BRIT HEART J, V68, P282; LANTINGA LJ, 1988, AM J CARDIOL, V62, P209, DOI 10.1016/0002-9149(88)90213-5; LEGRAND V, 1985, J AM COLL CARDIOL, V6, P1245, DOI 10.1016/S0735-1097(85)80209-6; LEVY RD, 1986, BRIT HEART J, V56, P353; LIKOFF W, 1967, NEW ENGL J MED, V276, P1063, DOI 10.1056/NEJM196705112761904; LYNN RB, 1993, NEW ENGL J MED, V329, P1940, DOI 10.1056/NEJM199312233292608; MASERI A, 1991, J AM COLL CARDIOL, V17, P499, DOI 10.1016/S0735-1097(10)80122-6; MILLER TD, 1988, J AM COLL CARDIOL, V12, P637, DOI 10.1016/S0735-1097(88)80049-4; MONTORSI P, 1989, AM J CARDIOL, V63, P1198, DOI 10.1016/0002-9149(89)90178-1; MOTZ W, 1991, AM J CARDIOL, V68, P996, DOI 10.1016/0002-9149(91)90485-4; NIHOYANNOPOULOS P, 1991, J AM COLL CARDIOL, V18, P1463, DOI 10.1016/0735-1097(91)90676-Z; OCKENE IS, 1980, NEW ENGL J MED, V303, P1249, DOI 10.1056/NEJM198011273032201; OPHERK D, 1989, CIRCULATION, V80, P1610, DOI 10.1161/01.CIR.80.6.1610; OPHERK D, 1983, ARCH MAL COEUR VAISS, V76, P231; PAMELIA FX, 1985, AM J CARDIOL, V55, P920, DOI 10.1016/0002-9149(85)90718-0; PAPANICOLAOU MN, 1986, AM J CARDIOL, V58, P1181, DOI 10.1016/0002-9149(86)90378-4; PASTERNAK RC, 1980, AM J MED, V68, P813, DOI 10.1016/0002-9343(80)90199-0; PROUDFIT WL, 1966, CIRCULATION, V33, P901, DOI 10.1161/01.CIR.33.6.901; QUYYUMI AA, 1992, CIRCULATION, V86, P1864, DOI 10.1161/01.CIR.86.6.1864; REIS SE, 1994, CIRCULATION, V89, P52, DOI 10.1161/01.CIR.89.1.52; RICHTER JE, 1989, ANN INTERN MED, V110, P66, DOI 10.7326/0003-4819-110-1-66; RICHTER JE, 1986, GASTROENTEROLOGY, V91, P845, DOI 10.1016/0016-5085(86)90685-2; ROSANO GMC, 1994, AM J CARDIOL, V73, P1174, DOI 10.1016/0002-9149(94)90177-5; ROSEN SD, 1994, CIRCULATION, V90, P50, DOI 10.1161/01.CIR.90.1.50; SHAPIRO LM, 1988, BRIT MED J, V296, P170, DOI 10.1136/bmj.296.6616.170-a; SYLVEN C, 1986, BRIT MED J, V293, P227, DOI 10.1136/bmj.293.6541.227; TRAUBE M, 1983, JAMA-J AM MED ASSOC, V250, P2655, DOI 10.1001/jama.250.19.2655; TREASURE CB, 1993, CIRCULATION, V87, P86, DOI 10.1161/01.CIR.87.1.86; TURIEL M, 1987, AM J CARDIOL, V60, P503, DOI 10.1016/0002-9149(87)90294-3; WIELGOSZ AT, 1984, AM HEART J, V108, P67, DOI 10.1016/0002-8703(84)90546-5; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391	62	48	51	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					883	887		10.1001/jama.273.11.883	http://dx.doi.org/10.1001/jama.273.11.883			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869561				2022-12-28	WOS:A1995QL40200028
J	MORGAN, DO				MORGAN, DO			PRINCIPLES OF CDK REGULATION	NATURE			English	Article							CYCLIN-DEPENDENT KINASES; WEE1 TYROSINE KINASE; YEAST-CELL CYCLE; PROTEIN-KINASE; NEGATIVE REGULATION; G1 CYCLIN; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; PHOSPHORYLATION; INHIBITOR	As hey regulators of the cell cycle, the cyclin-dependent kinases must be tightly regulated by extra- and intracellular signals. The activity of cyclin-dependent kinases is controlled by four highly conserved biochemical mechanisms, forming a web of regulatory pathways unmatched in its elegance and intricacy.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	MORGAN, DO (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Morgan, David/0000-0001-8753-4416				AMON A, 1993, CELL, V74, P993, DOI 10.1016/0092-8674(93)90722-3; AMON A, 1994, CELL, V77, P1037, DOI 10.1016/0092-8674(94)90443-X; ATHERTONFESSLER S, 1993, MOL CELL BIOL, V13, P1675, DOI 10.1128/MCB.13.3.1675; ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; BONETTA L, 1994, NATURE, V370, P180, DOI 10.1038/370180a0; BROWN AJ, 1994, MOL BIOL CELL, V5, P921, DOI 10.1091/mbc.5.8.921; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; COLEMAN TR, 1993, CELL, V72, P919, DOI 10.1016/0092-8674(93)90580-J; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1995, MOL CELL BIOL, V15, P345, DOI 10.1128/MCB.15.1.345; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Dunphy William G., 1994, Trends in Cell Biology, V4, P202; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ESPINOZA FH, 1994, SCIENCE, V266, P1388, DOI 10.1126/science.7973730; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HESHKO A, 1994, J BIOL CHEM, V269, P4940; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; IZUMI T, 1993, MOL BIOL CELL, V4, P1337, DOI 10.1091/mbc.4.12.1337; KAFFMAN A, 1994, SCIENCE, V263, P1153, DOI 10.1126/science.8108735; KATO J, 1994, J CELL SCI, V79, P487; KOBAYASHI H, 1992, MOL BIOL CELL, V3, P1279, DOI 10.1091/mbc.3.11.1279; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KREK W, 1991, EMBO J, V10, P305, DOI 10.1002/j.1460-2075.1991.tb07951.x; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; MAKELA TP, 1994, NATURE, V371, P254, DOI 10.1038/371254a0; MATSUOKA M, 1994, J MOL CELL BIOL, V14, P7265; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MCKINNEY JD, 1993, GENE DEV, V7, P833, DOI 10.1101/gad.7.5.833; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; MORGAN DO, 1994, CURR OPIN CELL BIOL, V6, P239, DOI 10.1016/0955-0674(94)90142-2; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; PARGE HE, 1993, SCIENCE, V262, P287; PARKER LL, 1993, NATURE, V363, P736, DOI 10.1038/363736a0; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PETER M, 1994, SCIENCE, V265, P1228, DOI 10.1126/science.8066461; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOLOMON MJ, 1993, EMBO J, V12, P3133, DOI 10.1002/j.1460-2075.1993.tb05982.x; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; TANG ZH, 1993, EMBO J, V12, P3427, DOI 10.1002/j.1460-2075.1993.tb06017.x; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VALAY JG, 1993, J MOL BIOL, V234, P307, DOI 10.1006/jmbi.1993.1587; WAINWRIGHT B, 1994, NAT GENET, V8, P3, DOI 10.1038/ng0994-3; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WU L, 1993, NATURE, V363, P738, DOI 10.1038/363738a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	77	2924	3011	9	203	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					131	134		10.1038/374131a0	http://dx.doi.org/10.1038/374131a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877684				2022-12-28	WOS:A1995QL39700049
J	TAKEI, K; MCPHERSON, PS; SCHMID, SL; DECAMILLI, P				TAKEI, K; MCPHERSON, PS; SCHMID, SL; DECAMILLI, P			TUBULAR MEMBRANE INVAGINATIONS COATED BY DYNAMIN RINGS ARE INDUCED BY GTP-GAMMA-S IN NERVE-TERMINALS	NATURE			English	Article							FROG NEUROMUSCULAR JUNCTION; SYNAPTIC VESICLE MEMBRANE; I PROTEIN-I; BINDING PROTEINS; MECHANOCHEMICAL ENZYME; TRANSMITTER RELEASE; ENDOCYTOSIS; DROSOPHILA; PHOSPHOPROTEIN; MICROTUBULES	THE mechanisms through which synaptic vesicle membranes are reinternalized after exocytosis remain a matter of debate(1-5). Because several vesicular transport steps require GTP hydrolysis(6-9), GTP-gamma S may help identify intermediates in synaptic vesicle recycling. In GTP-gamma S-treated nerve terminals, we observed tubular invaginations of the plasmalemma that were often, but not always, capped by a clathrin-coated bud, Strikingly, the walls of these tubules were decorated by transverse electron-dense rings that were morphologically similar to structures formed by dynamin around tubular templates(10,11). Dynamin is a GTPase implicated in synaptic vesicle endocytosis(12-14) and here we show that the wails of these membranous tubules, but not their distal ends, were positive for dynamin immunoreactivity, These findings demonstrate that dynamin and clathrin act at different sites in the formation of endocytic vesicles, They strongly support a role for dynamin in the fission reaction and suggest that stabilization of the GTP-bound conformation of dynamin leads to tubule formation by progressive elongation of the vesicle stalk.	YALE UNIV, SCH MED, DEPT CELL BIOL, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, HOWARD HUGHES MED RES INST, NEW HAVEN, CT 06510 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Yale University; Yale University; Scripps Research Institute				Takei, Kohji/0000-0002-6555-9425; Schmid, Sandra/0000-0002-1690-7024				CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CECCARELLI B, 1973, J CELL BIOL, V57, P499, DOI 10.1083/jcb.57.2.499; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; FERRONOVICK S, 1993, ANNU REV CELL BIOL, V9, P575; Fesce Riccardo, 1994, Trends in Cell Biology, V4, P1, DOI 10.1016/0962-8924(94)90025-6; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; MCPHERSON PS, 1994, P NATL ACAD SCI USA, V91, P6486, DOI 10.1073/pnas.91.14.6486; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; MCPHERSON PS, 1990, J BIOL CHEM, V265, P18454; MCPHERSON PS, 1994, SEMIN NEUROSCI, V6, P137; MUNDIGL O, 1994, CURR OPIN CELL BIOL, V6, P561, DOI 10.1016/0955-0674(94)90077-9; NAVONE F, 1986, J CELL BIOL, V103, P2511, DOI 10.1083/jcb.103.6.2511; NUOFFER C, 1994, REV BIOCH, V63, P949; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; RAMASWAMI M, 1994, NEURON, V13, P363, DOI 10.1016/0896-6273(94)90353-0; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TAKEI K, 1992, J NEUROSCI, V12, P489; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WILLINGHAM MC, 1983, P NATL ACAD SCI-BIOL, V80, P5617, DOI 10.1073/pnas.80.18.5617	35	643	652	0	20	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					186	190		10.1038/374186a0	http://dx.doi.org/10.1038/374186a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877693				2022-12-28	WOS:A1995QL39700066
J	NEIL, HAW; ROE, L; GODLEE, RJP; MOORE, JW; CLARK, GMG; BROWN, J; THOROGOOD, M; STRATTON, IM; LANCASTER, T; MANT, D; FOWLER, GH				NEIL, HAW; ROE, L; GODLEE, RJP; MOORE, JW; CLARK, GMG; BROWN, J; THOROGOOD, M; STRATTON, IM; LANCASTER, T; MANT, D; FOWLER, GH			RANDOMIZED TRIAL OF LIPID-LOWERING DIETARY ADVICE IN GENERAL-PRACTICE - THE EFFECTS ON SERUM-LIPIDS, LIPOPROTEINS, AND ANTIOXIDANTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							LOW-DENSITY LIPOPROTEIN; CHOLESTEROL; PLASMA; RISK; CAROTENE; FAT	Objective-To determine the relative efficacy in general practice of dietary advice given by a dietitian, a practice nurse, or a diet leaflet alone in reducing total and low density lipoprotein cholesterol concentration. Design-andoomised six month parallel trial. Setting-A general practice in Oxfordshire. Subjects-2004 subjects aged 35-64 years were screened for hypercholesterolaemia; 163 men and 146 women with a repeat total cholesterol concentration of 6 . 0-8 . 5 mmol/l entered the trial. Interventions-Individual advice provided by a dietitian using a diet history, a practice nurse using a structured food frequency questionnaire, or a detailed diet leaflet sent by post. Ah three groups were advised to Limit the energy provided by fat to 30% or less and to increase carbohydrate and dietary fibre. Main outcome measures-Concentrations of total cholesterol and low density and high density lipoprotein cholesterol after six months; antioddant concentration and body mass index. Results-No significant differences were found at the end ofthe trial between groups in mean concentrations of lipids, lipoproteins, and antioxidants or body mass index. After data were pooled from the three groups, the mean total cholesterol concentration fell by 1 . 9% (0 . 13 mmol/l 95% confidence interval 0 . 06 to 0 . 22, P<0 . 001) to 7 . 00 mmol/l, and low density lipoprotein cholesterol also fell. The total carotenoid concentration increased by 53 nmol/l (95% confidence interval 3 . to 103, P=0 . 039). Conclusions-Dietary advice is equally effective when given by a dietitian, a practice nurse, or a diet leaflet alone but results in only a small reduction in total and low density lipoprotein cholesterol. To obtain a better response more intensive intervention than is normally available in primary care is probably necessary.	RADCLIFFE INFIRM, IMPERIAL CANC RES FUND, RES ASSAY LAB, OXFORD OX2 6HE, ENGLAND; OXFORDSHIRE HLTH AUTHOR, DEPT NUTR & DIETET, OXFORD OX3 9DZ, ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED, HLTH PROMOT SCI UNIT, LONDON, ENGLAND; RADCLIFFE INFIRM, DIABET RES LABS, OXFORD OX2 6HE, ENGLAND; UNIV SOUTHAMPTON, ALDERMOOR HLTH CTR, DEPT PRIMARY MED CARE, SOUTHAMPTON SO1 6ST, HANTS, ENGLAND	Radcliffe Infirmary; University of Oxford; University of London; London School of Hygiene & Tropical Medicine; Radcliffe Infirmary; University of Oxford; University of Southampton	NEIL, HAW (corresponding author), UNIV OXFORD, RADCLIFFE INFIRM, DEPT PUBL HLTH & PRIMARY CARE, OXFORD OX2 6HE, ENGLAND.		Mant, David CA/C-7763-2009; stratton, irene/AAZ-3627-2020	stratton, irene/0000-0003-1172-7865				BETTERIDGE DJ, 1993, POSTGRAD MED J, V69, P359, DOI 10.1136/pgmj.69.811.359; BURR ML, 1989, LANCET, V2, P757; CAMPBELL MK, 1994, AM J PUBLIC HEALTH, V84, P783, DOI 10.2105/AJPH.84.5.783; COULTER A, 1994, BRIT MED J, V308, P308; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GEY KF, 1991, AM J CLIN NUTR, V53, pS326, DOI 10.1093/ajcn/53.1.326S; GORDON DJ, 1987, CIRCULATION, V76, P1224, DOI 10.1161/01.CIR.76.6.1224; Gregory F., 1990, DIETARY NUTR SURVEY; HEGSTED DM, 1993, AM J CLIN NUTR, V57, P875, DOI 10.1093/ajcn/57.6.875; KEYS A, 1959, CIRCULATION, V19, P201, DOI 10.1161/01.CIR.19.2.201; KEYS A, 1965, METABOLIS, V14, P766, DOI 10.1016/0026-0495(65)90003-X; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LEWIS B, 1988, EUR HEART J, V9, P571; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MENSINK RP, 1992, ARTERIOSCLER THROMB, V12, P911, DOI 10.1161/01.ATV.12.8.911; NORUSIS MJ, 1986, SPSS PC PLUS IBM PC; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; ROBBINS H, 1951, ANN MATH STAT, V22, P400, DOI 10.1214/aoms/1177729586; ROE L, IN PRESS FAM PRACT; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; THURNHAM DI, 1988, CLIN CHEM, V34, P377; ULBRICHT TLV, 1991, LANCET, V338, P985, DOI 10.1016/0140-6736(91)91846-M; VARTIAINEN E, 1994, BMJ-BRIT MED J, V309, P23, DOI 10.1136/bmj.309.6946.23; WOOD DA, 1994, BRIT MED J, V308, P313, DOI 10.1136/bmj.308.6924.313; 1992, NUTR METAB, V3, P113	29	89	89	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 4	1995	310	6979					569	573		10.1136/bmj.310.6979.569	http://dx.doi.org/10.1136/bmj.310.6979.569			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888933	Green Published			2022-12-28	WOS:A1995QK70000021
J	GIBBONS, A				GIBBONS, A			LANGUAGES LAST STANDS	SCIENCE			English	Editorial Material																			0	4	4	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1272	1272		10.1126/science.7871421	http://dx.doi.org/10.1126/science.7871421			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871421				2022-12-28	WOS:A1995QK06800023
J	CAPLAN, RP				CAPLAN, RP			STRESS, ANXIETY, AND DEPRESSION IN-HOSPITAL CONSULTANTS, GENERAL-PRACTITIONERS, AND SENIOR HEALTH-SERVICE MANAGERS	BRITISH MEDICAL JOURNAL			English	Article							MENTAL-HEALTH; QUESTIONNAIRE	Objective-To study stress, anxiety, and depression in a group of senior health service staff. Design-Postal survey. Subjects-81 hospital consultants, 322 general practitioners, and 121 senior hospital managers (total 524). Main outcome measures-Scores on the general health questionnaire and the hospital anxiety and depression scale. Results-Sixty five (80%) consultants, 257 (80%) general practitioners, and 67 (56%) managers replied. Of all 389 subjects, 183 (47%) scored positively on the general health questionnaire, indicating high levels of stress. From scores on the hospital anxiety and depression scale only 178 (46%) would be regarded as free from anxiety, with 100 (25%) scoring as borderline cases and 111 (29%) likely to be experiencing clinically measurable symptoms. The findings for depression were also of some concern, especially for general practitioners, with 69 (27%) scoring as borderline or Likely to be depressed. General practitioners were more likely to be depressed than managers (69 (27%) v 4 (6%) scored greater than or equal to 8 on hospital anxiety and depression scale-D; P = 0.004) with no significant difference between general practitioners and consultants. General practitioners were significantly more Likely to show suicidal thinking than were consultants (36 (14%) v 3 (5%); P = 0.04) but not managers (9 (13%)). No significant difference could be found between the three groups on any other measure. Conclusions-The levels of stress, anxiety, and depression in senior doctors and managers in the NHS seem to be high and perhaps higher than expected.			CAPLAN, RP (corresponding author), LINCOLN CTY HOSP,DEPT PSYCHIAT,LINCOLN LN2 5QY,ENGLAND.							BANKS MH, 1980, J OCCUP PSYCHOL, V53, P187, DOI 10.1111/j.2044-8325.1980.tb00024.x; BANKS MH, 1983, PSYCHOL MED, V13, P349, DOI 10.1017/S0033291700050972; BRAMLEY PN, 1988, ACTA PSYCHIAT SCAND, V77, P133, DOI 10.1111/j.1600-0447.1988.tb05089.x; FIRTH J, 1986, BRIT MED J, V292, P1177, DOI 10.1136/bmj.292.6529.1177; FIRTHCOZENS J, 1987, BRIT MED J, V295, P533, DOI 10.1136/bmj.295.6597.533; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; Huppert F, 1993, HLTH LIFESTYLE SURVE; LEWIS G, 1992, J EPIDEMIOL COMMUN H, V46, P608, DOI 10.1136/jech.46.6.608; SUTHERLAND VJ, 1992, BMJ-BRIT MED J, V304, P1545, DOI 10.1136/bmj.304.6841.1545; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1992, STRESS MED PROFESSIO	12	234	240	0	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1261	1263		10.1136/bmj.309.6964.1261	http://dx.doi.org/10.1136/bmj.309.6964.1261			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PT033	7888846	Green Published			2022-12-28	WOS:A1994PT03300019
J	RADER, DJ; IKEWAKI, K; DUVERGER, N; FEUERSTEIN, I; ZECH, L; CONNOR, W; BREWER, HB				RADER, DJ; IKEWAKI, K; DUVERGER, N; FEUERSTEIN, I; ZECH, L; CONNOR, W; BREWER, HB			VERY-LOW HIGH-DENSITY-LIPOPROTEINS WITHOUT CORONARY ATHEROSCLEROSIS	LANCET			English	Article							APOLIPOPROTEIN-A-I; ISCHEMIC HEART-DISEASE; INVIVO METABOLISM; PARTICLES; DEFICIENCY; MUTATION; GENE	Epidemiological studies have established that concentrations of plasma high-density lipoproteins (HDL) are inversely associated with premature atherosclerosis, but the physiological basis of this relationship remains unknown. We investigated 5 probands with very low plasma HDL. None had clinical or biochemical findings typical of the known genetic disorders with low HDL nor had evidence of premature coronary atherosclerosis by sensitive diagnostic methods. All 5 probands and the son of 1 of them had rapid catabolism of the HDL apolipoproteins A-I and A-II. These results indicate that not all people with low HDL are necessarily at risk of premature coronary heart disease and that further investigation is required before decisions can be made about their management.	OREGON HLTH SCI UNIV, DEPT MED, CLIN NUTR & LIPID METAB SECT, PORTLAND, OR 97201 USA	Oregon Health & Science University	RADER, DJ (corresponding author), NHLBI, MOLEC DIS BRANCH, BLDG 10, ROOM 7N117, BETHESDA, MD 20892 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK040566] Funding Source: NIH RePORTER; NCRR NIH HHS [RR334] Funding Source: Medline; NIDDK NIH HHS [DK40566] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BREWER HB, 1988, CLIN CHEM, V34, pB4; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRINTON EA, 1989, J CLIN INVEST, V84, P262, DOI 10.1172/JCI114149; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; FRUCHART JC, 1992, CLIN CHEM, V38, P793; FUNKE H, 1991, J CLIN INVEST, V87, P371, DOI 10.1172/JCI114997; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; LIPTON MJ, 1991, CIRCULATION, V84, pI72; MATSUNAGA T, 1991, P NATL ACAD SCI USA, V88, P2793, DOI 10.1073/pnas.88.7.2793; MILLER GJ, 1975, LANCET, V1, P16; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; Norum K, 1989, METABOLIC BASIS INHE, P1181; PARRA HJ, 1990, CLIN CHEM, V36, P1431; RADER DJ, 1992, J LIPID RES, V33, P755; RADER DJ, 1991, J LIPID RES, V32, P1849; SCHAEFER EJ, 1982, ARTERIOSCLEROSIS, V2, P16, DOI 10.1161/01.ATV.2.1.16; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; SPRECHER DL, 1984, CLIN CHEM, V30, P2084; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; WARNICK GR, 1979, CLIN CHEM, V25, P596	21	56	56	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1455	1458		10.1016/0140-6736(93)92933-K	http://dx.doi.org/10.1016/0140-6736(93)92933-K			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902482				2022-12-28	WOS:A1993ML21700009
J	SANDE, MA; CARPENTER, CCJ; COBBS, CG; HOLMES, KK; SANFORD, JP				SANDE, MA; CARPENTER, CCJ; COBBS, CG; HOLMES, KK; SANFORD, JP			ANTIRETROVIRAL THERAPY FOR ADULT HIV-INFECTED PATIENTS - RECOMMENDATIONS FROM A STATE-OF-THE-ART CONFERENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PLACEBO-CONTROLLED TRIAL; AIDS-RELATED COMPLEX; DOUBLE-BLIND; AZIDOTHYMIDINE AZT; ZIDOVUDINE; EFFICACY	This document summarizes recommendations from a state-of-the-art conference convened to evaluate the role of nucleoside analogue reverse transcriptase inhibitors in the treatment of human immunodeficiency virus (HIV) infection. Data from controlled clinical trials of zidovudine, didanosine, and zalcitabine were reviewed by an expert panel, which then formulated guidelines to assist clinicians and HIV-infected patients in the use of these agents. Recommendations were framed in the context of clinical scenarios for patients with asymptomatic HIV infection who have not had prior antiretroviral therapy; those with signs and symptoms of HIV-related disease who have not received prior therapy; clinically stable patients who are tolerating initial zidovudine therapy; patients experiencing clinical progression while on zidovudine therapy; and those who are intolerant of antiretroviral therapy. The panel concluded that physicians need to integrate up-to-date scientific knowledge with other relevant needs to improve the care of HIV-infected patients.	DEPT VET AFFAIRS MED CTR,BIRMINGHAM,AL; NIAID,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; BROWN UNIV,SCH MED,DIV BIOL & MED,PROVIDENCE,RI 02912; UNIV WASHINGTON,CTR AIDS & SEXUALLY TRANSMITTED DIS,SEATTLE,WA 98195; UNIV TEXAS,DEPT INTERNAL MED,DALLAS,TX 75230	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); University of California System; University of California San Francisco; Brown University; University of Washington; University of Washington Seattle; University of Texas System; University of Texas Dallas			, Holmes/K-6215-2019					ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; ABRAMS D, 1993, CPCRA 002 EXECUTIVE; ABRAMS D, IN PRESS N ENGL J ME; ALLAN J, 1993, ACTG 118 EXECUTIVE S; COLLIER AC, 1993, ANN INTERN MED, V119, P786, DOI 10.7326/0003-4819-119-8-199310150-00003; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; DAQUILA R, 1993, 9TH INT C AIDS; DARBYSHIRE JH, 1992, LANCET, V340, P1346, DOI 10.1016/0140-6736(92)92524-J; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; FISCHL MA, 1990, NEW ENGL J MED, V323, P1009, DOI 10.1056/NEJM199010113231501; FISCHL MA, 1993, ANN INTERN MED, V118, P762, DOI 10.7326/0003-4819-118-10-199305150-00002; GAO WY, 1993, J CLIN INVEST, V91, P2326, DOI 10.1172/JCI116463; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; KAHN JO, 1992, NEW ENGL J MED, V327, P582; LANGE JMA, 1992, 3RD EUR C CLIN ASP H; MCLEOD GX, 1992, ANN INTERN MED, V117, P487, DOI 10.7326/0003-4819-117-6-487; MENG TC, 1992, ANN INTERN MED, V116, P13, DOI 10.7326/0003-4819-116-1-13; RAGNI M, 1992, 8TH INT C AIDS; REMICK S, 1993, 9TH INT C AIDS; RICHMAN DD, 1987, NEW ENGL J MED, V317, P192, DOI 10.1056/NEJM198707233170402; SKOWRON G, 1993, ANN INTERN MED, V118, P321, DOI 10.7326/0003-4819-118-5-199303010-00001; SPRUANCE SL, 1993, ANTIVIR RES, V205, P51; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YARCHOAN R, 1992, J CELL BIOCH E S, V16, P89; 1990, AM J MED, V89, P335; 1992, DELTA TRIAL RANDOMIZ; 1993, PHYSICIANS DESK REFE, P1985; 1993, ACTG175 NAT I ALL IN; 1992, BMJ, V304, P13; 1989, MMWR MORB MORTAL WKL, V38, P1	31	151	154	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2583	2589		10.1001/jama.270.21.2583	http://dx.doi.org/10.1001/jama.270.21.2583			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	7901434				2022-12-28	WOS:A1993MJ26600026
J	MOSSEL, DAA; STRUIJK, CB				MOSSEL, DAA; STRUIJK, CB			FOOD-BORNE ILLNESS 1993 - UPDATING WILSON TRIAD	LANCET			English	Editorial Material											MOSSEL, DAA (corresponding author), UNIV UTRECHT,EIJKMAN FDN,UTRECHT,NETHERLANDS.							CHRISTIAN JHB, 1980, FOOD RES Q, V40, P13; Lund B. M., 1993, Food Technology International, Europe, P196; Mossel D. A. A., 1988, Animal & Human Health, V1, P13; Mossel D. A. A., 1987, Elimination of pathogenic organisms from meat and poultry., P305; MOSSEL DAA, 1989, LETT APPL MICROBIOL, V9, P207, DOI 10.1111/j.1472-765X.1989.tb00327.x; MOSSEL DAA, 1992, INT J FOOD MICROBIOL, V15, P1, DOI 10.1016/0168-1605(92)90131-L; MOSSEL DAA, 1990, FOOD TECHNOL-CHICAGO, V44, P63; POTTER ME, 1984, JAMA-J AM MED ASSOC, V252, P2048, DOI 10.1001/jama.252.15.2048; RAMPLING A, 1993, LANCET, V342, P317, DOI 10.1016/0140-6736(93)91466-Y; VANNETTEN P, 1992, PREDICTIVE MICROBIOL, P181; Wilson GS, 1933, LANCET, V2, P829; WILSON GS, 1935, MRC SPEC REP SER, V206	12	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1254	1254		10.1016/0140-6736(93)92357-Y	http://dx.doi.org/10.1016/0140-6736(93)92357-Y			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901581				2022-12-28	WOS:A1993MH56600007
J	LEE, HS; CROSS, SJ; RAWLES, JM; JENNINGS, KP				LEE, HS; CROSS, SJ; RAWLES, JM; JENNINGS, KP			PATIENTS WITH SUSPECTED MYOCARDIAL-INFARCTION WHO PRESENT WITH ST DEPRESSION	LANCET			English	Article							NON-Q-WAVE; NATURAL-HISTORY; UNSTABLE ANGINA; CHEST PAIN; SEGMENT; THROMBOLYSIS; ELECTROCARDIOGRAM; MYOGLOBIN	Patients with suspected myocardial infarction who present with ST depression have a high mortality which is not reduced by thrombolytic therapy. Despite this, there are few data on these patients. We studied the electrocardiographic and clinical characteristics of these patients, the diagnostic and prognostic value of the presenting electrocardiogram (ECG), and the reasons for the high mortality and apparent lack of thrombolytic efficacy. We studied all patients with suspected infarction admitted during 1990 with ST depression. Of the 136 patients (84 men, mean [SD] age 68 [11] years), 74 (54%) had confirmed infarction and 73 (54%) had previous infarction. 1-year mortality was 26% for all patients, 31% for those with confirmed infarcts, and 19% for those in whom infarction was subsequently excluded. Patients with infarction had more severe ST depression (mean 2.5 mm [SD 1.5]) and more ECG leads with ST depression (mean 4.7 leads [1.81]) compared with patients without infarction (1.4 mm [0.8], p < 0.001; 3.6 leads [1.7], p < 0.001). Sensitivity and specificity for the subsequent diagnosis of infarction with ST depression were 20% and 97%, respectively, for at least 4 mm; and 21% and 95%, respectively, for at least 7 leads. 1-year mortality was low in patients with 1 mm ST depression (14%) or no more than 2 leads (11%), but high in patients with at least 2 mm ST depression (39%, p < 0.001) and at least 3 leads (30%, p = 0.08). Patients with suspected infarction and ST depression had a high mean age, high incidence of previous infarction, and poor prognosis. The presenting ECG is helpful in predicting prognosis, and ST depression of at least 4 mm or involving at least 7 leads is highly specific for diagnosis of infarction.	UNIV ABERDEEN, MED ASSESSMENT RES UNIT, ABERDEEN AB9 1FX, SCOTLAND; ABERDEEN ROYAL INFIRM, DEPT CARDIOL, ABERDEEN AB9 2ZB, SCOTLAND	University of Aberdeen; University of Aberdeen								ABBOTT JA, 1973, AM J MED, V55, P608, DOI 10.1016/0002-9343(73)90182-4; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V1, P397; BERLAND J, 1986, AM HEART J, V111, P481, DOI 10.1016/0002-8703(86)90052-9; BOSSAERT L, 1991, EUR HEART J, V12, P965; CHOUHAN L, 1991, AM J CARDIOL, V68, P446, DOI 10.1016/0002-9149(91)90776-H; GHEORGHIADE M, 1991, AM HEART J, V122, P1548, DOI 10.1016/0002-8703(91)90270-R; GIBSON RS, 1986, CIRCULATION, V73, P1186, DOI 10.1161/01.CIR.73.6.1186; KAGEN LJ, 1978, CRC CR REV CL LAB SC, V9, P273, DOI 10.3109/10408367809150922; LEE HS, 1992, BRIT HEART J, V68, P145; MAIR J, 1992, BRIT HEART J, V68, P462; METCALFE MJ, 1990, BRIT HEART J, V63, P267; MIRANDA CP, 1991, CIRCULATION, V84, P2357, DOI 10.1161/01.CIR.84.6.2357; ODEMUYIWA O, 1985, BRIT HEART J, V54, P479; PELL ACH, 1992, BMJ-BRIT MED J, V304, P83, DOI 10.1136/bmj.304.6819.83; PRUITT RD, 1963, PROG CARDIOVASC DIS, V6, P85, DOI 10.1016/S0033-0620(63)80023-7; RAUNIO H, 1979, AM HEART J, V98, P176, DOI 10.1016/0002-8703(79)90219-9; SCHECHTMAN KB, 1989, CIRCULATION, V80, P1148, DOI 10.1161/01.CIR.80.5.1148; SCRUTINIO D, 1991, AM J CARDIOL, V68, pB99, DOI 10.1016/0002-9149(91)90391-W; SERNERI GGN, 1990, LANCET, V335, P615; SUGIURA M, 1969, JPN HEART J, V10, P203; WILLICH SN, 1987, AM HEART J, V114, P1110, DOI 10.1016/0002-8703(87)90186-4	22	71	72	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1204	1207		10.1016/0140-6736(93)92186-W	http://dx.doi.org/10.1016/0140-6736(93)92186-W			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901530				2022-12-28	WOS:A1993MG27400010
J	LEVITZKI, A; GAZIT, A				LEVITZKI, A; GAZIT, A			TYROSINE KINASE INHIBITION - AN APPROACH TO DRUG DEVELOPMENT	SCIENCE			English	Review							EPIDERMAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; INSULIN-RECEPTOR GENE; PROTEIN-KINASE; EGF-RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; SELECTIVE-INHIBITION; PSORIATIC EPIDERMIS; TYRPHOSTINS INHIBIT	Protein tyrosine kinases (PTKs) regulate cell proliferation, cell differentiation, and signaling processes in the cells of the immune system. Uncontrolled signaling from receptor tyrosine kinases and intracellular tyrosine kinases can lead to inflammatory responses and to diseases such as cancer, atherosclerosis, and psoriasis. Thus, inhibitors that block the activity of tyrosine kinases and the signaling pathways they activate may provide a useful basis for drug development. This article summarizes recent progress in the development of PTK inhibitors and demonstrates their potential use in the treatment of disease.			LEVITZKI, A (corresponding author), HEBREW UNIV JERUSALEM,ALEXANDER SILBERMAN INST LIFE SCI,DEPT BIOL CHEM,IL-91904 JERUSALEM,ISRAEL.							ACCILI D, 1992, J ENDOCRINOL INVEST, V15, P857, DOI 10.1007/BF03348820; AGBOTOUNOU WK, 1994, MOL PHARMACOL, V45, P922; Akyama T, 1987, J BIOL CHEM, V262, P5592; ANAFI M, 1993, FEBS LETT, V330, P260, DOI 10.1016/0014-5793(93)80884-W; ANAFI M, 1993, BLOOD, V82, P3524; ANAFI M, 1992, J BIOL CHEM, V267, P4518; ATADJA PM, 1991, THESIS HEBREW U JERU; BACUS SS, 1992, CANCER RES, V52, P2580; BAKER AJ, 1992, Patent No. [0520722, 520722]; BAKER LP, 1991, NEURON, V6, P23; BENBASSAT H, IN PRESS EXP DERMATO; BETSHOLTZ C, 1986, P NATL ACAD SCI USA, V83, P6440, DOI 10.1073/pnas.83.17.6440; BEUTLER B, 1968, ANN REV BIOCH, V57, P505; BILDER GE, 1991, AM J PHYSIOL, V260, pC721, DOI 10.1152/ajpcell.1991.260.4.C721; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BOCKER GW, 1993, CELL, V73, P813; BOHMER F, UNPUB; BRENNAN FM, 1992, BRIT J RHEUMATOL, V31, P293; BRYCKAERT M, 1991, EXP CELL RES, V199, P255; BUCHDUNGER E, 1994, P NATL ACAD SCI USA, V91, P2334, DOI 10.1073/pnas.91.6.2334; BURKE TR, 1992, BIORG MED CHEM LETT, V12, P1711; BURKE TR, 1992, DRUGS FUTURE, V17, P17; CHEN HX, 1993, J MED CHEM, V36, P4094, DOI 10.1021/jm00077a014; COHENDAYAG A, 1992, INT IMMUNOL, V4, P447; COOK PW, 1992, CANCER RES, V52, P3224; CUSHMAN M, 1991, J MED CHEM, V34, P798, DOI 10.1021/jm00106a047; CUSHMAN M, 1991, BIOORG MED CHEM LETT, V2, P15; DONG ZY, 1993, J LEUKOCYTE BIOL, V53, P53, DOI 10.1002/jlb.53.1.53; DONG ZY, 1993, J EXP MED, V177, P1071, DOI 10.1084/jem.177.4.1071; DONG ZY, 1993, J IMMUNOL, V151, P2717; DUKES M, 1992, J ENDOCRINOL, V135, P239, DOI 10.1677/joe.0.1350239; DVIR A, 1991, J CELL BIOL, V113, P257; ELDER JT, 1989, SCIENCE, V243, P811, DOI 10.1126/science.2916128; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; EVERAERDT B, 1989, BIOCHEM BIOPH RES CO, V163, P378, DOI 10.1016/0006-291X(89)92146-3; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GAZIT A, 1993, J MED CHEM, V36, P3556, DOI 10.1021/jm00075a010; GAZIT A, 1989, J MED CHEM, V32, P2344, DOI 10.1021/jm00130a020; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; GAZIT A, UNPUB; GEAHLEN RL, 1989, BIOCHEM BIOPH RES CO, V165, P241, DOI 10.1016/0006-291X(89)91060-7; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; GILLESPIE PJ, 1993, BRIT J CANCER, V66, P1122; GOLOMB G, UNPUB; GOLOMB G, IN PRESS AM ASS PHAR; GRAZIANI Y, 1983, EUR J BIOCHEM, V135, P583, DOI 10.1111/j.1432-1033.1983.tb07692.x; GRAZIANI Y, 1981, BIOCHIM BIOPHYS ACTA, V714, P415; GROSSMAN RM, 1989, P NATL ACAD SCI USA, V86, P6367, DOI 10.1073/pnas.86.16.6367; GUY GR, 1991, J BIOL CHEM, V266, P14343; Hashimoto Koji, 1992, Journal of Dermatology (Tokyo), V19, P648; Hawking F, 1978, Adv Pharmacol Chemother, V15, P289, DOI 10.1016/S1054-3589(08)60486-X; HOFFBARD AV, 1990, BLOOD, V75, P88; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; IMOTO M, 1987, BIOCH INT, V15, P98; IWASAKI T, 1992, FEBS LETT, V298, P240, DOI 10.1016/0014-5793(92)80067-Q; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KAUR G, 1994, ANTI-CANCER DRUG, V5, P213, DOI 10.1097/00001813-199404000-00013; KOHDA D, 1993, CELL, V72, P953, DOI 10.1016/0092-8674(93)90583-C; KOHL NE, 1993, SCIENCE, V260, P1934, DOI 10.1126/science.8316833; KOHMO M, 1990, BIOCHEM J, V267, P91; KOVALENKO M, 1994, CANCER RES, V54, P6106; KRANE JF, 1991, J INVEST DERMATOL, V96, P419, DOI 10.1111/1523-1747.ep12469799; KRIEGER M, 1992, EUR J IMMUNOL, V22, P2907, DOI 10.1002/eji.1830221123; LAVENS SE, 1992, AM J RESP CELL MOL, V7, P637, DOI 10.1165/ajrcmb/7.6.637; LEVITZKI A, 1992, FASEB J, V6, P3275, DOI 10.1096/fasebj.6.14.1426765; LEVITZKI A, 1994, EUR J BIOCHEM, V226, P1, DOI 10.1111/j.1432-1033.1994.tb20020.x; LEVITZKI A, 1993, Patent No. 5196446; LIA X, 1994, RECENT PROG HORM RES, V49, P149; LYALL R, 1989, J BIOL CHEM, V264, P14053; MAINI RN, 1993, CLIN EXP RHEUMATOL, V11, pS173; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MEYDAN N, UNPYUB; MEYDAN N, 1993, BLOOD S1, V82, pA360; MOTZER RJ, 1992, CANCER RES, V52, P5775; MUNOZ E, 1992, IMMUNOLOGY, V77, P43; MUNOZ E, 1993, EUR J IMMUNOL, V22, P1391; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MYERS C, 1992, J CLIN ONCOL, V10, P881, DOI 10.1200/JCO.1992.10.6.881; NOBLE MEM, 1993, EMBO J, V12, P2617, DOI 10.1002/j.1460-2075.1993.tb05922.x; NOVOGRODSKY A, 1994, SCIENCE, V264, P1319, DOI 10.1126/science.8191285; OHMICHI M, 1993, BIOCHEMISTRY-US, V32, P4650, DOI 10.1021/bi00068a024; OKABE T, 1994, J ANTIBIOT, V47, P289, DOI 10.7164/antibiotics.47.289; OKUSAWA S, 1988, J CLIN INVEST, V81, P1162, DOI 10.1172/JCI113431; ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009; OSHEROV N, 1994, EUR J BIOCHEM, V225, P1047, DOI 10.1111/j.1432-1033.1994.1047b.x; OSHEROV N, 1993, J BIOL CHEM, V268, P11134; PADEH S, 1991, J CLIN INVEST, V87, P1114, DOI 10.1172/JCI115074; Parrillo J E, 1993, N Engl J Med, V328, P1471; PASTAN I, 1993, ANN NY ACAD SCI, V685, P740; PAWSON T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P239; PENG HB, 1993, J CELL BIOL, V120, P197, DOI 10.1083/jcb.120.1.197; POSNER I, 1989, FEBS LETT, V257, P287, DOI 10.1016/0014-5793(89)81554-6; POSNER I, 1992, J BIOL CHEM, V267, P20638; POSNER I, 1994, MOL PHARMACOL, V45, P673; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; RAPPOPORT BL, 1993, ANAL ONCOL, V4, P567; REDDY KB, 1992, CANCER RES, V52, P3636; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; RENDU F, 1992, BIOCHEM PHARMACOL, V44, P881, DOI 10.1016/0006-2952(92)90119-4; Rendu F, 1990, Blood Coagul Fibrinolysis, V1, P713; ROIFMAN CM, 1991, J IMMUNOL, V146, P2965; ROSS R, 1989, LANCET, V1, P1179; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SALARI H, 1990, FEBS LETT, V263, P104, DOI 10.1016/0014-5793(90)80715-U; SANGUEDOLCE MV, 1993, J IMMUNOL, V151, P405; SAPERSTEIN R, 1989, BIOCHEMISTRY-US, V28, P5694, DOI 10.1021/bi00439a053; SHIRAISHI T, 1989, CANCER RES, V49, P2374; SHIRAISHI T, 1988, CHEM PHARM BULL, V36, P974; SHIRAISHI T, 1990, JPN J CANCER RES, V81, P645, DOI 10.1111/j.1349-7006.1990.tb02622.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SMYTH MS, 1993, J MED CHEM, V36, P3010, DOI 10.1021/jm00072a022; SPONA J, UNPUB; STANLEY JB, 1991, J IMMUNOL, V145, P2180; STEFANOVA I, 1993, J BIOL CHEM, V268, P20725; TANAKA S, 1994, J ANTIBIOT, V47, P294, DOI 10.7164/antibiotics.47.294; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; TRAXLER PM, 1991, J MED CHEM, V34, P2328, DOI 10.1021/jm00112a003; TRINKS U, 1994, J MED CHEM, V37, P1015, DOI 10.1021/jm00033a019; Tsai C.-E., UNPUB; TUSKADA S, 1993, CELL, V72, P279; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; UEHARA Y, 1988, J ANTIBIOT, V41, P831, DOI 10.7164/antibiotics.41.831; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; UMEZAWA H, 1986, J ANTIBIOT, V39, P170, DOI 10.7164/antibiotics.39.170; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WAKSMAN G, 1993, CELL, V72, P773; WARD HJ, 1994, BIOCHEM PHARMACOL, V48, P659; WEINSTEIN SL, 1991, P NATL ACAD SCI USA, V88, P4148, DOI 10.1073/pnas.88.10.4148; WEINSTEIN SL, 1993, J IMMUNOL, V151, P3829; YAISH P, 1988, SCIENCE, V242, P933, DOI 10.1126/science.3263702; YONEDA T, 1991, CANCER RES, V51, P4430	131	1580	1667	0	123	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1782	1788		10.1126/science.7892601	http://dx.doi.org/10.1126/science.7892601			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892601				2022-12-28	WOS:A1995QN70200028
J	LIN, D; SUGAWARA, T; STRAUSS, JF; CLARK, BJ; STOCCO, DM; SAENGER, P; ROGOL, A; MILLER, WL				LIN, D; SUGAWARA, T; STRAUSS, JF; CLARK, BJ; STOCCO, DM; SAENGER, P; ROGOL, A; MILLER, WL			ROLE OF STEROIDOGENIC ACUTE REGULATORY PROTEIN IN ADRENAL AND GONADAL STEROIDOGENESIS	SCIENCE			English	Article							CHAIN CLEAVAGE ENZYME; LEYDIG TUMOR-CELLS; MITOCHONDRIAL PROTEINS; CHOLESTEROL; HYPERPLASIA; PRECURSORS; MOVEMENT; PATIENT; GENES	Congenital lipoid adrenal hyperplasia is an autosomal recessive disorder that is characterized by impaired synthesis of all adrenal and gonadal steroid hormones. In three unrelated individuals with this disorder, steroidogenic acute regulatory protein, which enhances the mitochondrial conversion of cholesterol into pregnenolone, was mutated and nonfunctional, providing genetic evidence that this protein is indispensable for normal adrenal and gonadal steroidogenesis.	UNIV PENN,SCH MED,DEPT OBSTET & GYNECOL,PHILADELPHIA,PA 19104; TEXAS TECH UNIV,HLTH SCI CTR,DEPT BIOCHEM & CELL BIOL,LUBBOCK,TX 79430; MONTEFIORE MED CTR,ALBERT EINSTEIN COLL MED,DEPT PEDIAT,BRONX,NY 10467; UNIV VIRGINIA,HLTH SCI CTR,DEPT PEDIAT,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,HLTH SCI CTR,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,METAB RES UNIT,SAN FRANCISCO,CA 94143	University of Pennsylvania; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; University of Virginia; University of Virginia; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LIN, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,CHILD HLTH RES CTR,CORE LAB,SAN FRANCISCO,CA 94143, USA.		Miller, Walter L/J-3696-2012; Rogol, A.D./H-5871-2019	Rogol, A.D./0000-0002-7526-3142; Clark, Barbara/0000-0003-1558-1904	NICHD NIH HHS [HD 06274, HD 28825, HD 07688] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028825] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CRIVELLO JF, 1980, J BIOL CHEM, V255, P8144; DEGENHART HJ, 1972, ACTA ENDOCRINOL-COP, V71, P215; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; HARIKRISHNA JA, 1993, DNA CELL BIOL, V12, P371, DOI 10.1089/dna.1993.12.371; HAUFFA BP, 1985, CLIN ENDOCRINOL, V23, P481, DOI 10.1111/j.1365-2265.1985.tb01107.x; JEFCOATE CR, 1987, J STEROID BIOCHEM, V27, P721, DOI 10.1016/0022-4731(87)90142-7; JOHN ME, 1986, P NATL ACAD SCI USA, V83, P4715, DOI 10.1073/pnas.83.13.4715; KOIZUMI S, 1977, CLIN CHIM ACTA, V77, P301; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; LIN D, 1993, GENOMICS, V18, P643, DOI 10.1016/S0888-7543(05)80367-2; LIN D, 1991, J CLIN INVEST, V88, P1955, DOI 10.1172/JCI115520; Lin D.Y., UNPUB; MELLON SH, 1994, J CLIN ENDOCR METAB, V78, P1003, DOI 10.1210/jc.78.5.1003; MOORE CCD, 1990, MOL CELL BIOL, V10, P6013, DOI 10.1128/MCB.10.11.6013; ROBEL P, 1994, TRENDS ENDOCRIN MET, V5, P1, DOI 10.1016/1043-2760(94)90114-7; SAENGER P, 1995, J CLIN ENDOCR METAB, V80, P200, DOI 10.1210/jc.80.1.200; SAKAI Y, 1994, J CLIN ENDOCR METAB, V79, P1198, DOI 10.1210/jc.79.4.1198; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; STOCCO DM, 1993, ENDOCRINOLOGY, V132, P959, DOI 10.1210/en.132.3.959; STRAUSS JF, 1995, ENDOCRINOLOGY, V3, P2171; SUGAWARA T, IN PRESS P NATL ACAD; TOAFF ME, 1982, ENDOCRINOLOGY, V111, P1785, DOI 10.1210/endo-111-6-1785	23	792	818	0	30	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1828	1831		10.1126/science.7892608	http://dx.doi.org/10.1126/science.7892608			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892608				2022-12-28	WOS:A1995QN70200041
J	ANSARI, AZ; BRADNER, JE; OHALLORAN, TV				ANSARI, AZ; BRADNER, JE; OHALLORAN, TV			DNA-BEND MODULATION IN A REPRESSOR-TO-ACTIVATOR SWITCHING MECHANISM	NATURE			English	Article							TRANSCRIPTIONAL ACTIVATION; MER PROMOTER; COMPLEX; DISTORTION; DIRECTION	RECENT discoveries of activator proteins that distort DNA but bear no obvious activation domains have focused attention on the role of DNA structure in transcriptional regulation(1). Here we describe how the transcription factor MerR can mediate repression as well as activation through stereospecific modulation of DNA structure. The repressor form of MerR binds between the -10 and -35 promoter elements of the bacterial mercury-detoxification genes, P-T, allowing RNA polymerase to form an inactive complex with P-T and MerR at this stress-inducible promoter(2,3). Upon mercuric ion binding, Hg-MerR converts this polymerase complex into the transcriptionally active or 'open' form(2-4). We show here that MerR bends DNA towards itself in a manner similar to the bacterial catabolite-activator protein CAP, namely at two loci demarked by DNase I sensitivity, and that the activator conformation, Hg-MerR, relaxes these bends. This activator-induced unbending, when coupled with the previously described untwisting of the operator(5), remodels the promoter and makes it a better template for the poised polymerase.	NORTHWESTERN UNIV,DEPT CHEM,EVANSTON,IL 60208; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Northwestern University; Northwestern University			O'Halloran, Thomas/ABE-6125-2021; Ansari, Aseem/AAF-4945-2019	O'Halloran, Thomas/0000-0001-8732-5059; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038784] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM038784] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI AZ, 1992, NATURE, V355, P87, DOI 10.1038/355087a0; ANSARI AZ, 1994, TRANSCRIPTION MECHAN, P369; BOROWIEC JA, 1986, BIOCHEMISTRY-US, V25, P5051, DOI 10.1021/bi00366a012; BURKHOFF AM, 1989, NATURE, V331, P455; COMESS KM, 1994, BIOCHEMISTRY-US, V33, P4175, DOI 10.1021/bi00180a010; Cozzarelli N. R., 1990, DNA TOPOLOGY ITS BIO, P139; CROTHERS DM, 1991, METHOD ENZYMOL, V208, P118; DRAK J, 1991, P NATL ACAD SCI USA, V88, P3074, DOI 10.1073/pnas.88.8.3074; FRANTZ B, 1990, BIOCHEMISTRY-US, V29, P4747, DOI 10.1021/bi00472a001; GASTON K, 1990, CELL, V62, P733, DOI 10.1016/0092-8674(90)90118-X; HELTZEL A, 1990, BIOCHEMISTRY-US, V29, P9572, DOI 10.1021/bi00493a011; HIDALGO E, 1993, EMBO J, V13, P138; HOGAN ME, 1989, P NATL ACAD SCI USA, V86, P9273, DOI 10.1073/pnas.86.23.9273; HUNTER CA, 1993, J MOL BIOL, V256, P1025; KAHN JD, 1994, NATURE, V368, P163, DOI 10.1038/368163a0; LAHM A, 1991, NUCLEIC ACIDS MOL BI, V5, P171; MULLER HP, 1994, EMBO J, V13, P4704, DOI 10.1002/j.1460-2075.1994.tb06794.x; OHALLORAN TV, 1989, CELL, V56, P119, DOI 10.1016/0092-8674(89)90990-2; PARKHILL J, 1990, NUCLEIC ACIDS RES, V18, P5157, DOI 10.1093/nar/18.17.5157; PARKHILL J, 1993, EMBO J, V12, P413, DOI 10.1002/j.1460-2075.1993.tb05673.x; Ptashne M, 1986, GENETIC SWITCH, P13; RAUMANN BE, 1994, NATURE, V367, P754, DOI 10.1038/367754a0; ROSS W, 1989, J BACTERIOL, V171, P4009, DOI 10.1128/jb.171.7.4009-4018.1989; SALVO JJ, 1987, NUCLEIC ACIDS RES, V15, P9771, DOI 10.1093/nar/15.23.9771; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SNYDER UK, 1989, NATURE, V341, P255, DOI 10.1038/341255a0; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Travers A. A., 1990, DNA TOPOLOGY ITS BIO, P57; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	31	184	186	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					371	375						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885478				2022-12-28	WOS:A1995QN63000063
J	LIU, LS; WANG, W; PAN, XW; CHEN, ZM; COLLINS, R; PETO, R; TAO, SC; LIU, LS; CHEN, HZ; GONG, LS; CHEN, SX; CUI, JJ; FANG, C; WU, XG; GUO, XR; BAI, MY; FANG, WQ; HAO, JS; WANG, W; WU, AL; LI, HS; HE, XY; LI, X; MA, LY; WANG, LH; HONG, ZG; WU, SY; DIN, WH; WANG, JY; SHUN, NL; LI, YC; YIN, GX; ZHUN, DC; ZHOU, BL; LI, JZ; LI, JY; HUANG, JY; ZHAO, YY; SHI, XY; WANG, GH; CHEN, ZY; GE, H; KUN, XT; HU, ZX; HUN, HX; LI, X; TUN, WR; CHAO, ZC; LI, DZ; FU, RN; WANG, JY; WANG, ML; KANG, SP; LI, H; LI, Y; GAO, GD; GUO, WQ; HONG, ZG; ZHANG, ZG; GAO, BW; LUE, W; JIN, YZ; TU, XH; RU, H; WANG, SL; GAO, J; ZHANG, RY; WEN, ZY; JIANG, YQ; ZHANG, CX; XIE, HF; ZENG, DY; GUO, BX; TUN, M; YE, XY; LIU, YH; LI, HF; SHUN, JL; XU, GY; XU, BY; ZHANG, XL; WANG, DM; ZHAO, XL; SHUN, DL; QU, NL; WANG, FQ; ZHOU, Z; LIU, JY; ZHOU, SM; HAO, LQ; SHUN, NQ; FENG, Y; LI, XH; SHUN, BF; ZHEN, JS; WANG, QX; ZHANG, Y; PIAO, YS; WANG, XW; ZHUANG, YM; LI, FJ; SHI, HZ; ZHANG, SX; WANG, WM; WU, LL; LI, WX; WANG, YF; SHUN, S; HUNG, TG; SHEN, ZF; SHI, JL; CHEN, DS; NI, SZ; LIU, YS; TANG, HY; JIANG, YC; ZHOU, TC; GAO, CR; CHEN, Y; CHEN, Z; LIN, K; LIU, YF; BAI, JH; LI, ZY; JIANG, TM; MA, G; MEN, HH; PAN, W; CHEN, JY; ZHANG, WQ; FENG, H; ZHU, DQ; LI, XF; WANG, SZ; ZHANG, ZB; ZHANG, F; REN, GZ; SHUN, QB; ZHANG, QY; GEN, HY; YANG, QM; ZHONG, PL; JIN, ZG; CUI, JY; XU, HB; GUO, YQ; WANG, FZ; WANG, TM; WANG, ZH; CHEN, YS; CHEN, QQ; XIANG, RX; FAN, XT; LUO, SJ; DENG, SZ; MU, RQ; DU, M; SHUN, YQ; LI, LM; YOU, NZ; ZHANG, GZ; XU, GF; HUANG, XZ; DU, QS; HUA, ZS; YUAN, BM; WEI, W; QIAO, DR; WANG, XZ; ZHAN, GE; YU, FC; NING, PY; MA, JJ; GU, LH; SHU, QL; LI, ZG; WU, WC; WANG, HM; WANG, WB; SHI, RZ; XIA, HQ; ZHANG, XS; ZHANG, XZ; ZHAO, XL; ZHANG, S; LIU, ZH; ZHANG, GQ; LI, GL; LIU, ZM; WANG, BW; ZHOU, FJ; LIU, TK; GUO, X; GUO, XW; LIU, WD; ZHANG, DX; WANG, C; LU, JX; SHU, HC; WU, LJ; MEN, TY; ZHANG, SH; LUO, JZ; ZHEN, Y; DAI, GZ; FENG, KY; LU, YX; ZHEN, YL; WANG, RY; CAO, MY; XU, JL; HU, XY; MU, G; ZHU, ZH; ZHANG, QL; CHEN, JQ; CHEN, ZF; LI, ZX; XIA, JX; DIA, ZD; YAN, XL; LIU, RY; WEI, JH; HUANG, ZW; ZHAO, G; KUN, XY; SHEN, YX; XIAO, X; ZHANG, CX; MIAO, YH; ZHANG, ZY; YAN, YX; MA, HB; WANG, SQ; OUYANG, CQ; ZHAO, WX; HE, P; WANG, JF; LI, XB; LI, GQ; HUANG, XH; CHUI, TX; QIAO, CL; HUANG, YL; LIU, FQ; SHUN, YQ; SHUN, JS; LIU, CR; CHEN, GJ; YANG, XZ; YU, CQ; ZHAO, CY; ZHANG, JT; LIU, Z; LI, YQ; LIU, ZM; ZHANG, PY; WANG, ZX; REN, LJ; LIANG, ZZ; ZHAO, ZL; LI, BR; HUANG, RY; WANG, ZJ; DU, SL; XU, DY; WANG, ZY; WANG, YG; WANG, XP; WANG, DP; LI, QY; ZHOU, M; ZHOU, JC; MA, FZ; LI, RS; MA, ZQ; ZHOU, JX; LI, PX; HUANG, P; WU, SL; FENG, JZ; HOU, JX; XU, KL; QU, ZY; LI, ZJ; ZHANG, YJ; LUO, WH; YUANG, EY; HUANG, YH; XU, KJ; FANG, WH; YANG, DY; WANG, WM; ZUO, JQ; SHI, P; ZHAO, LY; ZHANG, AM; YAN, KG; DONG, GX; HUANG, J; ZHANG, SQ; DU, FC; LU, DC; SHEN, LL; GU, JG; CA, MF; SHI, GF; PAN, XW; QI, WH; TONG, BG; DAI, RH; ZHANG, GY; CHEN, SC; CUI, SZ; CHEN, WC; HE, ZY; HUANG, DJ; PAN, PW; WANG, MH; XU, Q; HU, LX; HU, WY; ZHANG, TH; CHEN, SL; SHA, Y; LIN, YH; LIU, XF; LU, JF; FANG, Q; NA, L; SHU, DY; WU, HP; CHEN, ZW; ZHANG, MX; YAO, Z; CHE, GL; WU, LY; FANG, Y; ZHEN, XB; GUO, YC; ZHOU, Y; HU, JS; YAO, LY; WU, ZY; XIA, SY; ZHANG, LY; CHEN, XK; XIA, ZN; HUANG, DJ; CHEN, XP; TANG, FR; HE, GX; LIU, S; CHEN, J; KUANG, YZ; XIN, N; HE, BX; FENG, YY; CHEN, ZH; TAN, JZ; ZHANG, FG; LU, YH; HU, SH; CHAO, WF; REN, GJ; WANG, SL; ZHEN, SS; SHUN, M; WANG, ZL; OUYANG, GY; LIN, ZD; CHEN, H; LU, JQ; QIN, WJ				LIU, LS; WANG, W; PAN, XW; CHEN, ZM; COLLINS, R; PETO, R; TAO, SC; LIU, LS; CHEN, HZ; GONG, LS; CHEN, SX; CUI, JJ; FANG, C; WU, XG; GUO, XR; BAI, MY; FANG, WQ; HAO, JS; WANG, W; WU, AL; LI, HS; HE, XY; LI, X; MA, LY; WANG, LH; HONG, ZG; WU, SY; DIN, WH; WANG, JY; SHUN, NL; LI, YC; YIN, GX; ZHUN, DC; ZHOU, BL; LI, JZ; LI, JY; HUANG, JY; ZHAO, YY; SHI, XY; WANG, GH; CHEN, ZY; GE, H; KUN, XT; HU, ZX; HUN, HX; LI, X; TUN, WR; CHAO, ZC; LI, DZ; FU, RN; WANG, JY; WANG, ML; KANG, SP; LI, H; LI, Y; GAO, GD; GUO, WQ; HONG, ZG; ZHANG, ZG; GAO, BW; LUE, W; JIN, YZ; TU, XH; RU, H; WANG, SL; GAO, J; ZHANG, RY; WEN, ZY; JIANG, YQ; ZHANG, CX; XIE, HF; ZENG, DY; GUO, BX; TUN, M; YE, XY; LIU, YH; LI, HF; SHUN, JL; XU, GY; XU, BY; ZHANG, XL; WANG, DM; ZHAO, XL; SHUN, DL; QU, NL; WANG, FQ; ZHOU, Z; LIU, JY; ZHOU, SM; HAO, LQ; SHUN, NQ; FENG, Y; LI, XH; SHUN, BF; ZHEN, JS; WANG, QX; ZHANG, Y; PIAO, YS; WANG, XW; ZHUANG, YM; LI, FJ; SHI, HZ; ZHANG, SX; WANG, WM; WU, LL; LI, WX; WANG, YF; SHUN, S; HUNG, TG; SHEN, ZF; SHI, JL; CHEN, DS; NI, SZ; LIU, YS; TANG, HY; JIANG, YC; ZHOU, TC; GAO, CR; CHEN, Y; CHEN, Z; LIN, K; LIU, YF; BAI, JH; LI, ZY; JIANG, TM; MA, G; MEN, HH; PAN, W; CHEN, JY; ZHANG, WQ; FENG, H; ZHU, DQ; LI, XF; WANG, SZ; ZHANG, ZB; ZHANG, F; REN, GZ; SHUN, QB; ZHANG, QY; GEN, HY; YANG, QM; ZHONG, PL; JIN, ZG; CUI, JY; XU, HB; GUO, YQ; WANG, FZ; WANG, TM; WANG, ZH; CHEN, YS; CHEN, QQ; XIANG, RX; FAN, XT; LUO, SJ; DENG, SZ; MU, RQ; DU, M; SHUN, YQ; LI, LM; YOU, NZ; ZHANG, GZ; XU, GF; HUANG, XZ; DU, QS; HUA, ZS; YUAN, BM; WEI, W; QIAO, DR; WANG, XZ; ZHAN, GE; YU, FC; NING, PY; MA, JJ; GU, LH; SHU, QL; LI, ZG; WU, WC; WANG, HM; WANG, WB; SHI, RZ; XIA, HQ; ZHANG, XS; ZHANG, XZ; ZHAO, XL; ZHANG, S; LIU, ZH; ZHANG, GQ; LI, GL; LIU, ZM; WANG, BW; ZHOU, FJ; LIU, TK; GUO, X; GUO, XW; LIU, WD; ZHANG, DX; WANG, C; LU, JX; SHU, HC; WU, LJ; MEN, TY; ZHANG, SH; LUO, JZ; ZHEN, Y; DAI, GZ; FENG, KY; LU, YX; ZHEN, YL; WANG, RY; CAO, MY; XU, JL; HU, XY; MU, G; ZHU, ZH; ZHANG, QL; CHEN, JQ; CHEN, ZF; LI, ZX; XIA, JX; DIA, ZD; YAN, XL; LIU, RY; WEI, JH; HUANG, ZW; ZHAO, G; KUN, XY; SHEN, YX; XIAO, X; ZHANG, CX; MIAO, YH; ZHANG, ZY; YAN, YX; MA, HB; WANG, SQ; OUYANG, CQ; ZHAO, WX; HE, P; WANG, JF; LI, XB; LI, GQ; HUANG, XH; CHUI, TX; QIAO, CL; HUANG, YL; LIU, FQ; SHUN, YQ; SHUN, JS; LIU, CR; CHEN, GJ; YANG, XZ; YU, CQ; ZHAO, CY; ZHANG, JT; LIU, Z; LI, YQ; LIU, ZM; ZHANG, PY; WANG, ZX; REN, LJ; LIANG, ZZ; ZHAO, ZL; LI, BR; HUANG, RY; WANG, ZJ; DU, SL; XU, DY; WANG, ZY; WANG, YG; WANG, XP; WANG, DP; LI, QY; ZHOU, M; ZHOU, JC; MA, FZ; LI, RS; MA, ZQ; ZHOU, JX; LI, PX; HUANG, P; WU, SL; FENG, JZ; HOU, JX; XU, KL; QU, ZY; LI, ZJ; ZHANG, YJ; LUO, WH; YUANG, EY; HUANG, YH; XU, KJ; FANG, WH; YANG, DY; WANG, WM; ZUO, JQ; SHI, P; ZHAO, LY; ZHANG, AM; YAN, KG; DONG, GX; HUANG, J; ZHANG, SQ; DU, FC; LU, DC; SHEN, LL; GU, JG; CA, MF; SHI, GF; PAN, XW; QI, WH; TONG, BG; DAI, RH; ZHANG, GY; CHEN, SC; CUI, SZ; CHEN, WC; HE, ZY; HUANG, DJ; PAN, PW; WANG, MH; XU, Q; HU, LX; HU, WY; ZHANG, TH; CHEN, SL; SHA, Y; LIN, YH; LIU, XF; LU, JF; FANG, Q; NA, L; SHU, DY; WU, HP; CHEN, ZW; ZHANG, MX; YAO, Z; CHE, GL; WU, LY; FANG, Y; ZHEN, XB; GUO, YC; ZHOU, Y; HU, JS; YAO, LY; WU, ZY; XIA, SY; ZHANG, LY; CHEN, XK; XIA, ZN; HUANG, DJ; CHEN, XP; TANG, FR; HE, GX; LIU, S; CHEN, J; KUANG, YZ; XIN, N; HE, BX; FENG, YY; CHEN, ZH; TAN, JZ; ZHANG, FG; LU, YH; HU, SH; CHAO, WF; REN, GJ; WANG, SL; ZHEN, SS; SHUN, M; WANG, ZL; OUYANG, GY; LIN, ZD; CHEN, H; LU, JQ; QIN, WJ			ORAL CAPTOPRIL VERSUS PLACEBO AMONG 13634 PATIENTS WITH SUSPECTED ACUTE MYOCARDIAL-INFARCTION - INTERIM-REPORT FROM THE CHINESE CARDIAC STUDY (CCS-1)	LANCET			English	Article								13 634 patients entering 650 Chinese hospitals up to 36 h after the onset of suspected acute myocardial infarction (MI) were randomised between one month of oral captopril (6.25 mg initial dose, 12.5 mg 2 h later, and then 12.5 mg three times daily) or matching placebo. Captopril was associated with a non-significant reduction in 4-week mortality (617 [9.05%] captopril-allocated vs 654 [9.59%] placebo-allocated deaths; 2p=0.3). There was a significant excess of hypotension, mostly early after the start of treatment, but no evidence of any adverse effect on early mortality (even among patients who were hypotensive at entry). Taken together with the other trials of converting enzyme inhibitors started early in acute MI, these results indicate that such therapy is generally safe and typically prevents about 5 deaths per 1000 patients treated for the first month.	CHINESE ACAD MED SCI,FU WAI HOSP,BEIJING 100037,PEOPLES R CHINA	Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS	LIU, LS (corresponding author), CHINESE ACAD MED SCI,INST CARDIOVASC,BEIJING 100037,PEOPLES R CHINA.		Luo, Jikui/AAA-4912-2021; zhang, qiu/GXG-5600-2022	Luo, Jikui/0000-0003-0310-2443				[Anonymous], 1995, LANCET, V345, P669; Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, 1994, LANCET, V343, P1115; SWEDBERG K, 1992, NEW ENGL J MED, V327, P678, DOI 10.1056/NEJM199209033271002	3	228	235	0	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					686	687						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885123				2022-12-28	WOS:A1995QM73200007
J	ROWE, PC; BOUHOLAIGAH, I; KAN, JS; CALKINS, H				ROWE, PC; BOUHOLAIGAH, I; KAN, JS; CALKINS, H			NEURALLY-MEDIATED HYPOTENSION AN UNRECOGNIZED CAUSE OF CHRONIC FATIGUE	LANCET			English	Note							HEAD-UP TILT; UNEXPLAINED SYNCOPE	Neurally mediated hypotension is now recognised as a common cause of otherwise unexplained recurrent syncope, but has not been reported in association with chronic fatigue. We describe seven consecutive non-syncopal adolescents with chronic post-exertional fatigue, four of whom satisfied strict criteria for chronic fatigue syndrome. Upright tilt-table testing induced significant hypotension in all seven (median systolic blood pressure 65 mm Hg, range 37-75), consistent with the physiology of neurally mediated hypotension. Four had prompt improvement. in their chronic fatigue when treated with atenolol or disopyramide. These observations suggest an overlap in the symptoms of chronic fatigue syndrome and neurally mediated hypotension.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, BALTIMORE, MD 21287 USA	Johns Hopkins University	ROWE, PC (corresponding author), JOHNS HOPKINS UNIV, SCH MED, DEPT PEDIAT, BALTIMORE, MD 21287 USA.							ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; CALKINS H, IN PRESS AM J MED; HOLMES GP, 1988, ANN INTERN MED, V108, P387, DOI 10.7326/0003-4819-108-3-387; KAPOOR WN, 1994, AM J MED, V97, P78, DOI 10.1016/0002-9343(94)90051-5; KENNY RA, 1986, LANCET, V1, P1352; KOMAROFF AL, 1991, REV INFECT DIS, V13, pS8; MANU P, 1993, CIBA F SYMP, V173, P23; ROSS BA, 1991, AM HEART J, V122, P748, DOI 10.1016/0002-8703(91)90521-I; RUBIN AM, 1993, AM HEART J, V125, P476, DOI 10.1016/0002-8703(93)90029-9; SCHONDORF R, 1993, NEUROLOGY, V43, P132, DOI 10.1212/WNL.43.1_Part_1.132	10	186	198	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 11	1995	345	8950					623	624		10.1016/S0140-6736(95)90525-1	http://dx.doi.org/10.1016/S0140-6736(95)90525-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898182	hybrid			2022-12-28	WOS:A1995QM07500013
J	RUETER, SM; BURNS, CM; COODE, SA; MOOKHERJEE, P; EMESON, RB				RUETER, SM; BURNS, CM; COODE, SA; MOOKHERJEE, P; EMESON, RB			GLUTAMATE-RECEPTOR RNA EDITING IN-VITRO BY ENZYMATIC CONVERSION OF ADENOSINE TO INOSINE	SCIENCE			English	Article							B MESSENGER-RNA; CA2+ PERMEABILITY; STRUCTURAL DETERMINANTS; ION FLOW; CHANNELS; KAINATE; EXPRESSION	RNA encoding the B subunit of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptor (GluR-B) undergoes a posttranscriptional modification in which a genomically encoded adenosine is represented as a guanosine in the GluR-B complementary DNA. In vitro editing of GluR-B RNA transcripts with HeLa cell nuclear extracts was found to result from an activity that converts adenosine to inosine in regions of double-stranded RNA by enzymatic base modification. This activity is consistent with that of a double-stranded RNA-specific adenosine deaminase previously described in Xenopus oocytes and widely distributed in mammalian tissues.	VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Vanderbilt University				Emeson, Ronald/0000-0002-4585-1648	NIEHS NIH HHS [ES00267] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ausubel FM, 1988, MOL REPROD DEV; BASS B, 1993, RNA WORLD, pCH15; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BOULTER J, 1989, NEURON, V3, P589; DINGLEDINE R, 1992, J NEUROSCI, V12, P4080; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; EGEBJERG J, 1993, P NATL ACAD SCI USA, V90, P755, DOI 10.1073/pnas.90.2.755; EGEBJERG J, 1994, P NATL ACAD SCI USA, V91, P10270, DOI 10.1073/pnas.91.22.10270; ELLIOTT MS, 1984, J BIOL CHEM, V259, P2407; GARCIA GA, 1993, J MOL BIOL, V231, P489, DOI 10.1006/jmbi.1993.1296; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MISHINA M, 1991, BIOCHEM BIOPH RES CO, V180, P813, DOI 10.1016/S0006-291X(05)81137-4; NAKANISHI N, 1990, TOXICON, V28, P1333; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; SAKIMURA K, 1990, FEBS LETT, V272, P73, DOI 10.1016/0014-5793(90)80452-O; SHULDINER AR, 1993, PCR PROTOCOLS CURREN, P169; Silberklang M, 1979, Methods Enzymol, V59, P58; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WU JH, 1990, J BIOL CHEM, V265, P12312	26	118	126	0	5	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1491	1494		10.1126/science.7878468	http://dx.doi.org/10.1126/science.7878468			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878468				2022-12-28	WOS:A1995QL49700036
J	AKIL, M; AMOS, RS				AKIL, M; AMOS, RS			ABC OF RHEUMATOLOGY - RHEUMATOID-ARTHRITIS .1. CLINICAL-FEATURES AND DIAGNOSIS	BRITISH MEDICAL JOURNAL			English	Article											AKIL, M (corresponding author), NEITHER EDGE HOSP,SHEFFIELD CTR RHEUMAT DIS,SHEFFIELD,S YORKSHIRE,ENGLAND.								0	47	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					587	590		10.1136/bmj.310.6979.587	http://dx.doi.org/10.1136/bmj.310.6979.587			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888939	Green Published			2022-12-28	WOS:A1995QK70000028
J	WEST, RA; KARKOSCHKA, E; FRIEDSON, AJ; SEYMOUR, M; BAINES, KH; HAMMEL, HB				WEST, RA; KARKOSCHKA, E; FRIEDSON, AJ; SEYMOUR, M; BAINES, KH; HAMMEL, HB			IMPACT DEBRIS PARTICLES IN JUPITER STRATOSPHERE	SCIENCE			English	Article							OPTICAL-PROPERTIES; ICE; CIRCULATION; ULTRAVIOLET; CONSTANTS	The aftermath of the impacts of periodic comet Shoemaker-Levy 9 on Jupiter was studied With the Wide Field Planetary Camera 2 on the Hubble Space Telescope. The impact debris particles may owe their dark brown color to organic material rich in sulfur and nitrogen. The total volume of aerosol 1 day after the last impact is equal to the volume of a sphere of radius 0.5 kilometer. In the optically thick core regions, the particle mean radius is between 0.15 and 0.3 micrometer, and the aerosol is spread over many scale heights, from approximately 1 millibar to 200 millibars of pressure or more. Particle coagulation can account for the evolution of particle radius and total optical depth during the month following the impacts.	UNIV ARIZONA, LUNAR & PLANETARY LAB, TUCSON, AZ 85721 USA; UCL, LONDON, ENGLAND; MIT, DEPT EARTH ATMOSPHER & PLANETARY SCI, CAMBRIDGE, MA 02139 USA	University of Arizona; University of London; University College London; Massachusetts Institute of Technology (MIT)	WEST, RA (corresponding author), CALTECH, JET PROP LAB, DIV EARTH & SPACE SCI, PASADENA, CA 91109 USA.							BAINES KH, 1994, 26TH ANN M AM ASTR S; BJORAKER GL, 1994, 26TH ANN M AM ASTR S; CONRATH BJ, 1990, ICARUS, V83, P255, DOI 10.1016/0019-1035(90)90068-K; DRAINE BT, 1985, ASTROPHYS J SUPPL S, V57, P587, DOI 10.1086/191016; FIELD GB, IN PRESS ASTRON ASTR; GUSTAVSEN RL, 1989, THESIS WASHINGTON ST; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; KARKOSCHKA E, 1994, ICARUS, V111, P174, DOI 10.1006/icar.1994.1139; KHARE BN, 1994, CAN J CHEM, V72, P678, DOI 10.1139/v94-093; LANDRY B, 1991, ICARUS, V89, P377, DOI 10.1016/0019-1035(91)90184-U; LATTIMER JM, 1982, 1980 P C FORM PLAN S, P190; MARTONCHIK JV, 1984, APPL OPTICS, V23, P541, DOI 10.1364/AO.23.000541; MORENO F, IN PRESS GEOPHYS RES; NICHOLSON PD, UNPUB; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; ORTON G, 1995, SCIENCE, V267, P1277, DOI 10.1126/science.7871423; OWEN T, 1994, 26TH ANN M AM ASTR S; PRUPPACHER HR, 1978, MICROPHYSICS CLOUDS, P358; SASSON R, 1985, ICARUS, V64, P368, DOI 10.1016/0019-1035(85)90061-2; TINGLE TN, 1992, ORIGINS LIFE EVOL B, V21, P385; TREPTE CR, 1992, NATURE, V355, P626, DOI 10.1038/355626a0; WALLACE L, 1986, ASTROPHYS J, V172, P755; WARREN SG, 1986, APPL OPTICS, V25, P2650, DOI 10.1364/AO.25.002650; WARREN SG, 1984, APPL OPTICS, V23, P1206, DOI 10.1364/AO.23.001206; WEST RA, 1992, ICARUS, V100, P245, DOI 10.1016/0019-1035(92)90033-4; ZHANLE K, COMMUNICATION	26	83	83	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1296	1301		10.1126/science.7871426	http://dx.doi.org/10.1126/science.7871426			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871426				2022-12-28	WOS:A1995QK06800031
J	KAWAI, K; OHASHI, PS				KAWAI, K; OHASHI, PS			IMMUNOLOGICAL FUNCTION OF A DEFINED T-CELL POPULATION TOLERIZED TO LOW-AFFINITY SELF-ANTIGENS	NATURE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MAJOR HISTOCOMPATIBILITY COMPLEX; CLONAL DELETION; POSITIVE SELECTION; TRANSGENIC MICE; RECEPTOR; TOLERANCE; ANERGY; INDUCTION; ANTIBODY	IN the thymus there are two major mechanisms of T-lymphocyte tolerance: clonal deletion and clonal inactivation(1-3). One important problem underlying the mechanism of clonal inactivation is why unresponsive cells are maintained in the mature peripheral T-cell repertoire. Here we report that transgenic alpha beta T-cells may be tolerized to a self antigen Mls-1(a), but still retain proliferative responses for alternative peptide antigens and superantigens. These self-tolerant T cells can also provide immunopathological and memory cytotoxic function in vivo. We propose that high-affinity/avidity self-reactive T cells are deleted in the thymus, whereas lower-affinity/avidity interactions lead to unresponsiveness and define the 'resting threshold' for a given T cell. These low-affinity self-tolerant T cells remain functionally competent for high-affinity foreign antigens, and efficiently eliminate natural pathogens in vivo.	UNIV TORONTO,ONTARIO CANC INST,DEPT MED BIOPHYS,TORONTO,ON M4X 1K9,CANADA; UNIV TORONTO,ONTARIO CANC INST,DEPT IMMUNOL,TORONTO,ON M4X 1K9,CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto			Kawai, Kazuhiro/D-4998-2011	Kawai, Kazuhiro/0000-0001-9375-0713; Ohashi, Pamela S./0000-0003-2915-9317				BAENZIGER J, 1986, EUR J IMMUNOL, V16, P387, DOI 10.1002/eji.1830160413; BLACKMAN MA, 1990, NATURE, V345, P540, DOI 10.1038/345540a0; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KAPPLER JW, 1988, NATURE, V332, P35, DOI 10.1038/332035a0; OHASHI PS, 1990, NATURE, V346, P861, DOI 10.1038/346861a0; PIRCHER H, 1992, EUR J IMMUNOL, V22, P399, DOI 10.1002/eji.1830220217; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; PIRCHER H, 1989, NATURE, V342, P559, DOI 10.1038/342559a0; PIRCHER H, 1987, EUR J IMMUNOL, V17, P159, DOI 10.1002/eji.1830170202; RAMSDELL F, 1992, SCIENCE, V257, P1130, DOI 10.1126/science.257.5073.1130; RAMSDELL F, 1990, SCIENCE, V248, P1342, DOI 10.1126/science.1972593; ROCHA B, 1993, J EXP MED, V177, P1517, DOI 10.1084/jem.177.5.1517; ROCKEN M, 1992, NATURE, V359, P79, DOI 10.1038/359079a0; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; TOMONARI K, 1988, IMMUNOGENETICS, V28, P455, DOI 10.1007/BF00355379; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; VONBOEHMER H, 1991, J EXP MED, V174, P1001, DOI 10.1084/jem.174.5.1001; WHITE J, 1989, CELL, V56, P27, DOI 10.1016/0092-8674(89)90980-X; YAN XJ, 1993, J IMMUNOL, V150, P3873; YUI K, 1990, P NATL ACAD SCI USA, V87, P7135, DOI 10.1073/pnas.87.18.7135	22	77	78	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					68	69		10.1038/374068a0	http://dx.doi.org/10.1038/374068a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870174				2022-12-28	WOS:A1995QK07900054
J	CHANG, HC; SOLOMON, NM; WASSARMAN, DA; KARIM, FD; THERRIEN, M; RUBIN, GM; WOLFF, T				CHANG, HC; SOLOMON, NM; WASSARMAN, DA; KARIM, FD; THERRIEN, M; RUBIN, GM; WOLFF, T			PHYLLOPOD FUNCTIONS IN THE FATE DETERMINATION OF A SUBSET OF PHOTORECEPTORS IN DROSOPHILA	CELL			English	Article							RECEPTOR TYROSINE KINASE; SEVENLESS PROTEIN; DEVELOPING EYE; COMPOUND EYE; CELL FATE; GENE; RAS; MELANOGASTER; ACTIVATION; EXPRESSION	phyllopod (phyl) encodes a novel protein required for fate determination of photoreceptors R1, R6, and R7, the last three photoreceptors to be recruited into the ommatidia of the developing Drosophila eye. Genetic data suggests that phyl acts downstream of Ras1, raf, and van to promote neuronal differentiation in this subset of photoreceptors. Ectopic expression of phyl in the cone cell precursors mimics the effect of ectopic activation of Ras1, suggesting that phyl expression is regulated by Ras1. phyl is also required for embryonic nervous system and sensory bristle development.			CHANG, HC (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.			Rubin, Gerald/0000-0001-8762-8703				BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BIGGS WH, 1994, EMBO J, V13, P1628, DOI 10.1002/j.1460-2075.1994.tb06426.x; BOWTELL DDL, 1989, P NATL ACAD SCI USA, V86, P6245, DOI 10.1073/pnas.86.16.6245; BOWTELL DDL, 1991, P NATL ACAD SCI USA, V88, P6853, DOI 10.1073/pnas.88.15.6853; BRUNNER D, 1994, NATURE, V370, P386, DOI 10.1038/370386a0; BRUNNER D, 1994, CELL, V76, P875, DOI 10.1016/0092-8674(94)90362-X; CARTHEW RW, 1990, CELL, V63, P561, DOI 10.1016/0092-8674(90)90452-K; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; Dickson Barry, 1993, P1327; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FORTINI ME, 1990, GENE DEV, V4, P444, DOI 10.1101/gad.4.3.444; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; HAY BA, 1994, DEVELOPMENT, V120, P2121; Jan Yuh Nung, 1993, P1207; KARPEN GH, 1992, GENETICS, V132, P737; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KUSSICK SJ, 1993, ONCOGENE, V8, P2791; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; MELAMED J, 1975, J ULTRA MOL STRUCT R, V51, P79, DOI 10.1016/S0022-5320(75)80010-4; MLODZIK M, 1990, CELL, V60, P211, DOI 10.1016/0092-8674(90)90737-Y; NILSSON DE, 1983, CELL TISSUE RES, V230, P401; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; REICHMANFRIED M, 1994, GENE DEV, V8, P428, DOI 10.1101/gad.8.4.428; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TOMLINSON A, 1986, SCIENCE, V231, P400, DOI 10.1126/science.231.4736.400; WOLFF T, 1991, DEVELOPMENT, V113, P841; Wolff Tanya, 1993, P1277; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU T, 1993, DEVELOPMENT, V117, P1223; ZIPURSKY SL, 1994, ANNU REV NEUROSCI, V17, P373, DOI 10.1146/annurev.neuro.17.1.373	41	95	98	0	1	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 10	1995	80	3					463	472		10.1016/0092-8674(95)90497-2	http://dx.doi.org/10.1016/0092-8674(95)90497-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QG470	7888014	Bronze			2022-12-28	WOS:A1995QG47000013
J	JOHNSTON, SRD; HAYNES, BP; SMITH, IE; JARMAN, M; SACKS, NPM; EBBS, SR; DOWSETT, M				JOHNSTON, SRD; HAYNES, BP; SMITH, IE; JARMAN, M; SACKS, NPM; EBBS, SR; DOWSETT, M			ACQUIRED TAMOXIFEN RESISTANCE IN HUMAN BREAST-CANCER AND REDUCED INTRA-TUMORAL DRUG CONCENTRATION	LANCET			English	Note								Reduced intra-tumoral drug concentrations have been investigated as a mechanism of tamoxifen resistance in 51 patients with locally recurrent breast cancer. Serum tamoxifen was similar in patients with acquired and de-novo resistance, but intra-tumoral concentrations were significantly lower in patients with acquired resistance. Tumour oestrogen-receptor concentrations at relapse did not support the hypothesis that selective outgrowth of oestrogen-receptor-negative cells is a major mechanism for acquired tamoxifen resistance. Reduced intra-tumoral tamoxifen levels during prolonged therapy may be an important mechanism for acquired resistance in breast cancer.	ROYAL MARSDEN HOSP,BREAST UNIT,LONDON SW3 6JJ,ENGLAND; INST CANC RES,DRUG DEV SECT,SUTTON SM2 5PX,SURREY,ENGLAND; MAYDAY UNIV HOSP,DEPT SURG,CROYDON,SURREY,ENGLAND	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Croydon University Hospital	JOHNSTON, SRD (corresponding author), ROYAL MARSDEN HOSP,ACAD DEPT BIOCHEM,LONDON SW3 6JJ,ENGLAND.							JENSEN EV, 1982, RECENT PROG HORM RES, V38, P1; JOHNSTON SRD, 1992, ANN ONCOL, V3, P503, DOI 10.1093/oxfordjournals.annonc.a058251; JULIANO RL, 1976, BIOCHIM BIOPHYS ACTA, V455, P152, DOI 10.1016/0005-2736(76)90160-7; LANGANFAHEY SM, 1990, EUR J CANCER, V26, P883, DOI 10.1016/0277-5379(90)90191-U; MCCAGUE R, 1989, J MED CHEM, V32, P2527, DOI 10.1021/jm00132a006; OSBORNE CK, 1992, J CLIN ONCOL, V10, P304, DOI 10.1200/JCO.1992.10.2.304; OSBORNE CK, 1991, J NATL CANCER I, V83, P1477, DOI 10.1093/jnci/83.20.1477; SMITH IE, 1982, CANCER RES, V42, P3430	8	78	79	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1521	1522		10.1016/S0140-6736(05)80088-1	http://dx.doi.org/10.1016/S0140-6736(05)80088-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902904				2022-12-28	WOS:A1993MM40200015
J	ZIEGLER, JB				ZIEGLER, JB			BREAST-FEEDING AND HIV	LANCET			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; INFANT				ZIEGLER, JB (corresponding author), PRINCE WALES CHILDRENS HOSP,DEPT IMMUNOL ALLERGY,RANDWICK,NSW,AUSTRALIA.							DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; HU DJ, 1992, AIDS, V6, P1505, DOI 10.1097/00002030-199212000-00014; LEDERMAN SA, 1992, PEDIATRICS, V89, P290; MACEDO CG, 1988, PAHO B, V22, P303; PALASANTHIRAN P, 1993, J INFECT DIS, V167, P441, DOI 10.1093/infdis/167.2.441; VANDEPERRE P, 1993, LANCET, V341, P914, DOI 10.1016/0140-6736(93)91210-D; ZIEGLER JB, 1985, LANCET, V1, P896; 1987, WKLY EPIDEMIOL REC, V33, P245; 1992, WKLY EPIDEMIOL REC, V67, P177	9	14	15	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1437	1438		10.1016/0140-6736(93)92926-K	http://dx.doi.org/10.1016/0140-6736(93)92926-K			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902476				2022-12-28	WOS:A1993ML21700002
J	HESSLER, NA; SHIRKE, AM; MALINOW, R				HESSLER, NA; SHIRKE, AM; MALINOW, R			THE PROBABILITY OF TRANSMITTER RELEASE AT A MAMMALIAN CENTRAL SYNAPSE	NATURE			English	Article							EXCITATORY POSTSYNAPTIC POTENTIALS; GROUP-IA SYNAPSES; TIME COURSE; TRANSMISSION; GLUTAMATE; RECEPTOR; CURRENTS	WHEN an action potential reaches a synaptic terminal, fusion of a transmitter-containing vesicle with the presynaptic membrane occurs with a probability (p(r)) of less than one1. Despite the fundamental importance of this parameter, p(r) has not been directly measured in the central nervous system. Here we describe a novel approach to determine p(r), monitoring the decrement of NMDA (N-methyl-D-aspartate)-receptor mediated synaptic currents in the presence of the use-dependent channel blocker MK-801 (ref. 2). On a single postsynaptic CA1 hippocampal slice neuron, two classes of synapses with a sixfold difference in p(r) are resolved. Synapses with low p(r) contribute to over half of transmission and are more sensitive to drugs enhancing transmitter release. Switching between these two classes of synapses provides the potential for large changes in synaptic efficacy and could underlie forms of activity-dependent plasticity.	UNIV IOWA,NEUROSCI PROGRAM,IOWA CITY,IA 52242; UNIV IOWA,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	University of Iowa; University of Iowa			hessler, neal/A-7328-2010					ATWOOD HL, 1967, NATURE, V215, P57, DOI 10.1038/215057a0; CLAMANN HP, 1989, J NEUROPHYSIOL, V61, P403, DOI 10.1152/jn.1989.61.2.403; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; CLEMENTS JD, 1992, SCIENCE, V258, P1498, DOI 10.1126/science.1359647; EDMONDS B, 1992, P ROY SOC B-BIOL SCI, V250, P279, DOI 10.1098/rspb.1992.0160; HESTRIN S, 1990, NEURON, V5, P247, DOI 10.1016/0896-6273(90)90162-9; HEUTTNER JE, 1988, P NATL ACAD SCI USA, V85, P1307; JACK JJB, 1981, J PHYSIOL-LONDON, V321, P111, DOI 10.1113/jphysiol.1981.sp013974; JAHR CE, 1992, SCIENCE, V255, P470, DOI 10.1126/science.1346477; Katz B., 1969, RELEASE NEURAL TRANS; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; LESTER RAJ, 1992, J NEUROSCI, V12, P635; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; LIN JW, 1988, J NEUROSCI, V8, P1313; RAHAMIMOFF R, 1968, J PHYSIOL-LONDON, V195, P471, DOI 10.1113/jphysiol.1968.sp008468; REDMAN S, 1983, J PHYSIOL-LONDON, V343, P135, DOI 10.1113/jphysiol.1983.sp014885; ROSENMUND C, 1993, SCIENCE, V262, P754, DOI 10.1126/science.7901909; ROSENMUND C, 1993, BIOPH SOC ABSTR, pA327; STRICHARTZ GR, 1973, J GEN PHYSIOL, V62, P37, DOI 10.1085/jgp.62.1.37; WALMSLEY B, 1988, J NEUROPHYSIOL, V60, P889, DOI 10.1152/jn.1988.60.3.889	20	472	474	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					569	572		10.1038/366569a0	http://dx.doi.org/10.1038/366569a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	7902955				2022-12-28	WOS:A1993ML21800071
J	COX, P				COX, P			INDICATORS FOR POTENTIAL-DRUG USE	LANCET			English	Editorial Material											COX, P (corresponding author), ACAD UNIT PUBL HLTH MED,LEEDS,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1376	1377		10.1016/0140-6736(93)92747-H	http://dx.doi.org/10.1016/0140-6736(93)92747-H			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901676				2022-12-28	WOS:A1993MK09500004
J	WALLACE, CJ				WALLACE, CJ			MAGNETIC-RESONANCE FOR DETECTION OF ABNORMALITIES IN PARTIAL EPILEPSY	LANCET			English	Editorial Material							HIPPOCAMPAL				WALLACE, CJ (corresponding author), FOOTHILLS PROV GEN HOSP,DEPT RADIOL SCI,CALGARY,AB,CANADA.							COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; CROSS JH, 1993, ARCH DIS CHILD, V69, P104, DOI 10.1136/adc.69.1.104; DUCHOWNY M, 1992, EPILEPSIA, V33, P298, DOI 10.1111/j.1528-1157.1992.tb02319.x; HIRSCHORN K A, 1991, Neurology, V41, P170; JACK CR, 1990, RADIOLOGY, V175, P423, DOI 10.1148/radiology.175.2.2183282; JACKSON GD, 1990, NEUROLOGY, V40, P1869, DOI 10.1212/WNL.40.12.1869; TSURUDA JS, 1992, ASNR M NOTES VANCOUV, P174	7	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1252	1252		10.1016/0140-6736(93)92354-V	http://dx.doi.org/10.1016/0140-6736(93)92354-V			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901578				2022-12-28	WOS:A1993MH56600004
J	BRENNER, MK; RILL, DR; HOLLADAY, MS; HESLOP, HE; MOEN, RC; BUSCHLE, M; KRANCE, RA; SANTANA, VM; ANDERSON, WF; IHLE, JN				BRENNER, MK; RILL, DR; HOLLADAY, MS; HESLOP, HE; MOEN, RC; BUSCHLE, M; KRANCE, RA; SANTANA, VM; ANDERSON, WF; IHLE, JN			GENE MARKING TO DETERMINE WHETHER AUTOLOGOUS MARROW INFUSION RESTORES LONG-TERM HEMATOPOIESIS IN CANCER-PATIENTS	LANCET			English	Article							HEMATOPOIETIC STEM-CELLS; HIGH-DOSE CHEMOTHERAPY; COLONY-STIMULATING FACTOR; ACUTE MYELOID-LEUKEMIA; BONE-MARROW; TRANSPLANTATION; EXPRESSION; PROGENITORS; RECOVERY; RECONSTITUTION	The contribution of infused bone marrow cells to long-term haemopoietic recovery in patients undergoing autologous bone marrow transplantation is unknown. Such information would help to clarify the role of this procedure in cancer therapy and would aid in the development of strategies to reduce the risk of subsequent aplasia. By transferring a neomycin resistance marker gene into the marrow cells of 20 patients before transplantation, we were able to trace the pattern of haemopoietic reconstitution postinfusion. The marker gene was present and expressed in all haemopoietic lineages in vivo in 15 of 18 evaluable patients at 1 month post-transplantation, in 8 of 9 patients at 6 months, and in 5 of 5 at 1 year. The marker has remained detectable for up to 18 months-the duration of our study. Our findings indicate that harvested bone marrow consistently contributes to long-term multilineage recovery of haemopoiesis after autologous marrow transplantation in cancer patients. These results, provide a rationale for the continued exploration of more ablative preparative regimens with single or sequential autologous marrow transplants.	UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA; UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT MED, MEMPHIS, TN 38163 USA; GENET THERAPY INC, GAITHERSBURG, MD 20878 USA; USC, SCH MED, LOS ANGELES, CA 90033 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; Novartis; University of Southern California; St Jude Children's Research Hospital	BRENNER, MK (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, DIV BONE MARROW TRANSPLANTAT, MEMPHIS, TN 38105 USA.		Heslop, Helen/AAC-9500-2020; Brenner, Malcolm/Y-2509-2019		NATIONAL CANCER INSTITUTE [P30CA021765, U01CA058211] Funding Source: NIH RePORTER; NCI NIH HHS [CA 58211, CA 21765, CA 59479] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON WF, 1992, SCIENCE, V256, P808, DOI 10.1126/science.1589762; BENDER MA, 1987, J VIROL, V61, P1639, DOI 10.1128/JVI.61.5.1639-1646.1987; BODINE DM, 1991, EXP HEMATOL, V19, P206; BRANDT SJ, 1988, NEW ENGL J MED, V318, P869, DOI 10.1056/NEJM198804073181401; BRENNER MK, 1993, LANCET, V341, P85, DOI 10.1016/0140-6736(93)92560-G; CHOPRA R, 1991, J CLIN ONCOL, V9, P1840, DOI 10.1200/JCO.1991.9.10.1840; EKHTERAE D, 1990, BLOOD, V75, P365; GALE RP, 1989, LANCET, V2, P315; GIANNI AM, 1989, LANCET, V2, P580; GRAHAMPOLE J, 1991, BLOOD, V78, P1607; LAPORTE JP, 1991, LANCET, V338, P601, DOI 10.1016/0140-6736(91)90609-S; LI CL, 1992, J EXP MED, V175, P1443, DOI 10.1084/jem.175.6.1443; LOTHROP CD, 1991, BLOOD, V78, P237; MCMILLAN AK, 1990, BLOOD, V76, P480; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1990, BLOOD, V76, P271; RILL DR, 1992, BLOOD, V79, P2694; RILL DR, 1992, HUM GENE THER, V3, P129, DOI 10.1089/hum.1992.3.2-129; SCHUENING FG, 1991, BLOOD, V78, P2568; SHERIDAN WP, 1992, LANCET, V339, P640, DOI 10.1016/0140-6736(92)90795-5; SIENA S, 1991, BLOOD, V77, P400; STEWART FM, 1989, EXP HEMATOL, V17, P974; VANBEUSECHEM VW, 1992, P NATL ACAD SCI USA, V89, P7640, DOI 10.1073/pnas.89.16.7640; WIEDER R, 1991, BLOOD, V77, P448; 1989, LANCET, V2, P317	25	384	395	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1134	1137		10.1016/0140-6736(93)92122-A	http://dx.doi.org/10.1016/0140-6736(93)92122-A			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901474				2022-12-28	WOS:A1993MF19800008
J	MELLORS, JW; KINGSLEY, LA; RINALDO, CR; TODD, JA; HOO, BS; KOKKA, RP; GUPTA, P				MELLORS, JW; KINGSLEY, LA; RINALDO, CR; TODD, JA; HOO, BS; KOKKA, RP; GUPTA, P			QUANTITATION OF HIV-1 RNA IN PLASMA PREDICTS OUTCOME AFTER SEROCONVERSION	ANNALS OF INTERNAL MEDICINE			English	Article						HUMAN IMMUNODEFICIENEY VIRUS-1; HUMAN IMMUNODEFICIENCY VIRUS SEROPOSITIVITY; ACQUIRED IMMUNODEFICIENCY SYNDROME; OUTCOME ASSESSMENT (HEALTH CARE); CD4-POSITIVE LYMPHOCYTES	IMMUNODEFICIENCY-VIRUS TYPE-1; MULTICENTER AIDS COHORT; PROGNOSTIC VALUE; HOMOSEXUAL MEN; INFECTION; PROGRESSION; ANTIGEN	Objective: To investigate the relation between the quantity of human immunodeficiency virus type 1 (HIV-1) RNA in plasma and the risk for the acquired immunodeficiency syndrome (AIDS) or a decline in the CD4+ T-cell count after seroconversion. Design: Prospective study. Patients: 62 homosexual men with documented HIV-1 seroconversion. Setting: University outpatient setting. Measurements: Clinical status, CD4+ T-cell counts, and plasma and serum samples were obtained every 6 months. Human immunodeficiency virus RNA in plasma was quantitated with a branched-DNA (bDNA) assay. Serum samples were assayed for neopterin, beta(2)-microglobulin, and immune complex dissociated HIV-1 p24 antigen. Results: 18 of 62 (29%) men developed AIDS; 21 (34%) had a significant decline in the CD4+ T-cell count without AIDS; and 23 (37%) had a stable CD4+ T-cell count. For each participant, HIV-1 RNA results were categorized into one of four groups: 1) detection of HIV-I RNA(>1 x 10(4) genome equivalents/mL. [Eq/mL]) in all samples; 2) detection in most samples (greater than or equal to 50%); 3) detection in fewer than 50% of samples; and 4) detection in none of the samples. Detection of HIV-1 RNA in all or most samples was strongly associated with AIDS (16 of 18 patients) and a decline in the CD4+ T-cell count (13 of 21 patients) compared with a stable CD4+ T-cell count (4 of 23 patients; P < 0.001), Conversely, the absence of HIV-1 RNA(<1 x 10(4) Eq/ml) in all or most samples was associated with stable CD4+ T-cell counts (19 of 23 patients) and a lower risk for AIDS or decline in the CD4+ T-cell count (10 of 39 patients; P < 0.001). In multivariate analysis of all laboratory values at the seroconversion visit, a plasma HIV-1 RNA level greater than 1 x 10(5) Eq/mL was the most powerful predictor of AIDS (odds ratio, 10.8; P = 0.01), Conclusions: Plasma HIV-1 RNA is a strong, CD4+ T-cell-independent predictor of a rapid progression to AIDS after HIV-1 seroconversion.	CHIRON CORP, EMERYVILLE, CA USA; UNIV PITTSBURGH, PITTSBURGH, PA USA	Novartis; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Pillay, Nischalan/F-9536-2012	Kingsley, Lawrence/0000-0002-7000-8556	NIAID NIH HHS [N01-AI-72632, U01-AI-35041, R01 AI34301-01] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034301, U01AI035041, N01AI072632] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAIN JP, 1987, NEW ENGL J MED, V317, P1114, DOI 10.1056/NEJM198710293171804; BLATT SP, 1993, ANN INTERN MED, V119, P177, DOI 10.7326/0003-4819-119-3-199308010-00001; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DEWOLF F, 1987, BMJ-BRIT MED J, V295, P569, DOI 10.1136/bmj.295.6598.569; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; GUPTA P, 1993, VIROLOGY, V196, P586, DOI 10.1006/viro.1993.1514; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; JURRIAANS S, 1994, VIROLOGY, V204, P223, DOI 10.1006/viro.1994.1526; KASLOW RA, 1990, LANCET, V335, P927, DOI 10.1016/0140-6736(90)90995-H; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; MUNOZ A, 1989, AM J EPIDEMIOL, V130, P530, DOI 10.1093/oxfordjournals.aje.a115367; PACHL C, 1995, IN PRESS J AQUIR IMM; PHAIR J, 1992, J ACQ IMMUN DEF SYND, V5, P490; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; REDFIELD RR, 1986, NEW ENGL J MED, V314, P131, DOI 10.1056/NEJM198601093140232; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; TSOUKAS CM, 1994, CLIN MICROBIOL REV, V7, P14, DOI 10.1128/CMR.7.1.14-28.1994; WEBSTER A, 1989, LANCET, V2, P63	21	823	845	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					573	579		10.7326/0003-4819-122-8-199504150-00003	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887550				2022-12-28	WOS:A1995QR52500003
J	ELREFAEY, H; RAJASEKAR, D; ABDALLA, M; CALDER, L; TEMPLETON, A				ELREFAEY, H; RAJASEKAR, D; ABDALLA, M; CALDER, L; TEMPLETON, A			INDUCTION OF ABORTION WITH MIFEPRISTONE (RU-486) AND ORAL OR VAGINAL MISOPROSTOL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EARLY-PREGNANCY; PROSTAGLANDIN ANALOG; ACTIVE PROSTAGLANDIN; 1ST TRIMESTER; RU-486; TERMINATION	Background. Medical termination of pregnancy can be successfully performed with a combination of mifepristone (RU 486) and a prostaglandin analogue. We conducted a prospective, randomized trial to compare oral with vaginal administration of the prostaglandin E(1), analogue misoprostol for first-trimester abortion in women treated initially with mifepristone. Methods. The study population consisted of 270 women seeking abortion within 63 days after the onset of amenorrhea. The dose of mifepristone was 600 mg, and the dose of misoprostol was 800 mu g. The study had two primary end points: expulsion of the conceptus without the need for a surgical procedure, and abortion within four hours after the administration of misoprostol. Results. Expulsion of the conceptus without the need for a surgical procedure occurred in 95 percent of the women who received misoprostol vaginally and in 87 percent of those who received it orally (P=0.03). The rate of continued pregnancy was 7 percent with the oral regimen and 1 percent with the vaginal regimen (P=0.01). Ninety-three percent of the women receiving misoprostol vaginally had abortions within four hours, as compared with only 78 percent of the women receiving the drug orally (P<0.001). Vomiting and diarrhea were reported more frequently by the women who received oral misoprostol than by those who received vaginal misoprostol (P=0.04 and P=0.002, respectively). Conclusions. After the administration of mifepristone, vaginal administration of misoprostol is more effective and better tolerated than oral administration for the induction of first-trimester abortion.	UNIV ABERDEEN SCH MED,DEPT OBSTET & GYNAECOL,ABERDEEN,SCOTLAND; UNIV ABERDEEN SCH MED,HLTH SERV RES UNIT,ABERDEEN,SCOTLAND	University of Aberdeen; University of Aberdeen								Armitage P., 1994, STAT METHODS MED RES, V3; AUBENY E, 1991, CR ACAD SCI III-VIE, V312, P539; ELREFAEY H, 1994, LANCET, V343, P1207, DOI 10.1016/S0140-6736(94)92406-6; ELREFAEY H, 1994, LANCET, V343, P1650; ELREFAEY H, 1994, BRIT J OBSTET GYNAEC, V101, P792, DOI 10.1111/j.1471-0528.1994.tb11948.x; ELREFAEY H, 1994, CONTRACEPTION, V49, P111, DOI 10.1016/0010-7824(94)90085-X; Fonseca W, 1993, Clin Dysmorphol, V2, P76; GONZALEZ CH, 1993, AM J MED GENET, V47, P59, DOI 10.1002/ajmg.1320470113; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P76, DOI 10.2307/2135512; HENSHAW SK, 1990, FAM PLANN PERSPECT, V22, P114; KEIRSE MJN, 1989, EFFECTIVE CARE PREGN, V2, P1057; MCKINLEY C, 1993, HUM REPROD, V8, P1502, DOI 10.1093/oxfordjournals.humrep.a138287; NORMAN JE, 1991, LANCET, V338, P1233, DOI 10.1016/0140-6736(91)92102-8; PEYRON R, 1993, NEW ENGL J MED, V328, P1509, DOI 10.1056/NEJM199305273282101; Poulsen H K, 1991, Acta Obstet Gynecol Scand, V70, P549, DOI 10.3109/00016349109007915; Schonhofar P S, 1991, Lancet, V337, P1534, DOI 10.1016/0140-6736(91)93212-R; SILVESTRE L, 1990, NEW ENGL J MED, V322, P645, DOI 10.1056/NEJM199003083221001; THONG KJ, 1992, BRIT J OBSTET GYNAEC, V99, P1004, DOI 10.1111/j.1471-0528.1992.tb13707.x; ULMANN A, 1992, ACTA OBSTET GYN SCAN, V71, P278, DOI 10.3109/00016349209021052; 1990, BRIT J OBSTET GYNAEC, V97, P480; 1991, LANCET, V337, P969; 1991, LANCET, V338, P1241; 1991, LANCET, V338, P11	23	249	255	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					983	987		10.1056/NEJM199504133321502	http://dx.doi.org/10.1056/NEJM199504133321502			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT737	7885426				2022-12-28	WOS:A1995QT73700002
J	AGUNDEZ, JAG; LEDESMA, MC; BENITEZ, J; LADERO, JM; RODRIGUEZLESCURE, A; DIAZRUBIO, E; DIAZRUBIO, M				AGUNDEZ, JAG; LEDESMA, MC; BENITEZ, J; LADERO, JM; RODRIGUEZLESCURE, A; DIAZRUBIO, E; DIAZRUBIO, M			CYP2D6 GENES AND RISK OF LIVER-CANCER	LANCET			English	Note							DEBRISOQUINE; AMPLIFICATION; PHENOTYPE	We have studied by use of PCR and Xbal and EcoRI restriction-fragment-length polymorphism whether mutations at the polymorphic CYP2D6 (debrisoquine hydroxylase) gene locus are associated with liver cancer. The frequency of CYP2D6 genes containing inactivating mutations was lower among 75 liver cancer patients than 200 healthy controls, and 40 cirrhotic subjects that did not develop liver cancer (frequency for carriers of two or more functional genes was 95% vs 74% vs 78%, respectively). Subjects who were homozygous for functional CYP2D6 genes appear to be at higher risk of developing primary liver cancer (odds ratio 6.40 [95% CI] 2.4-17.5).	UNIV EXTREMADURA,SCH MED,DEPT PHARMACOL,E-06071 BADAJOZ,SPAIN; UNIV COMPLUTENSE MADRID,SAN CARLOS UNIV HOSP,SERV ONCOL,MADRID,SPAIN; UNIV COMPLUTENSE MADRID,SAN CARLOS UNIV HOSP,SERV GASTROENTEROL,MADRID,SPAIN	Universidad de Extremadura; Complutense University of Madrid; Hospital Clinico San Carlos; Complutense University of Madrid; Hospital Clinico San Carlos			Agúndez, José A. G./A-5503-2008; Rodríguez-Lescure, Álvaro/AAB-7039-2019; Diaz-Rubio, Manuel/B-5359-2010; Ledesma, M  Carmen/K-1689-2017	Agúndez, José A. G./0000-0001-6895-9160; Rodríguez-Lescure, Álvaro/0000-0002-6823-5290; Ledesma, M  Carmen/0000-0001-5546-0598; Diaz-Rubio, Eduardo/0000-0003-2792-5348				AGUNDEZ JAG, 1994, CLIN PHARMACOL THER, V55, P10, DOI 10.1038/clpt.1994.3; AGUNDEZ JAG, IN PRESS CLIN PHARM; AOYAMA T, 1990, P NATL ACAD SCI USA, V87, P4790, DOI 10.1073/pnas.87.12.4790; BROLY F, 1991, DNA CELL BIOL, V10, P545, DOI 10.1089/dna.1991.10.545; CAPORASO N, 1991, PHARMACOGENETICS, V1, P4, DOI 10.1097/00008571-199110000-00003; CRESPI CL, 1991, CARCINOGENESIS, V12, P1197, DOI 10.1093/carcin/12.7.1197; HEIM M, 1990, LANCET, V336, P529, DOI 10.1016/0140-6736(90)92086-W; JOHANSSON I, 1993, P NATL ACAD SCI USA, V90, P11825, DOI 10.1073/pnas.90.24.11825; TYNDALE R, 1991, PHARMACOGENETICS, V1, P26, DOI 10.1097/00008571-199110000-00005; WOLF CR, 1992, CARCINOGENESIS, V13, P1035, DOI 10.1093/carcin/13.6.1035	10	61	69	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					830	831		10.1016/S0140-6736(95)92965-7	http://dx.doi.org/10.1016/S0140-6736(95)92965-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898230				2022-12-28	WOS:A1995QQ19500010
J	DUPONT, HL; CHAPPELL, CL; STERLING, CR; OKHUYSEN, PC; ROSE, JB; JAKUBOWSKI, W				DUPONT, HL; CHAPPELL, CL; STERLING, CR; OKHUYSEN, PC; ROSE, JB; JAKUBOWSKI, W			THE INFECTIVITY OF CRYPTOSPORIDIUM-PARVUM IN HEALTHY-VOLUNTEERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DRINKING-WATER; INVITRO EXCYSTATION; OUTBREAK; OOCYSTS; IMMUNOCOMPETENT; GIARDIA; DISINFECTANTS; VIABILITY; OZONE; MICE	Background. Small numbers of Cryptosporidium parvum oocysts can contaminate even treated drinking water, and ingestion of oocysts can cause diarrheal disease in normal as well as immunocompromised hosts. Since the number of organisms necessary to cause infection in humans is unknown, we performed a study to determine the infective dose of the parasite in healthy adults. Methods. After providing informed consent, 29 healthy volunteers without evidence of previous C. parvum infection, as determined by the absence of anti-cryptosporidium-specific antibodies, were given a single dose of 30 to 1 million C. parvum oocysts obtained from a calf. They were then monitored for oocyst excretion and clinical illness for eight weeks. Household contacts were monitored for secondary spread. Reuslts. Of the 16 subjects who received an intended dose of 300 or more oocysts, 14 (88 percent) became infected. After a dose of 30 oocysts, one of five subjects (20 percent) became infected, whereas at a dose of 1000 or more oocysts, seven of seven became infected. The median infective dose, calculated by linear regression, was 132 oocysts. Of the 18 subjects who excreted oocysts after the challenge dose, 11 had enteric symptoms and 7 (39 percent) had clinical cryptosporidiosis, consisting of diarrhea plus at least one other enteric symptom. All recovered, and there were no secondary cases of diarrhea among household contacts. Conclusions. In healthy adults with no serologic evidence of past infection with C. parvum, a low dose of C. parvum oocysts is sufficient to cause infection.	UNIV TEXAS, SCH MED, HOUSTON, TX USA; UNIV TEXAS, SCH PUBL HLTH, HOUSTON, TX USA; UNIV ARIZONA, TUCSON, AZ USA; UNIV S FLORIDA, TAMPA, FL USA; US EPA, CINCINNATI, OH 45268 USA	University of Texas System; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Arizona; State University System of Florida; University of South Florida; United States Environmental Protection Agency			DuPont, Herbert/AAH-6776-2021	Okhuysen, Pablo/0000-0002-1596-3411	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002558] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR-02558] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANGUS KW, 1982, RES VET SCI, V33, P379, DOI 10.1016/S0034-5288(18)32320-8; ARROWOOD MJ, 1987, J PARASITOL, V73, P314, DOI 10.2307/3282084; BLACKLOW NR, 1979, J CLIN MICROBIOL, V10, P903, DOI 10.1128/JCM.10.6.903-909.1979; CAMPBELL AT, 1992, APPL ENVIRON MICROB, V58, P3488, DOI 10.1128/AEM.58.11.3488-3493.1992; CAMPBELL I, 1982, VET REC, V111, P414, DOI 10.1136/vr.111.18.414; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; DUPONT HL, 1992, CLIN INFECT DIS, V15, pS228, DOI 10.1093/clind/15.Supplement_1.S228; FINCH GR, 1993, APPL ENVIRON MICROB, V59, P4203, DOI 10.1128/AEM.59.12.4203-4210.1993; GOODGAME RW, 1993, J INFECT DIS, V167, P704, DOI 10.1093/infdis/167.3.704; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; ISAACRENTON JL, 1987, LANCET, V1, P973; JOKIPII L, 1985, GASTROENTEROLOGY, V89, P838, DOI 10.1016/0016-5085(85)90581-5; JOKIPII L, 1986, NEW ENGL J MED, V315, P1643, DOI 10.1056/NEJM198612253152604; KORICH DG, 1990, APPL ENVIRON MICROB, V56, P1423, DOI 10.1128/AEM.56.5.1423-1428.1990; KUHLS TL, 1994, CLIN INFECT DIS, V18, P731, DOI 10.1093/clinids/18.5.731; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; Lederberg J., 1992, EMERGING INFECTIONS; LENGERICH EJ, 1993, J INFECT DIS, V167, P1252, DOI 10.1093/infdis/167.5.1252; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MADORE MS, 1987, J PARASITOL, V73, P702, DOI 10.2307/3282398; MOON HW, 1988, INFECT IMMUN, V56, P649, DOI 10.1128/IAI.56.3.649-653.1988; NEWMAN RD, 1994, ANN INTERN MED, V120, P500, DOI 10.7326/0003-4819-120-6-199403150-00009; REGLI S, 1991, J AM WATER WORKS ASS, V83, P76, DOI 10.1002/j.1551-8833.1991.tb07252.x; RENDTORFF ROBERT C., 1954, AMER JOUR HYG, V59, P209; ROSE JB, 1991, AM J PUBLIC HEALTH, V81, P709, DOI 10.2105/AJPH.81.6.709; TANGERMANN RH, 1991, AM J EPIDEMIOL, V133, P471, DOI 10.1093/oxfordjournals.aje.a115914; UNGAR BLP, 1989, ARCH INTERN MED, V149, P894, DOI 10.1001/archinte.149.4.894; UNGAR BLP, 1986, J INFECT DIS, V153, P570, DOI 10.1093/infdis/153.3.570; WOLFSON JS, 1985, NEW ENGL J MED, V312, P1278, DOI 10.1056/NEJM198505163122002; WOODMANSEE DB, 1987, J PROTOZOOL, V34, P398, DOI 10.1111/j.1550-7408.1987.tb03199.x	31	690	738	2	53	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					855	859		10.1056/NEJM199503303321304	http://dx.doi.org/10.1056/NEJM199503303321304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7870140	Bronze			2022-12-28	WOS:A1995QP22800004
J	LEBOVITZ, HE				LEBOVITZ, HE			DIABETIC-KETOACIDOSIS	LANCET			English	Article							CEREBRAL EDEMA; BICARBONATE THERAPY; BRAIN HERNIATION; HYPERGLYCEMIA; DERANGEMENTS; REHYDRATION; MECHANISM; CHILDREN; PRESSURE; INSULIN				LEBOVITZ, HE (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV ENDOCRINOL,450 CLARKSON AVE,BOX 1205,BROOKLYN,NY 11203, USA.							ADROGUE HJ, 1989, JAMA-J AM MED ASSOC, V262, P2108, DOI 10.1001/jama.262.15.2108; Akhter J., 1993, JPMA (Journal of the Pakistan Medical Association), V43, P137; ALBERTI KGMM, 1977, ARCH INTERN MED, V137, P1367, DOI 10.1001/archinte.137.10.1367; ANDROGUE HJ, 1982, NEW ENGL J MED, V307, P1603; ARIEFF AI, 1973, J CLIN INVEST, V52, P571, DOI 10.1172/JCI107218; BELLO FA, 1990, LANCET, V336, P64, DOI 10.1016/0140-6736(90)91587-Z; BONADIO WA, 1988, AM J DIS CHILD, V142, P448, DOI 10.1001/archpedi.1988.02150040102029; BURGE MR, 1993, J CLIN ENDOCR METAB, V76, P1192, DOI 10.1210/jc.76.5.1192; CLEMENTS RS, 1971, LANCET, V2, P671; DUCK SC, 1988, J PEDIATR-US, V113, P10, DOI 10.1016/S0022-3476(88)80521-3; FEIN IA, 1982, ANN INTERN MED, V96, P570, DOI 10.7326/0003-4819-96-5-570; FISHER JN, 1983, J CLIN ENDOCR METAB, V57, P117; FOSTER DW, 1983, NEW ENGL J MED, V309, P159; GAMBA G, 1991, REV INVEST CLIN, V43, P234; GLASGOW AM, 1991, DIABETES CARE, V14, P77, DOI 10.2337/diacare.14.1.77; HALE PJ, 1984, BMJ-BRIT MED J, V289, P1035, DOI 10.1136/bmj.289.6451.1035; HAMBLIN PS, 1989, MED J AUSTRALIA, V151, P439, DOI 10.5694/j.1326-5377.1989.tb101253.x; HAMMOND P, 1992, BRIT MED J, V305, P203, DOI 10.1136/bmj.305.6847.203; HARRIS GD, 1990, J PEDIATR-US, V117, P22, DOI 10.1016/S0022-3476(05)82439-4; HARRIS GD, 1993, LIFE SCI, V53, P185, DOI 10.1016/0024-3205(93)90668-S; HOFFMAN WH, 1988, AM J NEURORADIOL, V9, P733; JENKINS D, 1993, ACTA DIABETOL, V30, P251, DOI 10.1007/BF00569937; KELLER U, 1986, DIABETOLOGIA, V29, P71, DOI 10.1007/BF00456113; KELLER U, 1980, DIABETES, V29, P87, DOI 10.2337/diab.29.2.87; KITABCHI AE, 1976, ANN INTERN MED, V84, P633, DOI 10.7326/0003-4819-84-6-633; KRANE EJ, 1985, NEW ENGL J MED, V312, P1147, DOI 10.1056/NEJM198505023121803; LEVER E, 1983, AM J MED, V5, P263; MALONE ML, 1992, J AM GERIATR SOC, V40, P1100, DOI 10.1111/j.1532-5415.1992.tb01797.x; Matoo V K, 1991, J Assoc Physicians India, V39, P379; MORRIS LR, 1986, ANN INTERN MED, V105, P836, DOI 10.7326/0003-4819-105-6-836; MUNRO JF, 1973, BRIT MED J, V2, P578, DOI 10.1136/bmj.2.5866.578; OWEN OE, 1981, DIABETES, V30, P510, DOI 10.2337/diab.30.6.510; ROSENBLOOM AL, 1990, DIABETES CARE, V13, P22, DOI 10.2337/diacare.13.1.22; SOLER NG, 1972, LANCET, V2, P665; VANDERMEULEN JA, 1987, LANCET, V2, P306; WACHTEL TJ, 1991, J GEN INTERN MED, V6, P495, DOI 10.1007/BF02598216; WALDHAUSL W, 1979, DIABETES, V28, P577, DOI 10.2337/diab.28.6.577; WETHERALL SF, 1992, DIABETES CARE, V15, P960; WILSON HK, 1982, ARCH INTERN MED, V142, P517, DOI 10.1001/archinte.142.3.517; 1982, LANCET, V2, P308; 1994, DIABETOLOGIA, V37, P278	41	139	144	1	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					767	772		10.1016/S0140-6736(95)90645-2	http://dx.doi.org/10.1016/S0140-6736(95)90645-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891491				2022-12-28	WOS:A1995QN70100016
J	LORENZ, M; JUNG, S; RADBRUCH, A				LORENZ, M; JUNG, S; RADBRUCH, A			SWITCH TRANSCRIPTS IN IMMUNOGLOBULIN CLASS SWITCHING	SCIENCE			English	Article							HEAVY-CHAIN TRANSCRIPTS; RESTING B-CELLS; MAMMALIAN-CELLS; STEM-CELLS; RECOMBINATION; GENE; INDUCTION; INTERLEUKIN-4; REGION; REARRANGEMENT	B cells can exchange gene segments for the constant region of the immunoglobulin heavy chain, altering the class and effector function of the antibodies that they produce. Class switching is directed to distinct classes by cytokines, which induce transcription of the targeted DNA sequences. These transcripts are processed, resulting in spliced ''switch'' transcripts. Switch recombination can be directed to immunoglobulin G1 (IgG1) by the heterologous human metallothionein IIA promoter in mutant mice. Induction of the structurally conserved, spliced switch transcripts is sufficient to target switch recombination to IgG1, whereas transcription alone is not.	UNIV COLOGNE, INST GENET, D-50931 COLOGNE, GERMANY; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, LAUTENBERG CTR GEN & TUMOR IMMUNOL, IL-91120 JERUSALEM, ISRAEL	University of Cologne; Hebrew University of Jerusalem			Jung, Steffen/K-1409-2012	Jung, Steffen/0000-0003-4290-5716; Radbruch, Andreas/0000-0001-5753-0000				ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; BERTON MT, 1989, P NATL ACAD SCI USA, V86, P2829, DOI 10.1073/pnas.86.8.2829; BERTON MT, 1990, J EXP MED, V172, P375, DOI 10.1084/jem.172.1.375; BOTTARO A, 1994, EMBO J, V13, P665, DOI 10.1002/j.1460-2075.1994.tb06305.x; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; DUNNICK W, 1989, MOL CELL BIOL, V9, P1850, DOI 10.1128/MCB.9.5.1850; ESSER C, 1989, EMBO J, V8, P483, DOI 10.1002/j.1460-2075.1989.tb03401.x; ESSER C, 1990, ANNU REV IMMUNOL, V8, P717, DOI 10.1146/annurev.iy.08.040190.003441; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; HARRIMAN W, 1993, ANNU REV IMMUNOL, V11, P361, DOI 10.1146/annurev.iy.11.040193.002045; HU MCT, 1987, CELL, V48, P555, DOI 10.1016/0092-8674(87)90234-0; ILLGES H, 1992, MOL IMMUNOL, V29, P1265, DOI 10.1016/0161-5890(92)90063-4; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KEPRON MR, 1989, J IMMUNOL, V143, P334; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LAYTON JE, 1984, J EXP MED, V160, P1850, DOI 10.1084/jem.160.6.1850; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MOWATT MR, 1986, J IMMUNOL, V136, P2674; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; RADBRUCH A, 1986, P NATL ACAD SCI USA, V83, P3954, DOI 10.1073/pnas.83.11.3954; SCHMITZ J, 1990, INT IMMUNOL, V144, P952; SCROCH P, 1993, PROG CLIN BIOL RES, V380, P113; SEVERINSON E, 1990, EUR J IMMUNOL, V20, P1079, DOI 10.1002/eji.1830200520; SEVERINSONGRONOWICZ E, 1979, J IMMUNOL, V123, P2057; SHIMIZU A, 1982, CELL, V28, P499, DOI 10.1016/0092-8674(82)90204-5; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; SWAPAN KD, 1990, J BIOL CHEM, V265, P15267; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; XU LX, 1993, P NATL ACAD SCI USA, V90, P3705, DOI 10.1073/pnas.90.8.3705; Xu M, 1990, Dev Immunol, V1, P11, DOI 10.1155/1990/47659; YANCOPOULOS GD, 1986, EMBO J, V5, P3259, DOI 10.1002/j.1460-2075.1986.tb04637.x; ZHANG J, 1993, EMBO J, V12, P3529, DOI 10.1002/j.1460-2075.1993.tb06027.x	36	210	213	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 24	1995	267	5205					1825	1828		10.1126/science.7892607	http://dx.doi.org/10.1126/science.7892607			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892607				2022-12-28	WOS:A1995QN70200040
J	CHEN, JJ; JACKSON, PK; KIRSCHNER, MW; DUTTA, A				CHEN, JJ; JACKSON, PK; KIRSCHNER, MW; DUTTA, A			SEPARATE DOMAINS OF P21 INVOLVED IN THE INHIBITION OF CDK KINASE AND PCNA	NATURE			English	Article							DNA-REPLICATION; P53	THE protein p21 (WAF1, CIP1 or sdi1), induced by the tumour-suppressor protein p53, interacts with and inhibits two different targets essential for cell-cycle progression(1-8). One of these is the cyclin-Cdk family of kinases and the other is the essential DNA replication factor, proliferating-cell nuclear antigen (PCNA). We report here that separate domains of p21 are responsible for interacting with and inhibiting the two targets. An amino-terminal domain inhibits cyclin-Cdk kinases and a carboxy-terminal domain inhibits PCNA. Using these separated domains, we have determined that p21 inhibits different biological systems through different targets. The PCNA-binding domain is sufficient for inhibition of DNA replication based on sinian virus 40, whereas the Cdk2-binding domain is sufficient for inhibition of DNA replication based on Xenopus egg extract and for growth suppression in transformed human cells.	HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT PATHOL,DIV MOLEC ONCOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Jackson, Peter/0000-0002-1742-2539				DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; DUTTA A, 1922, EMBO J, V11, P2189; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	16	525	543	0	23	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					386	388		10.1038/374386a0	http://dx.doi.org/10.1038/374386a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885482				2022-12-28	WOS:A1995QN63000067
J	SCHEFFZEK, K; KLEBE, C; FRITZWOLF, K; KABSCH, W; WITTINGHOFER, A				SCHEFFZEK, K; KLEBE, C; FRITZWOLF, K; KABSCH, W; WITTINGHOFER, A			CRYSTAL-STRUCTURE OF THE NUCLEAR RAS-RELATED PROTEIN RAN IN ITS GDP-BOUND FORM	NATURE			English	Article							ELONGATION-FACTOR TU; ESCHERICHIA-COLI; AMINO-ACIDS; REGULATOR; BINDING; DOMAIN; LOCATION; RAN/TC4; RCC1	THE Ran proteins constitute a distinct branch of the superfamily of Ras-related GTP-binding proteins(1) which function as molecular switches cycling between GTP-bound 'on' and GDP-bound 'off' states(2). Ran is located predominantly in the nucleus of eukaryotic cells(3) and is involved in the nuclear import of proteins(4,5) as well as in control of DNA synthesis and of cell-cycle progression(6-8). We report here the crystal structure at 2.3 Angstrom resolution of human Ran (M(r) 24K) complexed with GDP and Mg2+. This structure reveals a similarity with the Ras core (G-domain) but with significant variations in regions involved in GDP and Mg2+ coordination (switch I and switch II regions in Ras)(9,10), suggesting that there could be major conformational changes upon GTP binding. In addition to the G-domain, an extended chain and an alpha-helix were identified at the carboxy terminus. The amino-terminal (amino-acid residues (1)MAAQGEP(7)) stretch and the acidic tail ((211)DEDDDL(216)) appear to be flexible in the crystal structure.	MAX PLANK INST MOLEK PHYSIOL, STRUKT BIOL ABT, D-44139 DORTMUND, GERMANY; MAX PLANCK INST MED RES, BIOPHYS ABT, D-69120 HEIDELBERG, GERMANY	Max Planck Society; Max Planck Society								AEVARSSON A, 1994, EMBO J, V13, P3669, DOI 10.1002/j.1460-2075.1994.tb06676.x; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER A, 1993, XPLOR VERSION 3 1; CLARKE PR, IN PRESS J CELL SCI; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COUTAVAS E, 1993, NATURE, V366, P585, DOI 10.1038/366585a0; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KLEBE C, 1993, BIOCHEMISTRY-US, V32, P11923, DOI 10.1021/bi00095a023; KLEBE C, 1995, BIOCHEMISTRY-US, V34, P639, DOI 10.1021/bi00002a031; KOMBLUTH S, 1994, J CELL BIOL, V125, P705; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MELCHIOR F, 1993, J CELL BIOL, V123, P1649, DOI 10.1083/jcb.123.6.1649; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REN MD, 1994, MOL CELL BIOL, V14, P4216, DOI 10.1128/MCB.14.6.4216; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; WITTINGHOFER A, 1991, TRENDS BIOCHEM SCI, V16, P382, DOI 10.1016/0968-0004(91)90156-P	30	172	176	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	1995	374	6520					378	381		10.1038/374378a0	http://dx.doi.org/10.1038/374378a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885480				2022-12-28	WOS:A1995QN63000065
J	SAINT, S; BENT, S; VITTINGHOFF, E; GRADY, D				SAINT, S; BENT, S; VITTINGHOFF, E; GRADY, D			ANTIBIOTICS IN CHRONIC OBSTRUCTIVE PULMONARY-DISEASE EXACERBATIONS - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CHRONIC-BRONCHITIS; THERAPY; TRIALS	Objective.-A meta-analysis of randomized trials was performed to estimate the effectiveness of antibiotics in treating exacerbations of chronic obstructive pulmonary disease (COPD). Data Sources.-English-language studies published from 1955 through 1994 were retrieved using MEDLINE, Index Medicus, bibliographies, and consultation with experts. MEDLINE search terms included ''COPD,'' ''chronic bronchitis,'' and ''antibiotic(s). Study Selection.-Only randomized trials that enrolled patients having an exacerbation of COPD, used an antibiotic in the treatment group and placebo in the control group, and provided sufficient data to calculate an effect size were included in the meta-analysis. Data Extraction.-Descriptive and outcome data from each study were independently abstracted by two authors. Data Synthesis.-Overall summary effect size of the nine trials satisfying all inclusion criteria was 0.22 (95% confidence interval [CI], 0.10 to 0.34), indicating a smalt benefit in the antibiotic-treated group. Similar analysis of the six studies that provided data on peak expiratory flow rate changes revealed a summary effect size of 0.19 (95% CI, 0.03 to 0.35) and a summary change in peak expiratory flow rate of 10.75 L/min (95% CI, 4.96 to 16.54 L/min) in favor of the antibiotic-treated group. Sensitivity analyses did not Significantly affect these results. Conclusions.-These analyses suggest a small but statistically significant improvement due to antibiotic therapy in patients with exacerbations of COPD. This antibiotic-associated improvement may be clinically significant, especially in patients with low baseline flow rates.	VET AFFAIRS MED CTR,MED SERV,SAN FRANCISCO,CA 94105; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA; SAN FRANCISCO GEN HOSP,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center			Saint, Sanjay/AAF-5126-2019					ANDERSON G, 1983, POSTGRAD MED J, V59, P179; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196, DOI 10.7326/0003-4819-106-2-196; BERRY DG, 1960, LANCET, V1, P137; BURROWS B, 1972, ANN INTERN MED, V77, P993, DOI 10.7326/0003-4819-77-6-993; CHODOSH S, 1992, AM J MED S6A, V91, pS87; Elmes P C, 1965, Br Med J, V2, P904; ELMES PC, 1957, BRIT MED J, V2, P1272, DOI 10.1136/bmj.2.5056.1272; FANTL JA, 1994, OBSTET GYNECOL, V83, P12; FEAR EC, 1962, BRIT J DIS CHEST, V56, P153, DOI 10.1016/S0007-0971(62)80012-6; GROSS NJ, 1990, CHEST, V97, pS19, DOI 10.1378/chest.97.2_Supplement.19S; HENNEKENS CH, 1987, STAT MED, V6, P397, DOI 10.1002/sim.4780060337; HIGGINS M, 1984, Chest, V85, p3S; HOSKER H, 1994, BRIT MED J, V308, P871, DOI 10.1136/bmj.308.6933.871; JORGENSEN A F, 1992, Scandinavian Journal of Primary Health Care, V10, P7, DOI 10.3109/02813439209014027; KESTEN S, 1993, CHEST, V104, P254, DOI 10.1378/chest.104.1.254; LIGHT RJ, 1987, STAT MED, V6, P221, DOI 10.1002/sim.4780060304; LIGHT RJ, 1984, SUMMING UP SCI REV R; LITTENBERG B, 1988, JAMA-J AM MED ASSOC, V259, P1678, DOI 10.1001/jama.259.11.1678; LODE H, 1991, CLIN THER, V13, P149; MANRESA F, 1987, LANCET, V2, P394; MCHARDY VU, 1980, BRIT J DIS CHEST, V74, P228, DOI 10.1016/0007-0971(80)90048-0; MURPHY TF, 1992, AM REV RESPIR DIS, V146, P1067, DOI 10.1164/ajrccm/146.4.1067; NICOTRA MB, 1982, ANN INTERN MED, V97, P18, DOI 10.7326/0003-4819-97-1-18; PETERSEN ES, 1967, ACTA MED SCAND, V182, P293; PETITTI D, 1994, META ANAL DECISION A; PINES A, 1968, BMJ-BRIT MED J, V2, P735, DOI 10.1136/bmj.2.5607.735; PINES A, 1972, British Journal of Diseases of the Chest, V66, P107, DOI 10.1016/S0007-0971(72)80032-9; RODNICK JE, 1988, WESTERN J MED, V149, P347; ROSENTHAL R, 1982, PSYCHOL BULL, V92, P500, DOI 10.1037/0033-2909.92.2.500; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; Skudlarska B A, 1992, Mo Med, V89, P289; STALEY H, 1993, J ANTIMICROB CHEMOTH, V31, P193, DOI 10.1093/jac/31.2.193; TAGER I, 1975, NEW ENGL J MED, V292, P563, DOI 10.1056/NEJM197503132921105; Tager I B, 1977, Med Times, V105, P85; WOOLCOCK AJ, 1989, CHEST, V96, pS302, DOI 10.1378/chest.96.3.302S; YUSUF S, 1987, STAT MED, V6, P281, DOI 10.1002/sim.4780060314; 1962, AM REV RESPIR DIS, V85, P762; 1987, AM REV RESPIR DIS, V136, P225; 1987, LANCET, V2, P23; 1975, LANCET, V1, P505; 1994, STAT ABSTR US 1994, P95	41	395	401	1	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					957	960		10.1001/jama.273.12.957	http://dx.doi.org/10.1001/jama.273.12.957			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884956				2022-12-28	WOS:A1995QM17300032
J	ORRELL, MW; ODWYER, AM				ORRELL, MW; ODWYER, AM			DEMENTIA, AGING, AND THE STRESS-CONTROL SYSTEM	LANCET			English	Editorial Material							ALZHEIMERS		UNIV CAMBRIDGE, DEPT PSYCHIAT, CAMBRIDGE, ENGLAND	University of Cambridge	ORRELL, MW (corresponding author), UCL, SCH MED, DEPT PSYCHIAT, LONDON W1N 8AA, ENGLAND.			Orrell, Martin/0000-0002-1169-3530				AMADUCCI L, 1992, INT J GERIATR PSYCH, V7, P383, DOI 10.1002/gps.930070602; BRAYNE C, 1988, LANCET, V1, P1265; BROE GA, 1990, NEUROLOGY, V40, P1699; DODT C, 1991, J CLIN ENDOCR METAB, V72, P272, DOI 10.1210/jcem-72-2-272; ELLIOTT EM, 1993, BRAIN RES, V602, P84, DOI 10.1016/0006-8993(93)90245-I; FRENCH SL, 1992, AM J COMMUN PSYCHOL, V20, P243, DOI 10.1007/BF00940838; JORM AF, 1991, INT J EPIDEMIOL S2, V20, P43; MILLER AH, 1994, AM J PSYCHIAT, V151, P267; Mullan Michael J., 1993, International Review of Psychiatry, V5, P351, DOI 10.3109/09540269309037798; OBRIEN JT, 1993, INT J GERIATR PSYCH, V8, P887, DOI 10.1002/gps.930081103; SAPOLSKY RM, 1990, BIOL PSYCHIAT, V27, P937, DOI 10.1016/0006-3223(90)90032-W; SAPOLSKY RM, 1986, ENDOCR REV, V7, P285	12	14	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 18	1995	345	8951					666	667		10.1016/S0140-6736(95)90862-5	http://dx.doi.org/10.1016/S0140-6736(95)90862-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM732	7885120				2022-12-28	WOS:A1995QM73200003
J	TAKALA, AK; JERO, J; KELA, E; RONNBERG, PR; KOSKENNIEMI, E; ESKOLA, J				TAKALA, AK; JERO, J; KELA, E; RONNBERG, PR; KOSKENNIEMI, E; ESKOLA, J			RISK-FACTORS FOR PRIMARY INVASIVE PNEUMOCOCCAL DISEASE AMONG CHILDREN IN FINLAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFLUENZAE TYPE-B; STREPTOCOCCUS-PNEUMONIAE; HEMOPHILUS-INFLUENZAE; HAEMOPHILUS-INFLUENZAE; OTITIS-MEDIA; EPIDEMIOLOGY; INFECTIONS; POPULATION; INFANTS; COUNTY	Objective.-To study risk factors for invasive pneumococcal disease among children. Design.-A population-based, case-control study of 149 cases and 284 controls matched for age, sex, and place of residence. Setting.-Finland, November 1986 through November 1989. Patients and Controls.-Patients were identified from a prospective nationwide surveillance for invasive bacterial diseases among children (0 to 15 years of age) through a network of bacteriologic laboratories. Two matched controls were selected for 135 of the cases and one matched control for 14 of the cases from the respective cases' child health center or school. Questionnaires evaluating potential risk factors were mailed to families of cases and controls. Results.-An increased risk for invasive pneumococcal disease among children younger than 2 years was associated with day care center attendance (odds ratio [OR]=36; 95% confidence interval [CI], 5.7 to 233), family day care (OR=4.4; 95% CI, 1.7 to 12), and history of frequent otitis media (OR=8.8; 95% CI, 2.5 to 31). For those at least 2 years of age, existence of siblings younger than school-age indicated increased risk for invasive pneumococcal disease (OR=2.2; 95% CI, 1.1 to 4.4). Conclusions.-Day care center attendance is a major risk factor for invasive pneumococcal disease for children younger than 2 years, with significantly higher risk than the risk associated with family day care.			TAKALA, AK (corresponding author), NATL PUBL HLTH INST,DEPT INFECT DIS & EPIDEMIOL,MANNERHEIMINTIE 170A,SF-00300 HELSINKI,FINLAND.							ANDERSSON B, 1986, J INFECT DIS, V153, P232, DOI 10.1093/infdis/153.2.232; ANIANSSON G, 1990, MICROB PATHOGENESIS, V8, P315, DOI 10.1016/0882-4010(90)90090-D; BLACK S, 1994, 34TH INT C ANT AG CH; BLUESTONE CD, 1992, PEDIATR INFECT DIS J, V11, pS7, DOI 10.1097/00006454-199208001-00002; BROOME CV, 1981, REV INFECT DIS, V3, P277; BURMAN LA, 1985, REV INFECT DIS, V7, P133; CHERIAN T, 1994, JAMA-J AM MED ASSOC, V271, P695, DOI 10.1001/jama.271.9.695; COCHI SL, 1986, J PEDIATR-US, V108, P887, DOI 10.1016/S0022-3476(86)80922-2; CORTESE MM, 1992, ARCH INTERN MED, V152, P2277, DOI 10.1001/archinte.152.11.2277; DAGAN R, 1992, JAMA-J AM MED ASSOC, V268, P3328, DOI 10.1001/jama.268.23.3328; DAVIDSON M, 1989, JAMA-J AM MED ASSOC, V261, P715, DOI 10.1001/jama.261.5.715; ESKOLA J, 1992, JAMA-J AM MED ASSOC, V268, P3323, DOI 10.1001/jama.268.23.3323; FADEN H, 1991, ANN OTO RHINOL LARYN, V100, P612, DOI 10.1177/000348949110000802; FRASER DW, 1973, J INFECT DIS, V127, P271, DOI 10.1093/infdis/127.3.271; GRAY BM, 1982, AM J EPIDEMIOL, V116, P692, DOI 10.1093/oxfordjournals.aje.a113452; HALL PG, 1988, REPORT COMMITTEE INF, P328; HENDLEY JO, 1975, J INFECT DIS, V132, P55, DOI 10.1093/infdis/132.1.55; ISTRE GR, 1985, J PEDIATR-US, V106, P190, DOI 10.1016/S0022-3476(85)80285-7; JACOBS NM, 1979, PEDIATRICS, V64, P296; KARMA P, 1987, ANN OTO RHINOL LARYN, V96, pS1; KLEIN JO, 1981, REV INFECT DIS, V3, P246; LEHMANN D, 1992, J INFECT DIS, V165, pS20, DOI 10.1093/infdis/165-Supplement_1-S20; LUOTONEN J, 1981, SCAND J INFECT DIS, V13, P177, DOI 10.3109/inf.1981.13.issue-3.04; MCGOWAN JE, 1973, NEW ENGL J MED, V288, P1309, DOI 10.1056/NEJM197306212882501; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; MICHAELS RH, 1976, J CLIN MICROBIOL, V4, P413; NOHYNEK H, 1991, AM J DIS CHILD, V145, P618, DOI 10.1001/archpedi.1991.02160060036016; PETERSEN GM, 1991, AM J EPIDEMIOL, V134, P1212, DOI 10.1093/oxfordjournals.aje.a116024; REICHLER M, 1991, 31ST INT C ANT AG CH; SABHARWAL H, 1992, OCT EUR RES C RES C; SHAPIRO ED, 1994, J INFECT DIS, V169, P212, DOI 10.1093/infdis/169.1.212; SIPILA M, 1988, ACTA OTO-LARYNGOL, V106, P94, DOI 10.3109/00016488809107375; SNIADAK D, 1993, 33RD INT C ANT AG CH; TAKALA AK, 1992, J INFECT DIS, V165, pS11, DOI 10.1093/infdis/165-Supplement_1-S11; TAKALA AK, 1989, PEDIATR INFECT DIS J, V8, P297; TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P189, DOI 10.1097/00006454-199303000-00003; TAKALA AK, 1989, J PEDIATR-US, V115, P694, DOI 10.1016/S0022-3476(89)80644-4; TAKALA AK, 1994, DEV CLIN USES HAEMOP; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83; TODD JK, 1984, PEDIATR INFECT DIS J, V3, P159, DOI 10.1097/00006454-198403000-00021; VADHEIM CM, 1992, AM J EPIDEMIOL, V136, P221, DOI 10.1093/oxfordjournals.aje.a116488; VINTHER S, 1992, CLIN INFECT DIS, V15, P794; 1989, MMWR-MORBID MORTAL W, V38, P733	43	75	75	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 15	1995	273	11					859	864		10.1001/jama.273.11.859	http://dx.doi.org/10.1001/jama.273.11.859			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL402	7869556				2022-12-28	WOS:A1995QL40200023
J	LASIC, DD; PAPAHADJOPOULOS, D				LASIC, DD; PAPAHADJOPOULOS, D			LIPOSOMES REVISITED	SCIENCE			English	Editorial Material							STERICALLY STABILIZED LIPOSOMES; LONG-CIRCULATING LIPOSOMES; LIPID-COMPOSITION; HIGHLY EFFICIENT; MICE BEARING; DNA; DOXORUBICIN; PHARMACOKINETICS; VESICLES; DELIVERY		UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CANC RES INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	LASIC, DD (corresponding author), MEGABIOS CORP,863A MITTEN RD,BURLINGAME,CA 94010, USA.							AHMAD I, 1993, CANCER RES, V53, P1484; ALLEN TM, 1987, FEBS LETT, V223, P42, DOI 10.1016/0014-5793(87)80506-9; ALVING CR, 1992, BIOCHIM BIOPHYS ACTA, V1113, P307, DOI 10.1016/0304-4157(92)90004-T; BAR KL, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201; BEHR JP, 1986, TETRAHEDRON LETT, V27, P5861, DOI 10.1016/S0040-4039(00)85347-2; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; FRALEY R, 1981, BIOCHEMISTRY-US, V20, P6978, DOI 10.1021/bi00527a031; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; Gregoriadis G, 1993, LIPOSOME TECHNOLOGY; HARRIGAN PR, 1993, BIOCHIM BIOPHYS ACTA, V1149, P329, DOI 10.1016/0005-2736(93)90218-O; HUANG SK, 1993, AM J PATHOL, V143, P10; HUANG SK, 1992, CANCER RES, V52, P6774; HUANG SK, 1994, CANCER RES, V54, P2186; LASIC DD, 1992, FEBS LETT, V312, P255, DOI 10.1016/0014-5793(92)80947-F; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LASIC DD, 1994, ANGEW CHEM INT EDIT, V33, P1479; LASIC DD, 1993, LIPOSOMES PHYSICS AP; Lasic DD, 1995, STEALTH LIPOSOMES; LOPEZBERESTEIN G, 1989, LIPOSOMES THERAPY IN; MARTIN F, 1982, J BIOL CHEM, V275, P286; MARUYAMA K, 1990, P NATL ACAD SCI USA, V87, P5744, DOI 10.1073/pnas.87.15.5744; MAYHEW EG, 1992, INT J CANCER, V51, P302, DOI 10.1002/ijc.2910510221; NABEL EG, 1992, HUM GENE THER, V3, P649, DOI 10.1089/hum.1992.3.6-649; NICOLAU C, 1989, CRIT REV THER DRUG, V6, P239; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11460, DOI 10.1073/pnas.88.24.11460; Papahadjopoulos D., 1978, ANN NY ACAD SCI, V308, P1, DOI [10.1111/j.1749-6632.1978.tb22009.x, DOI 10.1111/J.1749-6632.1978.TB22009.X]; SCHUBER F, 1994, LIPOSOMES TOOLS BASI; STERNBERG B, 1994, FEBS LETT, V356, P361, DOI 10.1016/0014-5793(94)01315-2; VAAGE J, 1992, INT J CANCER, V51, P942, DOI 10.1002/ijc.2910510618; WILLIAMS SS, 1993, CANCER RES, V53, P3964; WILSON T, 1977, P NATL ACAD SCI USA, V74, P3471, DOI 10.1073/pnas.74.8.3471; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	33	436	531	4	39	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1275	1276		10.1126/science.7871422	http://dx.doi.org/10.1126/science.7871422			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871422				2022-12-28	WOS:A1995QK06800027
J	FALL, CHD; OSMOND, C; BARKER, DJP; CLARK, PMS; HALES, CN; STIRLING, Y; MEADE, TW				FALL, CHD; OSMOND, C; BARKER, DJP; CLARK, PMS; HALES, CN; STIRLING, Y; MEADE, TW			FETAL AND INFANT GROWTH AND CARDIOVASCULAR RISK-FACTORS IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							IMPAIRED GLUCOSE-TOLERANCE; ADULT LIFE; HEART-DISEASE; HYPERTENSION; MORTALITY; INUTERO; DEATH	Objective-To examine whether cardiovascular risk factors in women are related to fetal and infant growth. Design-Follow up study of women born 1923-30 whose birth weights and weights at one year were recorded. Setting-Hertfordshire. Subjects-297 women born and still living in East Hertfordshire. Main outcome measures-Plasma glucose and insulin concentrations during a standard oral glucose tolerance test; fasting plasma proinsulin and 32-33 split proinsulin concentrations; blood pressure; fasting serum total, low density lipoprotein and high density lipoprotein cholesterol, triglyceride, and apolipoprotein A I and B concentrations; and plasma fibrinogen and factor VII concentrations. Results-Fasting plasma concentrations of glucose, insulin, and 32-33 split proinsulin fell with increasing birth weight (P=0.04, P-0.002, and P=0.0002 respectively, when current body mass index was allowed for). Glucose and insulin concentrations 120 minutes after an oral glucose load showed similar trends (P=0.03 and P=0.02). Systolic blood pressure, waist:hip ratio, and serum triglyceride concentrations also fell with increasing birth weight (P=0.08, P=0.07, and P=0.07 respectively), while serum high density lipoprotein cholesterol concentrations rose (P=0.04). At each birth weight women who currently had a higher body mass index had higher levels of risk factors. Conclusion-In women, as in men, reduced fetal growth leads to insulin resistance and the associated disorders: raised blood pressure and high serum triglyceride and low serum high density lipoprotein cholesterol concentrations. The highest values of these coronary risk factors occur in people who were small at birth and become obese. In contrast with men, low rates of infant growth did not predict levels of risk factors in women.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND; ST BARTHOLOMEWS HOSP,WOLFSON INST PREVENT MED,MRC,EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of London; Queen Mary University London	FALL, CHD (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.			Osmond, Clive/0000-0002-9054-4655				[Anonymous], 1980, CLASSIFICATION OCCUP; Barker D, 1994, MOTHER BABIES DISEAS; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; FALL CHD, 1995, BRIT MED J, V310, P17, DOI 10.1136/bmj.310.6971.17; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FONTBONNE A, 1991, DIABETOLOGIA, V34, P356, DOI 10.1007/BF00405009; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; LAW CM, 1992, J EPIDEMIOL COMMUN H, V46, P184, DOI 10.1136/jech.46.3.184; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LUCAS A, 1991, CIBA F S, V156; MARTYN CN, IN PRESS BR HEART J; MCKEIGUE PM, 1994, DIABETIC MED S2, V11, pA17; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PHILLIPS DIW, 1994, DIABETIC MED, V11, P286, DOI 10.1111/j.1464-5491.1994.tb00273.x; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/s001250050157	23	353	364	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					428	432		10.1136/bmj.310.6977.428	http://dx.doi.org/10.1136/bmj.310.6977.428			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873947	Green Published			2022-12-28	WOS:A1995QJ24200017
J	OPELZ, G; HENDERSON, R				OPELZ, G; HENDERSON, R			INCIDENCE OF NON-HODGKIN-LYMPHOMA IN KIDNEY AND HEART-TRANSPLANT RECIPIENTS	LANCET			English	Article							LYMPHOPROLIFERATIVE DISORDER; OKT3	Organ transplant recipients receive immunosuppressive drugs to prevent graft rejection. This treatment has been associated with higher rates of non-Hodgkin lymphoma (NHL) than in the general population. We assessed the incidence of NHL in a multicentre study of 45 141 kidney transplant patients and 7634 heart transplant recipients. The NHL rate was especially high during the first post-transplant year among both kidney transplant recipients (101 cases vs 2.7 expected in general population; 224 per 10(5)) and heart transplant recipients (93 vs 0.6 expected; 1218 per 10(5)). The incidence was lower in subsequent years (43 and 371 per 10(5) in kidney and heart transplant recipients). During the first year the NHL incidence was higher in North America than in Europe (relative risk 2.12 [95% CI 1.55-2.89]). There were also significant increases in risk for patients who received rejection prophylaxis with antilymphocyte antibodies (1.80 [1.31-2.46]) and in those who received both cyclosporin and azathioprine rather than another immunosuppressive combination (1.47 [1.03-2.08]). This study quantified the risk of NHL after kidney or heart transplantation. It suggests that the risk of NHL is related to the aggressiveness of the immunosuppressive regimen.	UNIV NEWCASTLE UPON TYNE,DEPT MATH & STAT,NEWCASTLE TYNE NE1 7RU,TYNE & WEAR,ENGLAND	Newcastle University - UK	OPELZ, G (corresponding author), UNIV HEIDELBERG,INST IMMUNOL,DEPT TRANSPLANTAT IMMUNOL,NEUENHEIMER FELD 305,D-69120 HEIDELBERG,GERMANY.							COCKFIELD SM, 1991, TRANSPLANT P, V23, P1106; CRAWFORD DH, 1980, LANCET, V1, P1355, DOI 10.1016/S0140-6736(80)91800-0; LAND W, 1987, TRANSPLANT P, V19, P130; McCullagh P., 1989, GENERALIZED LINEAR M, DOI DOI 10.1007/978-1-4899-3242-6; MUIR C, 1987, CANCER INCIDENCE 5 C, V5; PENN I, 1991, TRANSPLANT P, V23, P1101; PENN I, 1969, TRANSPLANT P, V1, P106; SWINNEN LJ, 1990, NEW ENGL J MED, V323, P1723, DOI 10.1056/NEJM199012203232502; YORK L J, 1990, Viral Immunology, V3, P127, DOI 10.1089/vim.1990.3.127; 1992, COLLABORATIVE TRANSP, V4	10	532	540	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1514	1516		10.1016/S0140-6736(05)80084-4	http://dx.doi.org/10.1016/S0140-6736(05)80084-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902900				2022-12-28	WOS:A1993MM40200011
J	BROGAN, P; CHILDS, C; PHILLIPS, BM; MOULTON, C				BROGAN, P; CHILDS, C; PHILLIPS, BM; MOULTON, C			EVALUATION OF A TYMPANIC THERMOMETER IN CHILDREN	LANCET			English	Letter									MANCHESTER ROYAL INFIRM,DEPT ACCID & EMERGENCY MED,MANCHESTER M13 9WL,LANCS,ENGLAND	University of Manchester	BROGAN, P (corresponding author), BOOTH HALL CHILDRENS HOSP,MANCHESTER,ENGLAND.		Brogan, Paul A/C-6992-2008; Childs, Charmaine/G-9928-2012	Brogan, Paul/0000-0001-6178-6893				ABBEY JC, 1976, AM J NURS, V76, P1375; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; KENNEY RD, 1990, PEDIATRICS, V85, P854; MILEWSKI A, 1991, CLIN PEDIATR, V30, P13, DOI 10.1177/0009922891030004S05; SHENEP JL, 1991, CLIN PEDIATR, V30, P36, DOI 10.1177/000992289103000411; TERNDRUP TE, 1991, CLIN PEDIATR, V30, P18, DOI 10.1177/0009922891030004S07	6	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1364	1365		10.1016/0140-6736(93)92275-X	http://dx.doi.org/10.1016/0140-6736(93)92275-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901656				2022-12-28	WOS:A1993MJ03900041
J	ETSUDA, H; MIZUNO, K; ARAKAWA, K; SATOMURA, K; SHIBUYA, T; ISOJIMA, K				ETSUDA, H; MIZUNO, K; ARAKAWA, K; SATOMURA, K; SHIBUYA, T; ISOJIMA, K			ANGIOSCOPY IN VARIANT ANGINA - CORONARY-ARTERY SPASM AND INTIMAL INJURY	LANCET			English	Article							ACETYLCHOLINE; INVIVO; PIGS; PATHOGENESIS; VASOSPASM	Studies in pigs and dogs show that intimal injury is related to coronary artery spasm; it is not known whether intimal injury is related to coronary artery spasm in human beings. We examined intima at the site of coronary artery spasm by percutaneous transluminal coronary angioscopy in 10 of 13 consecutive patients with variant angina. Coronary artery spasms occurred spontaneously or were induced by intracoronary acetylcholine (10-100 mug). Angioscopy showed intimal injuries (haemorrhage, flap, thrombus, or ulcer) in 4 of the 10. We suggest that intimal injury is related to coronary artery spasm in human beings.	NATL DEF MED COLL,DEPT INTERNAL MED 1,3-2 NAMIKI,TOKOROZAWA,SAITAMA 359,JAPAN	National Defense Medical College - Japan								EGASHIRA K, 1986, CIRCULATION, V74, P826, DOI 10.1161/01.CIR.74.4.826; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GANZ P, 1985, AM J CARDIOL, V56, P11; GERRITY RG, 1977, AM J PATHOL, V89, P313; GERTZ SD, 1981, CIRCULATION, V63, P476, DOI 10.1161/01.CIR.63.3.476; KASKI JC, 1989, J AM COLL CARDIOL, V14, P1456, DOI 10.1016/0735-1097(89)90382-3; LAM JYT, 1987, CIRCULATION, V75, P243, DOI 10.1161/01.CIR.75.1.243; LAMPING KG, 1985, CIRC RES, V57, P46, DOI 10.1161/01.RES.57.1.46; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MACALPIN RN, 1980, AM J CARDIOL, V46, P143, DOI 10.1016/0002-9149(80)90616-5; MCFADDEN EP, 1991, NEW ENGL J MED, V324, P648, DOI 10.1056/NEJM199103073241002; MIZUNO K, 1992, NEW ENGL J MED, V326, P287, DOI 10.1056/NEJM199201303260502; MIZUNO K, 1989, J AM COLL CARDIOL, V13, P363, DOI 10.1016/0735-1097(89)90513-5; MIZUNO K, 1991, LANCET, V337, P809, DOI 10.1016/0140-6736(91)92514-3; NAGASAWA K, 1989, CIRC RES, V65, P272, DOI 10.1161/01.RES.65.2.272; OKAMOTO Y, 1991, Japanese Circulation Journal, V55, P95; SHIMOKAWA H, 1983, SCIENCE, V221, P560, DOI 10.1126/science.6408736; VANHOUTTE PM, 1989, CIRCULATION, V80, P1, DOI 10.1161/01.CIR.80.1.1; YASUE H, 1986, CIRCULATION, V74, P955, DOI 10.1161/01.CIR.74.5.955	19	21	22	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1322	1324		10.1016/0140-6736(93)92245-O	http://dx.doi.org/10.1016/0140-6736(93)92245-O			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901635				2022-12-28	WOS:A1993MJ03900008
J	COLLINS, J				COLLINS, J			FEMALE INTUITION	LANCET			English	Editorial Material											COLLINS, J (corresponding author), GUYS HOSP,NEWCOMEN CTR,LONDON SE1 9RT,ENGLAND.							KOLB B, 1990, FUNDAMENTALS HUMAN N, P440; MONEY JOHN, 1966, J MED GENET, V3, P47, DOI 10.1136/jmg.3.1.47; RESKENIELSEN E, 1982, CORTEX, V18, P181, DOI 10.1016/S0010-9452(82)80001-4; YOUNG S, 1992, NEW SCI         1121, P2; ZINN AR, 1993, TRENDS GENET, V9, P90, DOI 10.1016/0168-9525(93)90230-F	5	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1188	1189		10.1016/0140-6736(93)92178-V	http://dx.doi.org/10.1016/0140-6736(93)92178-V			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901522				2022-12-28	WOS:A1993MG27400002
J	BAUR, X; AMMON, J; CHEN, Z; BECKMANN, U; CZUPPON, AB				BAUR, X; AMMON, J; CHEN, Z; BECKMANN, U; CZUPPON, AB			HEALTH RISK IN HOSPITALS THROUGH AIRBORNE ALLERGENS FOR PATIENTS PRESENSITIZED TO LATEX	LANCET			English	Note							RUBBER	Two nurses had to stop practising because of severe work-related allergic respiratory or systemic symptoms. Both developed similar symptoms within a short time when they attended hospitals as outpatients or visitors or consulted a doctor or dentist, even when they had no direct contact with latex articles. The airborne latex allergen concentration in one room that induced symptoms was 128 ng per m3. In skinprick tests both women showed positive reactions to the phosphated cornstarch powder used to prevent latex gloves sticking together, but only when the powder had been in contact with latex. This powder seems a likely vehicle for the airborne latex allergen.	RUHR UNIV BOCHUM,PROFESS ASSOC INST OCCUPAT MED,W-4630 BOCHUM,GERMANY; RES INST HAZARDOUS SUBST,BOCHUM,GERMANY	Ruhr University Bochum								AAS K, 1972, ACTA ALLERGOL, V27, P439; AXELSSON JGK, 1987, ALLERGY, V42, P46, DOI 10.1111/j.1398-9995.1987.tb02186.x; CZUPPON AB, IN PRESS J ALLERGY C; JAEGER D, 1991, Journal of Allergy and Clinical Immunology, V87, P268, DOI 10.1016/0091-6749(91)91796-V; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; SLATER JE, 1990, ANN ALLERGY, V65, P411; SWANSON MC, 1993, J ALLERGY CLIN IMMUN, V91, P385; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x	8	57	59	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1148	1149		10.1016/0140-6736(93)92127-F	http://dx.doi.org/10.1016/0140-6736(93)92127-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901479				2022-12-28	WOS:A1993MF19800013
J	HOWARD, R				HOWARD, R			SCHIZOPHRENIA AND THE GUT, AGAIN	LANCET			English	Editorial Material							LIPID-PEROXIDATION; PERMEABILITY				HOWARD, R (corresponding author), INST PSYCHIAT,LONDON SE5,ENGLAND.			Howard, Robert/0000-0002-3071-2338				BEAUCHAMP RO, 1983, CRC CR REV TOXICOL, V11, P169, DOI 10.3109/10408448309128255; HUMAD S, 1988, FREE RADICAL RES COM, V5, P101, DOI 10.3109/10715768809066917; KOVALEVA ES, 1989, ZH NEVROPATOL PSIKH, V89, P108; Kretschmer Ernst, 1925, PHYSIQUE CHARACTER; LAMBERT MT, 1989, BRIT J PSYCHIAT, V155, P619; PHILLIPS M, 1993, J CLIN PATHOL, V46, P861, DOI 10.1136/jcp.46.9.861; SMYTHIES JR, 1963, SCHIZOPHRENIA CHEM M; VANGOSSUM A, 1989, EUR RESPIR J, V2, P787; WEITZ ZW, 1991, LANCET, V337, P933, DOI 10.1016/0140-6736(91)91569-G; WOOD NC, 1987, BRIT J PSYCHIAT, V150, P853, DOI 10.1192/bjp.150.6.853	10	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1128	1129		10.1016/0140-6736(93)92118-D	http://dx.doi.org/10.1016/0140-6736(93)92118-D			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901470				2022-12-28	WOS:A1993MF19800004
J	WATKINS, H; MCKENNA, WJ; THIERFELDER, L; SUK, HJ; ANAN, R; ODONOGHUE, A; SPIRITO, P; MATSUMORI, A; MORAVEC, CS; SEIDMAN, JG; SEIDMAN, CE				WATKINS, H; MCKENNA, WJ; THIERFELDER, L; SUK, HJ; ANAN, R; ODONOGHUE, A; SPIRITO, P; MATSUMORI, A; MORAVEC, CS; SEIDMAN, JG; SEIDMAN, CE			MUTATIONS IN THE GENES FOR CARDIAC TROPONIN-T AND ALPHA-TROPOMYOSIN IN HYPERTROPHIC CARDIOMYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOSIN HEAVY-CHAIN; CLINICAL MANIFESTATIONS; MISSENSE MUTATION; PATHO-PHYSIOLOGY; EXPRESSION; INTERRELATIONS; SEQUENCE; THERAPY; DISEASE; LOCUS	Background. Familial hypertrophic cardiomyopathy can be caused by mutations in the genes for beta cardiac myosin heavy chain, alpha-tropomyosin, or cardiac troponin T. It is not known how often the disease is caused by mutations in the tropomyosin and troponin genes, and the associated clinical phenotypes have not been carefully studied. Methods. Linkage between polymorphisms of the alpha-tropomyosin gene or the cardiac troponin T gene and hypertrophic cardiomyopathy was assessed in 27 families. In addition, 100 probands were screened for mutations in the alpha-tropomyosin gene, and 26 were screened for mutations in the cardiac troponin T gene. Life expectancy, the incidence of sudden death, and the extent of left ventricular hypertrophy were compared in patients with different mutations. Results. Genetic analyses identified only one alpha-tropomyosin mutation, identical to one previously described. Five novel mutations in cardiac troponin were identified, as well as a further example of a previously described mutation. The clinical phenotype of four troponin T mutations in seven unrelated families was similar and was characterized by a poor prognosis (life expectancy, approximately 35 years) and a high incidence of sudden death. The mean (+/-SD) maximal thickness of the left ventricular wall in subjects with cardiac troponin T mutations (16.7+/-5.5 mm) was significantly less than that in subjects with beta cardiac myosin heavy-chain mutations (23.7+/-7.7 mm, P<0.001). Conclusions. Mutations in alpha-tropomyosin are a rare cause of familial hypertrophic cardiomyopathy, accounting for approximately 3 percent of cases. Mutations in cardiac troponin T account for approximately 15 percent of cases of familial hypertrophic cardiomyopathy in this referral-center population. These mutations are characterized by relatively mild and sometimes subclinical hypertrophy but a high incidence of sudden death. Genetic testing may therefore be especially important in this group.	HOWARD HUGHES MED INST,BOSTON,MA; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115; ST GEORGE HOSP,SCH MED,DEPT CARDIOL SCI,LONDON SW17 0RE,ENGLAND; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; FRANZ VOLHARD KLIN,BERLIN,GERMANY; MAX DELBRUCK CTR,BERLIN,GERMANY; OSPED GALLIERA,DIV CARDIOL,GENOA,ITALY; KYOTO UNIV,DEPT INTERNAL MED,KYOTO,JAPAN; CLEVELAND CLIN FDN,CTR ANESTHESIOL RES,CLEVELAND,OH	Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; St Georges University London; Harvard University; Harvard Medical School; Franz-Volhard Clinical Research Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ente Ospedaliero Ospedali Galliera; Kyoto University; Cleveland Clinic Foundation			McKenna, William J/C-3243-2008	McKenna, William J/0000-0001-7994-2460; Watkins, Hugh/0000-0002-5287-9016	Telethon [600] Funding Source: Medline	Telethon(Fondazione Telethon)		ANAN R, 1994, J CLIN INVEST, V93, P280, DOI 10.1172/JCI116957; CARRIER L, 1993, NAT GENET, V4, P311, DOI 10.1038/ng0793-311; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; Cox D. R., 1984, ANAL SURVIVAL DATA; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; GEISTERFERLOWRA.AA, 1990, CELL, V62, P999; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P277; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P276; HENGSTENBERG C, 1994, J MOL CELL CARDIOL, V26, P3, DOI 10.1006/jmcc.1994.1002; JARCHO JA, 1989, NEW ENGL J MED, V321, P1372, DOI 10.1056/NEJM198911163212005; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LATHROP GM, 1984, P NATL ACAD SCI-BIOL, V81, P3443, DOI 10.1073/pnas.81.11.3443; LEE ET, 1980, STATISTICAL METHODS; MACRAE CA, 1994, CIRCULATION, V89, P33, DOI 10.1161/01.CIR.89.1.33; MARON BJ, 1987, NEW ENGL J MED, V316, P844, DOI 10.1056/NEJM198704023161405; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MCKENNA WJ, 1989, DISEASES HEART, P933; MCKENNA WJ, 1995, METABOLIC MOL BASES, V3, P4253; MESNARD L, 1993, FEBS LETT, V328, P139, DOI 10.1016/0014-5793(93)80981-Y; PEARLSTONE JR, 1986, J BIOL CHEM, V261, P6795; PERRYMAN MB, 1992, J CLIN INVEST, V90, P271, DOI 10.1172/JCI115848; Solomon SD, 1993, J AM COLL CARDIOL, V22, P498, DOI 10.1016/0735-1097(93)90055-6; THIERFELDER L, 1993, P NATL ACAD SCI USA, V90, P6270, DOI 10.1073/pnas.90.13.6270; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOWNSEND PJ, 1994, GENOMICS, V21, P311, DOI 10.1006/geno.1994.1271; WATKINS H, 1993, NAT GENET, V3, P333, DOI 10.1038/ng0493-333; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; WATKINS H, 1994, HUM MOL GENET, V3, P2267, DOI 10.1093/hmg/3.12.2267; WATKINS H, 1994, CURRENT PROTOCOLS HU; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	31	696	722	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1058	1064		10.1056/NEJM199504203321603	http://dx.doi.org/10.1056/NEJM199504203321603			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898523				2022-12-28	WOS:A1995QT18700003
J	CALDWELL, SH; POPENOE, R				CALDWELL, SH; POPENOE, R			PERCEPTIONS AND MISPERCEPTIONS OF SKIN COLOR	ANNALS OF INTERNAL MEDICINE			English	Editorial Material								Case presentations are part of many clinicians' daily routines. The format for such presentations often involves stating the age, sex, and race of the patient in the opening description. However, although single-word racial labels such as ''black'' or ''white'' are of occasional help to the clinician, they are of limited diagnostic and therapeutic help in many routine cases. Because of their broad scope and lack of scientific clarity, these terms often poorly represent information-for example, about genetic risks and perceptions of disease-that they are supposed to convey. In many instances, they are superficial and potentially misleading terms that fail to serve the patient's medical needs. Demoting these terms from the opening line of routine case presentations shows a recognition of their limitations as scientific labels. Our patients will be better served by more detailed explorations of ethnicity, when germane, in the History of Present Illness or Social History sections of the case presentation in question.			CALDWELL, SH (corresponding author), UNIV VIRGINIA, HLTH SCI CTR, DIV GASTROENTEROL & HEPATOL, BOX 145, CHARLOTTESVILLE, VA 22908 USA.							BUCKLEY TE, 1994, VA MAG HIST BIOG, V102, P349; FINUCANE TE, 1990, J GEN INTERN MED, V5, P120, DOI 10.1007/BF02600511; Gould S. J., 1981, MISMEASURE OF MAN; HAIZLIP ST, 1994, SWEETER JUICE; HOLMES SJ, 1994, NY TIMES        0708; LEWONTIN RD, 1982, INTRO PHYSICAL ANTHR, P203; LOK ASF, 1994, HEPATOLOGY, V19, P1302, DOI 10.1002/hep.1840190531; MOLNAR S, 1983, HUMAN VARIATION RACE, P128; National Railways of Mexico, 1911, FACTS FIG MEX ITS GR; PACHTER LM, 1994, JAMA-J AM MED ASSOC, V271, P690, DOI 10.1001/jama.271.9.690; SHIPMAN P, 1994, CHRON HIGHER EDUC, V40, pB1; Shipman Pat., 1994, EVOLUTION RACISM HUM; STOECKLE JD, 1987, J GEN INTERN MED, V2, P119, DOI 10.1007/BF02596310; WALKER HK, 1990, CLIN METHODS HIST PH, P17; WULFSBERG EA, 1994, JAMA-J AM MED ASSOC, V271, P217, DOI 10.1001/jama.271.3.217	15	47	47	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					614	617		10.7326/0003-4819-122-8-199504150-00010	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00010			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887557				2022-12-28	WOS:A1995QR52500010
J	JACOBSON, JA; DANFORTH, DN; COWAN, KH; DANGELO, T; STEINBERG, SM; PIERCE, L; LIPPMAN, ME; LICHTER, AS; GLATSTEIN, E; OKUNIEFF, P				JACOBSON, JA; DANFORTH, DN; COWAN, KH; DANGELO, T; STEINBERG, SM; PIERCE, L; LIPPMAN, ME; LICHTER, AS; GLATSTEIN, E; OKUNIEFF, P			10-YEAR RESULTS OF A COMPARISON OF CONSERVATION WITH MASTECTOMY IN THE TREATMENT OF STAGE-I AND STAGE-II BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; RADIATION-THERAPY; RECURRENCE; SURGERY; IRRADIATION; LUMPECTOMY; CARCINOMA	Background. Breast-conservation therapy for early-stage breast cancer is now an accepted treatment, but there is still controversy about its comparability with mastectomy. Between 1979 and 1987, the National Cancer Institute conducted a randomized, single-institution trial comparing lumpectomy, axillary dissection, and radiation with mastectomy and axillary dissection for stage I and II breast cancer, We update the results of that trial after a median potential follow-up of 10.1 years. Methods. Two hundred forty-seven patients with clinical stage I and II breast cancer were randomly assigned to undergo either modified radical mastectomy or lumpectomy, axillary dissection, and radiation therapy, The 237 patients who actually underwent randomization have been followed for a median of 10.1 years, The primary points were overall survival and disease-free survival. Results. At 10 years overall survival was 75 percent for the patients assigned to mastectomy and 77 percent for those assigned to lumpectomy plus radiation (P=0.89). Disease-free survival at 10 years was 69 percent for the patients assigned to mastectomy and 72 percent for those assigned to lumpectomy plus radiation (P=0.93). The rate of local regional recurrence at 10 years was 10 percent after mastectomy and 5 percent after lumpectomy plus radiation (P=0.17) after recurrences successfully treated by mastectomy were censored from the analysis. Conclusions, In the management of stage I and II breast cancer, breast conservation with lumpectomy and radiation offers results at 10 years that are equivalent to those with mastectomy.	NCI,DIV CANC TREATMENT,CLIN ONCOL PROGRAM,SURG BRANCH,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,CLIN ONCOL PROGRAM,MED BRANCH,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,CLIN ONCOL PROGRAM,BIOSTAT & DATA MANAGEMENT SECT,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,CLIN ONCOL PROGRAM,CANC NURSING SERV,BETHESDA,MD 20892; UNIV MICHIGAN,MED CTR,DEPT RADIAT ONCOL,ANN ARBOR,MI 48109; GEORGETOWN UNIV HOSP,LOMBARDI CANC CTR,WASHINGTON,DC 20007; UNIV TEXAS,SW MED CTR,SIMMONS CANC CTR,DEPT RADIAT ONCOL,DALLAS,TX	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Michigan System; University of Michigan; Georgetown University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	JACOBSON, JA (corresponding author), NCI,DIV CANC TREATMENT,CLIN ONCOL PROGRAM,RADIAT ONCOL BRANCH,BLDG 10,RM B3-B69,BETHESDA,MD 20892, USA.							ABNER AL, 1993, J CLIN ONCOL, V11, P44, DOI 10.1200/JCO.1993.11.1.44; ANGELL M, 1994, NEW ENGL J MED, V330, P1448, DOI 10.1056/NEJM199405193302010; Blichert-Toft M, 1992, J Natl Cancer Inst Monogr, P19; BOYAGES J, 1990, RADIOTHER ONCOL, V19, P29, DOI 10.1016/0167-8140(90)90163-Q; CHAUVET B, 1990, INT J RADIAT ONCOL, V19, P1125, DOI 10.1016/0360-3016(90)90215-6; DANFORTH DN, 1986, J CLIN ONCOL, V4, P655, DOI 10.1200/JCO.1986.4.5.655; FISHER B, 1991, LANCET, V338, P327, DOI 10.1016/0140-6736(91)90475-5; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1989, NEW ENGL J MED, V320, P822, DOI 10.1056/NEJM198903303201302; FOWBLE BL, 1991, INT J RADIAT ONCOL, V21, P269, DOI 10.1016/0360-3016(91)90771-U; FRAASS BA, 1988, INT J RADIAT ONCOL, V14, P179, DOI 10.1016/0360-3016(88)90066-1; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KURTZ JM, 1987, INT J RADIAT ONCOL, V13, P1327, DOI 10.1016/0360-3016(87)90224-0; LICHTER AS, 1992, J CLIN ONCOL, V10, P976, DOI 10.1200/JCO.1992.10.6.976; LICHTER AS, 1983, COMPUT TOMOGR, P99; LIPPMAN ME, 1986, NCI MONOGRAPHS, V1, P99; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; SARRAZIN D, 1989, RADIOTHER ONCOL, V14, P177, DOI 10.1016/0167-8140(89)90165-5; STOTTER A, 1990, ANN SURG, V212, P166, DOI 10.1097/00000658-199008000-00009; STOTTER AT, 1989, CANCER-AM CANCER SOC, V64, P2217, DOI 10.1002/1097-0142(19891201)64:11<2217::AID-CNCR2820641106>3.0.CO;2-2; STRAUS K, 1992, MONOGR NATL CANCER I, V11, P27; van Dongen J A, 1992, J Natl Cancer Inst Monogr, P15; VERONESI U, 1990, EUR J CANCER, V26, P668, DOI 10.1016/0277-5379(90)90113-8	23	649	664	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					907	911		10.1056/NEJM199504063321402	http://dx.doi.org/10.1056/NEJM199504063321402			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877647				2022-12-28	WOS:A1995QP89300002
J	LIPTON, SA; GENDELMAN, HE				LIPTON, SA; GENDELMAN, HE			DEMENTIA ASSOCIATED WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RECEPTOR-MEDIATED NEUROTOXICITY; TUMOR-NECROSIS-FACTOR; VASOACTIVE-INTESTINAL-PEPTIDE; VIRUS-INFECTED MACROPHAGES; PRIMARY CORTICAL CULTURES; BLOOD-BRAIN-BARRIER; HIV COAT PROTEIN; NITRIC-OXIDE; CEREBROSPINAL-FLUID; ARACHIDONIC-ACID		HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT NEUROL,BOSTON,MA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT NEUROL,BOSTON,MA 02115; HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT NEUROL,BOSTON,MA; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115; UNIV NEBRASKA,MED CTR,DEPT PATHOL & MICROBIOL,VIRAL PATHOGENESIS LABF,OMAHA,NE; UNIV NEBRASKA,MED CTR,DEPT MED,OMAHA,NE 68105; UNIV NEBRASKA,MED CTR,EPPLEY INST RES CANC & ALLIED DIS,OMAHA,NE	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	LIPTON, SA (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT NEUROL,CELLULAR & MOLEC NEUROSCI LAB,300 LONGWOOD AVE,BOSTON,MA 02115, USA.		Gendelman, Howard E/G-8242-2012	Lipton, Stuart/0000-0002-3490-1259				BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BENOS DJ, 1994, P NATL ACAD SCI USA, V91, P494, DOI 10.1073/pnas.91.2.494; BRENNEMAN DE, 1988, NATURE, V335, P639, DOI 10.1038/335639a0; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; Budka H, 1991, BRAIN PATHOL, V1, P163, DOI 10.1111/j.1750-3639.1991.tb00656.x; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; BUZY J, 1992, BRAIN RES, V598, P10, DOI 10.1016/0006-8993(92)90161-2; CHEN HSV, 1992, J NEUROSCI, V12, P4427; DAWSON VL, 1993, P NATL ACAD SCI USA, V90, P3256, DOI 10.1073/pnas.90.8.3256; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; Dreyer E. B., 1994, Society for Neuroscience Abstracts, V20, P1049; DREYER EB, 1990, SCIENCE, V248, P364, DOI 10.1126/science.2326646; EVERALL IP, 1991, LANCET, V337, P1119, DOI 10.1016/0140-6736(91)92786-2; GELBARD HA, 1994, J VIROL, V68, P4628, DOI 10.1128/JVI.68.7.4628-4635.1994; GENDELMAN HE, 1994, J LEUKOCYTE BIOL, V56, P389, DOI 10.1002/jlb.56.3.389; GENIS P, 1992, J EXP MED, V176, P1703, DOI 10.1084/jem.176.6.1703; GIULIAN D, 1993, P NATL ACAD SCI USA, V90, P2769, DOI 10.1073/pnas.90.7.2769; GIULIAN D, 1990, SCIENCE, V250, P1593, DOI 10.1126/science.2148832; GOMATOS PJ, 1990, J IMMUNOL, V144, P4183; GRIFFIN DE, 1994, ANN NEUROL, V35, P592, DOI 10.1002/ana.410350513; GRIFFIN DE, 1991, NEUROLOGY, V41, P69, DOI 10.1212/WNL.41.1.69; HAYMAN M, 1993, NEUROSCIENCE, V53, P1, DOI 10.1016/0306-4522(93)90278-N; HEWETT SJ, 1994, NEURON, V13, P487, DOI 10.1016/0896-6273(94)90362-X; HEYES MP, 1991, ANN NEUROL, V29, P202, DOI 10.1002/ana.410290215; HEYES MP, 1992, BIOCHEM J, V283, P633, DOI 10.1042/bj2830633; KETZLER S, 1990, ACTA NEUROPATHOL, V80, P92, DOI 10.1007/BF00294228; KOENIG S, 1986, SCIENCE, V233, P1089, DOI 10.1126/science.3016903; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LEI SHZ, 1992, BRAIN RES, V598, P196, DOI 10.1016/0006-8993(92)90183-A; Lipton S A, 1991, Adv Pharmacol, V22, P271, DOI 10.1016/S1054-3589(08)60038-1; LIPTON S A, 1990, Society for Neuroscience Abstracts, V16, P289; LIPTON SA, 1992, EUR J NEUROSCI, V4, P1411, DOI 10.1111/j.1460-9568.1992.tb00167.x; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LIPTON SA, 1994, NATURE, V367, P320; LIPTON SA, 1993, ANN NEUROL, V33, P227, DOI 10.1002/ana.410330218; LIPTON SA, 1989, TRENDS NEUROSCI, V12, P265, DOI 10.1016/0166-2236(89)90026-X; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LIPTON SA, 1992, NEUROREPORT, V3, P913, DOI 10.1097/00001756-199210000-00023; LIPTON SA, 1992, TRENDS NEUROSCI, V15, P75, DOI 10.1016/0166-2236(92)90013-X; LIPTON SA, 1991, NEURON, V7, P111, DOI 10.1016/0896-6273(91)90079-F; LIPTON SA, 1992, NEUROLOGY, V42, P1403, DOI 10.1212/WNL.42.7.1403; LIPTON SA, 1994, NATURE, V367, P113, DOI 10.1038/367113a0; Lipton Stuart A., 1992, Society for Neuroscience Abstracts, V18, P757; LO TM, 1992, BRAIN RES, V594, P189, DOI 10.1016/0006-8993(92)91125-X; MCARTHUR JC, 1992, NEUROLOGY, V42, P1707, DOI 10.1212/WNL.42.9.1707; MESLIAH E, 1992, ANN NEUROL, V32, P321; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MOLLACE V, 1993, BIOCHEM BIOPH RES CO, V194, P439, DOI 10.1006/bbrc.1993.1839; MULLER WEG, 1992, EUR J PHARM-MOLEC PH, V226, P209, DOI 10.1016/0922-4106(92)90063-2; NOTTET SLM, IN PRESS J IMMUNOL; OLNEY JW, 1990, SCIENCE, V248, P596, DOI 10.1126/science.2185543; PETITO CK, 1992, ANN NEUROL, V32, P658, DOI 10.1002/ana.410320509; PIETRAFORTE D, 1994, J LEUKOCYTE BIOL, V55, P175, DOI 10.1002/jlb.55.2.175; POWER C, 1993, ANN NEUROL, V34, P339, DOI 10.1002/ana.410340307; PRICE RW, 1988, SCIENCE, V239, P586, DOI 10.1126/science.3277272; PULLIAM L, 1991, J CLIN INVEST, V87, P503, DOI 10.1172/JCI115024; SAITO Y, 1994, NEUROLOGY, V44, P474, DOI 10.1212/WNL.44.3_Part_1.474; SAVIO T, 1993, J NEUROSCI RES, V34, P265, DOI 10.1002/jnr.490340303; SEILHEAN D, 1993, NEUROLOGY, V43, P1492, DOI 10.1212/WNL.43.8.1492; SELMAJ KW, 1990, J IMMUNOL, V144, P129; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; SIMMONS ML, 1993, EUR J NEUROSCI, V5, P825, DOI 10.1111/j.1460-9568.1993.tb00934.x; SOLIVEN B, 1992, J NEUROSCI, V12, P2665; TENHULA WN, 1992, AM J OPHTHALMOL, V113, P14, DOI 10.1016/S0002-9394(14)75746-0; TOGGAS SM, 1994, NATURE, V367, P188, DOI 10.1038/367188a0; TORNATORE C, 1994, NEUROLOGY, V44, P481, DOI 10.1212/WNL.44.3_Part_1.481; TYOR WR, 1992, ANN NEUROL, V31, P349, DOI 10.1002/ana.410310402; VALONE FH, 1988, J IMMUNOL, V141, P3945; VOLTERRA A, 1992, J NEUROCHEM, V59, P600, DOI 10.1111/j.1471-4159.1992.tb09411.x; WAHL LM, 1989, P NATL ACAD SCI USA, V86, P621, DOI 10.1073/pnas.86.2.621; WESSELINGH SL, 1993, ANN NEUROL, V33, P576, DOI 10.1002/ana.410330604; WILEY CA, 1991, ANN NEUROL, V29, P651, DOI 10.1002/ana.410290613; Yeh Michael W., 1994, Society for Neuroscience Abstracts, V20, P451	76	433	448	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					934	940		10.1056/NEJM199504063321407	http://dx.doi.org/10.1056/NEJM199504063321407			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877652				2022-12-28	WOS:A1995QP89300007
J	PETTIFOR, JM; BIKLE, DD; CAVALEROS, M; ZACHEN, D; KAMDAR, MC; ROSS, FP				PETTIFOR, JM; BIKLE, DD; CAVALEROS, M; ZACHEN, D; KAMDAR, MC; ROSS, FP			SERUM LEVELS OF FREE 1,25-DIHYDROXYVITAMIN-D IN VITAMIN-D TOXICITY	ANNALS OF INTERNAL MEDICINE			English	Note							D-BINDING PROTEIN; HYPERVITAMINOSIS-D; ASSAY; METABOLITES	Objective: To determine the serum level of free 1,25-dihydroxyvitamin D [1,25-(OH)(2)D] in patients with vitamin D toxicity and to assess the in vitro effect of differing concentrations of vitamin D metabolites on the free serum levels of 1,25-(OH)(2)D. Design: 1) A case study of patients hospitalized with Vitamin D toxicity after accidentally ingesting a veterinary vitamin D concentrate and 2) an in vitro experiment in which vitamin D metabolites in various concentrations were added to normal serum and their effect was noted on percentage of free 1,25-(OH)(2)D. Patients: 11 patients (age range, 8 to 69 years) were studied 10 to 40 days after hospitalization for hypercalcemia. Measurements: Serum total 25-hydroxyvitamin D (25-OHD) and 1,25-(OH)(2)D levels were measured by radioreceptor assays. The percentage of free 1,25(OH)(2)D was measured by centrifugal ultrafiltration isodialysis and was used to calculate actual free 1,25(OH)(2)D levels. In the in vitro studies, vitamin D metabolites [25-OHD; 24,25-(OH)(2)D; 25,26-(OH)(2)D; and 25-OHD-26,23 lactone] were added to normal serum in concentrations expected to occur with vitamin D toxicity. The percentage of free 1,25-(OH)(2)D was measured by isodialysis. Results: All patients presented with marked hypercalcemia (mean calcium level, 3.99 +/- 0.33 mmol/L). Serum 25-OHD levels ranged from 847 to 1652 nmol/L, and total 1,25-(OH)(2)D levels (mean, 106 +/- 86 pmol/L) were elevated in only three patients. The percentage of free 1,25-(OH)(2)D (mean, 1.023% +/- 0.366%) was elevated in all nine patients in whom it was measured. Actual free 1,25-(OH)(2)D levels (mean, 856 +/- 600 fmol/L) were elevated in six of the nine patients. Total 1,25(OH)(2)D levels were correlated with 25-OHD levels (r = 0.66; P= 0.03), whereas total and free 1,25-(OH)(2)D levels were highly correlated (r = 0.957; P < 0.001). In the in vitro studies, the percentage of free 1,25-(OH)(2)D increased after 25-OHD or 24,25-(OH)(2)D was added. Conclusions: Although the patients had normal or near-normal total 1,25-(OH)(2)D values, most patients had elevated free 1,25-(OH)(2)D levels. These findings suggest that elevated free 1,25-(OH)(2)D levers might play a role in the pathogenesis of hypercalcemia in vitamin D toxicity.	UNIV WITWATERSRAND, JOHANNESBURG, SOUTH AFRICA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; UNIV NATAL, DURBAN 4001, SOUTH AFRICA	University of Witwatersrand; University of California System; University of California San Francisco; University of Kwazulu Natal			Pettifor, John/M-4579-2019	Pettifor, John/0000-0003-1155-0334				BIKLE DD, 1985, J CLIN ENDOCR METAB, V61, P969, DOI 10.1210/jcem-61-5-969; BIKLE DD, 1984, J CLIN INVEST, V74, P1966, DOI 10.1172/JCI111617; BIKLE DD, 1986, J CLIN ENDOCR METAB, V63, P954, DOI 10.1210/jcem-63-4-954; BOUILLON R, 1977, J CLIN ENDOCR METAB, V45, P225, DOI 10.1210/jcem-45-2-225; CHAPUY MC, 1990, METABOLIC MOL BASIS, P1824; COUNTS SJ, 1975, ANN INTERN MED, V82, P196, DOI 10.7326/0003-4819-82-2-196; HADDAD JG, 1971, J CLIN ENDOCR METAB, V33, P992, DOI 10.1210/jcem-33-6-992; HORST RL, 1979, BIOCHEM BIOPH RES CO, V89, P286, DOI 10.1016/0006-291X(79)90976-8; HORST RL, 1981, J CLIN INVEST, V67, P274, DOI 10.1172/JCI110023; HUGHES MR, 1976, J CLIN INVEST, V58, P61, DOI 10.1172/JCI108459; JACOBUS CH, 1992, NEW ENGL J MED, V326, P1173, DOI 10.1056/NEJM199204303261801; MASON RS, 1980, CLIN CHEM, V26, P444; MAWER EB, 1985, CLIN SCI, V68, P135, DOI 10.1042/cs0680135; ORIORDAN JLH, 1982, VITAMIN D CHEM BIOCH, P751; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; SHEPARD RM, 1980, ARCH BIOCHEM BIOPHYS, V202, P43, DOI 10.1016/0003-9861(80)90404-X; VIETH R, 1990, BONE MINER, V11, P267, DOI 10.1016/0169-6009(90)90023-9	17	88	91	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					511	513		10.7326/0003-4819-122-7-199504010-00006	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00006			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872586				2022-12-28	WOS:A1995QP00800006
J	WATTS, GF				WATTS, GF			FAMILIAL HYPERCHOLESTEROLEMIA REGRESSION STUDY AND ITS IMPLICATIONS	LANCET			English	Editorial Material							CORONARY ATHEROSCLEROSIS; LIPOPROTEIN(A); DISEASE				WATTS, GF (corresponding author), UNIV WESTERN AUSTRALIA, DEPT MED, PERTH, WA, AUSTRALIA.			Watts, Gerald/0000-0003-2276-1524				ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; DAHLEN GH, 1994, ATHEROSCLEROSIS, V108, P111, DOI 10.1016/0021-9150(94)90106-6; GIBSON M, 1992, AM J CARDIOL, V69, P1286, DOI 10.1016/0002-9149(92)91222-P; GORDON BR, 1994, AM J CARDIOL, V74, P1109, DOI 10.1016/0002-9149(94)90461-8; Gordon Bruce R., 1994, Current Opinion in Lipidology, V5, P69, DOI 10.1097/00041433-199402000-00011; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; MARBURGER C, 1994, AM J CARDIOL, V73, P742, DOI 10.1016/0002-9149(94)90874-5; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WATTS GF, 1994, CLIN CHEM, V40, P2240	12	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	1995	345	8953					807	808		10.1016/S0140-6736(95)92958-4	http://dx.doi.org/10.1016/S0140-6736(95)92958-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898224				2022-12-28	WOS:A1995QQ19500003
J	BRYSON, YJ; PANG, S; WEI, LS; DICKOVER, R; DIAGNE, A; CHEN, ISY				BRYSON, YJ; PANG, S; WEI, LS; DICKOVER, R; DIAGNE, A; CHEN, ISY			CLEARANCE OF HIV-INFECTION IN A PERINATALLY INFECTED INFANT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SERONEGATIVE HOMOSEXUAL MEN; POLYMERASE CHAIN-REACTION; ANTIBODY-PRODUCTION; TYPE-1 INFECTION; BRAIN-TISSUE; DRUG-ABUSERS; CHILDREN; RESPONSES; EXPOSURE	Background. We describe a child who was identified shortly after birth as infected with the human immunodeficiency virus type 1 (HIV-1), but whose infection appears to have completely cleared. Asymptomatic HIV-1 infection was diagnosed in the mother during the fourth month of pregnancy. The infant was delivered vaginally at 36 weeks, received no blood products, and was not breast-fed. Methods and Results. HIV-1 was detected by culture of the infant's peripheral-blood mononuclear cells at 19 and 51 days of age. Plasma from the infant was also culture-positive for HIV-1 at 51 days of age by DNA polymerase chain reaction (PCR). Nucleotide-sequence analysis of HIV-1 DNA showed extremely close homology of the cultures obtained 32 days apart, and forensic markers of genetic identity for the two cultures were identical. Hence, inadvertent viral contamination or error in the collection of specimens was highly unlikely. At 12 months of age the infant was seronegative for HIV-1, and numerous subsequent cultures and tests by PCR have also been negative for HIV-1. The child is five years of age at this writing, is HIV-seronegative, and remains well, with normal growth and development and no laboratory or clinical evidence of HIV-1 infection. Conclusions. The infant we describe was infected perinatally with HIV-1, but the infection subsequently cleared and the infant remained without detectable HIV-1 infection five years later.	UNIV CALIF LOS ANGELES,SCH MED,DEPT UROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MICROBIOL & IMMUNOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	BRYSON, YJ (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,DIV INFECT DIS,LOS ANGELES,CA 90024, USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027550] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27550] Funding Source: Medline; NICHD NIH HHS [R01 HD26221, R01 HD30629] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUR A, 1989, LANCET, V2, P1045; BORKOWSKY W, 1990, AIDS RES HUM RETROV, V6, P673, DOI 10.1089/aid.1990.6.673; BORKOWSKY W, 1989, J PEDIATR-US, V114, P940, DOI 10.1016/S0022-3476(89)80434-2; BRYSON YJ, 1992, NEW ENGL J MED, V327, P1246, DOI 10.1056/NEJM199210223271718; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; CHEYNIER R, 1992, EUR J IMMUNOL, V22, P2211, DOI 10.1002/eji.1830220905; CLERICI M, 1991, J INFECT DIS, V164, P178, DOI 10.1093/infdis/164.1.178; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1991, J INFECT DIS, V164, P832; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HORSBURGH CR, 1989, LANCET, V2, P637; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; MARTIN NL, 1991, J PEDIATR-US, V118, P354, DOI 10.1016/S0022-3476(05)82146-8; MYERS G, 1992, HUMAN RETROVIRUSES A; PAHWA S, 1993, 9TH INT C AIDS 4TH S, V1, P306; PAN LZ, 1991, J INFECT DIS, V164, P962, DOI 10.1093/infdis/164.5.962; PANG S, 1991, J ACQ IMMUN DEF SYND, V4, P1082; PANG S, 1990, NATURE, V343, P85, DOI 10.1038/343085a0; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POLLACK H, 1993, P NATL ACAD SCI USA, V90, P2340, DOI 10.1073/pnas.90.6.2340; SALK J, 1993, SCIENCE, V260, P1270, DOI 10.1126/science.8098553; Sambrook J, 1989, MOL CLONING LABORATO; SHEARER GM, 1992, J CELL BIOCH E S, V16, P112; SORIANO V, 1990, LANCET, V335, P860, DOI 10.1016/0140-6736(90)90978-E; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; 1992, LANCET, V339, P1007	31	174	177	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					833	838		10.1056/NEJM199503303321301	http://dx.doi.org/10.1056/NEJM199503303321301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7870139				2022-12-28	WOS:A1995QP22800001
J	DUPIN, N; GRANDADAM, M; CALVEZ, V; GORIN, I; AUBIN, JT; HAVARD, S; LAMY, F; LEIBOWITCH, M; HURAUX, JM; ESCANDE, JP; AGUT, H				DUPIN, N; GRANDADAM, M; CALVEZ, V; GORIN, I; AUBIN, JT; HAVARD, S; LAMY, F; LEIBOWITCH, M; HURAUX, JM; ESCANDE, JP; AGUT, H			HERPESVIRUS-LIKE DNA-SEQUENCES IN PATIENTS WITH MEDITERRANEAN KAPOSIS-SARCOMA	LANCET			English	Note								DNA sequences closely related to herpesvirus-like sequences have been found in AIDS-associated Kaposi's sarcoma. Using PCR, we found herpesvirus-like DNA sequences in Kaposi's lesions and normal adjacent skin in five patients with Mediterranean Kaposi's sarcoma. We did not find these sequences in tissues from patients without Kaposi's sarcoma. Semi-quantitative PCR revealed many more herpesvirus-like sequences in Kaposi's lesions than in unaffected skin. Our results reinforce the hypothesis that an infectious agent closely related to gamma-herpesvirus is implicated in the pathogenesis of Mediterranean and AIDS-associated Kaposi's sarcoma.	GRP HOSP PITIE SALPETRIERE,VIROL LAB,CNRS,EP 57,F-75634 PARIS,FRANCE; TARNIER HOSP,DEPT DERMATOL,PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite			GRANDADAM, Marc/GNP-7470-2022	Dupin, Nicolas/0000-0002-6237-4951				CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; LAURE F, 1988, LANCET, V2, P538; SAIKI RK, 1988, SCIENCE, V39, P487; SCHULZ TF, 1995, NATURE, V373, P17, DOI 10.1038/373017a0; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	7	353	364	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					761	762		10.1016/S0140-6736(95)90642-8	http://dx.doi.org/10.1016/S0140-6736(95)90642-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891488				2022-12-28	WOS:A1995QN70100013
J	MCNAMEE, D				MCNAMEE, D			TAXOLS PEDIGREE	LANCET			English	Editorial Material																		1995, NATURE, V374, P11; 1995, NATURE, V374, P208	2	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					743	743		10.1016/S0140-6736(95)90634-7	http://dx.doi.org/10.1016/S0140-6736(95)90634-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891481				2022-12-28	WOS:A1995QN70100005
J	HURIE, MB; GENNIS, MA; HERNANDEZ, LV; DINDZANS, VJ; DAVIS, JP				HURIE, MB; GENNIS, MA; HERNANDEZ, LV; DINDZANS, VJ; DAVIS, JP			PREVALENCE OF HEPATITIS-B MARKERS AND MEASLES, MUMPS, AND RUBELLA ANTIBODIES AMONG JEWISH REFUGEES FROM THE FORMER SOVIET-UNION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SEROSURVEY; RECRUITS	Objective.-To assess the prevalence of hepatitis B virus (HBV) infection and immunity to measles, mumps, and rubella among refugees from the former Soviet Union (FSU). Design.-Descriptive study. Setting.-Soviet Immigrant Health Care Program, Sinai Samaritan Hospital, Milwaukee, Wis. Patients.-Consecutive sample of 496 Jewish refugees from the FSU presenting for new arrival screening from December 1, 1990, through January 11, 1993. Outcome Measures.-Hepatitis B surface antigen (HBsAg), hepatitis B core antibody, hepatitis B surface antibody, and measles, mumps, and rubella antibodies. Results.-At least one hepatitis B marker was detected in 22% of the refugees, and HBsAg was detected in 0.4%. The rate of HBV infection (any marker present) increased with increasing age, ranging from 4% among those aged 0 through 19 years to 31% among those aged 50 through 59 years (chi(2) test for trend, 13.5; P<.001). Among those aged 0 through 19 years, 19% lacked antibody to measles, 8% lacked antibody to mumps, and 13% lacked antibody to rubella. Refugees who were less than 30 years of age were more than twice as likely to lack antibodies to measles, mumps, or rubella compared with those who were 30 years of age or older (relative risk, 2.8; 95% confidence interval, 1.8 to 4.2; P<.001). Conclusions.-In our sample of Jewish refugees from the FSU (primarily Ukraine, Russia, and Belorussia), the rate of HBsAg positivity was low, suggesting that routine screening for HBV infection is not needed. Seronegativity to measles, mumps, and rubella was relatively common among those less than 30 years old. Those refugees who were born after 1957 should be given combined measles, mumps, and rubella vaccine unless their written documentation indicates previous receipt of these antigens according to the immunization schedule recommended in the United States.	UNIV WISCONSIN, SCH MED, SINAI SAMARITAN MED CTR, MILWAUKEE, WI USA; UNIV WISCONSIN, DEPT PEDIAT, MADISON, WI USA; UNIV WISCONSIN, DEPT PREVENT MED, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Milwaukee; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	HURIE, MB (corresponding author), BUR PUBL HLTH, WISCONSIN DIV HLTH, COMMUN DIS SECT, 1414 E WASHINGTON AVE, ROOM 167, MADISON, WI 53703 USA.							[Anonymous], 1994, MMWR Recomm Rep, V43, P1; Brinton K, 1992, Nurse Pract, V17, P21, DOI 10.1097/00006205-199204000-00008; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; KNAUS W, 1981, INSIDE RUSSIAN MED, P137; MAYNARD JE, 1989, REV INFECT DIS, V11, pS574; MILLER B, 1990, TB NOTES         SUM, P9; MORGANCAPNER P, 1988, BRIT MED J, V297, P770, DOI 10.1136/bmj.297.6651.770; SEALE JR, 1987, J ROY SOC MED, V80, P301, DOI 10.1177/014107688708000515; SOBESLAVSKY O, 1980, B WORLD HEALTH ORGAN, V58, P621; STRUEWING JP, 1993, AM J PUBLIC HEALTH, V83, P1717, DOI 10.2105/AJPH.83.12.1717; 1992, MMWR-MORBID MORTAL W, V41, P89; 1989, MMWR-MORBID MORTAL W, V38, P818; 1991, MMWR-MORBID MORTAL W, V40, P784; 1993, REFUGEE REP, V14, P8	14	6	6	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					954	956		10.1001/jama.273.12.954	http://dx.doi.org/10.1001/jama.273.12.954			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884955				2022-12-28	WOS:A1995QM17300031
J	LUCCHINI, R; SOGO, JM				LUCCHINI, R; SOGO, JM			REPLICATION OF TRANSCRIPTIONALLY ACTIVE CHROMATIN	NATURE			English	Article							RIBOSOMAL-RNA GENES; PSORALEN-CROSSLINKING; RDNA ENHANCER; DNA; FORK	IN eukaryotic cells, active genes and their regulatory sequences are organized into open chromatin conformations in which nucleosomes can be modified, disrupted or totally absent(1-3). It has been proposed that these characteristic chromatin structures and their associated factors might be directly inherited by the newly synthesized daughter strands during chromosome duplication(4-6). Here we show that in the yeast Saccharomyces cerevisiae, replication machinery entering upstream of a transcriptionally active ribosomal RNA gene generates two newly replicated coding regions regularly packaged into nucleosomes, indicating that the active chromatin structure cannot be directly inherited at the replication fork. Whereas the establishment of an exposed chromatin conformation at some newly replicated rRNA gene promoters can occur shortly after the passage of the replication fork, regeneration of the active chromatin structure along the coding region is always a post-replicative process involving disruption of preformed nucleosomes.			LUCCHINI, R (corresponding author), ETH HONGGERBERG,INST CELL BIOL,CH-8093 ZURICH,SWITZERLAND.							ALBERTS B, 1977, P INT S EUKARYOTIC G, P165; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; CHASMAN DI, 1990, GENE DEV, V4, P403; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; CONCONI A, 1984, J MOL BIOL, V178, P920, DOI 10.1016/0022-2836(84)90319-X; DAMMANN R, 1993, NUCLEIC ACIDS RES, V10, P2331; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; JACKSON V, 1990, BIOCHEMISTRY-US, V29, P719, DOI 10.1021/bi00455a019; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KULKENS T, 1989, CURR GENET, V16, P351, DOI 10.1007/BF00340714; LINSKENS MHK, 1988, MOL CELL BIOL, V8, P4927, DOI 10.1128/MCB.8.11.4927; LUCCHINI R, 1992, MOL CELL BIOL, V12, P4288, DOI 10.1128/MCB.12.10.4288; LUCCHINI R, 1994, MOL CELL BIOL, V14, P318, DOI 10.1128/MCB.14.1.318; MORROW BE, 1989, J BIOL CHEM, V264, P9061; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; SVAREN J, 1990, TRENDS GENET, V6, P52, DOI 10.1016/0168-9525(90)90074-G; WEINTRAUB H, 1985, CELL, V42, P705, DOI 10.1016/0092-8674(85)90267-3; WOLFFE AP, 1991, J CELL SCI, V99, P201	20	86	87	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					276	280		10.1038/374276a0	http://dx.doi.org/10.1038/374276a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885449				2022-12-28	WOS:A1995QM38700054
J	STEUER, A; CAVAN, DA; LOWY, C				STEUER, A; CAVAN, DA; LOWY, C			SARCOIDOSIS PRESENTING AFTER RESECTION OF AN ADRENOCORTICAL ADENOMA	BRITISH MEDICAL JOURNAL			English	Article									ST THOMAS HOSP,DEPT ENDOCRINOL,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust								AKAMA H, 1992, INTERNAL MED, V31, P1329, DOI 10.2169/internalmedicine.31.1329; RACCAH D, 1992, REV MED INTERNE, V13, P302, DOI 10.1016/S0248-8663(05)80307-8; SCADDING JG, 1967, SARCOIDOSIS, P307	3	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					567	568		10.1136/bmj.310.6979.567	http://dx.doi.org/10.1136/bmj.310.6979.567			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888931	Green Published			2022-12-28	WOS:A1995QK70000019
J	CLARKE, JT; PRANGE, R; BALLESTER, GE; TRAUGER, J; EVANS, R; REGO, D; STAPELFELDT, K; IP, W; GERARD, JC; HAMMEL, H; BALLAV, M; BENJAFFEL, L; BERTAUX, JL; CRISP, D; EMERICH, C; HARRIS, W; HORANYI, M; MILLER, S; STORRS, A; WEAVER, H				CLARKE, JT; PRANGE, R; BALLESTER, GE; TRAUGER, J; EVANS, R; REGO, D; STAPELFELDT, K; IP, W; GERARD, JC; HAMMEL, H; BALLAV, M; BENJAFFEL, L; BERTAUX, JL; CRISP, D; EMERICH, C; HARRIS, W; HORANYI, M; MILLER, S; STORRS, A; WEAVER, H			HST FAR-ULTRAVIOLET IMAGING OF JUPITER DURING THE IMPACTS OF COMET SHOEMAKER-LEVY-9	SCIENCE			English	Article							HUBBLE-SPACE-TELESCOPE; POLAR AURORA	Hubble Space Telescope far-ultraviolet images of Jupiter during the Shoemaker-Levy 9 impacts show the impact regions darkening over the 2 to 3 hours after the impact, becoming darker and more extended than at longer wavelengths, which indicates that ultraviolet-absorbing gases or aerosols are more extended, more absorbing, and at higher altitudes than the absorbers of visible light, Transient auroral emissions were observed near the magnetic conjugate point of the K impact site just after that impact. The global auroral activity was fainter than average during the impacts, and a variable auroral emission feature was observed inside the southern auroral oval preceding the impacts of fragments Q1 and Q2.	UNIV PARIS 11, CNRS, INST ASTROPHYS SPATIALE, F-91405 ORSAY, FRANCE; CNRS, INST ASTROPHYS SPATIALE, F-75014 PARIS, FRANCE; JET PROPULS LAB, PASADENA, CA 91109 USA; MAX PLANCK INST AERON, D-37191 KATLENBURG DUHM, GERMANY; UNIV LIEGE, INST ASTROPHYS, B-4000 LIEGE, BELGIUM; MIT, CAMBRIDGE, MA 02139 USA; CNRS, SERV AERON, F-91371 VERRIERES LE BUISSON, FRANCE; UNIV COLORADO, ATMOSPHER & SPACE PHYS LAB, BOULDER, CO 80309 USA; UCL, DEPT PHYS & ASTRON, LONDON, ENGLAND; SPACE TELESCOPE SCI INST, BALTIMORE, MD 21218 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Max Planck Society; University of Liege; Massachusetts Institute of Technology (MIT); Centre National de la Recherche Scientifique (CNRS); University of Colorado System; University of Colorado Boulder; University of London; University College London; Space Telescope Science Institute	CLARKE, JT (corresponding author), UNIV MICHIGAN, SPACE PHYS RES LAB, ANN ARBOR, MI 48109 USA.		Crisp, David/F-6642-2017; Stapelfeldt, Karl R/D-2721-2012; Clarke, John/C-8644-2013; Weaver, Harold A/D-9188-2016	Crisp, David/0000-0002-4573-9998; Weaver, Harold A/0000-0003-0951-7762; Stapelfeldt, Karl/0000-0002-2805-7338; GERARD, Jean-Claude/0000-0002-8565-8746; Horanyi, Mihaly/0000-0002-5920-9226; Miller, Steven/0000-0002-7159-6871				BALLESTER G, UNPUB; BOLIN O, 1994, GEOPHYS RES LETT, V21, P1063, DOI 10.1029/94GL00890; BOSLOUGH MB, 1994, GEOPHYS RES LETT, V21, P1555, DOI 10.1029/94GL01582; CALDWELL J, 1992, SCIENCE, V257, P1512, DOI 10.1126/science.257.5076.1512; CLARKE JS, UNPUB; CLARKE JT, 1980, ASTROPHYS J, V241, pL179, DOI 10.1086/183386; Connerney J.E.P., 1992, PLANETARY RADIO EMIS, P13; CONNERNEY JEP, COMMUNICATION; CRAVENS TE, 1994, GEOPHYS RES LETT, V21, P1075, DOI 10.1029/94GL01070; DEPATER I, UNPUB; DESSLER AJ, 1994, B AM ASTRON SOC, V26, P1593; DOLS V, 1992, GEOPHYS RES LETT, V19, P1803, DOI 10.1029/92GL02104; FARRELL WM, 1994, GEOPHYS RES LETT, V21, P1067, DOI 10.1029/94GL01066; GERARD JC, 1993, J GEOPHYS RES-PLANET, V98, P18793, DOI 10.1029/93JE01334; GOMBOSI TI, 1989, J GEOPHYS RES, V94, P359, DOI 10.1029/JA094iA01p00359; HAMMEL HB, 1995, SCIENCE, V267, P1288, DOI 10.1126/science.7871425; HARRIS W, 6040 INT ASTR UN CIR; HARRIS WM, 1994, 6040 INT ASTR UN CIR; HARRIS WM, 1990, J GEOPHYS RES, V95, P10375; HERBERT F, 1994, GEOPHYS RES LETT, V21, P1047, DOI 10.1029/94GL00884; HOLTZMAN J, IN PRESS PUBL ASTRON; IP WH, 1994, GEOPHYS RES LETT, V21, P1051, DOI 10.1029/94GL01063; KELLOGG PJ, 1994, GEOPHYS RES LETT, V21, P1055, DOI 10.1029/94GL01293; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; PRANGE R, 1995, SCIENCE, V267, P1317, DOI 10.1126/science.7871430; PRYOR WR, 1991, ICARUS, V91, P161, DOI 10.1016/0019-1035(91)90135-G; SHOEMAKER CS, 1993, 5725 INT ASTR UN CIR; SOMMERIA J, UNPUB; TAUGER JT, 1994, ASTROPHYS J, V435, pL3; WAGENER R, 1985, ICARUS, V63, P222, DOI 10.1016/0019-1035(85)90007-7; WAGENER R, 1988, ICARUS, V74, P141, DOI 10.1016/0019-1035(88)90036-X; WAITE JH, 1994, J GEOPHYS RES-SPACE, V99, P14799, DOI 10.1029/94JA01005; WAITE JH, UNPUB; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424; WEST RA, 1995, SCIENCE, V267, P1296, DOI 10.1126/science.7871426; YEOMANS DK, 1993, 22197 MIN PLAN CIRC	37	59	59	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1302	1307		10.1126/science.7871427	http://dx.doi.org/10.1126/science.7871427			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871427				2022-12-28	WOS:A1995QK06800032
J	BRYDEN, AA; ROTHWELL, PJN; OREILLY, PH				BRYDEN, AA; ROTHWELL, PJN; OREILLY, PH			URINARY RETENTION WITH MISUSE OF ECSTASY	BRITISH MEDICAL JOURNAL			English	Letter											BRYDEN, AA (corresponding author), STEPPING HILL HOSP,STOCKPORT SK2 7JE,CHESHIRE,ENGLAND.							GREER G, 1986, J PSYCHOACTIVE DRUGS, V18, P319, DOI 10.1080/02791072.1986.10472364; HENRY JA, 1992, BRIT MED J, V305, P5, DOI 10.1136/bmj.305.6844.5; STERNBACH GL, 1992, POSTGRAD MED, V91, P169; WORSEY J, 1989, BRIT J UROL, V64, P320, DOI 10.1111/j.1464-410X.1989.tb06028.x	4	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					504	504		10.1136/bmj.310.6978.504a	http://dx.doi.org/10.1136/bmj.310.6978.504a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ598	7888894	Green Published			2022-12-28	WOS:A1995QJ59800026
J	RAIHA, IJ; PIHA, SJ; SEPPANEN, A; PUUKKA, P; SOURANDER, LB				RAIHA, IJ; PIHA, SJ; SEPPANEN, A; PUUKKA, P; SOURANDER, LB			PREDICTIVE VALUE OF CONTINUOUS AMBULATORY ELECTROCARDIOGRAPHIC MONITORING IN ELDERLY PEOPLE	BRITISH MEDICAL JOURNAL			English	Article							VENTRICULAR ECTOPIC BEATS; MYOCARDIAL-INFARCTION; HEART-DISEASE; FOLLOW-UP; ARRHYTHMIAS; POPULATION; FREQUENT; SUDDEN; DEATH; AGE	Objective-To determine the predictive value of findings on continuous ambulatory electrocardiographic monitoring in elderly subjects. Design-Retrospective cohort study. Ten year follow up of randomly selected elderly subjects who participated in ambulatory electrocardiography study in 1982, Mortality data derived from official registers. Setting-Turku, Finland. Subjects-480 people aged 65 or older in 1982 who were living in the community, of whom 72% agreed to participate. Main outcome measures-Mortality from cardiac and non-cardiac causes during 10 year follow up. Results-In the univariate analysis adjusted for age, risk of death from cardiac causes was increased among those with ventricular ectopy of more than 100 beats during the day (odds ratio 2.6; 99% confidence interval 1.4 to 6.1) or at night (3.3; 1.1 to 9.8) and in those with multifocal ventricular ectopic beats during the day (2.3; 1.0 to 5.0) or night (3.0; 1.3 to 7.1) compared with those with no ventricular ectopy. Sinoatrial pauses exceeding 1.5 seconds during the day (4.5; 1.8 to 11.1) were also associated with excess mortality from cardiac causes. None of the findings on ambulatory electrocardiography predicted death from non-cardiac causes. A further study of explanatory variables in the stepwise logistic regression analysis showed that sinoatrial pauses exceeding 1.5 seconds (4.0; 95% confidence interval 1.8 to 8.9) and night time multifocal ventricular ectopy (2.7; 1.2 to 5.9) predicted excess mortality from cardiac causes independently of age or clinically evident heart disease. Conclusion-Daytime sinoatrial pauses exceeding 1.5 seconds and night time multifocal ventricular ectopy in the ambulatory electrocardiogram predict increased mortality from cardiac causes independently of clinically evident cardiac diseases in unselected elderly subjects.	SOCIAL INSURANCE INST,RES CTR,SF-20720 TURKU,FINLAND		RAIHA, IJ (corresponding author), UNIV TURKU,DEPT GERIATR,KUNNALLISSAIRAALANTIE 20,SF-20700 TURKU,FINLAND.							BRODSKY M, 1977, AM J CARDIOL, V39, P390, DOI 10.1016/S0002-9149(77)80094-5; BUSBY MJ, 1989, J AM COLL CARDIOL, V14, P1659; CALIFF RM, 1982, AM J CARDIOL, V50, P23, DOI 10.1016/0002-9149(82)90004-2; CAMM AJ, 1980, AM HEART J, V99, P598, DOI 10.1016/0002-8703(80)90733-4; FLEG JL, 1992, AM J CARDIOL, V70, P748, DOI 10.1016/0002-9149(92)90553-B; FLEG JL, 1982, CHEST, V81, P302, DOI 10.1378/chest.81.3.302; GERSTEN G, 1976, PROG CARDIOVASC DIS, V77, P5; HINKLE LE, 1969, AM J CARDIOL, V24, P629, DOI 10.1016/0002-9149(69)90451-2; KANTELIP JP, 1986, AM J CARDIOL, V57, P398, DOI 10.1016/0002-9149(86)90760-5; KENNEDY HL, 1985, NEW ENGL J MED, V312, P193, DOI 10.1056/NEJM198501243120401; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; KOSTIS JB, 1979, AM J CARDIOL, V43, P420; LOWN B, 1971, CIRCULATION, V44, P130, DOI 10.1161/01.CIR.44.1.130; MANYARI DE, 1990, AM HEART J, V119, P1069, DOI 10.1016/S0002-8703(05)80236-4; MARTIN A, 1984, EUR HEART J, V5, P592, DOI 10.1093/oxfordjournals.eurheartj.a061710; MOSS AJ, 1979, CIRCULATION, V60, P998, DOI 10.1161/01.CIR.60.5.998; PIHA SJ, 1993, CLIN PHYSIOL, V13, P507, DOI 10.1111/j.1475-097X.1993.tb00466.x; ROSE GA, 1968, WHO MONOGRAPH SERIES, V56; SAVAGE DD, 1983, AM HEART J, V106, P582, DOI 10.1016/0002-8703(83)90706-8; SOURANDERLB, 1986, J CLIN EXP GERONTOL, V4, P315; VISMARA LA, 1977, J ELECTROCARDIOL, V10, P299, DOI 10.1016/S0022-0736(77)80001-0; 1979, NOMENCLATURE CRITERI, P188	22	14	15	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 12	1994	309	6964					1263	1267		10.1136/bmj.309.6964.1263	http://dx.doi.org/10.1136/bmj.309.6964.1263			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT033	7888847	Green Published			2022-12-28	WOS:A1994PT03300020
J	BURACK, JH; BARRETT, DC; STALL, RD; CHESNEY, MA; EKSTRAND, ML; COATES, TJ				BURACK, JH; BARRETT, DC; STALL, RD; CHESNEY, MA; EKSTRAND, ML; COATES, TJ			DEPRESSIVE SYMPTOMS AND CD4 LYMPHOCYTE DECLINE AMONG HIV-INFECTED MEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; FOLLOW-UP; AIDS; COHORT; HEALTH; RISK; MARKERS	Objective.-To investigate whether high levels of depressive symptomatology. at baseline predict more rapid decline of CD4 lymphocyte counts and progression of clinical disease in persons infected with the human immunodeficiency virus (HIV). Design.-Prospective cohort study with semiannual data collection waves and up to 66 months of follow-up. Setting.-Population-based probability sample of single men in areas of San Francisco with high case rates of the acquired immunodeficiency syndrome (AIDS). Subjects.-All 330 homosexual or bisexual men who by January 1985 had serological evidence of HIV infection but had not had an AIDS diagnosis. Analysis of CD4 lymphocyte change was performed for 277 subjects (83.9%) who had three or more CD4 lymphocyte counts recorded during the study period January 1985 through July 1990. Outcome Measures.-Depressive symptoms were assessed using the Center for Epidemiologic Studies-Depression scale (CES-D). All subjects were classified according to two indicators of depression: (1) as overall depressed using a cut point of 16 or higher on the complete CES-D, and (2) as affectively depressed using a cut point of more than 1 SD above the mean on a subscale of the CES-D measuring affective depression. Laboratory and symptom measures, antiretroviral use, demographics, and behavioral measures were also used. The primary outcome measure was the rate of change of the CD4 lymphocyte count. Secondary outcomes were AIDS-free survival and mortality. Results.-At baseline 65 subjects (19.7%) were classified as depressed on the overall scale and 53 (16.1%) were classified as depressed on the affective scale. The unadjusted mean rate of CD4 change was 38% greater for overall depressed subjects than for the overall nondepressed (-0.0812 vs -0.0588 x 10(9)/L [-81.2 vs -58.8/muL per year; P=.07) and 34% greater for affectively depressed subjects than for the affectively nondepressed (-0.0804 vs -0.0598 x 10(9)/L per year; P=.06). In hierarchical multivariate analysis controlling for antiretroviral use, symptoms, and other predictors, baseline overall depression was associated with an excess decline in CD4 count of -0.0285 x 10(9)/L per year (95% confidence interval, -0.0496 to -0.0073), and baseline affective depression was associated with an excess decline in CD4 count of -0.0236 x 10(9)/L per year (95% confidence interval, -0.0464 to -0.0008). Neither overall depression nor affective depression was significantly associated with earlier AIDS diagnosis or earlier mortality. Conclusions.-Overall depression and affective depression predicted a more rapid decline in CD4 lymphocyte counts; this association was not attributable to baseline physiological differences. While the mechanism of the association remains unknown and cannot be addressed directly by this study, the data suggest that it can be explained neither as simply a reflection of perceived somatic symptoms nor as the result of differences in recreational drug and alcohol use. Further study is necessary to determine whether treating depression can alter the course of HIV infection.	UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,74 NEW MONTGOMERY ST,SUITE 600,SAN FRANCISCO,CA 94105; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,AIDS PROGRAM,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL,DIV CLIN EPIDEMIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIMH NIH HHS [MH42459] Funding Source: Medline; PHS HHS [N01-A1-82515, N01-A1-32519] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ASCHER MS, 1993, NATURE, V362, P103, DOI 10.1038/362103a0; BORNSTEIN RA, 1991, ARCH NEUROL-CHICAGO, V48, P704, DOI 10.1001/archneur.1991.00530190050015; COOKE M, 1991, APR C ADH AIDS CLIN; DEGRUTTOLA V, 1991, J AM STAT ASSOC, V86, P569, DOI 10.2307/2290384; EKSTRAND ML, 1990, AM J PUBLIC HEALTH, V80, P973, DOI 10.2105/AJPH.80.8.973; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; GLASER R, 1987, Brain Behavior and Immunity, V1, P107, DOI 10.1016/0889-1591(87)90013-4; GOEDERT JJ, 1987, JAMA-J AM MED ASSOC, V257, P331, DOI 10.1001/jama.257.3.331; HAYS RB, 1992, J CONSULT CLIN PSYCH, V60, P463, DOI 10.1037/0022-006X.60.3.463; HERBERT TB, 1993, PSYCHOL BULL, V113, P472, DOI 10.1037/0033-2909.113.3.472; HOOVER DR, 1992, J ACQ IMMUN DEF SYND, V5, P794; HOPKINS A, 1990, BMDP STATISTICAL SOF, P769; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KASLOW RA, 1989, JAMA-J AM MED ASSOC, V261, P3424, DOI 10.1001/jama.261.23.3424; KATZ MH, 1992, ANN INTERN MED, V117, P797, DOI 10.7326/0003-4819-117-9-797_1; KEMENY ME, IN PRESS NEUROPSYCHI; LANG W, 1987, JAMA-J AM MED ASSOC, V257, P326, DOI 10.1001/jama.257.3.326; MOSS AR, 1988, BRIT MED J, V296, P745, DOI 10.1136/bmj.296.6624.745; OSMOND DH, 1991, AIDS, V5, P505, DOI 10.1097/00002030-199105000-00005; PERSKY VW, 1987, PSYCHOSOM MED, V49, P435, DOI 10.1097/00006842-198709000-00001; PIAZZA T, 1989, 3 U CAL CAL SURV RES; RABKIN JG, 1993, HOSP COMMUNITY PSYCH, V44, P162; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; ROYCE RA, 1991, AIDS, V5, P355, DOI 10.1097/00002030-199104000-00001; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; Solomon G F, 1989, Psychiatr Med, V7, P47; VALENTINE F T, 1990, AIDS (London), V4, pS201; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P1037; WINKELSTEIN W, 1987, JAMA-J AM MED ASSOC, V257, P321, DOI 10.1001/jama.257.3.321; 1987, MMWR MORB MORTAL S2S, V36, P1	30	268	270	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1993	270	21					2568	2573		10.1001/jama.270.21.2568	http://dx.doi.org/10.1001/jama.270.21.2568			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ266	7901433				2022-12-28	WOS:A1993MJ26600023
J	SEINO, Y; TOMITA, Y; TAKANO, T; HAYAKAWA, H				SEINO, Y; TOMITA, Y; TAKANO, T; HAYAKAWA, H			EARLY IDENTIFICATION OF CARDIAC EVENTS WITH SERUM TROPONIN-T IN PATIENTS WITH UNSTABLE ANGINA	LANCET			English	Letter											SEINO, Y (corresponding author), NIPPON MED COLL,DEPT MED 1,1-1-5 SENDAGI,BUNKYO KU,TOKYO 113,JAPAN.							BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; CAMM CW, 1992, NEW ENGL J MED, V327, P146; DONNELLY R, 1993, LANCET, V341, P410, DOI 10.1016/0140-6736(93)92996-7; GERHARDT W, 1991, CLIN CHEM, V37, P1405	4	46	47	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1236	1237		10.1016/0140-6736(93)92216-G	http://dx.doi.org/10.1016/0140-6736(93)92216-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901550				2022-12-28	WOS:A1993MG27400040
J	PHILLIPS, DP; RUTH, TE; WAGNER, LM				PHILLIPS, DP; RUTH, TE; WAGNER, LM			PSYCHOLOGY AND SURVIVAL	LANCET			English	Article							METASTATIC BREAST-CANCER; PSYCHOSOCIAL FACTORS; MOOD	We examined the deaths of 28 169 adult Chinese-Americans, and 412 632 randomly selected, matched controls coded ''white'' on the death certificate. Chinese-Americans, but not whites, die significantly earlier than normal (1.3-4.9 yr) if they have a combination of disease and birth year which Chinese astrology and medicine consider ill-fated. The more strongly a group is attached to Chinese traditions, the more years of life are lost. Our results hold for nearly all major causes of death studied. The reduction in survival cannot be completely explained by a change in the behaviour of the Chinese patient, doctor, or death-registrar, but seems to result at least partly from psychosomatic processes.	UNIV CALIF SAN DIEGO,DEPT MATH,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT POLIT SCI,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego	PHILLIPS, DP (corresponding author), UNIV CALIF SAN DIEGO,DEPT SOCIOL,LA JOLLA,CA 92093, USA.							Beinfield H., 1991, HEAVEN EARTH GUIDE C; CASSILETH BR, 1985, NEW ENGL J MED, V312, P1551, DOI 10.1056/NEJM198506133122406; COLON EA, 1991, PSYCHOSOMATICS, V32, P420, DOI 10.1016/S0033-3182(91)72045-8; CRAWFORD EA, 1990, CHINESE ELEMENTAL AS; DEAN C, 1989, J PSYCHOSOM RES, V33, P561, DOI 10.1016/0022-3999(89)90063-9; DEROGATIS LR, 1979, JAMA-J AM MED ASSOC, V242, P1504, DOI 10.1001/jama.242.14.1504; GOODWIN JS, 1987, JAMA-J AM MED ASSOC, V258, P3125, DOI 10.1001/jama.258.21.3125; GREER S, 1991, PSYCHOL MED, V21, P43, DOI 10.1017/S003329170001463X; GREER S, 1979, LANCET, V2, P785, DOI 10.1016/S0140-6736(79)92127-5; HISLOP TG, 1987, J CHRON DIS, V40, P729; JAMISON RN, 1987, J CLIN ONCOL, V5, P768, DOI 10.1200/JCO.1987.5.5.768; JENSEN AB, 1991, CANCER TREAT REV, V18, P191, DOI 10.1016/0305-7372(91)90007-M; Kaptchuk T, 1983, WEB HAS NO WEAVER; LAU T, 1979, HDB CHINESE HOROSCOP; LEVENSON JL, 1991, PSYCHOSOMATICS, V32, P124, DOI 10.1016/S0033-3182(91)72083-5; PALOS S, 1971, CHINESE ART HEALING; PHILLIPS DP, 1988, LANCET, V2, P728; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; PHILLIPS DP, 1992, PSYCHOSOM MED, V54, P532, DOI 10.1097/00006842-199209000-00001; REDD WH, 1991, CANCER, V67, P813, DOI 10.1002/1097-0142(19910201)67:3+<813::AID-CNCR2820671411>3.0.CO;2-W; ROSENTHAL R, 1978, PSYCHOL BULL, V85, P185, DOI 10.1037/0033-2909.85.1.185; Rosenthal R, 1991, METAANALYTIC PROCEDU; SILBERFARB PM, 1991, J CLIN ONCOL, V9, P2219, DOI 10.1200/JCO.1991.9.12.2219; SPIEGEL D, 1989, LANCET, V2, P888; Sun R., 1974, ASIAN ANIMAL ZODIAC; Williams C.A.S., 1976, OUTLINES CHINESE SYM; YANCHI L, 1988, ESSENTIAL BOOK TRADI, V1; ZONDERMAN AB, 1989, JAMA-J AM MED ASSOC, V262, P1191, DOI 10.1001/jama.262.9.1191; 1969, VITAL STATISTICS US; 1980, INT CLASSIFICATION D; 1979, SMOKING HLTH REPORT; 1980, CENSUS POPULATION HO; 1967, 8TH REVISION INT CLA; 1969, CALIFORNIA MORTALITY	34	67	67	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1142	1145		10.1016/0140-6736(93)92124-C	http://dx.doi.org/10.1016/0140-6736(93)92124-C			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MF198	7901476				2022-12-28	WOS:A1993MF19800010
J	DEBOER, W; DRIESSEN, W; JANSZ, A; TYTGAT, G				DEBOER, W; DRIESSEN, W; JANSZ, A; TYTGAT, G			EFFECT OF ACID SUPPRESSION ON EFFICACY OF TREATMENT FOR HELICOBACTER-PYLORI INFECTION	LANCET			English	Article							DUODENAL-ULCER; GASTRIC-MUCOSA; OMEPRAZOLE; THERAPY; AMOXICILLIN	Eradication of Helicobacter pylori from the stomach by triple therapy with bismuth, tetracycline, and metronidazole cures peptic ulcer disease. We investigated whether concomitant acid inhibition with omeprazole would improve the results of triple therapy. 108 consecutive patients with peptic-ulcer disease and biopsy-proven H pylori infection were randomised to 7 days of triple therapy with or without omeprazole 20 mg twice daily. Patients in the omeprazole-treated group were pretreated with 3 days of omeprazole. Eradication of H pylori was assessed by 10 endoscopic biopsies for urease test, histology, and culture 4-6 weeks treatment. 53 of 54 (98.1%) patients treated omeprazole were cured compared with 45 of 54 (83.3%) of those not treated (p=0.02), a difference in efficacy of 14.8% (95% CI 4.2-25.4%). Most side effects were mild and did not interfere with compliance; 105 patients (97.2%) finished treatment. Gastro-intestinal side effects were significantly fewer in the omeprazole group. We conclude that the addition of omeprazole to triple therapy improves efficacy, lessens side effects, and is sufficiently efficacious to obviate the need for a diagnostic test of cure in compliant patients.	ST JOSEPH HOSP,DEPT INTERNAL MED,5500 MB VELDHOVEN,NETH ANTILLES; ST JOSEPH HOSP,DEPT MICROBIOL,5500 MB VELDHOVEN,NETH ANTILLES; ACAD MED CENTRUM,DEPT GASTROENTEROL,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam								ALASSI MT, 1994, ALIMENT PHARM THERAP, V8, P259; BAYERDORFFER E, 1992, EUR J GASTROEN HEPAT, V4, P697; BECX MCJM, 1990, LANCET, V335, P539, DOI 10.1016/0140-6736(90)90772-W; BELL GD, 1992, ALIMENT PHARM THERAP, V6, P427; BORODY TJ, 1994, GASTROENTEROLOGY, V106, pA55; CEDERBERG C, 1992, GASTROENTEROLOGY, V103, P913, DOI 10.1016/0016-5085(92)90025-T; CEDERBERG C, 1905, SCAND J GASTROE S108, V20, P105; CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716; DASKALOPOULOS G, 1992, IR J MED SCI S10, V161, P16; DEBOER WA, 1994, AM J GASTROENTEROL, V89, P1993; DEBOER WA, 1994, J CLIN GASTROENTEROL, V19, P347, DOI 10.1097/00004836-199412000-00023; GOODWIN CS, 1992, HELICOBACTER PYLORI, P224; GRAHAM DY, 1993, GASTROENTEROLOGY, V105, P279, DOI 10.1016/0016-5085(93)90038-E; HOSKING SW, 1992, BRIT MED J, V305, P502, DOI 10.1136/bmj.305.6852.502; HOSKING SW, 1994, LANCET, V343, P508, DOI 10.1016/S0140-6736(94)91460-5; LABENZ J, 1993, AM J GASTROENTEROL, V88, P491; LABENZ J, 1994, AM J GASTROENTEROL, V89, P726; LAENZ J, 1994, SCAND J GASTRENTEROL, V29, P1070; LOGAN RPH, 1994, GUT, V35, P323, DOI 10.1136/gut.35.3.323; LOUW JA, 1992, EUR J GASTROEN HEPAT, V4, P481; MCCARTHY CJ, 1993, ALIMENT PHARM THER, V7, P463; MCNULTY CAM, 1988, J ANTIMICROB CHEMOTH, V22, P729, DOI 10.1093/jac/22.5.729; NOACH LA, 1994, EUR J GASTROEN HEPAT, V6, P585, DOI 10.1097/00042737-199407000-00004; NWOKOLO CU, 1991, GASTROENTEROLOGY, V101, P889, DOI 10.1016/0016-5085(91)90712-T; NWOKOLO CU, 1992, GASTROENTEROLOGY, V102, P163, DOI 10.1016/0016-5085(92)91796-7; RODIONOFF P, 1990, AUG WORLD C GASTR SY; THYS JC, 1993, SCAND J GASTROENTERO, V28, P934; WESTBLOM TU, 1991, DIGEST DIS SCI, V36, P25, DOI 10.1007/BF01300082; XIA HX, 1993, EUR J GASTROEN HEPAT, V5, P141, DOI 10.1097/00042737-199303000-00004; 1994, JAMA-J AM MED ASSOC, V272, P65	30	232	232	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					817	820		10.1016/S0140-6736(95)92962-2	http://dx.doi.org/10.1016/S0140-6736(95)92962-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898228				2022-12-28	WOS:A1995QQ19500007
J	BARDRAM, L; FUNCHJENSEN, P; JENSEN, P; CRAWFORD, ME; KEHLET, H				BARDRAM, L; FUNCHJENSEN, P; JENSEN, P; CRAWFORD, ME; KEHLET, H			RECOVERY AFTER LAPAROSCOPIC COLONIC SURGERY WITH EPIDURAL ANALGESIA, AND EARLY ORAL NUTRITION AND MOBILIZATION	LANCET			English	Note								The rate of postoperative recovery is determined by pain, stress-induced organ dysfunction, and limitations in conventional postoperative care. We attempted to provide ''stress-free'' colonic resection for neoplastic disease in eight elderly high-risk patients by a combination of laparoscopically assisted surgery, epidural analgesia, and early oral nutrition and mobilisation. Effective pain relief allowed early mobilisation, and hospital stay was reduced to 2 days without nausea, vomiting, or ileus. Postoperative fatigue and impairment in functional activity were avoided. Major advances in postoperative recovery can be achieved by early aggressive perioperative care in elderly high-risk patients undergoing colonic surgery.	HVIDOVRE UNIV HOSP,DEPT ANAESTHESIOL,DK-2650 HVIDOVRE,DENMARK	University of Copenhagen	BARDRAM, L (corresponding author), HVIDOVRE UNIV HOSP,DEPT GASTROINTESTINAL SURG,DK-2650 HVIDOVRE,DENMARK.							CHRISTENSEN T, 1993, WORLD J SURG, V17, P220, DOI 10.1007/BF01658930; FRANKLIN ME, 1993, WORLD J SURG, V17, P51, DOI 10.1007/BF01655705; GUILLOU PJ, 1994, SURG ENDOSC-ULTRAS, V8, P669, DOI 10.1007/BF00678563; JAKEWAYS MSR, 1994, BRIT J SURG, V81, P127, DOI 10.1002/bjs.1800810146; Kehlet H., 1993, PRINCIPLES PRACTICE, P1218; KHELET H, 1991, CAN J SURG, V34, P565; MOINICHE S, IN PRESS EUR J SURG; MONSON JRT, 1992, LANCET, V340, P831, DOI 10.1016/0140-6736(92)92694-B; NDUKA CC, 1994, BRIT J SURG, V81, P648, DOI 10.1002/bjs.1800810506; WATTERS JM, 1993, ANN SURG, V218, P380, DOI 10.1097/00000658-199309000-00017	10	392	402	6	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					763	764		10.1016/S0140-6736(95)90643-6	http://dx.doi.org/10.1016/S0140-6736(95)90643-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891489				2022-12-28	WOS:A1995QN70100014
J	PARSONS, CA; STASIAK, A; BENNETT, RJ; WEST, SC				PARSONS, CA; STASIAK, A; BENNETT, RJ; WEST, SC			STRUCTURE OF A MULTISUBUNIT COMPLEX THAT PROMOTES DNA BRANCH MIGRATION	NATURE			English	Article							ESCHERICHIA-COLI; RUVB PROTEINS; HOLLIDAY JUNCTION; HELICASE	THE RuvA and RuvB proteins of Escherichia coli, which are induced in response to DNA damage, are important in the formation of heteroduplex DNA during genetic recombination and related recombinational repair processes(1). In vitro studies show that RuvA binds Holliday junctions(2-5) and acts as a specificity factor that targets the RuvB ATPase, a hexameric ring protein(6,7), to the junction. Together, RuvA and RuvB promote branch migration, an ATP-dependent reaction that increases the length of the heteroduplex DNA(3,8-10). Electron microscopic visualization of RuvAB now provides a new insight into the mechanism of this process. We observe the formation of a tripartite protein complex in which RuvA binds the crossover and is sandwiched between two hexameric rings of RuvB. The Holliday junction within this complex adopts a square-planar structure. We propose a molecular model for branch migration, a unique feature of which is the role played by the two oppositely oriented RuvB ring motors.	IMPERIAL CANC RES FUND,GENET RECOMBINAT LAB,S MIMMS EN6 3LD,HERTS,ENGLAND; UNIV LAUSANNE,ULTRASTRUCT ANAL LAB,CH-1015 LAUSANNE,SWITZERLAND	University of Lausanne			Stasiak, Andrzej/E-5551-2010	Stasiak, Andrzej/0000-0002-0398-1989; West, Stephen/0000-0001-8848-9418; Bennett, Richard/0000-0001-7563-484X				ADAMS DE, 1995, J MOL BIOL, V247, P404, DOI 10.1006/jmbi.1995.0149; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DUCKETT DR, 1990, EMBO J, V9, P583, DOI 10.1002/j.1460-2075.1990.tb08146.x; DUCKETT DR, 1988, CELL, V55, P79, DOI 10.1016/0092-8674(88)90011-6; HIOM K, 1995, CELL, V80, P787, DOI 10.1016/0092-8674(95)90357-7; IWASAKI H, 1992, GENE DEV, V6, P2214, DOI 10.1101/gad.6.11.2214; IYPE LE, 1994, J BIOL CHEM, V269, P24967; LILLEY DMJ, 1993, ANNU REV BIOPH BIOM, V22, P299, DOI 10.1146/annurev.bb.22.060193.001503; MCCULLOCH R, 1994, EMBO J, V13, P1844, DOI 10.1002/j.1460-2075.1994.tb06453.x; MITCHELL AH, 1994, J MOL BIOL, V243, P208, DOI 10.1006/jmbi.1994.1648; MULLER B, 1993, J BIOL CHEM, V268, P17179; MULLER B, 1992, EMBO J, V11, P2685, DOI 10.1002/j.1460-2075.1992.tb05334.x; PANYUTIN IG, 1994, P NATL ACAD SCI USA, V91, P2021, DOI 10.1073/pnas.91.6.2021; PARSONS CA, 1993, J MOL BIOL, V232, P397, DOI 10.1006/jmbi.1993.1399; PARSONS CA, 1992, P NATL ACAD SCI USA, V89, P5452, DOI 10.1073/pnas.89.12.5452; SHIBA T, 1991, P NATL ACAD SCI USA, V88, P8445, DOI 10.1073/pnas.88.19.8445; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TSANEVA IR, 1992, MOL GEN GENET, V235, P1, DOI 10.1007/BF00286175; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WEST SC, 1994, CELL, V76, P9, DOI 10.1016/0092-8674(94)90168-6	22	161	161	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					375	378		10.1038/374375a0	http://dx.doi.org/10.1038/374375a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885479				2022-12-28	WOS:A1995QN63000064
J	AYER, DE; LAWRENCE, QA; EISENMAN, RN				AYER, DE; LAWRENCE, QA; EISENMAN, RN			MAD-MAX TRANSCRIPTIONAL REPRESSION IS MEDIATED BY TERNARY COMPLEX-FORMATION WITH MAMMALIAN HOMOLOGS OF YEAST REPRESSOR SIN3	CELL			English	Article							THYROID-HORMONE RECEPTOR; SACCHAROMYCES-CEREVISIAE; C-MYC; GENE-PRODUCT; PROTEIN; ACTIVATION; INTERACTS; HO; DIMERIZATION; EXPRESSION	The bHLH-ZIP protein Mad heterodimerizes with Max as a sequence-specific transcriptional repressor. Mad is rapidly induced upon differentiation, and the associated switch from Myc-Max to Mad-Max heterocomplexes seem to repress genes normally activated by Myc-Max. We have identified two related mammalian cDNAs that encode Mad-binding proteins. Both possess sequence homology with the yeast transcription repressor Sin3, including four conserved paired amphipathic helix (PAH) domains. mSin3A and mSin3B bind specifically to Mad and the related protein Mxi1. Mad-Max and mSin3 form ternary complexes in solution that specifically recognize the Mad-Max E box-binding site. Mad-mSin3 association requires PAHS of mSin3A/mSin3B and the first 25 residues of Mad, which contains a putative amphipathic alpha-helical region. Point mutations in this region eliminate interaction with mSin3 proteins and block Mad transcriptional repression. We suggest that Mad-Max represses transcription by tethering mSin3 to DNA as corepressors and that a transcriptional repression mechanism is conserved from yeast to mammals.			AYER, DE (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,ROOM A2-025,SEATTLE,WA 98104, USA.			Ayer, Donald/0000-0002-5595-3269	NATIONAL CANCER INSTITUTE [R01CA057138] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA57138] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; AMATI B, 1993, EMBO J, V12, P5083, DOI 10.1002/j.1460-2075.1993.tb06202.x; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; AUBLE DT, 1994, IN PRESS GENES DEV, V8; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; BANIAHMAD A, 1992, EMBO J, V11, P1015, DOI 10.1002/j.1460-2075.1992.tb05140.x; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Blackwood EM, 1992, CURR OPIN GENET DEV, V2, P227, DOI 10.1016/S0959-437X(05)80278-3; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; COOPER JP, 1994, GENE DEV, V8, P1400, DOI 10.1101/gad.8.12.1400; ELLEDGE SJ, 1991, P NATL ACAD SCI USA, V88, P1731, DOI 10.1073/pnas.88.5.1731; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; GRAY S, 1994, GENE DEV, V8, P1829, DOI 10.1101/gad.8.15.1829; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HENIKOFF S, 1987, GENETICS, V117, P711; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUDAK KA, 1994, GENETICS, V136, P475; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kretzner L, 1992, Curr Top Microbiol Immunol, V182, P435; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LAHOZ EG, 1994, P NATL ACAD SCI USA, V91, P5503, DOI 10.1073/pnas.91.12.5503; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; MEICHLE A, 1992, BIOCHIM BIOPHYS ACTA, V1114, P129, DOI 10.1016/0304-419X(92)90011-M; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; MUKHERJEE B, 1992, GENE DEV, V6, P1480, DOI 10.1101/gad.6.8.1480; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHULTZ J, 1990, MOL CELL BIOL, V10, P4744, DOI 10.1128/MCB.10.9.4744; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; STRICH R, 1989, P NATL ACAD SCI USA, V88, P10018; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; VIDAL M, 1990, GENETICS, V125, P313; VIDAL M, 1991, MOL CELL BIOL, V11, P6306, DOI 10.1128/MCB.11.12.6306; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WANG HM, 1994, MOL GEN GENET, V245, P675, DOI 10.1007/BF00297274; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, MOL CELL BIOL, V10, P5927, DOI 10.1128/MCB.10.11.5927; WANG HM, 1990, P NATL ACAD SCI USA, V87, P9761, DOI 10.1073/pnas.87.24.9761; WEINBERG RA, 1992, SCIENCE, V254, P1138; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90167-3; YEW PR, 1994, GENE DEV, V8, P190, DOI 10.1101/gad.8.2.190; YOSHIMOTO H, 1992, MOL GEN GENET, V233, P327, DOI 10.1007/BF00587597; ZAWEL L, 1992, CURR OPIN CELL BIOL, V4, P448; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, CELL, V79	61	530	538	1	13	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					767	776		10.1016/0092-8674(95)90355-0	http://dx.doi.org/10.1016/0092-8674(95)90355-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889570	Bronze			2022-12-28	WOS:A1995QM39900013
J	LISMAN, JE; IDIART, MAP				LISMAN, JE; IDIART, MAP			STORAGE OF 7+/-2 SHORT-TERM MEMORIES IN OSCILLATORY SUBCYCLES	SCIENCE			English	Article							RAT-ASSOCIATION CORTEX; PYRAMIDAL CELLS; RESPONSES; MONKEY	Psychophysical measurements indicate that human subjects can store approximately seven short-term memories. Physiological studies suggest that short-term memories are stored by patterns of neuronal activity. Here it is shown that activity patterns associated with multiple memories can be stored in a single neural network that exhibits nested oscillations similar to those recorded from the brain. Each memory is stored in a different high-frequency (''40 hertz'') subcycle of a low-frequency oscillation. Memory patterns repeat on each low-frequency (5 to 12 hertz) oscillation, a repetition that relies on activity-dependent changes in membrane excitability rather than reverberatory circuits. This work suggests that brain oscillations are a timing mechanism for controlling the serial processing of short-term memories.	BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT PHYS,WALTHAM,MA 02254	Brandeis University; Brandeis University	LISMAN, JE (corresponding author), BRANDEIS UNIV,CTR COMPLEX SYST,WALTHAM,MA 02254, USA.		idiart, marco/F-7389-2015	idiart, marco/0000-0002-7129-3520	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027337] Funding Source: NIH RePORTER; NINDS NIH HHS [NS27337] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amit D. J., 1989, MODELING BRAIN FUNCT, DOI 10.1017/CBO9780511623257; AMIT DJ, 1994, J NEUROSCI, V14, P6435; ANDRADE R, 1991, BRAIN RES, V548, P81, DOI 10.1016/0006-8993(91)91109-E; ARANEDA R, 1991, NEUROSCIENCE, V40, P399, DOI 10.1016/0306-4522(91)90128-B; Atkinson RC., 1968, PSYCHOL LEARNING MOT, V2, P89, DOI [10.1016/S0079-7421(08)60422-3, DOI 10.1016/S0079-7421(08)60422-3]; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BRAGIN A, 1995, J NEUROSCI, V15, P47; CAESER M, 1993, EUR J NEUROSCI, V5, P560, DOI 10.1111/j.1460-9568.1993.tb00521.x; CHANG HT, 1950, J NEUROPHYSIOL, V13, P235, DOI 10.1152/jn.1950.13.3.235; Fahle M., 1994, Society for Neuroscience Abstracts, V20, P319; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1982, J NEUROSCI, V2, P361; HEBB DO, 1949, ORG BEHAVIOR; Horn D, 1991, NEURAL COMPUT, V3, P31, DOI 10.1162/neco.1991.3.1.31; HORN D, 1994, ADV NEURAL INFORMATI, V4, P125; JOLIOT M, 1994, P NATL ACAD SCI USA, V91, P11748, DOI 10.1073/pnas.91.24.11748; KAUFMAN L, 1992, ELECTROENCEPHALOGR C, V82, P226; Koch C., 1994, SOME FURTHER IDEAS R, P93; KREITER AK, 1992, EUR J NEUROSCI, V4, P369, DOI 10.1111/j.1460-9568.1992.tb00884.x; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; MILLER GA, 1956, PSYCHOL REV, V63, P81, DOI 10.1037/h0043158; NAKAMURA K, 1992, NEUROREPORT, V3, P117, DOI 10.1097/00001756-199201000-00031; Oberly HS, 1928, AM J PSYCHOL, V40, P295, DOI 10.2307/1414490; OKEEFE J, 1993, HIPPOCAMPUS, V3, P317, DOI 10.1002/hipo.450030307; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; Skaggs W. E., 1993, Society for Neuroscience Abstracts, V19, P795; SOLTESZ I, 1993, J NEUROPHYSIOL, V70, P97, DOI 10.1152/jn.1993.70.1.97; STERIADE M, 1991, P NATL ACAD SCI USA, V88, P4396, DOI 10.1073/pnas.88.10.4396; STERNBERG S, 1966, SCIENCE, V153, P652, DOI 10.1126/science.153.3736.652; STORM JF, 1989, J PHYSIOL-LONDON, V409, P171, DOI 10.1113/jphysiol.1989.sp017491; VONDERMALSBURG C, 1986, BIOL CYBERN, V54, P29, DOI 10.1007/BF00337113; WINGFIELD A, 1972, SCIENCE, V176, P690, DOI 10.1126/science.176.4035.690; ZIPSER D, 1993, J NEUROSCI, V13, P3406	33	977	987	0	81	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1512	1515		10.1126/science.7878473	http://dx.doi.org/10.1126/science.7878473			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878473				2022-12-28	WOS:A1995QL49700042
J	VONCKEN, JW; VANSCHAICK, H; KAARTINEN, V; DEEMER, K; COATES, T; LANDING, B; PATTENGALE, P; DORSEUIL, O; BOKOCH, GM; GROFFEN, J; HEISTERKAMP, N				VONCKEN, JW; VANSCHAICK, H; KAARTINEN, V; DEEMER, K; COATES, T; LANDING, B; PATTENGALE, P; DORSEUIL, O; BOKOCH, GM; GROFFEN, J; HEISTERKAMP, N			INCREASED NEUTROPHIL RESPIRATORY BURST IN BCR-NULL MUTANTS	CELL			English	Article							CHRONIC MYELOID-LEUKEMIA; ABL TYROSINE KINASE; NADPH OXIDASE; C-ABL; SUPEROXIDE PRODUCTION; NUCLEOTIDE EXCHANGE; B-CELL; PROTEIN; ONCOGENE; ACTIVATION	Philadelphia (Ph)-positive leukemias invariably contain a chromosomal translocation fusing BCR to ABL. The BCR-ABL protein is responsible for leukemogenesis. Here we show that exposure of bcr-null mutant mice to gram-negative endotoxin led to severe septic shock and increased tissue injury by neutrophils. Neutrophils of bcr (-/-) mice showed a pronounced increase in reactive oxygen metabolite production upon activation and were more sensitive to priming stimuli. Activated (-/-) neutrophils displayed a 3-fold increased p21(rac2) membrane translocation compared with (+/+) neutrophils. These results connect Bcr in vivo with the regulation of Rac-mediated superoxide production by the NADPH-oxidase system of leukocytes and suggest a link between Bcr function and the cell type affected in Ph-positive leukemia.	CHILDRENS HOSP LOS ANGELES, DEPT HEMATOL, LOS ANGELES, CA 90027 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Children's Hospital Los Angeles; Scripps Research Institute; Scripps Research Institute	VONCKEN, JW (corresponding author), CHILDRENS HOSP LOS ANGELES, DEPT PATHOL, LOS ANGELES, CA 90027 USA.		Kaartinen, Vesa/AAU-5396-2021; Coates, Thomas/AAN-3556-2020; Heisterkamp, Nora/C-1698-2012	Coates, Thomas/0000-0001-9878-6029; Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NATIONAL CANCER INSTITUTE [R01CA050248] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048008] Funding Source: NIH RePORTER; NCI NIH HHS [CA50248] Funding Source: Medline; NHLBI NIH HHS [HL 48008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; AHMED S, 1994, J BIOL CHEM, V269, P17642; BEDI A, 1993, BLOOD, V81, P2898; BENNA JE, 1994, J BIOL CHEM, V269, P6729; BOKOCH GM, 1994, CURR OPIN IMMUNOL, V6, P98, DOI 10.1016/0952-7915(94)90040-X; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; DEFORGE LE, 1994, AM J PATHOL, V144, P599; DEMLING RH, 1990, CIRC SHOCK, V30, P297; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; DORSEUIL O, 1992, J BIOL CHEM, V267, P20540; EDWARDS SW, 1994, BIOCH PHYSL NEUTROPH, P235; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; FIORETOS T, 1994, BLOOD, V83, P3441; GROFFEN J, 1984, CELL, V36, P93, DOI 10.1016/0092-8674(84)90077-1; HAAS OA, 1992, NATURE, V359, P414, DOI 10.1038/359414a0; HARLOW E, 1988, ANTIBODIES LAB MANUA, P473; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HEISTERKAMP N, 1993, J BIOL CHEM, V268, P16903; HEISTERKAMP N, 1993, CAUSES CONSEQUENCES, P359; HEWETT JA, 1992, LAB INVEST, V66, P347; HEYWORTH PG, 1993, MOL BIOL CELL, V4, P1217, DOI 10.1091/mbc.4.11.1217; HIMMELFARB J, 1992, CYTOMETRY, V13, P83, DOI 10.1002/cyto.990130113; JUTILA MA, 1991, CELL IMMUNOL, V132, P201, DOI 10.1016/0008-8749(91)90019-8; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; LEUNG T, 1994, J BIOL CHEM, V269, P12888; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LIU JX, 1993, ONCOGENE, V8, P101; LOFGREN R, 1993, J CELL BIOL, V123, P1597, DOI 10.1083/jcb.123.6.1597; LU D, 1993, BLOOD, V82, P1257; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; MCWHIRTER JR, 1991, MOL CELL BIOL, V11, P1553, DOI 10.1128/MCB.11.3.1553; MELO JV, 1993, BLOOD, V81, P158; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; SHAAFI RI, 1988, J LEUKOCYTE BIOL, V43, P18, DOI 10.1002/jlb.43.1.18; SHASBY DM, 1982, AM REV RESPIR DIS, V125, P443; SHIRATORI Y, 1990, HEPATOLOGY, V11, P83; SIMPSON R, 1993, ANN SURG, V218, P444, DOI 10.1097/00000658-199310000-00005; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANETTEN RA, 1993, ADV RES TREATMENT, P295; WAKIYAMA H, 1993, CLIN EXP IMMUNOL, V92, P218; WATT SM, 1979, J CELL PHYSIOL, V100, P1, DOI 10.1002/jcp.1041000102; WETZLER M, 1993, J CLIN INVEST, V92, P1925, DOI 10.1172/JCI116786; YOSHIKAWA T, 1994, CIRC SHOCK, V42, P53	52	152	156	0	3	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					719	728		10.1016/0092-8674(95)90350-X	http://dx.doi.org/10.1016/0092-8674(95)90350-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889565	Bronze			2022-12-28	WOS:A1995QM39900008
J	HINSHAW, JE; SCHMID, SL				HINSHAW, JE; SCHMID, SL			DYNAMIN SELF-ASSEMBLES INTO RINGS SUGGESTING A MECHANISM FOR COATED VESICLE BUDDING	NATURE			English	Article							GTP-BINDING PROTEINS; MECHANOCHEMICAL ENZYME; DROSOPHILA; MICROTUBULES; ENDOCYTOSIS; SHIBIRE; DOMAIN	DYNAMIN, a 100K member of the GTPase superfamily(1), is the mammalian homologue of the Drosophila shihire gene product(2,3). Mutations in shibire cause a defect in endocytosis Leading to accumulation of coated pits and deep invaginations at the plasma membrane of all tissues examined(4,5). Similarly, invaginated coated pits accumulate in mammalian cells overexpressing dominant-negative mutants of dynamin, establishing that dynamin is required for the formation of 'constricted' coated pits and for coated vesicle budding(6). Whether dynamin functions in the classic GTPase mode as a molecular switch to regulate events leading to coated vesicle budding or instead actively participates as a mechanochemical enzyme driving coated vesicle formation is unclear(7). Here we show that dynamin spontaneously self-assembles into rings and stacks of interconnected rings, comparable in dimension to the 'collars' observed at the necks of invaginated coated pits that accumulate at synaptic terminals in shibire flies(4). We propose that invaginated coated pits become constricted by the assembly of dynamin into rings around their necks. A concerted conformational change would then close the rings and pinch off the budding coated vesicles.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute				Schmid, Sandra/0000-0002-1690-7024				CARTER LL, 1993, J CELL BIOL, V120, P37, DOI 10.1083/jcb.120.1.37; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; MUSACCHIO A, 1993, TRENDS BIOCHEM SCI, V18, P343, DOI 10.1016/0968-0004(93)90071-T; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; Schmid Sandra L., 1993, Trends in Cell Biology, V3, P145, DOI 10.1016/0962-8924(93)90129-O; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TSURUHARA T, 1990, CELL TISSUE RES, V259, P199, DOI 10.1007/BF00318441; VALLEE RB, 1992, J MUSCLE RES CELL M, V13, P493, DOI 10.1007/BF01737991; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WARNOCK DE, IN PRESS EMBO J	17	650	663	4	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					190	192		10.1038/374190a0	http://dx.doi.org/10.1038/374190a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877694				2022-12-28	WOS:A1995QL39700067
J	SCHOENHERR, CJ; ANDERSON, DJ				SCHOENHERR, CJ; ANDERSON, DJ			THE NEURON-RESTRICTIVE SILENCER FACTOR (NRSF) - A COORDINATE REPRESSOR OF MULTIPLE NEURON-SPECIFIC GENES	SCIENCE			English	Article							SODIUM-CHANNEL GENE; NERVE GROWTH-FACTOR; BINDING-PROTEIN; SCG10 GENE; CELL LINE; EXPRESSION; DIFFERENTIATION; SEQUENCE; FAMILY; DNA	The neuron-restrictive silencer factor (NRSF) binds a DNA sequence element, called the neuron-restrictive silencer element (NRSE), that represses neuronal gene transcription in nonneuronal cells. Consensus NRSEs have been identified in 18 neuron-specific genes, Complementary DNA clones encoding a functional fragment of NRSF were isolated and found to encode a novel protein containing eight noncanonical zinc fingers. Expression of NRSF mRNA was detected in most nonneuronal tissues at several developmental stages, In the nervous system, NRSF mRNA was detected in undifferentiated neuronal progenitors, but not in differentiated neurons, NRSF represents the first example of a vertebrate silencer protein that potentially regulates a large battery of cell type-specific genes, and therefore may function as a master negative regulator of neurogenesis.	CALTECH,HOWARD HUGHES MED INST,DIV BIOL 21676,PASADENA,CA 91125	California Institute of Technology; Howard Hughes Medical Institute					NINDS NIH HHS [NS23476] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023476] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BIRREN SJ, 1993, DEVELOPMENT, V119, P597; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BLAV HM, 1991, ANN REV BIOCH, V61, P1213; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; KIMURA H, 1990, NATURE, V348, P257, DOI 10.1038/348257a0; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUMAR S, 1990, J NEUROSCI RES, V27, P408, DOI 10.1002/jnr.490270320; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEBER SM, 1990, J NEUROSCI, V10, P2451; LI L, P NATL ACAD SCI USA, V90, P1460; LI S, 1990, NATURE, V347, P528, DOI 10.1038/347528a0; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MORITA H, 1992, ZOOL SCI, V9, P1; OU SKH, 1993, J IMMUNOL METHODS, V165, P75, DOI 10.1016/0022-1759(93)90108-J; PATHAK BG, 1984, NUCLEIC ACIDS RES, V22, P4748; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; PFEIFFER SE, 1978, GLIAL CELL LINES, P287; RUPPERT JM, 1988, MOL CELL BIOL, V8, P3104, DOI 10.1128/MCB.8.8.3104; SCHOENHERR CS, UNPUB; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X	35	905	930	1	59	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1360	1363		10.1126/science.7871435	http://dx.doi.org/10.1126/science.7871435			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871435				2022-12-28	WOS:A1995QK06800049
J	STEER, P; ALAM, MA; WADSWORTH, J; WELCH, A				STEER, P; ALAM, MA; WADSWORTH, J; WELCH, A			RELATION BETWEEN MATERNAL HEMOGLOBIN CONCENTRATION AND BIRTH-WEIGHT IN DIFFERENT ETHNIC-GROUPS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HEMOGLOBIN CONCENTRATION; FOLATE SUPPLEMENTS; GROWTH-RETARDATION; PREGNANCY; IRON; ANEMIA; 2ND-TRIMESTER; HEMATOCRIT	Objective-To assess the relation of the lowest haemoglobin concentration in pregnancy with birth weight and the rates of low birth weight and preterm delivery in different ethnic groups. Design-Retrospective analysis of 153 602 pregnancies with ethnic group and birth weight recorded on a regional pregnancy database during 1988-91. The haemoglobin measurement used was the lowest recorded during pregnancy. Setting-North West Thames region. Subjects-115 262 white women, 22 206 Indo-Pakistanis, 4570 Afro-Caribbeans, 2642 mediterraneans, 3905 black Africans, 2351 orientals, and 2666 others. Main outcome measures-Birth weight and rates of low birth weight (<2500 g) and preterm delivery (<37 completed weeks). Results-Maximum mean birth weight in white women was achieved with a lowest haemoglobin concentration in pregnancy of 85-95 g/l; the lowest incidence of low birth weight and preterm labour occurred with a lowest haemoglobin of 95-105 g/l. A similar pattern occurred in all ethnic groups. Conclusions-The magnitude of the fall in haemoglobin concentration in pregnancy is related to birth weight; failure of the haemoglobin concentration to fall below 105 g/l indicates an increased risk of low birth weight and preterm delivery. This phenomenon is seen in all ethnic groups. Some ethnic groups have higher rates of low birth weight and preterm delivery than white women, and they also have higher rates of low haemoglobin concentrations. This increased rate of ''anaemia,'' however, does not account for their higher rates of low birth weight, which occurs at all haemoglobin concentrations.	UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL, LONDON EC1A 7BE, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT PUBL HLTH, LONDON W2 1PG, ENGLAND; ST MARYS HOSP, SCH MED, ACAD DEPT OBSTET & GYNAECOL, LONDON W2 1PG, ENGLAND	University of London; Queen Mary University London; Imperial College London; Imperial College London	STEER, P (corresponding author), CHELSEA & WESTMINSTER HOSP, CHARING CROSS & WESTMINSTER MED SCH, ACAD DEPT OBSTET & GYNAECOL, LONDON SW10 9NH, ENGLAND.							Dieckmann WJ, 1934, ARCH INTERN MED, V53, P71, DOI 10.1001/archinte.1934.00160070076007; DUNLOP W, 1978, BRIT J OBSTET GYNAEC, V85, P938, DOI 10.1111/j.1471-0528.1978.tb15857.x; FENTON V, 1977, BRIT J HAEMATOL, V37, P145, DOI 10.1111/j.1365-2141.1977.tb08819.x; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; GOODLIN RC, 1982, J REPROD MED, V27, P639; HIBBARD BM, 1988, BRIT MED J, V297, P1324, DOI 10.1136/bmj.297.6659.1324; HORN E, 1988, BRIT MED J, V297, P1325, DOI 10.1136/bmj.297.6659.1325; HUISMAN A, 1986, ACTA OBSTET GYN SCAN, V65, P605, DOI 10.3109/00016348609158396; HYTTEN FE, 1963, J OBSTET GYN BR COMM, V70, P402; KLEBANOFF MA, 1989, JAMA-J AM MED ASSOC, V262, P511, DOI 10.1001/jama.262.4.511; KLEBANOFF MA, 1991, AM J OBSTET GYNECOL, V164, P59, DOI 10.1016/0002-9378(91)90626-3; KOLLER O, 1979, ACTA OBSTET GYN SCAN, V58, P9, DOI 10.3109/00016347909154904; LETSKY EA, 1994, HIGH RISK PREGNANCY, P337; LU ZM, 1991, OBSTET GYNECOL, V77, P190; MAHOMED K, 1993, PREGNANCY CHILDBIRTH; MAU G, 1977, J PERINAT MED, V5, P172, DOI 10.1515/jpme.1977.5.4.172; MURPHY JF, 1986, LANCET, V1, P992; PAINTIN D. B., 1966, Journal of Obstetrics and Gynaecology of the British Commonwealth, V73, P181, DOI 10.1111/j.1471-0528.1966.tb05144.x; SAGEN N, 1984, ACTA OBSTET GYN SCAN, V63, P245, DOI 10.3109/00016348409155506; TAYLOR DJ, 1979, BRIT J OBSTET GYNAEC, V86, P364, DOI 10.1111/j.1471-0528.1979.tb10611.x; 1978, BRIT MED J, V2, P1317; 1965, WHO TECH REP SER, V302, P5	22	208	218	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 25	1995	310	6978					489	491		10.1136/bmj.310.6978.489	http://dx.doi.org/10.1136/bmj.310.6978.489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888886	Green Published			2022-12-28	WOS:A1995QJ59800018
J	EPSTEIN, PR; FORD, TE; COLWELL, RR				EPSTEIN, PR; FORD, TE; COLWELL, RR			MARINE ECOSYSTEMS	LANCET			English	Article							TEMPERATURE; CHOLERA; WATER		HARVARD UNIV,DEPT ENVIRONM BIOL,CAMBRIDGE,MA 02138; UNIV MARYLAND,INST BIOTECHNOL,COLL PK,MD 20742	Harvard University; University System of Maryland; University of Maryland College Park	EPSTEIN, PR (corresponding author), HARVARD UNIV,CAMBRIDGE HOSP,SCH MED,DIV SOCIAL & COMMUNITY MED,CAMBRIDGE,MA 02139, USA.			Ford, Timothy/0000-0001-5194-5459				[Anonymous], TOXIC PHYTOPLANKTON; BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; BYRD JJ, 1991, APPL ENVIRON MICROB, V57, P875, DOI 10.1128/AEM.57.3.875-878.1991; DANSGAARD W, 1993, NATURE, V364, P218, DOI 10.1038/364218a0; Glantz M.H., 1991, TELECONNECTIONS LINK; Hayes R.L., 1991, WORLD RES REV, V3, P306; Houghton J.T., 1990, CLIMATE CHANGE IPCC; HUQ A, 1984, APPL ENVIRON MICROB, V48, P420, DOI 10.1128/AEM.48.2.420-424.1984; ISLAM S, 1990, J TROP MED HYG, V93, P133; MACKENZIE D, 1988, NEW SCI         0128, P30; MANABE S, 1993, NATURE, V364, P215, DOI 10.1038/364215a0; MEEHL GA, 1993, SCIENCE, V260, P1101, DOI 10.1126/science.260.5111.1101; SAMADI AR, 1983, T ROY SOC TROP MED H, V77, P853, DOI 10.1016/0035-9203(83)90306-1; SHERMAN L, 1993, LARGE MARINE ECOSYST, P301; SWERDLOW DL, 1992, LANCET, V340, P28, DOI 10.1016/0140-6736(92)92432-F; Valiela I., 1984, MARINE ECOLOGICAL PR, DOI 10.1007/978-1-4757-4125-4; YAN XH, 1992, SCIENCE, V258, P1643, DOI 10.1126/science.258.5088.1643	17	74	74	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1216	1219		10.1016/0140-6736(93)92191-U	http://dx.doi.org/10.1016/0140-6736(93)92191-U			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901535				2022-12-28	WOS:A1993MG27400015
J	STEVENS, DA				STEVENS, DA			COCCIDIOIDOMYCOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PROGRESSIVE COCCIDIOIDOMYCOSIS; ITRACONAZOLE THERAPY; IMMITIS; INVITRO; MENINGITIS; INFECTION; NEUTROPHILS; LYMPHOCYTES; SUPPRESSION; ACTIVATION		STANFORD UNIV,SCH MED,DEPT MED,STANFORD,CA; CALIF INST MED RES,SAN JOSE,CA	Stanford University	STEVENS, DA (corresponding author), SANTA CLARA VALLEY MED CTR,DEPT MED,DIV INFECT DIS,751 S BASCOM AVE,SAN JOSE,CA 95128, USA.							AMPEL NM, 1993, AM J MED, V94, P235, DOI 10.1016/0002-9343(93)90054-S; BEAMAN L, 1983, INFECT IMMUN, V39, P1201, DOI 10.1128/IAI.39.3.1201-1207.1983; BEAMAN L, 1979, INFECT IMMUN, V23, P681, DOI 10.1128/IAI.23.3.681-685.1979; BOUZA E, 1981, MEDICINE, V60, P139, DOI 10.1097/00005792-198105000-00001; BRASS C, 1982, INFECT IMMUN, V35, P431, DOI 10.1128/IAI.35.2.431-436.1982; BRUMMER E, 1985, COCCIDIOIDOMYCOSIS, P201; CATANZARO A, 1981, CELL IMMUNOL, V64, P235, DOI 10.1016/0008-8749(81)90476-7; CATANZARO A, 1975, CELL IMMUNOL, V15, P360, DOI 10.1016/0008-8749(75)90014-3; Cole G. T., 1991, The fungal spore and disease initiation in plants and animals., P403; COX RA, 1982, INFECT IMMUN, V37, P609, DOI 10.1128/IAI.37.2.609-616.1982; COX RA, 1982, AM REV RESPIR DIS, V126, P439; COX RA, 1976, AM REV RESPIR DIS, V114, P937; DEFELICE R, 1982, AM REV RESPIR DIS, V125, P49; DERESINSKI SC, 1980, COCCIDIOIDOMYCOSIS T, P195; DIAZ M, 1992, CLIN INFECT DIS, V14, pS68, DOI 10.1093/clinids/14.Supplement_1.S68; DRUTZ DJ, 1983, DRUGS, V26, P337, DOI 10.2165/00003495-198326040-00003; DUGGER KO, 1991, INFECT IMMUN, V59, P2245, DOI 10.1128/IAI.59.7.2245-2251.1991; EINSTEIN HE, 1961, CALIF MED, V94, P339; FREY CL, 1986, J INFECT DIS, V153, P933, DOI 10.1093/infdis/153.5.933; GALGIANI JN, 1988, AM J MED, V84, P603, DOI 10.1016/0002-9343(88)90143-X; GALGIANI JN, 1993, ANN INTERN MED, V119, P28, DOI 10.7326/0003-4819-119-1-199307010-00005; GALGIANI JN, 1986, J INFECT DIS, V153, P217, DOI 10.1093/infdis/153.2.217; GALGIANI JN, 1978, INFECT IMMUN, V21, P862, DOI 10.1128/IAI.21.3.862-865.1978; GALGIANI JN, 1980, INFECT IMMUN, V28, P944; GRAYBILL JR, 1990, AM J MED, V89, P282, DOI 10.1016/0002-9343(90)90339-F; HALL KA, 1993, TRANSPLANTATION, V55, P1422, DOI 10.1097/00007890-199306000-00039; HARVEY RP, 1981, AM REV RESPIR DIS, V123, P665; IBRAHIM AB, 1973, INFECT IMMUN, V7, P786, DOI 10.1128/IAI.7.5.786-794.1973; JOHNSON JE, 1964, ANN INTERN MED, V60, P941, DOI 10.7326/0003-4819-60-6-941; Kelly P.C., 1980, COCCIDIOIDOMYCOSIS T, P163, DOI [10.1007/978-1-4757-1712-9_11, DOI 10.1007/978-1-4757-1712-9_11]; KERRICK SS, 1985, AM REV RESPIR DIS, V131, P100; KIRKLAND TN, 1991, INFECT IMMUN, V59, P3952, DOI 10.1128/IAI.59.11.3952-3961.1991; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; OPELZ G, 1975, J INFECT DIS, V132, P250, DOI 10.1093/infdis/132.3.250; Pappagianis D., 1988, Current Topics in Medical Mycology, V2, P199; PAPPAGIANIS D, 1990, CLIN MICROBIOL REV, V3, P247, DOI 10.1128/CMR.3.3.247-268.1990; PAPPAGIANIS D, 1993, AM REV RESPIR DIS, V148, P656, DOI 10.1164/ajrccm/148.3.656; Peterson C M, 1993, Obstet Gynecol Surv, V48, P149, DOI 10.1097/00006254-199303000-00002; RODENBIKER HT, 1981, ARCH OPHTHALMOL-CHIC, V99, P71, DOI 10.1001/archopht.1981.03930010073005; SCOGINS JT, 1947, PHS PUBLICATION, V575, P132; SMITH CE, 1946, AM J PUBLIC HEALTH, V36, P1394; Stevens D. A., 1990, Principles and practice of infectious diseases., P2008; STEVENS DA, 1991, FUNGAL INFECT COMPRO, P207; TUCKER RM, 1990, J AM ACAD DERMATOL, V23, P593, DOI 10.1016/0190-9622(90)70261-F; TUCKER RM, 1990, REV INFECT DIS, V12, pS380; TUCKER RM, 1990, ANN INTERN MED, V112, P108, DOI 10.7326/0003-4819-112-2-108; TUCKER RM, 1992, CLIN INFECT DIS, V14, P165, DOI 10.1093/clinids/14.1.165; WERNER SB, 1972, NEW ENGL J MED, V286, P507, DOI 10.1056/NEJM197203092861003; 1994, MMWR-MORBID MORTAL W, V43, P421	49	270	283	1	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1077	1082		10.1056/NEJM199504203321607	http://dx.doi.org/10.1056/NEJM199504203321607			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898527				2022-12-28	WOS:A1995QT18700007
J	TSEVAT, J; COOK, EF; GREEN, ML; MATCHAR, DB; DAWSON, NV; BROSTE, SK; WU, AW; PHILLIPS, RS; OYE, RK; GOLDMAN, L				TSEVAT, J; COOK, EF; GREEN, ML; MATCHAR, DB; DAWSON, NV; BROSTE, SK; WU, AW; PHILLIPS, RS; OYE, RK; GOLDMAN, L			HEALTH VALUES OF THE SERIOUSLY ILL	ANNALS OF INTERNAL MEDICINE			English	Note							SICKNESS IMPACT PROFILE; ADJUSTED LIFE-YEARS; TECHNICAL SOLUTION; POLITICAL PROBLEM; MYOCARDIAL-INFARCTION; COST-EFFECTIVENESS; LARYNGEAL-CANCER; QUALITY; UTILITIES; STATES	Objective: To assess 1)the health values and health ratings of seriously ill hospitalized patients, their surrogate decision makers, and their physicians; 2) the determinants of health values; and 3) whether health values change over time. Design: Prospective, longitudinal, multicenter study. Setting: 5 academic medical centers. Participants: 1438 seriously ill patients with at least one of nine diseases who had a projected overall 6-month mortality rate of 50%; their surrogates; and their physicians. Measurements: Time-tradeoff utilities (reflecting preferences for a shorter but healthy life) and health ratings. Results: At study day 3, patients had a mean time-tradeoff utility of 0.73 +/- 0.32 (median I:25th, 75th percentile], 0.92 [0.63, 1.01), indicating that they equated living 1 year in their current state of health with living 8.8 months in excellent health. However, scores varied widely; 34.8% of patients were unwilling to exchange any time in their current state of health for a shorter life in excellent health (utility, 1.0), and 9.0% were willing to live 2 weeks or less in excellent health rather than 1 year in their current state of health (utility, 0.04). Health rating scores averaged 57.8 +/- 24.0 (median [25th percentile, 75th percentile], 60 [50, 75]) on a scale of 0 (death) to 100 (perfect health). The patients' mean time-tradeoff score exceeded that of their paired surrogates (n = 1041) by 0.08 (P < 0.0001). Time-tradeoff scores were related to psychosocial well-being; health ratings; desire for resuscitation and extension of life rather than relief of pain and discomfort; degree of willingness to live with constant pain; and perceived prognosis for survival and independent functioning. Scores of surviving patients increased by an average of 0.06 after 2 months (P < 0.0001) and 0.08 after 6 months (P < 0.0001). Conclusions: Health values of seriously ill patients vary widely, are higher than patients' surrogates believe, are related to few other preference and health status measures, and increase over time.	HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; DUKE UNIV, MED CTR, DURHAM, NC USA; METROHLTH MED CTR, CLEVELAND, OH 44109 USA; CASE WESTERN RESERVE UNIV, CLEVELAND, OH 44106 USA; MARSHFIELD CLIN FDN MED RES & EDUC, DEPT BIOSTAT & EPIDEMIOL, MARSHFIELD, WI 54449 USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, CTR HSR&D, BALTIMORE, MD 21205 USA; UNIV CALIF LOS ANGELES, MED CTR, LOS ANGELES, CA 90024 USA	Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Duke University; MetroHealth System; Case Western Reserve University; Marshfield Clinic; Johns Hopkins University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center			Wu, Albert/AAJ-4780-2021; Matchar, David/M-3951-2019	Matchar, David/0000-0003-3020-2108				[Anonymous], 1971, EITS MANUAL PROFILE; BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001; BERGNER M, 1976, INT J HEALTH SERV, V6, P393, DOI 10.2190/RHE0-GGH4-410W-LA17; BOMBARDIER C, 1986, AM J MED, V81, P565, DOI 10.1016/0002-9343(86)90539-5; BOYD NF, 1990, MED DECIS MAKING, V10, P58, DOI 10.1177/0272989X9001000109; CARRHILL RA, 1991, INT J HEALTH SERV, V21, P371, DOI 10.2190/GUJF-A8DR-94G9-BPBT; CARRHILL RA, 1991, INT J HEALTH SERV, V21, P351, DOI 10.2190/HPLM-EGXV-BWKY-5XBN; CARTER WB, 1976, HEALTH SERV RES, V11, P516; CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14; CONNORS AF, 1990, J CLIN EPIDEMIOL, V43, pS59, DOI 10.1016/0895-4356(90)90221-A; COULTON CJ, 1990, J CLIN EPIDEMIOL, V43, pS51, DOI 10.1016/0895-4356(90)90219-F; COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; DESBIENS NA, 1990, J CLIN EPIDEMIOL, V43, pS79, DOI 10.1016/0895-4356(90)90225-E; EDDY DM, 1991, JAMA-J AM MED ASSOC, V266, P2135, DOI 10.1001/jama.266.15.2135; EMANUEL LL, 1994, MED CARE, V32, P95, DOI 10.1097/00005650-199402000-00001; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HARRELL FE, 1990, J CLIN EPIDEMIOL, V43, pS89, DOI 10.1016/0895-4356(90)90227-G; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HORNBERGER JC, 1992, J CLIN EPIDEMIOL, V45, P505, DOI 10.1016/0895-4356(92)90099-9; KAPLAN RM, 1994, MED CARE, V32, P975, DOI 10.1097/00005650-199410000-00001; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1895, DOI 10.1056/NEJM199406303302611; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1976, INT J HEALTH SERV, V6, P493, DOI 10.2190/UURL-2RYU-WRYD-EY3K; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; Kolata Gina, 1992, NY TIMES, pC3; KRELING B, 1990, J CLIN EPIDEMIOL, V43, pS5, DOI 10.1016/0895-4356(90)90212-8; LANDEFELD CS, 1990, J CLIN EPIDEMIOL, V43, pS37, DOI 10.1016/0895-4356(90)90216-C; LAPUMA J, 1990, JAMA-J AM MED ASSOC, V263, P2917, DOI 10.1001/jama.263.21.2917; LAUPACIS A, 1990, BMJ-BRIT MED J, V300, P573; LLEWELLYNTHOMAS HA, 1991, MED DECIS MAKING, V11, P180, DOI 10.1177/0272989X9101100307; LLEWELLYNTHOMAS HA, 1984, J CHRON DIS, V37, P283, DOI 10.1016/0021-9681(84)90136-X; LLEWELLYNTHOMAS HA, 1993, MED CARE, V31, P1002, DOI 10.1097/00005650-199311000-00003; LLEWELLYNTHOMAS HA, 1992, MED DECIS MAKING, V12, P115, DOI 10.1177/0272989X9201200204; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; MEHREZ A, 1989, MED DECIS MAKING, V9, P142, DOI 10.1177/0272989X8900900209; Miyamoto J M, 1985, Med Decis Making, V5, P191, DOI 10.1177/0272989X8500500208; MURPHY DJ, 1990, JAMA-J AM MED ASSOC, V264, P2103, DOI 10.1001/jama.264.16.2103; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pS11, DOI 10.1016/0895-4356(90)90213-9; MURPHY DJ, 1990, J CLIN EPIDEMIOL, V43, pR5, DOI 10.1016/0895-4356(90)90210-G; OCONNOR AMC, 1987, J CHRON DIS, V40, P811, DOI 10.1016/0021-9681(87)90133-0; OYE RK, 1990, J CLIN EPIDEMIOL, V43, pS83, DOI 10.1016/0895-4356(90)90226-F; Patrick D L, 1973, Health Serv Res, V8, P228; PHILLIPS RS, 1990, J CLIN EPIDEMIOL, V43, pS29, DOI 10.1016/0895-4356(90)90214-A; PHILLIPS RS, 1990, J CLIN EPIDEMIOL, V43, pS33, DOI 10.1016/0895-4356(90)90215-B; PHILLIPS RS, 1990, J CLIN EPIDEMIOL, V43, pS41, DOI 10.1016/0895-4356(90)90217-D; PHILLIPS RS, 1990, J CLIN EPIDEMIOL, V43, pS55, DOI 10.1016/0895-4356(90)90220-J; PLISKIN JS, 1980, OPER RES, V28, P206, DOI 10.1287/opre.28.1.206; REVICKI DA, 1992, MED CARE, V30, pMS274, DOI 10.1097/00005650-199205001-00027; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SACKETT DL, 1978, J CHRON DIS, V31, P697, DOI 10.1016/0021-9681(78)90072-3; SHACHAM S, 1983, J PERS ASSESS, V47, P305, DOI 10.1207/s15327752jpa4703_14; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; Torrance G W, 1972, Health Serv Res, V7, P118; TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; TSEVAT J, 1992, CLIN RES, V40, pA569; TSEVAT J, 1991, MED CARE, V29, P1153, DOI 10.1097/00005650-199111000-00007; TSEVAT J, 1993, MED DECIS MAKING, V13, P161, DOI 10.1177/0272989X9301300210; TSEVAT J, 1994, J GEN INTERN MED, V9, P576, DOI 10.1007/BF02599287; WILLIAMS A, 1991, INT J HEALTH SERV, V21, P365, DOI 10.2190/WFMX-Y3VX-4UN8-8XMP; 1990, J CLIN EPIDEMIOL S, V43, pS109; [No title captured]	63	141	141	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					514	520		10.7326/0003-4819-122-7-199504010-00007	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP008	7872587				2022-12-28	WOS:A1995QP00800007
J	ROELKE, M; ONUNAIN, SS				ROELKE, M; ONUNAIN, SS			SHOCK DELIVERED BY AN IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IN RESPONSE TO SPONTANEOUS VENTRICULAR FIBRILLATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Harvard University; Massachusetts General Hospital	ROELKE, M (corresponding author), NEWARK BETH ISRAEL MED CTR,NEWARK,NJ 07112, USA.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					860	860		10.1056/NEJM199503303321305	http://dx.doi.org/10.1056/NEJM199503303321305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7870141				2022-12-28	WOS:A1995QP22800005
J	TORIBARA, NW; SLEISENGER, MH				TORIBARA, NW; SLEISENGER, MH			CURRENT CONCEPTS - SCREENING FOR COLORECTAL-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FECAL OCCULT BLOOD; FAMILIAL ADENOMATOUS POLYPOSIS; COLON-CANCER; MUTATIONS OCCUR; NATURAL-HISTORY; FOLLOW-UP; GENE; IDENTIFICATION; TUMORIGENESIS; SIGMOIDOSCOPY		UNIV CALIF SAN FRANCISCO,DEPT MED,DIV GASTROENTEROL,SAN FRANCISCO,CA	University of California System; University of California San Francisco	TORIBARA, NW (corresponding author), DEPT VET AFFAIRS MED CTR,MED SERV,GASTROENTEROL SECT,GASTROINTESTINAL RES LAB 151M2,SAN FRANCISCO,CA 94121, USA.							AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; ALLISON JE, 1990, ANN INTERN MED, V112, P328, DOI 10.7326/0003-4819-112-5-328; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; ATKIN WS, 1993, LANCET, V341, P736, DOI 10.1016/0140-6736(93)90499-7; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1990, CANCER RES, V50, P7717; BODMER W, 1994, NAT GENET, V6, P217, DOI 10.1038/ng0394-217; BOLAND CR, 1993, GASTROINTESTINAL DIS, V2, P1430; BRESALIER RS, 1991, PREMALIGNANT CONDITI, P227; BRESALIER RS, 1993, GASTROINTESTINAL DIS, V2, P1449; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; BROWN ML, 1993, NEW ENGL J MED, V329, P1352; CHO KR, 1994, GENOMICS, V19, P525, DOI 10.1006/geno.1994.1102; CHUI DW, 1994, NEW ENGL J MED, V331, P1685, DOI 10.1056/NEJM199412223312504; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FISHEL R, 1994, CELL, V77, P167; FORRESTER K, 1987, NATURE, V327, P298, DOI 10.1038/327298a0; GAREWAL HS, 1994, ANN INTERN MED, V121, P303, DOI 10.7326/0003-4819-121-4-199408150-00013; GILBERTS.VA, 1974, CANCER, V34, P936, DOI 10.1002/1097-0142(197409)34:3+<936::AID-CNCR2820340722>3.0.CO;2-5; GIOVANNUCCI E, 1994, J NATL CANCER I, V86, P183, DOI 10.1093/jnci/86.3.183; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GROSSMAN S, 1989, GASTROENTEROLOGY, V96, P299, DOI 10.1016/0016-5085(89)91551-5; HAENSZEL W, 1968, JNCI-J NATL CANCER I, V40, P43; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HOULSTON RS, 1992, ANN HUM GENET, V56, P99, DOI 10.1111/j.1469-1809.1992.tb01136.x; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; ITZKOWITZ SH, 1993, GASTROINTESTINAL DIS, V2, P1402; JEN J, 1994, NEW ENGL J MED, V331, P213, DOI 10.1056/NEJM199407283310401; KERN SE, 1989, JAMA-J AM MED ASSOC, V261, P3099, DOI 10.1001/jama.261.21.3099; KERN SE, 1989, JAMA-J AM MED ASSOC, V262, P1952; KEWENTER J, 1991, CANCER SCREENING, P116; KOI M, 1994, CANCER RES, V54, P4308; KRONBORG O, 1991, CANCER SCREENING, P126; LANAS A, 1992, GASTROENTEROLOGY, V103, P862, DOI 10.1016/0016-5085(92)90018-T; LANG CA, 1994, JAMA-J AM MED ASSOC, V271, P1011, DOI 10.1001/jama.271.13.1011; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LIEBERMAN D, 1991, AM J GASTROENTEROL, V86, P1789; LIMBERG B, 1992, NEW ENGL J MED, V327, P65, DOI 10.1056/NEJM199207093270201; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; LYNCH HT, 1992, DIS COLON RECTUM, V35, P411, DOI 10.1007/BF02049396; LYNCH HT, 1988, DIS COLON RECTUM, V31, P439, DOI 10.1007/BF02552613; MANDEL JS, 1993, NEW ENGL J MED, V328, P1365, DOI 10.1056/NEJM199305133281901; MARKUS JB, 1990, RADIOLOGY, V175, P155, DOI 10.1148/radiology.175.1.2315474; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, 1993, NEW ENGL J MED, V329, P1982, DOI 10.1056/NEJM199312303292702; RANSOHOFF DF, 1994, GASTROENTEROLOGY, V106, pA24; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1993, ANN INTERN MED, V118, P1, DOI 10.7326/0003-4819-118-1-199301010-00001; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; SPIRIO L, 1993, CELL, V75, P951, DOI 10.1016/0092-8674(93)90538-2; STROEHLEIN JR, 1984, CA-CANCER J CLIN, V34, P148, DOI 10.3322/canjclin.34.3.148; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS W, 1991, CANCER SCREENING, P106; VARESCO L, 1993, CANCER RES, V53, P5581; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WINAWER SJ, 1980, CANCER, V45, P2959, DOI 10.1002/1097-0142(19800615)45:12<2959::AID-CNCR2820451212>3.0.CO;2-E; WINAWER SJ, 1993, NEW ENGL J MED, V328, P901, DOI 10.1056/NEJM199304013281301; WINAWER SJ, 1993, J NATL CANCER I, V85, P1311, DOI 10.1093/jnci/85.16.1311; WINAWER SJ, 1993, GASTROENTEROLOGY, V104, pA462; WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; ZARCHY TM, 1994, GASTROENTEROLOGY, V106, P1501, DOI 10.1016/0016-5085(94)90403-0	70	151	158	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1995	332	13					861	867		10.1056/NEJM199503303321306	http://dx.doi.org/10.1056/NEJM199503303321306			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP228	7870142				2022-12-28	WOS:A1995QP22800006
J	MOL, CD; KUO, CF; THAYER, MM; CUNNINGHAM, RP; TAINER, JA				MOL, CD; KUO, CF; THAYER, MM; CUNNINGHAM, RP; TAINER, JA			STRUCTURE AND FUNCTION OF THE MULTIFUNCTIONAL DNA-REPAIR ENZYME EXONUCLEASE-III	NATURE			English	Article							ESCHERICHIA-COLI; RESOLUTION; SEQUENCE; CDNA; REFINEMENT; HOMOLOGY; COMPLEX	THE repair of DNA requires the removal of abasic sites, which are constantly generated in vivo both spontaneously(1) and by enzymatic removal of uracil(2), and of bases damaged by active oxygen species, alkylating agents and ionizing radiation The major apurinic/apyrimidinic (AP) DNA-repair endonuclease in Escherichia coli is the multifunctional enzyme exonuclease In, which also exhibits 3'-repair diesterase, 3'-->5' exonuclease, 3'-phosphomonoesterase and ribonuclease activities(5). We report here the 1.7 Angstrom resolution crystal structure of exonuclease III which reveals a 2-fold symmetric, four-layered ap fold,vith similarities to both deoxyribonuclease I-6 and RNase H-7. In the ternary complex determined at 2.6 Angstrom resolution, Mn2+ and dCMP bind to exonuclease III at one end of the alpha beta-sandwich, in a region dominated by positive electrostatic potential. Residues conserved among AP endonucleases from bacteria to man cluster within this active site and appear to participate in phosphate-bond cleavage at AP sites through a nucleophilic attack facilitated by a single bound metal ion.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; SUNY ALBANY, CTR BIOCHEM & BIOPHYS, DEPT BIOL SCI, ALBANY, NY 12222 USA	Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany			Tainer, John/GWQ-4878-2022	Tainer, John/0000-0003-1659-2429				BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BORGSTAHL GEO, 1994, J MOL BIOL, V236, P817, DOI 10.1006/jmbi.1994.1191; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; DEMPLE B, 1991, P NATL ACAD SCI USA, V88, P11450, DOI 10.1073/pnas.88.24.11450; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; KAYANA S, 1991, EUR J BIOCHEM, V198, P437; KUO CF, 1993, J MOL BIOL, V229, P239, DOI 10.1006/jmbi.1993.1021; LAHM A, 1991, J MOL BIOL, V222, P645, DOI 10.1016/0022-2836(91)90502-W; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; OEFNER C, 1986, J MOL BIOL, V192, P605, DOI 10.1016/0022-2836(86)90280-9; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; ROBSON CN, 1991, NUCLEIC ACIDS RES, V19, P1087, DOI 10.1093/nar/19.5.1087; SAKUMI K, 1990, MUTAT RES, V236, P161, DOI 10.1016/0921-8777(90)90003-N; SAPORITO SM, 1988, J BACTERIOL, V170, P4542, DOI 10.1128/jb.170.10.4542-4547.1988; SEKI S, 1991, J BIOL CHEM, V266, P20797; TAYLOR AF, 1982, J BACTERIOL, V151, P351, DOI 10.1128/JB.151.1.351-357.1982; WESTON SA, 1992, J MOL BIOL, V226, P1237, DOI 10.1016/0022-2836(92)91064-V	24	338	363	1	67	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					381	386		10.1038/374381a0	http://dx.doi.org/10.1038/374381a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885481				2022-12-28	WOS:A1995QN63000066
J	DESSEN, A; QUEMARD, A; BLANCHARD, JS; JACOBS, WR; SACCHETTINI, JC				DESSEN, A; QUEMARD, A; BLANCHARD, JS; JACOBS, WR; SACCHETTINI, JC			CRYSTAL-STRUCTURE AND FUNCTION OF THE ISONIAZID TARGET OF MYCOBACTERIUM-TUBERCULOSIS	SCIENCE			English	Article							CATALASE-PEROXIDASE GENE; MYCOLIC ACID SYNTHESIS; RESISTANT STRAINS; SEQUENCES	Resistance to isoniazid in Mycobacterium tuberculosis can be mediated by substitution of alanine for serine 94 in the InhA protein, the drug's primary target. InhA was shown to catalyze the beta-nicotinamide adenine dinucleotide (NADH)-specific reduction of 2-trans-enoyl-acyl carrier protein, an essential step in fatty acid elongation. Kinetic analyses suggested that isoniazid resistance is due to a decreased affinity of the mutant protein for NADH. The three-dimensional structures of wild-type and mutant InhA, refined to 2.2 and 2.7 angstroms, respectively, revealed that drug resistance is directly related to a perturbation in the hydrogen-bonding network that stabilizes NADH binding.	YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT MICROBIOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT IMMUNOL,BRONX,NY 10461; YESHIVA UNIV ALBERT EINSTEIN COLL MED,HOWARD HUGHES MED INST,BRONX,NY 10461	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine				Dessen, Andrea/0000-0001-6487-4020; Jacobs, William/0000-0003-3321-3080; Quemard, Annaik/0000-0002-5545-3424	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030189, R01AI033696, U01AI036849] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30189, AI33696, AI36849] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERGLER H, 1994, J BIOL CHEM, V269, P5493; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GRASSBERGER MA, 1984, J MED CHEM, V27, P947, DOI 10.1021/jm00374a003; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; HOWARD AJ, 1986, GUIDE DATA REDUCTION; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MCREE DE, 1993, PRACTICAL PROTEIN CR, P303; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; QUEMARD A, UNPUB; Rossman M.G., 1975, ENZYMES, V11, P61, DOI 10.1016/S1874-6047(08)60210-3; SLABAS AR, 1986, BIOCHIM BIOPHYS ACTA, V877, P271, DOI 10.1016/0005-2760(86)90304-8; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TRONRUD DE, 1988, ACTA CRYSTALLOGR A, V43, P489; WANG BC, 1985, METHOD ENZYMOL, V115, P90; Winder F, 1982, BIOL MYCOBACTERIA, V1, P354; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	27	380	397	2	56	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1638	1641		10.1126/science.7886450	http://dx.doi.org/10.1126/science.7886450			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886450				2022-12-28	WOS:A1995QM39700034
J	SZATHMARY, E; SMITH, JM				SZATHMARY, E; SMITH, JM			THE MAJOR EVOLUTIONARY TRANSITIONS	NATURE			English	Review							NATURAL-SELECTION; ORIGIN; CHROMOSOMES; MECHANISMS; TEMPLATES; MODELS; GROWTH; CELLS; LIFE	There is no theoretical reason to expect evolutionary lineages to increase in complexity with time, and no empirical evidence that they do so. Nevertheless, eukaryotic cells are more complex than prokaryotic ones, animals and plants are more complex than protists, and so on. This increase in complexity may have been achieved as a result of a series of major evolutionary transitions. These involved changes in the way information is stored and transmitted.	EOTVOS LORAND UNIV, DEPT PLANT TAXON & ECOL, ECOL MODELLING RES GRP, H-1083 BUDAPEST, HUNGARY; UNIV SUSSEX, SCH BIOL SCI, BRIGHTON BN1 9QG, E SUSSEX, ENGLAND	Eotvos Lorand University; University of Sussex	SZATHMARY, E (corresponding author), COLLEGIUM BUDAPEST, INST ADV STUDY, SZENTHAROMSAG U2, H-1014 BUDAPEST, HUNGARY.		Szathmáry, Eörs/A-5007-2011; Szathmary, Eors/AAS-1202-2021	Szathmary, Eors/0000-0001-5227-2997				BACHMANN PA, 1992, NATURE, V357, P57, DOI 10.1038/357057a0; Bell G., 1985, ORIGIN EVOLUTION SEX, P221; BENNER SA, 1987, COLD SPRING HARB SYM, V52, P53, DOI 10.1101/SQB.1987.052.01.009; Bickerton Derek, 1990, LANGUAGE SPECIES; Bonner JT., 1988, EVOLUTION COMPLEXITY; Buss LW, 1987, EVOLUTION INDIVIDUAL, DOI DOI 10.1515/9781400858712; CAIRNS-SMITH A G, 1974, Biosystems, V5, P173, DOI 10.1016/0303-2647(74)90030-6; Cavalier-Smith T, 1985, EVOLUTION GENOME SIZ; CAVALIERSMITH T, 1987, ANN NY ACAD SCI, V503, P17, DOI 10.1111/j.1749-6632.1987.tb40596.x; CHAMOV E, 1976, NATURE, V263, P125; CHARLESWORTH B, 1994, NATURE, V371, P215, DOI 10.1038/371215a0; Chomsky Noam., 1965, ASPECTS THEORY SYNTA; CROW JF, 1991, BIOESSAYS, V13, P305, DOI 10.1002/bies.950130609; Dawkins Richard, 1976, SELFISH GENE; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; FAMULOK M, IN PRESS J AM CHEM S; Ganti T., 1979, THEORY BIOCH SUPERSY; Ganti T, 1975, BIOSYSTEMS, V7, P189, DOI [10.1016/0303-2647(75)90057-X, DOI 10.1016/0303-2647(75)90057-X]; Ganti T., 1987, PRINCIPLE LIFE; GOPNIK M, 1990, NATURE, V344, P715, DOI 10.1038/344715a0; HAMILTON WD, 1964, J THEOR BIOL, V7, P1, DOI [10.1016/0022-5193(64)90038-4, 10.1016/0022-5193(64)90039-6]; Hinton G. E., 1987, Complex Systems, V1, P495; HURST LD, 1992, P ROY SOC B-BIOL SCI, V247, P189, DOI 10.1098/rspb.1992.0027; HURST LD, 1992, P ROY SOC B-BIOL SCI, V248, P135, DOI 10.1098/rspb.1992.0053; HUTSON V, 1993, P ROY SOC LOND B BIO, V283, P43; JABLONKA E, 1994, J THEOR BIOL, V170, P301, DOI 10.1006/jtbi.1994.1191; Jablonka E., 1995, EPIGENETIC INHERITAN; JEON KW, 1991, SYMBIOSIS SOURCE EVO, P118; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; JOYCE GF, 1987, P NATL ACAD SCI USA, V84, P4398, DOI 10.1073/pnas.84.13.4398; KACSER H, 1984, J MOL EVOL, V20, P38, DOI 10.1007/BF02101984; KING GAM, 1980, BIOSYSTEMS, V13, P23, DOI 10.1016/0303-2647(80)90003-9; KIRK DL, 1988, TRENDS GENET, V4, P32, DOI 10.1016/0168-9525(88)90063-7; KOCH AL, 1985, J MOL EVOL, V21, P270, DOI 10.1007/BF02102359; KOUFOPANOU V, 1994, AM NAT, V143, P907, DOI 10.1086/285639; LAZCANO A, 1988, J MOL EVOL, V27, P283, DOI 10.1007/BF02101189; Leigh E.G., 1971, ADAPTATION DIVERSITY; LEIGH EG, 1991, TRENDS ECOL EVOL, V6, P257, DOI 10.1016/0169-5347(91)90073-7; MAIZELS N, 1994, P NATL ACAD SCI USA, V91, P6729, DOI 10.1073/pnas.91.15.6729; Margulis L., 1993, SYMBIOSIS CELL EVOLU; MAYNARD SMITH J., 1978, EVOLUTION SEX; MOLNAR I, 1993, ABSTR BOT, V17, P207; PINKER S, 1990, BEHAV BRAIN SCI, V13, P707, DOI 10.1017/S0140525X00081061; Pinker S, 1994, LANGUAGE INSTINCT NE; PRUDENT JR, 1994, SCIENCE, V264, P1924; Rasbach H., 1979, BER BAYER BOT GES, V50, P23; RENSCH B, 1966, EVOLUTION SPECIES LE; SMITH A, 1777, WEALTH NATIONS; SMITH JM, 1983, PROC R SOC SER B-BIO, V219, P315, DOI 10.1098/rspb.1983.0076; SMITH JM, 1993, J THEOR BIOL, V164, P437, DOI 10.1006/jtbi.1993.1165; SZATHMARY E, 1989, J THEOR BIOL, V138, P55, DOI 10.1016/S0022-5193(89)80177-8; SZATHMARY E, 1990, NATURE, V344, P115, DOI 10.1038/344115a0; SZATHMARY E, 1993, P NATL ACAD SCI USA, V90, P9916, DOI 10.1073/pnas.90.21.9916; SZATHMARY E, 1987, J THEOR BIOL, V128, P463, DOI 10.1016/S0022-5193(87)80191-1; SZATHMARY E, 1991, TRENDS ECOL EVOL, V6, P366, DOI 10.1016/0169-5347(91)90228-P; SZATHMARY E, 1989, TRENDS ECOL EVOL, V4, P200, DOI 10.1016/0169-5347(89)90073-6; SZATHMARY E, 1993, J THEOR BIOL, V164, P447, DOI 10.1006/jtbi.1993.1166; Szathmary E., 1989, Oxford Surveys in Evolutionary Biology, V6, P169; SZATHMARY E, 1994, J THEOR BIOL, V169, P125, DOI 10.1006/jtbi.1994.1134; Szathmary E, 1995, MAJOR TRANSITIONS EV; TARUMI K, 1987, B MATH BIOL, V49, P307, DOI 10.1016/S0092-8240(87)80026-5; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113; VONKLEDROWSKI G, 1986, ANGEW CHEM INT EDIT, V25, P923; WACHTERSHAUSER G, 1994, P NATL ACAD SCI USA, V91, P4283, DOI 10.1073/pnas.91.10.4283; WACHTERSHAUSER G, 1988, MICROBIOL REV, V52, P452; WACHTERSHAUSER G, 1992, PROG BIOPHYS MOL BIO, V58, P85, DOI 10.1016/0079-6107(92)90022-X; Williams G. C., 1966, P307; WILSON DS, 1989, J THEOR BIOL, V136, P337, DOI 10.1016/S0022-5193(89)80169-9; Wilson E.O., 1975, P1; WOLPERT L, 1990, BIOL J LINN SOC, V39, P109, DOI 10.1111/j.1095-8312.1990.tb00506.x; YCAS M, 1955, P NATL ACAD SCI USA, V41, P714, DOI 10.1073/pnas.41.10.714	72	646	660	3	209	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 16	1995	374	6519					227	232		10.1038/374227a0	http://dx.doi.org/10.1038/374227a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885442				2022-12-28	WOS:A1995QM38700040
J	MCMANUS, IC; RICHARDS, P; WINDER, BC; SPROSTON, KA; STYLES, V				MCMANUS, IC; RICHARDS, P; WINDER, BC; SPROSTON, KA; STYLES, V			MEDICAL-SCHOOL APPLICANTS FROM ETHNIC-MINORITY GROUPS - IDENTIFYING IF AND WHEN THEY ARE DISADVANTAGED	BRITISH MEDICAL JOURNAL			English	Article							DISCRIMINATION; ADMISSION; STUDENTS	Objective-To assess whether people from ethnic minority groups are less likely to be accepted at British medical schools, and to explore the mechanisms of disadvantage. Design-Prospective study of a national cohort of medical school applicants. Setting-All 28 medical schools in the United Kingdom. Subjects-6901 subjects who had applied through the Universities' Central Council on Admissions in 1990 to study medicine. Main outcome measures-Offers and acceptance at medical school by ethnic group. Results-Applicants from ethnic minority groups constituted 26.3% of those applying to medical school. They were less likely to be accepted, partly because they were less well qualified and applied later. Nevertheless, taking educational and some other predictors into account, applicants from ethnic minority groups were 1.46 times (95% confidence interval 1.19 to 1.74) less likely to be accepted. Having a European surname predicted acceptance better than ethnic origin itself, implying direct discrimination rather than disadvantage secondary to other possible differences between white and non-white applicants. Applicants from ethnic minority groups fared significantly less well in 12 of the 28 British medical schools. Analysis of the selection process suggests that medical schools make fewer offers to such applicants than to others with equivalent estimated A level grades. Conclusions-People from ethnic minority groups applying to medical school are disadvantaged, principally because ethnic origin is assessed from candidate's surname; the disadvantage has diminished since 1986. For subjects applying before A level the mechanism is that less credit is given to referees' estimates of A level grades. Selection would be fairer if (a) application forms were anonymous; (b) forms did not include estimates of A level grades; and (c) selection took place after A level results are known.			MCMANUS, IC (corresponding author), UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,ST MARYS HOSP,SCH MED,LONDON W2 1PG,ENGLAND.			McManus, Ian/0000-0003-3510-4814; Winder, Belinda/0000-0002-9118-679X				AITKIN M, 1989, STATISTICAL MODELLIN; Bentler P M, 1992, Stat Methods Med Res, V1, P159, DOI 10.1177/096228029200100203; COHEN J, 1960, EDUC PSYCHOL MEAS, V10, P37; COLLIER J, 1986, MED EDUC, V20, P86, DOI 10.1111/j.1365-2923.1986.tb01052.x; JORESKOG K, 1993, PRELIS 2 USERS REFER; Jû┬reskog KG., 1993, LISREL 8 USERS REFER; Kenny D.A, 1979, CORRELATION CAUSALIT; KINGMAN S, 1992, BRIT MED J, V304, P1266; Loehlin J. C., 1992, LATENT VARIABLE MODE; MCKEIGUE PM, 1990, BRIT MED J, V301, P961, DOI 10.1136/bmj.301.6758.961; MCMANUS IC, 1990, STUD HIGH EDUC, V15, P57, DOI 10.1080/03075079012331377591; MCMANUS IC, 1984, BRIT MED J, V289, P1201, DOI 10.1136/bmj.289.6453.1201; MCMANUS IC, 1985, BRIT MED J, V290, P319, DOI 10.1136/bmj.290.6464.319-c; MCMANUS IC, 1989, BRIT MED J, V298, P723, DOI 10.1136/bmj.298.6675.723; Rosenthal R., 1984, META ANAL PROCEDURES; TAYLOR P, 1992, ETHNIC GROUP DATA U; 1993, CENSUS REPORTS REPOR, P134; 1988, REPORT FORMAL INVEST; 1992, UCCA STATISTICAL S 2	19	67	67	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					496	500		10.1136/bmj.310.6978.496	http://dx.doi.org/10.1136/bmj.310.6978.496			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ598	7888888	Green Accepted, Green Published			2022-12-28	WOS:A1995QJ59800020
J	WEBB, DJ; HAYNES, WG				WEBB, DJ; HAYNES, WG			ENDOTHELINS COME OF AGE	LANCET			English	Editorial Material							RECEPTOR; CLONING				WEBB, DJ (corresponding author), UNIV EDINBURGH,WESTERN GEN HOSP,DEPT MED,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND.		Haynes, William G/D-5374-2013	Haynes, William G/0000-0003-1004-6136				ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; BENIGNI A, 1993, KIDNEY INT, V44, P440, DOI 10.1038/ki.1993.263; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CLOZEL M, 1993, CIRCULATION, V88, P316; HAYNES WG, 1993, CLIN SCI, V84, P485, DOI 10.1042/cs0840485; MCMAHON EG, 1991, J CARDIOVASC PHARM, V17, pS29, DOI 10.1097/00005344-199100177-00009; NISHIKIBE M, 1993, LIFE SCI, V52, P717, DOI 10.1016/0024-3205(93)90233-S; ROUX SP, 1993, CIRCULATION, V88, P170; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0	10	23	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1439	1440		10.1016/0140-6736(93)92928-M	http://dx.doi.org/10.1016/0140-6736(93)92928-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902478				2022-12-28	WOS:A1993ML21700004
J	BERNHARD, JD				BERNHARD, JD			BRINGING ON THE BACON FOR MYIASIS	LANCET			English	Editorial Material											BERNHARD, JD (corresponding author), UNIV MASSACHUSETTS,MED CTR,DIV DERMATOL,WORCESTER,MA 01605, USA.							BREWER TF, 1993, JAMA-J AM MED ASSOC, V270, P2087, DOI 10.1001/jama.270.17.2087; CANIZARES O, 1992, CLIN TROPICAL DERMAT, P404; JAMES AS, 1992, ARCH EMERG MED, V9, P58; LYELL A, 1983, J AM ACAD DERMATOL, P895; PAMPIGLIONE S, 1992, BRIT J DERMATOL, V126, P418, DOI 10.1111/j.1365-2133.1992.tb00698.x; SANUSI ID, 1989, J AM ACAD DERMATOL, V20, P941, DOI 10.1016/S0190-9622(89)70115-8	6	9	10	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1377	1378						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901678				2022-12-28	WOS:A1993MK09500006
J	MAHMOUD, HH; HURWITZ, CA; ROBERTS, WM; SANTANA, VM; RIBEIRO, RC; KRANCE, RA				MAHMOUD, HH; HURWITZ, CA; ROBERTS, WM; SANTANA, VM; RIBEIRO, RC; KRANCE, RA			TRETINOIN TOXICITY IN CHILDREN WITH ACUTE PROMYELOCYTIC LEUKEMIA	LANCET			English	Note							TRANS-RETINOIC ACID; DIFFERENTIATION THERAPY; LEUKEMIA; CANCER	Tretinoin is effective in acute promyelocytic leukaemia in adults. Data about its efficacy and safety in children are limited. We have treated 9 children with tretinoin at 45 mg/m2 per day. Pseudotumour cerebri or hyperleucocytosis occurred in 5 patients. Retinoic acid syndrome was seen in 3 cases. 1 of 2 children who developed hyperleucocytosis, pseudotumour cerebri, and retinoic acid syndrome died despite steroids and mechanical ventilation. Complete remissions with tretinoin alone were achieved in 5 patients. All 8 surviving children received consolidation chemotherapy. Our experience with tretinoin therapy suggests that toxicity is frequent in children.	UNIV TENNESSEE, CTR HLTH SCI, COLL MED, DEPT PEDIAT, MEMPHIS, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	MAHMOUD, HH (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 323 N LAUDERDALE, POB 318, MEMPHIS, TN 38101 USA.				NATIONAL CANCER INSTITUTE [P01CA020180] Funding Source: NIH RePORTER; NCI NIH HHS [CA 20180] Funding Source: Medline; PHS HHS [21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AVVISATI G, 1991, HAEMATOLOGICA S4, V76, P16; CASTAIGNE S, 1990, BLOOD, V76, P1704; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; FRANKEL SR, 1992, ANN INTERN MED, V117, P292, DOI 10.7326/0003-4819-117-4-292; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAHN MJ, 1992, J NATL CANCER I, V84, P1669, DOI 10.1093/jnci/84.21.1669; KURZROCK R, 1993, J CLIN ONCOL, V11, P1489, DOI 10.1200/JCO.1993.11.8.1489; SMITH MA, 1992, J CLIN ONCOL, V10, P1666, DOI 10.1200/JCO.1992.10.11.1666; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307	10	77	79	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1394	1395		10.1016/0140-6736(93)92755-I	http://dx.doi.org/10.1016/0140-6736(93)92755-I			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901684				2022-12-28	WOS:A1993MK09500012
J	KAMOGAWA, Y; MINASI, LAE; CARDING, SR; BOTTOMLY, K; FLAVELL, RA				KAMOGAWA, Y; MINASI, LAE; CARDING, SR; BOTTOMLY, K; FLAVELL, RA			THE RELATIONSHIP OF IL-4-PRODUCING AND IFN-GAMMA-PRODUCING T-CELLS STUDIED BY LINEAGE ABLATION OF IL-4-PRODUCING CELLS	CELL			English	Article							STIMULATORY FACTOR-I; SIMPLEX VIRUS TYPE-1; EXPRESSES B-CELL; MONOCLONAL-ANTIBODY; THYMIDINE KINASE; MESSENGER-RNA; TH2 CLONES; IL-4; INTERLEUKIN-4; MICE	Subsets of CD4 T cells are defined by the cytokines that they produce; these cytokines determine the effector function of these cells. Cloned CD4 T cells fall into two subsets, producing either interferon-gamma (IFNgamma) or interleukin-4 (IL-4) in combination with other cytokines, and are called Th1 and Th2 cells, respectively. The lineage relationship between naive T cells and effector Th1- and Th2-type cells is unclear. We generated transgenic mice in which IL-4-producing cells express herpes simplex virus 1 thymidine kinase and are eliminated by ganciclovir (GANC). Activation of transgenic T cells in the presence of GANC eliminates IL-4 and IFNgamma production, showing that IL-4- and IFNgamma-producing cells express or have expressed IL-4. These results show that effector cells producing either IL-4 or IFNgamma have a common precursor, which expresses the IL-4 gene.	UNIV PENN,SCH MED,HOWARD HUGHES MED INST,PHILADELPHIA,PA 19106; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19106	Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	KAMOGAWA, Y (corresponding author), YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06510, USA.			Carding, Simon/0000-0002-2383-9701				ABEHSIRAAMAR O, 1992, J IMMUNOL, V148, P3820; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; BETZ M, 1990, J IMMUNOL, V145, P1046; BOOM WH, 1988, J EXP MED, V167, P1350, DOI 10.1084/jem.167.4.1350; BORRELLI E, 1988, P NATL ACAD SCI USA, V85, P1; Bottomly K, 1989, Semin Immunol, V1, P21; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; CARDING SR, 1989, EUR J IMMUNOL, V19, P231, DOI 10.1002/eji.1830190203; CHER DJ, 1987, J IMMUNOL, V138, P3688; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; EHLERS S, 1991, J EXP MED, V173, P25, DOI 10.1084/jem.173.1.25; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FIRESTEIN GS, 1989, J IMMUNOL, V143, P518; HEINZEL FP, 1993, J EXP MED, V177, P1505, DOI 10.1084/jem.177.5.1505; HENKEL G, 1992, J IMMUNOL, V149, P3239; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; JONES B, 1983, EUR J IMMUNOL, V13, P678, DOI 10.1002/eji.1830130813; KILLAR L, 1987, J IMMUNOL, V138, P1674; KIM J, 1985, J EXP MED, V162, P188, DOI 10.1084/jem.162.1.188; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LANDAIS D, 1986, J IMMUNOL, V137, P3002; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MAGGI E, 1992, J IMMUNOL, V148, P2142; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MINASI LAE, 1993, J EXP MED, V177, P1451, DOI 10.1084/jem.177.5.1451; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MURRAY JS, 1989, J EXP MED, V170, P2135, DOI 10.1084/jem.170.6.2135; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; OHARA J, 1985, NATURE, V315, P333, DOI 10.1038/315333a0; OTSUKA T, 1987, NUCLEIC ACIDS RES, V15, P333, DOI 10.1093/nar/15.1.333; PLATZER C, 1992, EUR J IMMUNOL, V22, P1179, DOI 10.1002/eji.1830220511; POWERS GD, 1988, J IMMUNOL, V140, P3352; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SIDERAS P, 1988, P NATL ACAD SCI USA, V85, P218, DOI 10.1073/pnas.85.1.218; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; STOUT RD, 1989, J IMMUNOL, V142, P760; STREET NE, 1990, J IMMUNOL, V144, P1629; SUMMERS WC, 1977, J VIROL, V24, P314, DOI 10.1128/JVI.24.1.314-318.1977; SWAIN SL, 1991, J IMMUNOL, V147, P2991; SWAIN SL, 1988, J IMMUNOL, V141, P3445; SWAIN SL, 1990, J IMMUNOL, V145, P3796; SYPEK JP, 1993, J EXP MED, V177, P1797, DOI 10.1084/jem.177.6.1797; TITE JP, 1985, J IMMUNOL, V135, P25; TODD MD, 1993, J EXP MED, V177, P1663, DOI 10.1084/jem.177.6.1663; WAGNER MJ, 1981, P NATL ACAD SCI-BIOL, V78, P1441, DOI 10.1073/pnas.78.3.1441	48	269	273	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 3	1993	75	5					985	995		10.1016/0092-8674(93)90542-X	http://dx.doi.org/10.1016/0092-8674(93)90542-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MK966	7902780	hybrid			2022-12-28	WOS:A1993MK96600018
J	LAU, JYN; WRIGHT, TL				LAU, JYN; WRIGHT, TL			MOLECULAR VIROLOGY AND PATHOGENESIS OF HEPATITIS-B	LANCET			English	Article							VIRUS NUCLEOCAPSID ANTIGEN; LARGE ENVELOPE POLYPEPTIDE; CORE ANTIGEN; INTERFERON-GAMMA; SURFACE-ANTIGEN; TRANSGENIC MICE; PRECORE REGION; INFECTION; EXPRESSION; WITHDRAWAL		UNIV CALIF SAN FRANCISCO, GASTROENTEROL SECT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, VET ADM MED CTR, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	LAU, JYN (corresponding author), UNIV FLORIDA, DEPT MED, DIV GASTROENTEROL HEPATOL & NUTR, HEPATOBILIARY DIS SECT, GAINESVILLE, FL 32610 USA.							BIRD GLA, 1989, Q J MED, V73, P895; BRUNETTO MR, 1990, J HEPATOL, V10, P258, DOI 10.1016/0168-8278(90)90062-V; CARMAN WF, 1990, LANCET, V336, P325, DOI 10.1016/0140-6736(90)91874-A; CARMAN WF, 1989, LANCET, V2, P588; CARMAN WF, 1991, HEPATOLOGY, V14, P219, DOI 10.1002/hep.1840140203; CHISARI FV, 1987, P NATL ACAD SCI USA, V84, P6909, DOI 10.1073/pnas.84.19.6909; CHISARI FV, 1986, J VIROL, V60, P880, DOI 10.1128/JVI.60.3.880-887.1986; Chu CM, 1987, GASTROENTEROLOGY, V92, P220, DOI 10.1016/0016-5085(87)90863-8; CHU CM, 1987, HEPATOLOGY, V7, P1311, DOI 10.1002/hep.1840070622; EHATA T, 1992, J CLIN INVEST, V89, P332, DOI 10.1172/JCI115581; FERRARI C, 1991, J CLIN INVEST, V88, P214, DOI 10.1172/JCI115280; FOSTER GR, 1991, P NATL ACAD SCI USA, V88, P2888, DOI 10.1073/pnas.88.7.2888; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; GERLICH WH, 1993, J HEPATOL, V17, pS10, DOI 10.1016/S0168-8278(05)80417-9; HEATHCOTE J, 1989, HEPATOLOGY, V9, P105, DOI 10.1002/hep.1840090118; IKEDA T, 1986, HEPATOLOGY, V6, P962, DOI 10.1002/hep.1840060525; LAU JYN, 1991, J MED VIROL, V34, P184, DOI 10.1002/jmv.1890340310; LAU JYN, 1992, GASTROENTEROLOGY, V102, P956, DOI 10.1016/0016-5085(92)90182-X; LAU JYN, 1989, Q J MED, V73, P911; LAU JYN, 1991, LANCET, V337, P802, DOI 10.1016/0140-6736(91)91433-U; LAU JYN, 1992, J CLIN PATHOL, V45, P314, DOI 10.1136/jcp.45.4.314; LAU JYN, 1991, GUT, V5, pS47; LIANG TJ, 1991, NEW ENGL J MED, V324, P1705, DOI 10.1056/NEJM199106133242405; LIN HJ, 1990, LANCET, V336, P208, DOI 10.1016/0140-6736(90)91735-S; Maynard JE, 1988, VIRAL HEPATITIS LIVE, P967; MIELIVERGANI G, 1982, GUT, V23, P1029, DOI 10.1136/gut.23.12.1029; MILICH DR, 1990, P NATL ACAD SCI USA, V87, P6599, DOI 10.1073/pnas.87.17.6599; MILLER RH, 1986, P NATL ACAD SCI USA, V83, P2531, DOI 10.1073/pnas.83.8.2531; NAUMOV NV, 1984, HEPATOLOGY, V4, P63, DOI 10.1002/hep.1840040111; NOURIARIA KT, 1991, HEPATOLOGY, V13, P1029, DOI 10.1016/0270-9139(91)92467-M; OMATA M, 1991, NEW ENGL J MED, V324, P1699, DOI 10.1056/NEJM199106133242404; ONJI M, 1989, HEPATOLOGY, V9, P92, DOI 10.1002/hep.1840090115; OU JH, 1986, P NATL ACAD SCI USA, V83, P1578, DOI 10.1073/pnas.83.6.1578; PENNA A, 1991, J EXP MED, V174, P1565, DOI 10.1084/jem.174.6.1565; PERSING DH, 1986, SCIENCE, V234, P1388, DOI 10.1126/science.3787251; ROINGEARD P, 1990, VIROLOGY, V179, P113, DOI 10.1016/0042-6822(90)90280-5; ROSSI S, 1989, J INFECT DIS, V169, P815; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SHERON N, 1990, LANCET, V336, P321, DOI 10.1016/0140-6736(90)91866-9; SUMMERS J, 1990, J VIROL, V64, P2819, DOI 10.1128/JVI.64.6.2819-2824.1990; TWU JS, 1988, P NATL ACAD SCI USA, V85, P252, DOI 10.1073/pnas.85.1.252; UY A, 1986, VIROLOGY, V155, P89, DOI 10.1016/0042-6822(86)90170-4; VENTO S, 1987, LANCET, V2, P119; WAKITA T, 1991, J CLIN INVEST, V88, P1793, DOI 10.1172/JCI115500; WU PC, IN PRESS AM J CLIN P	45	176	186	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1993	342	8883					1335	1340						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901639				2022-12-28	WOS:A1993MJ03900012
J	PARRY, ML; ROSENZWEIG, C				PARRY, ML; ROSENZWEIG, C			FOOD-SUPPLY AND RISK OF HUNGER	LANCET			English	Article									COLUMBIA UNIV,NEW YORK,NY 10027; GODDARD INST SPACE STUDIES,NEW YORK,NY 10025	Columbia University; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	PARRY, ML (corresponding author), UNIV OXFORD,ENVIRONM CHANGE UNIT,1A MANSFIELD RD,OXFORD OX1 3TB,ENGLAND.							[Anonymous], 1992, CLIMATE CHANGE SUPPL; Peart R.M., 1989, POTENTIAL EFFECTS GL; ROSENZWEIG C, 1993, 3 ENV CHANG UN ENV C; ROSENZWEIG C, IN PRESS IMPLICATION; 1989, DECISION SUPPORT SYS	5	24	26	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1345	1347		10.1016/0140-6736(93)92251-N	http://dx.doi.org/10.1016/0140-6736(93)92251-N			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901640				2022-12-28	WOS:A1993MJ03900014
J	WATLING, D; GUSCHIN, D; MULLER, M; SILVENNOINEN, O; WITTHUHN, BA; QUELLE, FW; ROGERS, NC; SCHINDLER, C; STARK, GR; IHLE, JN; KERR, IM				WATLING, D; GUSCHIN, D; MULLER, M; SILVENNOINEN, O; WITTHUHN, BA; QUELLE, FW; ROGERS, NC; SCHINDLER, C; STARK, GR; IHLE, JN; KERR, IM			COMPLEMENTATION BY THE PROTEIN-TYROSINE KINASE JAK2 OF A MUTANT-CELL LINE DEFECTIVE IN THE INTERFERON-GAMMA SIGNAL-TRANSDUCTION PATHWAY	NATURE			English	Article							IFN-GAMMA; PHOSPHORYLATION; TRANSCRIPTION; ACTIVATION; RECEPTOR; ANTIGEN; DOMAIN	INTERFERONS (IFNs) alpha/beta (type I) and gamma (type II) bind to distinct cell surface receptors1, inducing transcription of overlapping sets of genes by intracellular pathways that have recently attracted much attention2,3. Previous studies using cell lines selected for their inability to respond to IFN-alpha (ref. 4) have shown that the protein kinase Tyk2 plays a central role in the IFN alpha/beta response5. Here we report the isolation of the cell line gamma1A, selected for its inability to express IFN-gamma-inducible cell-surface markers, that is deficient in all aspects of the IFN-gamma response tested, but responds normally to IFNs alpha and beta. The mutant cells can be complemented by the expression of another member of the JAK family of protein tyrosine kinases, JAK2 (refs 6-9). Unlike IFNs alpha and beta, IFN-gamma induces rapid tyrosine phosphorylation of JAK2 in wild-type cells, and JAK2 immunoprecipitates from these cells show tyrosine kinase activity. These responses are absent in gamma1A cells. JAK2 is therefore required for the response to IFN-gamma but not to IFNs alpha and beta.	NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA; COLUMBIA UNIV, MED CTR, DEPT MOLEC MED, NEW YORK, NY 10032 USA; CLEVELAND CLIN FDN, RES INST, DEPT MOLEC BIOL, CLEVELAND, OH 44195 USA	New York University; St Jude Children's Research Hospital; Columbia University; Cleveland Clinic Foundation	WATLING, D (corresponding author), IMPERIAL CANC RES FUND, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.		Guschin, Dmitry/U-3731-2019; witthuhn, bruce/GSE-3193-2022; Guschin, Dmitry/O-7594-2018	Guschin, Dmitry/0000-0002-4184-0001; Guschin, Dmitry/0000-0002-4184-0001; Rogers, Neil/0000-0001-8977-7585; Quelle, Frederick/0000-0002-1184-6170; Muller, Mathias/0000-0002-7879-3552				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1328; HARPUR AG, 1992, ONCOGENE, V7, P1347; IGARASHI K, 1993, MOL CELL BIOL, V13, P3984, DOI 10.1128/MCB.13.7.3984; KANNO Y, 1993, MOL CELL BIOL, V13, P3951, DOI 10.1128/MCB.13.7.3951; KHAN KD, 1993, P NATL ACAD SCI USA, V90, P6806, DOI 10.1073/pnas.90.14.6806; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P1068, DOI 10.1093/nar/18.4.1068; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; PEARSE RN, 1993, P NATL ACAD SCI USA, V90, P4314, DOI 10.1073/pnas.90.9.4314; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; PELLEGRINI S, 1989, MOL CELL BIOL, V9, P4605, DOI 10.1128/MCB.9.11.4605; PEREZ C, 1993, MOL CELL BIOL, V13, P2182, DOI 10.1128/MCB.13.4.2182; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; REID LE, 1989, P NATL ACAD SCI USA, V86, P840, DOI 10.1073/pnas.86.3.840; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEWELL WA, 1986, P NATL ACAD SCI USA, V83, P8718, DOI 10.1073/pnas.83.22.8718; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STASHL N, 1993, CELL, V74, P587; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	27	478	486	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 11	1993	366	6451					166	170		10.1038/366166a0	http://dx.doi.org/10.1038/366166a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MG216	7901766				2022-12-28	WOS:A1993MG21600060
J	OBOYLE, CA				OBOYLE, CA			DISEASES WITH PASSION	LANCET			English	Editorial Material							SURVIVAL; CANCER				OBOYLE, CA (corresponding author), ROYAL COLL SURGEONS IRELAND,SCH MED,DEPT PSYCHOL,DUBLIN 2,IRELAND.			O'Boyle, Ciaran/0000-0003-0254-8603				ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; GREER S, 1991, PSYCHOL MED, V21, P43, DOI 10.1017/S003329170001463X; PHILLIPS DP, 1988, LANCET, V2, P728; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P728; SPIEGEL D, 1989, LANCET, V2, P888; Taylor S. E., 1989, POSITIVE ILLUSIONS C	6	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1126	1127		10.1016/0140-6736(93)92116-B	http://dx.doi.org/10.1016/0140-6736(93)92116-B			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901468				2022-12-28	WOS:A1993MF19800002
J	SHERLOCK, S				SHERLOCK, S			EUROPEAN LIVERS	LANCET			English	Editorial Material											SHERLOCK, S (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT SURG,LONDON,ENGLAND.								0	8	8	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1127	1128		10.1016/0140-6736(93)92117-C	http://dx.doi.org/10.1016/0140-6736(93)92117-C			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901469				2022-12-28	WOS:A1993MF19800003
J	COYLE, JT; PUTTFARCKEN, P				COYLE, JT; PUTTFARCKEN, P			OXIDATIVE STRESS, GLUTAMATE, AND NEURODEGENERATIVE DISORDERS	SCIENCE			English	Article							EXCITATORY AMINO-ACIDS; AMYOTROPHIC-LATERAL-SCLEROSIS; CEREBELLAR GRANULE CELLS; FOCAL CEREBRAL-ISCHEMIA; CENTRAL-NERVOUS-SYSTEM; FREE-RADICAL FORMATION; NITRIC-OXIDE; KAINIC ACID; STRIATAL NEURONS; SUPEROXIDE-DISMUTASE	There is an increasing amount of experimental evidence that oxidative stress is a causal, or at least an ancillary, factor in the neuropathology of several adult neurodegenerative disorders, as well as in stroke, trauma, and seizures. At the same time, excessive or persistent activation of glutamate-gated ion channels may cause neuronal degeneration in these same conditions. Glutamate and related acidic amino acids are thought to be the major excitatory neurotransmitters in brain and may be utilized by 40 percent of the synapses. Thus, two broad mechanisms-oxidative stress and excessive activation of glutamate receptors-are converging and represent sequential as well as interacting processes that provide a final common pathway for cell vulnerability in the brain. The broad distribution in brain of the processes regulating oxidative stress and mediating glutamatergic neurotransmission may explain the wide range of disorders in which both have been implicated. Yet differential expression of components of the processes in particular neuronal systems may account for selective neurodegeneration in certain disorders.			COYLE, JT (corresponding author), HARVARD UNIV,SCH MED,DEPT PSYCHIAT,115 MILL ST,BELMONT,MA 02178, USA.							BALLARD PA, 1985, NEUROLOGY, V35, P949, DOI 10.1212/WNL.35.7.949; BAZZETT TJ, 1993, EXP NEUROL, V120, P177, DOI 10.1006/exnr.1993.1053; BEAL MF, 1991, J NEUROSCI, V11, P1649; BEAL MF, 1993, J NEUROCHEM, V61, P1147, DOI 10.1111/j.1471-4159.1993.tb03633.x; BEAL MF, 1988, J NEUROSCI, V8, P3901; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BENNAI S, 1980, J BIOL CHEM, V255, P2373; BENVENISTE H, 1984, J NEUROCHEM, V43, P1369, DOI 10.1111/j.1471-4159.1984.tb05396.x; BIERI JG, 1983, NEW ENGL J MED, V308, P1063, DOI 10.1056/NEJM198305053081805; BOUILLET E, 1993, J NEUROCHEM, V60, P356; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; CHAN PH, 1993, PROG BRAIN RES, V96, P97; CHAN PH, 1990, STROKE, V21, P80; CHAN PH, 1980, J NEUROCHEM, V35, P1004, DOI 10.1111/j.1471-4159.1980.tb07100.x; CHOI DW, 1990, CEREBROVAS BRAIN MET, V2, P105; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J NEUROSCI, V7, P357; COHEN G, 1989, ANN NEUROL, V26, P689, DOI 10.1002/ana.410260518; COYLE JT, 1983, J NEUROCHEM, V41, P1; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; COYLE JT, 1976, NATURE, V263, P244, DOI 10.1038/263244a0; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DERMERLEPALLARD.C, 1991, BIOCH RES COMMUN, V181, P456; DICHTER M, 1989, EPILEPSIA, V30, P53; DIFIGLIA M, 1990, TRENDS NEUROSCI, V13, P286, DOI 10.1016/0166-2236(90)90111-M; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; DYKENS JA, 1987, J NEUROCHEM, V49, P1222, DOI 10.1111/j.1471-4159.1987.tb10014.x; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; FAHN S, 1992, ANN NEUROL, V32, P804, DOI 10.1002/ana.410320616; FAVARON M, 1988, P NATL ACAD SCI USA, V85, P7351, DOI 10.1073/pnas.85.19.7351; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; FRIDOVICH I, 1989, J BIOL CHEM, V264, P7761; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; HALL E D, 1989, Journal of Neurotrauma, V6, P169, DOI 10.1089/neu.1989.6.169; HALL ED, 1993, J NEUROCHEM, V60, P588, DOI 10.1111/j.1471-4159.1993.tb03189.x; Halliwell B., 1989, FREE RADICAL BIO MED, P1; HALLIWELL B, 1989, ACTA NEUROL SCAND, V126, P23; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; HEIKKILA RE, 1973, SCIENCE, V181, P456, DOI 10.1126/science.181.4098.456; HEWETT SJ, IN PRESS BRAIN RES; HOLOPAINEN I, 1989, NEUROSCI LETT, V98, P57, DOI 10.1016/0304-3940(89)90373-X; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; INAGAKI S, 1991, BRAIN RES, V549, P174, DOI 10.1016/0006-8993(91)90618-6; JENNER P, 1991, ACTA NEUROL SCAND, V84, P6, DOI 10.1111/j.1600-0404.1991.tb05013.x; KATCHMAN AN, 1993, J NEUROPHYSIOL, V70, P1; KATO K, 1991, J PHARMACOL EXP THER, V256, P402; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; LAFONCAZAL M, 1993, NATURE, V364, P535, DOI 10.1038/364535a0; LAZAREWICZ JW, 1988, NEUROPHARMACOLOGY, V27, P765, DOI 10.1016/0028-3908(88)90088-3; LEHMANN A, 1990, EUR J NEUROSCI, V2, P620, DOI 10.1111/j.1460-9568.1990.tb00451.x; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCDONALD JW, 1990, BRAIN RES REV, V15, P41, DOI 10.1016/0165-0173(90)90011-C; MECOCCI P, IN PRESS ANN NEUROL; MELDRUM B, 1993, BRAIN RES REV, V18, P293, DOI 10.1016/0165-0173(93)90014-Q; MICHAELS RL, 1990, J NEUROSCI, V10, P283; MIYAMOTO M, 1989, J PHARMACOL EXP THER, V250, P1132; MIYAMOTO M, 1990, EXP NEUROL, V108, P38, DOI 10.1016/0014-4886(90)90005-D; MONCADA S, 1991, PHARMACOL REV, V43, P109; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; MURPHY SN, 1989, J PHARMACOL EXP THER, V249, P184; MURPHY TH, 1991, J NEUROCHEM, V56, P990, DOI 10.1111/j.1471-4159.1991.tb02019.x; MURPHY TH, 1990, FASEB J, V4, P1624, DOI 10.1096/fasebj.4.6.2180770; MURPHY TH, 1989, NEURON, V2, P1547, DOI 10.1016/0896-6273(89)90043-3; MURPHY TH, 1989, ANN NY ACAD SCI, V349, P474; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; NOVELLI A, 1988, BRAIN RES, V451, P205, DOI 10.1016/0006-8993(88)90765-2; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; OKA A, 1993, J NEUROSCI, V13, P1441; Olney J.W., 1978, KAINIC ACID TOOL NEU, P95; OLNEY JW, 1971, EXP BRAIN RES, V14, P61; PAUWELS PJ, 1992, NEUROSCI LETT, V143, P27, DOI 10.1016/0304-3940(92)90225-V; PELLEGRINIGIAMPIETRO DE, 1988, J NEUROCHEM, V51, P1960, DOI 10.1111/j.1471-4159.1988.tb01187.x; PERRY TL, 1990, NEUROLOGY, V40, P20, DOI 10.1212/WNL.40.1.20; PRZEDBORSKI S, 1992, J NEUROSCI, V12, P1658; PUTTFARCKEN PS, 1992, NEUROPHARMACOLOGY, V31, P565, DOI 10.1016/0028-3908(92)90189-V; PUTTFARCKEN PS, IN PRESS BRAIN RES; RATAN RR, IN PRESS J NEUROCHEM; RETZ KC, 1982, J NEUROCHEM, V38, P196, DOI 10.1111/j.1471-4159.1982.tb10872.x; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROTHMAN SM, 1987, NEUROSCIENCE, V22, P471, DOI 10.1016/0306-4522(87)90347-2; ROTHSTEIN JD, 1993, P NATL ACAD SCI USA, V90, P6591, DOI 10.1073/pnas.90.14.6591; ROTHSTEIN JD, 1992, NEW ENGL J MED, V326, P1464, DOI 10.1056/NEJM199205283262204; ROTHSTEIN JD, 1990, ANN NEUROL, V28, P18, DOI 10.1002/ana.410280106; SCHAPIRA AHV, 1992, MUTAT RES, V275, P133, DOI 10.1016/0921-8734(92)90018-K; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SCHWARCZ R, 1984, LIFE SCI, V35, P19, DOI 10.1016/0024-3205(84)90148-6; SCHWARCZ R, 1978, NEUROPHARMACOLOGY, V17, P145, DOI 10.1016/0028-3908(78)90127-2; SIESJO BK, 1992, J NEUROSURG, V77, P337, DOI 10.3171/jns.1992.77.3.0337; SIESJPO B K, 1989, Cerebrovascular and Brain Metabolism Reviews, V1, P165; SONSALLA PK, 1989, SCIENCE, V243, P398, DOI 10.1126/science.2563176; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; SUN AY, 1992, MOL CHEM NEUROPATHOL, V17, P51, DOI 10.1007/BF03159981; TELLEZNAGEL I, 1973, ADV NEUROL, V1, P387; TSAI G, IN PRESS BRAIN RES; TSAI GC, 1991, BRAIN RES, V556, P151, DOI 10.1016/0006-8993(91)90560-I; TURSKI L, 1991, NATURE, V349, P414, DOI 10.1038/349414a0; VORNOV JJ, 1991, BRAIN RES, V555, P99, DOI 10.1016/0006-8993(91)90865-S; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; YAMAMOTO S, 1992, J CEREBR BLOOD F MET, V12, P717, DOI 10.1038/jcbfm.1992.102; 1993, CELL, V72, P971	108	3328	3465	8	353	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 29	1993	262	5134					689	695		10.1126/science.7901908	http://dx.doi.org/10.1126/science.7901908			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MD952	7901908				2022-12-28	WOS:A1993MD95200031
J	LUBITZ, J; BEEBE, J; BAKER, C				LUBITZ, J; BEEBE, J; BAKER, C			LONGEVITY AND MEDICARE EXPENDITURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH; CARE; COMPRESSION; MORBIDITY; PAYMENTS; DEATH	Background. In the United States, the elderly account for over one third of health care spending. The total population over the age of 65 is projected to increase, as is life expectancy beyond the age of 65. We studied current patterns of Medicare expenses according to age at death and the possible effect of future demographic changes on Medicare spending. Methods. We used data from the Medicare program to estimate lifetime Medicare expenses for a sample of 129, 166 beneficiaries, 65 or older, who died in 1989 and 1990, according to age at death. Spending for nursing home care not covered by Medicare was excluded. (Nursing home costs represent about 20 percent of total health care spending for the elderly and increase with age.) Through simulation, we assessed the lifetime payments by Medicare for enrollees who turned 65 in 1990 and those who will do so in 2020. Results. Estimated lifetime Medicare payments (in 1990 dollars) ranged from $13,044 for persons who died at 65 years of age, to $56,094 for those who died at 80, to $65,633 for those who died at 101 or older. The payments associated with an additional year of life and the average annual payments over an enrollee's lifetime both decreased as the age at death increased. The estimated 7.9 percent increase in life expectancy beyond 65 years that will have taken place between 1990 and 2020 (19.1 years past the age of 65 in 2020, as compared with 17.7 years in 1990) was associated with an estimated increase of 2.0 percent in lifetime Medicare payments. Of the estimated $98 billion increase in total lifetime payments (in 1990 dollars) from the 1990 group to the 2020 group, 74.3 percent was due to the larger size of the original birth cohort who will reach the age of 65 in 2020, 22.5 percent to an increase in the proportion of that birth cohort projected to survive to 65 years of age, and 3.2 percent to improved life expectancy beyond 65. Conclusions. The effect on Medicare spending of increased longevity beyond the age of 65 may not be great. Total Medicare payments will be more substantially affected by the expected increase in the absolute number of elderly people.	HLTH ECON RES,WALTHAM,MA		LUBITZ, J (corresponding author), US HLTH CARE FINANCING ADM,OFF RES & DEMONSTRAT,ROOM 2504,OAK MEADOWS BLDG,6325 SECUR BLDG,BALTIMORE,MD 21207, USA.							FRIES JF, 1989, MILBANK Q, V67, P208, DOI 10.2307/3350138; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FUCHS VR, 1984, MILBANK FUND Q, V62, P143; GORNICK M, 1993, HEALTH AFFAIR, V12, P140, DOI 10.1377/hlthaff.12.2.140; KEMPER P, 1991, NEW ENGL J MED, V324, P595, DOI 10.1056/NEJM199102283240905; Letsch S W, 1992, Health Care Financ Rev, V14, P1; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; MANTON KG, 1991, POPUL DEV REV, V7, P603; OLSHANSKY SJ, 1993, SCI AM, V268, P46, DOI 10.1038/scientificamerican0493-46; OLSHANSKY SJ, 1990, SCIENCE, V250, P634, DOI 10.1126/science.2237414; Peden E A, 1991, Health Care Financ Rev, V13, P75; RICE DP, 1983, VITAL HLTH STATIST 3, V23; ROOS NP, 1987, MILBANK Q, V65, P231, DOI 10.2307/3350021; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; Waldo D R, 1989, Health Care Financ Rev, V10, P111; 1993, 1993 BOARD TRUST ANN; 1993, CURRENT POPULATION R, V1104	17	152	153	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	1995	332	15					999	1003		10.1056/NEJM199504133321506	http://dx.doi.org/10.1056/NEJM199504133321506			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QT737	7885430				2022-12-28	WOS:A1995QT73700006
J	TESCH, BJ; WOOD, HM; HELWIG, AL; NATTINGER, AB				TESCH, BJ; WOOD, HM; HELWIG, AL; NATTINGER, AB			PROMOTION OF WOMEN PHYSICIANS IN ACADEMIC MEDICINE - GLASS CEILING OR STICKY FLOOR	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNAL-MEDICINE; CAREER; MEN	Objective.-To assess possible explanations for the finding that the percentage of women medical school faculty members holding associate or full professor rank remains well below the percentage of men. Design.-Cross-sectional survey of physician faculty of US medical schools using the Association of American Medical Colleges (AAMC) database. Subjects.-Surveyed were 153 women and 263 men first appointed between 1979 and 1981, matched for institutions of original faculty appointment. Main Outcome Measures.-Academic rank achieved, career preparation, academic resources at first appointment, familial responsibilities, and academic productivity. Results.-After a mean of 11 years on a medical school faculty, 59% of women compared with 83% of men had achieved associate or full professor rank, and 5% of women compared with 23% of men had achieved full professor rank. Women and men reported similar preparation for an academic career, but women began their careers with fewer academic resources. The number of children was not associated with rank achieved. Women worked about 10% fewer hours per week and had authored fewer publications. After adjustment for productivity factors, women remained less likely to be associate or full professors (adjusted odds ratio [OR]=0.37; 95% confidence interval [CI], 0.21 to 0.66) or to achieve full professor rank (adjusted OR=0.27; 95% CI, 0.12 to 0.63). Based on the AAMC database, 50% of both women and men originally appointed as faculty members between 1979 and 1981 had left academic medicine by 1991. Conclusion.-Women physician medical school faculty are promoted more slowly than men. Gender differences in rank achieved are not explained by productivity or by differential attrition from academic medicine.			TESCH, BJ (corresponding author), MED COLL WISCONSIN,DEPT MED,DIV GEN INTERNAL MED,8700 W WISCONSIN AVE DH-135,MILWAUKEE,WI 53226, USA.			Nattinger, Ann/0000-0002-8189-3300				APPLEGATE WB, 1990, AM J MED, V88, P263, DOI 10.1016/0002-9343(90)90152-4; Bennett N M, 1992, J Am Med Womens Assoc (1972), V47, P115; BICKEL J, 1988, NEW ENGL J MED, V319, P1579, DOI 10.1056/NEJM198812153192405; BICKEL J, 1991, ACAD MED, V66, P497, DOI 10.1097/00001888-199108000-00025; BICKEL J, 1992, AAMC REPORTER, V1, P1; CARR P, 1993, ACAD MED, V68, P219, DOI 10.1097/00001888-199303000-00015; CARR PL, 1993, ANN INTERN MED, V119, P908, DOI 10.7326/0003-4819-119-9-199311010-00008; CONLEY FK, 1993, NEW ENGL J MED, V328, P351, DOI 10.1056/NEJM199302043280513; EISENBERG C, 1989, NEW ENGL J MED, V321, P1542, DOI 10.1056/NEJM198911303212210; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KOLB DM, 1991, J STATE GOVT, V64, P68; LEVEY BA, 1990, ACAD MED, V65, P102, DOI 10.1097/00001888-199002000-00011; LEVINSON W, 1989, NEW ENGL J MED, V321, P1511, DOI 10.1056/NEJM198911303212205; Levinson W, 1991, ANN INTERN MED, V114, P63; NADELSON CC, 1989, PSYCHIAT CLIN N AM, V12, P25; NICKERSON KG, 1990, JAMA-J AM MED ASSOC, V264, P1813, DOI 10.1001/jama.264.14.1813; VANDENBROOK T, 1993, MILWAUKEE SENTI 0724, pA4; VANDENBROOK T, 1993, MILWAUKEE SENTI 0724, pA1; WALLIS LA, 1981, JAMA-J AM MED ASSOC, V246, P2350, DOI 10.1001/jama.246.20.2350; WHITING BE, 1990, ACAD MED, V65, P277, DOI 10.1097/00001888-199004000-00013; 1992, STATA REFERENCE MANU	21	355	356	0	42	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1022	1025		10.1001/jama.273.13.1022	http://dx.doi.org/10.1001/jama.273.13.1022			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897785				2022-12-28	WOS:A1995QP89000032
J	NAYLOR, CD				NAYLOR, CD			GREY ZONES OF CLINICAL-PRACTICE - SOME LIMITS TO EVIDENCE-BASED MEDICINE	LANCET			English	Editorial Material							APPROPRIATENESS; CARE				NAYLOR, CD (corresponding author), SUNNYBROOK HLTH SCI CTR, INST CLIN EVALUAT SCI, 6106, 2075 BAYVIEW AVE, N YORK, ON M4N 3M5, CANADA.							[Anonymous], 1994, CANADIAN GUIDE CLIN; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Bernstein S J, 1993, Int J Technol Assess Health Care, V9, P3; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P2398, DOI 10.1001/jama.269.18.2398; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BROOK RH, 1988, LANCET, V1, P750; CHALMERS I, 1991, EFFECTIVE CARE PREGN; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; Fraser G M, 1993, Qual Assur Health Care, V5, P75; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; KAHN KL, 1988, J CLIN EPIDEMIOL, V41, P115, DOI 10.1016/0895-4356(88)90085-6; KASSIRER JP, 1987, ANN INTERN MED, V106, P275, DOI 10.7326/0003-4819-106-2-275; Leape L L, 1992, Qual Assur Health Care, V4, P151; LOMAS J, 1988, JAMA-J AM MED ASSOC, V259, P3001, DOI 10.1001/jama.259.20.3001; MCGLYNN EA, 1994, JAMA-J AM MED ASSOC, V272, P934, DOI 10.1001/jama.272.12.934; MERRICK NJ, 1986, JAMA-J AM MED ASSOC, V256, P2531, DOI 10.1001/jama.256.18.2531; PARK RE, 1989, AM J PUBLIC HEALTH, V79, P445, DOI 10.2105/AJPH.79.4.445; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; SCOTT E, 1991, J PUBLIC HEALTH MED, V13, P344; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; THOMAS L, 1977, DAEDALUS, V106, P35	21	448	470	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	1995	345	8953					840	842		10.1016/S0140-6736(95)92969-X	http://dx.doi.org/10.1016/S0140-6736(95)92969-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898234				2022-12-28	WOS:A1995QQ19500014
J	PARR, BA; MCMAHON, AP				PARR, BA; MCMAHON, AP			DORSALIZING SIGNAL WNT-7A REQUIRED FOR NORMAL POLARITY OF D-V AND A-P AXES OF MOUSE LIMB	NATURE			English	Article							APICAL ECTODERMAL RIDGE; CHICK LIMB; PATTERN-FORMATION; BUD CELLS; MORPHOGENESIS; INFORMATION; OUTGROWTH; MESODERM; DOMAINS; EMBRYOS	FORMATION Of the vertebrate limb requires specification of cell position along three axes(1). Proximal-distal identity is regulated by the apical ectodermal ridge (AER) at the distal tip of the growing limb(2-6). Anterior-posterior identity is controlled by signals from the zone of polarizing activity (ZPA) within the posterior limb mesenchyme(7-9). Dorsal-ventral identity is regulated by ectodermally derived signals(10-14). Recent studies have begun to identify signalling molecules that may mediate these patterning activities. Members of the fibroblast growth factor (FGF) family are expressed in the AER and can mimic its proximal-distal signalling activity(15,16). Similarly, the gene Sonic hedgehog (Shh) is expressed in the ZPA, and Shh-expressing cells, like ZPA cells, can cause digit duplications when transplan ted to the anterior limb margin. In contrast, no signal has yet been identified for the dorsal-ventral axis, although Wnt-7a is expressed in the dorsal ectoderm, suggesting that it mag play such a role(19,20). To test this possibility, we have generated mice lacking Wnt-7a activity. The limb mesoderm of these mice shows dorsal-to-ventral transformations of cell fate, indicating that Wnt-7a is a dorsalizing signal. Many mutant mice also lack posterior digits, demonstrating that Wnt-7a is also required for anterior-posterior patterning. We propose that normal limb development requires interactions between the signalling systems for these two axes.			PARR, BA (corresponding author), HARVARD UNIV, DEPT MOLEC & CELLULAR BIOL, 16 DIVIN AVE, CAMBRIDGE, MA 02138 USA.		McMahon, Andrew P/ABE-7520-2020					ANDERSON R, 1993, DEVELOPMENT, V117, P1421; BULFONE A, 1993, MECH DEVELOP, V40, P129, DOI 10.1016/0925-4773(93)90071-5; DAVIS CA, 1991, DEVELOPMENT, V111, P287; DEALY CN, 1993, MECH DEVELOP, V43, P175, DOI 10.1016/0925-4773(93)90034-U; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; FINCH RA, 1971, J EXP ZOOL, V176, P397, DOI 10.1002/jez.1401760403; GEDUSPAN JS, 1987, DEV BIOL, V124, P398, DOI 10.1016/0012-1606(87)90492-1; GEDUSPAN JS, 1989, ANAT REC, V224, P79, DOI 10.1002/ar.1092240110; GLOBUS M, 1976, DIFFERENTIATION, V6, P91, DOI 10.1111/j.1432-0436.1976.tb01474.x; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; LEE JJ, 1994, SCIENCE, V266, P1528, DOI 10.1126/science.7985023; LYONS KM, 1990, DEVELOPMENT, V109, P833; MACCABE JA, 1974, DEV BIOL, V39, P69, DOI 10.1016/S0012-1606(74)80009-6; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; PARR BA, 1993, DEVELOPMENT, V119, P247; REITER RS, 1982, DEV BIOL, V93, P28, DOI 10.1016/0012-1606(82)90235-4; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1948, J EXP ZOOL, V108, P363, DOI 10.1002/jez.1401080304; SMITH JC, 1978, NATURE, V272, P612, DOI 10.1038/272612a0; STARK RJ, 1974, DEV BIOL, V38, P51, DOI 10.1016/0012-1606(74)90258-9; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P651; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TABIN CJ, 1991, CELL, V66, P199, DOI 10.1016/0092-8674(91)90612-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; YANG Y, IN PRESS CELL	31	595	611	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 23	1995	374	6520					350	353		10.1038/374350a0	http://dx.doi.org/10.1038/374350a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885472				2022-12-28	WOS:A1995QN63000057
J	SHAPIRO, L; FANNON, AM; KWONG, PD; THOMPSON, A; LEHMANN, MS; GRUBEL, G; LEGRAND, JF; ALSNIELSEN, J; COLMAN, DR; HENDRICKSON, WA				SHAPIRO, L; FANNON, AM; KWONG, PD; THOMPSON, A; LEHMANN, MS; GRUBEL, G; LEGRAND, JF; ALSNIELSEN, J; COLMAN, DR; HENDRICKSON, WA			STRUCTURAL BASIS OF CELL-CELL ADHESION BY CADHERINS	NATURE			English	Article							INTERCELLULAR ADHERENS JUNCTIONS; EXPRESSION; IDENTIFICATION; MOLECULE	Crystal structures of the amino-terminal domain of N-cadherin provide a picture at the atomic level of a specific adhesive contact between cells. A repeated set of dimer interfaces is common to the structure in three lattices. These interactions combine to form a linear zipper of molecules that mirrors the linear structure of the intracellular filaments with which cadherins associate. This cell-adhesion zipper may provide a mechanism to marshal individual molecular adhesive interactions into strong bonds between cells.	COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; CUNY MT SINAI SCH MED,BROOKDALE CTR MOLEC BIOL,NEW YORK,NY 10029; EUROPEAN MOLEC BIOL LAB,F-38042 GRENOBLE,FRANCE; EUROPEAN SYNCHROTRON RADIAT FACIL,F-38043 GRENOBLE,FRANCE; INST MAX VON LAUE PAUL LANGEVIN,F-38042 GRENOBLE,FRANCE; UNIV GRENOBLE 1,SPECTROMETRIE PHYS LAB,CNRS,URA 8,F-38402 ST MARTIN DHERES,FRANCE; RISO NATL LAB,DK-4000 ROSKILDE,DENMARK	Columbia University; Howard Hughes Medical Institute; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; European Molecular Biology Laboratory (EMBL); European Synchrotron Radiation Facility (ESRF); Institut Laue-Langevin (ILL); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Technical University of Denmark	SHAPIRO, L (corresponding author), COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,630 W 168TH ST,NEW YORK,NY 10032, USA.		Shapiro, Lawrence/AAE-7172-2019					AMAGAI M, 1992, J CLIN INVEST, V90, P919, DOI 10.1172/JCI115968; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BODIAN DL, 1994, STRUCTURE, V2, P755, DOI 10.1016/S0969-2126(94)00076-X; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CAMPBELL RD, 1971, ORIGIN CONTINUITY DE; CCP4, 1979, CCP4 SUITE PROGRAMS; COWIN P, 1994, P NATL ACAD SCI USA, V91, P10759, DOI 10.1073/pnas.91.23.10759; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; FAWCETT DW, 1958, ATLAS FINE STRUCTURE, P365; FREUND AK, 1993, SPIE P, V1997, P223; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; Galtsoff PS, 1925, J EXP ZOOL, V42, P183, DOI 10.1002/jez.1400420109; GRUBEL G, 1994, PHYSIQUE 4, V4, P27; HATTA K, 1988, J CELL BIOL, V106, P873, DOI 10.1083/jcb.106.3.873; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; INUZUKA H, 1991, NEURON, V7, P69, DOI 10.1016/0896-6273(91)90075-B; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1979, BIOPOLYMERS, V22, P2577; KELLY DE, 1966, J CELL BIOL, V28, P51, DOI 10.1083/jcb.28.1.51; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LACLARE JL, 1994, J SYNCHROTRON RADIAT, V1, P12, DOI 10.1107/S0909049594006564; Magee AI, 1991, CURR OPIN CELL BIOL, V3, P854, DOI 10.1016/0955-0674(91)90060-C; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; McNutt N S, 1970, Am J Cardiol, V25, P169, DOI 10.1016/0002-9149(70)90577-1; McNutt N S, 1973, Prog Biophys Mol Biol, V26, P45; Nagafuchi A, 1993, Semin Cell Biol, V4, P175, DOI 10.1006/scel.1993.1021; NICHOLLS A, 1989, PROTEINS, V11, P281; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; ODA H, 1994, DEV BIOL, V165, P716, DOI 10.1006/dbio.1994.1287; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; POKUTTA S, 1994, EUR J BIOCH; ROGERS DC, 1965, J ULTRA MOL STRUCT R, V13, P478, DOI 10.1016/S0022-5320(65)90010-9; SHAPIRO L, IN PRESS P NATN ACAD; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STAEHELIN LA, 1974, INT REV CYTOL, V39, P191, DOI 10.1016/S0074-7696(08)60940-7; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1990, COLD SH Q B, V55, P319; TONG KI, 1994, FEBS LETT, V352, P318; VANDERMERWE PA, 1994, TRENDS BIOCHEM SCI, V19, P354; VOLBERG T, 1986, J CELL BIOL, V102, P1832, DOI 10.1083/jcb.102.5.1832; VOLK T, 1986, J CELL BIOL, V103, P1451, DOI 10.1083/jcb.103.4.1451; WESSELLS NK, 1971, SCIENCE, V171, P135, DOI 10.1126/science.171.3967.135; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; YOSHIDA C, 1982, CELL, V28, P217, DOI 10.1016/0092-8674(82)90339-7; [No title captured]	51	962	1003	1	80	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 23	1995	374	6520					327	337		10.1038/374327a0	http://dx.doi.org/10.1038/374327a0			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN630	7885471				2022-12-28	WOS:A1995QN63000051
J	MOTOYAMA, N; WANG, FP; ROTH, KA; SAWA, H; NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; SENJU, S; ZHANG, Q; FUJII, S; LOH, DY				MOTOYAMA, N; WANG, FP; ROTH, KA; SAWA, H; NAKAYAMA, K; NAKAYAMA, K; NEGISHI, I; SENJU, S; ZHANG, Q; FUJII, S; LOH, DY			MASSIVE CELL-DEATH OF IMMATURE HEMATOPOIETIC-CELLS AND NEURONS IN BCL-X-DEFICIENT MICE	SCIENCE			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; MUTANT CHIMERIC MICE; B-CELL; GENE; APOPTOSIS; PROTOONCOGENE; MECHANISMS; EXPRESSION; MUTATION; SYSTEM	bcl-x is a member of the bcl-2 gene family, which may regulate programmed cell death. Mice were generated that lacked Bcl-x. The Bcl-x-deficient mice died around embryonic day 13. Extensive apoptotic cell death was evident in postmitotic immature neurons of the developing brain, spinal cord, and dorsal root ganglia. Hematopoietic cells in the liver were also apoptotic. Analyses of bcl-x double-knockout chimeric mice showed that the maturation of Bcl-x-deficient lymphocytes was diminished. The life-span of immature lymphocytes, but not mature lymphocytes, was shortened. Thus, Bcl-x functions to support the viability of immature cells during the development oi the nervous and hematopoietic systems.	WASHINGTON UNIV,SCH MED,HOWARD HUGHES MED INST,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT BIOL MOLEC,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PHARMACOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV CARDIOVASC MED,ST LOUIS,MO 63110	Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)			wang, fang/GYD-4295-2022; Sawa, Hirofumi/F-6954-2012; Sawa, Hirofumi/AAW-8816-2021	Sawa, Hirofumi/0000-0003-2569-2755; Roth, Kevin/0000-0002-0643-995X				ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BATISTATOU A, 1993, J NEUROSCI, V13, P4422; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CHEN JZ, 1994, IMMUNITY, V1, P65, DOI 10.1016/1074-7613(94)90010-8; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DUBOISDAUPHIN M, 1994, P NATL ACAD SCI USA, V91, P3309, DOI 10.1073/pnas.91.8.3309; FANG W, 1994, J IMMUNOL, V153, P4388; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HERMISTON ML, 1992, J HISTOCHEM CYTOCHEM, V40, P1283, DOI 10.1177/40.9.1506665; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAKOBOVITS A, 1993, P NATL ACAD SCI USA, V90, P2551, DOI 10.1073/pnas.90.6.2551; Kaufman MH, 1992, ATLAS MOUSE DEV, P128; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; KRAJEWSKI S, 1994, CANCER RES, V54, P5501; LEBRUN DP, 1993, AM J PATHOL, V142, P743; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LIN EY, 1993, J IMMUNOL, V151, P1979; MERRY DE, 1994, DEVELOPMENT, V120, P301; MOTOYAMA N, UNPUB; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NAKAYAMA K, 1994, P NATL ACAD SCI USA, V91, P3700, DOI 10.1073/pnas.91.9.3700; NAKAYAMA K, UNPUB; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; RIEDERER B, 1985, P NATL ACAD SCI USA, V82, P6006, DOI 10.1073/pnas.82.17.6006; SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671; SAWYERS CL, 1994, CELL, V177, P121; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; TUCKER RP, 1988, J COMP NEUROL, V271, P44, DOI 10.1002/cne.902710106; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VAUX DL, 1993, P NATL ACAD SCI USA, V90, P786, DOI 10.1073/pnas.90.3.786; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VEISNOVACK D, 1994, AM J PATHOL, V145, P61; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; WILLIAMS GT, 1993, CELL, V74, P777, DOI 10.1016/0092-8674(93)90457-2; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	40	988	1013	0	6	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 10	1995	267	5203					1506	1510		10.1126/science.7878471	http://dx.doi.org/10.1126/science.7878471			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878471				2022-12-28	WOS:A1995QL49700040
J	KRAPIVINSKY, G; GORDON, EA; WICKMAN, K; VELIMIROVIC, B; KRAPIVINSKY, L; CLAPHAM, DE				KRAPIVINSKY, G; GORDON, EA; WICKMAN, K; VELIMIROVIC, B; KRAPIVINSKY, L; CLAPHAM, DE			THE G-PROTEIN-GATED ATRIAL K+ CHANNEL I-KACH IS A HETEROMULTIMER OF 2 INWARDLY RECTIFYING K+-CHANNEL PROTEINS	NATURE			English	Article							SUBUNIT; HEART	Heart rate is slowed in part by acetylcholine-dependent activation of a cardiac potassium (K+) channel, I-KACh. Activated muscarinic receptors stimulate I-KACh via the G-protein beta gamma-subunits. It has been assumed that the inwardly rectifying K+-channel gene, GIRK1, alone encodes I-KACh. It is now shown that I-KACh is a heteromultimer of two distinct inwardly rectifying K+-channel subunits, GIRK1 and a newly cloned member of the family, CIR.	MAYO CLIN & MAYO FDN,DEPT PHARMACOL,ROCHESTER,MN 55905	Mayo Clinic			Clapham, David/R-5974-2019	Wickman, Kevin/0000-0002-5179-9540; Clapham, David/0000-0002-4459-9428				AGULLARBRYAN L, 1995, BIOPHYS J, V68, pA234; ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; KRAPIVINSKY GB, 1994, CELL, V76, P439, DOI 10.1016/0092-8674(94)90109-0; KUBO Y, 1993, NATURE, V384, P802; LIM N, 1995, J GEN PHYSIOL, V105, P1; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; NESBITT SA, 1992, ANAL BIOCHEM, V206, P267, DOI 10.1016/0003-2697(92)90365-E; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SAKMANN B, 1983, NATURE, V303, P250, DOI 10.1038/303250a0; SINE SM, 1993, P NATL ACAD SCI USA, V90, P9436, DOI 10.1073/pnas.90.20.9436; SLAUGHTER RS, 1983, J BIOL CHEM, V258, P3183; TUNG R T, 1992, Journal of the American College of Cardiology, V19, p245A; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0	15	741	770	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					135	141		10.1038/374135a0	http://dx.doi.org/10.1038/374135a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877685				2022-12-28	WOS:A1995QL39700050
J	GRAHAM, JR; DEPATER, I; JERNIGAN, JG; LIU, MC; BROWN, ME				GRAHAM, JR; DEPATER, I; JERNIGAN, JG; LIU, MC; BROWN, ME			THE FRAGMENT-R COLLISION - WM-KEEK-TELESCOPE OBSERVATIONS OF SL9	SCIENCE			English	Article								The W. M. Keck telescope was used to observe the impact of comet Shoemaker-Levy 9 (SL9) fragment R at a wavelength of 2.3 micrometers on 21 July 1994. The data showed three outbursts. The first flash lasted about 40 seconds and was followed 1 minute after its peak by a second flash that lasted about 3 minutes. A third, longer lasting flare began 6 minutes after the first flash and lasted for 10 minutes. At its maximum brightness, the flare outshone Jupiter. The two short flashes are probably associated with the initial meteor trail and the subsequent fireball, respectively. The bright flare occurred when the impact site rotated into view. These data show that the explosion ejected material at least 1300 kilometers above the visible cloud tops. The luminosity of the impact site during the long bright flare was probably maintained by the release of gravitational potential energy, as this material fell back onto the lower atmosphere.	UNIV CALIF BERKELEY, SPACE SCI LAB, BERKELEY, CA USA	University of California System; University of California Berkeley	GRAHAM, JR (corresponding author), UNIV CALIF BERKELEY, DEPT ASTRON, 601 CAMPBELL HALL, BERKELEY, CA 94720 USA.			Liu, Michael C/0000-0003-2232-7664; Brown, Michael E./0000-0002-8255-0545				AHRENS TJ, 1994, GEOPHYS RES LETT, V21, P1087, DOI 10.1029/94GL01325; ASPHAUG E, 1994, NATURE, V370, P120, DOI 10.1038/370120a0; BOSLOUGH MB, 1994, GEOPHYS RES LETT, V21, P1555, DOI 10.1029/94GL01582; CHEVALIER RA, 1994, ASTROPHYS J, V429, P863, DOI 10.1086/174371; FROGEL JA, 1978, ASTROPHYS J, V220, P75, DOI 10.1086/155883; JEWITT D, 1993, B AM ASTRON SOC, V25, P1042; MACLOW MM, 1994, ASTROPHYS J, V434, pL33, DOI 10.1086/187565; MATTHEWS K, 1994, INFRARED ARRAYS ASTR; TAKATA T, 1994, ICARUS, V109, P3, DOI 10.1006/icar.1994.1074; WEAVER HA, 1994, SCIENCE, V263, P787, DOI 10.1126/science.263.5148.787; Zahnle Kevin, COMMUNICATION; ZELDOVICH YB, 1967, PHYSICS SHOCK WAVES	13	33	33	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1320	1323						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871431				2022-12-28	WOS:A1995QK06800036
J	CHRISTENSEN, K; VAUPEL, JW; HOLM, NV; YASHIN, AI				CHRISTENSEN, K; VAUPEL, JW; HOLM, NV; YASHIN, AI			MORTALITY AMONG TWINS AFTER AGE-6 - FETAL ORIGINS HYPOTHESIS VERSUS TWIN METHOD	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; MEDICAL-RESEARCH; SINGLETONS	Objective-To test the validity of the fetal origins hypothesis and the classic twin method. Design-Follow up study of pairs of same twins in which both twins survived to age 6. Setting-Denmark. Subjects-8495 twin individuals born 1870-1900, followed through to 31 December 1991. Main outcome measures-Mortality calculated on a cohort basis, Results-Mortality among twins and the general population was not significantly different except among females aged 60-89, in whom mortality among twins was 1.14 times (SE 0.03) higher than in the general population, Mortality among female dizygotic twins was 1.77 times (0.18) higher than among monozygotic twins at age 30.59. Otherwise, mortality for monozygotic and dizygotic twins did not consistently differ after age 6. Conclusion-According to the fetal origins hypothesis the risk of adult morbidity and mortality is heightened by retardation in intrauterine growth. Twins, and in particular monozygotic twins, experience growth retardation in utero. The findings in the present study suggest that the fetal origins hypothesis is not true for the retardation in intrauterine growth experienced by twins. Furthermore, the data are inconsistent with the underlying assumption of a recent claim that the classic twin method is invalid for studies of adult diseases. The present study is, however, based on the one third of all pairs of twins in which both twins survived to age 6. The possible impact of this selection can be evaluated in future studies of cohorts of younger twins with lower perinatal and infant mortality.			CHRISTENSEN, K (corresponding author), ODENSE UNIV,SCH MED,STAT LAB,WINSLOWPARKEN 17,DK-5000 ODENSE C,DENMARK.		Christensen, Kaare/C-2360-2009	Christensen, Kaare/0000-0002-5429-5292; Vaupel, James/0000-0003-0783-3905	NCI NIH HHS [CA 42581] Funding Source: Medline; NIA NIH HHS [P01-AG08761] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG008761] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Barker DJP, 1992, FETAL INFANT ORIGINS; DUFFY DL, 1993, LANCET, V341, P1418; Hauge M, 1981, PROSPECTIVE LONGITUD, P217; HAUGE M, 1968, ACTA GENET MED GEMEL, V2, P15; HOLM NV, 1983, THESIS ODENSE U ODEN; HRUBEC Z, 1981, HUM GENET, V59, P39, DOI 10.1007/BF00278852; KIELY JL, 1991, ACTA GENET MED GEMEL, V40, P303, DOI 10.1017/S0001566000003482; KLEINMAN JC, 1991, AM J EPIDEMIOL, V133, P133, DOI 10.1093/oxfordjournals.aje.a115852; KLINE J, 1989, CONCEPTION BIRTH; MACDONALD AM, 1993, LANCET, V341, P1419; MacGillivray I, 1988, TWINNING TWINS; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; PHILLIPS DIW, 1993, LANCET, V341, P1008, DOI 10.1016/0140-6736(93)91086-2; PHILLIPS DIW, 1993, LANCET, V342, P52, DOI 10.1016/0140-6736(93)91916-A; RAMOSARROYO MA, 1988, ACTA GENET MED GEMEL, V37, P229, DOI 10.1017/S0001566000003834; ROTHWELL PM, 1994, LANCET, V343, P731, DOI 10.1016/S0140-6736(94)91610-1; SELTZER CC, 1974, AM J EPIDEMIOL, V100, P367, DOI 10.1093/oxfordjournals.aje.a112047; VAGERO D, 1994, LANCET, V343, P260, DOI 10.1016/S0140-6736(94)91112-6; WYSHAK G, 1978, SOC BIOL, V25, P315, DOI 10.1080/19485565.1978.9988353; 1993, CAUSES DEATH 1991	21	202	203	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					432	436		10.1136/bmj.310.6977.432	http://dx.doi.org/10.1136/bmj.310.6977.432			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873948	Green Published			2022-12-28	WOS:A1995QJ24200018
J	KOSTER, T; ROSENDAAL, FR; DERONDE, H; BRIET, E; VANDENBROUCKE, JP; BERTINA, RM				KOSTER, T; ROSENDAAL, FR; DERONDE, H; BRIET, E; VANDENBROUCKE, JP; BERTINA, RM			VENOUS THROMBOSIS DUE TO POOR ANTICOAGULANT RESPONSE TO ACTIVATED PROTEIN-C - LEIDEN THROMBOPHILIA STUDY	LANCET			English	Article							INACTIVATION	We undertook a population-based case-control study to test the clinical importance of a hereditary abnormality in the coagulation system, characterised by poor anticoagulant response to activated protein C (APC), which is associated with familial thrombophilia. The abnormality was detected in 64 (21%) of 301 unselected consecutive patients younger than 70 years,with a first, objectively confirmed episode of deep-vein thrombosis and without underlying malignant disease. Among 301 healthy control subjects matched for age and sex, the frequency was 5% (14 subjects). Thus, there is a seven-fold increase in risk of deep-vein thrombosis in subjects with a poor response to APC (matched odds ratio 6.6 [95% CI 3.6-12.0]). In addition, there was a clear inverse relation between the degree of response to APC and thrombosis risk. In the families of the patients an autosomal dominant mode of transmission of the abnormality was confirmed. 9 of 10 thrombosis patients with a poor response to APC had 1 parent with a similar poor response, whereas 9 of 10 patients with normal tests had parents with equally normal tests. The abnormality was found in both parents of 1 patient with an extremely poor response to APC; this patient is probably homozygous for the abnormality. We conclude that the poor response to APC is the most important hereditary cause of venous thrombosis. Its high prevalence in a series of unselected patients will make testing of all thrombosis patients for this abnormality worth while.	UNIV HOSP LEIDEN, HEMOSTASIS & THROMBOSIS RES CTR, 2300 RC LEIDEN, NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC)	KOSTER, T (corresponding author), UNIV HOSP LEIDEN, DEPT CLIN EPIDEMIOL, BLDG 1, CO-P, POB 9600, 2300 RC LEIDEN, NETHERLANDS.		Bertina, Rogier/AGQ-5246-2022; Vandenbroucke, Jan/AAM-3928-2020	Vandenbroucke, Jan/0000-0001-5668-6716				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BAKKER HM, 1992, EUR J BIOCHEM, V208, P171, DOI 10.1111/j.1432-1033.1992.tb17171.x; BOYERNEUMANN C, IN PRESS THROMB HAEM; CLOUSE LH, 1986, NEW ENGL J MED, V314, P1298, DOI 10.1056/NEJM198605153142006; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1993, THROMB HAEMOSTASIS, V69, P529; DEUTZTERLOUW PP, 1990, CLIN CHIM ACTA, V186, P321, DOI 10.1016/0009-8981(90)90318-M; ESMON CT, 1983, BLOOD, V62, P1155; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HIRSH J, 1986, J AM COLL CARDIOL, V8, pB104, DOI 10.1016/S0735-1097(86)80012-2; KOEDAM JA, 1988, J CLIN INVEST, V82, P1236, DOI 10.1172/JCI113721; LOELIGER EA, 1984, ANTICOAGULANTS MYOCA, P157; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MILETICH J, 1987, NEW ENGL J MED, V317, P919; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; SVENSSON PJ, 1993, THROMB HAEMOSTASIS, V69, P1252; SVENSSON PJ, 1993, THROMB HAEMOSTASIS, V69, P999; VANHINSBERGH VWM, 1985, BLOOD, V65, P444	18	1276	1296	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1503	1506		10.1016/S0140-6736(05)80081-9	http://dx.doi.org/10.1016/S0140-6736(05)80081-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902898				2022-12-28	WOS:A1993MM40200008
J	MANNS, A; CLEGHORN, FR; FALK, R; HANCHARD, B; JAFFE, ES; BARTHOLOMEW, C; HARTGE, P; BENICHOU, J; BLATTNER, WA				MANNS, A; CLEGHORN, FR; FALK, R; HANCHARD, B; JAFFE, ES; BARTHOLOMEW, C; HARTGE, P; BENICHOU, J; BLATTNER, WA			ROLE OF HTLV-I IN DEVELOPMENT OF NON-HODGKIN-LYMPHOMA IN JAMAICA AND TRINIDAD-AND-TOBAGO	LANCET			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; RISK-FACTORS; DETERMINANTS; RETROVIRUS; INFECTION; MODEL; AGE	Human T-cell lymphotropic virus type I (HTLV-I) has been implicated in the aetiology of adult T-cell leukaemia/lymphoma in Japan and elsewhere, particularly the Caribbean. We have carried out parallel case-control studies in Jamaica and in Trinidad and Tobago to quantify the role of HTLV-I in the development of non-Hodgkin lymphoma (NHL). 135 cases of NHL were enrolled in Jamaica and 104 in Trinidad and Tobago. Controls were selected from patients treated in the same wards or clinics at the same time as the cases. Overall, patients with NHL were 10 times more likely than were controls to be seropositive for HTLV-I (Jamaica odds ratio 10.3 [95% CI 6.0-18.0], Trinidad and Tobago 14.4 [7.6-27.2]). In both countries the association between NHL and HTLV-I was greatest for T-cell lymphomas (18.3 [9.5-35.6] and 63.3 [25-167]). Among T-cell lymphomas especially, there was no significant difference between men and women in the association between NHL and HTLV-I, but there was a significant inverse relation between age and likelihood of HTLV-I seropositivity. B-cell lymphomas were predominant in the older age groups and were not associated with HTLV-I seropositivity. These findings are consistent with the hypothesis that early life exposure to HTLV-I is important for risk of subsequent ATL. Prevention of vertical transmission of HTLV-I could reduce by 70-80% cases of NHL in people under 60 years in this region.	UNIV W INDIES, DEPT PATHOL, KINGSTON 7, JAMAICA; NCI, PATHOL LAB, BETHESDA, MD 20892 USA; NCI, DIV CANC ETIOL, EPIDEMIOL & BLOSTAT PROGRAM, BETHESDA, MD 20892 USA; DEPT MED, PORT OF SPAIN, TRINIDAD TOBAGO	University West Indies Mona Jamaica; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Jaffe, Elaine/G-8981-2014		DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP031006] Funding Source: NIH RePORTER; NCI NIH HHS [NCI N01-CP-61002, NCI N01-CP-31006] Funding Source: Medline	DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMITAGE JO, 1993, NEW ENGL J MED, V328, P1023; BARTHOLOMEW C, 1985, BMJ-BRIT MED J, V290, P1243, DOI 10.1136/bmj.290.6477.1243; BENICHOU J, 1990, BIOMETRICS, V46, P991, DOI 10.2307/2532443; BLATTNER WA, 1990, J ACQ IMMUN DEF SYND, V3, P1102; BLATTNER WA, 1990, HUMAN RETROVIROLOGY : HTLV, P251; BROOKS SEH, 1991, W INDIAN MED J, V40, P134; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CLEGHORN FR, 1990, HUMAN RETROVIROLOGY : HTLV, P185; DEVESA SS, 1992, CANCER RES, V52, pS5432; Francis D P, 1981, Prog Med Virol, V27, P127; GESSAIN A, 1984, LANCET, V1, P1183; GIBBS WN, 1987, ANN INTERN MED, V106, P361, DOI 10.7326/0003-4819-106-3-361; HANAOKA M, 1982, ACTA PATHOL JPN, V29, P2112; HOOVER EA, 1976, J NATL CANCER I, V57, P365, DOI 10.1093/jnci/57.2.365; JAFFE ES, 1992, MANUAL CLIN LABORATO, P288; KUREC AS, 1988, CLIN LAB MED, V8, P223, DOI 10.1016/S0272-2712(18)30708-X; LEVINE PH, 1992, CANCER EPIDEM BIOMAR, V1, P515; LIU MC, 1993, ONCOLOGY, V7, P66; MANN DL, 1987, SCIENCE, V236, P1103, DOI 10.1126/science.2883731; MILLER GJ, 1986, INT J CANCER, V38, P801, DOI 10.1002/ijc.2910380604; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; MURPHY EL, 1991, AM J EPIDEMIOL, V133, P1114, DOI 10.1093/oxfordjournals.aje.a115824; OKAMOTO T, 1989, JPN J CANCER RES, V80, P191; POIESZ BJ, 1981, NATURE, V294, P268, DOI 10.1038/294268a0; PRENTICE R, 1976, BIOMETRICS, V32, P599, DOI 10.2307/2529748; REZANKA LJ, 1992, CANCER INVEST, V10, P371, DOI 10.3109/07357909209024796; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; Takatsuki K., 1977, TOPICS HEMATOLOGY, P73; 1988, MMWR, V37, P736; 1982, CANCER, V49, P211	30	61	62	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1447	1450		10.1016/0140-6736(93)92931-I	http://dx.doi.org/10.1016/0140-6736(93)92931-I			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902480				2022-12-28	WOS:A1993ML21700007
J	LEUNG, DYM; MEISSNER, HC; FULTON, DR; MURRAY, DL; KOTZIN, BL; SCHLIEVERT, PM				LEUNG, DYM; MEISSNER, HC; FULTON, DR; MURRAY, DL; KOTZIN, BL; SCHLIEVERT, PM			TOXIC SHOCK SYNDROME TOXIN-SECRETING STAPHYLOCOCCUS-AUREUS IN KAWASAKI SYNDROME	LANCET			English	Article							STREPTOCOCCAL PYROGENIC EXOTOXINS; SELECTIVE EXPANSION; GAMMA-GLOBULIN; DISEASE; V-BETA-2; AGR	Kawasaki syndrome (KS), the main cause of acquired heart disease in children, is associated with the selective expansion of Vbeta2+ T cells in peripheral blood. Our study suggests that KS may be caused by a superantigen-a staphylococcal or streptococcal toxin. Bacteria were cultured without knowledge of their origin, from the throat, rectum, axilla, and groin of 16 patients with untreated acute KS and 15 controls. Bacteria producing toxins were isolated from 13 of 16 KS patients but from only 1 of 15 controls (p<0.0001). Toxic shock syndrome toxin (TSST) -secreting Staphylococcus aureus was isolated from 11 of the 13 toxin-positive cultures, and streptococcal pyrogenic exotoxin (SPE) B and C were found in the other 2. These toxins are known to stimulate Vbeta2+ T cells. All TSST-producing KS isolates were tryptophan auxotrophs indicating they were clonally related. S aureus isolates from acute KS patients were unusual because they produced less lipase, haemolysin, and protease compared to other isolates (p<0.01). S aureus colonies from KS patients were white, and could be easily mistaken for coagulase-negative staphylococci, whereas colonies of non-KS isolates were gold. These observations suggest that the expansion of Vbeta2+ T cells in most patients with KS may be caused by a new clone of TSST-producing S aureus, and, in a minority of patients, SPEB-producing or SPEC-producing streptococci.	NATL JEWISH CTR IMMUNOL & RESP MED, DEPT MED, DENVER, CO 80206 USA; TUFTS UNIV NEW ENGLAND MED CTR, DEPT PEDIAT, BOSTON, MA 02111 USA; UNIV MINNESOTA, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA	National Jewish Health; Tufts Medical Center; University of Minnesota System; University of Minnesota Twin Cities	LEUNG, DYM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED, DEPT PEDIAT, 1400 JACKSON ST, DENVER, CO 80206 USA.			Schlievert, Patrick/0000-0001-8314-9369	NHLBI NIH HHS [HL36611, HL37260] Funding Source: Medline; NIAMS NIH HHS [AR41256] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037260, R01HL036611, R37HL037260, R55HL036611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041256] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE J, 1993, J EXP MED, V177, P791, DOI 10.1084/jem.177.3.791; ABE J, 1992, P NATL ACAD SCI USA, V89, P4066, DOI 10.1073/pnas.89.9.4066; CHOI YW, 1990, J EXP MED, V172, P981, DOI 10.1084/jem.172.3.981; CHU MC, 1988, INFECT IMMUN, V56, P2702, DOI 10.1128/IAI.56.10.2702-2708.1988; DRAKE CG, 1992, J CLIN IMMUNOL, V12, P149, DOI 10.1007/BF00918083; HOKONOHARA M, 1987, JPN CIRC J, V51, P1353, DOI 10.1253/jcj.51.1353; HYNES WL, 1985, J MICROBIOL METH, V4, P25, DOI 10.1016/0167-7012(85)90004-1; KASS EH, 1988, J INFECT DIS, V158, P44, DOI 10.1093/infdis/158.1.44; KAWASAKI T, 1967, JAP J ALLERG, V16, P178, DOI DOI 10.4070/KCJ.2018.0214; LEE PK, 1989, J CLIN MICROBIOL, V27, P1890, DOI 10.1128/JCM.27.8.1890-1892.1989; LEE PK, 1992, J INFECT DIS, V165, P1056, DOI 10.1093/infdis/165.6.1056; Leung D Y, 1993, Curr Opin Rheumatol, V5, P41; LEUNG DYM, 1987, J CLIN INVEST, V79, P468, DOI 10.1172/JCI112835; LEUNG DYM, 1983, J IMMUNOL, V130, P2002; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MUSSER JM, 1990, P NATL ACAD SCI USA, V87, P225, DOI 10.1073/pnas.87.1.225; NEWBURGER JW, 1991, NEW ENGL J MED, V324, P1633, DOI 10.1056/NEJM199106063242305; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; RECSEI P, 1986, MOL GEN GENET, V202, P58, DOI 10.1007/BF00330517; RIDER LG, 1991, LANCET, V337, P1100, DOI 10.1016/0140-6736(91)91751-F; SCHLIEVERT PM, 1982, ANN INTERN MED, V96, P937, DOI 10.7326/0003-4819-96-6-937; SCHLIEVERT PM, 1983, J INFECT DIS, V147, P236, DOI 10.1093/infdis/147.2.236; SUZUKI A, 1986, PEDIATR CARDIOL, V7, P3, DOI 10.1007/BF02315475; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; TODD JK, 1984, INFECT IMMUN, V45, P339, DOI 10.1128/IAI.45.2.339-344.1984; TOMAI MA, 1992, INFECT IMMUN, V60, P701, DOI 10.1128/IAI.60.2.701-705.1992; 1990, JAMA-J AM MED ASSOC, V44, P1218	27	310	333	1	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1993	342	8884					1385	1388		10.1016/0140-6736(93)92752-F	http://dx.doi.org/10.1016/0140-6736(93)92752-F			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901681				2022-12-28	WOS:A1993MK09500009
J	ADLERCREUTZ, H; MARKKANEN, H; WATANABE, S				ADLERCREUTZ, H; MARKKANEN, H; WATANABE, S			PLASMA-CONCENTRATIONS OF PHYTO-ESTROGENS IN JAPANESE MEN	LANCET			English	Note							PROSTATE-CANCER; DIET	A low mortality from prostatic cancer is found in Japanese men consuming a low-fat diet with high content of soy products, a rich source of isoflavonoids. We therefore assayed four isoflavonoids in plasma of 14 Japanese and 14 Finnish men. The geometric mean plasma total individual isoflavonoid levels were 7 to 110 times higher in the Japanese than in the Finnish men. Genistein, a tyrosine kinase inhibitor, occurred in the highest concentration (geometric mean 276 nmol/L). We hypothesise that these high phyto-oestrogen levels may inhibit the growth of prostatic cancer in Japanese men, which may explain the low mortality from prostatic cancer in that country.	NATL CANC CTR, RES INST, DIV EPIDEMIOL, TOKYO 104, JAPAN	National Cancer Center - Japan	ADLERCREUTZ, H (corresponding author), UNIV HELSINKI, MEILAHTI HOSP, DEPT CLIN CHEM, SF-00290 HELSINKI 29, FINLAND.				NATIONAL CANCER INSTITUTE [R01CA056289] Funding Source: NIH RePORTER; NCI NIH HHS [1 R01 CA56289-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLERCREUTZ H, 1990, SCAND J CLIN LAB INV, V50, P3, DOI 10.3109/00365519009085798; ADLERCREUTZ H, 1991, AM J CLIN NUTR, V54, P1093, DOI 10.1093/ajcn/54.6.1093; ADLERCREUTZ H, 1993, SCAND J CLIN LAB INV, V53, P5, DOI 10.3109/00365519309090693; MAKELA S, 1991, 3 EURO FOOD TOX P IN, P135; MILLS PK, 1989, CANCER, V64, P598, DOI 10.1002/1097-0142(19890801)64:3&lt;598::AID-CNCR2820640306&gt;3.0.CO;2-6; PETERSON G, 1993, PROSTATE, V22, P335, DOI 10.1002/pros.2990220408; PRICE KR, 1985, FOOD ADDIT CONTAM A, V2, P73, DOI 10.1080/02652038509373531; SEVERSON RK, 1989, CANCER RES, V49, P1857; SHIMIZU H, 1991, BRIT J CANCER, V63, P963, DOI 10.1038/bjc.1991.210; YATANI R, 1982, INT J CANCER, V29, P611, DOI 10.1002/ijc.2910290602	10	632	652	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1993	342	8881					1209	1210		10.1016/0140-6736(93)92188-Y	http://dx.doi.org/10.1016/0140-6736(93)92188-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901532				2022-12-28	WOS:A1993MG27400012
J	SHUMAK, KH; ROCK, GA; NAIR, RC; ADAMS, G; BENNY, B; BUSKARD, NA; CAPLAN, S; CARD, R; CLARK, WF; FORD, P; FREEDMAN, J; GORDON, P; GORELICK, M; KELTON, J; KLASSEN, J; LEBLOND, P; LEPINEMARTIN, M; MCBRIDE, J; MONTE, M; RAYNER, H; SHORE, T; STERNBACH, M; SUTTON, DMC; JONES, JV				SHUMAK, KH; ROCK, GA; NAIR, RC; ADAMS, G; BENNY, B; BUSKARD, NA; CAPLAN, S; CARD, R; CLARK, WF; FORD, P; FREEDMAN, J; GORDON, P; GORELICK, M; KELTON, J; KLASSEN, J; LEBLOND, P; LEPINEMARTIN, M; MCBRIDE, J; MONTE, M; RAYNER, H; SHORE, T; STERNBACH, M; SUTTON, DMC; JONES, JV			LATE RELAPSES IN PATIENTS SUCCESSFULLY TREATED FOR THROMBOTIC THROMBOCYTOPENIC PURPURA	ANNALS OF INTERNAL MEDICINE			English	Article						PURPURA, THROMBOTIC THROMBOCYTOPENIC; ANEMIA, HEMOLYTIC; PLASMA EXCHANGE; KIDNEY FAILURE, ACUTE; PLATELET COUNT	EXPERIENCE; PLASMA	Objective: To determine the incidence and timing of relapses in patients who h Design: Clinical follow-up for 3 to 10 years. Setting: General community outpatient study; patients who had relapse were hospitalized. Participants: 63 of 72 surviving patients who had participated in a randomized study that compared plasma exchange and plasma infusion as treatments for thrombotic thrombocytopenic purpura and for whom continued clinical follow-up was obtained. Outcome Measures: Recurrence of thrombotic thrombocytopenic purpura as defined by a decrease in platelet count to less than 100 x 10(9)/L and by the onset of microangiopathic hemolytic anemia as identified by erythrocyte fragmentation in a peripheral blood film, Results: 37 of the 63 patients have not had recurrence of thrombotic thrombocytopenic purpura and have remained completely well; 6 patients have not had recurrence but have developed other medical problems; 3 patients have not had recurrence but have residual neurologic defects from the original episode; and 17 patients have had one or more recurrences, occurring 7 months to 8 years after the original episode. As determined by Kaplan-Meier analysis, the projected recurrence rate after 10 years in all surviving patients is 36% (95% CI, 23% to 59%). Conclusions: More than one third of patients who survive an acute episode of thrombotic thrombocytopenic purpura will have at least one relapse during the following 10 years.	UNIV TORONTO, TORONTO, ON, CANADA; UNIV OTTAWA, OTTAWA, ON, CANADA	University of Toronto; University of Ottawa			Shore, Tsiporah/K-3819-2019; Nair, Rama C/G-5674-2011; Clark, Bill/G-3287-2011	Shore, Tsiporah/0000-0001-6033-0747; Nair, Rama C/0000-0002-9101-0516; 				AMOROSI EL, 1966, MEDICINE, V45, P139, DOI 10.1097/00005792-196603000-00003; BELL WR, 1991, NEW ENGL J MED, V325, P398, DOI 10.1056/NEJM199108083250605; BYRNES JJ, 1990, AM J HEMATOL, V34, P169, DOI 10.1002/ajh.2830340303; CUTTNER J, 1980, BLOOD, V56, P302; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Moschcowitz E, 1925, ARCH INTERN MED, V36, P89, DOI 10.1001/archinte.1925.00120130092009; RIDOLFI RL, 1981, MEDICINE, V60, P413, DOI 10.1097/00005792-198111000-00003; ROCK G, 1994, BLOOD, V84, pA246; ROCK GA, 1991, NEW ENGL J MED, V325, P393, DOI 10.1056/NEJM199108083250604; ROSE M, 1987, AM J MED, V83, P437, DOI 10.1016/0002-9343(87)90753-4; SIMON R, 1986, ANN INTERN MED, V105, P429, DOI 10.7326/0003-4819-105-3-429	11	156	161	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					569	572		10.7326/0003-4819-122-8-199504150-00002	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00002			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887549				2022-12-28	WOS:A1995QR52500002
J	NIGHTINGALE, SL				NIGHTINGALE, SL			MONOCLONAL-ANTIBODY LICENSED FOR USE IN ANGIOPLASTY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,560 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-28	WOS:A1995QP89000007
J	YOU, WC; ZHAO, L; CHANG, YS; BLOT, WJ; FRAUMENI, JF				YOU, WC; ZHAO, L; CHANG, YS; BLOT, WJ; FRAUMENI, JF			PROGRESSION OF PRECANCEROUS GASTRIC-LESIONS	LANCET			English	Letter							CANCER		BEIJING INST CANC RES,BEIJING,PEOPLES R CHINA; INT EPIDEMIOL INST,ROCKVILLE,MD		YOU, WC (corresponding author), NCI,EPIDEMIOL & BIOSTAT PROGRAM,EPN ROOM 431,BETHESDA,MD 20892, USA.			You, Wei-cheng/0000-0003-2190-1812				CORREA P, 1992, CANCER RES, V52, P6735; YOU WC, 1993, CANCER RES, V53, P1317	2	15	17	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					866	867		10.1016/S0140-6736(95)93006-X	http://dx.doi.org/10.1016/S0140-6736(95)93006-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898258				2022-12-28	WOS:A1995QQ19500056
J	BONENKAMP, JJ; SONGUN, I; HERMANS, J; SASAKO, M; WELVAART, K; PLUKKER, JTM; VANELK, P; OBERTOP, H; GOUMA, DJ; TAAT, CW; VANLANSCHOT, J; MEYER, S; DEGRAAF, PW; VONMEYENFELDT, MF; TILANUS, H; VANDEVELDE, CJH				BONENKAMP, JJ; SONGUN, I; HERMANS, J; SASAKO, M; WELVAART, K; PLUKKER, JTM; VANELK, P; OBERTOP, H; GOUMA, DJ; TAAT, CW; VANLANSCHOT, J; MEYER, S; DEGRAAF, PW; VONMEYENFELDT, MF; TILANUS, H; VANDEVELDE, CJH			RANDOMIZED COMPARISON OF MORBIDITY AFTER D1 AND D2 DISSECTION FOR GASTRIC-CANCER IN 996 DUTCH PATIENTS	LANCET			English	Article							CARCINOMA; RESECTION; STOMACH; GERMAN; R1	For patients with gastric cancer deemed curable the only treatment option is surgery, but there is disagreement about whether accompanying lymph-node dissection should be limited to the perigastric nodes (D1) or should extend to regional lymph nodes outside the perigastric area (D2). We carried out a multicentre randomised comparison of D1 and D2 dissection. 1078 patients were randomised (539 to each group). 26 allocated D1 and 56 allocated D2 were found not to satisfy eligibility criteria (histologically confirmed adenocarcinoma of the stomach without clinical evidence of distant metastasis). Each of the remainder was attended by one of eleven supervising surgeons who decided whether curative resection was possible and, if so, assisted with the allocated procedure. Among the 711 patients (380 D1, 331 D2) judged to have curable lesions, D2 patients had a higher operative mortality rate than D1 patients (10 vs 4%, p=0.004) and experienced more complications (43 vs 25%, p<0.001). They also needed longer postoperative hospital stays (median 25 [range 7-277] vs 18 [7-143] days, p<0.001). Morbidity and mortality differences persisted in almost all subgroup analyses. While we await survival results, D2 dissection should not be used as standard treatment for western patients.	LEIDEN UNIV HOSP,DEPT SURG,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV,DEPT MED STAT,2300 RA LEIDEN,NETHERLANDS; NATL CANC CTR,DIV GASTR CANC,TOKYO,JAPAN; UNIV GRONINGEN HOSP,GRONINGEN,NETHERLANDS; ST GEERTRUIDEN HOSP,DEVENTER,NETHERLANDS; UNIV AMSTERDAM,MED CTR,AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,AMSTERDAM,NETHERLANDS; UNIV UTRECHT HOSP,UTRECHT,NETHERLANDS; UNIV MAASTRICHT HOSP,MAASTRICHT,NETHERLANDS; ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,ROTTERDAM,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University - Excl LUMC; National Cancer Center - Japan; University of Groningen; University of Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Utrecht University; Utrecht University Medical Center; Maastricht University; Maastricht University Medical Centre (MUMC); Erasmus University Rotterdam; Erasmus MC			van de Velde, Cornelis/AAY-8360-2020					BONENKAMP JJ, 1993, WORLD J SURG, V17, P410, DOI 10.1007/BF01658714; BONENKAMP JJ, 1992, EUR J SURG, V158, P413; BUNT AMG, 1994, J CLIN ONCOL, V12, P417, DOI 10.1200/JCO.1994.12.2.417; BUNT AMG, 1994, CANCER, V73, P1544; DENT DM, 1988, BRIT J SURG, V75, P110, DOI 10.1002/bjs.1800750206; DIGGORY RT, 1985, BRIT J SURG, V72, P146, DOI 10.1002/bjs.1800720226; Hermanek P, 1993, UICC TNM S; KAJITANI T, 1981, JPN J SURG, V11, P127; MARUYAMA K, 1987, WORLD J SURG, V11, P418, DOI 10.1007/BF01655804; MCCULLOUGH P, 1994, BRIT J SURG, V81, P417, DOI 10.1002/bjs.1800810332; RODER JD, 1993, CANCER-AM CANCER SOC, V72, P2089, DOI 10.1002/1097-0142(19931001)72:7<2089::AID-CNCR2820720706>3.0.CO;2-H; SASKO M, 1992, JPN J CLIN ONCOL, V22, P41; SHIU MH, 1989, HEPATO-GASTROENTEROL, V36, P7; SMITH JW, 1991, ARCH SURG-CHICAGO, V126, P1469; WANEBO HJ, 1993, ANN SURG, V218, P583, DOI 10.1097/00000658-199321850-00002	15	867	910	0	24	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					745	748		10.1016/S0140-6736(95)90637-1	http://dx.doi.org/10.1016/S0140-6736(95)90637-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891484				2022-12-28	WOS:A1995QN70100008
J	TYRER, P; MORGAN, J; VANHORN, E; JAYAKODY, M; EVANS, K; BRUMMELL, R; WHITE, T; BALDWIN, D; HARRISONREAD, P; JOHNSON, T				TYRER, P; MORGAN, J; VANHORN, E; JAYAKODY, M; EVANS, K; BRUMMELL, R; WHITE, T; BALDWIN, D; HARRISONREAD, P; JOHNSON, T			A RANDOMIZED CONTROLLED-STUDY OF CLOSE MONITORING OF VULNERABLE PSYCHIATRIC-PATIENTS	LANCET			English	Article							CONTROLLED TRIAL; CASE MANAGEMENT; CARE	The care programme approach was introduced in mental health services in the UK in 1991. It was intended to improve the quality of care and prevent patients losing contact with care services and, by implication, to reduce psychiatric admissions. We did a study to find out if the approach worked. 400 patients from a London inner-city area who had been identified as psychiatrically vulnerable and included on a case register of patients with special needs were randomised into two groups of 200 each. One group received close supervision by nominated key-workers (as recommended in the care programme approach of the UK Department of Health), and the other received standard follow-up from psychiatric and social services. Outcome was recorded after eighteen months. Data on 393 patients was available for analysis. Of 197 patients allocated to standard care, 64 (32.5%) were lost to follow-up compared with 40 (20.4%) of 196 patients receiving close supervision (p=<0.005). However, patients under close supervision had significantly more admissions (30% vs 18%, chi(2)=7.61, p<0.01) and spent 68% more days in hospital than the standard group. The findings of greater hospital-bed use, which differ from those of studies with community-based psychiatric teams, suggest that close supervision by a single key worker, as recommended in the care programme approach, will lead to greater success in maintaining contact with vulnerable patients, but is likely to lead to more psychiatric admissions.	UNIV SOUTHAMPTON,DEPT PSYCHIAT,SOUTHAMPTON,HANTS,ENGLAND; NW LONDON MENTAL HLTH NATL HLTH SERV TRUST,LONDON,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND	University of Southampton; MRC Biostatistics Unit	TYRER, P (corresponding author), ST CHARLES HOSP,ST MARYS HOSP,SCH MED,ACAD UNIT PSYCHIAT,LONDON W10 6DZ,ENGLAND.							[Anonymous], 1992, ICD10 CLASSIFICATION; BURNS T, 1993, BRIT J PSYCHIAT, V163, P49, DOI 10.1192/bjp.163.1.49; CONWAY AS, 1994, BRIT MED J, V308, P627, DOI 10.1136/bmj.308.6929.627a; FRANKLIN JL, 1987, AM J PUBLIC HEALTH, V77, P674, DOI 10.2105/AJPH.77.6.674; GOERING PN, 1988, HOSP COMMUNITY PSYCH, V39, P272; HOULT J, 1986, BRIT J PSYCHIAT, V149, P137, DOI 10.1192/bjp.149.2.137; KINGDON D.G, 1994, PSYCHIATRIC B, V18, P68; MERSON S, 1992, LANCET, V339, P1311, DOI 10.1016/0140-6736(92)91959-C; MUIJEN M, 1992, BRIT MED J, V304, P749, DOI 10.1136/bmj.304.6829.749; NORTH C, 1993, FACTORS INFLUENCING; OCONNOR DW, 1991, BRIT MED J, V302, P871, DOI 10.1136/bmj.302.6781.871; ONYETT S, 1992, CASE MANAGEMENT MENT; ROSSLER W, 1993, ACTA PSYCHIATRY SCAN, V86, P445; SHEPHERD M, 1966, PSYCHIATRIC ILLNESS; STEIN LI, 1980, ARCH GEN PSYCHIAT, V37, P392; 1993, HLTH NATION KEY AREA, P111; 1990, CARING PEOPLE; 1992, CARE MANAGEMENT ASSE	18	86	86	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					756	759		10.1016/S0140-6736(95)90640-1	http://dx.doi.org/10.1016/S0140-6736(95)90640-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QN701	7891486				2022-12-28	WOS:A1995QN70100011
J	WEINTRAUB, H; ASHBURNER, M; GOODFELLOW, PN; LODISH, HF; ARNTZEN, CJ; ANDERSON, PW; RICE, TM; GEBALLE, TH; MEANS, AR; RANNEY, HM; CECH, TR; COLWELL, RR; BOURNE, HR; RICHTER, B; SINGER, IM; MARRACK, P; FEARON, DT; PENZIAS, A; BARD, AJ; BRINKMAN, WF; MARKS, PA; VOGELSTEIN, B; KINZLER, KW; BISHOP, JM; ZARE, RN; SCHATZ, G; BENKOVIC, SJ; GRAY, HB; VALENTINE, JS; CRUTZEN, PJ; CHOI, DW; NAKANISHI, S; KOSSLYN, SM; BRAUMAN, JI; REES, DC; BRILL, WJ; SCHELL, J; LUHRMANN, R; WILL, CL; WULF, W; VERMEIJ, GJ; ARROW, KJ; SMELSER, NJ; ANDERSON, DL; ABELSON, PH				WEINTRAUB, H; ASHBURNER, M; GOODFELLOW, PN; LODISH, HF; ARNTZEN, CJ; ANDERSON, PW; RICE, TM; GEBALLE, TH; MEANS, AR; RANNEY, HM; CECH, TR; COLWELL, RR; BOURNE, HR; RICHTER, B; SINGER, IM; MARRACK, P; FEARON, DT; PENZIAS, A; BARD, AJ; BRINKMAN, WF; MARKS, PA; VOGELSTEIN, B; KINZLER, KW; BISHOP, JM; ZARE, RN; SCHATZ, G; BENKOVIC, SJ; GRAY, HB; VALENTINE, JS; CRUTZEN, PJ; CHOI, DW; NAKANISHI, S; KOSSLYN, SM; BRAUMAN, JI; REES, DC; BRILL, WJ; SCHELL, J; LUHRMANN, R; WILL, CL; WULF, W; VERMEIJ, GJ; ARROW, KJ; SMELSER, NJ; ANDERSON, DL; ABELSON, PH			THROUGH THE GLASS LIGHTLY	SCIENCE			English	Discussion									UNIV CAMBRIDGE,DEPT GENET,CAMBRIDGE,ENGLAND; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,COLLEGE STN,TX 77843; PRINCETON UNIV,JOSEPH HENRY LABS PHYS,PRINCETON,NJ 08544; AT&T BELL LABS,MURRAY HILL,NJ 07974; STANFORD UNIV,DEPT APPL PHYS,STANFORD,CA 94305; DUKE UNIV,MED CTR,DEPT PHARMACOL,DURHAM,NC 27706; ALLIANCE PHARMACEUT CORP,SAN DIEGO,CA 92121; HOWARD HUGHES MED INST,BOULDER,CO; UNIV MARYLAND,MARYLAND BIOTECHNOL INST,COLLEGE PK,MD 20742; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; STANFORD LINEAR ACCELERATOR CTR,STANFORD,CA 94309; MIT,DEPT MATH,CAMBRIDGE,MA 02139; HOWARD HUGHES MED INST,DENVER,CO; UNIV CAMBRIDGE,SCH CLIN MED,CAMBRIDGE,ENGLAND; UNIV TEXAS,DEPT CHEM & BIOCHEM,AUSTIN,TX 78712; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; JOHNS HOPKINS UNIV,CTR ONCOL,BALTIMORE,MD 21218; UNIV CALIF SAN FRANCISCO,GEORGE WILLIAMS HOOPER FDN,SAN FRANCISCO,CA 94143; STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; UNIV BASEL,BIOZENTRUM,BASEL,SWITZERLAND; PENN STATE UNIV,DEPT CHEM,UNIVERSITY PK,PA 16802; CALTECH,BECKMAN INST,PASADENA,CA 91125; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90024; MAX PLANCK INST CHEM,W-6500 MAINZ,GERMANY; WASHINGTON UNIV,SCH MED,DEPT NEUROL,ST LOUIS,MO 63110; KYOTO UNIV,INST IMMUNOL,KYOTO,JAPAN; HARVARD UNIV,DEPT PSYCHOL,CAMBRIDGE,MA 02138; CALTECH,DIV CHEM & CHEM ENGN,PASADENA,CA 91125; R&D INNOVATOR,MADISON,WI; MAX PLANCK INST ZUCHTUNGSFORSCH,W-5000 COLOGNE,GERMANY; UNIV MARBURG,INST MOLEC BIOL & TUMOR RES,W-3550 MARBURG,GERMANY; UNIV VIRGINIA,DEPT COMP SCI,CHARLOTTESVILLE,VA 22903; UNIV CALIF DAVIS,DEPT GEOL,DAVIS,CA 95616; STANFORD UNIV,DEPT ECON,STANFORD,CA 94305; CTR ADV STUDY BEHAV SCI,STANFORD,CA 94305; CALTECH,SEISMOL LAB,PASADENA,CA 91125; AAAS,WASHINGTON,DC	University of Cambridge; Massachusetts Institute of Technology (MIT); Whitehead Institute; Texas A&M University System; Texas A&M University College Station; Princeton University; AT&T; Nokia Corporation; Nokia Bell Labs; Stanford University; Duke University; Alliance Pharmaceuticals Corporation; Howard Hughes Medical Institute; University System of Maryland; University of Maryland College Park; University of California System; University of California San Francisco; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; University of Cambridge; University of Texas System; University of Texas Austin; Memorial Sloan Kettering Cancer Center; Johns Hopkins University; Johns Hopkins Medicine; University of California System; University of California San Francisco; Stanford University; University of Basel; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; California Institute of Technology; University of California System; University of California Los Angeles; Max Planck Society; Washington University (WUSTL); Kyoto University; Harvard University; California Institute of Technology; Max Planck Society; Philipps University Marburg; University of Virginia; University of California System; University of California Davis; Stanford University; California Institute of Technology	WEINTRAUB, H (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.		Crutzen, Paul J/F-6044-2012; Rice, Treva K/D-1385-2009; Valentine, Joan S/B-6665-2008; Zare, Richard N./A-8410-2009; Marrack, Philippa/AHE-6316-2022	Valentine, Joan S/0000-0002-7174-925X; Zare, Richard/0000-0001-5266-4253					0	22	25	2	112	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1609	1618						10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886446				2022-12-28	WOS:A1995QM39700026
J	BERN, C; NATHANAIL, L				BERN, C; NATHANAIL, L			IS MID-UPPER-ARM CIRCUMFERENCE A USEFUL TOOL FOR SCREENING IN EMERGENCY SETTINGS	LANCET			English	Article							CHILDREN	In refugee emergencies, rapid collection of nutritional data provides important information for public-health planning. In Rwandan refugee camps in eastern Zaire in August, 1994, a two-step procedure of screening for referral to supplementary feeding programmes was used-mid-upper-arm circumference (MUAC) followed by weight-for-height for children with MUAC of less than 12 cm. To assess the usefulness of this procedure, we analysed data from complete screening of 3681 children in three camps. The performance of MUAC varied with the cut-off chosen; a high cut-off of 14 cm allowed detection of 88% of children with low weight-for-height but at the cost of measuring more than 40% of children in the second step. MUAC preferentially selects younger children as malnourished, and misses older children with low weight-for-height. The groups of children chosen by low MUAC and by low weight-for-height have poor overlap, varying from 20% to 391 overlap depending on age. Thus two-step screening does not save as much time as might be expected and low MUAC cannot be used as a substitute for low weight-for-height. For decision-making in refugee settings, weight-for-height surveys or screening are probably more efficient strategies for data collection.	SAVE CHILDREN FUND,POLICY DEPT UNIT,LONDON,ENGLAND	Save the Children	BERN, C (corresponding author), CTR DIS CONTROL & PREVENT,DIV NUTR,MATERNAL & CHILD HLTH BRANCH,ATLANTA,GA 30341, USA.							[Anonymous], 1986, WEIGH MEASURE CHILDR; BRIEND A, 1986, BRIT MED J, V293, P373, DOI 10.1136/bmj.293.6543.373; DEONIS M, 1993, B WORLD HEALTH ORGAN, V71, P703; GAYLE HD, 1988, J TROP PEDIATRICS, V34, P213, DOI 10.1093/tropej/34.5.213; GOLAZ A, 1994, 43RD EP INT SERV ANN; HALL G, 1993, LANCET, V341, P1481, DOI 10.1016/0140-6736(93)90927-9; JELIFFE DB, 1969, J TROP PEDIATRICS, V15, P177; LINDTJORN B, 1985, LANCET, V2, P1229; REES DG, 1987, LANCET, V1, P87; YOUNG H, 1992, FOOD SCARCITY FAMINE; 1986, B WORLD HEALTH ORGAN, V64, P929; 1993, GUIDELINES SUPPLEMEN; IN PRESS REPORT EXPE; 1992, MMWR-MORBID MORTAL W, V41, P1	14	24	24	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					631	633		10.1016/S0140-6736(95)90527-8	http://dx.doi.org/10.1016/S0140-6736(95)90527-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898183				2022-12-28	WOS:A1995QM07500015
J	VERBEEK, S; IZON, D; HOFHUIS, F; ROBANUSMAANDAG, E; TERIELE, H; VANDEWETERING, M; OOSTERWEGEL, M; WILSON, A; MACDONALD, HR; CLEVERS, H				VERBEEK, S; IZON, D; HOFHUIS, F; ROBANUSMAANDAG, E; TERIELE, H; VANDEWETERING, M; OOSTERWEGEL, M; WILSON, A; MACDONALD, HR; CLEVERS, H			AN HMG-BOX-CONTAINING T-CELL FACTOR REQUIRED FOR THYMOCYTE DIFFERENTIATION	NATURE			English	Article							TRANSCRIPTION FACTOR; RECEPTOR GENES; MICE; LYMPHOCYTES; PROTEIN; DOMAIN; TCF-1; LEF-1; BLOCK	Two candidate genes for controlling thymocyte differentiation, T-cell factor-1 (Tcf-1) and lymphoid enhancer-binding factor (Lef-1), encode closely related DNA-binding HMG-box proteins(1,2). Their expression pattern is complex and largely overlapping during embryogenesis, yet restricted to lymphocytes postnatally(3). Here we generate two independent germline mutations in Tcf-1 and find that thymocyte development is (otherwise normal) mutant mice is blocked at the transition from the CD8(+), immature single-positive to the CD4(+)/CD8(+) double-positive stage. Is contrast to wild-type mice, most of the immature single-positive cells in the mutants are not in the cell cycle and the number of immunocompetent T cells in peripheral lymphoid organs is reduced. We conclude that Tcf-1 controls an essential step in thymocyte differentiation.	UNIV UTRECHT HOSP,DEPT IMMUNOL,3508 GA UTRECHT,NETHERLANDS; NETHERLANDS CANC INST,DIV IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,DIV MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS; UNIV LAUSANNE,LUDWIG INST CANC RES,CH-1066 EPALINGES,SWITZERLAND	Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; Netherlands Cancer Institute; Ludwig Institute for Cancer Research; University of Lausanne			Wilson, Anne/A-7131-2011					CLEVERS HC, 1993, IMMUNOL TODAY, V14, P591, DOI 10.1016/0167-5699(93)90198-T; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; LEIDEN JM, 1993, ANNU REV IMMUNOL, V11, P539, DOI 10.1146/annurev.iy.11.040193.002543; MACDONALD HR, 1988, EUR J IMMUNOL, V18, P519, DOI 10.1002/eji.1830180405; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; OOSTERWEGEL M, 1993, DEVELOPMENT, V118, P439; OOSTERWEGEL M, 1992, J EXP MED, V173, P1133; PHILPOTT KL, 1992, SCIENCE, V256, P1448, DOI 10.1126/science.1604321; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, J BIOL CHEM, V267, P8530; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; VANGENDEREN C, 1994, GENE DEV, V8, P2691, DOI 10.1101/gad.8.22.2691; WILSON A, 1994, J EXP MED, V179, P1355, DOI 10.1084/jem.179.4.1355	20	423	426	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					70	74		10.1038/374070a0	http://dx.doi.org/10.1038/374070a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870176	Green Submitted			2022-12-28	WOS:A1995QK07900055
J	JONES, A; DOHERTY, M				JONES, A; DOHERTY, M			ABC OF RHEUMATOLOGY - OSTEOARTHRITIS	BRITISH MEDICAL JOURNAL			English	Article											JONES, A (corresponding author), CITY HOSP NOTTINGHAM,RHEUMATOL UNIT,NOTTINGHAM,ENGLAND.			Doherty, Michael/0000-0002-5763-8326					0	20	21	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					457	460		10.1136/bmj.310.6977.457	http://dx.doi.org/10.1136/bmj.310.6977.457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873956	Green Published			2022-12-28	WOS:A1995QJ24200028
J	SAUTER, C				SAUTER, C			DOXORUBICIN ADJUVANT COMBINATIONS FOR BREAST-CANCER	LANCET			English	Letter							THERAPY				SAUTER, C (corresponding author), UNIV HOSP ZURICH,DEPT MED,DIV ONCOL,CH-8091 ZURICH,SWITZERLAND.							BONADONNA G, 1989, J CLIN ONCOL, V7, P1380, DOI 10.1200/JCO.1989.7.10.1380; CARPENTER JT, 1991, P ASCO, V10, P45; DOROSHOW JH, 1991, NEW ENGL J MED, V324, P843, DOI 10.1056/NEJM199103213241210; ETTINGHAUSEN SE, 1986, ARCH SURG-CHICAGO, V121, P1445; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; HENDERSON IC, 1980, AM HEART J, V99, P671, DOI 10.1016/0002-8703(80)90743-7; OBRIAN R, 1992, P AM SOC CLIN ONCOL, V11, P61	7	5	5	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1550	1551		10.1016/S0140-6736(05)80116-3	http://dx.doi.org/10.1016/S0140-6736(05)80116-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902917				2022-12-28	WOS:A1993MM40200035
J	TAKESHIMA, Y; SEYAMA, T; BENNETT, WP; AKIYAMA, M; TOKUOKA, S; INAI, K; MABUCHI, K; LAND, CE; HARRIS, CC				TAKESHIMA, Y; SEYAMA, T; BENNETT, WP; AKIYAMA, M; TOKUOKA, S; INAI, K; MABUCHI, K; LAND, CE; HARRIS, CC			P53 MUTATIONS IN LUNG CANCERS FROM NONSMOKING ATOMIC-BOMB SURVIVORS	LANCET			English	Note							GENE	Tobacco smoke contains many carcinogens and has been linked with the development of lung cancer. We sequenced the conserved regions of the p53 tumour suppressor gene in lung cancers from 17 non-smokers from Hiroshima, Japan; 9 were atomic-bomb survivors. The mutations were predominantly transitions (all G:C to A:T); there were no G:C to T:A transversions. By contrast, lung cancers from 77 Japanese smokers have a predominance of G:C to T:A transversions in which the guanine residues occur on the non-transcribed DNA strand. These findings further implicate tobacco smoke carcinogens in the molecular pathogenesis of lung cancer.	NCI,BLDG 37,ROOM 2C05,BETHESDA,MD 20892; HIROSHIMA UNIV,SCH MED,HIROSHIMA 730,JAPAN; RADIAT EFFECTS RES FDN,HIROSHIMA 730,JAPAN	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Hiroshima University; Radiation Effects Research Foundation - Japan					NCI NIH HHS [NCI N01-CP-71128] Funding Source: Medline; DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS [N01CP071128] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Epidemiology & Genetics)		EVANS MK, IN PRESS CANCER RES; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; KISHIMOTO Y, 1992, CANCER RES, V52, P4799; MILLER CW, 1992, CANCER RES, V52, P1695; SAMESHIMA Y, 1992, ONCOGENE, V7, P451; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; SUZUKI H, 1992, CANCER RES, V52, P734; TAKAHASHI T, 1991, ONCOGENE, V6, P1775; VAHAKANGAS KH, 1992, LANCET, V339, P576, DOI 10.1016/0140-6736(92)90866-2	10	108	109	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1520	1521		10.1016/S0140-6736(05)80087-X	http://dx.doi.org/10.1016/S0140-6736(05)80087-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902903				2022-12-28	WOS:A1993MM40200014
J	WORLD, MJ				WORLD, MJ			PESTILENCE, WAR, AND LICE	LANCET			English	Editorial Material							JARISCH-HERXHEIMER REACTION; BORNE RELAPSING FEVER				WORLD, MJ (corresponding author), ROYAL ARMY MED COLL,LONDON SW1P 4RJ,ENGLAND.							ALEXANDER JO, 1984, ARTHROPODS HUMAN SKI, P32; BORGNOLO G, 1993, ANN TROP PAEDIATR, V13, P165, DOI 10.1080/02724936.1993.11747641; BORGNOLO G, 1993, TROP GEOGR MED, V45, P66; BROWN V, 1988, ANN TROP MED PARASIT, V82, P499, DOI 10.1080/00034983.1988.11812282; BURGESS NRH, 1992, PROSPECTUS ARMY MED, P46; DANIEL E, 1992, ETHIOPIAN MED J, V30, P207; GEBREHIWOT T, 1992, ETHIOPIAN MED J, V30, P175; GORDON RM, 1962, ENTOMOLOGY STUDENTS, P230; NEGUSSIE Y, 1992, J EXP MED, V175, P1207, DOI 10.1084/jem.175.5.1207; TEKLU B, 1985, T ROY SOC TROP MED H, V79, P74, DOI 10.1016/0035-9203(85)90241-X; ZEIN ZA, 1987, J ROY SOC HEALTH, V107, P146, DOI 10.1177/146642408710700410	11	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1192	1192		10.1016/0140-6736(93)92182-S	http://dx.doi.org/10.1016/0140-6736(93)92182-S			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MG274	7901526				2022-12-28	WOS:A1993MG27400006
J	BAILEY, TC; FRASER, VJ; SPITZNAGEL, EL; DUNAGAN, WC				BAILEY, TC; FRASER, VJ; SPITZNAGEL, EL; DUNAGAN, WC			RISK-FACTORS FOR A POSITIVE TUBERCULIN SKIN-TEST AMONG EMPLOYEES OF AN URBAN, MIDWESTERN TEACHING HOSPITAL	ANNALS OF INTERNAL MEDICINE			English	Article						TUBERCULIN TEST; AGE FACTORS; RACIAL STOCKS; SOCIOECONOMIC FACTORS; TUBERCULOSIS	HEALTH-CARE WORKERS; MYCOBACTERIUM-TUBERCULOSIS; NOSOCOMIAL TRANSMISSION; INFECTION; OUTBREAK; PROGRAM	Objective: To determine the prevalence and incidence of and the relative risks for positive tuberculin skin tests among employees of a large, urban teaching hospital. Design: Retrospective cohort study. Setting: Barnes Hospital, St, Louis, Missouri. Participants: Hospital personnel employed at any time between January 1989 and July 1991. Results: 684 of 6070 employees screened (11.3% [95% CI, 10.4% to 12.1%]) had positive tuberculin skin tests. Factors associated with a positive result were age (odds ratio, 2.02 per decade [CI, 1.87 to 2.18]; P < 0.0001); black race (odds ratio, 1.58 [CI, 1.26 to 2.00]; P < 0.0001); Asian race (odds ratio, 16.7 [CI, 9.33 to 29.9]; P < 0.0001); Hispanic ethnicity (odds ratio, 9.45 [CI, 3.58 to 25.0]; P < 0.0001); and percentage of low-income persons within the employee's residential postal zone (odds ratio, 1.14 per 10% [CI, 1.05 to 1.23]; P = 0.001). Twenty-nine of 3106 employees who had at least two tests had skin-test conversions (0.93% [CI, 0.60% to 1.3%]); 15 of these conversions (52%) occurred among employees who had no direct contact with patients. Only the percentage of low-income persons within the employee's residential postal zone (odds ratio 1.39 [CI, 1.09 to 1.78]; P = 0.0075) was independently associated with conversion. Conclusions: The most important associations with a positive tuberculin skin test were older age, minority group status, and the proportion of low-income persons within the employee's residential postal zone. Skin-test conversion was independently associated only with the percentage of low-income persons in the employee's postal zone. Stratifying employees according to degree of contact with patients or according to departmental group was not useful in determining risk for a positive tuberculin skin test or for skin-test conversion. For certain groups of employees, an exposure to tuberculosis in the community probably poses a greater risk than exposure in the hospital setting.			BAILEY, TC (corresponding author), WASHINGTON UNIV, SCH MED, BOX 8217, 660 S EUCLID, ST LOUIS, MO 63110 USA.			Fraser, Victoria/0000-0001-6251-0733				ADAL KA, 1994, NEW ENGL J MED, V331, P169, DOI 10.1056/NEJM199407213310306; AITKEN ML, 1987, AM REV RESPIR DIS, V136, P805, DOI 10.1164/ajrccm/136.4.805; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; BERMAN J, 1981, AM J PUBLIC HEALTH, V71, P1217, DOI 10.2105/AJPH.71.11.1217; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; Centers for Disease Control (CDC), 1991, MMWR Morb Mortal Wkly Rep, V40, P585; DALEY CL, 1992, NEW ENGL J MED, V326, P231, DOI 10.1056/NEJM199201233260404; DECKER MD, 1993, INFECT CONT HOSP EP, V14, P689, DOI 10.1086/646671; DIPERRI G, 1992, LANCET, V340, P682; Dooley S W Jr, 1990, MMWR Recomm Rep, V39, P1; DOOLEY SW, 1992, JAMA-J AM MED ASSOC, V267, P2632, DOI 10.1001/jama.267.19.2632; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; FEREBEE SH, 1970, BIBL TUBERC MED THOR, V17, P28; FISCHL MA, 1992, ANN INTERN MED, V117, P177, DOI 10.7326/0003-4819-117-3-177; FRASER VJ, 1994, INFECT CONT HOSP EP, V15, P95; FRASER VJ, 1993, INFECT CONT HOSP EP, V14, P623; GOSTIN LO, 1993, JAMA-J AM MED ASSOC, V269, P255, DOI 10.1001/jama.269.2.255; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; HOGE CW, 1994, AM J EPIDEMIOL, V139, P520, DOI 10.1093/oxfordjournals.aje.a117035; JARVIS WR, 1995, ANN INTERN MED, V122, P142, DOI 10.7326/0003-4819-122-2-199501150-00011; Jereb J A, 1991, MMWR CDC Surveill Summ, V40, P23; LIFSON AR, 1993, J INFECT DIS, V168, P1048, DOI 10.1093/infdis/168.4.1048; MALONEY SA, 1995, ANN INTERN MED, V122, P90, DOI 10.7326/0003-4819-122-2-199501150-00002; NETTLEMAN MD, 1994, ANN INTERN MED, V121, P37, DOI 10.7326/0003-4819-121-1-199407010-00007; PEARSON ML, 1992, ANN INTERN MED, V117, P191, DOI 10.7326/0003-4819-117-3-191; RAAD I, 1989, INFECT CONT HOSP EP, V10, P465, DOI 10.1086/645922; RILEY RL, 1962, AM REV RESPIR DIS, V85, P511; SNIDER DE, 1984, AM J INFECT CONTROL, V12, P305, DOI 10.1016/0196-6553(84)90001-4; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STROUD L, 1993, INTERSCIENCE C ANTIM; 1990, MMWR-MORBID MORTAL W, V39, P9; 1994, FED REGISTER, V59, P54242	33	61	63	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					580	585		10.7326/0003-4819-122-8-199504150-00004	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887551				2022-12-28	WOS:A1995QR52500004
J	COHN, MJ; IZPISUABELMONTE, JC; ABUD, H; HEATH, JK; TICKLE, C				COHN, MJ; IZPISUABELMONTE, JC; ABUD, H; HEATH, JK; TICKLE, C			FIBROBLAST GROWTH-FACTORS INDUCE ADDITIONAL LIMB DEVELOPMENT FROM THE FLANK OF CHICK-EMBRYOS	CELL			English	Article							APICAL ECTODERMAL RIDGE; POLARIZING ACTIVITY; EXPRESSION; RECEPTOR; BUD; MOUSE; CELLS; LOCALIZATION; GENES; FGF-4	Fibroblast growth factors (FGFs) act as signals in the developing limb and can maintain proliferation of limb bud mesenchyme cells. Remarkably, beads soaked in FGF-1, FGF-2, or FGF-4 and placed in the presumptive flank of chick embryos induce formation of ectopic limb buds, which can develop into complete limbs. The entire flank can produce additional limbs, but generally wings are formed anteriorly and legs posteriorly. FGF application activates Sonic hedgehog in cells with polarizing potential to make a discrete polarizing region. Hoxd-13 is also expressed in the ectopic bud, and an apical ectodermal ridge forms. A limb bud is thus established that can generate the appropriate signals to develop into a complete limb. The additional limbs have reversed polarity. This can be explained by the distribution of cells in the flank with potential polarizing activity. The results suggest that local production of an FGF may initiate limb development.	SALK INST BIOL STUDIES,GENE EXPRESS LABS,LA JOLLA,CA 92037; UNIV OXFORD,DEPT BIOCHEM,OXFORD OX1 3QU,ENGLAND; UNIV BIRMINGHAM,DEPT BIOCHEM,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	Salk Institute; University of Oxford; University of Birmingham	COHN, MJ (corresponding author), UNIV COLL & MIDDLESEX SCH MED,DEPT ANAT & DEV BIOL,LONDON W1P 6DB,ENGLAND.			Abud, Helen/0000-0003-3792-4023	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; Balinsky B. I., 1933, ROUXS ARCH, V130, P704; BALINSKY BI, 1925, ROUX ARCH DEV BIOL, V143, P718; CHARITE J, 1994, CELL, V78, P589, DOI 10.1016/0092-8674(94)90524-X; CROSSLEY PH, 1995, IN PRESS DEVELOPMENT; FALLON JF, 1994, SCIENCE, V264, P104, DOI 10.1126/science.7908145; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; HEMMATIBRIVANLOU A, 1990, DEVELOPMENT, V110, P325; HORNBRUCH A, 1991, DEVELOPMENT, V111, P725; HORNBRUCH A, 1986, J EMBRYOL EXP MORPH, V94, P257; IZPISUABELMONTE JC, 1992, DEVELOPMENT, V115, P553; IZPISUABELMONTE JC, 1993, CELL, V74, P645, DOI 10.1016/0092-8674(93)90512-O; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KIORTSIS VASSILI, 1953, REV SUISSE ZOOL, V60, P301; KLAGSBRUN M, 1991, CELL, V67, P229, DOI 10.1016/0092-8674(91)90173-V; LOCATELLI P, 1924, B SOC MED CHIR PA, P36; MANSUKHANI A, 1990, P NATL ACAD SCI USA, V87, P4378, DOI 10.1073/pnas.87.11.4378; MESCHER AL, 1979, J EXP ZOOL, V207, P497, DOI 10.1002/jez.1402070318; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOLVEN A, 1990, DEVELOPMENT, V109, P279; NISWANDER L, 1993, CELL, V75, P579, DOI 10.1016/0092-8674(93)90391-3; NISWANDER L, 1992, DEVELOPMENT, V114, P755; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NISWANDER L, 1993, NATURE, V361, P68, DOI 10.1038/361068a0; NOHNO T, 1991, CELL, V64, P1197, DOI 10.1016/0092-8674(91)90274-3; OHUCHI H, 1994, BIOCHEM BIOPH RES CO, V204, P882, DOI 10.1006/bbrc.1994.2542; OLIVER G, 1988, CELL, V55, P1017, DOI 10.1016/0092-8674(88)90246-2; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PETERS KG, 1992, DEVELOPMENT, V114, P233; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; Saunders J. W., 1968, EPITHELIAL MESENCHYM, P78; SAUNDERS JW, 1974, DEV BIOL, V38, P41, DOI 10.1016/0012-1606(74)90257-7; SAVAGE MP, 1993, DEV DYNAM, V198, P159, DOI 10.1002/aja.1001980302; SEARLS RL, 1971, DEV BIOL, V24, P198, DOI 10.1016/0012-1606(71)90095-9; SEARLS RL, 1964, DEV BIOL, V9, P35; SUMMERBELL D, 1973, NATURE, V224, P492; SUZUKI HR, 1992, DEV BIOL, V150, P219, DOI 10.1016/0012-1606(92)90020-H; THOMAS KA, 1993, NEUROTROPHIC FACTORS, P285; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VOGEL A, 1993, DEVELOPMENT, V119, P199; WAGNER M, 1990, NATURE, V345, P819, DOI 10.1038/345819a0; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO	48	484	491	0	22	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					739	746		10.1016/0092-8674(95)90352-6	http://dx.doi.org/10.1016/0092-8674(95)90352-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889567	Bronze			2022-12-28	WOS:A1995QM39900010
J	MURATA, Y; WHARTON, RP				MURATA, Y; WHARTON, RP			BINDING OF PUMILIO TO MATERNAL HUNCHBACK MESSENGER-RNA IS REQUIRED FOR POSTERIOR PATTERNING IN DROSOPHILA EMBRYOS	CELL			English	Article							3' UNTRANSLATED REGION; POLE CELL-FORMATION; C-ELEGANS; DETERMINANT NANOS; HEAD DEVELOPMENT; BICOID PROTEIN; BODY PATTERN; GENE NANOS; RNA; SEGMENTATION	Posterior patterning in Drosophila embryos is governed by nanos (nos), which acts by repressing the translation of maternal transcripts of the hunchback (hb) gene. Sites in hb mRNA that mediate this repression, named nanos response elements (NREs), have been identified. However, we know of no evidence of a direct interaction between nos, or any other protein, and the NRE. Here, we show that two proteins present in embryonic extracts, neither one nos, bind specifically to the NRE in vitro. Furthermore, we show that binding in vitro correlates with NRE function in vivo. One of the NRE-binding factors is encoded by pumilio (pum), a gene that, like nos, is essential for abdominal segmentation. These and other observations suggest that pum acts by recognizing the NRE and then recruiting nos. Presumably, the resulting complex inhibits some component of the translation machinery.	DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT MICROBIOL, DURHAM, NC 27710 USA	Duke University; Howard Hughes Medical Institute	MURATA, Y (corresponding author), DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DEPT GENET, DURHAM, NC 27710 USA.							AHRINGER J, 1991, NATURE, V349, P346, DOI 10.1038/349346a0; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; ARMEIN H, 1994, CELL, V76, P735; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; CHEN WN, 1991, YEAST, V7, P309, DOI 10.1002/yea.320070314; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; EVANS TC, 1994, CELL, V77, P183, DOI 10.1016/0092-8674(94)90311-5; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; GAVIS ER, 1992, CELL, V71, P301, DOI 10.1016/0092-8674(92)90358-J; GAVIS ER, 1994, NATURE, V369, P315, DOI 10.1038/369315a0; GILMARTIN GM, 1989, GENE DEV, V3, P2180, DOI 10.1101/gad.3.12b.2180; GOODWIN EB, 1993, CELL, V75, P329, DOI 10.1016/0092-8674(93)80074-O; HARLOW E, 1988, ANTIBODIES LABORATOR; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MACDONALD PM, 1992, DEVELOPMENT, V114, P221; MOLITOR JA, 1990, P NATL ACAD SCI USA, V87, P10028, DOI 10.1073/pnas.87.24.10028; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TIAN M, 1994, GENE DEV, V8, P1703, DOI 10.1101/gad.8.14.1703; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VASSALLI JD, 1989, GENE DEV, V3, P2163, DOI 10.1101/gad.3.12b.2163; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9; WIGHTMAN B, 1993, CELL, V75, P855, DOI 10.1016/0092-8674(93)90530-4	47	335	342	0	18	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAR 10	1995	80	5					747	756		10.1016/0092-8674(95)90353-4	http://dx.doi.org/10.1016/0092-8674(95)90353-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889568	Bronze			2022-12-28	WOS:A1995QM39900011
J	HAY, JC; FISETTE, PL; JENKINS, GH; FUKAMI, K; TAKENAWA, T; ANDERSON, RA; MARTIN, TFJ				HAY, JC; FISETTE, PL; JENKINS, GH; FUKAMI, K; TAKENAWA, T; ANDERSON, RA; MARTIN, TFJ			ATP-DEPENDENT INOSITIDE PHOSPHORYLATION REQUIRED FOR CA2+-ACTIVATED SECRETION	NATURE			English	Article							PHOSPHATIDYLINOSITOL TRANSFER PROTEIN; CYTOSOLIC PROTEINS; CHROMAFFIN CELLS; PHOSPHOLIPASE-C; EXOCYTOSIS; MEMBRANES; ANTIBODY; FUSION	REGULATED fusion of secretory granules with the plasma membrane in secretory cells requires ATP, Ca2+ and cytosolic(1-3) as well as membrane(4) proteins. ATP-dependent steps in Ca2+-activated secretion from PC12 cells require three cytosolic PEP proteins (priming in exocytosis proteins, PEP1-3)(5,6), the identity of which will provide insights into the required ATP-using reactions. PEP3 was recently identified as phosphatidylinositol transfer protein (PtdInsTP)(6), and here we report that PEP1 consists of the type I phosphatidylinositol-4-phosphate 5-kinase (PtdInsP5K), The roles of PEP3/PtdInsTP and PEP1/PtdInsP5K in sequential phosphoinositide recruitment and phosphorylation explains their synergistic activity in ATP-dependent priming, Moreover, inhibition of Ca2+-activated secretion by PtdIns(4,5)P-2-specific antibodies and phospholipase C implies that 5-phosphorylated inositides play a novel, necessary role in the regulated secretory pathway. The results indicate that lipid kinase-mediated phosphorylation is an important basis for ATP use in the exocytotic pathway.	UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706; UNIV WISCONSIN,DEPT PHARMACOL,MADISON,WI 53706; UNIV WISCONSIN,CELL & MOLEC BIOL PROGRAM,MADISON,WI 53706; UNIV TOKYO,DEPT MOLEC ONCOL,TOKYO 108,JAPAN	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Tokyo				Anderson, Richard/0000-0001-6265-8359				ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAZENET CE, 1990, J BIOL CHEM, V265, P18012; BITTNER MA, 1993, CELL MOL NEUROBIOL, V13, P649, DOI 10.1007/BF00711564; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HAY JC, 1993, NATURE, V366, P572, DOI 10.1038/366572a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWRENCE GW, 1994, EUR J BIOCHEM, V222, P325, DOI 10.1111/j.1432-1033.1994.tb18871.x; LISCOVITCH M, 1993, J BIOL CHEM, V269, P21403; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; PERRIN D, 1987, NATURE, V326, P498, DOI 10.1038/326498a0; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; SCHOLZ G, 1992, EUR J BIOCHEM, V210, P461, DOI 10.1111/j.1432-1033.1992.tb17443.x; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; WALENT JH, 1992, CELL, V70, P765, DOI 10.1016/0092-8674(92)90310-9; WU YN, 1992, BIOCHEM J, V285, P697, DOI 10.1042/bj2850697	30	444	451	1	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					173	177		10.1038/374173a0	http://dx.doi.org/10.1038/374173a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877690				2022-12-28	WOS:A1995QL39700062
J	NEWTON, JN; REDBURN, J				NEWTON, JN; REDBURN, J			INCIDENCE OF MELANOMA IN 4 ENGLISH COUNTIES, 1989-92	BRITISH MEDICAL JOURNAL			English	Article									ANGLIA & OXFORD REG HLTH AUTHOR,OXFORD CANC INTELLIGENCE UNIT,OXFORD OX3 7LF,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND	University of Oxford; University of Oxford				Newton, John/0000-0002-5641-6457				[Anonymous], 1992, IARC MONOGRAPHS EVAL, V55; ARMITRAGE P, 1987, STATISTICAL METHODS; GRAHAMBROWN RAC, 1990, BRIT J DERMATOL, V122, P53, DOI 10.1111/j.1365-2133.1990.tb08239.x; SHARP L, 1993, CANCER REGISTRATION; 1994, CANCER STATISTICS RE	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					502	503		10.1136/bmj.310.6978.502	http://dx.doi.org/10.1136/bmj.310.6978.502			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888890	Green Published			2022-12-28	WOS:A1995QJ59800023
J	PERRY, IJ; BEEVERS, DG; WHINCUP, PH; BAREFORD, D				PERRY, IJ; BEEVERS, DG; WHINCUP, PH; BAREFORD, D			PREDICTORS OF RATIO OF PLACENTAL WEIGHT TO FETAL WEIGHT IN MULTIETHNIC COMMUNITY	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IRON-DEFICIENCY; ADULT LIFE; HYPERTENSION; PREGNANCY	Objective-To determine whether placental ratio is influenced by maternal ethnic origin, obesity, hypertension, and haematological indices of iron deficiency anaemia. Design-Observational study. Setting-District general hospital in Birmingham. Subjects-692 healthy nulliparous pregnant women, of whom 367 were European, 213 Asian, 99 Afro-Caribbean, and 13 of other or undocumented ethnic origin. Main outcome measures-Placental ratio and maternal body mass index, blood pressure, and haematological indices. Results-Though birth weight and placental weight were lower in Asian women than in other groups, mean placental ratio was similar in Asian (19.5% (SD 3.3%)), European (20.0% (4.0%)), and Afro-Caribbean women (20.4% (5.3%)). Gestational age at birth was the main predictor of placental ratio in the univariate analysis (r=-0.34, P < 0.001) and multivariate analysis. The only other significant predictor of placental ratio in multivariate analysis was maternal body mass index, which was positively associated with placental ratio (r=0.1, P=0.01). Mean (SD) placental ratio was not significantly higher in women who developed gestational hypertension (20.4% (4.5%)) and pre-eclampsia (23.3% (7.3%)) than in normal women (19.8% (3.8%)). No evidence of a relation between placental ratio and first antenatal visit haemoglobin concentration or mean cell volume was detected, and placental ratio was not associated with change in mean cell volume during pregnancy or with third trimester serum ferritin concentration. Conclusions-These data do not support the proposed association between poor maternal nutrition and increased placental ratio. The association between high placental ratio and adult hypertension may be confounded by genetic and environmental factors associated with maternal obesity (and possibly maternal hypertension).	DUDLEY RD GEN HOSP, DEPT MED, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND; DUDLEY RD GEN HOSP, DEPT HAEMATOL, BIRMINGHAM B18 7QH, W MIDLANDS, ENGLAND		PERRY, IJ (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH, LONDON NW3 2PF, ENGLAND.			Whincup, Peter/0000-0002-5589-4107; Perry, Ivan/0000-0002-4965-9792	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ADDISON GM, 1972, J CLIN PATHOL, V25, P326, DOI 10.1136/jcp.25.4.326; BARKER DJP, 1991, J ROY COLL PHYS LOND, V25, P129; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; CHAMBERLAIN G, 1978, BRIT BIRTHS 1970, V2; DAVEY DA, 1988, AM J OBSTET GYNECOL, V158, P892, DOI 10.1016/0002-9378(88)90090-7; EATON PM, 1984, BR J NUTR, V52, P477; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; ESKENAZI B, 1991, JAMA-J AM MED ASSOC, V266, P237; Fox H, 1988, HDB HYPERTENSION, V10, P16; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; HIMMELMANN A, 1994, J INTERN MED, V235, P347, DOI 10.1111/j.1365-2796.1994.tb01085.x; PERRY IJ, 1993, BRIT MED J, V307, P420, DOI 10.1136/bmj.307.6901.420; PERRY IJ, 1994, BRIT J OBSTET GYNAEC, V101, P587, DOI 10.1111/j.1471-0528.1994.tb13648.x; WHARTON PA, 1984, BRIT J NUTR, V52, P469, DOI 10.1079/BJN19840114; WHINCUP P, 1994, J HUM HYPERTENS, V8, P337; 1989, MINITAG STATISTICAL	17	83	85	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 18	1995	310	6977					436	439		10.1136/bmj.310.6977.436	http://dx.doi.org/10.1136/bmj.310.6977.436			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873949	Green Published			2022-12-28	WOS:A1995QJ24200019
J	HOGERZEIL, HV; BIMO; ROSSDEGNAN, D; LAING, RO; OFORIADJEI, D; SANTOSO, B; CHOWDHURY, AKA; DAS, AM; KAFLE, KK; MABADEJE, AFB; MASSELE, AY				HOGERZEIL, HV; BIMO; ROSSDEGNAN, D; LAING, RO; OFORIADJEI, D; SANTOSO, B; CHOWDHURY, AKA; DAS, AM; KAFLE, KK; MABADEJE, AFB; MASSELE, AY			FIELD-TESTS FOR RATIONAL DRUG-USE IN 12 DEVELOPING-COUNTRIES	LANCET			English	Article								Increasing efforts are being made to improve drug-use practices and prescribing behaviour in developing countries. An essential tool for such work is an objective and standard method of assessment. We present here a set of drug-use indicators produced and tested in twelve developing countries. We describe practical applications, which include the use of indicators to increase awareness among prescribers in Malawi and Bangladesh, to identify priorities for action (eg, polypharmacy in Indonesia and Nigeria, overuse of injections in Uganda, Sudan, and Nigeria, and low percentage of patients who understood the dosage schedule in Malawi), and to quantify the impact of interventions in Yemen, Uganda, Sudan, and Zimbabwe.	YAYASAN INDONESIA SEJAHTERA,DIV HLTH,JAKARTA,INDONESIA; HARVARD UNIV,SCH MED,DRUG POLICY GRP,BOSTON,MA 02115; MANAGEMENT SCI HLTH,INT NETWORK RAT USE DRUGS,BOSTON,MA; UNIV GHANA,SCH MED,CTR TROP CLIN PHARMACOL,ACCRA,GHANA; GADJAH MADA UNIV,DEPT CLIN PHARMACOL,YOGYAKARTA,INDONESIA; NATL INST PREVENT & SOCIAL MED,DEPT BIOSTAT,DHAKA,BANGLADESH; UNIV DHAKA,DEPT PHARM,DHAKA,BANGLADESH; TRIBHUVAN UNIV HOSP,DEPT CLIN PHARMACOL,KATMANDU,NEPAL; UNIV LAGOS,COLL MED,DEPT PHARMACOL,LAGOS,NIGERIA; MAHIMBILL MED CTR,DEPT CLIN PHARMACOL,DAR ES SALAAM,TANZANIA	Harvard University; Harvard Medical School; University of Ghana; Gadjah Mada University; University of Dhaka; Tribhuvan University; Institute of Medicine (IoM) - Nepal; University of Lagos	HOGERZEIL, HV (corresponding author), WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA 27,SWITZERLAND.			Ofori-Adjei, David/0000-0003-1912-4188; Massele, Amos/0000-0003-3816-2040				Bannenberg WJ, 1991, WHODAP9110; BATES JA, 1992, GUATEMALA FIELD TEST; Bimo, 1992, INRUD NEWS, V3, P9; Christensen Rene Flamsholt, 1990, STRATEGY IMPROVEMENT; Gelders S, 1992, MALAWI ESSENTIAL DRU; HOGERZEIL HV, 1989, LANCET, V1, P141; KAFLE KK, 1992, INRUD NEWS, V3, P15; LAING RO, 1990, TROP DOCT, V20, P101, DOI 10.1177/004947559002000303; Ofori-Adjei D, 1992, INRUD NEWS, V3, P9; ROSSDEGNAN D, 1992, SOC SCI MED, V35, P1329, DOI 10.1016/0277-9536(92)90037-Q; SALLET JP, 1992, ECUADOR FIELD TEST P; 1991, FIELD TESTING DRUG I; 1993, WHODAP931, P1; 1993, BASELINE SURVEY DRUG; 1987, 1985 C EXP NAIR; 1991, ESSENTIAL DRUGS SURV	16	162	178	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1408	1410		10.1016/0140-6736(93)92760-Q	http://dx.doi.org/10.1016/0140-6736(93)92760-Q			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901689				2022-12-28	WOS:A1993MK09500017
J	BABINGTON, A				BABINGTON, A			A STAIN ON ARMY MEDICINE	LANCET			English	Editorial Material																		BABINGTON A, 1993, SAKE EXAMPLE CAPITAL; DEARDEN H, 1928, MED DUTY; MORAN, 1945, ANATOMY COURAGE; Richards Robert L., 1910, MIL SURG, V26, P177; Sassoon Siegfried, 1936, SHERSTONS PROGR	5	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1253	1254		10.1016/0140-6736(93)92356-X	http://dx.doi.org/10.1016/0140-6736(93)92356-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901580				2022-12-28	WOS:A1993MH56600006
J	VILLAR, J; CARROLI, G; BELIZAN, JM				VILLAR, J; CARROLI, G; BELIZAN, JM			PREDICTIVE ABILITY OF METAANALYSES OF RANDOMIZED CONTROLLED TRIALS	LANCET			English	Article							CLINICAL-TRIALS	Although meta-analysis of randomised clinical trials is increasingly used, the evaluation of its ability to predict the results of large trials is not available. We have calculated the relative risks (and 95% confidence intervals) for thirty meta-analyses of different interventions in perinatal medicine, covering 185 randomised controlled trials, but with the largest trial removed. We then compared those results with the result of the largest trial (total sample size more than 1000) done on that intervention and outcome. Twenty-four meta-analyses correctly predicted the direction of the treatment effect, but only eighteen of the thirty were the same both in direction of treatment effect and in statistical significance as the largest trial. There was moderate agreement, beyond chance, between meta-analysis and largest trial results (kappa statistic 0.46-0.53). A meta-analysis demonstrating a protective effect from an intervention of more than 40% had a 60% probability of correctly predicting results of the same magnitude of the largest trial. Researchers and funding agencies may use meta-analysis before recommending a clinical practice or to summarise results of three controlled trials before deciding on additional studies of promising interventions. However, further evaluation of the meta-analysis method is needed if the qualitative and quantitative results it yields are to be better understood.	CTR ROSARINO ESTUDIOS PERINATALES,ROSARIO,ARGENTINA		VILLAR, J (corresponding author), UNDP,UNFPA,WHO,WORLD BANK,SPECIAL PROGRAMME RES DEV & RES TRAINING HUMAN RE,CH-1211 GENEVA 27,SWITZERLAND.			Belizan, Jose/0000-0002-8412-3010				BRESLOW NE, 1987, IARC SCI PUB, V82, P110; CARROLI G, 1994, BRIT J OBSTET GYNAEC, V101, P753, DOI 10.1111/j.1471-0528.1994.tb11940.x; CHALMERS FT, 1988, CONTROL CLIN TRIALS, V9, P250, DOI 10.1016/0197-2456(88)90092-X; CHALMERS I, 1991, LANCET, V338, P1464, DOI 10.1016/0140-6736(91)92771-S; CHALMERS I, 1989, METHODS USED SYNTHES, P39; CHALMERS TC, 1991, STAT MED, V10, P971, DOI 10.1002/sim.4780100618; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; CLELAND JGF, 1994, LANCET, V344, P1222, DOI 10.1016/S0140-6736(94)90536-3; Dean A. G., 1990, EPI INFO VERSION 5 W; DICKERSIN K, 1992, EPIDEMIOL REV, V14, P154, DOI 10.1093/oxfordjournals.epirev.a036084; ENKIN MW, 1993, PREGNANCY CHILDBIRTH; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; FLEISS JL, 1986, CONTROL CLIN TRIALS, V7, P267, DOI 10.1016/0197-2456(86)90034-6; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P290, DOI 10.1093/oxfordjournals.aje.a117248; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HORTON R, 1993, LANCET, V342, P1499, DOI 10.1016/S0140-6736(05)80076-5; KASSIRER JP, 1992, NEW ENGL J MED, V327, P273, DOI 10.1056/NEJM199207233270411; KUBAN KCK, 1986, PEDIATRICS, V77, P443; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; MACMAHON B, 1964, INT J CANCER, V20, P1172; MANTEL N, 1959, J NATL CANCER I, V22, P719; OLKIN I, 1990, FUTURE META ANAL, P3; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PRENDIVILLE W, 1988, BRIT J OBSTET GYNAEC, V95, P3, DOI 10.1111/j.1471-0528.1988.tb06475.x; ROSENTHAL R, 1979, PSYCHOL BULL, V86, P638, DOI 10.1037/0033-2909.86.3.638; SCHLESSELMAN J, 1982, CASE CONTROL STUDIES, P195; THOMPSON SG, 1991, LANCET, V338, P1127, DOI 10.1016/0140-6736(91)91975-Z; WOODS KL, 1992, LANCET, V339, P1553, DOI 10.1016/0140-6736(92)91828-V; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P336	30	177	182	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					772	776		10.1016/S0140-6736(95)90646-0	http://dx.doi.org/10.1016/S0140-6736(95)90646-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891492				2022-12-28	WOS:A1995QN70100017
J	SCHOTT, GD				SCHOTT, GD			AN UNSYMPATHETIC VIEW OF PAIN	LANCET			English	Editorial Material							REFLEX SYMPATHETIC DYSTROPHY				SCHOTT, GD (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND.							BENNETT GJ, 1993, MUSCLE NERVE, V16, P1040, DOI 10.1002/mus.880161007; Blanchard J, 1990, J Pain Symptom Manage, V5, P357, DOI 10.1016/0885-3924(90)90030-N; Bonica J. J., 1979, ADV PAIN RES THER, V3, P141; CERVERO F, 1994, PHYSIOL REV, V74, P95, DOI 10.1152/physrev.1994.74.1.95; DRUMMOND PD, 1991, BRAIN, V114, P2025, DOI 10.1093/brain/114.5.2025; EVANS JA, 1946, SURG GYNECOL OBSTET, V82, P36; FINE PG, 1994, PAIN, V56, P235, DOI 10.1016/0304-3959(94)90099-X; GALER BS, 1994, LANCET, V344, P691, DOI 10.1016/S0140-6736(94)92130-X; Leriche R., 1916, PRESSE MED, V24, P178; LERICHE R, 1939, SURG PAIN, P119; LOH L, 1980, J NEUROL NEUROSUR PS, V43, P446, DOI 10.1136/jnnp.43.5.446; LYNCH ME, 1992, PAIN, V49, P337, DOI 10.1016/0304-3959(92)90241-3; Merskey H., 1994, CLASSIFICATION CHRON, P40; Mitchell SW., 1864, GUNSHOT WOUNDS OTHER; NATHAN PW, 1980, DAHLEM K LIFE SCI RE, V17, P311; OCHOA JL, 1994, CURR OPIN NEUROL, V7, P407, DOI 10.1097/00019052-199410000-00008; SCHOTT GD, 1986, BRAIN, V109, P717, DOI 10.1093/brain/109.4.717; SCHOTT GD, 1994, BRAIN, V117, P397, DOI 10.1093/brain/117.2.397; SCHWARTZMAN RJ, 1987, ARCH NEUROL-CHICAGO, V44, P555, DOI 10.1001/archneur.1987.00520170081028; TOREBJORK E, 1994, PROG PAIN RES MANAG, V2, P277; TOREBJORK E, 1990, REFLEX SYMPATHETIC D, P71; VELDMAN PHJM, 1993, LANCET, V342, P1012, DOI 10.1016/0140-6736(93)92877-V; WAHREN LK, 1991, PAIN, V46, P23, DOI 10.1016/0304-3959(91)90029-W; WEISS APC, 1994, LANCET, V344, P209, DOI 10.1016/S0140-6736(94)92990-4	24	64	65	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	MAR 11	1995	345	8950					634	636		10.1016/S0140-6736(95)90528-6	http://dx.doi.org/10.1016/S0140-6736(95)90528-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898184				2022-12-28	WOS:A1995QM07500016
J	CHAN, MK; MUKUND, S; KLETZIN, A; ADAMS, MWW; REES, DC				CHAN, MK; MUKUND, S; KLETZIN, A; ADAMS, MWW; REES, DC			STRUCTURE OF A HYPERTHERMOPHILIC TUNGSTOPTERIN ENZYME, ALDEHYDE FERREDOXIN OXIDOREDUCTASE	SCIENCE			English	Article							MOLYBDOPTERIN GUANINE DINUCLEOTIDE; ARCHAEBACTERIUM PYROCOCCUS-FURIOSUS; IRON-SULFUR PROTEIN; MOLYBDENUM COFACTOR; MACROMOLECULAR CRYSTALLOGRAPHY; D-GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; HEAT-STABILITY; ALPHA-HELICES; TUNGSTEN; CRYSTAL	The crystal structure of the tungsten-containing aldehyde ferredoxin oxidoreductase (AOR) from Pyrococcus furiosus, a hyperthermophilic archaeon (formerly archaebacterium) that grows optimally at 100 degrees C, has been determined at 2.3 angstrom resolution by means of multiple isomorphous replacement and multiple crystal form averaging. AOR consists of two identical subunits, each containing an Fe4S4 cluster and a molybdopterin-based tungsten cofactor that is analogous to the molybdenum cofactor found in a large class of oxotransferases. Whereas the general features of the tungsten coordination in this cofactor were consistent with a previously proposed structure, each AOR subunit unexpectedly contained two molybdopterin molecules that coordinate a tungsten by a total of four sulfur ligands, and the pterin system was modified by an intramolecular cyclization that generated a three-ringed structure. In comparison to other proteins, the hyperthermophilic enzyme AOR has a relatively small solvent-exposed surface area, and a relatively large number of both ion pairs and buried atoms. These properties may contribute to the extreme thermostability of this enzyme.	CALTECH, DIV CHEM & CHEM ENGN 14775CH, PASADENA, CA 91125 USA; UNIV GEORGIA, CTR METALLOENZYME STUDIES, DEPT BIOCHEM & MOLEC BIOL, ATHENS, GA 30602 USA	California Institute of Technology; University System of Georgia; University of Georgia			Kletzin, Arnulf/AAO-7366-2020	Adams, Michael/0000-0002-9796-5014; Kletzin, Arnulf/0000-0002-4500-2232	NIGMS NIH HHS [GM50775, 1F32 GM15006] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015006, R01GM050775] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams M.W.W., 1994, ENCY INORGANIC CHEM, P4284; ADAMS MWW, 1992, ACS SYM SER, V498, P1; ADAMS MWW, 1994, FEMS MICROBIOL REV, V15, P261, DOI 10.1111/j.1574-6976.1994.tb00139.x; ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; AURORA R, 1994, SCIENCE, V264, P1126, DOI 10.1126/science.8178170; BARLOW DJ, 1983, J MOL BIOL, V168, P867, DOI 10.1016/S0022-2836(83)80079-5; BEGUM NS, 1992, POLYHEDRON, V11, P2823; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETHGE PH, 1984, J APPL CRYSTALLOGR, V17, P215, DOI 10.1107/S0021889884011365; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; COLOVOS C, 1993, PROTEIN SCI, V2, P1511, DOI 10.1002/pro.5560020916; CONN JF, 1974, J AM CHEM SOC, V96, P7152, DOI 10.1021/ja00829a081; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; DAVIES GJ, 1993, PROTEINS, V15, P283, DOI 10.1002/prot.340150306; DAY MW, 1992, PROTEIN SCI, V1, P1494, DOI 10.1002/pro.5560011111; ENERNARK JH, 1994, ADV INORG CHEM, V40, P1; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; HENDSCH ZS, 1994, PROTEIN SCI, V3, P211; HETTRICH D, 1991, BIOL CHEM H-S, V372, P513, DOI 10.1515/bchm3.1991.372.2.513; HOLM RH, 1990, COORDIN CHEM REV, V100, P183, DOI 10.1016/0010-8545(90)85010-P; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JOHNSON JL, 1993, J BIOL CHEM, V268, P4848; JOHNSON JL, 1990, ARCH BIOCHEM BIOPHYS, V283, P542, DOI 10.1016/0003-9861(90)90681-N; JOHNSON JL, 1990, P NATL ACAD SCI USA, V87, P3190, DOI 10.1073/pnas.87.8.3190; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; JOHNSON JL, 1991, FEMS MICROBIOL LETT, V77, P213; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KARRASCH M, 1990, FEBS LETT, V274, P48, DOI 10.1016/0014-5793(90)81326-J; KENDRICK MJ, 1992, METALS BIOL SYSTEMS; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; KLETZIN A, UNPUB; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KRAMER SP, 1987, J BIOL CHEM, V262, P16357; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, 1994, P NATL ACAD SCI USA, V91, P423, DOI 10.1073/pnas.91.1.423; LUTHY R, 1992, NATURE, V356, P83, DOI 10.1038/356083a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MILLER S, 1987, NATURE, V328, P834, DOI 10.1038/328834a0; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MUKUND S, 1991, J BIOL CHEM, V266, P14208; MUKUND S, 1990, J BIOL CHEM, V265, P11508; MUKUND S, 1993, J BIOL CHEM, V268, P13592; MUKUND S, UNPUB; PERUTZ MF, 1975, NATURE, V255, P256, DOI 10.1038/255256a0; PERUTZ MF, 1978, SCIENCE, V201, P1187, DOI 10.1126/science.694508; Pilato R. S., 1993, BIOINORGANIC CATALYS, P131; RAJAGOPALAN KV, 1991, ADV ENZYMOL RAMB, V64, P215; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; REEKE GN, 1984, J APPL CRYSTALLOGR, V17, P125, DOI 10.1107/S0021889884011171; REES DC, UNPUB; RICHARDS FM, 1993, Q REV BIOPHYS, V26, P423, DOI 10.1017/S0033583500002845; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RICHMOND TJ, 1978, J MOL BIOL, V119, P537, DOI 10.1016/0022-2836(78)90201-2; SOYKA R, 1990, HELV CHIM ACTA, V73, P808, DOI 10.1002/hlca.19900730407; STEIFEL EI, 1993, ACS SYM SER, V535, P1; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; WALKER JE, 1980, EUR J BIOCHEM, V108, P581, DOI 10.1111/j.1432-1033.1980.tb04753.x; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007	72	532	550	1	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1463	1469		10.1126/science.7878465	http://dx.doi.org/10.1126/science.7878465			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878465				2022-12-28	WOS:A1995QL49700027
J	CURRAN, ME; SPLAWSKI, I; TIMOTHY, KW; VINCENT, GM; GREEN, ED; KEATING, MT				CURRAN, ME; SPLAWSKI, I; TIMOTHY, KW; VINCENT, GM; GREEN, ED; KEATING, MT			A MOLECULAR-BASIS FOR CARDIAC-ARRHYTHMIA - HERG MUTATIONS CAUSE LONG QT SYNDROME	CELL			English	Article							EARLY AFTERDEPOLARIZATIONS; GENE; DNA; LINKAGE; IDENTIFICATION; HETEROGENEITY; FRAGMENTS; CHANNEL; LOCUS; DEATH	To identify genes involved in cardiac arrhythmia, we investigated patients with long QT syndrome (LQT), an inherited disorder causing sudden death from a ventricular tachyarrhythmia, torsade de pointes. We previously mapped LQT loci on chromosomes 11 (LQT1), 7(LQT2), and 3(LQT3). Here, linkage and physical mapping place LQT2 and a putative potassium channel gene, HERG, on chromosome 7q35-36. Single strand conformation polymorphism and DNA sequence analyses reveal HERG mutations in six LQT families, including two intragenic deletions, one splice-donor mutation, and three missense mutations. In one kindred, the mutation arose de novo. Northern blot analyses show that HERG is strongly expressed in the heart. These data indicate that HERG is LQT2 and suggest a likely cellular mechanism for torsade de pointes.	UNIV UTAH,HLTH SCI CTR,ECCLES PROGRAM HUMAN MOLEC BIOL & GENET,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,DIV CARDIOL,SALT LAKE CITY,UT 84112; UNIV UTAH,HLTH SCI CTR,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; LATTER DAY ST HOSP,DEPT MED,SALT LAKE CITY,UT 84037; NIH,NATL CTR HUMAN GENOME RES,BETHESDA,MD 20892	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	CURRAN, ME (corresponding author), UNIV UTAH,HLTH SCI CTR,DEPT HUMAN GENET,SALT LAKE CITY,UT 84112, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000064] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1-RR00064] Funding Source: Medline; NHLBI NIH HHS [R01-HL 48074] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANTZELEVITCH C, 1994, J AM COLL CARDIOL, V23, P259, DOI 10.1016/0735-1097(94)90529-0; Bazett HC, 1920, HEART-J STUD CIRC, V7, P353; BENHORIN J, 1993, SCIENCE, V260, P1960, DOI 10.1126/science.8316839; BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; CURRAN M, 1993, J CLIN INVEST, V92, P799, DOI 10.1172/JCI116653; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GREEN ED, 1994, HUM MOL GENET, V3, P489, DOI 10.1093/hmg/3.3.489; GREEN ED, 1995, IN PRESS GENOMICS; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; JANUARY CT, 1989, CIRC RES, V64, P977, DOI 10.1161/01.RES.64.5.977; JIANG CA, 1994, NAT GENET, V8, P141, DOI 10.1038/ng1094-141; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KEATING M, 1991, AM J HUM GENET, V49, P1335; KEATING M, 1992, CIRCULATION, V85, P1973, DOI 10.1161/01.CIR.85.6.1973; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KOCH MC, 1992, SCIENCE, V257, P797, DOI 10.1126/science.1379744; LATHROP GM, 1985, AM J HUM GENET, V37, P482; LICHTER P, 1988, HUM GENET, V80, P224, DOI 10.1007/BF01790090; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MARCHUK D, 1990, NUCLEIC ACIDS RES, V19, P1154; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PTACEK LJ, 1991, CELL, V67, P1021; ROMANO C, 1965, LANCET, V1, P658; ROY N, 1994, NAT GENET, V8, P113, DOI 10.1038/ng1094-113; Schwartz PJ, 1995, CARDIAC ELECTROPHYSI, P788; SCHWARTZ PJ, 1975, AM HEART J, V109, P378; STERNBERG N, 1990, P NATL ACAD SCI USA, V87, P103, DOI 10.1073/pnas.87.1.103; SURAWICZ B, 1989, J AM COLL CARDIOL, V14, P172, DOI 10.1016/0735-1097(89)90069-7; TOWBIN JA, 1994, CIRCULATION, V90, P2635, DOI 10.1161/01.CIR.90.6.2635; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WARD O C, 1964, J Ir Med Assoc, V54, P103; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WILLICH SN, 1987, AM J CARDIOL, V60, P801, DOI 10.1016/0002-9149(87)91027-7	38	1818	1891	0	86	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					795	803		10.1016/0092-8674(95)90358-5	http://dx.doi.org/10.1016/0092-8674(95)90358-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889573	Bronze			2022-12-28	WOS:A1995QM39900016
J	HAYASHI, Y; MOMIYAMA, A; TAKAHASHI, T; OHISHI, H; OGAWAMEGURO, R; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S				HAYASHI, Y; MOMIYAMA, A; TAKAHASHI, T; OHISHI, H; OGAWAMEGURO, R; SHIGEMOTO, R; MIZUNO, N; NAKANISHI, S			ROLE OF A METABOTROPIC GLUTAMATE-RECEPTOR IN SYNAPTIC MODULATION IN THE ACCESSORY OLFACTORY-BULB	NATURE			English	Article							NERVOUS-SYSTEM; NEURONS; EXPRESSION; CLONING; BRAIN	VARIOUS functions of glutamate transmission are mediated by both ionotropic and metabotropic glutamate receptors1. The metabotropic glutamate receptors (mGluRs) consist of at least six different subtypes that are classified into three subgroups, mGluR1/mGluR5, mGluR2/mGluR3, and mGluR4/mGluR6 (refs 1-5), but their physiological roles are largely unknown. Here we report the identification of a very potent agonist for mGluR2/mGluR3, DCG-IV, and the specific localization of mGluR2 in granule cell dendrites that form dendrodendritic synapses with mitral cells in the accessory olfactory bulb. Using the DCG-IV agonist for mGluR2 in combination with slice patch-recording, we demonstrate that the granule cell mGluR2 presynaptically suppresses inhibitory GABA (gamma-aminobutyrate) transmission to the mitral cell. Our results indicate that mGluR2 in granule cells plays an important role in the persistent excitation of olfactory sensory transmission in the accessory olfactory bulb by relieving mitral cells from the GABA inhibition.	KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHARMACOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT PHYSIOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN	Kyoto University; Kyoto University; Kyoto University; Kyoto University			Takahashi, Tomoyuki/G-5951-2015; Shigemoto, Ryuichi/E-3628-2013; Hayashi, Yasunori/C-2249-2008; Hayashi, Yasunori/AAF-1408-2019	Takahashi, Tomoyuki/0000-0002-8771-7666; Shigemoto, Ryuichi/0000-0001-8761-9444; Hayashi, Yasunori/0000-0002-7560-3004; Hayashi, Yasunori/0000-0002-7560-3004				ABE T, 1992, J BIOL CHEM, V267, P13361; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; HAYASHI Y, 1992, BRIT J PHARMACOL, V107, P539, DOI 10.1111/j.1476-5381.1992.tb12780.x; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; ISHIDA M, 1993, BRIT J PHARMACOL, V109, P1169, DOI 10.1111/j.1476-5381.1993.tb13745.x; ITO S, 1991, J PHYSIOL-LONDON, V440, P67, DOI 10.1113/jphysiol.1991.sp018696; KAWAI M, 1992, EUR J PHARMACOL, V211, P195; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MORI K, 1987, PROG NEUROBIOL, V29, P275, DOI 10.1016/0301-0082(87)90024-4; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; OHFUNE Y, 1993, BIOORG MED CHEM LETT, V3, P15, DOI 10.1016/S0960-894X(00)80083-9; OHISHI H, 1993, J COMP NEUROL, V335, P252, DOI 10.1002/cne.903350209; OHISHI H, 1993, NEUROSCIENCE, V53, P1009, DOI 10.1016/0306-4522(93)90485-X; RALL W, 1968, J NEUROPHYSIOL, V31, P884, DOI 10.1152/jn.1968.31.6.884; SHEPHERD GM, 1978, SCI AM, V238, P92, DOI 10.1038/scientificamerican0278-92; SHIGEMOTO R, 1993, NEUROSCI LETT, V153, P157, DOI 10.1016/0304-3940(93)90311-8; TAKAHASHI T, 1992, J PHYSIOL-LONDON, V450, P593, DOI 10.1113/jphysiol.1992.sp019145; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; VANDERKLOOT W, 1991, PROG NEUROBIOL, V36, P93, DOI 10.1016/0301-0082(91)90019-W	20	348	353	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					687	690		10.1038/366687a0	http://dx.doi.org/10.1038/366687a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	7903116				2022-12-28	WOS:A1993MM26500070
J	LEGUENNO, B				LEGUENNO, B			IDENTIFYING A HANTAVIRUS ASSOCIATED WITH ACUTE RESPIRATORY ILLNESS - A PCR VICTORY	LANCET			English	Editorial Material											LEGUENNO, B (corresponding author), INST PASTEUR,CTR NATL REFERENCE FIEVRES HEMORRAG VIRALES,F-75724 PARIS 15,FRANCE.							CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; FRENCH GR, 1981, SCIENCE, V211, P1046, DOI 10.1126/science.6110243; GERDING MN, 1993, LANCET, V342, P495, DOI 10.1016/0140-6736(93)91620-2; KULZER P, 1993, LANCET, V342, P313, DOI 10.1016/0140-6736(93)91865-J; Lee HW., 1976, KOREAN J INTERN MED, V19, P371; LEE HW, 1978, J INFECT DIS, V137, P289; LLOYD G, 1990, CURRENT TOPICS CLIN; NEERURKAER V, 1993, LANCET, V342, P1059; NICHOL ST, 1993, SCIENCE, V262, P914, DOI 10.1126/science.8235615; 1993, MMWR, V42, P421	10	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1438	1439		10.1016/0140-6736(93)92927-L	http://dx.doi.org/10.1016/0140-6736(93)92927-L			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902477				2022-12-28	WOS:A1993ML21700003
J	ALMENDARES, J; SIERRA, M; ANDERSON, PK; EPSTEIN, PR				ALMENDARES, J; SIERRA, M; ANDERSON, PK; EPSTEIN, PR			CRITICAL REGIONS, A PROFILE OF HONDURAS	LANCET			English	Article									HARVARD UNIV,SCH MED,DEPT MED,CAMBRIDGE,MA 02138; COMIS NACL MOSCA BLANCA,MANAGUA,NICARAGUA; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Harvard University; Harvard T.H. Chan School of Public Health								ANDERSON PK, IN PRESS IN PRESS P; CABALLERO R, 1993, TURRIALBA, P50; KASPERSON JX, CRITICAL ENV REGIONS; KIRCHHOFF LV, 1993, NEW ENGL J MED, V329, P639, DOI 10.1056/NEJM199308263290909; SKOLE D, 1993, SCIENCE, V260, P1905, DOI 10.1126/science.260.5116.1905; Twilley Robert R., 1993, P105; WALSH JF, 1993, PARASITOLOGY, V106, P655; 1993, 1993 WORLD BANK WORL; 1991, TECH REP SER WHO, V811	9	17	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1400	1402		10.1016/0140-6736(93)92758-L	http://dx.doi.org/10.1016/0140-6736(93)92758-L			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901687				2022-12-28	WOS:A1993MK09500015
J	KARDINAAL, AFM; KOK, FJ; RINGSTAD, J; GOMEZARACENA, J; MAZAEV, VP; KOHLMEIER, L; MARTIN, BC; ARO, A; KARK, JD; DELGADORODRIGUEZ, M; RIEMERSMA, RA; VANTVEER, P; HUTTUNEN, JK; MARTINMORENO, JM				KARDINAAL, AFM; KOK, FJ; RINGSTAD, J; GOMEZARACENA, J; MAZAEV, VP; KOHLMEIER, L; MARTIN, BC; ARO, A; KARK, JD; DELGADORODRIGUEZ, M; RIEMERSMA, RA; VANTVEER, P; HUTTUNEN, JK; MARTINMORENO, JM			ANTIOXIDANTS IN ADIPOSE-TISSUE AND RISK OF MYOCARDIAL-INFARCTION - THE EURAMIC STUDY	LANCET			English	Article							LOW-DENSITY-LIPOPROTEIN; BETA-CAROTENE; VITAMIN-E; LIPID-PEROXIDATION; FATTY-ACIDS; ATHEROSCLEROSIS; PLASMA; SUPPLEMENTATION; PROTECTS; SELENIUM	Laboratory and epidemiological studies suggest that the antioxidants, vitamin E and beta-carotene, protect against coronary heart disease. In a European multicentre case-control study alpha-tocopherol and beta-carotene concentrations were measured in adipose-tissue samples collected in 1991-92 from 683 people with acute myocardial infarction and 727 controls. Mean adipose-tissue beta-carotene concentration was 0.35 mug/g in cases and 0.42 in controls, with age-adjusted and centre-adjusted mean difference 0.07 mug/g (95% confidence interval [CI] 0.04-0.10). Mean alpha-tocopherol concentrations were 193 mug/g and 192 mug/g for cases and controls, respectively. The age-adjusted and centre-adjusted odds ratio for risk of myocardial infarction in the lowest quintile of beta-carotene as compared with the highest was 2.62 (95% CI 1.79-3.83). Additional control for body-mass index and smoking reduced the odds ratio to 1.78 (95% CI 1.17-2.71); other established risk factors did not substantially alter this ratio. The increased risk was mainly confined to current smokers: the multivariate odds ratio in the lowest beta-carotene quintile in smokers was 2.39 (95% CI 1.35-4.25), whereas it was 1.07 for people who had never smoked. A low alpha-tocopherol concentration was not associated with risk of myocardial infarction. Our results support the hypothesis that high beta-carotene concentrations within the normal range reduce the risk of a first myocardial infarction. The findings for alpha-tocopherol are compatible with previous observations of reduced risk among vitamin E supplement users only. The consumption of beta-carotene-rich foods such as carrots and green-leaf vegetables may reduce the risk of myocardial infarction.	HADASSAH MED ORG,JERUSALEM,ISRAEL; HEBREW UNIV JERUSALEM,JERUSALEM,ISRAEL; UNIV GRANADA,GRANADA,SPAIN; UNIV EDINBURGH,CARDIOVASC RES UNIT,EDINBURGH EH8 9YL,MIDLOTHIAN,SCOTLAND; SCH PUBL HLTH MADRID,MADRID,SPAIN; OSTFOLD CTY HOSP,WAGENINGEN,NETHERLANDS; RES CTR PREVENT MED,MOSCOW,RUSSIA; AGR UNIV WAGENINGEN,6700 HB WAGENINGEN,NETHERLANDS; UNIV MALAGA,MALAGA,SPAIN; UNIV ZURICH,CH-8006 ZURICH,SWITZERLAND; FED HLTH OFF,BERLIN,GERMANY; NATL PUBL HLTH INST,SF-00280 HELSINKI 28,FINLAND	Hebrew University of Jerusalem; Hadassah University Medical Center; Hebrew University of Jerusalem; University of Granada; University of Edinburgh; National Medical Research Center for Therapy & Preventive Medicine; Wageningen University & Research; Universidad de Malaga; University of Zurich; Finland National Institute for Health & Welfare	KARDINAAL, AFM (corresponding author), TNO,EURAMIC COORDINATING CTR,INST TOXICOL & NUTR,EPIDEMIOL SECT,POB 360,3700 AJ ZEIST,NETHERLANDS.		Mazaev, Vladimir/M-8897-2013	Mazaev, Vladimir/0000-0002-9782-0296				BENDICH A, 1991, P NUTR SOC, V50, P263, DOI 10.1079/PNS19910036; BEYNEN AC, 1985, AM J CLIN NUTR, V42, P317, DOI 10.1093/ajcn/42.2.317; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; FREI B, 1991, BIOCHEM J, V277, P133, DOI 10.1042/bj2770133; GAZIANO JM, 1990, CIRCULATION, V82, P201; GAZIANO JM, 1992, J AM COLL CARDIOL, V19, P377; GEY KF, 1993, AM J CLIN NUTR, V57, P787; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GEY KF, 1991, AM J CLIN NUTR S, V53, P326; JIALAL I, 1991, BIOCHIM BIOPHYS ACTA, V1086, P134, DOI 10.1016/0005-2760(91)90164-D; JOHNSON EJ, 1993, FASEB J          FEB, pA275; KARDINAAL AFM, 1993, EUR J CLIN NUTR, V47, pS64; KOK FJ, 1987, AM J CLIN NUTR, V45, P462, DOI 10.1093/ajcn/45.2.462; KRINSKY NI, 1992, P SOC EXP BIOL MED, V200, P248; PRINCEN HMG, 1992, ARTERIOSCLER THROMB, V12, P554, DOI 10.1161/01.ATV.12.5.554; RIEMERSMA RA, 1991, LANCET, V337, P1, DOI 10.1016/0140-6736(91)93327-6; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RINGER TV, 1991, AM J CLIN NUTR, V53, P688, DOI 10.1093/ajcn/53.3.688; Rose GA, 1982, WHO MONOGRAPH SERIES, V56; SALONEN JT, 1985, AM J CARDIOL, V56, P226, DOI 10.1016/0002-9149(85)90839-2; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SCHAFER L, 1990, AM J CLIN NUTR, V52, P486, DOI 10.1093/ajcn/52.3.486; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STOFFEL W, 1959, ANAL CHEM, V31, P307, DOI 10.1021/ac60146a047; STREET DA, 1991, AM J EPIDEMIOL, V134, P719; TRABER MG, 1987, AM J CLIN NUTR, V46, P488, DOI 10.1093/ajcn/46.3.488; VANVLIET T, 1991, J CHROMATOGR, V553, P179, DOI 10.1016/S0021-9673(01)88486-7; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499	30	250	261	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1379	1384		10.1016/0140-6736(93)92751-E	http://dx.doi.org/10.1016/0140-6736(93)92751-E			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901680				2022-12-28	WOS:A1993MK09500008
J	MCCARTHY, M				MCCARTHY, M			UNLOCKING THE DATASETS	LANCET			English	Editorial Material											MCCARTHY, M (corresponding author), CAMDEN & ISLINGTON HLTH AUTHOR,DEPT PUBL HLTH,LONDON,ENGLAND.							[Anonymous], HIGH TECHNOLOGY MED; CHALMERS I, 1991, NEW ENGL J MED, V325, P1514; COX TM, 1993, LANCET, V342, P694, DOI 10.1016/0140-6736(93)91703-O; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; 1989, LANCET, V2, P195; 1993, ASSESSING EFFECTS HL	6	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1252	1253		10.1016/0140-6736(93)92355-W	http://dx.doi.org/10.1016/0140-6736(93)92355-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901579				2022-12-28	WOS:A1993MH56600005
J	OGREN, M; HEDBLAD, B; ISACSSON, SO; JANZON, L; JUNGQUIST, G; LINDELL, SE				OGREN, M; HEDBLAD, B; ISACSSON, SO; JANZON, L; JUNGQUIST, G; LINDELL, SE			NONINVASIVELY DETECTED CAROTID STENOSIS AND ISCHEMIC-HEART-DISEASE IN MEN WITH LEG ARTERIOSCLEROSIS	LANCET			English	Article							PERIPHERAL ARTERIAL-DISEASE; INTERMITTENT CLAUDICATION; MORTALITY; POPULATION; PREVALENCE	Since the excess mortality rate associated with an ankle-brachial blood-pressure index (ABPI) less than 0.9 was only partly explained by an excess cardiovascular mortality, we believe that leg artery disease should not only be regarded as a marker of generalised arteriosclerosis but also as a sign associated with an increased risk of premature death. 439 men who were part of a prospective population study in Malmo Sweden, were, at 68 years of age, invited to a health examination including, ABPI, carotid-artery ultrasonography, and 24 h ambulatory electrocardiographic monitoring. Cause-specific mortality and incidence of myocardial infarction (MI) during 8 years of follow-up was compared in men with and without signs of arteriosclerotic disease. Of 60 men with an ABPI < .9, 20 (33%) had angina pectoris or previous MI. Another 11 (18%) had silent ST-segment depression (greater-than-or-equal-to 1 mm); 3 (5%) had a history of stroke; and 17 (28%) had symptom-free carotid stenosis (> 0% reduction of the cross-sectional diameter). Total mortality rate in men with no signs of arteriosclerotic disease was 19.6 per 1000 person-ears and cardiac event rate (fatal and non-fatal MI and death from chronic ischaemic heart disease was 8.6 per 1000 person-years). Leg artery disease, carotid stenosis, and ischaemic heart disease were in a univariate analysis all associated with an increased cardiac event rate and an increased total mortality rate. In a multivariate analysis an ABPI less than 0.9 was associated with a 2. times higher total mortality (95% CI 1.-3.9) and a 2. times higher cardiac event rate (1.1-3.9). Carotid stenosis and ischaemic heart disease contributed to the risk for MI (RR 2.1; 95% CI 1.-3.8; and 2.1; 1.2-3.9, respectively), whereas no independent association with total mortality was found.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN PHYSIOL,S-21401 MALMO,SWEDEN	Lund University	OGREN, M (corresponding author), LUND UNIV,MALMO GEN HOSP,DEPT COMMUNITY HLTH SCI,S-21401 MALMO,SWEDEN.							ANDERSON S, 1980, STATISTICAL METHODS; CARTER SA, 1968, CIRCULATION, V37, P624, DOI 10.1161/01.CIR.37.4.624; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; DEANFIELD JE, 1984, AM J CARDIOL, V54, P1321, DOI 10.1016/S0002-9149(84)80090-9; DORMANDY J, 1989, J CARDIOVASC SURG, V30, P50; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FOWKES FGR, 1988, INT J EPIDEMIOL, V17, P248, DOI 10.1093/ije/17.2.248; GUNDERSEN J, 1972, ACTA CHIR SCAND S, V1; HEDBLAD B, 1989, EUR HEART J, V10, P149, DOI 10.1093/oxfordjournals.eurheartj.a059455; ISACSSON SO, 1972, ACTA MED SCAND S, V537; JANZON L, 1981, CIRCULATION, V6, P1339; JOHANSSON BW, 1984, DRUGS, V28, P77, DOI 10.2165/00003495-198400281-00008; JUNGQUIST G, 1986, CLIN PHYSIOL, V6, P319, DOI 10.1111/j.1475-097X.1986.tb00237.x; JUNGQUIST G, 1989, STROKE, V20, P1327, DOI 10.1161/01.STR.20.10.1327; KALLERO KS, 1981, J CHRON DIS, V34, P455, DOI 10.1016/0021-9681(81)90005-9; KANNEL WB, 1971, CARDIOVASC CLIN, V3, P38; OGREN M, 1993, EUR J VASCULAR SURG, V7, P500, DOI 10.1016/S0950-821X(05)80360-3; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; ROSE GA, 1968, WHO MONOGR SER, V56, P162; SHAPER AG, 1991, EPIDEMIOLOGY PERIPHE; SMITH GD, 1990, CIRCULATION, V82, P1925, DOI 10.1161/01.CIR.82.6.1925; STERN S, 1975, CIRCULATION, V52, P1045, DOI 10.1161/01.CIR.52.6.1045; STERNBY NH, 1968, ACTA PATHOL MICROB S, V194; TILLGREN C, 1965, ACTA MED SCAND, V178, P103; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; YAO JST, 1973, ARCH SURG-CHICAGO, V106, P600; YIN FCP, 1980, AGING-US, V12, P137; 1986, J HYPERTENS, V4, P383; 1991, OFFICIAL STATISTICS, V77	30	115	117	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1138	1141		10.1016/0140-6736(93)92123-B	http://dx.doi.org/10.1016/0140-6736(93)92123-B			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901475				2022-12-28	WOS:A1993MF19800009
J	[Anonymous]				[Anonymous]			THE EFFECT OF INTENSIVE DIABETES THERAPY ON THE DEVELOPMENT AND PROGRESSION OF NEUROPATHY	ANNALS OF INTERNAL MEDICINE			English	Article						DIABETIC NEUROPATHIES; DIABETES MELLITUS, INSULIN-DEPENDENT; INSULIN; BLOOD GLUCOSE; INSULIN INFUSION SYSTEMS	NERVE-CONDUCTION; COMPLICATIONS; TESTS; AGE	Objective: To examine whether intensive therapy designed to achieve glycemic levels as close to normal as possible prevents or slows the progression of neuropathy when compared with conventional therapy in patients with insulin-dependent diabetes mellitus in the Diabetes Control and Complications Trial. Design: Multicenter, randomized, controlled clinical trial. Setting: 29 U.S. and Canadian clinical centers. Participants: 1441 patients aged 13 to 39 years, of whom 726 had had insulin-dependent diabetes mellitus for 1 to 5 years and had no retinopathy at baseline (primary prevention cohort); 715 had had diabetes for 1 to 15 years and had minimal to moderate nonproliferative retinopathy at baseline (secondary intervention cohort). Intervention: Intensive therapy with three or more daily insulin injections or continuous subcutaneous insulin infusion guided by four or more glucose tests per day compared with conventional therapy with one or two daily insulin injections. Results: Intensive therapy reduced the development of confirmed clinical neuropathy (defined as a history or physical examination consistent with clinical neuropathy confirmed by either abnormal nerve conduction or autonomic nervous system testing) by 64% (95% CI, 45% to 76%) in the combined cohorts after 5 years of follow-up (5% of the intensive therapy group compared with 13% of the conventional therapy group). The prevalence of abnormal nerve conduction and abnormal autonomic nervous system function were reduced by 44% (CI, 34% to 53%) and 53% (CI, 24% to 70%), respectively (26% of the intensive treatment group developed abnormal nerve conduction compared with 46% of the conventional treatment group; 4% of the intensive treatment group had abnormal autonomic nervous system function compared with 9% of the conventional treatment group). Finally, nerve conduction velocities generally remained stable with intensive therapy but decreased significantly with conventional therapy. Conclusion: Intensive diabetes therapy markedly delays or prevents the development of clinically manifest diabetic polyneuropathy as confirmed by objective nerve function testing in patients with insulin-dependent diabetes mellitus.					Zinman, Bernard/E-7266-2013; Hramiak, Irene/G-3305-2011	Zeitler, Rodney/0000-0003-1394-7079				[Anonymous], 1988, DIABETES, V37, P1000; [Anonymous], 1988, DIABETES CARE, V11, P592, DOI 10.2337/diacare.11.7.592; BOULTON AJM, 1984, DIABETOLOGIA, V26, P15; DCCT Res Grp, 1986, DIABETES, V35, P530; DCCT Res Grp, 1988, DIABETES, V37, P476; DCCT Res Grp, 1990, DIABETES CARE, V13, P427; DYCK PJ, 1986, ANN NEUROL, V19, P288, DOI 10.1002/ana.410190311; DYCK PJ, 1989, DIABETES CARE, V12, P649, DOI 10.2337/diacare.12.9.649; GREENE D A, 1987, P177; GREENE DA, 1992, DIABETES CARE, V15, P1902, DOI 10.2337/diacare.15.12.1902; GREENE DA, 1990, DIABETES MELLITUS TH, P710; Gregersen G, 1968, Diabetologia, V4, P273, DOI 10.1007/BF01309900; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; LACHIN JM, 1992, STAT MED, V11, P1151, DOI 10.1002/sim.4780110903; MASER RE, 1989, DIABETES, V38, P1456, DOI 10.2337/diabetes.38.11.1456; PIRART J, 1978, DIABETES CARE, V1, P252; Pirart J., 1978, DIABETES CARE, V1, P168, DOI 10.2337/diacare.1.3.168; REICHARD P, 1993, NEW ENGL J MED, V329, P304, DOI 10.1056/NEJM199307293290502; SCHUMER M, 1988, AM J MED, V85, P137, DOI 10.1016/0002-9343(88)90406-8; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STETSON DS, 1992, MUSCLE NERVE, V15, P1095, DOI 10.1002/mus.880151007; ZIEGLER D, 1992, DIABETIC MED, V9, P166, DOI 10.1111/j.1464-5491.1992.tb01754.x	22	475	497	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					561	568		10.7326/0003-4819-122-8-199504150-00001	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887548				2022-12-28	WOS:A1995QR52500001
J	EVANS, JM; OFALLON, WM; HUNDER, GG				EVANS, JM; OFALLON, WM; HUNDER, GG			INCREASED INCIDENCE OF AORTIC-ANEURYSM AND DISSECTION IN GIANT-CELL (TEMPORAL) ARTERITIS - A POPULATION-BASED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article							BIOPSY; COUNTY	Objective: To determine the frequency of aneurysm and dissection of the aorta in patients with giant cell arteritis and to assess the effects of these events on these patients. Design: Population-based cohort study. Setting: A multispecialty and a primary care clinic in southern Minnesota. Patients: 96 residents of Olmsted County, Minnesota, who developed giant cell arteritis between 1950 and 1985, The presence of aortic aneurysm, dissection, or both was confirmed using computed tomography, ultrasonography, angiography, or autopsy. Results: 11 of the 96 patients were found to have thoracic aortic aneurysms. In 2 of these patients, the aneurysms were detected when giant cell arteritis was diagnosed. In the remaining 9 patients, the aneurysms occurred a median of 5.8 years after giant cell arteritis was diagnosed. Six of the 11 died suddenly of acute thoracic aortic dissection. Five patients who did not have thoracic aortic aneurysms developed isolated abdominal aortic aneurysms a median of 2.5 years after giant cell arteritis was diagnosed. The incidence of thoracic aortic aneurysm in patients with giant cell arteritis was 999 per 100 000 person-years; the incidence of abdominal aortic aneurysm in these patients was 555 per 100 000 person-years. Compared with all persons of the same age and sex living in Olmsted County, patients with giant cell arteritis were 17.3 times (95% CI, 7.9 to 33.0) more likely to develop thoracic aortic aneurysm and 2.4 times (CI, 0.8 to 5.5) more likely to develop isolated abdominal aortic aneurysm. Conclusions: Giant cell arteritis is associated with a markedly increased risk for the development of aortic aneurysm, which is often a late complication and may cause death.	MAYO CLIN & MAYO FDN, DEPT MED, DIV RHEUMATOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT INTERNAL MED, DIV COMMUNITY MED, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT HLTH SCI RES, ROCHESTER, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic								AIELLO PD, 1993, OPHTHALMOLOGY, V100, P550; ANIA BJ, 1994, MAYO CLIN PROC, V69, P730, DOI 10.1016/S0025-6196(12)61089-1; BICKERSTAFF LK, 1982, SURGERY, V92, P1103; BOESEN P, 1987, ARTHRITIS RHEUM, V30, P294, DOI 10.1002/art.1780300308; CALAMIA KT, 1981, ARTHRITIS RHEUM, V24, P1414, DOI 10.1002/art.1780241113; CASELLI RJ, 1988, NEUROLOGY, V38, P352, DOI 10.1212/WNL.38.3.352; DEBAKEY ME, 1965, J THORAC CARDIOV SUR, V49, P130, DOI 10.1016/S0022-5223(19)33323-9; EVANS JM, 1994, ARTHRITIS RHEUM-US, V37, P1539, DOI 10.1002/art.1780371020; FABER LP, 1991, AM CANCER SOC TXB CL, P194; HEALEY LA, 1980, ARTHRITIS RHEUM, V23, P641, DOI 10.1002/art.1780230605; HUNDER GG, 1990, ARTHRITIS RHEUM, V33, P1122; KLEIN RG, 1976, MAYO CLIN PROC, V51, P504; KLEIN RG, 1975, ANN INTERN MED, V83, P806, DOI 10.7326/0003-4819-83-6-806; Kurland LT, 1970, COMMUNITY EPIDEMIOLO, P47; MACHADO EBV, 1988, ARTHRITIS RHEUM, V31, P745, DOI 10.1002/art.1780310607; MAGAREY FR, 1950, J PATHOL BACTERIOL, V62, P445, DOI 10.1002/path.1700620318; MCMILLAN GC, 1950, ARCH PATHOL, V49, P63; MELTON LJ, 1984, AM J EPIDEMIOL, V120, P379, DOI 10.1093/oxfordjournals.aje.a113902; NORDBORG E, 1990, J INTERN MED, V227, P233, DOI 10.1111/j.1365-2796.1990.tb00150.x; PONGE T, 1988, J RHEUMATOL, V15, P997; REID JVO, 1957, BRIT HEART J, V19, P206; ROCCELLA EJ, 1986, JAMA-J AM MED ASSOC, V256, P70; SPROUL EE, 1942, NY J MED, V42, P345	23	414	425	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					502	507		10.7326/0003-4819-122-7-199504010-00004	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872584				2022-12-28	WOS:A1995QP00800004
J	MADHAVAN, S; STOCKWELL, D; COHEN, H; ALDERMAN, MH				MADHAVAN, S; STOCKWELL, D; COHEN, H; ALDERMAN, MH			RENAL-FUNCTION DURING ANTIHYPERTENSIVE TREATMENT	LANCET			English	Article							BLOOD-PRESSURE; ESSENTIAL-HYPERTENSION; WORK SITE; DISEASE; RISK	To determine the association of renal function and the course of blood pressure in antihypertensive therapy, we studied the changes in serum creatinine as a measure of renal function and in-treatment blood pressure in black and white hypertensive patients. We measured serum creatinine in 2125 mild and moderately hypertensive men during treatment over an average of 5 years. Both unadjusted mean initial and final serum creatinine of 758 blacks (113 and 117 mu mol/L respectively) were significantly higher than those of 1367 whites (108 and 107 mu mol/L), with a small increase of 4 mu mol/L (p<0.01) for blacks and a fall of 0.9 mu mol/L (p>0.05) for whites. Less than 2% of all patients attained or remained at a final serum creatinine of 177 mu mol/L or more. Of this small group (3% blacks, 1.4% whites), 31% had proteinuria at entry. After stratification by in-treatment diastolic blood pressure (<95 and greater than or equal to 95 mm Hg) in each race, mean slopes of reciprocal serum creatinine were estimated, adjusting for age at entry, initial serum creatinine, diastolic pressure, and body-mass index by analysis of covariance. The two adjusted mean slopes did not differ significantly within each race. Multiple regression analysis confirmed that in-treatment diastolic pressure was not independently associated with final serum creatinine. The change in renal function was most likely a reflection of regression towards the mean, and does not support the view that antihypertensive treatment is an important determinant of renal function in mild-to-moderate hypertensive patients. Patients with substantial renal insufficiency may have pre-existing intrinsic renal disease.			MADHAVAN, S (corresponding author), YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT EPIDEMIOL & SOCIAL MED, 1300 MORRIS PK AVE, BRONX, NY 10461 USA.			Cohen, Hillel/0000-0002-4524-0898				ALDERMAN MH, 1989, JAMA-J AM MED ASSOC, V262, P920, DOI 10.1001/jama.262.7.920; ALDERMAN MH, 1975, NEW ENGL J MED, V293, P65, DOI 10.1056/NEJM197507102930203; ALDERMAN MH, 1976, J OCCUP ENVIRON MED, V18, P793, DOI 10.1097/00043764-197612000-00004; BRAZY PC, 1990, KIDNEY INT, V37, P1113, DOI 10.1038/ki.1990.93; DUSTAN HP, 1987, AM J CARDIOL, V60, pI73; LUKE RG, 1993, HYPERTENSION, V21, P380, DOI 10.1161/01.HYP.21.3.380; MADHAVAN S, 1994, HYPERTENSION, V23, P395, DOI 10.1161/01.HYP.23.3.395; MITCH WE, 1976, LANCET, V2, P1326; NOLAN CR, 1992, RENAL ELECTROLYTE DI, V9, P447; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P1272, DOI 10.1001/jama.269.10.1272; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; ROLLINGTON F, 1987, AM J PUBLIC HEALTH, V77, P864; ROSANSKY SJ, 1990, ARCH INTERN MED, V150, P2073, DOI 10.1001/archinte.150.10.2073; ROSTAND SG, 1989, NEW ENGL J MED, V320, P684, DOI 10.1056/NEJM198903163201102; SELDIN DW, 1992, KIDNEY PHYSL PATHOPH, P947; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; Snedecor G.W., 1980, STAT METHODS, V7; WALKER WG, 1992, JAMA-J AM MED ASSOC, V268, P3085, DOI 10.1001/jama.268.21.3085; WHELTON PK, 1989, HYPERTENSION S1, V13, P19, DOI DOI 10.1161/HYPERTENSIONAHA.113.02250	19	66	67	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 25	1995	345	8952					749	751		10.1016/S0140-6736(95)90638-X	http://dx.doi.org/10.1016/S0140-6736(95)90638-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891485				2022-12-28	WOS:A1995QN70100009
J	MINTZ, ED; REIFF, FM; TAUXE, RV				MINTZ, ED; REIFF, FM; TAUXE, RV			SAFE WATER-TREATMENT AND STORAGE IN THE HOME - A PRACTICAL NEW STRATEGY TO PREVENT WATERBORNE DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIARRHEAL DISEASE; VIBRIO-CHOLERAE; DRINKING-WATER; TRANSMISSION; CONTAMINATION; DRACUNCULIASIS; INTERVENTION; SANITATION; EPIDEMIC; THAILAND	In many parts of the developing world, drinking water is collected from unsafe surface sources outside the home and is then held in household storage vessels. Drinking water may be contaminated at the source or during storage; strategies to reduce waterborne disease transmission must safeguard against both events. We describe a two-component prevention strategy, which allows an individual to disinfect drinking water immediately after collection (point-of-use disinfection) and then to store the water in narrow-mouthed, closed vessels designed to prevent recontamination (safe storage). New disinfectant generators and better storage vessel designs make this strategy practical and inexpensive. This approach empowers households and communities that lack potable water to protect themselves against a variety of waterborne pathogens and has the potential to decrease the incidence of waterborne diarrheal disease.	PAN AMER HLTH ORG, WASHINGTON, DC USA	Pan American Health Organization	MINTZ, ED (corresponding author), CTR DIS CONTROL & PREVENT, DIV BACTERIAL & MYCOT DIS, FOODBORNE & DIARRHEAL DIS BRANCH, ATLANTA, GA 30333 USA.							Barua Dhiman, 1992, P329; BERN C, 1992, B WORLD HEALTH ORGAN, V70, P705; BLAKE PA, 1993, J INFECT DIS, V167, P627, DOI 10.1093/infdis/167.3.627; BRISCOE J, 1978, AM J CLIN NUTR, V31, P2100, DOI 10.1093/ajcn/31.11.2100; DEB BC, 1986, B WORLD HEALTH ORGAN, V64, P127; DEB BC, 1982, INDIAN J MED RES, V76, P814; DEKONING HW, 1985, B WORLD HEALTH ORGAN, V63, P11; ECHEVERRIA P, 1987, B WORLD HEALTH ORGAN, V65, P207; ESREY SA, 1991, B WORLD HEALTH ORGAN, V69, P609; FAUBION M, 1994, YUIKON KUSKOKWIM HLT, V56, P6; GILMAN RH, 1985, B WORLD HEALTH ORGAN, V63, P157; GUNN RA, 1981, B WORLD HEALTH ORGAN, V59, P61; HAMMAD ZH, 1982, APPL ENVIRON MICROB, V43, P1238, DOI 10.1128/AEM.43.6.1238-1243.1982; HAN AM, 1989, TROP GEOGR MED, V41, P138; HAZEN TC, 1988, TOXIC ASSESS, V3, P461, DOI 10.1002/tox.2540030504; HOPKINS DR, 1991, B WORLD HEALTH ORGAN, V69, P533; KHAIRY AEM, 1982, J HYG-CAMBRIDGE, V88, P57, DOI 10.1017/S0022172400069898; KHAN MU, 1984, LANCET, V2, P1032; KHINNWEOO, 1993, J DIARRHOEAL DIS RES, V11, P172; KIRCHHOFF LV, 1985, J HYG-CAMBRIDGE, V94, P173, DOI 10.1017/S0022172400061374; KITTAYAPONG P, 1993, AM J TROP MED HYG, V49, P158, DOI 10.4269/ajtmh.1993.49.158; KOEHLER JE, 1993, 42ND ANN EP INT SERV; MILLER M, 1994, 34TH INT C ANT AG CH; MUJICA OJ, 1994, J INFECT DIS, V169, P1381, DOI 10.1093/infdis/169.6.1381; PATEL M, 1989, S AFR MED J, V76, P365; PINFOLD JV, 1990, EPIDEMIOL INFECT, V105, P377, DOI 10.1017/S0950268800047968; QUICK R, 1993, 33RD INT C ANT AG CH; RIES AA, 1992, J INFECT DIS, V166, P1429, DOI 10.1093/infdis/166.6.1429; ROBERTS L, 1994, 43RD ANN EP INT SERV; SOSBEY MD, 1989, WATER SCI TECH, V21, P179; SPIRA WM, 1980, B WORLD HEALTH ORGAN, V58, P731; STANTON B, 1992, SOC SCI MED, V35, P1405, DOI 10.1016/0277-9536(92)90044-Q; SWERDLOW DL, 1992, LANCET, V340, P28, DOI 10.1016/0140-6736(92)92432-F; SWERDLOW DL, 1991, 31ST INT C ANT AG CH; TUTTLE J, 1995, J INFECT DIS, V171, P371, DOI 10.1093/infdis/171.2.371; VANDERSLICE J, 1993, WATER RESOUR RES, V29, P1983, DOI 10.1029/92WR02994; VANZIJL WJ, 1966, B WORLD HEALTH ORGAN, V35, P249; WEBER JT, 1994, EPIDEMIOL INFECT, V112, P1, DOI 10.1017/S0950268800057368; WHITE GC, 1986, HDB CHLORINATION, P328; WITT VM, 1993, SERIE AMBIENTAL, V13; 1992, WHOCWS9212; 1994, WKLY EPIDEMIOL REC, V69, P205; 1993, WKLY EPIDEMIOL REC, V69, P13; 1993, TECHNICAL NOTE WATER, P1	44	172	179	2	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					948	953		10.1001/jama.273.12.948	http://dx.doi.org/10.1001/jama.273.12.948			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM173	7884954				2022-12-28	WOS:A1995QM17300030
J	DERMOTT, SF; SAGAN, C				DERMOTT, SF; SAGAN, C			TIDAL EFFECTS OF DISCONNECTED HYDROCARBON SEAS ON TITAN	NATURE			English	Article							SURFACE; DISSIPATION; OCEAN	THERMODYNAMIC and photochemical arguments(1-4) suggest that Titan, the largest satellite of Saturn, has a deep ocean of liquid hydrocarbons. At visible wavelengths, Titan's surface is obscured by a thick stratospheric haze, but radar observations(5-7) have revealed large regions of high surface reflectivity that are inconsistent with a global hydrocarbon ocean. Titan's surface has also been imaged at infrared wavelengths(8-10), and the highest-resolution data (obtained by the Hubble Space Telescope) show clear variations in surface albedo and/or topography(10). The natural interpretation of these observations is that Titan, like the Earth, has continents and oceans. But Titan's high orbital eccentricity poses a problem for this interpretation, as the effects of oceanic tidal friction would have circularized Titan's orbit for most configurations of oceans and continents(1,11). Here we argue that a more realistic topography, in which liquid hydrocarbons are confined to a number of disconnected seas or crater lakes, may satisfy both the dynamical and observational constraints.	CORNELL UNIV,PLANETARY STUDIES LAB,ITHACA,NY 14853	Cornell University	DERMOTT, SF (corresponding author), UNIV FLORIDA,DEPT ASTRON,POB 112055,GAINESVILLE,FL 32611, USA.							BURNS JA, 1986, SATELLITES, P117; Butler B. J, 1992, B AM ASTRON SOC, V24, P954; CHAPMAN CR, 1986, SATELLITES, P492; DERMOTT SF, 1979, ICARUS, V37, P310, DOI 10.1016/0019-1035(79)90137-4; ENGEL S, 1994, B AM ASTRON SOC, V26, P1183; FLASAR FM, 1983, SCIENCE, V221, P55, DOI 10.1126/science.221.4605.55; GRIFFITH CA, 1993, NATURE, V364, P511, DOI 10.1038/364511a0; GROSSMAN AW, 1992, B AM ASTRON SOC, V24, P954; LAMBECK K, 1980, EARTHS VARIABLE ROTA, P295; LEMMON MT, 1993, ICARUS, V103, P329, DOI 10.1006/icar.1993.1074; LUNINE JI, 1993, REV GEOPHYS, V31, P133, DOI 10.1029/92RG02794; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; Merian J. R., 1828, BEWEGUNG TROPFBARER; MUHLEMAN DO, 1990, SCIENCE, V248, P975, DOI 10.1126/science.248.4958.975; PEALE SJ, 1980, ICARUS, V43, P65, DOI 10.1016/0019-1035(80)90088-3; SAGAN C, 1982, NATURE, V300, P731, DOI 10.1038/300731a0; SAGAN C, 1994, B AM ASTRON SOC, V26, P1183; SEARS WD, IN PRESS ICARUS; SEARS WD, 1994, B AM ASTRON SOC, V26, P1184; SMITH BA, 1981, SCIENCE, V212, P163, DOI 10.1126/science.212.4491.163; SMITH PH, 1994, B AM ASTRON SOC, V26, P1181; Turcotte D., 2014, GEODYNAMICS, V3rd edn.; WEBB DJ, 1982, CONTEMP PHYS, V23, P419, DOI 10.1080/00107518208237094	23	34	34	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					238	240		10.1038/374238a0	http://dx.doi.org/10.1038/374238a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885443				2022-12-28	WOS:A1995QM38700042
J	HEPTONSTALL, J; MORTIMER, PP				HEPTONSTALL, J; MORTIMER, PP			NEW VIRUS, OLD STORY	LANCET			English	Editorial Material									PHLS,DIV VIRUS REFERENCE,LONDON,ENGLAND		HEPTONSTALL, J (corresponding author), PHLS,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON,ENGLAND.							ALLENDER T, 1994, J MED VIROL, V43, P415; BADER JM, 1994, LANCET, V343, P1628, DOI 10.1016/S0140-6736(94)93074-0; CHANT K, 1994, NEW S WALES PUBLIC H, V5, P47; DRESCHER J, 1994, J HOSP INFECT, V26, P81, DOI 10.1016/0195-6701(94)90049-3; DROLLER H, 1945, BMJ-BRIT MED J, V1, P623, DOI 10.1136/bmj.1.4400.623; Flaum A., 1926, ACTA MED SCAND, V16, P544; JARVIS WR, 1994, LANCET, V344, P1311, DOI 10.1016/S0140-6736(94)90687-4; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; NAVARRO V, 1988, LANCET, V1, P42; PIAZZA M, 1995, J MED VIROL, V45, P40, DOI 10.1002/jmv.1890450108; POLISH LB, 1992, NEW ENGL J MED, V326, P721, DOI 10.1056/NEJM199203123261101; Vickers J, 1994, Commun Dis Rep CDR Rev, V4, pR1	12	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					599	600		10.1016/S0140-6736(95)90514-6	http://dx.doi.org/10.1016/S0140-6736(95)90514-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898172	Bronze			2022-12-28	WOS:A1995QM07500002
J	HOLLANDER, AAMJ; VANSAASE, JLCM; KOOTTE, AMM; VANDORP, WT; VANBOCKEL, HJ; VANES, LA; VANDERWOUDE, FJ				HOLLANDER, AAMJ; VANSAASE, JLCM; KOOTTE, AMM; VANDORP, WT; VANBOCKEL, HJ; VANES, LA; VANDERWOUDE, FJ			BENEFICIAL-EFFECTS OF CONVERSION FROM CYCLOSPORINE TO AZATHIOPRINE AFTER KIDNEY-TRANSPLANTATION	LANCET			English	Article							RENAL-ALLOGRAFT RECIPIENTS; CONVENTIONAL IMMUNOSUPPRESSION; NEPHROTOXICITY; PREDNISOLONE; GLOBULIN	Immunosuppression with cyclosporin after renal transplantation is associated with better graft survival than is azathioprine treatment. However, nephrotoxicity and other side-effects have led to regimens that change treatment to azathioprine shortly after transplantation. Conversion has beneficial effects in the short term on renal function and hypertension. We report long-term follow-up (minimum 5 years) of 128 patients who had received a first or second cadaveric kidney graft and were treated with cyclosporin and prednisone; they were randomly assigned 3 months after transplantation to groups continuing to receive cyclosporin (n=68) or changing to azathioprine (n=60). 8 years after transplantation, patient survival was 75.3% in the cyclosporin group and in the azathioprine group 85.9% (p=0.14) and graft survival was 64.0% and 76.6%, respectively (p=0.38). The frequency of cardiovascular death with a functioning graft was 8% higher in the cyclosporin group (95% Cl -1 to 18). The relative risk of graft loss after conversion to azathioprine compared with cyclosporin maintenance was 0.71 (0.37-1.38) and the relative risk of patient death was 0.57 (0.23-1.41). The cyclosporin group had poorer mean creatinine clearance (17.8 ml/min [8.1-27.5] lower than azathioprine group) and a higher proportion needed hypertensive drugs (20% [4-36] more). Gout was found in 9 cyclosporin-treated patients and 1 azathioprine-treated patient (difference 12% [3 to 20]). Elective conversion from cyclosporin to azathioprine 3 months after transplantation is safe and cost-effective.	UNIV LEIDEN HOSP,DEPT SURG,2300 RC LEIDEN,NETHERLANDS; ST CLARA HOSP,DEPT INTERNAL MED,ROTTERDAM,NETHERLANDS; RIJNLAND HOSP,DEPT INTERNAL MED,ALPHEN AAN DE RIJN,NETHERLANDS; KENNEMER GASTHUIS,DEPT INTERNAL MED,HAARLEM,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Rijnland Hospital; Spaarne Hospital	HOLLANDER, AAMJ (corresponding author), UNIV LEIDEN HOSP,DEPT NEPHROL,POB 9600,2300 RC LEIDEN,NETHERLANDS.							[Anonymous], 1983, LANCET, V2, P986; CALNE RY, 1978, LANCET, V2, P1323; CANAFAX DM, 1986, TRANSPLANT P, V18, P192; CANAFAX DM, 1985, TRANSPLANT P, V17, P2677; HALL BM, 1988, NEW ENGL J MED, V318, P1499, DOI 10.1056/NEJM198806093182304; HOITSMA AJ, 1985, TRANSPLANTATION, V39, P274, DOI 10.1097/00007890-198503000-00013; HOITSMA AJ, 1987, LANCET, V1, P584; KASISKE BL, 1991, AM J KIDNEY DIS, V17, P700, DOI 10.1016/S0272-6386(12)80355-6; KASISKE BL, 1993, JAMA-J AM MED ASSOC, V269, P395, DOI 10.1001/jama.269.3.395; KOOTTE AMM, 1988, TRANSPLANTATION, V46, P677, DOI 10.1097/00007890-198811000-00010; KOOTTE AMM, 1988, NEPHROL DIAL TRANSPL, V3, P666, DOI 10.1093/oxfordjournals.ndt.a091725; LIN HY, 1989, NEW ENGL J MED, V321, P287, DOI 10.1056/NEJM198908033210504; MORRIS PJ, 1987, LANCET, V1, P586; MURRAY JE, 1963, NEW ENGL J MED, V268, P1315, DOI 10.1056/NEJM196306132682401; OPELZ G, 1992, TRANSPLANT P, V24, P2342; RAO KV, 1985, NEPHRON, V41, P75; ROCHER LL, 1984, TRANSPLANTATION, V38, P669, DOI 10.1097/00007890-198412000-00024; TEGZESS AM, 1987, TRANSPLANT P, V19, P2000; WEIDLE PJ, 1988, DRUG INTEL CLIN PHAR, V22, P443, DOI 10.1177/106002808802200601; 1983, NEW ENGL J MED, V309, P809	20	143	145	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					610	614		10.1016/S0140-6736(95)90520-0	http://dx.doi.org/10.1016/S0140-6736(95)90520-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898178				2022-12-28	WOS:A1995QM07500008
J	MAX, M; MCKINNON, PJ; SEIDENMAN, KJ; BARRETT, RK; APPLEBURY, ML; TAKAHASHI, JS; MARGOLSKEE, RF				MAX, M; MCKINNON, PJ; SEIDENMAN, KJ; BARRETT, RK; APPLEBURY, ML; TAKAHASHI, JS; MARGOLSKEE, RF			PINEAL OPSIN - A NONVISUAL OPSIN EXPRESSED IN CHICK PINEAL	SCIENCE			English	Article							VISUAL PIGMENT; RHODOPSIN; PROTEIN; SEQUENCE; GENES; CELL; ROD; PHYLOGENIES; RELEASE; CULTURE	Pineal opsin (P-opsin), an opsin from chick that is highly expressed in pineal but is not detectable in retina, was cloned by the polymerase chain reaction. It is likely that the P-opsin lineage diverged from the retinal opsins early in opsin evolution. The amino acid sequence of P-opsin is 42 to 46 percent identical to that of the retinal opsins. P-opsin is a seven-membrane spanning, G protein-linked receptor with a Schiff-base lysine in the seventh membrane span and a Schiff-base counterion in the third membrane span. The primary sequence of P-opsin suggests that it will be maximally sensitive to similar to 500-nanometer tight and produce a slow and prolonged phototransduction response consistent with the nonvisual function of pineal photoreception.	NORTHWESTERN UNIV, DEPT NEUROBIOL & PHYSIOL, NATL SCI FDN, CTR BIOL TIMING, EVANSTON, IL 60208 USA; HARVARD UNIV, SCH MED, HOWE LABS, BOSTON, MA 02114 USA	National Science Foundation (NSF); NSF - Center for Biological Timing; Northwestern University; Harvard University; Harvard Medical School	MAX, M (corresponding author), HOFFMANN LA ROCHE INC, ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA.		Takahashi, Joseph S/E-8482-2012; Takahashi, Joseph S./Y-2781-2019	Takahashi, Joseph S/0000-0003-0384-8878; Takahashi, Joseph S./0000-0003-0384-8878; Margolskee, Robert/0000-0002-9572-2887	NATIONAL EYE INSTITUTE [R01EY008467] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039592, R01MH039592, F31MH010287] Funding Source: NIH RePORTER; NEI NIH HHS [EYO8467] Funding Source: Medline; NIMH NIH HHS [MH39592, MH10287] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		APPLEBURY ML, 1994, MOL EVOLUTION PHYSL, P235; ARAKI M, 1992, DEV BRAIN RES, V65, P85, DOI 10.1016/0165-3806(92)90011-K; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEGUCHI T, 1981, NATURE, V290, P706, DOI 10.1038/290706a0; DEGUCHI T, 1979, SCIENCE, V203, P1245, DOI 10.1126/science.424750; DEGUCHI T, 1988, J NEUROSCI, V8, P22; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOLPH PJ, 1993, SCIENCE, V260, P1910, DOI 10.1126/science.8316831; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FLANNERY JG, 1990, EXP EYE RES, V51, P717, DOI 10.1016/0014-4835(90)90057-2; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; IBBOTSON RE, 1992, P ROY SOC B-BIOL SCI, V247, P145, DOI 10.1098/rspb.1992.0021; KHORANA HG, 1992, J BIOL CHEM, V267, P1; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Kuhn H, 1984, PROGR RETINAL RES, V3, P123; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maniatis T, 1989, MOL CLONING; MCLAUGHLIN SK, 1992, NATURE, V357, P563, DOI 10.1038/357563a0; MCLAUGHLIN SK, 1993, BIOTECHNIQUES, V15, P506; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; OKANO T, 1994, NATURE, V372, P94, DOI 10.1038/372094a0; OKANO T, 1992, P NATL ACAD SCI USA, V89, P5932, DOI 10.1073/pnas.89.13.5932; ROBERTSON LM, 1988, J NEUROSCI, V8, P12; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; VIGH B, 1982, Z MIKROSK ANAT FORSC, V96, P113; WANG SZ, 1992, BIOCHEMISTRY-US, V31, P3309, DOI 10.1021/bi00128a002; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YARFITZ S, 1994, J BIOL CHEM, V269, P14329; YOKOYAMA R, 1990, P NATL ACAD SCI USA, V87, P9315, DOI 10.1073/pnas.87.23.9315; ZATZ M, 1988, BRAIN RES, V453, P63, DOI 10.1016/0006-8993(88)90143-6; ZATZ M, 1994, J NEUROCHEM, V62, P2001	39	139	142	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1502	1506		10.1126/science.7878470	http://dx.doi.org/10.1126/science.7878470			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878470				2022-12-28	WOS:A1995QL49700039
J	FISHWICK, D; PRASAN, A; ADAMS, P				FISHWICK, D; PRASAN, A; ADAMS, P			THROMBOLYSIS AND LOW-BACK-PAIN	BRITISH MEDICAL JOURNAL			English	Letter							STREPTOKINASE				FISHWICK, D (corresponding author), ROYAL VICTORIA INFIRM TRUST,DEPT CARDIOL & GEN MED,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND.			Fishwick, David/0000-0001-5941-090X				[Anonymous], 1986, Lancet, V1, P397; BOURKE J, 1992, NEW ZEAL MED J, V105, P482; LEAR J, 1992, LANCET, V340, P851, DOI 10.1016/0140-6736(92)92726-V; SHAH M, 1990, BRIT MED J, V301, P1219, DOI 10.1136/bmj.301.6762.1219-a; 1991, BRIT MED J, V302, P111	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					504	504		10.1136/bmj.310.6978.504	http://dx.doi.org/10.1136/bmj.310.6978.504			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888893	Green Published			2022-12-28	WOS:A1995QJ59800025
J	HELLER, S; CHAPMAN, J; MCCLOUD, J; WARD, J				HELLER, S; CHAPMAN, J; MCCLOUD, J; WARD, J			UNRELIABILITY OF REPORTS OF HYPOGLYCEMIA BY DIABETIC-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							HUMAN INSULIN; HYPOGLYCEMIA		UNIV SHEFFIELD,SCH MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND; ROYAL HALLAMSHIRE HOSP,DEPT MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND	University of Sheffield; University of Sheffield	HELLER, S (corresponding author), NO GEN HOSP,DEPT MED,SHEFFIELD S5 7AU,S YORKSHIRE,ENGLAND.			Heller, Simon/0000-0002-2425-9565				BRENNAN P, 1992, BMJ-BRIT MED J, V304, P1491, DOI 10.1136/bmj.304.6840.1491; GALE EAM, 1989, LANCET, V2, P1264; HEPBURN DA, 1989, DIABETIC MED, V6, P586, DOI 10.1111/j.1464-5491.1989.tb01233.x; TEUSCHER A, 1987, LANCET, V2, P382; 1993, NEW ENGL J MED, V329, P977	5	31	31	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					440	440		10.1136/bmj.310.6977.440	http://dx.doi.org/10.1136/bmj.310.6977.440			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873951	Green Published			2022-12-28	WOS:A1995QJ24200021
J	ADAMSON, BB; GALLACHER, SJ; BYARS, J; RALSTON, SH; BOYLE, IT; BOYCE, BF				ADAMSON, BB; GALLACHER, SJ; BYARS, J; RALSTON, SH; BOYLE, IT; BOYCE, BF			MINERALIZATION DEFECTS WITH PAMIDRONATE THERAPY FOR PAGETS-DISEASE	LANCET			English	Note							BONE	Bone biopsy samples were taken from 20 patients with Paget's disease before and after intravenous pamidronate therapy. In 10 patients given 180 or 360 mg during 6 or 9 weeks, bone turnover decreased as measured biochemically and histologically, but osteomalacia developed in 1 patient and mineralisation defects in 3. 10 other patients received 45 mg every 3 months for 1 year. Bone turnover decreased biochemically but not histologically, and osteoid thickness increased, suggesting impaired mineralisation. Despite overall efficacy, pamidronate has a narrow therapeutic range between resorption inhibition and mineralisation defects. Short courses given to achieve biochemical remission should be administered with caution.	UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT MED,GLASGOW,SCOTLAND; UNIV TEXAS,HLTH SCI CTR,DEPT PATHOL,SAN ANTONIO,TX 78284	University of Glasgow; University of Texas System; University of Texas Health San Antonio	BOYCE, BF (corresponding author), UNIV GLASGOW,GLASGOW ROYAL INFIRM,DEPT PATHOL,GLASGOW,SCOTLAND.							ANDERSON DC, 1987, BRIT MED J, V294, P1486, DOI 10.1136/bmj.294.6585.1486; BOYCE BF, 1984, LANCET, V1, P821; BYCE BF, 1992, J CLIN PATHOL, V45, P502; CANTRILL JA, 1990, CLIN ENDOCRINOL, V32, P507, DOI 10.1111/j.1365-2265.1990.tb00892.x; FENTON AJ, 1991, CLIN ENDOCRINOL, V34, P197, DOI 10.1111/j.1365-2265.1991.tb00294.x; FLEISCH H, 1987, CLIN ORTHOP RELAT R, V217, P72; GALLACHER SJ, 1991, ANN RHEUM DIS, V50, P930, DOI 10.1136/ard.50.12.930; HARINCK HIJ, 1987, CLIN ORTHOP RELAT R, V217, P79	8	107	108	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1459	1460		10.1016/0140-6736(93)92935-M	http://dx.doi.org/10.1016/0140-6736(93)92935-M			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902484				2022-12-28	WOS:A1993ML21700011
J	HAINES, A; EPSTEIN, PR; MCMICHAEL, AJ; HUGHJONES, M; HUTCHINSON, CF; KALKSTEIN, LS; LLOYD, SA; MORSE, SS; NICHOLLS, N; PARRY, M; PATZ, J; POSTEL, S; SHERMAN, K; SLOOFF, R				HAINES, A; EPSTEIN, PR; MCMICHAEL, AJ; HUGHJONES, M; HUTCHINSON, CF; KALKSTEIN, LS; LLOYD, SA; MORSE, SS; NICHOLLS, N; PARRY, M; PATZ, J; POSTEL, S; SHERMAN, K; SLOOFF, R			GLOBAL HEALTH WATCH - MONITORING IMPACTS OF ENVIRONMENTAL-CHANGE	LANCET			English	Discussion									HARVARD UNIV,SCH MED,BOSTON,MA 02115; LOUISIANA STATE UNIV,SCH VET MED,WHO COLLABORATING CTR,BATON ROUGE,LA 70803; UNIV ARIZONA,COLL AGR,TUCSON,AZ 85721; UNIV DELAWARE,NEWARK,DE 19718; HARVARD UNIV,CAMBRIDGE,MA 02138; UNIV ADELAIDE,ADELAIDE,SA 5001,AUSTRALIA; ROCKEFELLER UNIV,NEW YORK,NY 10021; BUR METEOROL,RES CTR,MELBOURNE,AUSTRALIA; UNIV OXFORD,ENVIRONM CHANGE UNIT,OXFORD,ENGLAND; WHO,CH-1211 GENEVA 27,SWITZERLAND; WORLD WATCH INST,WASHINGTON,DC; NOAA,NARRAGANSETT,RI	Harvard University; Harvard Medical School; Louisiana State University School of Veterinary Medicine; Louisiana State University System; Louisiana State University; World Health Organization; University of Arizona; University of Delaware; Harvard University; University of Adelaide; Rockefeller University; Bureau of Meteorology - Australia; University of Oxford; World Health Organization; National Oceanic Atmospheric Admin (NOAA) - USA	HAINES, A (corresponding author), WHITTINGTON HOSP,UCLMS,DEPT PRIMARY HLTH CARE,HIGHGATE HILL,LONDON N19 5NF,ENGLAND.		Nicholls, Neville/A-1240-2008	Haines, Andy/0000-0002-8053-4605				BROWN K, IN PRESS BLUEPRINT 3; CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035; Dean S., 1991, RADIOL PROT B, V124, P6; ELDER GH, 1993, LANCET, V341, P1519, DOI 10.1016/0140-6736(93)90643-U; EPSTEIN PR, 1993, LANCET, V341, P1404, DOI 10.1016/0140-6736(93)90962-G; FLEMING DM, 1991, 53 ROY COLL GEN PRAC; GLEASON DF, 1993, NATURE, V365, P836, DOI 10.1038/365836a0; GLEASON JF, 1993, SCIENCE, V260, P523, DOI 10.1126/science.260.5107.523; HAINES A, 1991, J PUBLIC HEALTH MED, V13, P69; Henderson Donald A., 1993, P283; HOUGHTON JT, 1992, IPCC1992 SUPPL REP; KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032; Lederberg J., 1992, EMERGING INFECTIONS; LONGSTRETH JA, 1989, POTENTIAL EFFECTS GL; MAURICE J, 1993, NEW SCI         1016, P25; MCMICHAEL AJ, 1993, INT J EPIDEMIOL, V22, P1, DOI 10.1093/ije/22.1.1; NAKAZAWA H, IN PRESS P NATL ACAD; Postel S., 1992, LAST OASIS FACING WA; RODENBURG E, 1991, EYLESS GAIA STATE GL; Rosenzweig C., 1989, POTENTIAL EFFECTS GL; WAGGONER PE, 1990, CLIMATE CCHANGE US W; WIGLEY TML, 1992, NATURE, V357, P293, DOI 10.1038/357293a0; 1993, 1993 WORLD BANK WORL; 1993, WHO CONSULTATION DEV; 1990, POTENTIAL HLTH EFFEC, P58; 1993, JAMA-J AM MED ASSOC, V270, P2287; 1992, OUR PLANET OUR HLTH	27	36	41	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 11	1993	342	8885					1464	1469		10.1016/0140-6736(93)92937-O	http://dx.doi.org/10.1016/0140-6736(93)92937-O			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902486				2022-12-28	WOS:A1993ML21700013
J	KUKS, JBM; COOK, MJ; FISH, DR; STEVENS, JM; SHORVON, SD				KUKS, JBM; COOK, MJ; FISH, DR; STEVENS, JM; SHORVON, SD			HIPPOCAMPAL SCLEROSIS IN EPILEPSY AND CHILDHOOD FEBRILE SEIZURES	LANCET			English	Article							TEMPORAL-LOBE EPILEPSY; CONVULSIONS; RISK	The connection between hippocampal sclerosis and childhood febrile seizures (CFS) is a contentious issue in the study of epilepsy. We investigated 107 patients with drug-resistant epilepsy by high-resolution volumetric magnetic resonance imaging (MRI). 20 had a history of CFS, 45 had focal (26) or diffuse (19) hippocampal volume loss (HVL). The frequency of CFS was significantly (p < 0.001) higher in the patients with HVL, especially of the diffuse pattern, compared to other epileptic patients without HVL and to the general population. Furthermore, the severity of HVL was greatest in those with a history of CFS. No other clinical or demographic features were associated with either a history of CFS or HVL. The frequency of CFS in patients with other structural congenital causes of epilepsy did not differ from that in a general population. Although these findings show that hippocampal sclerosis is strongly associated with a history of CFS, they do not indicate whether this is a causal relationship. If CFS do cause some cases of hippocampal sclerosis, this can not be the only mechanism, as 64% of those with HVL gave no history of CFS. As diffuse HVL is more strongly associated with a history of CFS than focal HVL, it is also possible that CFS convert pre-existing congenital focal abnormalities into diffuse hippocampal sclerosis. Given the possibility that CFS may cause hippocampal damage and epilepsy, they require urgent medical intervention.	UCL NATL HOSP NEUROL & NEUROSURG, QUEEN SQ, LONDON WC1N 3BG, ENGLAND; ST MARYS HOSP, LONDON, ENGLAND; STATE UNIV HOSP GRONINGEN, DEPT NEUROL, GRONINGEN, NETHERLANDS	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; Imperial College London; University of Groningen			Cook, Mark J/A-7096-2010; Shorvon, Simon D/A-2019-2009	Cook, Mark J/0000-0002-8875-4135; 				AICARDI J, 1983, DELGADO, P115; ANNEGERS JF, 1979, NEUROLOGY, V29, P297, DOI 10.1212/WNL.29.3.297; BABB TL, 1984, EPILEPSIA, V25, P721, DOI 10.1111/j.1528-1157.1984.tb03483.x; Brown W., 1987, SURGICAL TREATMENT E, P511; BRUTON CJ, 1988, NEUROPATHOLOGY TEMPO, P1; Cook M. J., 1992, Epilepsia, V33, P72; COOK MJ, 1992, BRAIN, V115, P1001, DOI 10.1093/brain/115.4.1001; DAM AM, 1982, ACTA NEUROL SCAND, V66, P601, DOI 10.1111/j.1600-0404.1982.tb04528.x; FALCONER MA, 1971, EPILEPSIA, V12, P13, DOI 10.1111/j.1528-1157.1971.tb03912.x; FISH D, 1991, NEUROLOGY, V41, P1781, DOI 10.1212/WNL.41.11.1781; GASTAUT H, 1959, EPILEPSIA, V1, P56, DOI 10.1111/j.1528-1157.1959.tb04249.x; Hauser WA, 1981, FEBRILE SEIZURES, P5; JACK CR, 1992, ANN NEUROL, V31, P138, DOI 10.1002/ana.410310204; LENCZ T, 1992, ANN NEUROL, V31, P629, DOI 10.1002/ana.410310610; MARGERISON JH, 1966, BRAIN, V89, P499, DOI 10.1093/brain/89.3.499; NELSON KB, 1976, NEW ENGL J MED, V295, P1029, DOI 10.1056/NEJM197611042951901; RASMUSSEN T, 1979, EPILEPSIA, V20, P395, DOI 10.1111/j.1528-1157.1979.tb04819.x; SAGAR HJ, 1987, ANN NEUROL, V22, P334, DOI 10.1002/ana.410220309; Scheibel A B, 1991, Adv Neurol, V55, P59; VERITY CM, 1993, BMJ-BRIT MED J, V307, P225, DOI 10.1136/bmj.307.6898.225; VERITY CM, 1991, BMJ-BRIT MED J, V303, P1373, DOI 10.1136/bmj.303.6814.1373	21	131	135	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 4	1993	342	8884					1391	1394						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901683				2022-12-28	WOS:A1993MK09500011
J	JAVAHERI, S; PARKER, TJ; WEXLER, L; MICHAELS, SE; STANBERRY, E; NISHYAMA, H; ROSELLE, GA				JAVAHERI, S; PARKER, TJ; WEXLER, L; MICHAELS, SE; STANBERRY, E; NISHYAMA, H; ROSELLE, GA			OCCULT SLEEP-DISORDERED BREATHING IN STABLE CONGESTIVE-HEART-FAILURE	ANNALS OF INTERNAL MEDICINE			English	Article						HEART FAILURE, CONGESTIVE; VENTRICULAR FUNCTION, LEFT; SLEEP APNEA SYNDROMES; CHEYNE-STOKES RESPIRATION; OXYHEMOGLOBINS	CHEYNE-STOKES RESPIRATION; APNEA; ABNORMALITIES; VENTILATION; OXYGEN	Objective: To determine the prevalence and effect of sleep-disordered breathing in ambulatory patients with stable, optimally treated congestive heart failure. Design: A prospective, longitudinal study. Setting: Referral sleep laboratory of a Department of Veterans Affairs medical center. Patients: 42 of the 48 eligible patients with stable congestive heart failure and left ventricular systolic dysfunction (left ventricular ejection fraction less than or equal to 45%). Measurements: After an adaptation night, polysomnography and Holter monitoring were done in the sleep laboratory. Arterial blood gases and pH were measured, and cardiac radionuclide ventriculography and pulmonary, renal, and thyroid function tests were done. Results: Patients were divided into two groups. Group I (n = 23) had an hourly rate of apnea and hypopnea (apnea-hypopnea index) of 20 episodes per hour or less; group II (n = 19 [45%; CI, 30% to 60%]) had an index of more than 20 episodes per hour. In group II, the index varied from 26.5 to 82.2 episodes per hour (mean +/- SD, 44 +/- 13 episodes per hour; CI, 38 to 51 episodes per hour). Group II had significantly more arousals (24 +/- 12 compared with 3 +/- 3 in group I) that were directly attributable to episodes of apnea and hypopnea, longer periods of time with an arterial oxyhemoglobin saturation of less than 90% (23% +/- 24% of total sleep time compared with 2% +/- 4%), lower arterial oxyhemoglobin saturation during sleep (74% +/- 13% compared with 87% +/- 4%), lower left ventricular ejection fraction (22% +/- 9% compared with 30% +/- 10%), and a significantly increased number of episodes of nocturnal ventricular arrhythmias. Multiple regression analyses showed that left Ventricular systolic dysfunction was an independent risk factor for sleep apnea in patients with congestive heart failure. Conclusions: The prevalence of severe occult sleep-disordered breathing is high in ambulatory patients with stable, optimally treated chronic congestive heart failure. The breathing episodes are associated with severe nocturnal arterial blood oxyhemoglobin desaturation and excessive arousals. Severe untreated sleep-disordered breathing may adversely affect left ventricular function, resulting in a vicious cycle that could contribute to death in patients with congestive heart failure. Prospective, longitudinal studies on survival are needed.	VET AFFAIRS MED CTR, SERV PHARM, CINCINNATI, OH 45220 USA; UNIV CINCINNATI, COLL MED, CINCINNATI, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	JAVAHERI, S (corresponding author), VET AFFAIRS MED CTR, PULM SECT 111F, SLEEP DISORDERS LAB, 3200 VINE ST, CINCINNATI, OH 45220 USA.							Ancoli-Israel S, 1989, Clin Geriatr Med, V5, P347; [Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1992, SLEEP, V15, P174; BLUMBERG H, 1980, J AUTONOM NERV SYST, V2, P223, DOI 10.1016/0165-1838(80)90013-2; BRADLEY TD, 1992, CLIN CHEST MED, V13, P459; CHERNIACK NS, 1981, NEW ENGL J MED, V305, P325; DARK DS, 1987, CHEST, V91, P833, DOI 10.1378/chest.91.6.833; DOWDELL WT, 1990, AM REV RESPIR DIS, V141, P871, DOI 10.1164/ajrccm/141.4_Pt_1.871; DOWDELL WT, 1992, AM REV RESPIR DIS, V145, P137, DOI 10.1164/ajrccm/145.1.137; FINDLEY LJ, 1985, SOUTH MED J, V78, P11, DOI 10.1097/00007611-198501000-00004; FLEMONS WW, 1994, PRINCIPLES PRACTICE, P824; FLETCHER EC, 1992, HYPERTENSION, V19, P555, DOI 10.1161/01.HYP.19.6.555; FRANCIS GS, 1986, AM J CARDIOL, V57, pB3, DOI 10.1016/0002-9149(86)90991-4; HANLY P, 1993, CHEST, V104, P1079, DOI 10.1378/chest.104.4.1079; HANLY PJ, 1989, ANN INTERN MED, V111, P777, DOI 10.7326/0003-4819-111-10-777; HANLY PJ, 1989, CHEST, V96, P480, DOI 10.1378/chest.96.3.480; Harrison TR, 1934, ARCH INTERN MED, V53, P891, DOI 10.1001/archinte.1934.00160120085009; HARVEY RM, 1971, CHEST, V59, P82, DOI 10.1378/chest.59.1.82; HE J, 1988, CHEST, V94, P9, DOI 10.1378/chest.94.1.9; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; JAVAHERI S, 1990, RESP PHYSIOL, V81, P359, DOI 10.1016/0034-5687(90)90116-G; MASSUMI RA, 1968, CHEST, V54, P21; PACKER M, 1985, CIRCULATION, V72, P681, DOI 10.1161/01.CIR.72.4.681; PHILLIPSON EA, 1994, TXB RESP MED, P2301; PICKERING TG, 1978, AM J MED, V65, P575, DOI 10.1016/0002-9343(78)90844-6; REES PJ, 1979, LANCET, V2, P1315; ROSE CE, 1983, AM J PHYSIOL, V245, pH924, DOI 10.1152/ajpheart.1983.245.6.H924; ROTH T, 1994, PRINCIPLES PRACTICE, P40; SKATRUD JB, 1983, J APPL PHYSIOL, V55, P813, DOI 10.1152/jappl.1983.55.3.813; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; YASUMA F, 1989, JPN CIRC J, V53, P1506, DOI 10.1253/jcj.53.1506; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; ZARET BL, 1992, HEART DISEASE TXB CA, P276; 1988, SAS STAT USERS GUIDE	36	205	230	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1995	122	7					487	492		10.7326/0003-4819-122-7-199504010-00002	http://dx.doi.org/10.7326/0003-4819-122-7-199504010-00002			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP008	7872582				2022-12-28	WOS:A1995QP00800002
J	HUANG, YQ; LI, JJ; KAPLAN, MH; POIESZ, B; KATABIRA, E; ZHANG, WC; FEINER, D; FRIEDMANKIEN, AE				HUANG, YQ; LI, JJ; KAPLAN, MH; POIESZ, B; KATABIRA, E; ZHANG, WC; FEINER, D; FRIEDMANKIEN, AE			HUMAN HERPESVIRUS-LIKE NUCLEIC-ACID IN VARIOUS FORMS OF KAPOSIS-SARCOMA	LANCET			English	Note								The association between a new human herpesvirus-like agent and various forms of Kaposi's sarcoma was examined by PCR. The DNA sequences of this agent were detected in 7 of 8 classic Kaposi's sarcoma specimens, 12 of 12 AIDS-associated specimens from the United States, and 7 of 10 specimens from African endemic Kaposi's sarcoma. Polymorphism of the herpesvirus-like DNA in the Kaposi's tissue from different populations was observed by both single-strand conformational polymorphism and direct sequencing. Furthermore, the presence and expression of the virus was detected in some Kaposi's tumours by Southern and northern blotting. This herpesvirus may be involved in the pathogenesis of different kinds of Kaposi's sarcoma seen among distinct and unrelated populations.	NYU,MED CTR,DEPT DERMATOL,NEW YORK,NY 10016; NYU,MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; N SHORE UNIV HOSP,DEPT MED,MANHASSET,NY; SUNY HLTH SCI CTR,CTR REG ONCOL,SYRACUSE,NY 13210; MULAGO HOSP,DEPT MED,WHO,KAMPALA,UGANDA	New York University; New York University; Northwell Health; North Shore University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Mulago National Referral Hospital; World Health Organization				Friedman Kien, Alvin/0000-0002-5854-2852				ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Buchbinder Aby, 1992, Current Opinion in Oncology, V4, P867, DOI 10.1097/00001622-199210000-00009; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; LI JJ, 1992, J CLIN MICROBIOL, V30, P1051, DOI 10.1128/JCM.30.5.1051-1055.1992; Miles Steven A., 1992, Current Opinion in Oncology, V4, P875, DOI 10.1097/00001622-199210000-00010; NICOLAIDES A, 1994, ANTICANCER RES, V14, P921; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5	8	406	413	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					759	761		10.1016/S0140-6736(95)90641-X	http://dx.doi.org/10.1016/S0140-6736(95)90641-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891487	hybrid			2022-12-28	WOS:A1995QN70100012
J	SMALL, GW; MAZZIOTTA, JC; COLLINS, MT; BAXTER, LR; PHELPS, ME; MANDELKERN, MA; KAPLAN, A; LARUE, A; ADAMSON, CF; CHANG, L; GUZE, BH; CORDER, EH; SAUNDERS, AM; HAINES, JL; PERICAKVANCE, MA; ROSES, AD				SMALL, GW; MAZZIOTTA, JC; COLLINS, MT; BAXTER, LR; PHELPS, ME; MANDELKERN, MA; KAPLAN, A; LARUE, A; ADAMSON, CF; CHANG, L; GUZE, BH; CORDER, EH; SAUNDERS, AM; HAINES, JL; PERICAKVANCE, MA; ROSES, AD			APOLIPOPROTEIN-E TYPE-4 ALLELE AND CEREBRAL GLUCOSE-METABOLISM IN RELATIVES AT RISK FOR FAMILIAL ALZHEIMER-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSITRON EMISSION TOMOGRAPHY; SENILE DEMENTIA; ONSET; GENE; CHROMOSOME-14; RELIABILITY; PREVALENCE; EPSILON-4; PATTERNS; REGIONS	Objective.-Cerebral parietal hypometabolism and left-right asymmetry occur early in the course of Alzheimer disease (AD), and the apolipoprotein E type 4 allele (APOE epsilon 4) is a risk factor for familial AD. To determine if APOE epsilon 4 is associated with lowered brain function in nondemented relatives at risk for familiar AD, we studied 12 relatives with APOE epsilon 4 and 19 relatives without APOE epsilon 4. We also compared them with seven patients with probable AD. Design.-After grouping subjects according to diagnosis and genotype, brain function measures were compared among groups. Setting.-University medical center. Patients.-At-risk subjects had mild memory complaints, normal cognitive performance, and at least two relatives with AD. Subjects with APOE epsilon 4 did not differ from those without APOE epsilon 4 in mean age at examination (56.4 vs 55.5 years) or in neuropsychological performance (mean Mini-Mental State Examination score, 28.8 vs 29.3). Main Outcome Measures.-Cerebral glucose metabolism was measured using positron emission tomography and fludeoxyglucose F 18. Results.-Parietal metabolism was significantly lower and left-right parietal asymmetry was significantly higher in at-risk subjects with APOE epsilon 4 compared with those without APOE epsilon 4, Patients with dementia had significantly lower parietal metabolism than did at-risk subjects with APOE epsilon 4. Conclusions.-These results suggest that the inheritance of APOE epsilon 4 is associated with reduced cerebral parietal metabolism and increased asymmetry in nondemented relatives at risk for probable AD, Longitudinal study will determine if glucose metabolic measures provide a means to monitor experimental treatment responses during the early phases of the disorder.	UNIV CALIF LOS ANGELES,SCH MED,DEPT NEUROL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT PHARMACOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT RADIOL SCI,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DIV BRAIN MAPPING,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,CTR ALZHEIMERS DIS,LOS ANGELES,CA 90024; VET AFFAIRS MED CTR,LOS ANGELES,CA; UNIV CALIF IRVINE,DEPT PHYS,IRVINE,CA; UNIV NEW MEXICO,DEPT PSYCHIAT,ALBUQUERQUE,NM; DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZHEIMERS DIS RES CTR,DURHAM,NC; DUKE UNIV,MED CTR,DIV NEUROL,DURHAM,NC; DUKE UNIV,MED CTR,DIV NEUROBIOL,DURHAM,NC; MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Irvine; University of New Mexico; Duke University; Duke University; Duke University; Harvard University; Massachusetts General Hospital	SMALL, GW (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,INST NEUROPSYCHIAT,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024, USA.		Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728	NATIONAL INSTITUTE OF MENTAL HEALTH [R29MH046424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U24AG021886, P30AG010123] Funding Source: NIH RePORTER; NIA NIH HHS [AG10123, AG05128, U24 AG021886] Funding Source: Medline; NIMH NIH HHS [1R29 MH46424] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AZARI NP, 1993, J CEREBR BLOOD F MET, V13, P438, DOI 10.1038/jcbfm.1993.58; BACHMAN DL, 1992, NEUROLOGY, V42, P115, DOI 10.1212/WNL.42.1.115; BARRIO JR, 1981, J NUCL MED, V22, P372; BAXTER LR, 1987, PSYCHIAT RES, V21, P237, DOI 10.1016/0165-1781(87)90028-X; Benton A, 1978, PSYCHOL ASSESSMENT R; BLASS JP, 1993, ALZ DIS ASSOC DIS, V6, P205; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CORDER EH, 1994, NAT GENET, V7, P180, DOI 10.1038/ng0694-180; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Crook T, 1986, DEV NEUROPSYCHOL, V2, P261, DOI 10.1080/87565648609540348; DAVIS PC, 1992, NEUROLOGY, V42, P1676, DOI 10.1212/WNL.42.9.1676; DELEON MJ, 1993, AM J NEURORADIOL, V14, P897; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GILEWSKI MJ, 1990, PSYCHOL AGING, V5, P482, DOI 10.1037/0882-7974.5.4.482; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GRADY CL, 1988, J CLIN EXP NEUROPSYC, V10, P576, DOI 10.1080/01688638808402796; GRADY CL, 1993, NEUROBIOL AGING, V14, P35, DOI 10.1016/0197-4580(93)90018-7; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HART RP, 1987, PSYCHOL AGING, V2, P111, DOI 10.1037/0882-7974.2.2.111; HAXBY JV, 1990, ARCH NEUROL-CHICAGO, V47, P753, DOI 10.1001/archneur.1990.00530070043010; HENRY TR, 1990, J CEREBR BLOOD F MET, V10, P748, DOI 10.1038/jcbfm.1990.128; HERHOLZ K, 1993, J NUCL MED, V34, P1460; HIXSON JE, 1990, J LIPID RES, V31, P545; HUANG SC, 1980, AM J PHYSIOL, V238, pE69, DOI 10.1152/ajpendo.1980.238.1.E69; KILLIANY RJ, 1993, ARCH NEUROL-CHICAGO, V50, P949, DOI 10.1001/archneur.1993.00540090052010; KUHL DE, 1987, J CEREB BLOOD FLOW M, V7, pS406; LIU CK, 1992, NEUROLOGY, V42, P138, DOI 10.1212/WNL.42.1.138; MASUR DM, 1989, J CLIN EXP NEUROPSYC, V11, P615, DOI 10.1080/01688638908400920; MAX W, 1993, NEUROLOGY, V43, pS6; MAYEUX R, 1993, ANN NEUROL, V34, P752, DOI 10.1002/ana.410340527; MAZZIOTTA J C, 1986, P493; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MULLERGARTNER HW, 1992, J CEREBR BLOOD F MET, V12, P571, DOI 10.1038/jcbfm.1992.81; Osterrieth P., 1944, ARCH PSYCHOL-GENEVE, V30, P206; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PHELPS ME, 1985, SCIENCE, V228, P799, DOI 10.1126/science.2860723; PHELPS ME, 1981, J CEREB BLOOD FLOW M, V2, P113; REIVICH M, 1979, CIRC RES, V44, P127, DOI 10.1161/01.RES.44.1.127; SAMBROOK J, 1989, MOL CLONING LABORATO, pB24; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SMALL GW, 1989, ARCH GEN PSYCHIAT, V46, P527; SMALL GW, 1992, PSYCHIAT RES-NEUROIM, V45, P177, DOI 10.1016/0925-4927(92)90025-Y; SMALL GW, 1994, INT PSYCHOGERIATR, V6, P21; SMALL GW, 1988, ARCH GEN PSYCHIAT, V46, P945; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STORANDT M, 1984, ARCH NEUROL-CHICAGO, V41, P497, DOI 10.1001/archneur.1984.04050170043013; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; VANDUIJN CMG, 1991, INT J EPIDEMIOL S2, V20, pS48; VANGORP WG, 1990, DEV NEUROPSYCHOL, V6, P279, DOI 10.1080/87565649009540467; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wechsler D., 2008, WAIS 4 WECHSLER ADUL; WENHAM PR, 1991, LANCET, V337, P1158, DOI 10.1016/0140-6736(91)92823-K; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; 1988, ALZ DIS ASSOC DIS, V2, P4; 1993, LANCET, V342, P737	59	497	512	0	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 22	1995	273	12					942	947		10.1001/jama.273.12.942	http://dx.doi.org/10.1001/jama.273.12.942			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM173	7884953				2022-12-28	WOS:A1995QM17300029
J	HALANYCH, KM; BACHELLER, JD; AGUINALDO, AMA; LIVA, SM; HILLIS, DM; LAKE, JA				HALANYCH, KM; BACHELLER, JD; AGUINALDO, AMA; LIVA, SM; HILLIS, DM; LAKE, JA			EVIDENCE FROM 18S RIBOSOMAL DNA THAT THE LOPHOPHORATES ARE PROTOSTOME ANIMALS	SCIENCE			English	Article							SEQUENCES; ORIGIN; PHYLOGENY; RNA	The suspension-feeding metazoan subkingdom Lophophorata exhibits characteristics of both deuterostomes and protostomes. Because the morphology and embryology of lophophorates are phylogenetically ambiguous, their origin is a major unsolved problem of metazoan phylogenetics. The complete 18S ribosomal DNA sequences of all three lophophorate phyla were obtained and analyzed to clarify the phylogenetic relationships of this subkingdom. Sequence analyses show that lophophorates are protostomes closely related to mollusks and annelids, This conclusion deviates from the commonly held view of deuterostome affinity.	UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	HALANYCH, KM (corresponding author), UNIV TEXAS, DEPT ZOOL, AUSTIN, TX 78712 USA.		Halanych, Ken M/A-9480-2009; Hillis, David/L-5421-2019; Hillis, David M/B-4278-2008	Halanych, Ken M/0000-0002-8658-9674; 				BACKELJAU T, 1993, CLADISTICS, V9, P167, DOI 10.1111/j.1096-0031.1993.tb00216.x; BALLARD JWO, 1992, SCIENCE, V258, P1345, DOI 10.1126/science.1455227; CHRISTEN R, 1991, EMBO J, V10, P499, DOI 10.1002/j.1460-2075.1991.tb07975.x; DEQUEIROZ K, 1990, SYST ZOOL, V39, P307, DOI 10.2307/2992353; EERNISE DJ, 1993, SYST BIOL, V41, P305; EMIG C C, 1976, Zeitschrift fuer Zoologische Systematik und Evolutionsforschung, V14, P10; Emig C.C., 1982, P741; EMIG CC, 1982, ADV MAR BIOL, V19, P1, DOI 10.1016/S0065-2881(08)60086-3; FAITH DP, 1991, SYST ZOOL, V40, P366, DOI 10.2307/2992329; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Ghiselin M.T., 1988, Oxford Surveys in Evolutionary Biology, V5, P66; GUSTUS RM, 1972, ACTA ZOOL-STOCKHOLM, V53, P299; HALANYCH KM, 1993, BIOL BULL, V185, P417, DOI 10.2307/1542482; HIGGINS DG, 1992, COMPUT APPL BIOSCI, V8, P189; HILLIS DM, 1991, Q REV BIOL, V66, P411, DOI 10.1086/417338; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; Hyman L. H., 1940, INVERTEBRATES PROTOZ, V1; Hyman L. H., 1959, INVERTEBRATES SMALLE, VV; HYMAN LH, 1958, BIOL BULL, V114, P106, DOI 10.2307/1538968; Jagersten G, 1972, EVOLUTION METAZOAN L; LAKE JA, 1989, INT CONGR SER, V824, P273; LAKE JA, 1990, P NATL ACAD SCI USA, V87, P763, DOI 10.1073/pnas.87.2.763; LAKE JA, UNPUB; LOCKHART PJ, 1994, MOL BIOL EVOL, V11, P605; MASLOV DA, 1994, NATURE, V368, P345, DOI 10.1038/368345a0; Nielsen C, 1977, BIOL BRYOZOANS, P519; OLSEN GJ, 1994, P NATL ACAD SCI USA, V91, P1455; PATTERSON C, 1989, INT CONGR SER, V824, P471; ROWELL AJ, 1982, LETHAIA, V15, P299, DOI 10.1111/j.1502-3931.1982.tb01695.x; Rudall K. M., 1973, BIOL REV, V40, P597; Schram F.R., 1991, P35; SWOFFORDS DL, 1993, PHYLOGENETIC ANAL US; TELFORD MJ, 1993, MOL BIOL EVOL, V10, P660; VALENTINE JW, 1973, SYST ZOOL, V22, P97, DOI 10.2307/2412093; VALENTINE JW, 1975, AM ZOOL, V15, P391; WADA H, 1994, P NATL ACAD SCI USA, V91, P1801, DOI 10.1073/pnas.91.5.1801; WILLIAMS A, 1977, PATTERNS EVOLUTION I, P79; Willmer P., 1990, INVERTEBRATE RELATIO; Zimmer R.L., 1973, P593; [No title captured]	41	465	482	1	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 17	1995	267	5204					1641	1643		10.1126/science.7886451	http://dx.doi.org/10.1126/science.7886451			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886451				2022-12-28	WOS:A1995QM39700035
J	PERRY, IJ; WANNAMETHEE, SG; WALKER, MK; THOMSON, AG; WHINCUP, PH; SHAPER, AG				PERRY, IJ; WANNAMETHEE, SG; WALKER, MK; THOMSON, AG; WHINCUP, PH; SHAPER, AG			PROSPECTIVE-STUDY OF RISK-FACTORS FOR DEVELOPMENT OF NON-INSULIN-DEPENDENT DIABETES IN MIDDLE-AGED BRITISH MEN	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; PHYSICAL-ACTIVITY; MELLITUS; RESISTANCE; POPULATION	Objective-To determine the risk factors for noninsulin dependent diabetes in a cohort representative of middle aged British men. Design-Prospective study. Subjects and setting-7735 men aged 40-59, drawn from one group practice in each of 24 towns in Britain. Known and probable cases of diabetes at screening (n=158) were excluded. Main outcome measures-Non-insulin dependent diabetes (doctor diagnosed) over a mean follow up period of 12 . 8 years. Results-There were 194 new cases of non-insulin dependent diabetes. Body mass index was the dominant risk factor for diabetes, with an age adjusted relative risk (upper fifth to lower fifth) of 11 . 6; 95% confidence interval 5 . 4 to 16 . 8. Men engaged in moderate levels of physical activity had a substantially reduced risk of diabetes, relative to the physically inactive men, after adjustment for age and body mass index (0 . 4; 0 . 2 to 0 . 7), an association which persisted in full multivariate analysis. A nonlinear relation between alcohol intake and diabetes was observed, with the lowest risk among moderate drinkers (16-42 units/week) relative to the baseline group of occasional drinkers (0 . 6; 0 . 4 to 1 . 0). Additional significant predictors of diabetes in multivariate analysis included serum triglyceride concentration, high density lipoprotein cholesterol concentration (inverse association), heart rate, uric acid concentration, and prevalent coronary heart disease. Conclusion-These finding emphasise the interrelations between risk factors for non-insulin dependent diabetes and coronary heart disease and the potential value of an integrated approach to the prevention of these conditions based on the prevention of obesity and the promotion of physical activity.			PERRY, IJ (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT PUBL HLTH,LONDON NW3 2PF,ENGLAND.		Lennon, Lucy/ABB-9433-2020	Lennon, Lucy/0000-0002-1738-1351; Perry, Ivan/0000-0002-4965-9792; Wannamethee, Sasiwarang/0000-0001-9484-9977; Whincup, Peter/0000-0002-5589-4107	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		CHATURVEDI N, 1994, DIABETOLOGIA, V37, P765, DOI 10.1007/s001250050177; COOK DG, 1986, POSTGRAD MED J, V62, P1001, DOI 10.1136/pgmj.62.733.1001; COX DR, 1972, J R STAT SOC B, V34, P187; EVERHART J, 1985, DIABETES AM DIABETES; FACCHINI FS, 1992, LANCET, V339, P1128, DOI 10.1016/0140-6736(92)90730-Q; FESKENS EJM, 1989, AM J EPIDEMIOL, V130, P1101, DOI 10.1093/oxfordjournals.aje.a115437; HAFFNER SM, 1990, JAMA-J AM MED ASSOC, V263, P2893, DOI 10.1001/jama.263.21.2893; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; HOLBROOK TL, 1990, AM J EPIDEMIOL, V132, P902, DOI 10.1093/oxfordjournals.aje.a115733; JARRETT RJ, 1988, DIABETOLOGIA, V31, P737, DOI 10.1007/BF00274775; LAWS A, 1993, BAILLIERE CLIN ENDOC, V7, P1063, DOI 10.1016/S0950-351X(05)80245-9; LILLIOJA S, 1993, NEW ENGL J MED, V329, P1988, DOI 10.1056/NEJM199312303292703; MANSON JE, 1992, JAMA-J AM MED ASSOC, V268, P63, DOI 10.1001/jama.268.1.63; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; OHLSON LO, 1988, DIABETOLOGIA, V31, P798; PHILLIPS AN, 1986, THESIS U LONDON LOND; POCOCK SJ, 1989, J CLIN PATHOL, V42, P172, DOI 10.1136/jcp.42.2.172; SAAD MF, 1991, NEW ENGL J MED, V324, P733, DOI 10.1056/NEJM199103143241105; SAVAGE PJ, 1993, BRIT HEART J, V69, P473; SHAPER AG, 1985, J EPIDEMIOL COMMUN H, V39, P197, DOI 10.1136/jech.39.3.197; SHAPER AG, 1991, BRIT HEART J, V66, P384; SHAPER AG, 1981, BRIT MED J, V283, P179, DOI 10.1136/bmj.283.6285.179; SHAPER AG, 1984, BRIT HEART J, V51, P595, DOI 10.1136/hrt.51.6.595; SHAPER AG, 1988, LANCET, V2, P1268; STAMPFER MJ, 1988, AM J EPIDEMIOL, V128, P549, DOI 10.1093/oxfordjournals.aje.a115002; WALKER M, 1984, J R COLL GEN PRACT, V34, P197; WILLIAMS R, 1994, HLTH CARE NEEDS ASSE, V1, P31; 1992, CM1986 SECR STAT HLT	28	407	458	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					560	564		10.1136/bmj.310.6979.560	http://dx.doi.org/10.1136/bmj.310.6979.560			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888929	Green Published			2022-12-28	WOS:A1995QK70000017
J	QUINN, N				QUINN, N			FORTNIGHTLY REVIEW - DRUG-TREATMENT OF PARKINSONS-DISEASE	BRITISH MEDICAL JOURNAL			English	Article							LEVODOPA-INDUCED DYSKINESIAS; EARLY COMBINATION; FOLLOW-UP; BROMOCRIPTINE; FLUCTUATIONS; THERAPY; ONSET				QUINN, N (corresponding author), UCL NATL HOSP NEUROL & NEUROSURG, INST NEUROL, LONDON WC1N 3BG, ENGLAND.							BERGAMASCO B, 1990, ACTA NEUROL SCAND, V81, P383; DESMET Y, 1982, J NEUROL NEUROSUR PS, V45, P1161, DOI 10.1136/jnnp.45.12.1161; DUBOIS B, 1987, ANN NEUROL, V22, P26, DOI 10.1002/ana.410220108; DUVOISIN RC, 1989, NEUROLOGY S2, V39; FRIEDMAN JH, 1989, NEUROLOGY, V39, P1219, DOI 10.1212/WNL.39.9.1219; GOETZ CG, 1993, NEUROLOGY, V43, P1; HELY MA, 1989, J NEUROL NEUROSUR PS, V52, P324, DOI 10.1136/jnnp.52.3.324; HUGHES AJ, 1993, MOVEMENT DISORD, V8, P165, DOI 10.1002/mds.870080208; KOSTIC V, 1991, NEUROLOGY, V41, P202, DOI 10.1212/WNL.41.2_Part_1.202; LEES AJ, 1993, BRIT MED J, V307, P469; LHERMITTE F, 1978, ARCH NEUROL-CHICAGO, V35, P261, DOI 10.1001/archneur.1978.00500290007002; MADOPAR HBS, 1987, EUR NEUROL S1, V27; MARSDEN CD, 1976, LANCET, V1, P292, DOI 10.1016/S0140-6736(76)91416-1; MONTASTRUC JL, 1994, J NEUROL NEUROSUR PS, V57, P1034, DOI 10.1136/jnnp.57.9.1034; MOURADIAN MM, 1990, ANN NEUROL, V27, P18, DOI 10.1002/ana.410270105; NISSENBAUM H, 1987, PSYCHOL MED, V17, P899, DOI 10.1017/S0033291700000702; NUTT JG, 1984, NEW ENGL J MED, V310, P483, DOI 10.1056/NEJM198402233100802; NUTT JG, 1994, NEUROLOGY, V44, P913, DOI 10.1212/WNL.44.5.913; PINCUS JH, 1988, NEUROLOGY, V38, P481, DOI 10.1212/WNL.38.3.481; POEWE WH, 1988, ANN NEUROL, V23, P73, DOI 10.1002/ana.410230112; Quinn N, 1987, Mov Disord, V2, P73, DOI 10.1002/mds.870020201; RILEY DE, 1993, NEUROLOGY, V43, P1459, DOI 10.1212/WNL.43.8.1459; RINNE UK, 1987, NEUROLOGY, V37, P826, DOI 10.1212/WNL.37.5.826; RINNE UK, 1989, NEUROLOGY, V39, P336, DOI 10.1212/WNL.39.3.336; ROBERTS JW, 1993, NEUROLOGY, V43, P2685, DOI 10.1212/WNL.43.12.2685; SHOULSON I, 1989, NEW ENGL J MED, V321, P1364; SHOULSON I, 1993, NEW ENGL J MED, V328, P176, DOI 10.1056/NEJM199301213280305; SWANSON PD, 1994, J NEUROL NEUROSUR PS, V57, P401, DOI 10.1136/jnnp.57.4.401; WEINER WJ, 1993, NEUROLOGY, V43, P21, DOI 10.1212/WNL.43.1_Part_1.21; 1994, M NEED	30	96	101	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					575	579		10.1136/bmj.310.6979.575	http://dx.doi.org/10.1136/bmj.310.6979.575			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7888935	Green Published			2022-12-28	WOS:A1995QK70000023
J	LIUZZO, G; BIASUCCI, LM; GALLIMORE, JR; GRILLO, RL; REBUZZI, AG; PEPYS, MB; MASERI, A				LIUZZO, G; BIASUCCI, LM; GALLIMORE, JR; GRILLO, RL; REBUZZI, AG; PEPYS, MB; MASERI, A			THE PROGNOSTIC VALUE OF C-REACTIVE PROTEIN AND SERUM AMYLOID-A PROTEIN IN SEVERE UNSTABLE ANGINA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR INHIBITOR-1; CORONARY-ARTERY DISEASE; ISCHEMIC-HEART-DISEASE; ACUTE-PHASE RESPONSE; A-PROTEIN; NATURAL-HISTORY; SILENT ISCHEMIA; INFLAMMATION; MACROPHAGES	Background. The pathogenesis of unstable angina is poorly understood, and predicting the prognosis is problematic. Evidence suggests that there may be active inflammation, possibly in the coronary arteries, in this syndrome. We therefore studied the prognostic value of measurements of the circulating acute-phase reactants C-reactive protein and serum amyloid A protein, which are sensitive indicators of inflammation. Methods. We measured C-reactive protein, serum amyloid A protein, creatine kinase, and cardiac troponin T in 32 patients with chronic stable angina, 31 with severe unstable angina, and 29 with acute myocardial infarction. Results. At the time of hospital admission, creatine kinase and cardiac troponin T levels were normal in all the patients, but the levels of C-reactive protein and serum amyloid A protein were greater than or equal to 0.3 mg per deciliter (exceeding the 90th percentile of the normal distribution) in 4 of the patients with stable angina (13 percent), 20 of the patients with unstable angina (65 percent), and 22 of the patients with acute myocardial infarction (76 percent). The 20 patients with unstable angina who had levels of acute-phase reactants greater than or equal to 0.3 mg per deciliter had more ischemic episodes in the hospital than those with levels <0.3 mg per deciliter (mean [+/-SD] number of episodes per patient, 4.8+/-2.5 vs. 1.8+/-2.4; P = 0.004); 5 patients subsequently had a myocardial infarction, 2 died, and 12 required immediate coronary revascularization. In contrast, no deaths or myocardial infarction occurred among the 11 patients with levels of acute-phase reactants <0.3 mg per deciliter, and only 2 of them required coronary revascularization. Among the patients admitted with a diagnosis of acute myocardial infarction, unstable angina preceded infarction in 14 of the 22 patients (64 percent) with levels of acute-phase reactants greater than or equal to 0.3 mg per deciliter but in none of the 7 patients with levels <0.3 mg per deciliter. Conclusions. Elevation of C-reactive protein and serum amyloid A protein at the time of hospital admission predicts a poor outcome in patients with unstable angina and may reflect an important inflammatory component in the pathogenesis of this condition.	UNIV CATTOLICA SACRO CUORE, IST MICROBIOL, ROME, ITALY; HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, DEPT MED, LONDON, ENGLAND	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Imperial College London	LIUZZO, G (corresponding author), UNIV CATTOLICA SACRO CUORE, IST CARDIOL, LARGO AGOSTINO GEMELLI 8, I-00168 ROME, ITALY.		LIUZZO, GIOVANNA/J-8090-2018	LIUZZO, GIOVANNA/0000-0002-5714-0907; biasucci, luigi m/0000-0002-6921-6497				ANDREOTTI F, 1990, J AM COLL CARDIOL, V16, P1553, DOI 10.1016/0735-1097(90)90300-E; Baroldi G, 1988, Am J Cardiovasc Pathol, V2, P159; BAUSSERMAN LL, 1989, CLIN CHIM ACTA, V184, P297, DOI 10.1016/0009-8981(89)90063-6; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; BOGATY P, 1993, CIRCULATION, V87, P1938, DOI 10.1161/01.CIR.87.6.1938; CARRY M, 1992, CIRCULATION, V85, P230, DOI 10.1161/01.CIR.85.1.230; CIABATTONI G, 1993, J AM COLL CARDIOL, V21, P1377, DOI 10.1016/0735-1097(93)90312-O; DEBEER FC, 1982, BRIT HEART J, V47, P239; GLANTZ SA, 1987, PRIMER BIOSTATISTICS, P287; GOTTLIEB SO, 1987, J AM COLL CARDIOL, V10, P756, DOI 10.1016/S0735-1097(87)80267-X; GOTTLIEB SO, 1986, NEW ENGL J MED, V314, P1214, DOI 10.1056/NEJM198605083141903; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; JUHANVAGUE I, 1989, ARTERIOSCLEROSIS, V9, P362, DOI 10.1161/01.ATV.9.3.362; KOHCHI K, 1985, CIRCULATION, V71, P709, DOI 10.1161/01.CIR.71.4.709; KUSHNER I, 1978, J CLIN INVEST, V61, P235, DOI 10.1172/JCI108932; LANGER A, 1989, J AM COLL CARDIOL, V13, P1495, DOI 10.1016/0735-1097(89)90338-0; LINNANMAKI E, 1993, CIRCULATION, V87, P1130, DOI 10.1161/01.CIR.87.4.1130; MARHAUG G, 1986, ACTA MED SCAND, V220, P303; MAURY CPJ, 1988, J CLIN PATHOL, V41, P1263, DOI 10.1136/jcp.41.12.1263; MAZZONE A, 1993, CIRCULATION, V88, P358, DOI 10.1161/01.CIR.88.2.358; MULCAHY R, 1981, AM J CARDIOL, V48, P525, DOI 10.1016/0002-9149(81)90083-7; MULCAHY R, 1985, AM HEART J, V109, P753, DOI 10.1016/0002-8703(85)90634-9; NADEMANEE K, 1987, J AM COLL CARDIOL, V10, P1, DOI 10.1016/S0735-1097(87)80152-3; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; SATO T, 1987, ATHEROSCLEROSIS, V68, P191, DOI 10.1016/0021-9150(87)90198-5; SERNERI GGN, 1992, CIRCULATION, V86, P790, DOI 10.1161/01.CIR.86.3.790; SHAINKINKESTENBAUM R, 1986, J CLIN PATHOL, V39, P635, DOI 10.1136/jcp.39.6.635; SHINE B, 1981, CLIN CHIM ACTA, V117, P13, DOI 10.1016/0009-8981(81)90005-X; VEJAR M, 1990, THROMB HAEMOSTASIS, V63, P163; WALLSH E, 1986, TEX HEART I J, V13, P105; WILKINS J, 1994, CLIN CHEM, V40, P1284; YOSHIMOTO T, 1992, J IMMUNOL, V148, P3596; 1987, WHO TECH REP SER, V760, P21	35	1921	2045	0	38	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					417	424		10.1056/NEJM199408183310701	http://dx.doi.org/10.1056/NEJM199408183310701			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PB501	7880233				2022-12-28	WOS:A1994PB50100001
J	FREEMAN, H				FREEMAN, H			MOCLOBEMIDE	LANCET			English	Article							RANDOMIZED CLINICAL-TRIAL; ATYPICAL DEPRESSION; CLOMIPRAMINE; PLACEBO		UNIV SALFORD, SALFORD M5 4WT, LANCS, ENGLAND	University of Salford								ALEVIZOS B, 1993, ACTA PSYCHIAT SCAND, V87, P285, DOI 10.1111/j.1600-0447.1993.tb03373.x; AMREIN R, 1992, PSYCHOPHARMACOLOGY, V106, pS24, DOI 10.1007/BF02246229; Anand R, 1990, Adv Neurol, V51, P261; ANGST J, 1992, PSYCHOPHARMACOLOGY, V106, pS109, DOI 10.1007/BF02246250; BAKISH D, 1992, PSYCHOPHARMACOLOGY, V106, pS98, DOI 10.1007/BF02246248; BARRELET L, 1991, SCWEIZ RUNDSCHAU MED, V80, P3; BAUMHACKL U, 1989, BRIT J PSYCHIAT, V155, P78, DOI 10.1192/S0007125000297535; BEAUMONT G, 1992, PSYCHOPHARMACOLOGY, V106, pS123, DOI 10.1007/BF02246255; BOTTE L, 1990, ACTA PSYCHIATR  S360, V82, P42; BOUGEROL T, 1992, PSYCHOPHARMACOLOGY, V106, pS102, DOI 10.1007/BF02246249; BURNER M, 1990, MED HYG, V48, P2245; BURTON C J, 1984, Journal of Pharmacy and Pharmacology, V36, p53W; CASACCHIA M, 1984, PHARMACOPSYCHIATRY, V17, P122, DOI 10.1055/s-2007-1017421; DAVIDSON JRT, 1992, HDB AFFECTIVE DISORD, P345; De Vanna M, 1990, Acta Psychiatr Scand Suppl, V360, P64; FITTON A, 1992, DRUGS, V43, P561, DOI 10.2165/00003495-199243040-00009; GUELFI JD, 1992, BRIT J PSYCHIAT, V160, P519, DOI 10.1192/bjp.160.4.519; HAFFMANS J, 1993, J CLIN PSYCHOPHARM, V13, P291, DOI 10.1097/00004714-199308000-00015; HEALY D, 1991, BRIT J PSYCHIAT, V158, P737, DOI 10.1192/bjp.158.6.737; HEBENSTREIT GF, 1991, 5TH C INT PSYCH ASS; HINDMARCH I, 1992, PSYCHOPHARMACOLOGY, V106, pS49, DOI 10.1007/BF02246236; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; Kettler R, 1990, Acta Psychiatr Scand Suppl, V360, P101, DOI 10.1111/j.1600-0447.1990.tb05348.x; Kline N.S., 1970, DISCOVERIES BIOL PSY, P194; Korn A, 1988, J Neural Transm Suppl, V26, P57; LARSEN JK, 1991, ACTA PSYCHIAT SCAND, V84, P564, DOI 10.1111/j.1600-0447.1991.tb03196.x; LARSEN JK, 1989, ACTA PSYCHIAT SCAND, V79, P530, DOI 10.1111/j.1600-0447.1989.tb10299.x; LAUX G, 1989, J NEURAL TRANSM-GEN, P45; MACHER JP, 1992, PSYCHOPHARMACOLOGY, V106, pS116, DOI 10.1007/BF02246252; NEUVONEN PJ, 1993, LANCET, V342, P1419, DOI 10.1016/0140-6736(93)92774-N; OSE E, 1992, PSYCHOPHARMACOLOGY, V106, pS114, DOI 10.1007/BF02246251; RAMAEKERS JG, 1992, PSYCHOPHARMACOLOGY, V106, pS62, DOI 10.1007/BF02246238; STABL M, 1989, J NEURAL TRANSM-GEN, P77; TILLER J, 1989, J AFFECT DISORDERS, V16, P181, DOI 10.1016/0165-0327(89)90072-4; VERSIANI M, 1989, BRIT J PSYCHIAT, V155, P72, DOI 10.1192/S0007125000297523; Versiani M, 1990, Acta Psychiatr Scand Suppl, V360, P24	36	53	53	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1528	1532		10.1016/S0140-6736(05)80090-X	http://dx.doi.org/10.1016/S0140-6736(05)80090-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902906				2022-12-28	WOS:A1993MM40200017
J	BROWN, MJ				BROWN, MJ			ANGIOTENSIN RECEPTOR BLOCKERS IN ESSENTIAL-HYPERTENSION	LANCET			English	Editorial Material											BROWN, MJ (corresponding author), ADDENBROOKES HOSP,CLIN PHARMACOL UNIT,CAMBRIDGE CB2 2QQ,ENGLAND.							BURNIER M, 1991, AM J HYPERTENS, V4, P438, DOI 10.1093/ajh/4.5.438; CHRISTEN Y, 1991, CIRCULATION, V83, P133; DOIG JK, 1993, J CARDIOVASC PHARM, V21, P7323; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; MORICE AH, 1987, LANCET, V2, P1116; NEATON JD, 1993, JAMA-J AM MED ASSOC, V270, P713, DOI 10.1001/jama.270.6.713; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; WEBER MA, 1992, AM J HYPERTENS, V5, pS247, DOI 10.1093/ajh/5.12.247S	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1374	1375		10.1016/0140-6736(93)92745-F	http://dx.doi.org/10.1016/0140-6736(93)92745-F			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901674				2022-12-28	WOS:A1993MK09500002
J	GRUBER, A; PAL, A; KISS, RG; SAS, G; GRIFFIN, JH				GRUBER, A; PAL, A; KISS, RG; SAS, G; GRIFFIN, JH			GENERATION OF ACTIVATED PROTEIN-C DURING THROMBOLYSIS	LANCET			English	Note								The observation that urokinase infusion increases circulating levels of the anticoagulant activated protein C (APC) in baboons implies that APC might be elevated during thrombolytic therapy. Patients undergoing coronary thrombolysis showed an 11-fold increase (means from 6 to 69 mug/L) in APC during infusion of streptokinase. Thrombolytic therapy thus generates at least two potent antithrombotic factors in the circulation-the fibrinolytic enzyme, plasmin, and the anticoagulant enzyme, APC. APC may help prevent reocclusion during or after thrombolysis.	Scripps Res Inst, RES INST, LA JOLLA, CA 92037 USA; POSTGRAD MED UNIV, H-1389 BUDAPEST, HUNGARY	Scripps Research Institute				Griffin, John/0000-0002-4302-2547	NHLBI NIH HHS [HL-31950] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRANSON HE, 1983, LANCET, V2, P1165; COLLEN D, 1993, LANCET, V342, P34, DOI 10.1016/0140-6736(93)91888-S; EISENBERG PR, 1987, J AM COLL CARDIOL, V10, P527, DOI 10.1016/S0735-1097(87)80194-8; ESMON CT, 1981, P NATL ACAD SCI-BIOL, V78, P2249, DOI 10.1073/pnas.78.4.2249; ESPANA F, 1991, BLOOD, V77, P1754; GEIGER M, 1989, THROMB HAEMOSTASIS, V61, P86; GRUBER A, 1991, CIRCULATION, V84, P2454, DOI 10.1161/01.CIR.84.6.2454; GRUBER A, 1992, BLOOD, V79, P2340; HANSON SR, 1993, J CLIN INVEST, V92, P2003, DOI 10.1172/JCI116795; VARADI K, 1992, CIRCULATION, V86, pA736	10	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1275	1276		10.1016/0140-6736(93)92364-Y	http://dx.doi.org/10.1016/0140-6736(93)92364-Y			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901587				2022-12-28	WOS:A1993MH56600014
J	BOYLE, P; MACFARLANE, GJ; SCULLY, C				BOYLE, P; MACFARLANE, GJ; SCULLY, C			ORAL-CANCER - NECESSITY FOR PREVENTION STRATEGIES	LANCET			English	Editorial Material									BRISTOL DENT HOSP & SCH, CTR STUDY ORAL DIS, BRISTOL, ENGLAND	University of Bristol	BOYLE, P (corresponding author), EUROPEAN INST ONCOL, DIV EPIDEMIOL & BIOSTAT, MILAN, ITALY.		Macfarlane, Gary J/I-9521-2014; Boyle, Peter/A-4380-2014	Macfarlane, Gary J/0000-0003-2322-3314; Boyle, Peter/0000-0001-6251-0610				BOYLE P, 1990, J ROY SOC MED, V83, P724, DOI 10.1177/014107689008301116; DAVIS S, 1987, LANCET, V2, P910; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; JENSEN OM, 1990, EUR J CANCER, V26, P1167; LAVECCHIA C, 1992, EUR J CANCER, V28A, P132; LIPPMAN SM, 1993, NEW ENGL J MED, V328, P15, DOI 10.1056/NEJM199301073280103; MACFARLANE GJ, 1992, BRIT MED J, V305, P1121, DOI 10.1136/bmj.305.6862.1121; MACFARLANE GJ, 1987, LANCET, V2, P912; MALAOWALLA AM, 1976, CANCER-AM CANCER SOC, V37, P1882, DOI 10.1002/1097-0142(197604)37:4<1882::AID-CNCR2820370437>3.0.CO;2-2; PARKIN DM, 1988, INT J CANCER, V41, P184, DOI 10.1002/ijc.2910410205; SCULLY C, 1992, ORAL ONCOL, V28B, P87, DOI 10.1016/0964-1955(92)90033-W	11	32	32	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 6	1993	342	8880					1129	1129		10.1016/0140-6736(93)92119-E	http://dx.doi.org/10.1016/0140-6736(93)92119-E			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901471				2022-12-28	WOS:A1993MF19800005
J	TANG, WZ; LUO, HY; ENG, B; WAYE, JS; CHUI, DHK				TANG, WZ; LUO, HY; ENG, B; WAYE, JS; CHUI, DHK			IMMUNOCYTOLOGICAL TEST TO DETECT ADULT CARRIERS OF (--SEA/) DELETIONAL ALPHA-THALASSEMIA	LANCET			English	Note							GLOBIN; THALASSEMIA	The gene frequency for (--SEA/) deletional alpha-thalassaemia is high in Southeast Asian populations. We report a simple immunocytological test that is highly sensitive and specific for the detection of adult carriers of the (--SEA/) deletion. We prospectively studied 296 consecutive adult blood samples. All 41 with the (--SEA/) deletion had a positive test; all but 1 of the 165 non-carriers were negative. This test, whose major requirement is a fluorescence microscope, should be useful to identify couples at risk of conceiving fetuses with homozygous alpha-thalassaemia.	MCMASTER UNIV,SCH MED,DEPT PATHOL,1200 MAIN ST W,HAMILTON L8N 3Z5,ONTARIO,CANADA	McMaster University				Chui, David/0000-0002-1475-7309				BOWDEN DK, 1992, BRIT J HAEMATOL, V81, P104, DOI 10.1111/j.1365-2141.1992.tb08180.x; CHUI DHK, 1986, NEW ENGL J MED, V314, P76, DOI 10.1056/NEJM198601093140203; FUCHAROEN S, 1991, BLOOD, V78, pA198; HIGGS DR, 1989, BLOOD, V73, P1081; TANG WZ, 1992, BLOOD, V80, P517; WAYE JS, 1993, CLIN INVEST MED, V16, P358; WEATHERALL DJ, 1989, METABOLIC BASIS INHE, P2315; ZENG YT, 1985, LANCET, V1, P304	8	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1145	1147		10.1016/0140-6736(93)92125-D	http://dx.doi.org/10.1016/0140-6736(93)92125-D			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901477				2022-12-28	WOS:A1993MF19800011
J	GODFREY, RC				GODFREY, RC			UNDERGRADUATE EXAMINATIONS - A CONTINUING TYRANNY	LANCET			English	Article							MULTIPLE-CHOICE QUESTION; CLINICAL COMPETENCE				GODFREY, RC (corresponding author), SOUTHAMPTON GEN HOSP,SOUTHAMPTON UNIV HOSP NHS TRUST,DEPT MED,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.							Council GM, 1993, TOMORROWS DOCTORS RE; DEGRAAFF E, 1987, MED EDUC, V21, P213; EVANS LR, 1966, J MED EDUC, V41, P651; FLEMING PR, 1988, MED EDUC, V22, P509, DOI 10.1111/j.1365-2923.1988.tb00795.x; HARDEN R, 1975, MED EDUC, V13, P41; HILL DA, 1994, MED EDUC, V28, P394, DOI 10.1111/j.1365-2923.1994.tb02550.x; MAGUIRE P, 1989, BRIT MED J, V298, P4, DOI 10.1136/bmj.298.6665.4; NEWBLE DI, 1983, MED EDUC, V17, P165, DOI 10.1111/j.1365-2923.1983.tb00657.x; NEWBLE DI, 1988, MED EDUC, V222, P325; NORCINI JJ, 1985, MED EDUC, V19, P238, DOI 10.1111/j.1365-2923.1985.tb01314.x; Osler W, 1913, LANCET, V2, P1047; STILLMAN PL, 1980, J MED EDUC, V55, P186; SWARTZ MH, 1993, ACAD MED, V68, pS76, DOI 10.1097/00001888-199310000-00052; TRIGWELL K, 1987, ASSESS EVAL HIGH EDU, V12, P56; van der Vleuten C.P., 1990, TEACH LEARN MED, V2, P58, DOI [https://doi.org/10.1080/10401339009539432, DOI 10.1080/10401339009539432]; WIGTON RS, 1980, J MED EDUC, V55, P423; WILLIAMS RG, 1987, MED EDUC, V21, P482, DOI 10.1111/j.1365-2923.1987.tb01407.x; WILSON HD, 1981, MED EDUC, V15, P359, DOI 10.1111/j.1365-2923.1981.tb02414.x	18	22	23	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 25	1995	345	8952					765	767		10.1016/S0140-6736(95)90644-4	http://dx.doi.org/10.1016/S0140-6736(95)90644-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN701	7891490				2022-12-28	WOS:A1995QN70100015
J	WOLYNES, PG; ONUCHIC, JN; THIRUMALAI, D				WOLYNES, PG; ONUCHIC, JN; THIRUMALAI, D			NAVIGATING THE FOLDING ROUTES	SCIENCE			English	Editorial Material							PROTEINS		UNIV CALIF SAN DIEGO,DEPT PHYS,LA JOLLA,CA 92093; UNIV MARYLAND,INST PHYS SCI & TECHNOL,COLLEGE PK,MD 20742	University of California System; University of California San Diego; University System of Maryland; University of Maryland College Park	WOLYNES, PG (corresponding author), UNIV ILLINOIS,SCH CHEM SCI,URBANA,IL 61801, USA.							BRYNGELSON JD, IN PRESS PROTEINS ST; CAMACHO CJ, 1993, P NATL ACAD SCI USA, V90, P6369, DOI 10.1073/pnas.90.13.6369; ELOVE GA, 1994, BIOCHEMISTRY-US, V33, P6925, DOI 10.1021/bi00188a023; GOLDSTEIN RA, 1992, P NATL ACAD SCI USA, V89, P4918, DOI 10.1073/pnas.89.11.4918; HONEYCUTT JD, 1990, P NATL ACAD SCI USA, V87, P3526, DOI 10.1073/pnas.87.9.3526; JONAS J, 1994, ANNU REV BIOPH BIOM, V23, P287, DOI 10.1146/annurev.bb.23.060194.001443; JONES CM, 1993, P NATL ACAD SCI USA, V90, P11860, DOI 10.1073/pnas.90.24.11860; MILLER R, 1992, J CHEM PHYS, V96, P768, DOI 10.1063/1.462462; ONUCHIC JN, IN PRESS P NATL ACAD; OTZEN DE, 1994, P NATL ACAD SCI USA, V91, P10422, DOI 10.1073/pnas.91.22.10422; SALI A, 1994, J MOL BIOL, V235, P1614, DOI 10.1006/jmbi.1994.1110; SHAKHNOVICH EI, 1994, PHYS REV LETT, V72, P390; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; THIRUMALAI D, 1995, BIOPOLYMERS, V35, P137, DOI 10.1002/bip.360350114	14	971	988	2	111	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1619	1620		10.1126/science.7886447	http://dx.doi.org/10.1126/science.7886447			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886447				2022-12-28	WOS:A1995QM39700027
J	WANG, T; XIE, ZP; LU, B				WANG, T; XIE, ZP; LU, B			NITRIC-OXIDE MEDIATES ACTIVITY-DEPENDENT SYNAPTIC SUPPRESSION AT DEVELOPING NEUROMUSCULAR SYNAPSES	NATURE			English	Article							LONG-TERM POTENTIATION; GLYCERYL TRINITRATE; METHYLENE-BLUE; MESSENGER; MUSCLE; RELAXATION	TEMPORAL correlation between pre- and postsynaptic activities is an important mechanism that regulates synaptic connectivity during development and synaptic plasticity in the adult(1-3). In developing neuromuscular junctions, postsynaptic activity is critical in functional suppression and, ultimately, elimination of the synapses(4-6). Although repetitive postsynaptic firing asynchronous to the presynaptic activity results in a persistent synaptic suppression(7-10), the underlying molecular mechanism remains unknown. Here we provide evidence that nitric oxide (NO), a free radical implicated in several forms of synaptic plasticity(11-15), may serve as a retrograde signal for activity-dependent suppression in the neuromuscular synapse. NO donors and activators of the cyclic GMP pathway suppressed spontaneous and evoked synaptic currents. Moreover, the synaptic suppression induced by repetitive postsynaptic depolarization was prevented by the NO-binding protein haemoglobin and by inhibitors of NO synthase. Thus, synaptic suppression may be triggered by NO released from a postsynaptic myocyte that fires asynchronously to the presynaptic terminal.	ROCHE INST MOLEC BIOL,NUTLEY,NJ 07110				Lu, Bai/A-4018-2012	Lu, Bai/0000-0001-5418-9759				BETZ WJ, 1987, VERTEBRATE NEUROMUSC; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; CONSTAINTINEPAT.M, 1990, A REV NEUROSCI, V13, P129; Crepel F, 1990, Neuroreport, V1, P133, DOI 10.1097/00001756-199010000-00013; DAN Y, 1992, SCIENCE, V256, P1570, DOI 10.1126/science.1317971; GHEZ C, 1991, PRINCIPLE NEURAL SCI; GRUETTER CA, 1981, J PHARMACOL EXP THER, V219, P181; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; IZUMI Y, 1992, SCIENCE, V257, P1273, DOI 10.1126/science.1519065; KIDOKORO Y, 1984, Neuroscience Research, V1, P157, DOI 10.1016/S0168-0102(84)80013-9; LO YJ, 1994, J NEUROSCI, V14, P4684; LO YJ, 1991, SCIENCE, V254, P1019, DOI 10.1126/science.1658939; LO YJ, 1994, J NEUROSCI, V14, P4694; LU B, 1992, NEURON, V8, P521, DOI 10.1016/0896-6273(92)90280-Q; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; RIDGE RMAP, 1984, J NEUROSCI, V4, P2614; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SOUTHAM E, 1991, NEUROSCI LETT, V130, P107, DOI 10.1016/0304-3940(91)90239-P; SRIHARI T, 1978, J NEUROCYTOL, V7, P529, DOI 10.1007/BF01260887; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WOLIN MS, 1982, J BIOL CHEM, V257, P13312	28	169	172	1	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 16	1995	374	6519					262	266		10.1038/374262a0	http://dx.doi.org/10.1038/374262a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM387	7885445				2022-12-28	WOS:A1995QM38700050
J	MASU, M; IWAKABE, H; TAGAWA, Y; MIYOSHI, T; YAMASHITA, M; FUKUDA, Y; SASAKI, H; HIROI, K; NAKAMURA, Y; SHIGEMOTO, R; TAKADA, M; NAKAMURA, K; NAKAO, K; KATSUKI, M; NAKANISHI, S				MASU, M; IWAKABE, H; TAGAWA, Y; MIYOSHI, T; YAMASHITA, M; FUKUDA, Y; SASAKI, H; HIROI, K; NAKAMURA, Y; SHIGEMOTO, R; TAKADA, M; NAKAMURA, K; NAKAO, K; KATSUKI, M; NAKANISHI, S			SPECIFIC DEFICIT OF THE ON RESPONSE IN VISUAL TRANSMISSION BY TARGETED DISRUPTION OF THE MGLUR6 GENE	CELL			English	Article							ROD BIPOLAR CELLS; METABOTROPIC GLUTAMATE-RECEPTOR; LATERAL GENICULATE-NUCLEUS; C-LIKE IMMUNOREACTIVITY; MAMMALIAN RETINA; FIELD PROPERTIES; OLFACTORY-BULB; CONDUCTANCE; PROTEIN; ELECTRORETINOGRAM	Taking advantage of the restricted expression of metabotropic glutamate receptor subtype 6 (mGluR6) in retinal ON bipolar cells, we generated knockout mice lacking mGluRG6expression. The homozygous mutant mice showed a loss of ON responses but unchanged OFF responses to light. The mutant mice displayed no obvious changes in retinal cell organization nor in the projection of optic fibers to the brain. Furthermore, the mGluR6-deficient mice showed visual behavioral responses to light stimulation as examined by shuttle box avoidance behavior experiments using light exposure as a conditioned stimulus. The results demonstrate that mGluR6 is essential in synaptic transmission to the ON bipolar cell and that the OFF response provides an important means for transmitting visual information.	KYOTO UNIV,FAC MED,DEPT OPHTHALMOL,KYOTO 606,JAPAN; KYOTO UNIV,FAC MED,DEPT MORPHOL BRAIN SCI,KYOTO 606,JAPAN; OSAKA UNIV,SCH MED,DEPT PHYSIOL,OSAKA 565,JAPAN; HYOGO MED UNIV,DEPT PHYSIOL,NISHINOMIYA,HYOGO 663,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT ANAT,TOKYO 113,JAPAN; KYUSHU UNIV,MED INST BIOREGULAT,FUKUOKA 812,JAPAN	Kyoto University; Kyoto University; Osaka University; Hyogo College of Medicine; University of Hyogo; Tokyo Medical & Dental University (TMDU); Kyushu University	MASU, M (corresponding author), KYOTO UNIV,FAC MED,INST IMMUNOL,KYOTO 606,JAPAN.		Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444				AKAZAWA C, 1994, NEUROSCI LETT, V171, P52, DOI 10.1016/0304-3940(94)90602-5; ASHMORE JF, 1980, J PHYSIOL-LONDON, V300, P115, DOI 10.1113/jphysiol.1980.sp013155; BARNSTABLE CJ, 1985, DEV BRAIN RES, V20, P286, DOI 10.1016/0165-3806(85)90116-6; BARNSTABLE CJ, 1984, NEUROSCIENCE, V11, P847, DOI 10.1016/0306-4522(84)90195-7; BURESOVA O, 1976, TECHNIQUES BASIC EXP, P91; DAW NW, 1990, TRENDS NEUROSCI, V13, P110, DOI 10.1016/0166-2236(90)90187-F; DEVRIES SH, 1993, CELL, V72, P139, DOI 10.1016/S0092-8674(05)80033-9; DEVRIES SH, 1993, NEURON S, V10, P139; DODT E, 1951, NATURE, V168, P738, DOI 10.1038/168738a0; FUKUDA Y, 1978, JPN J PHYSIOL, V28, P385; GREFERATH U, 1990, J COMP NEUROL, V301, P433, DOI 10.1002/cne.903010308; HAYASHI Y, 1993, NATURE, V366, P687, DOI 10.1038/366687a0; HAYHOW WR, 1962, J COMP NEUROL, V118, P295, DOI 10.1002/cne.901180303; HORTON JC, 1984, J NEUROSCI, V4, P374; INOUE A, 1992, J BIOL CHEM, V267, P10613; KNAPP AG, 1983, J NEUROPHYSIOL, V50, P1236, DOI 10.1152/jn.1983.50.5.1236; KNAPP AG, 1984, VISION RES, V24, P1841, DOI 10.1016/0042-6989(84)90016-6; KOLB H, 1994, OPHTHALMOL VIS SCI, V35, P2385; MESULAM MM, 1978, J HISTOCHEM CYTOCHEM, V26, P106, DOI 10.1177/26.2.24068; MILLER RF, 1986, TRENDS NEUROSCI, V9, P211, DOI 10.1016/0166-2236(86)90061-5; NAKAJIMA Y, 1993, J BIOL CHEM, V268, P11868; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NAWY S, 1991, NEURON, V7, P677, DOI 10.1016/0896-6273(91)90380-I; NAWY S, 1990, NATURE, V346, P269, DOI 10.1038/346269a0; NEGISHI K, 1988, NEUROSCI LETT, V94, P247, DOI 10.1016/0304-3940(88)90025-0; NOMURA A, 1994, CELL, V77, P361, DOI 10.1016/0092-8674(94)90151-1; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; SASAKI H, 1993, PROG BRAIN RES, V95, P103, DOI 10.1016/S0079-6123(08)60361-1; SCHILLER PH, 1982, NATURE, V297, P580, DOI 10.1038/297580a0; SCHILLER PH, 1986, NATURE, V322, P824, DOI 10.1038/322824a0; SCHILLER PH, 1992, TRENDS NEUROSCI, V15, P86, DOI 10.1016/0166-2236(92)90017-3; Schiller PH, 1984, HDB PHYSL, VIII, P457; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SHERK H, 1984, J NEUROSCI, V4, P381; SHIELLS RA, 1990, P ROY SOC B-BIOL SCI, V242, P91, DOI 10.1098/rspb.1990.0109; SLAUGHTER MM, 1981, SCIENCE, V211, P182, DOI 10.1126/science.6255566; Steinberg RH., 1991, PROGR RETINAL RES, V10, P121, DOI 10.1016/0278-4327(91)90011-P; STOCKTON RA, 1989, J GEN PHYSIOL, V93, P101, DOI 10.1085/jgp.93.1.101; TESSIERLAVIGNE M, 1991, PRINCIPLES NEURAL SC, P400; WASSLE H, 1991, VISUAL NEUROSCI, V7, P99, DOI 10.1017/S095252380001097X; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; Wurst W., 1993, Gene targeting: a practical approach., P33	43	392	402	1	11	CELL PRESS	CAMBRIDGE	50 CHURCH ST CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	MAR 10	1995	80	5					757	765		10.1016/0092-8674(95)90354-2	http://dx.doi.org/10.1016/0092-8674(95)90354-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	QM399	7889569	Bronze			2022-12-28	WOS:A1995QM39900012
J	PRANGE, R; ENGLE, IM; CLARKE, JT; DUNLOP, M; BALLESTER, GE; IP, WH; MAURICE, S; TRAUGER, J				PRANGE, R; ENGLE, IM; CLARKE, JT; DUNLOP, M; BALLESTER, GE; IP, WH; MAURICE, S; TRAUGER, J			AURORAL SIGNATURE OF COMET SHOEMAKER-LEVY-9 IN THE JOVIAN MAGNETOSPHERE	SCIENCE			English	Article								The electrodynamic interaction of the dust and gas comae of comet Shoemaker-Levy 9 with the jovian magnetosphere was unique and different from the atmospheric effects. Early theoretical predictions of auroral-type processes on the comet magnetic field line and advanced modeling of the time-varying morphology of these lines allowed dedicated observations with the Hubble Space Telescope Wide Field Planetary Camera 2 and resulted in the detection of a bright auroral spot, In that respect, this observation of the surface signature of an externally triggered auroral process can be considered as a ''magnetospheric active experiment'' on Jupiter.	INST ASTROPHYS,PARIS,FRANCE; USN ACAD,DEPT PHYS,ANNAPOLIS,MD 21402; UNIV MICHIGAN,DEPT ATMOSPHER OCEAN & SPACE SCI,ANN ARBOR,MI 48109; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,SPACE & ATMOSPHER PHYS GRP,LONDON SW7 2BZ,ENGLAND; MAX PLANCK INST AERON,D-37191 KATLENBURG DUHM,GERMANY; EUROPEAN SPACE AGCY,ESTEC,DEPT SPACE SCI,SO,2200 AG NOORDWIJK,NETHERLANDS; JET PROPULS LAB,PASADENA,CA 91109	UDICE-French Research Universities; Sorbonne Universite; United States Department of Defense; United States Navy; United States Naval Academy; University of Michigan System; University of Michigan; Imperial College London; Max Planck Society; European Space Agency; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	PRANGE, R (corresponding author), UNIV PARIS 11,CNRS,INST ASTROPHYS SPATIALE,F-91405 ORSAY,FRANCE.		Clarke, John/C-8644-2013; dunlop, malcolm w/F-1347-2010	dunlop, malcolm w/0000-0002-8195-5137				BOLIN O, 1994, GEOPHYS RES LETT, V21, P1063, DOI 10.1029/94GL00890; CLARKE JT, 1995, SCIENCE, V267, P1302, DOI 10.1126/science.7871427; CONNERNEY JEP, 1981, J GEOPHYS RES-SPACE, V86, P8370, DOI 10.1029/JA086iA10p08370; CONNERNEY JEP, 1992, PLANETARY RADIO EM 3, V13; DOUGHERTY MK, COMMUNICATION; ENGLE I, UNPUB; ENGLE IM, 1992, J GEOPHYS RES-SPACE, V97, P17169, DOI 10.1029/92JA02036; ENGLE IM, 1991, J GEOPHYS RES-SPACE, V96, P7793, DOI 10.1029/90JA02391; FARRELL WM, 1994, GEOPHYS RES LETT, V21, P1067, DOI 10.1029/94GL01066; FELDMAN PD, 1994, 6027 INT ASTR UN CIR; GERARD JC, 1993, J GEOPHYS RES-PLANET, V98, P18793, DOI 10.1029/93JE01334; GERARD JC, IN PRESS PLANET SPAC; HERBERT F, 1994, GEOPHYS RES LETT, V21, P1047, DOI 10.1029/94GL00884; IP WH, 1994, GEOPHYS RES LETT, V21, P1051, DOI 10.1029/94GL01063; KELLOGG PJ, 1994, GEOPHYS RES LETT, V21, P1055, DOI 10.1029/94GL01293; LIPATOV AS, 1994, GEOPHYS RES LETT, V21, P1059, DOI 10.1029/94GL01295; MOURENAS D, 1993, PLANET SPACE SCI, V41, P347, DOI 10.1016/0032-0633(93)90068-D; WEAVER HA, 1995, SCIENCE, V267, P1282, DOI 10.1126/science.7871424	18	14	14	0	4	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1317	1320		10.1126/science.7871430	http://dx.doi.org/10.1126/science.7871430			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871430				2022-12-28	WOS:A1995QK06800035
J	STAHL, N; FARRUGGELLA, TJ; BOULTON, TG; ZHONG, Z; DARNELL, JE; YANCOPOULOS, GD				STAHL, N; FARRUGGELLA, TJ; BOULTON, TG; ZHONG, Z; DARNELL, JE; YANCOPOULOS, GD			CHOICE OF STATS AND OTHER SUBSTRATES SPECIFIED BY MODULAR TYROSINE-BASED MOTIFS IN CYTOKINE RECEPTORS	SCIENCE			English	Article							GAMMA SIGNAL-TRANSDUCTION; INTERFERON-ALPHA/BETA; KINASE; PATHWAY; GP-130; FAMILY; JAK2	Many members of the cytokine receptor superfamily initiate intracellular signaling by activating members of the Jak family of tyrosine kinases. Activation of the same Jaks by multiple cytokines raises the question of how these cytokines activate distinct intracellular signaling pathways. Selection of particular substrates-the transcriptional activator Stat3 and protein tyrosine phosphatase PTP1D-that characterize responses to the ciliary neurotrophic factor-interleukin-6 cytokine family depended not on which Jak was activated, but was instead determined by specific tyrosine-based motifs in the receptor components-gp130 and LIFR-shared by these cytokines. Further, these tyrosine-based motifs were modular, because addition of a Stat3-specifying motif to another cytokine receptor, that for erythropoietin, caused it to activate Stat3 in a ligand-dependent fashion.	ROCKEFELLER UNIV, MOLEC CELL BIOL LAB, NEW YORK, NY 10021 USA	Rockefeller University	STAHL, N (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOULTON TG, 1994, J BIOL CHEM, V269, P11648; CAMPBELL GS, 1994, P NATL ACAD SCI USA, V91, P5232, DOI 10.1073/pnas.91.12.5232; CASE RD, 1994, J BIOL CHEM, V269, P10467; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; IHLE JN, 1994, P SOC EXP BIOL MED, V206, P268; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, UNPUB; VALENZUELA DM, 1993, NEURON, V10, P963, DOI 10.1016/0896-6273(93)90211-9; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	33	876	890	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 3	1995	267	5202					1349	1353		10.1126/science.7871433	http://dx.doi.org/10.1126/science.7871433			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871433				2022-12-28	WOS:A1995QK06800046
J	WELL, D; BLANCHARD, S; KAPLAN, J; GUILFORD, P; GIBSON, F; WALSH, J; MBURU, P; VARELA, A; LEVILLERS, J; WESTON, MD; KELLEY, PM; KIMBERLING, WJ; WAGENAAR, M; LEVIACOBAS, F; LARGETPIET, D; MUNNICH, A; STEEL, KP; BROWN, SDM; PETIT, C				WELL, D; BLANCHARD, S; KAPLAN, J; GUILFORD, P; GIBSON, F; WALSH, J; MBURU, P; VARELA, A; LEVILLERS, J; WESTON, MD; KELLEY, PM; KIMBERLING, WJ; WAGENAAR, M; LEVIACOBAS, F; LARGETPIET, D; MUNNICH, A; STEEL, KP; BROWN, SDM; PETIT, C			DEFECTIVE MYOSIN VIIA GENE RESPONSIBLE FOR USHER SYNDROME TYPE 1B	NATURE			English	Article							SYNDROME TYPE-I; NASAL CILIA; HAIR-CELLS; CHROMOSOME-11; LINKAGE; MOTOR; MAPS	USHER syndrome represents the association of a hearing impairment with retinitis pigmentosa(1) and is the most frequent cause of deaf-blindness in humans. it is inherited as an autosomal recessive trait which is clinically and genetically heterogeneous(2,3). Some patients show abnormal organization of microtubules in the axoneme of their photoreceptors cells (connecting cilium)(4-6), nasal ciliar cells(7) and sperm cells(5), as well as widespread degeneration of the organ of Corti(8). Usher syndrome type 1 (USH1) is characterized by a profound congenital sensorineural hearing loss, constant vestibular dysfunction and prepubertal onset of retinitis pigmentosa. Of three different genes responsible for USH1(9-11) USH1B maps to 11q13.5 (ref. 10) and accounts for about 75% of USH1 patients(2,3). The mouse deafness shaker-1 (sh1) mutation has been localized to the homologous murine region(12,13). Taking into account the cytoskeletal abnormalities in USH patients, the identification of a gene encoding an unconventional myosin as a candidate for shaker-1 (ref. 14) led us to consider the human homologue as a good candidate for the gene that is defective in USH1B. Here we present evidence that a gene encoding myosin VIIA is responsible for USH1B. Two different premature stop codons, a six-base-pair deletion and two different missense mutations were detected in five unrelated families. In one of these families, the mutations were identified in both alleles. These mutations, which are located at the amino-terminal end of the motor domain of the protein, are likely to result in the absence of a functional protein. Thus USH1B appears as a primary cytoskeletal protein defect. These results implicate the genes encoding other unconventional myosins and their interacting proteins as candidates for other genetic forms of Usher syndrome.	INST PASTEUR, CNRS, UNITE GENET MOLEC HUMAINE 1968, F-75724 PARIS 15, FRANCE; HOP NECKER ENFANTS MALAD, INSERM, U393, UNITE RECH HANDICAPS GENET ENFANT, F-75743 PARIS 15, FRANCE; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, ST MARYS HOSP, SCH MED, DEPT BIOCHEM & MOLEC GENET, LONDON W2 1PG, ENGLAND; BOYS TOWN NATL RES HOSP, DEPT PATHOL, OMAHA, NE 68131 USA; CATHOLIC UNIV NIJMEGEN, ST RADBOUD HOSP, 6500 HB NIJMEGEN, NETHERLANDS; MRC, INST HEARING RES, NOTTINGHAM NG7 2RD, ENGLAND	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Imperial College London; Boys Town National Research Hospital; Radboud University Nijmegen				Guilford, Parry/0000-0002-7256-9576				ADAMS RJ, 1989, CELL MOTIL CYTOSKEL, V14, P178, DOI 10.1002/cm.970140203; ARDEN GB, 1979, NATURE, V279, P534, DOI 10.1038/279534a0; ASSAD JA, 1992, J NEUROSCI, V12, P3291; BARRONG SD, 1992, ARCH OPHTHALMOL-CHIC, V110, P706, DOI 10.1001/archopht.1992.01080170128040; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BONNEAU D, 1993, J MED GENET, V30, P253, DOI 10.1136/jmg.30.3.253; BROWN KA, 1992, GENOMICS, V13, P189, DOI 10.1016/0888-7543(92)90219-I; BROWN SDM, 1994, HUM MOL GENET, V3, P1453, DOI 10.1093/hmg/3.suppl_1.1453; CHENEY RE, 1993, CELL MOTIL CYTOSKEL, V24, P215, DOI 10.1002/cm.970240402; COLLUCIO LM, 1989, J CELL BIOL, V108, P495; EVANS KL, 1993, HUM MOL GENET, V2, P115, DOI 10.1093/hmg/2.2.115; GIBSON F, 1995, NATURE, V374, P62, DOI 10.1038/374062a0; GILLESPIE PG, 1993, NEURON, V11, P581, DOI 10.1016/0896-6273(93)90071-X; GUILFORD P, 1994, HUM MOL GENET, V3, P989, DOI 10.1093/hmg/3.6.989; HUNTER DG, 1986, ARCH OPHTHALMOL-CHIC, V104, P385; JAEGER RG, 1994, HEARING RES, V77, P207, DOI 10.1016/0378-5955(94)90268-2; KAPLAN J, 1992, GENOMICS, V14, P979, DOI 10.1016/S0888-7543(05)80120-X; KIMBERLING WJ, 1992, GENOMICS, V14, P988, DOI 10.1016/S0888-7543(05)80121-1; LARGETPIET D, 1994, GENOMICS, V21, P138, DOI 10.1006/geno.1994.1235; MERCER JA, 1991, NATURE, V349, P709, DOI 10.1038/349709a0; METCALF AB, 1994, P NATL ACAD SCI USA, V91, P11821, DOI 10.1073/pnas.91.25.11821; PIPERNO G, 1990, J CELL BIOL, V110, P379, DOI 10.1083/jcb.110.2.379; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SHINKAWA H, 1986, ANN OTO RHINOL LARYN, V95, P313, DOI 10.1177/000348948609500321; SMITH RJH, 1992, GENOMICS, V14, P995, DOI 10.1016/S0888-7543(05)80122-3; SMITH RJH, 1994, AM J MED GENET, V50, P32, DOI 10.1002/ajmg.1320500107; STEELKP, 1994, TRENDS GENET SCI, V10, P428; TILNEY LG, 1992, ANNU REV CELL BIOL, V8, P257, DOI 10.1146/annurev.cb.08.110192.001353; USHER CR, 1913, LOND OPHTHAL HOSDP R, V19, P130; WILLIAMS DS, 1992, J CELL SCI, V103, P183	31	831	849	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAR 2	1995	374	6517					60	61		10.1038/374060a0	http://dx.doi.org/10.1038/374060a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870171				2022-12-28	WOS:A1995QK07900051
J	YANG, JH; SKLAR, P; AXEL, R; MANIATIS, T				YANG, JH; SKLAR, P; AXEL, R; MANIATIS, T			EDITING OF GLUTAMATE-RECEPTOR SUBUNIT-B PRE-MESSENGER-RNA IN-VITRO BY SITE-SPECIFIC DEAMINATION OF ADENOSINE	NATURE			English	Article							UNWINDING ACTIVITY; CA2+ PERMEABILITY; ION FLOW; CHANNELS; RNA; DETERMINANTS	EDITING Of the glutamate receptor subunit B (GluR-B) pre-mRNA at a single adenosine residue results in an amino-acid change that profoundly alters the electrophysiological properties of the (1-7). Here we show that the GluR-B pre-mRNA is efficiently and accurately edited in vitro, and that base-pair interactions between the editing site and a sequence in the downstream introns are required for substrate recognition. In addition, we directly demonstrate that editing results from the conversion of adenosine to inosine by enzymatic deamination. The biochemical properties of this GluR-B editing activity are similar to those of a double-stranded-RNA-dependent adenosine deaminase(9-15), but RNA competition and column fractionation experiments indicate that the GluR-B editing and deaminase activities are distinct. Thus, the GluR-B editing enzyme may contain the adenosine deaminase, or a similar activity, and an RNA recognition subunit that specifically targets the enzyme to the editing site.	COLUMBIA UNIV,DEPT PSYCHIAT,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV,DEPT BIOCHEM,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute; Columbia University	YANG, JH (corresponding author), HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,7 DIVIN AVE,CAMBRIDGE,MA 01238, USA.			Axel, Richard/0000-0002-3141-4076				BAS BL, 1993, RNA WORLD, P383; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; Bass Brenda L., 1992, Seminars in Developmental Biology, V3, P425; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; KIM U, 1994, J BIOL CHEM, V269, P13480; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; MOORE MJ, 1993, SCIENCE, V256, P992; PASCHEN W, 1994, J NEUROCHEM, V63, P1596, DOI 10.1046/j.1471-4159.1994.63051596.x; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SMITH CWJ, 1989, NATURE, V342, P243, DOI 10.1038/342243a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647	21	115	118	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 2	1995	374	6517					77	81		10.1038/374077a0	http://dx.doi.org/10.1038/374077a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK079	7870177				2022-12-28	WOS:A1995QK07900057
J	BLAND, JM; ALTMAN, DG				BLAND, JM; ALTMAN, DG			STATISTICS NOTES .12. CALCULATING CORRELATION-COEFFICIENTS WITH REPEATED OBSERVATIONS .1. CORRELATION WITHIN-SUBJECTS	BRITISH MEDICAL JOURNAL			English	Article									IMPERIAL CANC RES FUND,MED STAT LAB,LONDON WC2A 3PX,ENGLAND	Cancer Research UK	BLAND, JM (corresponding author), ST GEORGE HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							Altman DG, 1991, PRACTICAL STATISTICS; Armitage P., 1994, STAT METHODS MED RES, V3; BLAND JM, 1994, BRIT MED J, V308, P896, DOI 10.1136/bmj.308.6933.896; BOYD O, 1993, LANCET, V341, P142, DOI 10.1016/0140-6736(93)90005-2	4	842	845	1	34	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 18	1995	310	6977					446	446		10.1136/bmj.310.6977.446	http://dx.doi.org/10.1136/bmj.310.6977.446			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ242	7873953	Green Published, Bronze			2022-12-28	WOS:A1995QJ24200024
J	BRAVEMAN, P; SCHAAF, VM; EGERTER, S; BENNETT, T; SCHECTER, W				BRAVEMAN, P; SCHAAF, VM; EGERTER, S; BENNETT, T; SCHECTER, W			INSURANCE-RELATED DIFFERENCES IN THE RISK OF RUPTURED APPENDIX	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FEE-FOR-SERVICE; RANDOMIZED CONTROLLED TRIAL; HEALTH-INSURANCE; RESOURCE UTILIZATION; HOSPITAL PATIENTS; PRENATAL-CARE; MEDICAL-CARE; MASSACHUSETTS; COVERAGE; OUTCOMES	Background. We studied differences in the incidence of appendiceal perforation in patients with acute appendicitis according to their insurance coverage. Methods. In a retrospective analysis of hospital-discharge data, we examined the likelihood of ruptured appendix among adults 18 to 64 years old who were hospitalized for acute appendicitis in California from 1984 to 1989. Results. After controlling for age, sex, psychiatric diagnoses, substance abuse, diabetes, poverty, race or ethnic group, and hospital characteristics, we found that ruptured appendix was more likely among both Medicaid-covered and uninsured patients with appendicitis than among patients with private capitated coverage (odds ratios, 1.49 [95 percent confidence interval, 1.41 to 1.59] and 1.46 [95 percent confidence interval, 1.39 to 1.54], respectively). After adjustment for the above factors, the risk of appendiceal rupture associated with a lack of private in-surance was elevated at both county and other hospitals, but admission to a county hospital was an independent risk factor. In all income groups, appendiceal rupture was more likely with fee-for-service than capitated private coverage (overall odds ratio, 1.20 [95 percent confidence interval, 1.15 to 1.25]). Conclusions. Among patients with appendicitis an increased risk of ruptured appendix may be due to insurance-related delays in obtaining medical care. Both organizational and financial features of Medicaid and various types or levels of private third-party coverage may be involved. The significant association between ruptured appendix and insurance coverage after adjustment for socioeconomic differences suggests barriers to receiving medically necessary acute care that should be considered in current deliberations on health policy.	UNIV CALIF SAN FRANCISCO,DEPT SURG,SAN FRANCISCO,CA 94143; SAN FRANCISCO GEN HOSP,MED CTR,DEPT MED,SAN FRANCISCO,CA 94110; SAN FRANCISCO GEN HOSP,MED CTR,DEPT SURG,SAN FRANCISCO,CA 94110	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center	BRAVEMAN, P (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,BOX 0900,SAN FRANCISCO,CA 94143, USA.							ADAY LA, 1984, ACCESS MED CARE; ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BILLINGS J, 1990, HEALTH AFFAIR, V9, P158, DOI 10.1377/hlthaff.9.4.158; BILLINGS J, 1990, CONSIDERATION USE SM; BLUMBERG MS, 1991, 169504 HOSP RES ED T; BRAVEMAN P, 1993, JAMA-J AM MED ASSOC, V269, P1285, DOI 10.1001/jama.269.10.1285; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BRAVEMAN PA, 1991, JAMA-J AM MED ASSOC, V266, P3300, DOI 10.1001/jama.266.23.3300; BRENDER JD, 1985, PEDIATRICS, V76, P301; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BUCHMAN TG, 1984, SURG GYNECOL OBSTET, V158, P260; BURSTIN HR, 1993, JAMA-J AM MED ASSOC, V270, P845, DOI 10.1001/jama.270.7.845; EPSTEIN AM, 1988, NEW ENGL J MED, V318, P1579, DOI 10.1056/NEJM198806163182405; FOSSETT JW, 1992, J HEALTH POLIT POLIC, V17, P273, DOI 10.1215/03616878-17-2-273; FOSSETT JW, 1990, MILBANK Q, V68, P111, DOI 10.2307/3350079; FRANKS P, 1993, AM J PUBLIC HEALTH, V83, P1295, DOI 10.2105/AJPH.83.9.1295; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; HAAS JS, 1993, JAMA-J AM MED ASSOC, V269, P87, DOI 10.1001/jama.269.1.87; HADLEY J, 1991, JAMA-J AM MED ASSOC, V265, P374, DOI 10.1001/jama.265.3.374; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; HUTTON N, 1985, EFFECTIVENESS MED CA, P120; KLEIN SR, 1988, POSTGRAD MED, V83, P247; LUCKMANN R, 1990, AM J EPIDEMIOL, V131, P1102; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; NEWHOUSE JP, 1981, NEW ENGL J MED, V305, P1501, DOI 10.1056/NEJM198112173052504; OGRADY KF, 1985, NEW ENGL J MED, V313, P484, DOI 10.1056/NEJM198508223130806; Pieper R, 1986, Acta Chir Scand Suppl, V530, P51; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; RICCI MA, 1988, AM SURGEON, V54, P273; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SCHER KS, 1980, SURG GYNECOL OBSTET, V150, P535; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SIU AL, 1988, JAMA-J AM MED ASSOC, V259, P1343, DOI 10.1001/jama.259.9.1343; STAFFORD RS, 1990, AM J PUBLIC HEALTH, V80, P313, DOI 10.2105/AJPH.80.3.313; STERN RS, 1989, ARCH INTERN MED, V149, P1185, DOI 10.1001/archinte.149.5.1185; UDVARHELYI IS, 1991, ANN INTERN MED, V115, P394, DOI 10.7326/0003-4819-115-5-394; WAY LW, 1988, CURRENT SURGICAL DIA, P556; WEISSMAN J, 1989, JAMA-J AM MED ASSOC, V261, P3572, DOI 10.1001/jama.261.24.3572; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WENNEKER MB, 1990, JAMA-J AM MED ASSOC, V264, P1255, DOI 10.1001/jama.264.10.1255; WOOLHANDLER S, 1988, JAMA-J AM MED ASSOC, V259, P2872; YELIN EH, 1985, NEW ENGL J MED, V312, P962, DOI 10.1056/NEJM198504113121506; 1991, INT CLASSIFICATION D; 1985, SAS USERS GUIDE STAT; 1989, 1989 1990 DIRECTORY	50	195	196	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 18	1994	331	7					444	449		10.1056/NEJM199408183310706	http://dx.doi.org/10.1056/NEJM199408183310706			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	PB501	7880234	Bronze			2022-12-28	WOS:A1994PB50100006
J	EVANS, DN				EVANS, DN			A VISIT TO WAKLEY,THOMAS	LANCET			English	Editorial Material											EVANS, DN (corresponding author), ST THOMAS COURT,CHURCH ST,AXMINSTER EX13 5AG,DEVON,ENGLAND.								0	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1535	1536		10.1016/S0140-6736(05)80092-3	http://dx.doi.org/10.1016/S0140-6736(05)80092-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902908				2022-12-28	WOS:A1993MM40200019
J	THOMPSON, C				THOMPSON, C			A SLIPPERY DEFENSE AGAINST HIV	LANCET			English	Editorial Material																		LEHNER T, 1993, P NATL ACAD SCI USA, V90, P8638, DOI 10.1073/pnas.90.18.8638; LEHNER T, 1992, SCIENCE, V258, P1365, DOI 10.1126/science.1360702; LEHNER T, IN PRESS J VIROL	3	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 18	1993	342	8886-7					1500	1500		10.1016/S0140-6736(05)80077-7	http://dx.doi.org/10.1016/S0140-6736(05)80077-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902894				2022-12-28	WOS:A1993MM40200004
J	BEDARIDA, GV; KIM, D; BLASCHKE, TF; HOFFMAN, BB				BEDARIDA, GV; KIM, D; BLASCHKE, TF; HOFFMAN, BB			VENODILATION IN RAYNAUDS-DISEASE	LANCET			English	Article							SUPERFICIAL HAND VEINS; NITRIC-OXIDE; L-ARGININE; SYSTEMIC-SCLEROSIS; ENDOTHELIUM; RESPONSIVENESS; PHENYLEPHRINE; RELAXATION; RESPONSES; THERAPY	The pathogenesis of Raynaud's disease is unclear; an enhanced reponse to catecholamines has been hypothesised to contribute to this vasospastic disorder. Impaired endothelium-dependent dilation occurs in other diseases associated with vasospasm, such as coronary atherosclerosis. We investigated both endothelium-dependent and endothelium-independent venodilatory function in Raynaud's disease using the hand-vein compliance technique. Full dose-response curves to noradrenaline were constructed in 10 subjects with primary Raynaud's disease and 10 age and sex matched control subjects. The two groups did not have a different response to noradrenaline. Mean (SD) log values of ED50s (the dose producing half maximum response) were 1.00 (0.59) (geometric mean 10 ng/min) in Raynaud's disease compared with 1.29 (0.66) (20 ng/min) in control subjects (p = 0.16). The efficacy of noradrenaline as a venoconstrictor was similar in the two groups: mean maximum dilation (E(max)) to noradrenaline was 81 (14)% in the Raynaud's group and 89 (8)% in the control group (p = 0.08). Full dose-response curves to the endothelium-dependent dilator bradykinin were constructed. E(max) to bradykinin was significantly lower in the Raynaud's group than in the control group (65 [21] vs 91 [29%], p = 0.02). ED50 values (doses producing half maximum response) for bradykinin were similar in the two groups. Maximum dilation with nitroprusside, a direct releaser of the vasodilator nitric oxide, was not diminished in the Raynaud's group (94 [23] vs 102 [15]% in controls, p = 0.26). These results suggest that endothelium-dependent venodilation is impaired in peripheral vessels in Raynaud's disease, possibly due to diminished release of nitric oxide, and may contribute to the pathogenesis of the disorder.	STANFORD UNIV, MED CTR, DIV CLIN PHARMACOL, STANFORD, CA 94305 USA; VET ADM MED CTR, CTR GERIATR RES EDUC & CLIN, PALO ALTO, CA 94304 USA	Stanford University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)				Blaschke, Terrence/0000-0001-5307-2620	NIA NIH HHS [AG 05627] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AELLIG WH, 1981, BRIT J CLIN PHARMACO, V11, P237, DOI 10.1111/j.1365-2125.1981.tb00527.x; AGOSTONI A, 1991, INT J CLIN LAB RES, V21, P202; Allen EV, 1932, AM J MED SCI, V183, P187, DOI 10.1097/00000441-193202000-00004; ARNOLD JMO, 1993, ANN INTERN MED, V118, P619, DOI 10.7326/0003-4819-118-8-199304150-00008; COFFMAN JD, 1991, HYPERTENSION, V17, P593, DOI 10.1161/01.HYP.17.5.593; COLLIER JG, 1972, CLIN SCI, V43, P455, DOI 10.1042/cs0430455; DACHMAN WD, 1993, J CARDIOVASC PHARM, V21, P241, DOI 10.1097/00005344-199302000-00009; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; DREXLER H, 1991, HYPERTENSION, V18, P90, DOI 10.1161/01.HYP.18.4_Suppl.II90; EDWARDS JM, 1987, J VASC SURG, V5, P38, DOI 10.1067/mva.1987.avs0050038; EICHLER HG, 1989, CLIN SCI, V76, P283, DOI 10.1042/cs0760283; EICHLER HG, 1989, J CLIN INVEST, V83, P108, DOI 10.1172/JCI113845; FLEMING WW, 1972, J PHARMACOL-PARIS, V181, P339; FREEDMAN RR, 1989, ARTHRITIS RHEUM, V32, P61, DOI 10.1002/anr.1780320110; FREEMONT AJ, 1992, BRIT J DERMATOL, V126, P561; FURCHGOTT RF, 1984, ANNU REV PHARMACOL, V24, P175, DOI 10.1146/annurev.pa.24.040184.001135; GRAAFSMA SJ, 1991, CLIN SCI, V80, P325, DOI 10.1042/cs0800325; LIU M-F, 1991, Taiwan yixuehui zazhi, V90, P221; MARASINI B, 1992, INT J MICROCIRC, V11, P375; MATUCCICERINIC M, 1990, CLIN EXP RHEUMATOL, V8, P561; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; OKEEFFE ST, 1992, ANN INTERN MED, V116, P985, DOI 10.7326/0003-4819-116-12-985; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PAN HYM, 1986, J PHARMACOL EXP THER, V239, P802; RAYNAUD M, 1888, LOCAL ASPHYXIA SYMME, P99; TERBORG EJ, 1990, SEMIN ARTHRITIS RHEU, V20, P164, DOI 10.1016/0049-0172(90)90057-M; VALLANCE P, 1989, CARDIOVASC RES, V23, P1053, DOI 10.1093/cvr/23.12.1053; VINCENT J, 1992, CLIN PHARMACOL THER, V51, P68, DOI 10.1038/clpt.1992.9; WOLLERSHEIM H, 1989, EUR J CLIN INVEST, V19, P535, DOI 10.1111/j.1365-2362.1989.tb00271.x	31	50	50	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 11	1993	342	8885					1451	1454		10.1016/0140-6736(93)92932-J	http://dx.doi.org/10.1016/0140-6736(93)92932-J			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML217	7902481				2022-12-28	WOS:A1993ML21700008
J	REES, M				REES, M			MENARCHE WHEN AND WHY	LANCET			English	Editorial Material											REES, M (corresponding author), JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND.							DANN TC, 1993, J BIOSOC SCI, V25, P531, DOI 10.1017/S0021932000021908; FRISCH RE, 1990, BAILLIERE CLIN OB GY, V4, P419, DOI 10.1016/S0950-3552(05)80302-5; KJAER K, 1992, J CLIN ENDOCR METAB, V75, P524, DOI 10.1210/jc.75.2.524; MOISAN J, 1990, AM J EPIDEMIOL, V132, P953, DOI 10.1093/oxfordjournals.aje.a115738; Rosetta L, 1993, Oxf Rev Reprod Biol, V15, P113	5	55	55	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1375	1376		10.1016/0140-6736(93)92746-G	http://dx.doi.org/10.1016/0140-6736(93)92746-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MK095	7901675				2022-12-28	WOS:A1993MK09500003
J	SCOTT, RAP; WILSON, NM; ASHTON, HA; KAY, DN				SCOTT, RAP; WILSON, NM; ASHTON, HA; KAY, DN			IS SURGERY NECESSARY FOR ABDOMINAL AORTIC-ANEURYSM LESS-THAN 6 CM IN DIAMETER	LANCET			English	Note								During 8 years of an ultrasound screening programme for abdominal aortic aneurysm (AAA), 8944 people aged 65-80 years were scanned. 356 (4%) had AAA of diameter 3 cm or greater. Under our criteria repair was indicated if the aortic diameter reached 6 cm, if expansion reached 1 cm per year, or if the AAA caused symptoms; 124 patients met these criteria. Among the 8820 screened patients who did not meet the criteria, 1 death (0.4%) was attributed to ruptured aneurysm, although the retroperitoneal haematoma had developed within 5 days of surgery for a colon tumour. The risk of aortic rupture in patients with AAA less than 6 cm diameter with these criteria (0.4%) is lower than that for elective surgery (1-8%). Surgical repair is unnecessary and possibly detrimental in such patients, provided that ultrasound surveillance is undertaken.	ST RICHARDS HOSP,DEPT RADIOL,CHICHESTER PO19 4SE,W SUSSEX,ENGLAND		SCOTT, RAP (corresponding author), ST RICHARDS HOSP,SCOTT RES UNIT,SPITALFIELD LANE,CHICHESTER PO19 4SE,W SUSSEX,ENGLAND.							Campbell W B, 1991, Eur J Vasc Surg, V5, P111; COLLIN J, 1987, LANCET, V1, P909; COOLEY DA, 1984, CIRCULATION, V70, P1; DARLING RC, 1977, CIRCULATION, V56, P161; INGOLDBY CJH, 1986, BRIT J SURG, V73, P551, DOI 10.1002/bjs.1800730711; Johansson G, 1990, Eur J Vasc Surg, V4, P497, DOI 10.1016/S0950-821X(05)80791-1; SCOTT A, 1992, ANN ROY COLL SURG, V74, P205; SCOTT RAP, 1991, BRIT J SURG, V78, P1122, DOI 10.1002/bjs.1800780929; SZILAGYI DE, 1972, ARCH SURG-CHICAGO, V104, P600; TURK KAD, 1965, P ROY SOC MED, V58, P869, DOI 10.1177/003591576505811P109	10	64	64	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 4	1993	342	8884					1395	1396		10.1016/0140-6736(93)92756-J	http://dx.doi.org/10.1016/0140-6736(93)92756-J			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK095	7901685				2022-12-28	WOS:A1993MK09500013
J	SUHARNO, D; WEST, CE; MUHILAL; KARYADI, D; HAUTVAST, JGAJ				SUHARNO, D; WEST, CE; MUHILAL; KARYADI, D; HAUTVAST, JGAJ			SUPPLEMENTATION WITH VITAMIN-A AND IRON FOR NUTRITIONAL ANEMIA IN PREGNANT-WOMEN IN WEST-JAVA, INDONESIA	LANCET			English	Article							CHILDREN; METABOLISM; DEFICIENCY	Nutritional anaemia, thought to be caused by iron deficiency, affects 50-70% of pregnant women in the developing world. The influence of vitamin A and iron supplementation was studied in anaemic pregnant women in West Java, in a randomised, double-masked, placebo-controlled field trial. 251 women aged 17-35 years, parity 0-4, gestation 16-24 weeks, and haemoglobin between 80 and 109 g/L were randomly allocated to four groups: vitamin A (2.4 mg retinol) and placebo iron tablets; iron (60 mg elemental iron) and placebo vitamin A; vitamin A and iron; or both placebos, all daily for 8 weeks. Maximum haemoglobin was achieved with both vitamin A and iron supplementation (12.78 g/L, 95% CI 10.86 to 14.70), with one-third of the response attributable to vitamin A (3.68 g/L, 2.03 to 5.33) and two-thirds to iron (7.71 g/L, 5.97 to 9.45). After supplementation, the proportion of women who became non-anaemic was 35% in the vitamin-A-supplemented group, 68% in the iron-supplemented group, 97% in the group supplemented with both, and 16% in the placebo group. Improvement in vitamin A status may contribute to the control of anaemic pregnant women.	WAGENINGEN UNIV AGR,DEPT HUMAN NUTR,POB 8129,6700 EV WAGENINGEN,NETHERLANDS; CTR RES & DEV NUTR,BOGOR,INDONESIA; EMORY UNIV,SCH PUBL HLTH,CTR INT HLTH,PROGRAM AGAINST MICRONUTRIENT MALNUTRIT,ATLANTA,GA 30322	Wageningen University & Research; Emory University								ARROYAVE G, 1982, BIOCH METHODOLOGY AS; BLOEM MW, 1990, AM J CLIN NUTR, V51, P76, DOI 10.1093/ajcn/51.1.76; BLOEM MW, 1989, AM J CLIN NUTR, V50, P332, DOI 10.1093/ajcn/50.2.332; Cook JD., 1985, MEASUREMENT IRON STA; HODGES RE, 1978, AM J CLIN NUTR, V31, P876, DOI 10.1093/ajcn/31.5.876; JELLIFFE DB, 1989, COMMUNITY NUTRITIONA; MEJIA LA, 1988, AM J CLIN NUTR, V48, P595, DOI 10.1093/ajcn/48.3.595; MEJIA LA, 1982, AM J CLIN NUTR, V36, P87, DOI 10.1093/ajcn/36.1.87; Mejia LA, 1977, AM J CLIN NUTR, V30, P1175; MOHANRAM M, 1977, INT J VITAM NUTR RES, V47, P389; MUHILAL PD, 1988, AM J CLIN NUTR, V48, P1271; PANTH M, 1990, BRIT J NUTR, V64, P351, DOI 10.1079/BJN19900037; SEMBA RD, 1992, NUTR RES, V12, P469, DOI 10.1016/S0271-5317(05)80017-X; SIJTSMA KW, IN PRESS BR J NUTR; SOMMER A, 1986, LANCET, V1, P1169; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090, DOI 10.1093/ajcn/40.5.1090; SUHARNO D, 1992, AM J CLIN NUTR, V56, P988, DOI 10.1093/ajcn/56.6.988; West C. E., 1992, Voeding (The Hague), V53, P201; WOLDEGEBRIEL Z, 1993, EUR J CLIN NUTR, V47, P104; WOLDEGEBRIEL Z, 1993, BRIT J NUTR, V70, P593, DOI 10.1079/BJN19930151; 1987, NATIONAL HLTH SURVEY; 1992, INT C NUTRITION ROME, P43; 1992, WHOMCHMSM922; 1992, 2ND REPORT WORLD NUT, V1	24	251	261	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 27	1993	342	8883					1325	1328		10.1016/0140-6736(93)92246-P	http://dx.doi.org/10.1016/0140-6736(93)92246-P			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MJ039	7901636				2022-12-28	WOS:A1993MJ03900009
J	BOWLING, TE; RAIMUNDO, AH; GRIMBLE, GK; SILK, DBA				BOWLING, TE; RAIMUNDO, AH; GRIMBLE, GK; SILK, DBA			REVERSAL BY SHORT-CHAIN FATTY-ACIDS OF COLONIC FLUID SECRETION INDUCED BY ENTERAL FEEDING	LANCET			English	Article							ABSORPTION; DIET; NUTRITION; INTESTINE; DIARRHEA; RAT	Diarrhoea complicates enteral feeding in up to 25% of patients. In-vivo perfusion studies in healthy subjects have shown secretion of salt and water in the ascending colon in response to enteral feeding. This study investigated the effect of short-chain fatty acids (SCFA) on this secretory response. Six healthy volunteers underwent segmental in-vivo colonic perfusion. First, baseline fasting colonic water and electrolyte movement was established, then a standard polymeric enteral diet was infused into the stomach while the colon was perfused with either a control electrolyte solution or a test solution containing SCFA. The electrolyte concentrations and osmolality of the two perfusates were identical. In the fasting state water was absorbed throughout the colon. During the control infusion there was significant (p < 0.05) secretion of water in the ascending colon (median rate 1.0 mL per min [95% CI 2.8 mL per min secretion to 0.8 mL per min absorption]). During the SCFA infusion the secretion was significantly reversed (p < 0.05) and there was net absorption (1.6 [0.8-3.7] mL per min). In the distal colon water absorption was significantly greater during the control infusion than during fasting (3.7 [2.5-4.6] vs 1.3 [0.3-2.2] mL per min); during the test infusion this absorption persisted (2.8 [1.3-3.6] mL per min). Movement of sodium, chloride, and potassium ions was similar to that of water in all stages of the study. Bicarbonate movement did not significantly change at any stage. Infusion of SCFA directly into the caecum reverses the fluid secretion seen in the ascending colon during enteral feeding. This finding could have implications for the management of diarrhoea related to enteral feeding.			SILK, DBA (corresponding author), CENT MIDDLESEX HOSP TRUST,DEPT GASTROENTEROL & NUTR,LONDON NW10 7NS,ENGLAND.							BINDER HJ, 1989, GASTROENTEROLOGY, V96, P989, DOI 10.1016/0016-5085(89)91614-4; BOWLING TE, 1993, EUR J GASTROEN HEPAT, V5, P809; BOWLING TE, 1993, GUT               S1, V34, pA54; BOWLING TE, 1993, CLIN NUTR S2, V12, P23; CUMMINGS JH, 1984, SCAND J GASTROENTERO, V19, P89; CUMMINGS JH, 1987, GUT, V28, P1221, DOI 10.1136/gut.28.10.1221; DEVROEDE GJ, 1969, GASTROENTEROLOGY, V56, P92; DOBB GJ, 1986, INTENS CARE MED, V12, P113; FORD EG, 1987, J PEDIATR SURG, V22, P597, DOI 10.1016/S0022-3468(87)80106-9; JACOBS LR, 1983, AM J CLIN NUTR, V37, P954, DOI 10.1093/ajcn/37.6.954; JONES BJM, 1983, GUT, V24, P78, DOI 10.1136/gut.24.1.78; KEOHANE PP, 1984, BMJ-BRIT MED J, V288, P678, DOI 10.1136/bmj.288.6418.678; Kritchevsky D., 1986, DIETARY FIBER, P131, DOI DOI 10.1007/978-1-4613-2111-8_10; LEVITAN R, 1962, J CLIN INVEST, V41, P1754, DOI 10.1172/JCI104634; MACFARLANE GT, 1992, J APPL BACTERIOL, V72, P57, DOI 10.1111/j.1365-2672.1992.tb05187.x; OKEEFE SJD, 1984, GUT, V25, P942, DOI 10.1136/gut.25.9.942; PHILLIPS SF, 1973, J LAB CLIN MED, V81, P733; RAIMUNDO AH, 1988, GUT, V29, pA1469; RAIMUNDO AH, 1990, GUT, V31, pA1195; ROEDIGER WEW, 1980, GUT, V21, P793, DOI 10.1136/gut.21.9.793; RUPPIN H, 1980, GASTROENTEROLOGY, V78, P1500; SILK DBA, 1987, CLIN NUTR, V6, P61, DOI 10.1016/0261-5614(87)90023-9; WAITZBERG D, 1988, CLIN NUTR S1, V7, P58; WHALEN GE, 1966, GASTROENTEROLOGY, V51, P975	24	97	99	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1266	1268		10.1016/0140-6736(93)92360-6	http://dx.doi.org/10.1016/0140-6736(93)92360-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901584				2022-12-28	WOS:A1993MH56600010
J	SACKS, SH; ZHOU, WD; ANDREWS, PA; HARTLEY, B				SACKS, SH; ZHOU, WD; ANDREWS, PA; HARTLEY, B			ENDOGENOUS COMPLEMENT C3 SYNTHESIS IN IMMUNE-COMPLEX NEPHRITIS	LANCET			English	Note							BIOSYNTHESIS; C-4	Human renal epithelial and mesangial cells have been shown to synthesise complement C3 in culture, but the relevance of this finding to the development of complement-mediated nephritis is uncertain. We investigated C3 gene expression in tissue biopsies that showed three main categories of renal injury. By semiquantitative polymerase chain reaction, biopsies from patients with immune-complex glomerulonephritis and those with cell-mediated interstitial nephritis showed increased C3 expression (p < 0.05), but biopsies from patients with non-immune glomerular injury did not. These findings suggest that local C3 production is enhanced in immune-mediated nephritis and are consistent with the hypothesis that locally synthesised complement components are involved in the pathogenesis of tissue injury.			SACKS, SH (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,RENAL LAB,3RD FLOOR GUYS TOWER,LONDON SE1 9RT,ENGLAND.			Sacks, Steven/0000-0001-6361-9095	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROOIMANS RA, 1991, J CLIN INVEST, V88, P379, DOI 10.1172/JCI115314; Colten H R, 1979, Ann N Y Acad Sci, V332, P482, DOI 10.1111/j.1749-6632.1979.tb47142.x; COUSER WG, 1985, KIDNEY INT, V28, P879, DOI 10.1038/ki.1985.214; FEUCHT HE, 1989, NEPHRON, V53, P338, DOI 10.1159/000185778; FEY G, 1981, FED PROC, V40, P2099; KINOSHITA T, 1991, IMMUNOL TODAY, V12, P291, DOI 10.1016/0167-5699(91)90001-A; PASSWELL J, 1988, J CLIN INVEST, V82, P1676, DOI 10.1172/JCI113780; SACKS SH, 1993, IMMUNOLOGY, V79, P348; SACKS SH, IN PRESS CLIN EXP IM; ZHOU W, IN PRESS EUR J IMMUN	10	68	71	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1273	1274		10.1016/0140-6736(93)92362-W	http://dx.doi.org/10.1016/0140-6736(93)92362-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901586				2022-12-28	WOS:A1993MH56600012
J	BLONDELGUINDI, S; CWIRLA, SE; DOWER, WJ; LIPSHUTZ, RJ; SPRANG, SR; SAMBROOK, JF; GETHING, MJH				BLONDELGUINDI, S; CWIRLA, SE; DOWER, WJ; LIPSHUTZ, RJ; SPRANG, SR; SAMBROOK, JF; GETHING, MJH			AFFINITY PANNING OF A LIBRARY OF PEPTIDES DISPLAYED ON BACTERIOPHAGES REVEALS THE BINDING-SPECIFICITY OF BIP	CELL			English	Article							MHC CLASS-I; SECRETORY PROTEINS; TRANSLOCATION; POLYPEPTIDE; LIGANDS; RESOLUTION; MOLECULES; PHAGE; GROEL; DNAK	We have used affinity panning of libraries of bacteriophages that display random octapeptide or dodecapeptide sequences at the N-terminus of the adsorption protein (pIII) to characterize peptides that bind to the endoplasmic reticulum chaperone BiP and to develop a scoring system that predicts potential BiP-binding sequences in naturally occurring polypeptides. BiP preferentially binds peptides containing a subset of aromatic and hydrophobic amino acids in alternating positions, suggesting that peptides bind in an extended conformation, with the side chains of alternating residues pointing into a cleft on the BiP molecule. Synthetic peptides with sequences corresponding to those displayed by BiP-binding bacteriophages bind to BiP and stimulate its ATPase activity, with a half-maximal concentration in the range 10-60 muM.	UNIV TEXAS,DALLAS,TX 75235; AFFYMAX RES INST,PALO ALTO,CA 94304	University of Texas System; University of Texas Dallas	BLONDELGUINDI, S (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED,DALLAS,TX 75235, USA.							BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; DOWER W J, 1992, Current Biology, V2, P251, DOI 10.1016/0960-9822(92)90368-K; Efron B., 1982, MONOGRAPH SOC IND AP; FLAJNIK MF, 1991, IMMUNOGENETICS, V33, P295, DOI 10.1007/BF00216688; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; KOZUTSUMI Y, 1989, J CELL SCI S, V11, P115; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; NGUYEN TH, 1991, P NATL ACAD SCI USA, V88, P1565, DOI 10.1073/pnas.88.4.1565; OBLAS B, 1990, BIOCHEM BIOPH RES CO, V166, P978, DOI 10.1016/0006-291X(90)90907-5; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; RIPPMANN F, 1991, EMBO J, V10, P1053, DOI 10.1002/j.1460-2075.1991.tb08044.x; SANDERS SL, 1992, CELL, V69, P353, DOI 10.1016/0092-8674(92)90415-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHONBERGER O, 1991, MOL MICROBIOL, V11, P2663; SCOTT JK, 1992, TRENDS BIOCHEM SCI, V17, P241, DOI 10.1016/0968-0004(92)90401-T; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Smith G P, 1991, Curr Opin Biotechnol, V2, P668, DOI 10.1016/0958-1669(91)90032-Z; TAYLOR WR, 1986, J THEOR BIOL, V119, P205, DOI 10.1016/S0022-5193(86)80075-3; VOGEL JP, 1990, J CELL BIOL, V110, P1885, DOI 10.1083/jcb.110.6.1885; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17	34	561	595	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	NOV 19	1993	75	4					717	728		10.1016/0092-8674(93)90492-9	http://dx.doi.org/10.1016/0092-8674(93)90492-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MH749	7902213	Bronze			2022-12-28	WOS:A1993MH74900017
J	KUEHN, MJ; OGG, DJ; KIHLBERG, J; SLONIM, LN; FLEMMER, K; BERGFORS, T; HULTGREN, SJ				KUEHN, MJ; OGG, DJ; KIHLBERG, J; SLONIM, LN; FLEMMER, K; BERGFORS, T; HULTGREN, SJ			STRUCTURAL BASIS OF PILUS SUBUNIT RECOGNITION BY THE PAPD CHAPERONE	SCIENCE			English	Article							TOXIGENIC ESCHERICHIA-COLI; AREA-DETECTOR DIFFRACTOMETER; NUCLEOTIDE-SEQUENCE; CRYSTAL-STRUCTURE; PEPTIDE-BINDING; PROTEIN SUBUNIT; GENE; EXPRESSION; FIMBRIAE; CELL	The assembly of different types of virulence-associated surface fibers called pili in Gram-negative bacteria requires periplasmic chaperones. PapD is the prototype member of the periplasmic chaperone family, and the structural basis of its interactions with pilus subunits was investigated. Peptides corresponding to the carboxyl terminus of pilus subunits bound PapD and blocked the ability of PapD to bind to the pilus adhesin PapG in vitro. The crystal structure of PapD complexed to the PapG carboxyl-terminal peptide was determined to 3.0 angstrom resolution. The peptide bound in an extended conformation with its carboxyl terminus anchored in the interdomain cleft of the chaperone via hydrogen bonds to invariant chaperone residues Arg8 and Lys112. Main chain hydrogen bonds and contacts between hydrophobic residues in the peptide and the chaperone stabilized the complex and may play a role in determining binding specificity. Site-directed mutations in Arg8 and Lys112 abolished the ability of PapD to bind pilus subunits and mediate pilus assembly in vivo, an indication that the PapD-peptide crystal structure is a reflection of at least part of the PapD-subunit interaction.	WASHINGTON UNIV,DEPT MOLEC MICROBIOL,BOX 8230,ST LOUIS,MO 63110; SYMBICOM AB,PROT STRUCT LAB,S-75183 UPPSALA,SWEDEN; LUND UNIV,DEPT ORGAN CHEM,S-22100 LUND,SWEDEN; UNIV UPPSALA,DEPT MICROBIOL,S-75105 UPPSALA,SWEDEN	Washington University (WUSTL); Lund University; Uppsala University			Kuehn, Meta/AAL-2950-2021; Kihlberg, Jan/S-4739-2019	Kuehn, Meta/0000-0003-0519-3019; 	NIAID NIH HHS [AI07172, R01AI29549] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029549, T32AI007172] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN BL, 1991, J BACTERIOL, V173, P916, DOI 10.1128/jb.173.2.916-920.1991; BAGA M, 1987, CELL, V49, P241, DOI 10.1016/0092-8674(87)90565-4; BRUNGER A, 1992, X PLOR MANUAL; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; CLOUTHIER SC, 1993, J BACTERIOL, V175, P2523, DOI 10.1128/JB.175.9.2523-2533.1993; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; DERRICK JP, 1992, NATURE, V359, P752, DOI 10.1038/359752a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DODSON KW, 1993, P NATL ACAD SCI USA, V90, P3670, DOI 10.1073/pnas.90.8.3670; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAASTRA W, 1981, FEMS MICROBIOL LETT, V12, P41; GAASTRA W, 1984, FEMS MICROBIOL LETT, V22, P253; GALYOV EE, 1991, FEBS LETT, V286, P79, DOI 10.1016/0014-5793(91)80945-Y; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILSDORF JR, 1990, INFECT IMMUN, V58, P1065, DOI 10.1128/IAI.58.4.1065-1072.1990; GONG MF, 1992, J MOL BIOL, V228, P735, DOI 10.1016/0022-2836(92)90860-M; HOLMGREN A, 1989, NATURE, V342, P248, DOI 10.1038/342248a0; HOLMGREN A, 1992, EMBO J, V11, P1617, DOI 10.1002/j.1460-2075.1992.tb05207.x; HOLMGREN A, UNPUB; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HULTGREN SJ, 1993, CELL, V73, P887, DOI 10.1016/0092-8674(93)90269-V; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; Jacob-Dubuisson Francoise, 1993, Trends in Microbiology, V1, P50, DOI 10.1016/0966-842X(93)90032-M; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; JALAJAKUMARI MB, 1989, MOL MICROBIOL, V3, P1685, DOI 10.1111/j.1365-2958.1989.tb00154.x; JONES AT, 1992, VERSION 5 6; JONES CH, 1993, P NATL ACAD SCI USA, V90, P8397, DOI 10.1073/pnas.90.18.8397; KLEMM P, 1987, MOL GEN GENET, V208, P439, DOI 10.1007/BF00328136; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; KUEHN MJ, 1991, P NATL ACAD SCI USA, V88, P10586, DOI 10.1073/pnas.88.23.10586; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LANDRY SJ, 1991, BIOCHEMISTRY-US, V30, P7359, DOI 10.1021/bi00244a001; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; LINDBERG F, 1989, J BACTERIOL, V171, P6052, DOI 10.1128/jb.171.11.6052-6058.1989; LINTERMANS P, 1988, INFECT IMMUN, V56, P1475, DOI 10.1128/IAI.56.6.1475-1484.1988; LINTERMANS P, 1990, THESIS RIJKSUNIVERSI; LIVEY I, 1987, MOL MICROBIOL, V1, P203, DOI 10.1111/j.1365-2958.1987.tb00513.x; MARKLUND BI, 1992, MOL MICROBIOL, V6, P2225, DOI 10.1111/j.1365-2958.1992.tb01399.x; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MOOI FR, 1990, FEMS MICROBIOL LETT, V54, P327; Normark S., 1986, Microbial lectins and agglutinins, P113; ORNDORFF PE, 1985, J BACTERIOL, V162, P454, DOI 10.1128/JB.162.1.454-457.1985; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; ROOSENDAAL B, 1989, J BACTERIOL, V171, P1262; SCHMOLL T, 1987, FEMS MICROBIOL LETT, V41, P229; SCHMOLL T, 1989, MOL MICROBIOL, V3, P1735, DOI 10.1111/j.1365-2958.1989.tb00159.x; SIMONS BL, 1990, FEMS MICROBIOL LETT, V67, P107, DOI 10.1111/j.1574-6968.1990.tb13845.x; SLONIM LN, 1992, EMBO J, V11, P4747, DOI 10.1002/j.1460-2075.1992.tb05580.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; XUONG NH, 1985, J APPL CRYSTALLOGR, V18, P342, DOI 10.1107/S0021889885010433; 1979, WA44AD DAR LAB	51	195	199	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 19	1993	262	5137					1234	1241		10.1126/science.7901913	http://dx.doi.org/10.1126/science.7901913			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MH324	7901913				2022-12-28	WOS:A1993MH32400030
J	CHAUVEAU, D; CHRISTOPHE, JL				CHAUVEAU, D; CHRISTOPHE, JL			RENAL ANEURYSMS IN HEPATITIS B-ASSOCIATED POLYARTERITIS-NODOSA	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											CHAUVEAU, D (corresponding author), HOP NECKER ENFANTS MALAD,F-75015 PARIS,FRANCE.								0	2	2	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 20	1995	332	16					1070	1070		10.1056/NEJM199504203321605	http://dx.doi.org/10.1056/NEJM199504203321605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT187	7898525				2022-12-28	WOS:A1995QT18700005
J	LEE, YM; KAPLAN, MM				LEE, YM; KAPLAN, MM			PRIMARY SCLEROSING CHOLANGITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PRIMARY BILIARY-CIRRHOSIS; INFLAMMATORY BOWEL-DISEASE; CHRONIC ULCERATIVE-COLITIS; ORTHOTOPIC LIVER-TRANSPLANTATION; URSODEOXYCHOLIC ACID; NATURAL-HISTORY; BILE-DUCTS; HEPATOBILIARY DISEASE; CONTROLLED TRIAL; HLA-DR		TUFTS UNIV NEW ENGLAND MED CTR,DIV GASTROENTEROL,BOSTON,MA 02111	Tufts Medical Center								AADLAND E, 1987, SCAND J GASTROENTERO, V22, P655, DOI 10.3109/00365528709011139; ALLAN RN, 1976, GUT, V17, P413, DOI 10.1136/gut.17.6.413; ALMASIO P, 1990, DRUGS, V40, P111, DOI 10.2165/00003495-199000403-00011; BALASUBRAMANIAM K, 1988, GASTROENTEROLOGY, V95, P1395, DOI 10.1016/0016-5085(88)90378-2; BARTHOLOMEW LG, 1963, NEW ENGL J MED, V269, P8, DOI 10.1056/NEJM196307042690102; BATTS KP, 1988, TRANSPLANTATION, V45, P376, DOI 10.1097/00007890-198802000-00026; BERGASA NV, 1992, GASTROENTEROLOGY, V102, P544, DOI 10.1016/0016-5085(92)90102-5; BEUERS U, 1992, HEPATOLOGY, V16, P707, DOI 10.1002/hep.1840160315; BLOOMER JR, 1975, ANN INTERN MED, V82, P310, DOI 10.7326/0003-4819-82-3-310; BODEN RW, 1959, LANCET, V2, P245; BODENHEIMER HC, 1983, HEPATOLOGY, V3, P150; BORKJE B, 1985, SCAND J GASTROENTERO, V20, P539; BRANDT DJ, 1988, AM J ROENTGENOL, V150, P571, DOI 10.2214/ajr.150.3.571; BRINCH L, 1982, SCAND J GASTROENTERO, V17, P523, DOI 10.3109/00365528209182243; BROOKE BN, 1961, POSTGRAD MED J, V37, P245, DOI 10.1136/pgmj.37.427.245; BROOME U, 1990, SCAND J GASTROENTERO, V25, P54, DOI 10.3109/00365529008999209; BURGERT SL, 1984, GASTROENTEROLOGY, V86, P1037; CALMUS Y, 1990, HEPATOLOGY, V11, P12, DOI 10.1002/hep.1840110104; CAMERON JL, 1988, ANN SURG, V207, P614, DOI 10.1097/00000658-198805000-00016; CANGEMI JR, 1989, GASTROENTEROLOGY, V96, P790; CAREY JB, 1964, GASTROENTEROLOGY, V46, P490; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; CHAPMAN RW, 1983, GUT, V24, P38, DOI 10.1136/gut.24.1.38; CHAPMAN RW, 1988, GUT, V29, P422, DOI 10.1136/gut.29.4.422; CHAPMAN RW, 1991, SEMIN LIVER DIS, V11, P1, DOI 10.1055/s-2008-1040415; CHAPMAN RWG, 1980, GUT, V21, P870, DOI 10.1136/gut.21.10.870; CHAZOUILLERES O, 1990, J HEPATOL, V11, P120, DOI 10.1016/0168-8278(90)90281-U; CHEN LY, 1984, GASTROINTEST RADIOL, V9, P39; COHEN LB, 1985, GUT, V26, P291, DOI 10.1136/gut.26.3.291; COTTON PB, 1991, SEMIN LIVER DIS, V11, P40, DOI 10.1055/s-2008-1040421; COWEN AE, 1975, GASTROENTEROLOGY, V69, P59; DATTA DV, 1966, GASTROENTEROLOGY, V50, P323; DICKSON ER, 1992, GASTROENTEROLOGY, V103, P1893, DOI 10.1016/0016-5085(92)91449-E; DONALDSON PT, 1991, HEPATOLOGY, V13, P129, DOI 10.1016/0270-9139(91)90225-K; DUERR RH, 1991, GASTROENTEROLOGY, V100, P1385; EDDLESTON ALWF, 1978, BRIT MED BULL, V34, P295, DOI 10.1093/oxfordjournals.bmb.a071515; EPSTEIN O, 1982, GASTROENTEROLOGY, V83, P1177; FARRANT JM, 1991, GASTROENTEROLOGY, V100, P1710, DOI 10.1016/0016-5085(91)90673-9; FAUSA O, 1991, SEMIN LIVER DIS, V11, P31, DOI 10.1055/s-2008-1040420; FAUSA O, 1989, SCAND J GASTR   S159, V24, P59; FINEGOLD MJ, 1982, HUM PATHOL, V13, P662, DOI 10.1016/S0046-8177(82)80011-7; GADACZ TR, 1976, GASTROENTEROLOGY, V70, P1125; GALAMBOS JT, 1985, ALCOHOLIC LIVER DISE, P230; GALLE P R, 1990, Gastroenterology, V98, pA588; GARAGLIANO CF, 1979, J CHRON DIS, V32, P543, DOI 10.1016/0021-9681(79)90117-6; GAVALER JS, 1991, DIGEST DIS SCI, V36, P321, DOI 10.1007/BF01318204; HANID MA, 1980, LANCET, V2, P530; HAY JE, 1993, GASTROENTEROLOGY, V104, pA913; HAY JE, 1988, ANN INTERN MED, V109, P713, DOI 10.7326/0003-4819-109-9-713; HAY JE, 1991, HEPATOLOGY, V14, P257, DOI 10.1016/0270-9139(91)91412-T; HAYASHI H, 1990, GASTROENTEROLOGY, V99, P533, DOI 10.1016/0016-5085(90)91038-8; HELZBERG JH, 1987, GASTROENTEROLOGY, V92, P1869, DOI 10.1016/0016-5085(87)90618-4; HERRMANN R, 1988, GUT, V29, pA1430; HIGASHI H, 1990, HEPATOLOGY, V11, P477, DOI 10.1002/hep.1840110320; HOBSON CH, 1988, GASTROENTEROLOGY, V94, P1006, DOI 10.1016/0016-5085(88)90560-4; HUIBREGTSE K, 1988, ENDOSCOPIC BILIARY P; HUNTER E B, 1989, Gastroenterology, V96, pA610; JAVETT SL, 1971, LANCET, V1, P810; JEFFREY GP, 1991, GUT, V32, P424, DOI 10.1136/gut.32.4.424; JOHNSON GK, 1991, GASTROINTEST ENDOSC, V37, P38, DOI 10.1016/S1052-5157(18)30684-6; JORGE AD, 1987, ENDOSCOPY, V19, P114, DOI 10.1055/s-2007-1018254; KAPLAN MM, 1989, Q J MED, V72, P757; KAPLAN MM, 1991, SEMIN LIVER DIS, V11, P56, DOI 10.1055/s-2008-1040423; KAPLAN MM, 1987, ANN INTERN MED, V106, P231, DOI 10.7326/0003-4819-106-2-231; KLATSKIN G, 1993, HISTOPATHOLOGY LIVER, V2, P99; KNOX TA, 1994, GASTROENTEROLOGY, V106, P494, DOI 10.1016/0016-5085(94)90610-6; KNOX TA, 1991, AM J GASTROENTEROL, V86, P546; KONO K, 1988, GASTROENTEROLOGY, V94, P787, DOI 10.1016/0016-5085(88)90255-7; LANGNAS AN, 1990, AM J GASTROENTEROL, V85, P1136; LARUSSO NF, 1984, NEW ENGL J MED, V310, P899, DOI 10.1056/NEJM198404053101407; LARUSSO NF, 1988, GASTROENTEROLOGY, V95, P1036, DOI 10.1016/0016-5085(88)90180-1; LEBOVICS E, 1987, ARCH INTERN MED, V147, P729, DOI 10.1001/archinte.147.4.729; LEFKOWITCH JH, 1982, ARCH INTERN MED, V142, P1157, DOI 10.1001/archinte.142.6.1157; LEISER A, 1986, AM J MED SCI, V291, P416, DOI 10.1097/00000441-198606000-00008; LETOURNEAU JG, 1988, RADIOLOGY, V167, P349, DOI 10.1148/radiology.167.2.3282255; LICHTMAN SN, 1990, GASTROENTEROLOGY, V98, P414, DOI 10.1016/0016-5085(90)90833-M; LINDOR KD, 1989, HEPATOLOGY, V10, P638; LINDOR KD, 1990, AM J MED, V89, P73, DOI 10.1016/0002-9343(90)90101-I; LINDOR KD, 1987, SEMIN LIVER DIS, V7, P322, DOI 10.1055/s-2008-1040588; LINDOR KD, 1987, HEPATOLOGY, V7, P884, DOI 10.1002/hep.1840070515; LINDOR KD, 1987, DIGEST DIS SCI, V32, P720, DOI 10.1007/BF01296138; LLOYDTHOMAS HGL, 1952, BRIT MED J, V2, P1289, DOI 10.1136/bmj.2.4797.1289; LUDWIG J, 1981, Hepatology, V1, P632, DOI 10.1002/hep.1840010612; LUDWIG J, 1989, HEPATOLOGY, V9, P215, DOI 10.1002/hep.1840090209; LUDWIG J, 1986, CONT ISSUES SURGICAL; MACCARTY RL, 1983, RADIOLOGY, V149, P39, DOI 10.1148/radiology.149.1.6412283; MARSH JW, 1988, ANN SURG, V207, P21; MARTIN FM, 1990, ANN SURG, V212, P551, DOI 10.1097/00000658-199010000-00017; MAY GR, 1985, AM J ROENTGENOL, V145, P1061, DOI 10.2214/ajr.145.5.1061; MCENTEE G, 1991, TRANSPLANT P, V23, P1563; MCFARLANE IG, 1979, GASTROENTEROLOGY, V76, P1333; MEHAL WZ, 1994, GASTROENTEROLOGY, V106, P160, DOI 10.1016/S0016-5085(94)95085-7; MEHAL WZ, 1992, J HEPATOL, V15, P396, DOI 10.1016/0168-8278(92)90076-2; MISTILIS SP, 1965, ANN INTERN MED, V63, P1, DOI 10.7326/0003-4819-63-1-1; MISTILIS SP, 1965, AUSTRALAS ANN MED, V14, P286; MUNOZ S J, 1991, Gastroenterology, V100, pA539; MYERS RN, 1970, AM J GASTROENTEROL, V53, P527; OBRIEN CB, 1991, HEPATOLOGY, V14, P838, DOI 10.1002/hep.1840140516; PALMER KR, 1980, GUT, V21, P851, DOI 10.1136/gut.21.10.851; PALMER RH, 1972, ARCH INTERN MED, V130, P606, DOI 10.1001/archinte.130.4.606; PHILLIPS JO, 1993, GASTROENTEROLOGY, V104, pA972; PODDA M, 1989, DIGEST DIS SCI, V34, pS59, DOI 10.1007/BF01536665; PODESTA A, 1991, DIGEST DIS SCI, V36, P216, DOI 10.1007/BF01300759; POLTER DE, 1980, GASTROENTEROLOGY, V79, P326; PORAYKO MK, 1990, GASTROENTEROLOGY, V98, P1594, DOI 10.1016/0016-5085(90)91096-O; PROCHAZKA EJ, 1990, NEW ENGL J MED, V322, P1842, DOI 10.1056/NEJM199006283222603; QUIGLEY EMM, 1983, GASTROENTEROLOGY, V85, P1160; RABINOVITZ M, 1990, HEPATOLOGY, V11, P7, DOI 10.1002/hep.1840110103; RADERER M, 1994, NEW ENGL J MED, V330, P1540, DOI 10.1056/NEJM199405263302117; RITCHIE JK, 1974, Q J MED, V43, P263; ROSEN CB, 1991, ANN SURG, V213, P21, DOI 10.1097/00000658-199101000-00004; ROSS AP, 1973, GUT, V14, P94, DOI 10.1136/gut.14.2.94; SARTIN JS, 1987, GASTROENTEROLOGY, V92, P1615; SCHRUMPF E, 1982, SCAND J GASTROENTERO, V17, P187, DOI 10.3109/00365528209182038; SCHRUMPF E, 1988, SEMIN LIVER DIS, V8, P201, DOI 10.1055/s-2008-1040541; SENALDI G, 1989, GASTROENTEROLOGY, V97, P1430, DOI 10.1016/0016-5085(89)90386-7; SHARMA AN, 1991, HEPATOLOGY, V14, pA196; SHEPHERD HA, 1983, Q J MED, V52, P503; SIEGEL JH, 1977, DIGESTION, V15, P469, DOI 10.1159/000198038; SIVAK MV, 1981, J CLIN GASTROENTEROL, V3, P261, DOI 10.1097/00004836-198109000-00010; SNOOK JA, 1989, CLIN EXP IMMUNOL, V76, P30; SNOOK JA, 1989, J HEPATOL, V9, P36, DOI 10.1016/0168-8278(89)90073-1; STIEBER AC, 1989, INT SURG, V74, P1; STOCKBRUGGER RW, 1988, HEPATO-GASTROENTEROL, V35, P289; STONNINGTON CM, 1987, GUT, V28, P402, DOI 10.1136/gut.28.4.402; TAUB W, 1988, GASTROENTEROLOGY, V94, pA598; THORNTON JR, 1988, BRIT MED J, V297, P1501, DOI 10.1136/bmj.297.6662.1501; TOBIAS R, 1983, S AFR MED J, V63, P229; VINNIK IE, 1963, ARCH INTERN MED, V112, P41, DOI 10.1001/archinte.1963.03860010087009; VINNIK IE, 1964, P SOC EXP BIOL MED, V115, P311, DOI 10.3181/00379727-115-28899; WAGNER A, 1971, LANCET, V2, P663; WARREN KW, 1966, AM J SURG, V111, P23, DOI 10.1016/0002-9610(66)90339-4; WEE A, 1985, ANN INTERN MED, V102, P581, DOI 10.7326/0003-4819-102-5-581; WHITESIDE TL, 1985, HEPATOLOGY, V5, P468, DOI 10.1002/hep.1840050321; Wiesner R H, 1988, Hepatology, V8, P970, DOI 10.1002/hep.1840080444; WIESNER RH, 1989, HEPATOLOGY, V10, P430, DOI 10.1002/hep.1840100406; WIESNER RH, 1986, GASTROENTEROLOGY, V90, P316, DOI 10.1016/0016-5085(86)90926-1; WIESNER RH, 1991, HEPATOLOGY, V14, pA63; WIESNER RH, 1993, DISEASES LIVER, V1, P411; ZAULI D, 1987, J HEPATOL, V5, P14, DOI 10.1016/S0168-8278(87)80055-7	140	453	462	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					924	933		10.1056/NEJM199504063321406	http://dx.doi.org/10.1056/NEJM199504063321406			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877651				2022-12-28	WOS:A1995QP89300006
J	HAMILTON, VH; RACICOT, FE; ZOWALL, H; COUPAL, L; GROVER, SA				HAMILTON, VH; RACICOT, FE; ZOWALL, H; COUPAL, L; GROVER, SA			THE COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITORS TO PREVENT CORONARY HEART-DISEASE - ESTIMATING THE BENEFITS OF INCREASING HDL-C	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HIGH BLOOD CHOLESTEROL; STAGE RENAL-DISEASE; HYPERCHOLESTEROLEMIA; MANAGEMENT; LEVEL; CARE; RISK	Objective.-To evaluate the lifetime cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors for treatment of high blood cholesterol levels. Design.-We added cost data to a validated coronary heart disease (CHD) prevention computer model that estimates the benefits of lifelong risk factor modification. The updated model takes into account the costs of cholesterol reduction, the savings in CHD health care costs attributable to intervention, the additional non-CHD costs resulting from patients' living longer, and the beneficial effects of reducing CHD risk by reducing total cholesterol and increasing high-density lipoprotein cholesterol (HDL-C). Patients.-Men and women aged 30 to 70 years who were free of CHD, had total cholesterol levels equal to the 90th percentile of the US distribution in their age and sex group, had HDL-C levels equal to the mean of the US distribution in their age and sex group, and were either with or without additional CHD risk factors. Intervention.-Use of 20 mg of lovastatin per day, which on average reduces total serum cholesterol by 17% and increases HDL-C by 7%. Main Outcome Measures.-Cost per year of life saved after discounting benefits and costs by 5% annually. Results.-The increase in HDL-C associated with lovastatin lowered cost-effectiveness ratios by approximately 40%, such that the treatment of hypercholesterolemia was relatively cost-effective for men (as low as $20 882 per year of life saved at age 50 years) and women ($36 627 per year of life saved at age 60 years) with additional risk factors. Non-CHD costs resulting from longer life expectancy after intervention added at most 23% to the cost-effectiveness ratios for patients who began treatment at age 70 years, and as little as 3% for patients at age 30 years. Conclusion.-The cost-effectiveness of HMG-CoA reductase inhibitors varied widely by age and sex and was sensitive to the presence of non-lipid CHD risk factors. The additional non-CHD costs due to increased life expectancy may be significant for the elderly, Accounting for the drug effects of raising HDL-C levels increased the proportion of the population for which medication treatment was relatively cost-effective.	MONTREAL GEN HOSP,CTR ANAL COST EFFECT CARE,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,CTR CARDIOVASC RICK ASSESSMENT,MONTREAL,PQ H3G 1A4,CANADA; MONTREAL GEN HOSP,DIV CLIN EPIDEMIOL,MONTREAL,PQ H3G 1A4,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT ECON,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA	McGill University; McGill University; McGill University; McGill University; McGill University; McGill University			Racicot, François-Éric/O-3079-2019	Coupal, Louis/0000-0003-0828-9665				BARER ML, 1987, SOC SCI MED, V24, P851, DOI 10.1016/0277-9536(87)90186-9; BENFANTE R, 1990, JAMA-J AM MED ASSOC, V263, P393, DOI 10.1001/jama.263.3.393; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; EDELSON JT, 1990, JAMA-J AM MED ASSOC, V263, P407, DOI 10.1001/jama.263.3.407; GARNER TI, 1987, MED CARE, V25, P25, DOI 10.1097/00005650-198701000-00004; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Gorecki P. K., 1992, CONTROLLING DRUG EXP; GREGOR RD, 1990, NOVA SCOTIA MED J, V69, P146; GROVER SA, 1992, JAMA-J AM MED ASSOC, V267, P816; GROVER SA, 1994, ARCH INTERN MED, V154, P679, DOI 10.1001/archinte.154.6.679; GROVER SA, 1994, DRUG SAFETY, V10, P301, DOI 10.2165/00002018-199410040-00004; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; KANNEL WB, 1988, NIH882969 NAT HEART; KANNEL WB, 1987, US DHEW NIH872284 PU; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MIELE NF, 1992, JAMA-J AM MED ASSOC, V267, P507, DOI 10.1001/jama.1992.03480040055017; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OSTER G, 1987, JAMA-J AM MED ASSOC, V258, P2381, DOI 10.1001/jama.258.17.2381; ROBERTS SD, 1980, ANN INTERN MED, V92, P243, DOI 10.7326/0003-4819-92-2-243; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; RUBIN SM, 1990, ANN INTERN MED, V113, P916, DOI 10.7326/0003-4819-113-12-916; Russell LB., 1986, IS PREVENTION BETTER; SCHULMAN KA, 1990, JAMA-J AM MED ASSOC, V264, P3025, DOI 10.1001/jama.264.23.3025; 1992, HLTH REP, V4, P8; 1989, MANUEL MED OMNIPRACT; 1989, HLTH REP S, V1; 1989, SCHEDULE BENEFITS PH; 1991, STATISTIQUES ANN, P77; 1981, 82538 STAT CAN CAT; [No title captured]; 1991, HLTH REP S5, V3, P32; 1992, HLTH REP, V4, P339; 1993, VITAL HLTH STAT 242, V11; 1989, 84532 STAT CAN HLTH; 1991, HLTH REP, V3, P229	40	80	80	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1032	1038		10.1001/jama.273.13.1032	http://dx.doi.org/10.1001/jama.273.13.1032			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897787				2022-12-28	WOS:A1995QP89000034
J	CONSTANTZ, BR; ISON, IC; FULMER, MT; POSER, RD; SMITH, ST; VANWAGONER, M; ROSS, J; GOLDSTEIN, SA; JUPITER, JB; ROSENTHAL, DI				CONSTANTZ, BR; ISON, IC; FULMER, MT; POSER, RD; SMITH, ST; VANWAGONER, M; ROSS, J; GOLDSTEIN, SA; JUPITER, JB; ROSENTHAL, DI			SKELETAL REPAIR BY IN-SITU FORMATION OF THE MINERAL PHASE OF BONE	SCIENCE			English	Article								A process has been developed for the in situ formation of the mineral phase of bone. inorganic calcium and phosphate sources are combined to form a paste that is surgically implanted by injection. Under physiological conditions, the material hardens in minutes concurrent with the formation of dahllite. After 12 hours, dahllite formation was nearly complete, and an ultimate compressive strength of 55 megapascals was achieved. The composition and crystal morphology of the dahllite formed are similar to those of bone. Animal studies provide evidence that the material is remodeled in vivo. A novel approach to skeletal repair is being tested in human trials for various applications; in one of the trials the new biomaterial is being percutaneously placed into acute fractures. After hardening, it serves as internal fixation to maintain proper alignment while healing occurs.	STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305; UNIV MICHIGAN,ORTHORPAED SURG SECT,ANN ARBOR,MI 48109; MASSACHUSETTS GEN HOSP,BOSTON,MA 02114	Stanford University; University of Michigan System; University of Michigan; Harvard University; Massachusetts General Hospital	CONSTANTZ, BR (corresponding author), NORIAN CORP,CUPERTINO,CA 95014, USA.							ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; CONSTANTZ BR, 1992, MATER RES SOC SYMP P, V252, P79; Cullity B.D, 1978, ELEMENTS XRAY DIFFRA, V2nd ed., P99; DIAS JJ, 1987, INJURY, V18, P304, DOI 10.1016/0020-1383(87)90047-7; Fess EE, CLIN ASSESSMENT RECO, P41; FRANKENBURG EP, 1994, 40TH T ANN M ORTH RE, V19, P157; GLIMCHER MJ, 1981, J CRYST GROWTH, V53, P100, DOI 10.1016/0022-0248(81)90058-0; JUPITER JB, 1991, J BONE JOINT SURG AM, V73A, P461, DOI 10.2106/00004623-199173030-00019; MCCONNELL D, 1952, J DENT RES, V31, P53, DOI 10.1177/00220345520310012301; NELSON DGA, 1981, J DENT RES, V60, P1621, DOI 10.1177/002203458106000312011; Pool C, 1973, J Bone Joint Surg Br, V55, P540; Posner A. S., 1984, Phosphate Minerals, P330; POST JE, 1989, REV MINERAL, V20, P277; REY C, 1991, CALCIFIED TISSUE INT, V49, P251, DOI 10.1007/BF02556214; ROHL L, 1991, J BIOMECH, V24, P1143, DOI 10.1016/0021-9290(91)90006-9; SCHLESINGER PH, 1991, AM J PHYS, V260, pC1315; SCHMALHOLZ A, 1990, CLIN ORTHOP RELAT R, V254, P236; Vaes G., 1988, CLIN ORTHOP RELAT R, V231, P239; Weiner S., 1989, BIOMINERALIZATION, P144; Wolff J, 1892, GESETZ TRANSFORMATIO	20	608	668	1	93	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1796	1799		10.1126/science.7892603	http://dx.doi.org/10.1126/science.7892603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892603				2022-12-28	WOS:A1995QN70200031
J	WATERMAN, MR				WATERMAN, MR			A RISING STAR - AN ESSENTIAL ROLE IN CHOLESTEROL TRANSPORT	SCIENCE			English	Editorial Material											WATERMAN, MR (corresponding author), VANDERBILT UNIV,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232, USA.							CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; GARREN LD, 1965, P NATL ACAD SCI USA, V53, P1443, DOI 10.1073/pnas.53.6.1443; JEFCOATE CR, 1992, J STEROID BIOCHEM, V43, P751, DOI 10.1016/0960-0760(92)90305-3; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; LIN D, 1991, J CLIN INVEST, V88, P1995; MUKHIN AG, 1989, P NATL ACAD SCI USA, V86, P9812; PEDERSEN RC, 1987, SCIENCE, V236, P188, DOI 10.1126/science.3563495; PRIVALLE CT, 1983, P NATL ACAD SCI-BIOL, V80, P702, DOI 10.1073/pnas.80.3.702; SAKAI Y, 1994, J CLIN ENDOCR METAB, V79, P1198, DOI 10.1210/jc.79.4.1198; YANGIBASHI, 1988, ENDOCRINOLOGY, V123, P2075	12	25	25	0	3	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 24	1995	267	5205					1780	1781		10.1126/science.7892600	http://dx.doi.org/10.1126/science.7892600			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QN702	7892600				2022-12-28	WOS:A1995QN70200027
J	OLIVER, MF				OLIVER, MF			AL, OR THE ANONYMITY OF AUTHORSHIP	LANCET			English	Editorial Material											OLIVER, MF (corresponding author), NATL HEART & LUNG INST,LONDON,ENGLAND.								0	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					668	668		10.1016/S0140-6736(95)90864-1	http://dx.doi.org/10.1016/S0140-6736(95)90864-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885122				2022-12-28	WOS:A1995QM73200005
J	TOMPKINS, LS; FALKOW, S				TOMPKINS, LS; FALKOW, S			THE NEW PATH TO PREVENTING ULCERS	SCIENCE			English	Editorial Material							HELICOBACTER-PYLORI INFECTION; CELL GASTRIC LYMPHOMA; CARCINOMA		STANFORD UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305	Stanford University	TOMPKINS, LS (corresponding author), STANFORD UNIV,SCH MED,DEPT MED INFECT DIS & GEOG MED,STANFORD,CA 94305, USA.							Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; CHEN M, 1994, INT J MED MICROBIOL, V280, P155; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; COVER TL, 1990, INFECT IMMUN, V58, P603, DOI 10.1128/IAI.58.3.603-610.1990; COVER TL, 1995, ASM NEWS, V61, P21; CRABTREE JE, 1993, GUT, V34, P1339, DOI 10.1136/gut.34.10.1339; CZINN SJ, 1991, INFECT IMMUN, V59, P2359, DOI 10.1128/IAI.59.7.2359-2363.1991; DONNENBERG MS, 1991, INFECT IMMUN, V59, P4310, DOI 10.1128/IAI.59.12.4310-4317.1991; EATON KA, 1992, J MED MICROBIOL, V37, P123, DOI 10.1099/00222615-37-2-123; Lingwood Clifford A., 1993, P209; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL BJ, 1983, LANCET, V1, P1311; NOMURA A, 1991, NEW ENGL J MED, V325, P1132, DOI 10.1056/NEJM199110173251604; PAPINI E, 1993, MOL MICROBIOL, V7, P323, DOI 10.1111/j.1365-2958.1993.tb01123.x; PARSONNET J, 1991, NEW ENGL J MED, V325, P1127, DOI 10.1056/NEJM199110173251603; SEGAL E, UNPUB; TELFORD JL, 1994, TRENDS BIOTECHNOL, V12, P420, DOI 10.1016/0167-7799(94)90031-0; TUMMURU MKR, 1994, INFECT IMMUN, V62, P2609, DOI 10.1128/IAI.62.6.2609-2613.1994; WOTHERSPOON AC, 1993, LANCET, V342, P575, DOI 10.1016/0140-6736(93)91409-F; WOTHERSPOON AC, 1991, LANCET, V338, P1175, DOI 10.1016/0140-6736(91)92035-Z; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995; 1994, NIH CONSENSUS DEV C	23	33	34	0	2	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 17	1995	267	5204					1621	1622		10.1126/science.7886448	http://dx.doi.org/10.1126/science.7886448			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QM397	7886448				2022-12-28	WOS:A1995QM39700028
J	SMITH, CD; AIN, KB				SMITH, CD; AIN, KB			BRAIN METABOLISM IN HYPOTHYROIDISM STUDIED WITH P-31 MAGNETIC-RESONANCE SPECTROSCOPY	LANCET			English	Note							SKELETAL-MUSCLE	Metabolic consequences of hypothyroidism in adult human brain, despite neuropsychological symptoms, have not been reported. We used P-31 nuclear magnetic-resonance spectroscopy of the frontal lobe to examine the effect of acute hypothyroidism on cerebral metabolism. Paired analysis showed that the phosphocreatine/inorganic-phosphate (PCr/Pi) ratio increased from a median of 2.04 (interquartile range 0.15) to 2.22 (0.25) after treatment with levothyroxine (p=0.01). These reversible alterations in adult cerebral phosphate metabolism during acute hypothyroidism parallel PCr/Pi ratio changes described in skeletal muscle. This is the first direct evidence of cerebral metabolic effects of hypothyroidism on adult brain.	UNIV KENTUCKY,MED CTR,DEPT MAGNET RESONANCE IMAGING,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,CTR SPECT,LEXINGTON,KY 40536; UNIV KENTUCKY,MED CTR,DEPT INTERNAL MED,DIV ENDOCRINOL DIABET & METAB,LEXINGTON,KY 40536; VET ADM MED CTR,MED SERV,LEXINGTON,KY 40511	University of Kentucky; University of Kentucky; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center	SMITH, CD (corresponding author), UNIV KENTUCKY,MED CTR,DEPT NEUROL,LEXINGTON,KY 40536, USA.		Ain, Kenneth/A-5179-2012	Ain, Kenneth/0000-0002-2668-934X	NCI NIH HHS [1-R29-CA58935-01A1] Funding Source: Medline; NINDS NIH HHS [NSO1421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA058935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS001421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARGOV Z, 1988, J CLIN INVEST, V81, P1695, DOI 10.1172/JCI113508; CHANCE B, 1985, P NATL ACAD SCI USA, V82, P8384, DOI 10.1073/pnas.82.24.8384; KAMINSKY P, 1992, J CLIN ENDOCR METAB, V74, P124, DOI 10.1210/jc.74.1.124; OBRIEN MD, 1968, LANCET, V1, P1170; RADDA G, 1984, BIOCHEM SOC T, V14, P517; SCHEINBERG P, 1950, J CLIN INVEST, V29, P1139, DOI 10.1172/JCI102351; SENSENBACH W, 1954, J CLIN INVEST, V33, P1434, DOI 10.1172/JCI103021; TAYLOR DJ, 1992, EUR J CLIN INVEST, V22, P358, DOI 10.1111/j.1365-2362.1992.tb01474.x	8	35	35	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 11	1995	345	8950					619	620		10.1016/S0140-6736(95)90522-7	http://dx.doi.org/10.1016/S0140-6736(95)90522-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM075	7898179				2022-12-28	WOS:A1995QM07500010
J	GREENBERG, AS; AVILA, D; HUGHES, M; HUGHES, A; MCKINNEY, EC; FLAJNIK, MF				GREENBERG, AS; AVILA, D; HUGHES, M; HUGHES, A; MCKINNEY, EC; FLAJNIK, MF			A NEW ANTIGEN RECEPTOR GENE FAMILY THAT UNDERGOES REARRANGEMENT AND EXTENSIVE SOMATIC DIVERSIFICATION IN SHARKS	NATURE			English	Article							MONOCLONAL-ANTIBODIES; CELL; IMMUNOGLOBULINS; RECOGNITION; EVOLUTION; PROTEINS; XENOPUS; TREES	IMMUNOGLOBULIN and T-cell receptor (TCR) molecules are central to the adaptive immune system, Sequence conservation, similarities in domain structure, and usage of similar recombination signal sequences and recombination machinery indicate that there was probably a time during evolution when an ancestral receptor diverged to the modern-day immunoglobulin and TCR(1-3). Other molecules that undergo rearrangement have not been described in vertebrates, nor have intermediates been identified that have features of both these gene families, We report here the isolation of a new member of the immunoglobulin superfamily from the nurse shark, Ginglymostoma cirratum, which contains one variable and five constant domains and is found as a dimer in serum. Analyses of complementary DNA clones show extensive sequence diversity within variable domains, which is generated by both rearrangement and somatic diversification mechanisms, Our results suggest that rearranging loci distinct from immunoglobulin and TCR have arisen during evolution.	BASEL INST IMMUNOL,CH-4058 BASEL,SWITZERLAND; PENN STATE UNIV,DEPT BIOL,ERWIN W MUELLER LAB 208,UNIVERSITY PK,PA 16802	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	GREENBERG, AS (corresponding author), UNIV MIAMI,SCH MED,DEPT MICROBIOL & IMMUNOL,POB 016960,R-138,MIAMI,FL 33101, USA.			Flajnik, Martin Francis/0000-0002-2792-5084				CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLEM LW, 1971, P NATL ACAD SCI USA, V68, P139, DOI 10.1073/pnas.68.1.139; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Du Pasquier Louis, 1993, P199; FLAJNIK MF, 1991, AM ZOOL, V31, P580; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P10603, DOI 10.1073/pnas.90.22.10603; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HSU E, 1984, MOL IMMUNOL, V21, P257, DOI 10.1016/0161-5890(84)90096-8; Kabat EA, 1991, SEQUENCES PROTEINS I; KEARNEY JF, 1979, J IMMUNOL, V123, P1548; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAKELA O, 1980, NATURE, V287, P639, DOI 10.1038/287639a0; REYNAUD CA, 1991, CELL, V64, P995, DOI 10.1016/0092-8674(91)90323-Q; RZHETSKY A, 1992, MOL BIOL EVOL, V9, P945; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SMITH LC, 1994, ANN NY ACAD SCI, V712, P213, DOI 10.1111/j.1749-6632.1994.tb33575.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; TAMURA GS, 1984, ANAL BIOCHEM, V136, P458, DOI 10.1016/0003-2697(84)90244-6; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; YANCOPOULOS GD, 1986, CELL, V44, P251, DOI 10.1016/0092-8674(86)90759-2	23	490	590	10	80	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAR 9	1995	374	6518					168	173		10.1038/374168a0	http://dx.doi.org/10.1038/374168a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL397	7877689				2022-12-28	WOS:A1995QL39700061
J	GIBBONS, A				GIBBONS, A			OUT OF AFRICA - AT LAST	SCIENCE			English	Editorial Material																		HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532	1	4	4	0	1	AMER ASSOC ADVAN SCIENCE	WASHINGTON	1333 H ST NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 3	1995	267	5202					1272	1273		10.1126/science.7871421	http://dx.doi.org/10.1126/science.7871421			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QK068	7871421				2022-12-28	WOS:A1995QK06800024
J	WOOD, N; STANDEN, G; HOWS, J; BRADLEY, B; BIDWELL, J				WOOD, N; STANDEN, G; HOWS, J; BRADLEY, B; BIDWELL, J			DIAGNOSIS OF SICKLE-CELL DISEASE WITH A UNIVERSAL HETERODUPLEX GENERATOR	LANCET			English	Note							ENZYMATIC AMPLIFICATION; GENOMIC DNA; ANEMIA	A new diagnostic technique, universal heteroduplex generator screening, has been developed to detect homozygosity and heterozygosity for sickle-cell disease. Since it is a polymerase chain reaction-based technique, it may be used to detect haemoglobin S and haemoglobin C genotypes in adults, neonates, or from coelocentesis during the first 10 weeks of pregnancy. Beta-globin gene nucleotide sequences are amplified by the polymerase chain reaction, and are heteroduplexed with a beta-globulin universal heteroduplex generator. Haemoglobins S and C mutations are identified by characteristic polyacrylamide minigel banding patterns. The technique is simple and rapid to do, even by nonspecialist laboratories, and is applicable to large-scale screening for haemoglobin S and C mutations as well as prenatal diagnosis of sickle cell disease.	UNIV BRISTOL, HOMOEOPATH HOSP, DEPT TRANSPLANTAT SCI, BRISTOL BS6 6JU, ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP, DEPT HAEMATOL, BRISTOL BS2 8HW, AVON, ENGLAND; SOUTHMEAD HLTH SERV, DEPT HAEMATOL, BRISTOL, ENGLAND	University of Bristol; Bristol Royal Infirmary								BIDWELL JL, 1993, HDB HLA TYPING TECHN, P99; CHEHAB FF, 1990, LANCET, V335, P15, DOI 10.1016/0140-6736(90)90138-U; HUISMAN THJ, 1993, BAILLIERE CLIN HAEM, V6, P1, DOI 10.1016/S0950-3536(05)80064-2; JURKOVIC D, 1993, LANCET, V341, P1623, DOI 10.1016/0140-6736(93)90761-5; LOSEKOOT M, 1990, BRIT J HAEMATOL, V76, P269, DOI 10.1111/j.1365-2141.1990.tb07883.x; RIGHETTI PG, 1986, METHODS HEMATOLOGY S, V15, P47; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; STEINBERG MH, 1993, AM J HEMATOL, V43, P110, DOI 10.1002/ajh.2830430208; WU DY, 1989, P NATL ACAD SCI USA, V86, P2757, DOI 10.1073/pnas.86.8.2757	10	20	22	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 18	1993	342	8886-7					1519	1520		10.1016/S0140-6736(05)80086-8	http://dx.doi.org/10.1016/S0140-6736(05)80086-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MM402	7902902				2022-12-28	WOS:A1993MM40200013
J	LAUPACIS, A				LAUPACIS, A			ANTICOAGULANTS FOR ATRIAL-FIBRILLATION	LANCET			English	Editorial Material							ANTITHROMBOTIC THERAPY; PREVENTION; WARFARIN				LAUPACIS, A (corresponding author), OTTAWA CIVIC HOSP, CLIN EPIDEMIOL UNIT, OTTAWA K1Y 4E9, ONTARIO, CANADA.							[Anonymous], 1988, BRIT MED J, V296, P320; BOYSEN G, 1993, NEUROLOGY, V43, pA390; BUSSEY HI, 1992, ARCH INTERN MED, V152, P278, DOI 10.1001/archinte.152.2.278; CONNOLLY SJ, 1991, J AM COLL CARDIOL, V18, P349, DOI 10.1016/0735-1097(91)90585-W; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; LAUPACIS A, 1992, CHEST, V102, pS426, DOI 10.1378/chest.102.4_Supplement.426S; MCBRIDE R, 1991, CIRCULATION, V84, P527, DOI 10.1161/01.CIR.84.2.527; PETERSEN P, 1989, LANCET, V1, P175; PETERSEN P, 1990, NEW ENGL J MED, V323, P482; SHERMAN DG, 1992, CHEST, V102, pS529, DOI 10.1378/chest.102.4_Supplement.529S	12	13	14	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1993	342	8882					1251	1252		10.1016/0140-6736(93)92353-U	http://dx.doi.org/10.1016/0140-6736(93)92353-U			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901577				2022-12-28	WOS:A1993MH56600003
J	ARTHUR, RR; ELSHARKAWY, MS; COPE, SE; BOTROS, BA; OUN, S; MORRILL, JC; SHOPE, RE; HIBBS, RG; DARWISH, MA; IMAM, IZE				ARTHUR, RR; ELSHARKAWY, MS; COPE, SE; BOTROS, BA; OUN, S; MORRILL, JC; SHOPE, RE; HIBBS, RG; DARWISH, MA; IMAM, IZE			RECURRENCE OF RIFT-VALLEY FEVER IN EGYPT	LANCET			English	Note								Rift Valley fever (RVF) has been recorded in man and in domestic animals in Egypt after a 12-year absence. Human infections were first noted in the Aswan Governorate in late May, 1993. Only cases of ocular disease, an infrequent and late manifestation, were reported. Of 41 cases, 35 were tested serologically and 27 (77%) had RVF virus-specific IgM antibodies. An estimated 600-1500 infections occurred in the region. Abortions in cattle and buffalo were seen concurrently and antibodies to RVFV were present in 39% of domestic livestock, presumably unvaccinated. RVFV was isolated from an aborted water buffalo fetus.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT IMMUNOL & INFECT DIS,BALTIMORE,MD 21218; MINIST HLTH CAIRO,CAIRO,EGYPT; USA,INFECT DIS RES INST,FT DETRICK,MD; YALE UNIV,YALE ARBOVIRUS RES UNIT,NEW HAVEN,CT 06520; AIN SHAMS UNIV,FAC MED,CAIRO,EGYPT	Johns Hopkins University; Egyptian Knowledge Bank (EKB); Ministry of Health & Population - Egypt; Yale University; Egyptian Knowledge Bank (EKB); Ain Shams University	ARTHUR, RR (corresponding author), USN,MED RES UNIT 3,CODE 307,PSC 452,BOX 5000,FPO AE 09835 000,CAIRO,EGYPT.				NIAID NIH HHS [AI 10984] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R22AI010984, R37AI010984, R01AI010984] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		IMAM IZE, 1981, J EGYPT PUBL HLTH AS, V56, P435; NIKLASSON B, 1984, J CLIN MICROBIOL, V19, P225, DOI 10.1128/JCM.19.2.225-229.1984; SIAM AL, 1980, T ROY SOC TROP MED H, V74, P539, DOI 10.1016/0035-9203(80)90074-7; 1985, INT CATALOGUE ARBOVI, P857	4	78	81	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 6	1993	342	8880					1149	1150		10.1016/0140-6736(93)92128-G	http://dx.doi.org/10.1016/0140-6736(93)92128-G			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF198	7901480				2022-12-28	WOS:A1993MF19800014
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR ADVANCED PANCREATIC-CANCER AUTHORIZED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-28	WOS:A1995QP89000009
J	NIGHTINGALE, SL				NIGHTINGALE, SL			TREATMENT IND FOR AIDS-RELATED WASTING AUTHORIZED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US OFF HLTH AFFAIRS,FDA PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					982	982		10.1001/jama.273.13.982	http://dx.doi.org/10.1001/jama.273.13.982			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897804				2022-12-28	WOS:A1995QP89000006
